0001628280-24-03497910-Q Bioventus Inc. 2024080620240806075146075146075146 0 0001628280-24-034979 10-Q 83 20240629 20240806 20240806 Bioventus Inc. 0001665988 3841 810980861 DE 1231 10-Q 34 001-37844 241177147 4721 EMPEROR BOULEVARD, SUITE 100 DURHAM NC 27703 (919) 474-6700 4721 EMPEROR BOULEVARD, SUITE 100 DURHAM NC 27703 10-Q 1 bvs-20240629.htm 10-Q bvs-20240629false0001665988--12-312024Q2http://fasb.org/us-gaap/2024#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationhttp://fasb.org/us-gaap/2024#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationxbrli:sharesiso4217:USDiso4217:USDxbrli:sharesbvs:employeexbrli:pur01-012024-06-290001665988us-gaap:CommonClassAMember2024-07-300001665988us-gaap:CommonClassBMember2024-07-300001665988us-gaap:CommonClassAMember2024-03-312024-06-290001665988us-gaap:CommonClassBMember2024-03-312024-06-290001665988us-gaap:CommonClassAMember2023-04-022023-07-010001665988us-gaap:CommonClassBMember2023-04-022023-07-010001665988us-gaap:CommonClassAMember2023-01-012023-07-010001665988us-gaap:CommonClassBMember2023-01-012023-07-010001665988us-gaap:CommonClassAMember2024-06-290001665988us-gaap:CommonClassBMember2024-06-290001665988us-gaap:CommonClassAMember2023-12-310001665988us-gaap:CommonClassBMember2023-12-310001665988us-gaap:CommonStockMemberus-gaap:CommonClassAMember2024-03-300001665988us-gaap:CommonClassBMemberus-gaap:CommonStockMember2024-03-300001665988us-gaap:AdditionalPaidInCapitalMember2024-03-300001665988us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2024-03-300001665988us-gaap:RetainedEarningsMember2024-03-300001665988us-gaap:NoncontrollingInterestMember2024-03-300001665988us-gaap:CommonStockMemberus-gaap:CommonClassAMember2024-03-312024-06-290001665988us-gaap:AdditionalPaidInCapitalMember2024-03-312024-06-290001665988us-gaap:RetainedEarningsMember2024-03-312024-06-290001665988us-gaap:NoncontrollingInterestMember2024-03-312024-06-290001665988us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2024-03-312024-06-290001665988us-gaap:CommonStockMemberus-gaap:CommonClassAMember2024-06-290001665988us-gaap:CommonClassBMemberus-gaap:CommonStockMember2024-06-290001665988us-gaap:AdditionalPaidInCapitalMember2024-06-290001665988us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2024-06-290001665988us-gaap:RetainedEarningsMember2024-06-290001665988us-gaap:NoncontrollingInterestMember2024-06-290001665988us-gaap:CommonStockMemberus-gaap:CommonClassAMember2023-04-010001665988us-gaap:CommonClassBMemberus-gaap:CommonStockMember2023-04-010001665988us-gaap:AdditionalPaidInCapitalMember2023-04-010001665988us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2023-04-010001665988us-gaap:RetainedEarningsMember2023-04-010001665988us-gaap:NoncontrollingInterestMember2023-04-010001665988us-gaap:CommonStockMemberus-gaap:CommonClassAMember2023-04-022023-07-010001665988us-gaap:AdditionalPaidInCapitalMember2023-04-022023-07-010001665988us-gaap:RetainedEarningsMember2023-04-022023-07-010001665988us-gaap:NoncontrollingInterestMember2023-04-022023-07-010001665988us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2023-04-022023-07-010001665988us-gaap:CommonStockMemberus-gaap:CommonClassAMember2023-07-010001665988us-gaap:CommonClassBMemberus-gaap:CommonStockMember2023-07-010001665988us-gaap:AdditionalPaidInCapitalMember2023-07-010001665988us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2023-07-010001665988us-gaap:RetainedEarningsMember2023-07-010001665988us-gaap:NoncontrollingInterestMember2023-07-010001665988us-gaap:CommonStockMemberus-gaap:CommonClassAMember2023-12-310001665988us-gaap:CommonClassBMemberus-gaap:CommonStockMember2023-12-310001665988us-gaap:AdditionalPaidInCapitalMember2023-12-310001665988us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2023-12-310001665988us-gaap:RetainedEarningsMember2023-12-310001665988us-gaap:NoncontrollingInterestMember2023-12-310001665988us-gaap:CommonStockMemberus-gaap:CommonClassAMember2024-01-012024-06-290001665988us-gaap:AdditionalPaidInCapitalMember2024-01-012024-06-290001665988us-gaap:RetainedEarningsMember2024-01-012024-06-290001665988us-gaap:NoncontrollingInterestMember2024-01-012024-06-290001665988us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2024-01-012024-06-290001665988us-gaap:CommonStockMemberus-gaap:CommonClassAMember2022-12-310001665988us-gaap:CommonClassBMemberus-gaap:CommonStockMember2022-12-310001665988us-gaap:AdditionalPaidInCapitalMember2022-12-310001665988us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2022-12-310001665988us-gaap:RetainedEarningsMember2022-12-310001665988us-gaap:NoncontrollingInterestMember2022-12-310001665988us-gaap:CommonStockMemberus-gaap:CommonClassAMember2023-01-012023-07-010001665988us-gaap:AdditionalPaidInCapitalMember2023-01-012023-07-010001665988us-gaap:RetainedEarningsMember2023-01-012023-07-010001665988us-gaap:NoncontrollingInterestMember2023-01-012023-07-010001665988us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2023-01-012023-07-010001665988bvs:BVLLCMember2024-06-290001665988us-gaap:DiscontinuedOperationsHeldforsaleMember2024-06-290001665988bvs:CustomerOneMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2024-01-012024-06-290001665988bvs:CustomerOneMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2023-01-012023-12-310001665988bvs:RehabilitationBusinessMemberus-gaap:DiscontinuedOperationsHeldforsaleMember2024-06-290001665988bvs:ComputerEquipmentAndSoftwareMember2024-06-290001665988bvs:ComputerEquipmentAndSoftwareMember2023-12-310001665988bvs:DemonstrationAndConsignmentInventoryMember2024-06-290001665988bvs:DemonstrationAndConsignmentInventoryMember2023-12-310001665988us-gaap:LeaseholdImprovementsMember2024-06-290001665988us-gaap:LeaseholdImprovementsMember2023-12-310001665988us-gaap:FurnitureAndFixturesMember2024-06-290001665988us-gaap:FurnitureAndFixturesMember2023-12-310001665988us-gaap:MachineryAndEquipmentMember2024-06-290001665988us-gaap:MachineryAndEquipmentMember2023-12-310001665988bvs:AssetsNotYetPlacedInServiceMember2024-06-290001665988bvs:AssetsNotYetPlacedInServiceMember2023-12-310001665988us-gaap:FurnitureAndFixturesMemberus-gaap:DiscontinuedOperationsHeldforsaleMember2024-06-290001665988us-gaap:MachineryAndEquipmentMemberus-gaap:DiscontinuedOperationsHeldforsaleMember2024-06-290001665988us-gaap:IntellectualPropertyMember2024-06-290001665988us-gaap:IntellectualPropertyMember2023-12-310001665988us-gaap:DistributionRightsMember2024-06-290001665988us-gaap:DistributionRightsMember2023-12-310001665988us-gaap:CustomerRelationshipsMember2024-06-290001665988us-gaap:CustomerRelationshipsMember2023-12-310001665988us-gaap:InProcessResearchAndDevelopmentMember2024-06-290001665988us-gaap:InProcessResearchAndDevelopmentMember2023-12-310001665988us-gaap:DevelopedTechnologyRightsMember2024-06-290001665988us-gaap:DevelopedTechnologyRightsMember2023-12-310001665988us-gaap:IntellectualPropertyMemberus-gaap:DiscontinuedOperationsHeldforsaleMember2024-06-290001665988us-gaap:IntellectualPropertyMemberus-gaap:DiscontinuedOperationsHeldforsaleMember2024-03-312024-06-290001665988us-gaap:IntellectualPropertyMemberus-gaap:DiscontinuedOperationsHeldforsaleMember2024-01-012024-06-290001665988bvs:RehabilitationBusinessMemberus-gaap:DiscontinuedOperationsHeldforsaleMember2024-05-310001665988bvs:RehabilitationBusinessMemberus-gaap:DiscontinuedOperationsHeldforsaleMember2024-01-012024-06-290001665988bvs:RehabilitationBusinessMemberus-gaap:DiscontinuedOperationsHeldforsaleMember2024-03-312024-06-290001665988us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberbvs:WoundBusinessMember2023-05-220001665988us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberbvs:WoundBusinessMember2023-05-222023-05-220001665988bvs:CartiHealLtdMember2023-05-222023-05-220001665988us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberbvs:WoundBusinessMember2023-01-012023-07-010001665988bvs:CartiHealLtdMember2022-07-120001665988bvs:DeferredConsiderationMemberbvs:CartiHealLtdMember2023-02-270001665988bvs:CartiHealLtdMemberbvs:SalesMilestoneMember2023-02-270001665988us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleMemberbvs:CartiHealLtdMember2023-02-272023-02-270001665988bvs:CartiHealLtdMember2023-02-272023-02-270001665988bvs:TermLoanMember2024-06-290001665988bvs:TermLoanMember2023-12-310001665988us-gaap:RevolvingCreditFacilityMember2024-06-290001665988us-gaap:RevolvingCreditFacilityMember2023-12-310001665988us-gaap:LineOfCreditMemberus-gaap:SecuredDebtMember2019-12-060001665988us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember2019-12-060001665988us-gaap:LineOfCreditMemberus-gaap:SecuredDebtMemberbvs:TermLoanMember2021-08-292021-12-290001665988us-gaap:LineOfCreditMemberus-gaap:SecuredDebtMemberbvs:TermLoanMember2021-10-290001665988bvs:TermLoanFacilityJuly2022Memberus-gaap:LineOfCreditMemberus-gaap:SecuredDebtMember2022-07-112022-07-110001665988us-gaap:SecuredDebtMemberus-gaap:SecuredOvernightFinancingRateSofrMember2022-07-122022-07-120001665988us-gaap:BaseRateMemberus-gaap:SecuredDebtMember2022-07-122022-07-120001665988us-gaap:SecuredDebtMemberus-gaap:SecuredOvernightFinancingRateSofrMember2023-03-312023-03-310001665988us-gaap:BaseRateMemberus-gaap:SecuredDebtMember2023-03-312023-03-310001665988us-gaap:SecuredDebtMember2023-03-310001665988us-gaap:LineOfCreditMemberbvs:TermLoanFacilityJanuary2024Memberus-gaap:SecuredDebtMember2024-06-290001665988us-gaap:LineOfCreditMemberbvs:TermLoanFacilityJanuary2024Memberus-gaap:SecuredDebtMember2024-01-012024-06-290001665988us-gaap:LineOfCreditMemberus-gaap:SecuredDebtMemberbvs:TermLoanFacilityMarch2023Member2023-07-010001665988us-gaap:LineOfCreditMemberus-gaap:SecuredDebtMemberbvs:TermLoanFacilityMarch2023Member2023-01-012023-07-010001665988us-gaap:LineOfCreditMember2023-03-012023-03-310001665988us-gaap:LineOfCreditMember2024-01-012024-01-310001665988us-gaap:LineOfCreditMemberus-gaap:SecuredDebtMemberbvs:TermLoanFacilitiesMember2024-06-290001665988us-gaap:LineOfCreditMemberus-gaap:SecuredDebtMemberbvs:TermLoanFacilitiesMember2023-04-022023-07-010001665988us-gaap:LineOfCreditMemberus-gaap:SecuredDebtMemberbvs:TermLoanFacilitiesMember2024-03-312024-06-290001665988us-gaap:LineOfCreditMemberus-gaap:SecuredDebtMemberbvs:TermLoanFacilitiesMember2024-01-012024-06-290001665988us-gaap:LineOfCreditMemberus-gaap:SecuredDebtMemberbvs:TermLoanFacilitiesMember2023-01-012023-07-010001665988us-gaap:FairValueInputsLevel2Memberbvs:TermLoanMember2024-06-290001665988us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember2024-01-012024-06-290001665988us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember2024-06-290001665988us-gaap:RevolvingCreditFacilityMember2023-12-312023-12-310001665988us-gaap:SubsequentEventMemberus-gaap:RevolvingCreditFacilityMember2024-06-302024-06-300001665988us-gaap:LineOfCreditMemberus-gaap:SubsequentEventMemberus-gaap:RevolvingCreditFacilityMember2024-06-300001665988us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember2023-12-310001665988us-gaap:LineOfCreditMemberus-gaap:LetterOfCreditMember2024-06-290001665988us-gaap:LineOfCreditMemberus-gaap:BridgeLoanMember2024-01-012024-06-290001665988bvs:BionessIncMemberus-gaap:FairValueMeasurementsRecurringMember2024-06-290001665988bvs:BionessIncMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2024-06-290001665988bvs:BionessIncMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001665988bvs:BionessIncMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2023-12-310001665988us-gaap:FairValueMeasurementsRecurringMember2024-06-290001665988us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2024-06-290001665988us-gaap:FairValueMeasurementsRecurringMember2023-12-310001665988us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2023-12-310001665988srt:MinimumMemberbvs:BionessIncMemberus-gaap:MeasurementInputDiscountRateMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ValuationTechniqueDiscountedCashFlowMember2024-06-290001665988bvs:BionessIncMemberus-gaap:MeasurementInputDiscountRateMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ValuationTechniqueDiscountedCashFlowMembersrt:MaximumMember2024-06-290001665988bvs:BionessIncMember2024-03-312024-06-290001665988bvs:BionessIncMember2023-04-022023-07-010001665988bvs:BionessIncMember2024-01-012024-06-290001665988bvs:BionessIncMember2023-01-012023-07-010001665988bvs:A2021PlanMemberus-gaap:CommonClassAMember2024-06-290001665988bvs:A2023RetentionEquityAwardPlanMemberus-gaap:CommonClassAMember2024-06-290001665988bvs:A2021And2023PlanMember2023-04-022023-07-010001665988bvs:A2021And2023PlanMember2023-01-012023-07-010001665988bvs:A2021PlanMember2024-03-312024-06-290001665988srt:MinimumMemberus-gaap:RestrictedStockUnitsRSUMember2024-01-012024-06-290001665988us-gaap:RestrictedStockUnitsRSUMembersrt:MaximumMember2024-01-012024-06-290001665988us-gaap:RestrictedStockUnitsRSUMember2024-06-290001665988us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-06-290001665988us-gaap:RestrictedStockUnitsRSUMember2023-12-310001665988srt:MinimumMemberus-gaap:EmployeeStockOptionMember2024-01-012024-06-290001665988us-gaap:EmployeeStockOptionMembersrt:MaximumMember2024-01-012024-06-290001665988us-gaap:EmployeeStockOptionMember2024-01-012024-06-290001665988us-gaap:CommonClassAMember2024-06-280001665988us-gaap:EmployeeStockMember2024-06-290001665988us-gaap:EmployeeStockMember2024-01-012024-06-290001665988us-gaap:EmployeeStockMember2024-03-312024-06-290001665988us-gaap:EmployeeStockMember2023-04-022023-07-010001665988us-gaap:EmployeeStockMember2023-01-012023-07-010001665988us-gaap:IPOMemberus-gaap:CommonClassAMember2021-02-162021-02-160001665988us-gaap:CommonClassAMember2021-02-160001665988us-gaap:CommonClassBMember2021-02-160001665982021-02-160001665988bvs:BVLLCMemberus-gaap:CommonClassAMember2021-02-162021-02-160001665988us-gaap:CommonClassAMember2024-01-012024-06-290001665988bvs:BVLLCMember2024-06-290001665988bvs:BVLLCMember2024-01-012024-06-290001665988bvs:BVLLCMember2023-12-310001665988bvs:BVLLCMember2023-01-012023-12-310001665988bvs:BVLLCMemberbvs:ContinuingLLCOwnerMember2024-06-290001665988bvs:BVLLCMemberbvs:ContinuingLLCOwnerMember2024-01-012024-06-290001665988bvs:BVLLCMemberbvs:ContinuingLLCOwnerMember2023-12-310001665988bvs:BVLLCMemberbvs:ContinuingLLCOwnerMember2023-01-012023-12-310001665988bvs:BVLLCMemberbvs:BioventusAndContinuingLLCOwnerMember2024-06-290001665988bvs:BVLLCMemberbvs:BioventusAndContinuingLLCOwnerMember2024-01-012024-06-290001665988bvs:BVLLCMemberbvs:BioventusAndContinuingLLCOwnerMember2023-12-310001665988bvs:BVLLCMemberbvs:BioventusAndContinuingLLCOwnerMember2023-01-012023-12-310001665988bvs:LimitedLiabilityCompanyInterestsMember2024-03-312024-06-290001665988bvs:LimitedLiabilityCompanyInterestsMember2023-04-022023-07-010001665988bvs:LimitedLiabilityCompanyInterestsMember2024-01-012024-06-290001665988bvs:LimitedLiabilityCompanyInterestsMember2023-01-012023-07-010001665988us-gaap:EmployeeStockOptionMember2024-03-312024-06-290001665988us-gaap:EmployeeStockOptionMember2023-04-022023-07-010001665988us-gaap:EmployeeStockOptionMember2024-01-012024-06-290001665988us-gaap:EmployeeStockOptionMember2023-01-012023-07-010001665988us-gaap:RestrictedStockUnitsRSUMember2024-03-312024-06-290001665988us-gaap:RestrictedStockUnitsRSUMember2023-04-022023-07-010001665988us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-06-290001665988us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-07-010001665988srt:MinimumMember2024-06-290001665988srt:MaximumMember2024-06-290001665988us-gaap:SubsequentEventMemberbvs:BioventusShareholderLitigationMember2024-07-152024-07-150001665988bvs:BioventusShareholderLitigationMember2024-03-312024-06-290001665988bvs:BioventusShareholderLitigationMember2024-01-012024-06-290001665988us-gaap:SubsequentEventMemberbvs:BioventusShareholderLitigationMember2024-07-150001665988bvs:BioventusShareholderLitigationMember2024-05-010001665988bvs:HAProductMember2021-11-102021-11-100001665988bvs:HAProductMember2022-01-012022-12-310001665988bvs:HAProductMember2023-03-082023-03-080001665988bvs:HAProductMember2024-01-312024-01-310001665988bvs:HarborMember2019-08-232019-08-230001665988bvs:SupplierOfSingleInjectionOAProductMember2024-03-312024-06-290001665988bvs:SupplierOfSingleInjectionOAProductMember2023-04-022023-07-010001665988bvs:SupplierOfSingleInjectionOAProductMember2024-01-012024-06-290001665988bvs:SupplierOfSingleInjectionOAProductMember2023-01-012023-07-010001665988bvs:ThreeInjectionOAProductMember2016-02-092016-02-090001665988bvs:HarborMember2020-12-222020-12-220001665988country:US2023-04-022023-07-010001665988country:US2023-01-012023-07-010001665988us-gaap:NonUsMember2023-04-022023-07-010001665988us-gaap:NonUsMember2023-01-012023-07-010001665988bvs:CustomerOneMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2024-03-312024-06-290001665988bvs:CustomerOneMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-06-290001665988bvs:PainTreatmentsMembercountry:US2024-03-312024-06-290001665988bvs:PainTreatmentsMembercountry:US2023-04-022023-07-010001665988bvs:PainTreatmentsMembercountry:US2024-01-012024-06-290001665988bvs:PainTreatmentsMembercountry:US2023-01-012023-07-010001665988bvs:RestorativeTherapiesMembercountry:US2024-03-312024-06-290001665988bvs:RestorativeTherapiesMembercountry:US2023-04-022023-07-010001665988bvs:RestorativeTherapiesMembercountry:US2024-01-012024-06-290001665988bvs:RestorativeTherapiesMembercountry:US2023-01-012023-07-

010001665988country:USbvs:SurgicalSolutionsMember2024-03-312024-06-290001665988country:USbvs:SurgicalSolutionsMember2023-04-022023-07-010001665988country:USbvs:SurgicalSolutionsMember2024-01-012024-06-290001665988country:USbvs:SurgicalSolutionsMember2023-01-012023-07-010001665988country:US2024-03-312024-06-290001665988country:US2024-01-012024-06-290001665988bvs:PainTreatmentsMemberus-gaap:NonUsMember2024-03-312024-06-290001665988bvs:PainTreatmentsMemberus-gaap:NonUsMember2023-04-022023-07-010001665988bvs:PainTreatmentsMemberus-gaap:NonUsMember2024-01-012024-06-290001665988bvs:PainTreatmentsMemberus-gaap:NonUsMember2023-01-012023-07-010001665988bvs:RestorativeTherapiesMemberus-gaap:NonUsMember2024-03-312024-06-290001665988bvs:RestorativeTherapiesMemberus-gaap:NonUsMember2023-04-022023-07-010001665988bvs:RestorativeTherapiesMemberus-gaap:NonUsMember2024-01-012024-06-290001665988bvs:RestorativeTherapiesMemberus-gaap:NonUsMember2023-01-012023-07-010001665988us-gaap:NonUsMemberbvs:SurgicalSolutionsMember2024-03-312024-06-290001665988us-gaap:NonUsMemberbvs:SurgicalSolutionsMember2023-04-022023-07-010001665988us-gaap:NonUsMemberbvs:SurgicalSolutionsMember2024-01-012024-06-290001665988us-gaap:NonUsMemberbvs:SurgicalSolutionsMember2023-01-012023-07-010001665988us-gaap:NonUsMember2024-03-312024-06-290001665988us-gaap:NonUsMember2024-01-012024-06-290001665988us-gaap:NonUsMember2023-01-012023-07-010001665988bvs:USSegmentMemberus-gaap:OperatingSegmentsMember2024-03-312024-06-290001665988bvs:USSegmentMemberus-gaap:OperatingSegmentsMember2023-04-022023-07-010001665988bvs:USSegmentMemberus-gaap:OperatingSegmentsMember2024-01-012024-06-290001665988bvs:USSegmentMemberus-gaap:OperatingSegmentsMember2023-01-012023-07-010001665988bvs:InternationalSegmentMemberus-gaap:OperatingSegmentsMember2024-03-312024-06-290001665988bvs:InternationalSegmentMemberus-gaap:OperatingSegmentsMember2023-04-022023-07-010001665988bvs:InternationalSegmentMemberus-gaap:OperatingSegmentsMember2024-01-012024-06-290001665988bvs:InternationalSegmentMemberus-gaap:OperatingSegmentsMember2023-01-012023-07-010001665988us-gaap:MaterialReconcilingItemsMember2024-03-312024-06-290001665988us-gaap:MaterialReconcilingItemsMember2023-04-022023-07-010001665988us-gaap:MaterialReconcilingItemsMember2024-01-012024-06-290001665988us-gaap:MaterialReconcilingItemsMember2023-01-012023-07-010001665988bvs:CartiHealMemberus-gaap:DiscontinuedOperationsDisposedOfBySaleMember2023-01-012023-07-010001665988us-gaap:DiscontinuedOperationsDisposedOfBySaleMember2023-07-010001665988us-gaap:DiscontinuedOperationsDisposedOfBySaleMember2024-06-29â€˜ mUNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549_____FORM 10-Q_____(Mark One)â˜’QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period ended June 29, 2024ORâ˜TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period from _____ to _____Commission File Number: 001-37844BIOVENTUS INC.(Exact Name of Registrant as Specified in Its Charter)Delaware81-0980861(State or Other Jurisdiction of Incorporation or Organization)(I.R.S. Employer Identification No.)4721 Emperor Boulevard, Suite 100Durham, North Carolina27703(Address of Principal Executive Offices)(Zip Code) (919) 474-6700(Registrantâ€™s Telephone Number, Including Area Code)Securities registered pursuant to Section 12(b) of the Act:Title of each classTrading Symbol(s)Name of each exchange on which registeredClass A Common Stock, $0.001 par value per shareBVSThe Nasdaq Global Select MarketIndicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.Â Â Â YesÂ Â â˜’Â Â Â Â NoÂ Â â˜ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Â§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).Â Â Â YesÂ Â Â â˜’Â Â Â NoÂ Â â˜Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of â€œlarge accelerated filer,â€ â€œaccelerated filer,â€ â€œsmaller reporting company,â€ and â€œemerging growth companyâ€ in Rule 12b-2 of the Exchange Act.LargeÂ acceleratedÂ filerâ˜Accelerated filerâ˜’Non-accelerated filerâ˜SmallerÂ reportingÂ companyâ˜Emerging growth companyâ˜’If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.Â Â Â â˜’Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Â Â Â YesÂ Â â˜Â Â Â NoÂ Â â˜’ As of July 30, 2024, there were 65,186,901 shares of Class A common stock outstanding and 15,786,737 shares of Class B common stock outstanding.BIOVENTUS INC.TABLE OF CONTENTSPART I. FINANCIAL INFORMATIONItem 1.Financial Statements (Unaudited)Consolidated Condensed Statements of Operations and Comprehensive Loss for the three and six months ended JuneÂ 29, 2024 and JulyÂ 1, 20231Consolidated Condensed Balance Sheets as of JuneÂ 29, 2024 and DecemberÂ 31, 20232Consolidated Condensed Statements of Changes in Stockholdersâ€™ Equity for the three and six months ended JuneÂ 29, 2024 and JulyÂ 1, 20233Consolidated Condensed Statements of Cash Flows for the six months ended JuneÂ 29, 2024 and JulyÂ 1, 20234Notes to the Unaudited Consolidated Condensed Financial Statements5Item 2.Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations22Item 3.Quantitative and Qualitative Disclosures About Market Risk32Item 4.Controls and Procedures33PART II. OTHER INFORMATIONItem 1.Legal Proceedings33Item 1A.Risk Factors34Item 2.Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities34Item 3.Defaults Upon Senior Securities34Item 4.Mine Safety Disclosures35Item 5.Other Information35Item 6.Exhibits35Signature36Table of ContentsSPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTSAs used in this Quarterly Report on Form 10-Q, unless expressly indicated or the context otherwise requires, references to "Bioventus," "we," "us," "our," the â€œCompany," and similar references refer to Bioventus Inc. and its consolidated subsidiaries, including Bioventus LLC (â€œBV LLCâ€).This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (â€œExchange Actâ€), and Section 27A of the Securities Act of 1933, as amended (â€œSecurities Actâ€), concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business operations and financial performance and condition. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements including, without limitation, statements regarding our business strategy, including, without limitation, expectations relating to our integration of Misonix and Bioness, potential acquisitions, expected expansion of our pipeline and research and development investment, cost savings initiatives, new therapy launches, expected timelines for clinical trial results and other development milestones, expected contractual obligations and capital expenditures, recent dispositions of non-core assets, our domestic and international operations and expected financial performance and condition, and impacts of the COVID-19 pandemic, inflation and ongoing conflicts in Israel. In some cases, you can identify forward-looking statements by terminology such as â€œaim,â€ â€œanticipate,â€ â€œassume,â€ â€œbelieve,â€ â€œcontemplate,â€ â€œcontinue,â€ â€œcould,â€ â€œdue,â€ â€œestimate,â€ â€œexpect,â€ â€œgoal,â€ â€œintend,â€ â€œmay,â€ â€œobjective,â€ â€œplan,â€ â€œpredict,â€ â€œpotential,â€ â€œpositioned,â€ â€œseek,â€ â€œshould,â€ â€œtarget,â€ â€œwill,â€ â€œwouldâ€ and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words.Forward-looking statements are based on managementâ€™s current expectations, estimates, forecasts and projections about our business and the industry in which we operate, and managementâ€™s beliefs and assumptions are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this Quarterly Report on Form 10-Q may turn out to be inaccurate. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. Important factors that may cause actual results to differ materially from current expectations include, among other things: we might not meet certain of our debt covenants under our Credit and Guaranty Agreement and might be required to repay our indebtedness; risks associated with the potential divestiture of our Advanced Rehabilitation Business and expected impacts on our business; restrictions on operations and other costs associated with our indebtedness; our ability to complete acquisitions or successfully integrate new businesses, products or technologies in a cost-effective and non-disruptive manner; we maintain cash at financial institutions, often in balance that exceed federally insured limits; we are subject to securities class action litigation and may be subject to similar or other litigation in the future, which will require significant management time and attention, result in significant legal expenses or costs not covered by our insurers, and may result in unfavorable outcomes; our ability to maintain our competitive position depends on our ability to attract, retain and motivate our senior management team and highly qualified personnel; we are highly dependent on a limited number of products; our long-term growth depends on our ability to develop, acquire and commercialize new products, line extensions or expanded indications; we may be unable to successfully commercialize newly developed or acquired products or therapies in the United States; demand for our existing portfolio of products and any new products, line extensions or expanded indications depends on the continued and future acceptance of our products by physicians, patients, third-party payers and others in the medical community; the proposed down classification of non-invasive bone growth stimulators, including our Exogen system, by the U.S. Food and Drug Administration (â€œFDAâ€) could increase future competition for bone growth stimulators and otherwise adversely affect the Companyâ€™s sales of Exogen; failure to achieve and maintain adequate levels of coverage and/or reimbursement for our products or future products, the procedures using our products, such as our hyaluronic acid (â€œHAâ€) viscosupplements, or future products we may seek to commercialize; pricing pressure and other competitive factors; governments outside the United States might not provide coverage or reimbursement of our products; we compete and may compete in the future against other companies, some of which have longer operating histories, more established products or greater resources than we do; if our HA products are reclassified from medical devices to drugs in the United States by the FDA, it could negatively impact our ability to market these products and may require that we conduct costly additional clinical studies to support current or future indications for use of those products; our failure to properly manage our anticipated growth and strengthen our brands; risks related to product liability claims; fluctuations in demand for our products; issues relating to the supply of our products, potential supply chain disruptions, and the increased cost of parts and components used to manufacture our products due to inflation; our reliance on a limited number of third-party manufacturers to manufacture certain of our products; if our facilities are damaged or become inoperable, we will be unable to continue to research, develop and manufacture certain of our products; economic, political, Table of Contentsregulatory and other risks related to international sales, manufacturing and operations; failure to maintain contractual relationships; security breaches, unauthorized access to our disclosure of information, cyberattacks, or other incidents, or the perception that confidential information in our or our vendorsâ€™ or service providersâ€™ possession or control is not secure; failure of key information technology and communications systems, process or sites; risks related to our debt and future capital needs; failure to comply with extensive governmental regulation relevant to us and our products; we may be subject to enforcement action if we engage in improper claims submission practices and resulting audits or denials of our claims by government agencies could reduce our net sales or profits; the FDA regulatory process is expensive, time-consuming and uncertain, and the failure to obtain and maintain required regulatory clearances and approvals could prevent us from commercializing our products; if clinical studies of our future product candidates do not produce results necessary to support regulatory clearance or approval in the United States or elsewhere, we will be unable to expand the indications for or commercialize these products; legislative or regulatory reforms; our business may continue to experience adverse impacts as a result of the COVID-19 pandemic or similar epidemics; risks related to intellectual property matters; and other important factors described in Part I. Item 1A. Risk Factors in our Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023, as may be further updated from time to time in our other filings with the SEC. You are urged to consider these factors carefully in evaluating these forward-looking statements. These forward-looking statements speak only as of the date hereof. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.Table of ContentsPART I. FINANCIAL INFORMATIONItem 1. Financial Statements.Bioventus Inc.Consolidated Condensed Statements of Operations and Comprehensive LossThree and Six Months Ended JuneÂ 29, 2024 and JulyÂ 1, 2023(Amounts in thousands, except share amounts)(Unaudited)Three Months EndedSix Months EndedJune 29, 2024July 1, 2023June 29, 2024July 1, 2023Net sales$151,217Â $137,069Â $280,674Â $256,128Â Cost of sales (including depreciation and amortization of Â Â Â Â $11,021, $12,301, $21,046 and $26,640, respectively)47,578Â 47,946Â 88,655Â 93,086Â Gross profit103,639Â 89,123Â 192,019Â 163,042Â Selling, general and administrative expense94,785Â 74,844Â 173,191Â 155,702Â Research and development expense3,988Â 3,398Â 6,585Â 7,169Â Restructuring costsâ€”Â 620Â â€”Â 937Â Change in fair value of contingent consideration300Â 240Â 595Â 527Â Depreciation and amortization2,064Â 2,294Â 3,819Â 4,423Â Impairments of assets31,870Â â€”Â 31,870Â 78,615Â Loss on disposalsâ€”Â 977Â â€”Â 977Â Operating (loss) income(29,368)6,750Â (24,041)(85,308)Interest expense, net9,924Â 10,587Â 20,263Â 20,281Â Other expense (income)159Â 513Â 222Â (1,075)Other expense10,083Â 11,100Â 20,485Â 19,206Â Loss before income taxes(39,451)(4,350)(44,526)(104,514)Income tax (benefit) expense, net(7,339)381Â (6,432)235Â Net loss from continuing operations(32,112)(4,731)(38,094)(104,749)Loss from discontinued operations, net of taxâ€”Â â€”Â â€”Â (74,429)Net loss(32,112)(4,731)(38,094)(179,178)Loss attributable to noncontrolling interest - Â Â Â Â continuing operations8,120Â 1,050Â 9,532Â 21,410Â Loss attributable to noncontrolling interest - Â Â Â Â discontinued operationsâ€”Â â€”Â â€”Â 14,937Â Net loss attributable to Bioventus Inc.$(23,992)$(3,681)$(28,562)$(142,831)Net loss$(32,112)$(4,731)$(38,094)$(179,178)Other comprehensive (loss) income, net of taxChange in foreign currency translation adjustments(426)303Â (1,011)960Â Comprehensive loss(32,538)(4,428)(39,105)(178,218)Comprehensive loss attributable to noncontrolling interest -Â Â Â Â continuing operations8,204Â 989Â 9,732Â 21,215Â Comprehensive loss attributable to noncontrolling interest -Â Â Â Â discontinued operationsâ€”Â â€”Â â€”Â 14,937Â Comprehensive loss attributable to Bioventus Inc.$(24,334)$(3,439)$(29,373)$(142,066)Loss per share of Class A common stock from continuing Â Â Â Â operations, basic and diluted:(0.37)(0.06)(0.45)(1.34)Loss per share of Class A common stock from discontinuedÂ Â Â Â operations, basic and diluted:â€”Â â€”Â â€”Â (0.95)Loss per share of Class A common stock, basic and diluted(0.37)(0.06)(0.45)(2.29)Weighted-average shares of Class A common stockÂ Â Â Â outstanding, basic and diluted:64,056,75962,551,28563,720,34262,338,018The accompanying notes are an integral part of these consolidated financial statements.1Table of ContentsBioventus Inc.Consolidated Condensed Balance Sheets as of JuneÂ 29, 2024 and DecemberÂ 31, 2023(Amounts in thousands, except share amounts)(Unaudited)June 29, 2024December 31, 2023AssetsCurrent assets:Cash and cash equivalents$31,994Â $36,964Â Accounts receivable, net137,305Â 122,789Â Inventory87,606Â 91,333Â Prepaid and other current assets23,570Â 16,913Â Assets held for sale28,408Â â€”Â Total current assets308,883Â 267,999Â Property and equipment, net31,938Â 36,605Â Goodwill7,462Â 7,462Â Intangible assets, net424,552Â 482,350Â Operating lease assets10,366Â 13,353Â Deferred tax assets6,884Â â€”Â Investment and other assets2,088Â 3,141Â Total assets$792,173Â $810,910Â Liabilities and Stockholders' EquityCurrent liabilities:Accounts payable$24,437Â $23,038Â Accrued liabilities139,978Â 119,795Â Current portion of long-term debt38,566Â 27,848Â Current portion of contingent consideration18,745Â â€”Â Other current liabilities3,829Â 4,816Â Liabilities held for sale5,908Â â€”Â Total current liabilities231,463Â 175,497Â Long-term debt, less current portion344,716Â 366,998Â Deferred income taxesâ€”Â 1,213Â Contingent considerationâ€”Â 18,150Â Other long-term liabilities26,932Â 27,934Â Total liabilities603,111Â 589,792Â Commitments and contingencies (Note 11)Stockholdersâ€™ EquityPreferred stock, $0.001 par value, 10,000,000 shares authorized, 0 shares issuedClass A common stock, $0.001 par value, 250,000,000 shares authorized as of JuneÂ 29, 2024 and Â Â Â DecemberÂ 31, 2023, 65,172,159 and 63,267,436 shares issued and outstanding as of JuneÂ 29, 2024Â Â Â and DecemberÂ 31, 2023, respectively65Â 63Â Class B common stock, $0.001 par value, 50,000,000 shares authorized, Â Â Â Â 15,786,737 shares issued and outstanding as of JuneÂ 29, 2024 and DecemberÂ 31, 202316Â 16Â Additional paid-in capital500,969Â 494,254Â Accumulated deficit(350,098)(321,536)Accumulated other comprehensive (loss) income(17)794Â Total stockholdersâ€™ equity attributable to Bioventus Inc.150,935Â 173,591Â Noncontrolling interest38,127Â 47,527Â Total stockholdersâ€™ equity189,062Â 221,118Â Total liabilities and stockholdersâ€™ equity$792,173Â $810,910Â The accompanying notes are an integral part of these consolidated financial statements.2Table of ContentsBioventus Inc.Consolidated Condensed Statements of Changes in Stockholdersâ€™ EquityThree and Six Months Ended JuneÂ 29, 2024 and JulyÂ 1, 2023(Amounts in thousands, except share amounts)(Unaudited)Three Months Ended JuneÂ 29, 2024Class A Common StockClass B Common StockSharesAmountSharesAmountAdditional Paid-in CapitalAccumulated other comprehensive income (loss)Accumulated DeficitNon-controlling interestTotal Stockholders'equityBalance at March 30, 202463,672,170Â $64Â 15,786,737Â $16Â $496,977Â $325Â $(326,106)$46,156Â $217,432Â Issuance of Class A common stock for equity plans1,499,989Â 1Â â€”Â Â â€”Â 495Â â€”Â Â â€”Â Â â€”Â 496Â Net lossâ€”Â Â â€”Â Â â€”Â Â â€”Â (23,992)(8,120)(32,112)Change in noncontrolling interest allocationâ€”Â Â â€”Â Â â€”Â 502Â â€”Â Â â€”Â (502)â€”Â Equity based compensationâ€”Â Â â€”Â Â â€”Â 2,995Â â€”Â Â â€”Â 677Â 3,672Â Translation

adjustmentâ€”Â â€”Â â€”Â â€”Â (342)â€”Â (84)(426)Balance at June 29, 202465,172,159Â $65Â 15,786,737Â $16Â $500,969Â (17)(350,098)$38,127Â $189,062Â Three Months Ended JulyÂ 1, 2023Class A Common StockClass B Common StockSharesAmountSharesAmountAdditional Paid-in CapitalAccumulated other comprehensive (loss) incomeAccumulated DeficitNon-controlling interestTotal Stockholders'equityBalance at April 1, 202362,507,917Â $63Â 15,786,737Â $16Â $492,475Â $413Â $(304,456)$51,851Â $240,362Â Issuance of Class A common stock for equity plans296,589Â â€”Â â€”Â â€”Â 139Â â€”Â â€”Â 139Â Net lossâ€”Â â€”Â â€”Â â€”Â (3,681)(1,050)(4,731)Change in noncontrolling interest allocationâ€”Â â€”Â â€”Â â€”Â 108Â â€”Â â€”Â (108)â€”Â Equity based compensationâ€”Â â€”Â â€”Â â€”Â (2,124)â€”Â â€”Â (608)(2,732)Translation adjustmentâ€”Â â€”Â â€”Â â€”Â 242Â â€”Â 61Â 303Â Balance at July 1, 202362,804,506Â $63Â 15,786,737Â $16Â $490,598Â $655Â $(308,137)$50,146Â $233,341Â Six Months Ended JuneÂ 29, 2024Class A Common StockClass B Common StockSharesAmountSharesAmountAdditional Paid-in CapitalAccumulated other comprehensive income (loss)Accumulated DeficitNon-controlling interestTotal Stockholders'equityBalance at December 31, 202363,267,436Â $63Â 15,786,737Â $16Â $494,254Â $794Â $(321,536)$47,527Â $221,118Â Issuance of Class A common stock for equity plans1,904,723Â 2Â â€”Â â€”Â 784Â â€”Â â€”Â 786Â Net lossâ€”Â â€”Â â€”Â â€”Â (28,562)(9,532)(38,094)Change in noncontrolling interest allocationâ€”Â â€”Â â€”Â â€”Â 821Â â€”Â â€”Â (821)â€”Â Equity based compensationâ€”Â â€”Â â€”Â â€”Â 5,110Â â€”Â â€”Â 1,153Â 6,263Â Translation adjustmentâ€”Â â€”Â â€”Â â€”Â (811)â€”Â (200)(1,011)Balance at June 29, 202465,172,159Â $65Â 15,786,737Â $16Â $500,969Â (17)(350,098)$38,127Â $189,062Â Six Months Ended JulyÂ 1, 2023Class A Common StockClass B Common StockSharesAmountSharesAmountAdditional Paid-in CapitalAccumulated other comprehensive (loss) incomeAccumulated DeficitNon-controlling interestTotal Stockholders'equityBalance at December 31, 202262,063,014Â $62Â 15,786,737Â $16Â $490,576Â (110)(165,306)$86,984Â $412,222Â Issuance of Class A common stock for equity plans741,492Â 1Â â€”Â â€”Â 222Â â€”Â â€”Â â€”Â 223Â Net lossâ€”Â â€”Â â€”Â â€”Â (142,831)(36,347)(179,178)Change in noncontrolling interest allocationâ€”Â â€”Â â€”Â â€”Â 385Â â€”Â â€”Â (385)â€”Â Equity based compensationâ€”Â â€”Â â€”Â â€”Â (585)â€”Â â€”Â (301)(886)Translation adjustmentâ€”Â â€”Â â€”Â â€”Â 765Â â€”Â 195Â 960Â Balance at July 1, 202362,804,506Â $63Â 15,786,737Â $16Â $490,598Â $655Â $(308,137)$50,146Â $233,341Â The accompanying notes are an integral part of these consolidated financial statements. 3Table of ContentsBioventus Inc.Consolidated Condensed Statements of Cash FlowsSix Months Ended JuneÂ 29, 2024 and JulyÂ 1, 2023(Amounts in thousands)(Unaudited)Six Months EndedJune 29, 2024July 1, 2023Operating activities:Net loss$(38,094)$(179,178)Less: Loss from discontinued operations, net of taxâ€”Â (74,429)Loss from continuing operations(38,094)(104,749)Adjustments to reconcile net loss to net cash from operating activities:Depreciation and amortization24,875Â 31,073Â (Benefit) provision for expected credit losses(537)640Â Equity-based compensation6,263Â (886)Change in fair value of contingent consideration595Â 527Â Deferred income taxes(8,098)(3,540)Impairment of assets31,870Â 78,615Â Loss on disposalsâ€”Â 977Â Unrealized loss on foreign currency fluctuations536Â 601Â Other, net961Â 1,139Â Changes in operating assets and liabilities:Accounts receivable(21,933)11,329Â Inventories(8,359)(13,074)Accounts payable and accrued expenses22,552Â 14,765Â Other current and noncurrent assets and liabilities(1,474)(1,963)Net cash from operating activities - continuing operations9,157Â 15,454Â Net cash from operating activities - discontinued operationsâ€”Â (2,169)Net cash from operating activities9,157Â 13,285Â Investing activities:Proceeds from sale of a businessâ€”Â 34,897Â Purchase of property and equipment(368)(4,957)Investments and acquisition of distribution rights(709)â€”Â Net cash from investing activities - continuing operations(1,077)29,940Â Net cash from investing activities - discontinued operationsâ€”Â (11,506)Net cash from investing activities(1,077)18,434Â Financing activities:Proceeds from issuance of Class A common stock786Â 223Â Borrowing on revolverâ€”Â 49,000Â Payment on revolverâ€”Â (42,000)Debt refinancing costs(1,180)(3,661)Payments on long-term debt(11,320)(38,264)Other, net(373)(166)Net cash from financing activities(12,087)(34,868)Effect of exchange rate changes on cash(963)701Â Net change in cash, cash equivalents and restricted cash(4,970)(2,448)Cash, cash equivalents and restricted cash at the beginning of the period36,964Â 31,837Â Cash, cash equivalents and restricted cash at the end of the period$31,994Â $29,389Â Supplemental disclosure of noncash investing and financing activitiesAccrued liabilities for intellectual property$â€”Â $709Â Accounts payable for purchase of property, plant and equipment$205Â $968Â The accompanying notes are an integral part of these consolidated financial statements.4Table of ContentsBioventus Inc.Notes to the unaudited consolidated condensed financial statements(Amounts in thousands, except unit and share amounts)1. OrganizationThe CompanyBioventus Inc. (together with its subsidiaries, the â€œCompanyâ€) was formed as a Delaware corporation for the purpose of facilitating an initial public offering and other related transactions in order to carry on the business of Bioventus LLC and its subsidiaries (â€œBV LLCâ€). Bioventus Inc. functions as a holding company with no direct operations, material assets or liabilities other than the equity interest in BV LLC. BV LLC is a limited liability company formed under the laws of the state of Delaware on November 23, 2011 and operates as a partnership. BV LLC commenced operations in May 2012. On February 16, 2021, the Company completed its initial public offering (â€œIPOâ€), which was conducted through what is commonly referred to as an umbrella partnership C Corporation (â€œUP-Câ€) structure. The Company has majority interest, sole voting interest and controls the management of BV LLC. As a result, the Company consolidates the financial results of BV LLC and reports a noncontrolling interest representing the interest of BV LLC held by its continuing LLC owner.The Company is focused on developing and commercializing clinically differentiated, cost efficient and minimally invasive treatments that engage and enhance the bodyâ€™s natural healing processes. The Company is headquartered in Durham, North Carolina and has approximately 1,030 employees.Interim periodsThe Company reports quarterly interim periods on a 13-week basis within a standard calendar year. Each annual reporting period begins on January 1 and ends on December 31. Each quarter ends on the Saturday closest to calendar quarter-end, with the exception of the fourth quarter, which ends on December 31. The 13-week quarterly periods for fiscal year 2024 end on March 30, June 29 and September 28. Comparable periods for 2023 ended on April 1, July 1 and September 30. The fourth and first quarters may vary in length depending on the calendar year. Unaudited interim financial informationThe accompanying unaudited consolidated condensed financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (â€œU.S. GAAPâ€) for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Pursuant to these rules and regulations, they do not include all information and notes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments, and the adjustments discussed in Note 1. Organization) considered necessary for a fair statement of the Companyâ€™s financial condition and results of operations have been included. Operating results for the periods presented are not necessarily indicative of the results that may be expected for the full year. As such, the information included in this report should be read in conjunction with the Companyâ€™s Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023. The consolidated balance sheet at DecemberÂ 31, 2023 has been derived from the audited consolidated financial statements of the Company, but does not include all the disclosures required by U.S. GAAP.ReclassificationsCertain prior period amounts have been reclassified to conform to current period presentation. During the first quarter of 2024, the Company reclassified revenue and expense of the SonicOne Ultrasonic Cleansing and Debridement Systems (â€œSonicOneâ€) from the Restorative Therapies to the Surgical Solutions business. The reclassification of SonicOne activity affected prior presentation of disaggregated revenue by business, refer to Note 12. Revenue recognition for further details. The reclassification had no effect on previously reported total revenues, net loss, other comprehensive loss, stockholdersâ€™ equity or cash flows. Unless otherwise noted, all financial information in the unaudited consolidated condensed financial statements reflects the Companyâ€™s results from continuing operations.5Table of ContentsUse of estimatesThe preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities, at the date of the financial statements, as well as the reported amounts of revenues and expenses during the period. On an ongoing basis, management evaluates these estimates, including those related to contractual allowances and sales incentives, allowance for credit losses, inventory reserves, goodwill and intangible assets impairment, valuation of assets and liabilities assumed in acquisitions, useful lives of long lived assets, fair value measurements, litigation and contingent liabilities, income taxes, and equity-based compensation. Management bases its estimates on historical experience, future expectations and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from those estimates.Recent accounting pronouncementsIn addition to being a smaller reporting and an emerging growth company, the Company also is an accelerated filer under SEC rules and regulations. Therefore, required effective dates for adopting new or revised accounting standards are generally earlier than when smaller reporting companies and emerging growth companies who are not accelerated filers are required to adopt.In December 2023, the Financial Accounting Standards Board (â€œFASBâ€) issued Accounting Standards Update 2023-09 (â€œASU 2023-09â€), Income Taxes, which enhances the transparency of income tax disclosures by expanding annual disclosure requirements related to the rate reconciliation and income taxes paid. The amendments are effective for fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments should be applied on a prospective basis. Retrospective application is permitted. The Company is currently evaluating this ASU to determine its impact on the Company's disclosures.In November 2023, the FASB issued Accounting Standards Update 2023-07 (â€œASU 2023-07â€), Segment Reporting, which improves reportable segment disclosure requirements. ASU 2023-07 primarily enhances disclosures about significant segment expenses by requiring that a public entity disclose significant segment expenses that are regularly provided to the Chief Operating Decision Maker (â€œCODMâ€) and included within each reported measure of segment profit or loss. This ASU also (i) requires that a public entity disclose, on an annual and interim basis, an amount for other segment items by reportable segment, and a description of its composition; (ii) requires that all annual disclosures are provided in the interim periods; (iii) clarifies that if the CODM uses more than one measure of profitability in assessing segment performance and deciding how to allocate resources, that one or more of those measures may be reported; (iv) requires disclosure of the title and position of the CODM and a description of how the reported measures are used by the CODM in assessing segment performance and in deciding how to allocate resources; (v) requires that an entity with a single segment provide all new required disclosures. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024 and requires retrospective application. Early adoption is permitted. The amendments under ASU 2023-07 relate to financial disclosures and its adoption will not have an impact on the Companyâ€™s results of operations, financial position or cash flows. The Company will adopt ASU 2023-07 for the annual reporting period ending December 31, 2024 and for interim reporting periods thereafter.2. Balance sheet informationAccounts receivable, netAccounts receivable, net are amounts billed and currently due from customers. The Company records the amounts due net of allowance for credit losses. Collection of the consideration that the Company expects to receive typically occurs within 30 to 90 days of billing. The Company applies the practical expedient for contracts with payment terms of one year or less which does not consider the effects of the time value of money. Occasionally, the Company enters into payment agreements with patients that allow payment terms beyond one year. In those cases, the financing component is not deemed significant to the contract.Accounts receivable, net of allowances, consisted of the following as of:June 29, 2024December 31, 2023Accounts receivable(a)$140,204Â $127,008Â Less: Allowance for credit losses(a)(2,899) (4,219)$137,305Â $122,789Â (a)Accounts receivable of $7,688 attributable to the Companyâ€™s advanced rehabilitation business was reclassified to assets held for sale within the JuneÂ 29, 2024 consolidated condensed balance sheets. Refer to Note 3. Acquisitions and divestitures for further details regarding assets held for sale.6Table of ContentsDue to the short-term nature of the Companyâ€™s receivables, the estimate of expected credit losses is based on aging of the account receivable balances. The allowance is adjusted on a specific identification basis for certain accounts as well as pooling of accounts with similar characteristics. The Company has a diverse customer base with no single customer representing ten percent or more of sales. The Company has one customer representing approximately 19.2% and 16.0% of the accounts receivable balance as of JuneÂ 29, 2024 and DecemberÂ 31, 2023, respectively. Historically, the Companyâ€™s reserves have been adequate to cover credit losses.InventoryInventory consisted of the following as of:June 29, 2024December 31, 2023Raw materials and supplies(a)$24,841Â $21,062Â Finished goods(a)62,765Â 70,271Â $87,606Â $91,333Â (a)Raw materials and supplies of $4,924 and finished goods inventory of $9,449 attributable to the Companyâ€™s advanced rehabilitation business were reclassified to assets held for sale within the JuneÂ 29, 2024 consolidated condensed balance sheets. Refer to Note 3. Acquisitions and divestitures for further details regarding assets held for sale.Property and equipment, netProperty and equipment consisted of the following as of:June 29, 2024December 31, 2023Computer equipment and software$39,713Â $37,860Â Demonstration and consignment inventory9,963Â 9,341Â Leasehold improvements3,933Â 3,763Â Furniture and fixtures(a)4,586Â 4,163Â Finance leases15,737Â 15,737Â Machinery and equipment(b)1,801Â 2,180Â Assets not yet placed in service2,021Â 4,065Â 77,754Â 77,109Â Less accumulated depreciation(45,816) (40,504)$31,938Â $36,605Â (a)Furniture and fixtures of $51 and accumulated depreciation of $31 attributable to the Companyâ€™s advanced rehabilitation business were reclassified to assets held for sale within the JuneÂ 29, 2024 consolidated condensed balance sheets. Refer to Note 3. Acquisitions and divestitures for further details regarding assets held for sale.(b)Machinery and equipment of $385 and accumulated depreciation of $133 attributable to the Companyâ€™s advanced rehabilitation business were reclassified to assets held for sale within the JuneÂ 29, 2024 consolidated condensed balance sheets. Refer to Note 3. Acquisitions and divestitures for further details regarding assets held for sale.7Table of ContentsIntangible assets, netIntangible assets consisted of the following as of:June 29, 2024December 31, 2023Intellectual property(a)(b)$626,007Â $677,258Â Distribution rights61,325Â 61,325Â Customer relationships57,950Â 57,950Â IPR&D5,500Â 5,500Â Developed technology and other13,998Â 13,998Â Total carrying amount764,780Â 816,031Â Less accumulated amortization:Intellectual property(a)(b)(221,261)(218,031)Distribution rights(51,790)(49,301)Customer relationships(57,950)(57,950)Developed technology and other(8,004)(7,521)Total accumulated amortization(339,005)(332,803)Intangible assets, net before currency translation425,775Â 483,228Â Currency translation(1,223)(878)$424,552Â $482,350Â (a)Intellectual property of $19,380 and accumulated amortization of $16,656 attributable to the Companyâ€™s advanced rehabilitation business were reclassified to assets held for sale within the JuneÂ 29, 2024 consolidated condensed balance sheets. Refer to Note 3.Acquisitions and divestitures for further details regarding assets held for sale.(b)The Company recorded an impairment loss of $31,870 for the three and six months ended JuneÂ 29, 2024 in the U.S. reporting segment of net intellectual property solely attributable to the Companyâ€™s advanced rehabilitation business. The loss was recorded in impairment of assets within the consolidated condensed statements of operations and comprehensive loss. Refer to Refer to Note 3. Acquisitions and divestitures for further details regarding businesses held for sale.Estimated amortization expense for intangibles subsequent to reclassifications, impairment and additions for the remainder of 2024 and for the years ended December 31, 2025 through 2028 is expected to be $19,629, $37,412, $34,192, $35,243 and $31,012, respectively.Accrued liabilitiesAccrued liabilities consisted of the following as of:June 29, 2024December 31, 2023Gross-to-net deductions$68,349Â $59,592Â Bonus and commission19,987Â 19,437Â Settlement and legal fees17,737Â 986Â Compensation and benefits9,081Â 9,709Â Accrued interest6,185Â 6,606Â Income and other taxes4,883Â 4,749Â Other liabilities(a)13,756Â 18,716Â $139,978Â $119,795Â (a)Accrued liabilities of $3,110 attributable to the Companyâ€™s advanced rehabilitation business were reclassified to liabilities held for sale within the JuneÂ 29, 2024 consolidated condensed balance sheets. Refer to Note 3. Acquisitions and divestitures for further details regarding assets held for sale.8Table of Contents3. Acquisitions and divestituresAdvanced Rehabilitation BusinessIn May 2024, the Company began contract negotiations with a third-party (the â€œBuyerâ€) to sell certain products within its advanced rehabilitation business, including the L100, L300 Go, L360, H200, Vector Gait & Safety System and BITS-Bioness Integrated Therapy System (collectively, the â€œAdvanced Rehabilitation Businessâ€). The Advanced Rehabilitation Business is considered non-core and will require additional research and development expenditures to achieve its next stage of growth. The potential divestiture of the Advanced Rehabilitation Business is expected to simplify the Companyâ€™s business structure and improve liquidity, as the proceeds, net of transactional fees, are required to be used to reduce long-term debt obligations. Contract negotiations are ongoing with the Buyer and as of the end of the second quarter of 2024, the Company had incurred $2,500 in transactional fees resulting from the potential divestiture of the Advanced Rehabilitation Business. The Company has classified the identifiable net assets of the Advanced Rehabilitation Business as held for sale. A significant portion of the Advanced Rehabilitation Business net assets were within the U.S. reporting segment. Assets and liabilities determined to be part of the Advanced Rehabilitation Business have been recorded as single amounts within the Companyâ€™s consolidated financial statements. Assets held for sale are reported at the lower of the carrying amount or fair value less costs to sell, which is expected to occur within one year. The Company has ceased depreciating and amortizing the assets classified as held for sale. Assets and liabilities held for sale are reviewed each reporting period to determine whether existing carrying values are fully recoverable in comparison to estimated fair values less costs to sell.The Company evaluated the Advanced Rehabilitation Business for impairment due to its potential divestiture and, as a result of this evaluation, recorded a $31,870 impairment under the U.S. reporting segment within the consolidated condensed statements of operations and comprehensive loss during the three and six months ended JuneÂ 29, 2024 to reduce the intangible assets of the Advanced Rehabilitation Business to reflect their respective fair values less any

costs to sell. The fair value of its intangibles was based on the preliminary consideration offered for the Advanced Rehabilitation Business.The carrying amounts for the major classes of assets and liabilities of the Advanced Rehabilitation Business classified as held for sale were as follows:June 29, 2024Carrying amounts of assets classified as held for sale:Accounts receivable$7,688Â Inventory14,373Â Prepaid and other current assets1,930Â Property and equipment, net272Â Intangible assets2,724Â Operating lease assets1,171Â Other assets250Â Total assets held for sale$28,408Â Carrying amounts of liabilities classified as held for sale:Accounts payable$1,566Â Accrued liabilities3,110Â Other liabilities1,232Â Total liabilities held for sale$5,908Â Wound BusinessOn May 22, 2023, the Company closed the sale of certain assets within its Wound Business, including the TheraSkin and TheraGenesis products (collectively, the â€œWound Businessâ€), for potential consideration of $84,675, including $34,675 at closing, $5,000 deferred for 18 months and up to $45,000 in potential earn-out payments, which are based on the achievement of certain revenue thresholds by the purchaser of the Wound Business for sales of the TheraSkin and TheraGenesis products during the 2024, 2025 and 2026 fiscal years.The Company incurred $3,880 in transactional fees resulting from the sale of the Wound Business. The Company used the proceeds from the sale of its Wound Business to prepay $30,000 of long-term debt obligations. Refer to Note 4. Financial Instruments for further details regarding the Companyâ€™s outstanding long-term debt obligations.9Table of ContentsThe Company evaluated the Wound Business for impairment prior to its sale and recorded a $78,615 impairment within the consolidated condensed statements of operations and comprehensive loss during the six months ended JulyÂ 1, 2023 as a result of this evaluation to reduce the intangible assets of the Wound Business to reflect their respective fair values less any costs to sell. The fair value of its intangibles was determined based on the consideration received for the Wound Business. The loss resulting from the deconsolidation of the Wound Business totaled $977 for the three and six months ended JulyÂ 1, 2023 and was recorded in loss on disposals within the consolidated condensed statements of operations and comprehensive loss.CartiHeal (2009) Ltd.On July 12, 2022, the Company completed the acquisition of 100% of the remaining shares in CartiHeal (2009) Ltd. (â€œCartiHealâ€), a developer of the proprietary Agili-C implant for the treatment of joint surface lesions in traumatic and osteoarthritic joints. On February 27, 2023, the Company entered into a settlement agreement (the â€œSettlement Agreementâ€) with Elron Ventures Ltd. (â€œElronâ€), as representative of CartiHealâ€™s former securityholders (the â€œFormer Securityholdersâ€). Pursuant to the Settlement Agreement, Elron, on behalf of the Former Securityholders, agreed to forbear from initiating any legal action or proceedings related to non-payment of any obligations including deferred purchase price and contingent consideration totaling $215,000 and $135,000, respectively, under the Companyâ€™s previous agreements to purchase CartiHeal from the Former Securityholders. Pursuant to the Settlement Agreement, the Company also transferred 100% of its shares in CartiHeal to a trustee (the â€œTrusteeâ€) for the benefit of the Former Securityholders and made a one-time non-refundable payment of $10,150 to Elron to be used for purposes set forth in the Settlement Agreement. Given that upon execution of the Settlement Agreement, the Company had no ownership interest or voting rights in CartiHeal, the Company concluded that it had ceased to control CartiHeal for accounting purposes, and therefore, deconsolidated CartiHeal effective February 27, 2023. CartiHeal was part of the Companyâ€™s international reporting segment and the Company treated the deconsolidation of CartiHeal as a discontinued operation. The loss on disposal was $60,639 and was recorded within discontinued operations, net of tax within the consolidated condensed statements of operations and comprehensive loss for the six months ended JulyÂ 1, 2023. Refer to Note 14. Discontinued operations for further information regarding the impact of CartiHeal on the Companyâ€™s consolidated condensed financial statements for the six months ended JulyÂ 1, 2023.4. Financial instrumentsLong-term debt consisted of the following as of:June 29, 2024December 31, 2023Amended Term Loan due October 2026 (9.34% at JuneÂ 29, 2024)$371,128Â $382,448Â Revolver due October 2025 (9.34% at JuneÂ 29, 2024)15,000Â 15,000Â Less:Current portion of long-term debt(38,566)(27,848)Unamortized debt issuance cost(1,459)(917)Unamortized discount(1,387)(1,685)$344,716Â $366,998Â Amended Term LoanOn December 6, 2019, the Company entered into a Credit and Guaranty Agreement (the â€œ2019 Credit Agreementâ€) that was comprised of a $200,000 term loan (the â€œOriginal Term Loanâ€) and a $50,000 revolving facility (the â€œRevolverâ€). The Company amended the 2019 Credit Agreement on August 29, 2021, and then again on October 29, 2021 in connection with the acquisition of Misonix, Inc., in which the Company prepaid $80,000 on the Original Term Loan. The 2019 Credit Agreement, as amended, subsequent to the prepayment, was comprised of a $360,750 term loan (â€œTerm Loanâ€) and the Revolver.On July 11, 2022, the Company further amended the 2019 Credit Agreement in conjunction with the acquisition of CartiHeal (the â€œCartiHeal Acquisitionâ€). Pursuant to that amendment, an $80,000 term loan facility (the â€œJuly 2022 Term Loanâ€ and, together with the Term Loan, the â€œTerm Loan Facilitiesâ€) was extended to the Company to be used for: (i) the financing of the CartiHeal Acquisition; (ii) the payment of related fees and expenses; (iii) repayment of the draws made on the Revolver; and (iv) working capital needs and general corporate purposes of the Company, including without limitation for permitted acquisitions.On March 31, 2023, the Company entered into an additional amendment to the 2019 Credit Agreement to, among other things, modify certain financial covenants, waive covenant noncompliance at December 31, 2022, and to modify interest rates applicable to borrowings under the 2019 Credit Agreement.10Table of ContentsOn January 18, 2024 (the â€œClosing Dateâ€), the Company further amended the 2019 Credit Agreement (collectively, with the August 2021, October 2021, July 2022 and March 2023 amendments, the â€œAmended 2019 Credit Agreementâ€), to further modify certain financial covenants under the 2019 Credit Agreement. The Company was in compliance as of June 29, 2024 with the financial covenants as stated within the 2019 Credit Agreement.SOFR loans and base rate loans had a margin of 3.25% and 2.25%, respectively, subsequent to July 11, 2022 and prior to the Closing Date. As of the March 31, 2023 amendment, SOFR loans and base rate loans had a margin of 4.25% and 3.25%, respectively. All obligations under the Amended 2019 Credit Agreement are guaranteed by the Company and certain wholly owned subsidiaries where substantially all the assets of the Company collateralize the obligations.The Amended 2019 Credit Agreement contains customary affirmative and negative covenants, including those related to financial reporting and notification, restrictions on the declaration or payment of certain distributions on or in respect of Bioventus LLCâ€™s equity interests, restrictions on acquisitions, investments and certain other payments, limitations on the incurrence of new indebtedness, limitations on transfers, sales and other dispositions of assets of Bioventus LLC and its subsidiaries, as well as limitations on making changes to the business and organizational documents of Bioventus LLC and its subsidiaries. Financial covenant requirements include a maximum debt leverage ratio and an interest coverage ratio. In addition, during the period commencing on the Closing Date and ending upon the satisfaction of certain conditions occurring not prior to the delivery of financial statements of the Company for the fiscal quarter ending October 29, 2025, the Company will be subject to certain additional requirements and covenants, including a requirement to maintain Liquidity (as defined in the Amended 2019 Credit Agreement) of not less than $10,000 as of the end of each calendar month during such period. The Term Loan Facilities will mature on October 29, 2026. The Revolver will mature on October 29, 2025.The January 2024 amendment had deferred financing costs of $1,180, of which $325 was recorded in selling, general and administrative expense within the consolidated condensed statements of operations and comprehensive loss and $855 was capitalized on the consolidated condensed balance sheets during the six months ended JuneÂ 29, 2024. The March 2023 amendment had deferred financing costs of $3,661, of which $1,617 was recorded in selling, general and administrative expense within the consolidated condensed statements of operations and comprehensive loss and $2,044 was capitalized on the consolidated condensed balance sheets during the six months ended JulyÂ 1, 2023. There were no losses on debt refinancing and modification as a result of either the January 2024 or March 2023 amendments.As of JuneÂ 29, 2024, $368,282 was outstanding on the Term Loan Facilities, net of original issue discount of $1,387 and deferred financing costs of $1,459. As previously discussed in Note 3. Acquisitions and divestitures, the Company made a prepayment of $30,000 on its Term Loan Facilities with the proceeds from the Wound Business divestiture during the second quarter of 2023. Capitalized deferred fees are amortized to interest expense on a straight-line basis over the term of the Term Loan Facilities, which approximates the effective interest method. Interest expense includes deferred cost amortization of $381, $915, $762 and $1,138 for the three months JuneÂ 29, 2024 and JulyÂ 1, 2023 and the six months ended JuneÂ 29, 2024 and JulyÂ 1, 2023, respectively. The estimated fair value of the Term Loan Facilities was $370,664 as of JuneÂ 29, 2024. The fair value of these obligations was determined based on the midpoint of the Bloomberg Valuation. This is classified as a Level 2 instrument within the fair value hierarchy.Revolver and Letters of CreditThe Revolver is a five-year revolving credit facility that includes revolving and swingline loans as well as letters of credit (â€œLOCâ€) and, inclusive of all, could not exceed $45,000 at any one time as the Revolver capacity was reduced by $5,000 at December 31, 2023 in accordance with the 2019 Credit Agreement then in effect. The Revolver was further reduced by $5,000 at June 30, 2024, limiting borrowing capacity to $40,000. The Company had $15,000 outstanding borrowings on its Revolver as of JuneÂ 29, 2024 and DecemberÂ 31, 2023. LOCs are available in an amount not to exceed $7,500. The Company had two LOCs outstanding as of JuneÂ 29, 2024, leaving approximately $5,800 available. Revolving loans are due at the earlier of termination or maturity. Swingline loans are available as base rate option loans only and must be outstanding for at least five days. Swingline loans are due the fifteenth or last day of a calendar month or maturity, whichever is earlier.5. Fair value measurementsThe process for determining fair value has not changed from that described in the Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023.11Table of ContentsThere were no assets measured at fair value on a recurring basis and there were no liabilities valued at fair value using Level 1 or Level 2 inputs. The following table provides information for assets and liabilities measured at fair value on a recurring basis using Level 3 inputs:June 29, 2024December 31, 2023TotalLevel 3TotalLevel 3Liabilities:Current portion of contingent consideration$18,745Â $18,745Â $â€”Â $â€”Â Contingent considerationâ€”Â â€”Â 18,150Â 18,150Â Total liabilities:$â€”Â $â€”Â $18,150Â $18,150Â Contingent considerationThe Company initially values contingent consideration related to business combinations using a probability-weighted calculation of potential payment scenarios discounted at rates reflective of the risks associated with the expected future cash flows for certain milestones. For other milestones, the Company used a variation of the income approach where revenue was simulated in a risk-neutral framework using Geometric Brownian Motion, a stock price behavior model.Key assumptions used to estimate the fair value of contingent consideration include projected financial information, market data and the probability and timing of achieving the specific targets. After the initial valuation, the Company generally uses its best estimate to measure contingent consideration at each subsequent reporting period using unobservable Level 3 inputs.Unobservable inputsA summary of unobservable Level 3 inputs utilized for the above liabilities are as follows:Valuation TechniqueUnobservable inputsRangeBioness contingent considerationDiscounted cash flowPayment discount rate6.4% - 6.8%Payment period2024 - 2025Significant changes in these assumptions could result in a significantly higher or lower fair value. The contingent consideration reported in the table above resulted from the acquisition of Bioness on March 30, 2021. Contingent consideration is adjusted quarterly based upon the passage of time or the anticipated success or failure of achieving certain milestones. Changes in contingent consideration related to Bioness for the three months ended JuneÂ 29, 2024 and JulyÂ 1, 2023 and six months ended JuneÂ 29, 2024 and JulyÂ 1, 2023 totaled $300, $240, $595 and $527, respectively, and were recorded as the change in fair value of contingent consideration within the consolidated condensed statements of operations and comprehensive loss.6. Equity-based compensation2021 PlanThe Company operates an equity-based compensation plan (the â€œ2021 Planâ€), which allows for the issuance of stock options (incentive and nonqualified), restricted stock, dividend equivalents, restricted stock units (â€œRSUsâ€), other stock-based awards, and cash awards (collectively, the â€œ2021 Plan Awardsâ€). As of JuneÂ 29, 2024, 19,564,333 shares of Class A common stock have been authorized to be awarded under the 2021 Plan and 8,921,686 shares were available for 2021 Plan Awards.2023 PlanThe Company also operates the 2023 Retention Equity Award Plan (the â€œ2023 Planâ€ and, together with the 2021 Plan, the â€œPlansâ€), the purpose of which is to retain and motivate critical personnel over the short-term by providing them additional incentives in the form of RSUs (the â€œRetention Awardsâ€ and together with the â€œ2021 Plan Awards,â€ the â€œAwardsâ€). As of JuneÂ 29, 2024, 600,000 shares of Class A common stock were authorized to be awarded under the 2023 Plan and 84,700 shares were available for Retention Awards.12Table of ContentsActivity under the PlansExpenseEquity-based compensation, net for Awards granted under the Plans for the three and six months ended JuneÂ 29, 2024 totaled $3,457 and $6,048, respectively. Equity-based compensation, net for Awards granted under the Plans for the three and six months ended JulyÂ 1, 2023 totaled $2,797 and $1,079, respectively, in expense reduction as a result of expense reversals due to executive leadership transitions. Expenses and expense reductions are primarily included in selling, general and administrative expense with a nominal amount in research and development expense within the consolidated condensed statements of operations and comprehensive loss based upon the department of the employee. There were no income tax benefits related to equity-based compensation expense for the three and six months ended JuneÂ 29, 2024 and JulyÂ 1, 2023.Restricted Stock UnitsDuring the three and six months ended JuneÂ 29, 2024, the Company granted time-based RSUs which vest at various dates through MarchÂ 15, 2028. RSU compensation expense is recognized over the vesting period, which is typically between 1 and 4 years. Unamortized compensation expense related to the RSUs totaled $7,091 at JuneÂ 29, 2024, and is expected to be recognized over a weighted average period of approximately 2.40 years. A summary of the RSU award activity for the six months ended JuneÂ 29, 2024 is as follows (number of units in thousands):Number of unitsWeighted-average grant-date fair value per unitUnvested at December 31, 20232,066Â $4.51Â Granted2,429Â 5.45Â Vested(1,550)4.56Â Forfeited or canceled(105)7.33Â Unvested at June 29, 20242,840Â $5.12Â Stock OptionsDuring the three and six months ended JuneÂ 29, 2024, the Company granted time-based stock options which vest over 1 to 4 years following the date of grant and expire within 10 years. The fair value of time-based stock options is determined using the Black-Scholes valuation model, with such value recognized as expense over the service period, which is typically 1 to 4 years, net of actual forfeitures. A summary of the Companyâ€™s assumptions used in determining the fair value of the stock options granted during the six months ended JuneÂ 29, 2024 is shown in the following table:Risk-free interest rate3.9% - 4.3%Expected dividend yieldâ€”Â %Expected stock price volatility36.1% - 36.4%Expected life of stock options (years)6.25The weighted-average grant date fair value of options granted during the six months ended JuneÂ 29, 2024 was $2.25 per share. The expected term of the options granted is estimated using the simplified method. Expected volatility is based on the historical volatility of the Companyâ€™s peersâ€™ common stock. The risk-free interest rate is determined based upon a constant U.S. Treasury security rate with a contractual life that approximates the expected term of the option. Unamortized compensation expense related to the options totaled $4,342 at JuneÂ 29, 2024, and is expected to be recognized over a weighted average period of approximately 2.86 years. A summary of stock option activity is as follows for the six months ended JuneÂ 29, 2024 (number of options in thousands):Number of optionsWeighted-average exercise priceWeighted average remaining contractual termAggregate intrinsic valueOutstanding at December 31, 20234,347Â $8.68Â Granted1,763Â 5.18Â Exercised(229)5.21Â Forfeited or canceled(747)10.51Â Outstanding at June 29, 20245,134Â 7.53Â 7.66$4,968Â Exercisable and vested at June 29, 20241,982Â $9.95Â 5.57$855Â 13Table of ContentsThe aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the market price of the Companyâ€™s Class A common stock for options that had exercise prices lower than $5.75 per share as this was the closing price of the Companyâ€™s Class A common stock on JuneÂ 28, 2024, the last trading day of the second quarter.Employee Stock Purchase PlanThe Company operates a non-qualified Employee Stock Purchase Plan (â€œESPPâ€), which provides for the issuance of shares of the Companyâ€™s Class A common stock to eligible employees of the Company that elect to participate in the plan and purchase shares of Class A common stock through payroll deductions at a discounted price. As of JuneÂ 29, 2024, the aggregate number of shares reserved for issuance under the ESPP was 1,393,982. A total of 125,622 shares were issued under the ESPP and $215 of expense was recognized during the three and six months ended JuneÂ 29, 2024. A total of 144,851 and 366,927 shares were issued under the ESPP and $65 and $193 of expense was recognized during the three and six months ended JulyÂ 1, 2023, respectively.7. Stockholdersâ€™ equityOn February 16, 2021, the Company closed an IPO of 9,200,000 shares of Class A common stock through an UP-C structure with BV LLC. In connection with the IPO, the Company amended and restated the limited liability agreement of BV LLC (â€œBV LLC Agreementâ€) to provide for a new single class of common membership interests in BV LLC (â€œLLC Interestsâ€) and exchange all of the existing membership interests in BV LLC (the â€œOriginal BV LLC Ownersâ€) for new LLC Interests. The Company also amended its certificate of incorporation to authorize the following shares: (i) 250,000,000 shares of Class A common stock with a par value of $0.001 per share; (ii) 50,000,000 shares of Class B common stock with a par value of $0.001 per share, which have voting rights but no economic interest, and some of which were issued to the Original BV LLC Owners; and (iii) 10,000,000 shares of undesignated preferred stock that may be issued from time to time by the Companyâ€™s board of directors. In connection with the completion of the IPO, the Company acquired, by merger, certain entities that were part of the Original BV LLC Owners (â€œFormer BV LLC Ownersâ€), for which the Company issued 31,838,589 Class A common stock as merger consideration (â€œIPO Mergersâ€) and cancelled the Class B common stock held by such Former BV LLC Owners. The IPO Mergers are deemed to be a recapitalization transaction.Holders of the Companyâ€™s Class A and Class B common stock are entitled to one vote per share and, except as otherwise required, will vote together as a single class on all matters on which stockholders generally are entitled to vote. Holders of Class B common stock are not entitled to receive dividends and will not be entitled to receive any distributions upon the liquidation, dissolution or winding up of the Company. Shares of Class B common stock may only be issued to the extent necessary to maintain the one-to-one ratio between the number of LLC Interests and the number of shares of Class B common stock held by Smith & Nephew, Inc. (the â€œContinuing LLC Ownerâ€). Shares of Class B common stock are transferable only together with an equal number of LLC Interests. Shares of Class B common stock will be canceled on a one-for-one basis upon the redemption or exchange

of any outstanding LLC Interests.Noncontrolling interestIn connection with any redemption pursuant to the BV LLC Agreement, the Company will receive a corresponding number of LLC Interests, increasing its ownership interest in BV LLC. Future redemptions of LLC Interests will result in a change in ownership and reduce the amount recorded as noncontrolling interest and increase additional paid-in capital. There were no redemptions during the six months ended June 29, 2024 or during the year ended DecemberÂ 31, 2023. The following table summarizes the ownership interest in BV LLC as of JuneÂ 29, 2024 and DecemberÂ 31, 2023 (number of units in thousands):June 29, 2024December 31, 2023LLC InterestsOwnership %LLC InterestsOwnership %Number of LLC Interests ownedBioventus Inc.65,172Â 80.5Â %63,267Â 80.0Â %Continuing LLC Owner15,787Â 19.5Â %15,787Â 20.0Â %Total80,959Â 100.0Â %79,054Â 100.0Â %14Table of Contents8. Earnings per shareThe following table sets forth the computation of basic and diluted loss per share of Class A common stock for the periods presented (amounts in thousands, except share and per share data):Three Months EndedSix Months EndedJune 29, 2024July 1, 2023June 29, 2024July 1, 2023Numerator:Net loss from continuing operations, net of tax$(32,112)$(4,731)$(38,094)$(104,749)Net loss attributable to noncontrolling interests â€” Â Â Â Â continuing operations8,120Â 1,050Â 9,532Â 21,410Â Net loss attributable to Bioventus Inc. Class A Â Â Â Â common stockholders â€” continuing operations$(23,992)$(3,681)$(28,562)$(83,339)Numerator:Net loss from discontinued operations, net of tax$â€”Â $â€”Â $â€”Â $(74,429)Net loss attributable to noncontrolling interests â€” Â Â Â Â discontinued operationsâ€”Â â€”Â â€”Â 14,937Â Net loss attributable to Bioventus Inc. Class A Â Â Â Â common stockholders â€” discontinued operations$â€”Â $â€”Â $â€”Â $(59,492)Denominator:Weighted-average shares of Class A common stock Â Â Â Â outstandingâ€”basic and diluted64,056,759Â 62,551,285Â 63,720,342Â 62,338,018Â Net loss per share of Class A common stock from Â Â Â Â continuing operations, basic and diluted(0.37)(0.06)(0.45)(1.34)Net loss per share of Class A common stock from Â Â Â Â discontinued operations, basic and dilutedâ€”Â â€”Â â€”Â (0.95)Net loss per share of Class A common stock, Â Â Â Â basic and diluted(0.37)(0.06)(0.45)(2.29)Shares of Class B common stock do not share in the losses of the Company and are therefore not participating securities. As such, separate presentation of basic and diluted losses per share of Class B common stock under the two-class method has not been presented.The following number of weighted-average potentially dilutive shares as of JuneÂ 29, 2024 and JulyÂ 1, 2023 were excluded from the calculation of diluted loss per share because the effect of including such potentially dilutive shares would have been antidilutive upon conversion:Three Months EndedSix Months EndedJune 29, 2024July 1, 2023June 29, 2024July 1, 2023LLC Interests held by Continuing LLC Owner(a)15,786,737Â 15,786,737Â 15,786,737Â 15,786,737Â 15,786,737Â Stock options4,208,043Â 6,730,685Â 4,177,250Â 7,623,865Â RSUs49,784Â 766,427Â 25,029Â 974,238Â Total20,044,564Â 23,283,849Â 19,989,016Â 24,384,840Â (a)Class A Shares reserved for future issuance upon redemption or exchange of LLC Interests by the Continuing LLC Owner.9. Restructuring costsRestructuring costs are not allocated to the Companyâ€™s reportable segments as they are not part of the segment performance measures regularly reviewed by management. These charges are included in restructuring costs in the consolidated statements of operations and comprehensive loss. Liabilities associated from restructuring costs are recorded in accrued liabilities on the consolidated balance sheets.15Table of ContentsThe Companyâ€™s prior restructuring plans adopted in 2021 and 2022 focused on aligning its organizational and management cost structure to improve profitability and cash flow, reduce headcount and the consolidation of facilities. These plans have been completed. There were no restructuring expenses incurred during the three and six months ended JuneÂ 29, 2024. Restructuring expenses incurred during three and six months ended JulyÂ 1, 2023 totaled $620 and $937, respectively. Payments for restructuring liabilities during the six months ended JuneÂ 29, 2024 and JulyÂ 1, 2023 totaled $961 and $3,085, respectively.10. Income taxesThe tax provision for interim periods is determined using an estimate of the Companyâ€™s annual effective tax rate, adjusted for discrete items, if any, that arise during the period. Each quarter, the Company updates its estimate of its annual effective tax rate, and if the estimated annual effective tax rate changes, the Company makes a cumulative adjustment in such period. The quarterly tax provision, and estimate of the Companyâ€™s annual effective tax rate, are subject to variation due to several factors, including variability in pre-tax income (or loss), the mix of jurisdictions to which such income relates, changes in how the Company conducts business, and tax law developments.For the three and six months ended JuneÂ 29, 2024 and JulyÂ 1, 2023, the Companyâ€™s effective tax rate was 18.6%, 8.8%, and 14.4% and 0.2%, respectively. The change in rate for the three and six months ended JuneÂ 29, 2024 compared to the prior year comparable period was primarily due to losses in certain entities.Tax Receivable AgreementThe Company expects to obtain an increase in the share of the tax basis of the assets of BV LLC when LLC Interests are redeemed or exchanged by the Continuing LLC Owner and other qualifying transactions. This increase in tax basis may have the effect of reducing the amounts that the Company would otherwise pay in the future to various tax authorities. The increase in tax basis may also decrease gains (or increase losses) on future dispositions of certain capital assets to the extent tax basis is allocated to those capital assets. On February 16, 2021, the Company entered into a tax receivable agreement (â€œTRAâ€) with the Continuing LLC Owner that provides for the payment by the Company to the Continuing LLC Owner of 85% of the amount of tax benefits, if any, that the Company actually realizes as a result of (i) increases in the tax basis of assets of BV LLC resulting from any redemptions or exchanges of LLC Interests or any prior sales of interests in BV LLC; and (ii) certain other tax benefits related to our making payments under the TRA.The Company maintains a full valuation allowance against deferred tax assets related to the tax attributes generated as a result of redemptions of LLC Interests or exchanges described above until it is determined that the benefits are more-likely-than-not to be realized. Subsequent to the consummation of the IPO Mergers, the Continuing LLC Owner has not exchanged LLC Interests for shares of Class A common stock.11. Commitments and contingenciesLeasesThe Company leases its office facilities as well as other property, vehicles and equipment under operating leases. The Company also leases certain office equipment under nominal finance leases. The remaining lease terms range from 1 month to 8.8 years.The components of lease cost were as follows:Three Months EndedSix Months EndedJune 29, 2024July 1, 2023June 29, 2024July 1, 2023Operating lease cost$938Â $1,010Â $1,826Â $2,079Â Short-term lease cost(a)326Â 229Â 406Â 435Â Financing lease cost:Amortization of finance lease assets174Â 393Â 332Â 628Â Interest on lease liabilities217Â 229Â 438Â 366Â Total lease cost$1,655Â $1,861Â $3,002Â $3,508Â (a)Includes variable lease cost and sublease income, which are immaterial.16Table of ContentsSupplemental cash flow information and non-cash activity related to leases were as follows:Six Months EndedJune 29, 2024July 1, 2023Cash paid for amounts included in measurement of lease liabilities:Operating cash flows from operating leases$2,319Â $2,227Â Operating cash flows from financing leases$438Â $337Â Financing cash flows from finance leases$373Â $175Â Right-of-use assets obtained in exchange for lease obligations:Operating lease obligations$132Â $254Â Financing lease obligations$â€”Â $15,567Â Supplemental balance sheet and other information related to leases were as follows:June 29, 2024December 31, 2023Operating lease assets(a)$10,366$13,353Operating lease liabilitiesâ€”current(b)$3,038$4,057Operating lease liabilitiesâ€”noncurrent(b)8,46910,573Total operating lease liabilities$11,507$14,630Property, plant and equipment, net (finance leases)$13,491$14,279Finance lease liabilitiesâ€”current$791$759Finance lease liabilitiesâ€”noncurrent9,98110,386Total financing lease liabilities$10,772$11,145Weighted average remaining lease term (years) for leasesOperating leases3.43.8Finance leases8.89.3Weighted average discount rate for leasesOperating leases4.8Â %4.7Â %Finance leases8.1Â %8.1Â %(a)Operating lease assets totaling $1,171 attributable to the Advanced Rehabilitation Business were reclassified to assets held for sale within the JuneÂ 29, 2024 consolidated condensed balance sheets. Refer to Note 3. Acquisitions and divestitures for further details regarding assets held for sale.(b)Current and noncurrent operating lease liabilities of $983 and $249, respectively, were reclassified to liabilities held for sale within the JuneÂ 29, 2024 consolidated condensed balance sheets. Refer to Note 3. Acquisitions and divestitures for further details regarding assets held for sale.Governmental and legal contingenciesIn the normal course of business, the Company periodically becomes involved in various claims and lawsuits, and governmental proceedings and investigations that are incidental to its business. The Company accrues a liability when a loss is considered probable and the amount can be reasonably estimated. When a material loss contingency is reasonably possible but not probable, the Company does not record a liability, but instead discloses the nature and amount of the claim, and an estimate of the possible loss or range of loss, if such an estimate can be made. Legal fees are expensed as incurred. With respect to governmental proceedings and investigations, like other companies in the industry, the Company is subject to extensive regulation by national, state and local governmental agencies in the United States and in other jurisdictions in which the Company and its affiliates operate. As a result, interaction with governmental agencies is ongoing. The Companyâ€™s standard practice is to cooperate with regulators and investigators in responding to inquiries.17Table of ContentsThe Company is presently unable to predict the duration, scope, or result of these matters. As such, the Company is presently unable to develop a reasonable estimate of a possible loss or range of losses, if any, related to these matters. While the Company intends to defend these matters vigorously, the outcome of such litigation or any other litigation is necessarily uncertain, is not within the Companyâ€™s complete control and might not be known for extended periods of time. In the opinion of management, the outcome of any existing claims and legal or regulatory proceedings, other than the specific matters described below, if decided adversely, is not expected to have a material adverse effect on the Companyâ€™s business, financial condition, results of operations, or cash flows.Bioventus shareholder litigationOn January 12, 2023, the Company and certain of its current and former directors and officers were named as defendants in a putative class action lawsuit filed in the Middle District of North Carolina (the â€œCourtâ€), Ciarciello v. Bioventus, Inc., No. 1:23â€“ CV â€“ 00032-CCE-JEP (M.D.N.C. 2023). The complaint asserted violations of Sections 10(b) and 20(a) of the Exchange Act and of Sections 11 and 15 of the Securities Act and generally alleges that the Company failed to disclose certain information regarding rebate practices, its business and financial prospects, and the sufficiency of internal controls regarding financial reporting. The complaint seeks damages in an unspecified amount. On April 12, 2023, the Court appointed Wayne County Employeesâ€™ Retirement System as lead plaintiff. The plaintiffâ€™s amended consolidated complaint was filed with the Court on June 12, 2023. On July 17, 2023, the defendants filed a motion to dismiss the complaint raising a number of legal and factual deficiencies with the amended consolidated complaint. In response to the defendantsâ€™ motion to dismiss, the lead plaintiff filed a second amended complaint on July 31, 2023. The defendants moved to dismiss the second amended complaint on August 21, 2023, which the Court granted in part and denied in part on November 6, 2023. The Court dismissed the plaintiffâ€™s Securities Act claims, but allowed the plaintiffâ€™s Exchange Act claims to proceed into discovery.On July 15, 2024, a Stipulation and Agreement of Settlement (the â€œSettlement Agreementâ€) by and between the lead plaintiff and the defendants was filed with the Court. The Settlement Agreement, which is subject to Court approval, provides among other things for (i) the dismissal of all claims against the defendants, including the Company; (ii) a settlement amount of $15,250, together with interest earned thereon, to be paid by the defendants and/or the defendantâ€™s insurers within 30 days after the later of (x) the date of entry by the Court of an order preliminarily approving the terms of the settlement or (y) receipt by the defendants from lead counsel of the information necessary to effectuate a transfer of the settlement funds; and (iii) no admission of liability or wrongdoing by any party. The Company incurred $12,502 and $13,670 of net shareholder litigation costs (including estimated settlement and reimbursement) during the three and six months ended JuneÂ 29, 2024 under the Settlement Agreement, which were recorded in selling, general and administrative expense within the consolidated condensed statements of operations and comprehensive loss. The Company expects to be reimbursed approximately $6,500 of the fees incurred to date, which was recorded in other current assets within the JuneÂ 29, 2024 consolidated condensed balance sheets.On October 4, 2023, certain of the Companyâ€™s current and former directors and officers were named as defendants in a derivative shareholder lawsuit (in which the Company is a nominal defendant) filed in the United States District Court for the District of Delaware, Grogan, on behalf of Bioventus Inc., v. Reali, et.al., No. 1:23-CV-01099-RGA (D. Del. 2023). The complaint asserts violations of Section 14(a) of the Exchange Act, breaches of fiduciary duties and related state law claims, and a claim for contribution, and generally alleges the same purported misconduct as alleged in the Ciarciello case. On January 12, 2024, the Court agreed to stay this case pending resolution of the Ciarciello case. The Company may incur further legal costs until settlement is ultimately approved and executed by the Court.On February 9, 2024, another plaintiff filed a derivative shareholder lawsuit against certain of the Companyâ€™s current and former directors and officers (in which the Company is a nominal defendant) filed in the United States District Court for the District of Delaware, Sanderson, on behalf of Bioventus Inc., v. Reali, et.al., No. 1:24-cv-00180-RGA (D. Del. 2024). Like the Grogan case, this case asserts violations of Section 10(b) of the Exchange Act, breaches of fiduciary duties and related state law claims, and a claim for contribution, and generally alleges the same purported misconduct as alleged in the Ciarciello case. On May 1, 2024, the parties filed a stipulation to consolidate the two derivative matters and stay them on terms similar to those entered in the Grogan case. On May 2, 2024, the United States District Court for the District of Delaware granted the stipulation and ordered the consolidation of the Sanderson and Grogan cases (as consolidated, the â€œGrogan Caseâ€).The Company believes the claims alleged in the Grogan Case lacks merit and intends to defend itself vigorously. The outcome of this matter is not presently determinable, and any loss is neither probable nor reasonably estimable.18Table of ContentsBioness stockholder litigationOn February 8, 2022, a minority shareholder of Bioness filed an action in the Delaware State Court of Chancery in connection with the Companyâ€™s acquisition of Bioness, Teuza, a Fairchild Technology Venture Ltd. v. Lindon, et. al., No. 2022-0130 -SG. This action names the former Bioness directors, the Alfred E. Mann Trust (â€œTrustâ€), which was the former majority shareholder of Bioness, the trustees of the Trust and Bioventus as defendants. The complaint alleges, among other things, that the individual directors, the Trust, and the trustees breached their fiduciary duty to the plaintiff in connection with their consideration and approval of the Companyâ€™s transaction. The complaint also alleges that the Company aided and abetted the other defendants in breaching their fiduciary duties to the plaintiff and that the Company breached the Merger Agreement by failing to pay the plaintiff its pro rata share of the merger consideration. The Company believes that it is indemnified under the indemnification provisions contained in the Bioness Merger Agreement for these claims. On July 20, 2022, the Company filed a motion to dismiss all claims made against it on various grounds, as did all the other named defendants in the suit. A hearing on Bionessâ€™ and other the defendantâ€™s motions was held before the Court of Chancery on January 19, 2023. On April 27, 2023, the Court issued an order which, among other things, dismissed Bioventus from the case.Other mattersOn November 10, 2021, the Company entered into an asset purchase agreement for an HA product and made an upfront payment of $853. An additional payment of $853 was made in 2022 upon the transfer of certain seller customer data. If the Company is able to obtain a Medical Device Regulation Certification for the product, $1,707 (the â€œMilestone Paymentâ€) will be paid to the seller within five days. The Company is also required to pay royalties if certifications are achieved before December 31, 2024. Royalties will be payable through 2026 of 5.0% on the first $569 in sales and 2.5% thereafter. On March 8, 2023, the parties amended the agreement under which the Milestone Payment was reduced to $1,418, of which $709 was paid on January 31, 2024, and the remainder is due upon receipt of the Medical Device Regulation Certification for the product provided that it is obtained prior to December 31, 2024. As a result, the Company recorded an intellectual property intangible asset totaling $709 for initial payment.On August 23, 2019, the Company was assigned a third-party license on a product currently in development and the Company is subject to a 3% royalty on certain commercial sales, or a nominal minimum amount per quarter.On December 9, 2016, the Company entered into an amended and restated license agreement for the exclusive U.S. distribution and commercialization rights of a single injection osteoarthritis (â€œOAâ€) product with the supplier of the Companyâ€™s single injection OA product for the non-U.S. market. The agreement requires the Company to meet annual minimum purchase requirements and pay royalties on net sales. Royalties related to this agreement during the three months ended JuneÂ 29, 2024 and JulyÂ 1, 2023 and the six months ended JuneÂ 29, 2024 and JulyÂ 1, 2023 totaled $4,594 $4,119, $8,173 and $6,440, respectively. These royalties are included in cost of sales within the consolidated condensed statements of operations and comprehensive loss.As part of a supply agreement entered on February 9, 2016 for the Companyâ€™s three injection OA product, the Company is subject to annual minimum purchase requirements for 10 years. After the initial 10 years, the agreement will automatically renew for an additional 5 years unless terminated by the Company or the seller in accordance with the agreement.As part of a supply agreement for the Companyâ€™s five injection OA product that was amended and restated on December 22, 2020, the Company is subject to annual minimum purchase requirements for 8 years.From time to time, the Company causes LOCs to be issued to provide credit support for guarantees, contractual commitments and insurance policies. The fair values of the LOCs reflect the amount of the underlying obligation and are subject to fees payable to the issuers, competitively determined in the marketplace. As of JuneÂ 29, 2024 and DecemberÂ 31, 2023, the Company had two LOCs outstanding for $1,700.The Company currently maintains insurance for risks associated with the operation of its business, provision of professional services and ownership of property. These policies provide coverage for a variety of potential losses, including loss or damage to property, bodily injury, general commercial liability, professional errors and omissions and medical malpractice. The Company is self-insured for health insurance covering most of its employees located in the United States. The Company maintains stop-loss insurance on a â€œclaims madeâ€ basis for expenses in excess of $250 per member per year.19Table of Contents12. Revenue recognitionOur policies for recognizing sales have not changed from those described in the Companyâ€™s Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023. The Company attributes net sales to external customers to the U.S. and to all foreign countries based on the legal entity from which the sale originated. As previously discussed in Note 1. Organization, SonicOne revenue was reclassified from Restorative Therapies to Surgical Solutions on a prospective and retrospective basis as its capabilities to remove devitalized or necrotic tissue and fiber deposits more closely aligns with Surgical Solutionsâ€™ soft tissue management. SonicOne revenue reclassified for the three and six months ended

JulyÂ 1, 2023 totaled $1,832 and $3,544, respectively, for the U.S. reporting segment and $84 and $149, respectively, for the International reporting segment. The Company had product sales to one customer totaling $18,266 and $31,409 in the U.S. segment during the three and six months ended JuneÂ 29, 2024, representing 12.2% and 11.3% of total net sales, respectively. There was no customers representing 10% or more of net sales during the three and six months ended JulyÂ 1, 2023. The following table presents the Companyâ€™s net sales disaggregated by major business within each segment as follows:Three Months EndedSix Months EndedJune 29, 2024July 1, 2023June 29, 2024July 1, 2023U.S.Pain Treatments$65,194Â $55,617Â $115,831Â $96,612Â Restorative Therapies27,435Â 30,012Â 52,739Â 60,788Â Surgical Solutions41,780Â 35,218Â 80,120Â 67,425Â Total U.S. net sales134,409Â 120,847Â 248,690Â 224,825Â InternationalPain Treatments7,066Â 6,024Â 13,118Â 11,355Â Restorative Therapies4,185Â 4,690Â 9,355Â 10,239Â Surgical Solutions5,557Â 5,508Â 9,511Â 9,709Â Total International net sales16,808Â 16,222Â 31,984Â 31,303Â Total net sales$151,217Â $137,069Â $280,674Â $256,128Â 13. SegmentsThe Companyâ€™s two reportable segments are U.S. and International. U.S. segment revenues totaled $134,409, $120,847, $248,690 and $224,825 for the three months ended JuneÂ 29, 2024 and JulyÂ 1, 2023 and the six months ended JuneÂ 29, 2024 and JulyÂ 1, 2023, respectively. International segment revenues totaled $16,808, $16,222, $31,984 and $31,303 for the three months ended JuneÂ 29, 2024 and JulyÂ 1, 2023 and the six months ended JuneÂ 29, 2024 and JulyÂ 1, 2023, respectively. The Companyâ€™s products are primarily sold to orthopedists, musculoskeletal and sports medicine physicians, podiatrists, neurosurgeons and orthopedic spine surgeons, as well as to their patients. The Company does not disclose segment information by asset as the Chief Operating Decision Maker does not review or use it to allocate resources or to assess the operating results and financial performance. Segment Adjusted EBITDA is the segment profitability metric reported to the Companyâ€™s Chief Operating Decision Maker for purposes of decisions about allocation of resources to, and assessing performance of, each reportable segment.20Table of ContentsThe following table presents segment Adjusted EBITDA reconciled to loss before income taxes:Three Months EndedSix Months EndedJune 29, 2024July 1, 2023June 29, 2024July 1, 2023Segment Adjusted EBITDAU.S.$31,590Â $24,712Â $51,346Â $39,424Â International2,862Â 3,446Â 5,729Â 5,685Â Interest expense, net(9,924)(10,587)(20,263)(20,281)Depreciation and amortization(13,090)(14,600)(24,875)(31,073)Acquisition and related costs(300)(1,448)(511)(2,623)Shareholder litigation costs(12,502)â€”Â (13,670)â€”Â Restructuring and succession charges40Â (620)(13)(937)Equity compensation(3,672)2,732Â (6,263)886Â Financial restructuring costs5Â (1,257)(347)(6,587)Impairments of assets(31,870)â€”Â (31,870)(78,615)Loss on disposal of a businessâ€”Â (977)â€”Â (977)Other items(2,590)(5,751)(3,789)(9,416)Loss before income taxes$(39,451)$(4,350)$(44,526)$(104,514)14. Discontinued operationsOn February 27, 2023 the Company reached a Settlement Agreement with the Former Securityholders of CartiHeal that resulted in the transfer of 100% of Companyâ€™s shares in CartiHeal to a Trustee. Refer to Note 3. Acquisitions and divestitures for further details concerning the Settlement Agreement and the deconsolidation of CartiHeal. CartiHeal had no sales during the year ended December 31, 2023.The following table summarizes the major income and expense line items of these discontinued operations, as reported in the consolidated statements of operations for the six months ended JulyÂ 1, 2023 as there was no activity for discontinued operations subsequent to the first quarter of 2023:Six Months EndedJuly 1, 2023Selling, general and administrative expense$1,728Â Research and development expense396Â Change in fair value of contingent consideration(a)1,710Â Depreciation and amortization(a)4,264Â Impairments of assetsâ€”Â Operating loss from discontinued operations(8,098)Interest expense, net4,889Â Other (income) expense(b)61,442Â Other (income) expense66,331Â Loss before income taxes(74,429)Income tax benefit, netâ€”Â Net loss from discontinued operations(74,429)Loss attributable to noncontrolling interest - discontinued operations14,937Â Net loss attributable to Bioventus Inc. - discontinued operations$(59,492)(a)Depreciation and amortization and the change in fair value of contingent consideration represents the significant operating non-cash items of discontinued operations.(b)Other expense includes the $60,639 loss on deconsolidation, of which $10,150 was attributable to non-refundable payments. Total investing cash outflows included these non-refundable payments and $1,356 cash on hand at disposal.21Table of ContentsItem 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations.The following discussion and analysis of Bioventus Inc.â€™s (sometimes referred to as â€œwe,â€ â€œus,â€ â€œour,â€ â€œBioventusâ€ or â€œthe Companyâ€) financial condition and results of operations should be read in conjunction with the â€œSpecial Note Regarding Forward-Looking Statementsâ€ and our unaudited consolidated condensed financial statements and related notes thereto appearing elsewhere in this Quarterly Report on Form 10-Q, as well as our audited consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023 filed with the Securities and Exchange Commission (â€œSECâ€) on March 12, 2024 (â€œ2023 10-Kâ€).Executive SummaryWe are a global medical device company focused on developing and commercializing clinically differentiated, cost efficient and minimally invasive treatments that engage and enhance the bodyâ€™s natural healing process. We operate our business through two reportable segments, U.S. and International, and our portfolio of products is grouped into three businesses:â€¢Pain Treatments is comprised of non-surgical joint pain injection therapies as well as peripheral nerve stimulation (â€œPNSâ€) products to help the patient get back to their normal activities.â€¢Surgical Solutions is comprised of bone graft substitutes (â€œBGSâ€) that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries, as well as a portfolio of ultrasonic products used for precise bone cutting and sculpting, soft tissue management (i.e., tumor and liver resections) and tissue debridement, in various surgeries, including minimally invasive applications.â€¢Restorative Therapies is comprised of a bone healing system, as well as devices designed to help patients regain leg or hand function due to stroke, multiple sclerosis or other central nervous system disorders.The following table sets forth total net sales, net loss and Adjusted EBITDA for the periods presented:Three Months EndedSix Months EndedJune 29, 2024July 1, 2023June 29, 2024July 1, 2023Net sales$151,217Â $137,069Â $280,674Â $256,128Â Net loss from continuing operations$(32,112)$(4,731)$(38,094)$(104,749)Adjusted EBITDA(1)$34,452Â $28,158Â $57,075Â $45,109Â Loss per Class A common stock, basic and diluted:Continuing operations(0.37)(0.06)(0.45)(1.34)Discontinued operationsâ€”Â â€”Â â€”Â (0.95)Loss per Class A common stock, basic and diluted(0.37)(0.06)(0.45)(2.29)(1)See below under results of operations-Adjusted EBITDA for a reconciliation of net loss to Adjusted EBITDA.Significant transactionsAdvanced Rehabilitation BusinessIn May 2024, we began contract negotiations with a third-party (the â€œBuyerâ€) to sell certain products within our advanced rehabilitation business, including the L100, L300 Go, L360, H200, Vector Gait & Safety System and BITS-Bioness Integrated Therapy System (collectively, the â€œAdvanced Rehabilitation Businessâ€). The Advanced Rehabilitation Business is considered non-core and will require additional research and development expenditures to achieve its next stage of growth. The potential divestiture of the Advanced Rehabilitation Business is expected to simplify our business structure and improve liquidity, as the proceeds, net of transactional fees, are required to be used to reduce long-term debt obligations. Contract negotiations are ongoing with the Buyer and as of the end of the second quarter 2024, we had incurred $2,500 in transactional fees resulting from the potential divestiture of the Advanced Rehabilitation Business.The Company evaluated the Advanced Rehabilitation Business for impairment due to its potential divestiture and, as a result of this evaluation, recorded a $31,870 impairment under the U.S. reporting segment within the consolidated condensed statements of operations and comprehensive loss during the three and six months ended JuneÂ 29, 2024 to reduce the intangible assets of the Advanced Rehabilitation Business to reflect their respective fair values less any costs to sell. The fair value of its intangibles was based on the consideration offered for the Advanced Rehabilitation Business.22Table of ContentsReclassificationWe reclassified revenue and expense of the SonicOne Ultrasonic Cleansing and Debridement Systems (â€œSonicOneâ€) from the Restorative Therapies to the Surgical Solutions business in the first quarter of 2024. SonicOneâ€™s capabilities to remove devitalized or necrotic tissue and fiber deposits more closely aligns with Surgical Solutionsâ€™ soft tissue management. SonicOne revenue reclassified for the three and six months ended JulyÂ 1, 2023 totaled $1.8 million and $3.5 million, respectively, for the U.S. reporting segment and $0.1 million in both periods for the International reporting segment.OSTEOAMPÂ®OSTEOAMP Cannula, a customized delivery system for our OSTEOAMPÂ® Flowable product, received FDA clearance in June 2024. OSTEOAMPÂ® is an allograft-derived bone graft with growth factors used for reconstructive bone grafting procedures. The Cannula delivery system will assist the use of OSTEOAMPÂ® Flowable, the fastest growing product in our portfolio, in minimally invasive surgical procedures as well as open procedures. FDA clearance will also allow us to bring the product to market in the US, starting with a limited launch planned in the fourth quarter of 2024.EU MDRThe European Union (â€œEUâ€) Medical Devices Regulation (â€œMDRâ€), which became effective in May 2021, was adopted with the aim of ensuring better protection of public health and patient safety. Among other things, the EU MDR imposed changes to clinical evidence for medical devices, post-market clinical follow-up evidence, annual reporting of safety information for Class III products, and bi-annual reporting for Class II products, Unique Device Identification (â€œUDIâ€) for all products, submission of core data elements to a European UDI database prior to placement of a device on the market, reclassification of medical devices, and multiple labeling changes. We were able to continue marketing our currently certified products in the EU after the effective date of EU MDR until the associated certifications expire. In April 2024, we received EU Certification for our Exogen Bone Stimulation System, which will allow us to market it throughout the EU. The certificate is valid for 5 years.Wound BusinessOn May 22, 2023, we closed the sale of certain assets within our Wound Business, including the TheraSkin and TheraGenesis products (collectively, the â€œWound Businessâ€), for potential consideration of $84.7 million, including $34.7 million at closing, $5.0 million deferred for 18 months and up to $45.0 million in potential earn-out payments, which are based on the achievement of certain revenue thresholds by the purchaser of the Wound Business for sales of the TheraSkin and TheraGenesis products during the 2024, 2025, and 2026 fiscal years. We incurred $3.9 million in transactional fees resulting from the sale of the Wound Business and used the proceeds from the sale of the Wound Business to prepay $30.0 million of long-term debt obligations.We evaluated the Wound Business for impairment prior to its sale and recorded a $78.6 million impairment within the consolidated statements of operations and comprehensive loss during the six months ended JulyÂ 1, 2023 as a result of this evaluation to reduce the intangible assets of the Wound Business to reflect their respective fair values, less any costs to sell. The fair values of its intangibles were determined based on the consideration received for the Wound Business.Amended 2019 Credit AgreementOn January 18, 2024, we further amended the 2019 Credit Agreement in order to modify certain financial covenants under the 2019 Credit Agreement. Refer to Part I. Item 1. Financial Informationâ€”Notes to the consolidated condensed financial statementsâ€”Note 4. Financial instruments for further information regarding the January 2024 amendment.Consolidated Appropriations ActIn July 2022, in connection with the Consolidated Appropriations Act, 2021 (â€œCAAâ€), the Centers for Medicare and Medicaid Services (â€œCMSâ€) began utilizing new pricing information the Company reported to it pursuant to the newly adopted reporting obligations to adjust the Medicare payment to healthcare providers using our Durolane and Gelsyn-3 products.Results of OperationsFor a description of the components of our results of operations, refer to Part II. Item 7. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations in our 2023 10-K.23Table of ContentsThe following table sets forth components of our consolidated condensed statements of operations as a percentage of net sales for the periods presented:Three Months EndedSix Months EndedJune 29, 2024July 1, 2023June 29, 2024July 1, 2023Net sales100.0Â %100.0Â %100.0Â %100.0Â %Cost of sales (including depreciation and amortization)31.5Â %35.0Â %31.6Â %36.3Â %Gross profit68.5Â %65.0Â %68.4Â %63.7Â %Selling, general and administrative expense62.7Â %54.6Â %61.7Â %60.8Â %Research and development expense2.6Â %2.4Â %2.3Â %2.8Â %Restructuring costsâ€”Â %0.5Â %â€”Â %0.4Â %Change in fair value of contingent consideration0.2Â %0.2Â %0.2Â %0.2Â %Depreciation and amortization1.3Â %1.7Â %1.4Â %1.7Â %Impairment of assets21.1Â %â€”Â %11.4Â %30.7Â %Loss on disposal of a businessâ€”Â %0.7Â %â€”Â %0.4Â %Operating (loss) income(19.4Â %)4.9Â %(8.6Â %)(33.3Â %)The following table presents a reconciliation of net loss to Adjusted EBITDA for the periods presented:Three Months EndedSix Months Ended(in thousands)June 29, 2024July 1, 2023June 29, 2024July 1, 2023Net loss from continuing operations$(32,112)$(4,731)$(38,094)$(104,749)Interest expense, net9,924Â 10,587Â 20,263Â 20,281Â Income tax expense (benefit), net(7,339)381Â (6,432)235Â Depreciation and amortization(a)13,090Â 14,600Â 24,875Â 31,073Â Acquisition and related costs(b)300Â 1,448Â 511Â 2,623Â Shareholder litigation costs(c)12,502Â â€”Â 13,670Â â€”Â Restructuring and succession charges(d)(40)620Â 13Â 937Â Equity compensation(e)3,672Â (2,732)6,263Â (886)Financial restructuring costs(f)(5)1,257Â 347Â 6,587Â Impairment of assets(g)31,870Â â€”Â 31,870Â 78,615Â Loss on disposal of a business(h)â€”Â 977Â â€”Â 977Other items(i)2,590Â 5,751Â 3,789Â 9,416Â Adjusted EBITDA$34,452Â $28,158Â $57,075Â $45,109Â (a)Includes for the three months ended JuneÂ 29, 2024 and JulyÂ 1, 2023 and the six months ended JuneÂ 29, 2024 and JulyÂ 1, 2023, respectively, depreciation and amortization of $11,021, $12,301, $21,046 and $26,640 in cost of sales and $2,069, $2,299, $3,829 and $4,433 in operating expenses presented in the consolidated statements of operations and comprehensive loss.(b)Includes acquisition and integration costs related to completed acquisitions and changes in fair value of contingent consideration.(c)Costs incurred as a result of certain shareholder litigation unrelated to our ongoing operations.(d)Costs incurred were the result of adopting restructuring plans to reduce headcount, reorganize management structure, and consolidate certain facilities.(e)Includes compensation expense resulting from awards granted under our equity-based compensation plans. The three and six months ended JulyÂ 1, 2023 includes the reversal of equity compensation expenses totaling $3,803 related to the transition of our executive leadership.(f)Financial restructuring costs include advisory fees and debt amendment related costs.(g)Represents a non-cash impairment charge for intangible assets solely attributable to our Advanced Rehabilitation Business in 2024 due to our decision to divest the business. Activity in 2023 relates to the non-cash impairment charge attributable to our divested Wound Business.(h)Represents the loss on disposal of the Wound Business.24Table of Contents(i)Other items primarily includes charges associated with strategic transactions, such as potential acquisitions or divestitures and a transformative project to redesign systems and information processing. We incurred $0.3 million and $1.2 million in costs, respectively, during the three and six months ended JulyÂ 1, 2023 related to MOTYS. Other items for the three and six months ended JulyÂ 1, 2023 also includes severance costs totaling $2.3 million related to the transition of our executive leadership.Non-GAAP Financial Measures - Adjusted EBITDAWe present Adjusted EBITDA, a non-GAAP financial measure, because we believe it is a useful indicator that management uses as a measure of operating performance as well as for planning purposes, including the preparation of our annual operating budget and financial projections. We believe that Adjusted EBITDA is useful to our investors because it is frequently used by securities analysts, investors and other interested parties in their evaluation of the operating performance of companies in industries similar to ours. We define Adjusted EBITDA as net loss from continuing operations before depreciation and amortization, provision of income taxes and interest expense, net, adjusted for the impact of certain cash, non-cash and other items that we do not consider in our evaluation of ongoing operating performance. These items include acquisition and related costs, certain shareholder litigation costs, impairments of assets, restructuring and succession charges, equity compensation expense, financial restructuring costs and other items. Adjusted EBITDA by segment is comprised of net sales and costs directly attributable to a segment, as well as an allocation of corporate overhead costs primarily based on a ratio of net sales by segment to total consolidated net sales.Non-GAAP financial measures have limitations as an analytical tool and should not be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with U.S. GAAP. These measures might exclude certain normal recurring expenses. Therefore, these measures might not provide a complete understanding of the Company's performance and should be reviewed in conjunction with the U.S. GAAP financial measures. Additionally, other companies might define their non-GAAP financial measures differently than we do. Investors are encouraged to review the reconciliation of the non-GAAP measure provided in this Quarterly Report on Form 10-Q, including all tables referencing Adjusted EBITDA to its most directly comparable U.S. GAAP measure.Net SalesThree Months EndedChange(in thousands, except for percentage)June 29, 2024July 1, 2023$%U.S.Pain Treatments$65,194Â $55,617Â $9,577Â 17.2Â %Restorative Therapies27,435Â 30,012Â (2,577)(8.6Â %)Surgical Solutions41,780Â 35,218Â 6,562Â 18.6Â %Total U.S. net sales134,409Â 120,847Â 13,562Â 11.2Â %InternationalPain Treatments7,066Â 6,024Â 1,042Â 17.3Â %Restorative Therapies4,185Â 4,690Â (505)(10.8Â %)Surgical Solutions5,557Â 5,508Â 49Â 0.9Â %Total International net sales16,808Â 16,222Â 586Â 3.6Â %Total net sales$151,217Â $137,069Â $14,148Â 10.3Â %U.S.Net sales increased $13.6 million, or 11.2%, compared to three months ended July 1, 2023. Changes by business were: (i) Pain Treatmentsâ€”$9.6 million increase due to volume; (ii) Restorative Therapiesâ€”$2.6 million decrease due to the divestiture of our Wound Business, partially offset with a volume increase for our Exogen Bone Stimulation System; and (iii) Surgical Solutionsâ€”$6.6 million increase due to volume growth.InternationalNet sales increased compared with the prior year comparable period. The net sales in Pain Treatments increased $1.0 million due to volume growth, partially offset by a decrease of $0.5 million in Restorative Therapies due to less volume.25Table of ContentsSix Months EndedChange(in thousands, except for percentage)June 29, 2024July 1, 2023$%U.S.Pain Treatments$115,831Â $96,612Â $19,219Â 19.9Â %Restorative Therapies52,739Â 60,788Â (8,049)(13.2Â %)Surgical Solutions80,120Â 67,425Â 12,695Â 18.8Â %Total U.S. net sales248,690Â 224,825Â 23,865Â 10.6Â %InternationalPain Treatments13,118Â 11,355Â 1,763Â 15.5Â %Restorative Therapies9,355Â 10,239Â (884)(8.6Â %)Surgical Solutions9,511Â 9,709Â (198)(2.0Â %)Total International net sales31,984Â 31,303Â 681Â 2.2Â %Total net sales$280,674Â $256,128Â $24,546Â 9.6Â %U.S.Net sales increased $23.9 million, or 10.6%, compared to the prior year period. Changes by business were: (i) Pain Treatmentsâ€”$19.2 million increase due to volume; (ii) Restorative Therapiesâ€”$8.0 million decrease due to the divestiture of our Wound Business and larger volumes in 2023 related to our Vector rehabilitation product, partially offset with an Exogen Bone Stimulation System volume increase; and (iii)

Surgical Solutionsâ€”$12.7 million increase due to volume growth.InternationalNet sales increased compared with the prior year comparable period. There was an increase in Pain Treatments of $1.8 million net sales due to volume growth, partially offset with decrease of $0.9 million in Restorative Therapies due to less volume.Gross profit and gross marginThree Months EndedChange(in thousands, except for percentage)June 29, 2024July 1, 2023$%U.S.$94,233Â $79,549Â $14,684Â 18.5Â %International9,406Â 9,574Â (168) (1.8Â %)Total$103,639Â $89,123Â $14,516Â 16.3Â %Three Months EndedJune 29, 2024July 1, 2023ChangeU.S.70.1Â %65.8Â %4.3Â %International56.0Â %59.0Â % (3.1Â %)Total68.5Â %65.0Â %3.5Â %U.S.Gross profit increased $14.7 million, or 18.5%, primarily due to volume growth in Pain Treatments, Surgical Solutions and our Exogen Bone Stimulation System, partially offset by the Wound Business divestiture. Gross margin increased due to product mix.InternationalGross profit decreased $0.2 million, or 1.8%, primarily due to a decline in Restorative Therapies and product mix, partially offset with growth in Pain Treatments.Six Months EndedChange(in thousands, except for percentage)June 29, 2024July 1, 2023$%U.S.$173,601Â $145,055Â $28,546Â 19.7Â %International18,418Â 17,987Â 431Â 2.4Â %Total$192,019Â $163,042Â $28,977Â 17.8Â %26Table of ContentsSix Months EndedJune 29, 2024July 1, 2023ChangeU.S.69.8Â %64.5Â %5.3Â %International57.6Â %57.5Â %0.1Â %Total68.4Â %63.7Â %4.8Â %U.S.Gross profit increased $28.5 million, or 19.7%, primarily due to volume growth in Pain Treatments, Surgical Solutions and our Exogen Bone Stimulation System, partially offset by the Wound Business divestiture. Gross margin increased due to product mix.InternationalGross profit increased $0.4 million, or 2.4%, primarily due to volume growth in Pain Treatments, partially offset with a volume decrease for Restorative Therapies. Gross margin remained consistent with the prior year comparable period.Selling, general and administrative expenseThree Months EndedChange(in thousands, except for percentage)June 29, 2024July 1, 2023$%Selling, general and administrative expense$94,785Â $74,844Â $19,941Â 73.4Â %Selling, general and administrative expenses increased $19.9 million, or 73.4%, primarily due to increases in (i) accounting and legal costs of $10.7 million, primarily related to the settlement of shareholder litigation; (ii) equity-based compensation of $6.2 million; and (iii) compensation related costs of $2.9 million.Six Months EndedChange(in thousands, except for percentage)June 29, 2024July 1, 2023$%Selling, general and administrative expense$173,191Â $155,702Â $17,489Â 11.2Â %Selling, general and administrative expenses increased $17.5 million, or 11.2%, due to increases in: (i) accounting and legal costs of $10.8 million, primarily related to the settlement of shareholder litigation; (ii) equity-based compensation of $7.6 million; and (iii) compensation-related costs of $7.1 million. These increases were partially offset with a decline in consulting expenses of $8.6 million.Research and development expenseThree Months EndedChange(in thousands, except for percentage)June 29, 2024July 1, 2023$%Research and development expense$3,988Â $3,398Â $590Â 17.4Â %Research and development increased by $0.6 million, or 17.4%, primarily due to increases in compensation related costs.Six Months EndedChange(in thousands, except for percentage)June 29, 2024July 1, 2023$%Research and development expense$6,585Â $7,169Â $(584)(8.1Â %)Research and development expense decreased by $0.6Â million, or 8.1%, primarily due to a decrease in consulting costs.Restructuring costsThree Months EndedChange(in thousands, except for percentage)June 29, 2024July 1, 2023$%Restructuring costs$â€”Â $620Â $(620)(100.0Â %)Six Months EndedChange(in thousands, except for percentage)June 29, 2024July 1, 2023$%Restructuring costs$â€”Â $937Â $(937)(100.0Â %)27Table of ContentsRestructuring activity related to our previously announced restructuring plans were completed in 2023. Costs incurred during the three and six months ended JulyÂ 1, 2023 are primarily the result of an initiative to align the Companyâ€™s organizational and management cost structure to improve profitability and cash flow through headcount reduction and cutting third-party related costs. Change in fair value of contingent considerationThree Months EndedChange(in thousands, except for percentage)June 29, 2024July 1, 2023$%Change in fair value of contingent consideration$300Â $240Â $60Â 25.0Â %Six Months EndedChange(in thousands, except for percentage)June 29, 2024July 1, 2023$%Change in fair value of contingent consideration$595Â $527Â $68Â 12.9Â %The fair value of contingent consideration during the three and six months ended JuneÂ 29, 2024 remained consistent with the prior year comparable period. The activity for both periods relates to contingent consideration associated with the acquisition of Bioness in March 2021.Depreciation and amortizationThree Months EndedChange(in thousands, except for percentage)June 29, 2024July 1, 2023$%Depreciation and amortization$2,064Â $2,294Â $(230)(10.0Â %)Six Months EndedChange(in thousands, except for percentage)June 29, 2024July 1, 2023$%Depreciation and amortization$3,819Â $4,423Â $(604)(13.7Â %)Depreciation and amortization decreased during the three and six months ended JuneÂ 29, 2024 compared with the prior year comparable period. The decrease was primarily the result of the impairment of intellectual property intangible assets associated with the Wound Business, which was divested during the second quarter of 2023.Impairment of assetsThree Months EndedChange(in thousands, except for percentage)June 29, 2024July 1, 2023$%Impairment of assets(NM = Not Meaningful)$31,870Â $â€”Â $31,870Â NMSix Months EndedChange(in thousands, except for percentage)June 29, 2024July 1, 2023$%Impairment of assets$31,870Â $78,615Â $(46,745)(59.5Â %)Our decision to potentially divest the Advanced Rehabilitation Business in 2024 and divest the Wound Business in 2023 required us to evaluate whether certain of their assets were impaired. We recorded a $31.9 million non-cash impairment charge as a result of the evaluation of the Advanced Rehabilitation Business during the three and six months ended JuneÂ 29, 2024 and a $78.6 million non-cash impairment charge related to the Wound Business during the six months ended JulyÂ 1, 2023 as a result of their respective evaluations to reduce the intangible assets to their fair values less costs to sell. The fair value of intangibles for the Advanced Rehabilitation and Wound Businesses were determined based on the consideration offered.Loss on disposalsThe loss on disposals during the three and six months ended JulyÂ 1, 2023 resulted from working capital adjustments associated with the sale of our Wound Business.28Table of ContentsOther expense (income)Three Months EndedChange(in thousands, except for percentage)June 29, 2024July 1, 2023$%Interest expense, net$9,924Â $10,587Â $(663)(6.3Â %)Other expense$159Â $513Â $(354)(69.0Â %)Interest expense, net decreased slightly during the three months ended JuneÂ 29, 2024 compared to the prior year comparable period primarily due to less debt outstanding. Other expense decreased due to reserving miscellaneous assets in 2023, mostly offset with changes in foreign currency.Six Months EndedChange(in thousands, except for percentage)June 29, 2024July 1, 2023$%Interest expense, net$20,263Â $20,281Â $(18)(0.1Â %)Other expense (income)$222Â $(1,075)$1,297Â (120.7Â %)Interest expense, net remained consistent with the prior year comparable period. Other expense (income) decreased $1.3 million due to the 2023 receipt of $1.5 million from the settlement of a legal claim.Income tax (benefit) expense, netThree Months EndedChange(in thousands, except for percentage)June 29, 2024July 1, 2023$%Income tax (benefit) expense, net$(7,339)$381Â $(7,720)NMEffective tax rate(NM = Not Meaningful)18.6Â %8.8Â %9.8Â %Six Months EndedChange(in thousands, except for percentage)June 29, 2024July 1, 2023$%Income tax (benefit) expense, net$(6,432)$235Â $(6,667)NMEffective tax rate14.4Â %0.2Â %14.2Â %Income tax expense was incurred for the three and six months ended JuneÂ 29, 2024 compared to a benefit in the prior year comparable period primarily due to losses in certain entities.Noncontrolling interestSubsequent to the IPO and related transactions, we are the sole managing member of BV LLC in which we owned 80.5% and 79.9% at JuneÂ 29, 2024 and December 31 2023, respectively. We have a majority economic interest, the sole voting interest in, and control the management of BV LLC. As a result, we consolidate the financial results of BV LLC and report a noncontrolling interest representing the 19.5% that is owned by the Continuing LLC Owner. Noncontrolling interest activity during the three and six months ended JuneÂ 29, 2024 was the result of losses recorded.Segment Adjusted EBITDAThree Months EndedChange(in thousands, except for percentage)June 29, 2024July 1, 2023$%U.S.$31,590Â $24,712Â $6,878Â 27.8Â %International$2,862Â $3,446Â $(584)(16.9)%U.S.Adjusted EBITDA increased $6.9 million, or 27.8%, due to higher gross profit, partially offset with an increase in compensation costs.InternationalAdjusted EBITDA decreased $0.6 million or 16.9%, primarily due to a decrease in gross profit and an increase in compensation costs.29Table of ContentsSix Months EndedChange(in thousands, except for percentage)June 29, 2024July 1, 2023$%U.S.$51,346Â $39,424Â $11,922Â 30.2Â %International$5,729Â $5,685Â $44Â 0.8Â %U.S.Adjusted EBITDA increased $11.9 million, or 30.2%, primarily due higher gross profit, partially offset with an increase in compensation costs and other administrative expenses.InternationalAdjusted EBITDA remained consistent with the prior year comparable period.Liquidity and Capital ResourcesSources of liquidityOur principal liquidity needs have historically been for acquisitions, working capital, research and development, clinical trials, and capital expenditures. We expect these needs to continue as we carry out our operations, develop and commercialize our existing product candidates and any new products candidates and possibly further our expansion into international markets.We began contract negotiations with a third-party to sell certain products within our advanced rehabilitation business, including the L100, L300 Go, L360, H200, Vector Gait & Safety System and BITS-Bioness Integrated Therapy System (collectively, the â€œAdvanced Rehabilitation Businessâ€). The potential divestiture of the Advanced Rehabilitation Business is expected to simplify our business structure and improve liquidity, as the proceeds, net of transactional fees, are required to be used to reduce long-term debt obligations.As previously discussed, on May 22, 2023, we closed the sale of our Wound Business for consideration of $84.7 million, including $34.7 million at closing, $5.0 million deferred for 18 months and up to $45.0 million in potential earn-out payments. The proceeds were used to prepay $30.0 million of long-term debt principal obligations during the second quarter of 2023.We anticipate that to the extent that we require additional liquidity, we will obtain funding through additional equity financings or the incurrence of other indebtedness or a combination of these potential sources of liquidity. We may explore additional divestiture opportunities for non-core assets to improve our liquidity position, as we did with the Wound Business. In addition, we may raise additional funds to finance future cash needs through receivables or royalty financings or corporate collaboration and licensing arrangements. If we raise additional funds by issuing equity securities or convertible debt, our stockholders will experience dilution. The covenants under the Amended 2019 Credit Agreement limit our ability to obtain additional debt financing. Debt financing, if allowed under the Amended 2019 Credit Agreement and if available, would result in increased payment obligations and might involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, or making capital expenditures. If we raise additional funds through collaboration and licensing arrangements with third-parties, it might be necessary to relinquish valuable rights to our products, future revenue streams or product candidates, or to grant licenses on terms that might not be favorable to us. We cannot be certain that additional funding will be available on acceptable terms, or at all. Any failure to raise capital in the future might have a negative impact on our financial condition and our ability to pursue our business strategies. Considering recent market conditions and our business assumptions, we have reevaluated our operating cash flows and cash requirements and believe that current cash, cash equivalents, future cash flows from operating activities and cash available under our 2019 Credit Facility will be sufficient to meet our anticipated cash needs, including working capital needs, capital expenditures and contractual obligations for at least 12 months from the issuance date of the unaudited consolidated condensed financial statements included herein.Cash RequirementsThere have been no material changes to our future cash requirements as disclosed in Part II. Item 7 of our 2023 10-K. We enter into contracts in the normal course of business with various third parties for development, collaboration and other services for operating purposes. These contracts generally provide for termination upon notice. Payments due upon cancellation generally consist only of payments for services provided or expenses incurred, including non-cancellable obligations of our service providers, up to the date of cancellation. Certain agreements include contingent events that upon occurrence would require payment. For information regarding commitments and contingencies, refer to Item 1. Financial Informationâ€”Notes to the unaudited consolidated condensed financial statementsâ€”Note 11. Commitments and contingencies.30Table of ContentsTax Receivable AgreementThe BV LLC Agreement provides for the payment of certain distributions to the Continuing LLC Owner in amounts sufficient to cover the income taxes imposed with respect to the allocation of taxable income from BV LLC as well as obligations within the tax receivable agreement (â€œTRAâ€) with the Continuing LLC Owner. Under the TRA, we are required to make cash payments to the Continuing LLC Owner equal to 85% of the tax benefits, if any, that we actually realize (or in certain circumstances are deemed to realize), as a result of (1) increases in the tax basis of assets of BV LLC resulting from (a) any future redemptions or exchanges of LLC Interests, and (b) certain distributions (or deemed distributions) by BV LLC and (2) certain other tax benefits arising from payments under the TRA. We expect the amount of the cash payments required to be made under the TRA will be significant. The actual amount and timing of any payments under the TRA will vary depending upon a number of factors, including the timing of redemptions or exchanges by the Continuing LLC Owner, the amount of gain recognized by the Continuing LLC Owner, the amount and timing of the taxable income we generate in the future, and the federal tax rates then applicable. Any payments made by us to the Continuing LLC Owner under the TRA will generally reduce the amount of overall cash flow that might have otherwise been available to us. To the extent that we are unable to make payments under the TRA for any reason, such payments generally will be deferred and will accrue interest until paid; provided, however, that nonpayment for a specified period may constitute a material breach of a material obligation under the TRA and therefore accelerate payments due under the TRA.IndebtednessOn January 18, 2024 (the â€œClosing Dateâ€), the Company entered into the Amended 2019 Credit Agreement. The Amended 2019 Credit Agreement, contains customary affirmative and negative covenants, including those related to financial reporting and notification, restrictions on the declaration or payment of certain distributions on or in respect of our equity interests, restrictions on acquisitions, investments and certain other payments, limitations on the incurrence of new indebtedness, limitations on transfers, sales and other dispositions of our assets, as well as limitations on making changes to the business and organizational documents. Financial covenant requirements include a maximum debt leverage ratio and an interest coverage ratio. In addition, during the period commencing on the Closing Date and ending upon the satisfaction of certain conditions occurring not prior to the delivery of our financial statements for the fiscal quarter ending October 29, 2025, we will be subject to certain additional requirements and covenants, including a requirement to maintain Liquidity (as defined in the Amended 2019 Credit Agreement) of not less than $10.0 million as of the end of each calendar month during such period. The Term Loan Facilities will mature on October 29, 2026. The Revolver will mature on October 29, 2025. We were in compliance with the financial covenants as stated with the Amended 2019 Credit Agreement as of JuneÂ 29, 2024. We have an outstanding Revolver balance of $15.0 million as of March 30, 2024, which was borrowed and used for working capital needs during the third quarter of 2023. Refer to Item 1. Financial Informationâ€”Notes unaudited consolidated condensed financial statementsâ€”Note 1. Organization for further details on the Companyâ€™s covenant compliance and Note 4. Financial instruments for further details on the Companyâ€™s indebtedness.OtherFor information regarding Commitments and Contingencies, refer to Item 1. Financial Informationâ€”Notes to the unaudited consolidated condensed financial statementsâ€”Note 11. Commitments and contingencies and â€”Note 3. Acquisitions and divestitures of this Quarterly Report on Form 10-Q.Information regarding cash flowsCash, cash equivalents and restricted cash as of JuneÂ 29, 2024 totaled $32.0 million, compared to $37.0 million as of DecemberÂ 31, 2023. The decrease in cash was primarily due to the following:Six Months EndedChange(in thousands, except for percentage)June 29, 2024July 1, 2023$%Cash flows from continuing operations:Net cash from operating activities$9,157Â $15,454Â $(6,297)(40.7Â %)Net cash from investing activities(1,077)29,940Â (31,017)(103.6Â %)Net cash from financing activities(12,087) (34,868)22,781Â (65.3Â %)Net cash from discontinued operationsâ€”Â (13,675)13,675Â (100.0Â %)Effect of exchange rate changes on cash(963)701Â (1,664)(237.4Â %)Net change in cash, cash equivalents and restricted cash$(4,970)$(2,448)$(2,522)103.0Â %31Table of ContentsOperating ActivitiesNet cash from operating activities from continuing operations decreased $6.3 million, due to: (i) increases in employee compensation as we annually pay bonuses and raise wages during the first quarter and no bonuses were paid during the first quarter of 2023; (ii) a rise in interest payments due to higher interest rates; and (iii) an increase in inventory purchases. These operating cash outflows were partially offset with an increase in cash collections from the growth in sales and timing of payments on accounts payable.Investing ActivitiesNet cash from investing activities from continuing operations decreased $31.0 million, due to the $34.9 million receipt of cash resulting from the sale of our Wound Business in 2023 and a $0.7 million purchase of distribution rights for one of our HA products in 2024. These were partially offset with a $4.6 million decrease in capital expenditures, primarily within information technology.Financing ActivitiesCash flows from financing activities increased $22.8 million, primarily due to $29.4 million less in principal and deferred financing payments during 2024, partially offset with $7.0 million in net borrowings on our Revolver during 2023.Discontinued OperationsNet cash flows from discontinued operations in 2023 were primarily the result of $10.2 million in fees used to settle the CartiHeal disposition and $1.4 million in cash held by the CartiHeal entity at the time of disposal.Off-balance Sheet ArrangementsWe do not have any off-balance sheet arrangements.Contractual ObligationsThere have been no material changes to our contractual obligations as disclosed in our 2023 10-K.Critical Accounting EstimatesOur discussion of operating results is based upon the unaudited consolidated condensed financial statements and accompanying notes, which have been prepared in accordance with U.S. GAAP. The preparation of these statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Our estimates are based on our historical experience and on various other assumptions that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Changes in the facts or circumstances underlying these estimates could result in material changes and actual results could differ from these estimates. In the event we dispose of assets before the end of their previously stated useful life, we may incur an impairment charge. Our critical accounting estimates are detailed in Item 7 of our 2023 10-K and we have no material changes to such disclosures.Emerging Growth Company and Smaller Reporting Company StatusThe Company is an â€œemerging growth company,â€ pursuant to the provisions of the Jumpstart Our Business Startups Act (the â€œJOBS ACTâ€). An emerging growth company can

delay its adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company has chosen to â€œopt outâ€ of such extended transition periods, and as a result, the Company plans to comply with any new or revised accounting standards on the relevant dates on which non-emerging growth companies must adopt such standards. Section 107 of the JOBS Act provides that the decision to opt out of the extended transition period for complying with new or revised accounting standards is irrevocable.The Company is also considered a â€œsmaller reporting company,â€ as defined by Rule 12b-2 of the Securities Exchange Act of 1934 (the â€œExchange Actâ€), which was determined as of the last day of the Companyâ€™s second fiscal quarter of 2023. The Company will continue to be categorized as a smaller reporting company-accelerated filer until the Companyâ€™s public float reaches a certain threshold. The Company may rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Item 3. Quantitative and Qualitative Disclosures about Market Risk.There have been no material changes to our market risks as disclosed in our 2023 10-K.32Table of ContentsItem 4. Controls and Procedures.Limitations on Effectiveness of Controls and ProceduresIn designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.Evaluation of Disclosure Controls and ProceduresOur management, including our President and Chief Executive Officer and Chief Financial Officer, conducted an evaluation of the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) promulgated under the Exchange Act) as of JuneÂ 29, 2024 (the end of the period covered by this Quarterly Report on Form 10-Q). Based upon that evaluation, our President and Chief Executive Officer and Chief Financial Officer concluded that, as of JuneÂ 29, 2024, our disclosure controls and procedures are designed at a reasonable assurance level and are effective to provide reasonable assurance that information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SECâ€™s rules and forms, and that such information is accumulated and communicated to our management, including our President and Chief Executive Officer and our Chief Financial Officer as appropriate, to allow timely decisions regarding required disclosure.Changes in Internal Control over Financial ReportingThere were no changes in our internal control over financial reporting that occurred during the second quarter of 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.PART II. OTHER INFORMATIONItem 1. Legal Proceedings.Bioventus shareholder litigationOn January 12, 2023, the Company and certain of its current and former directors and officers were named as defendants in a putative class action lawsuit filed in the Middle District of North Carolina (the â€œCourtâ€), Ciarciello v. Bioventus, Inc., No. 1:23â€“ CV â€“ 00032-CCE-JEP (M.D.N.C. 2023). The complaint asserted violations of Sections 10(b) and 20(a) of the Exchange Act and of Sections 11 and 15 of the Securities Act and generally alleges that the Company failed to disclose certain information regarding rebate practices, its business and financial prospects, and the sufficiency of internal controls regarding financial reporting. The complaint seeks damages in an unspecified amount. On April 12, 2023, the Court appointed Wayne County Employeesâ€™ Retirement System as lead plaintiff. The plaintiffâ€™s amended consolidated complaint was filed with the Court on June 12, 2023. On July 17, 2023, the defendants filed a motion to dismiss the complaint raising a number of legal and factual deficiencies with the amended consolidated complaint. In response to the defendantsâ€™ motion to dismiss, the lead plaintiff filed a second amended complaint on July 31, 2023. The defendants moved to dismiss the second amended complaint on August 21, 2023, which the Court granted in part and denied in part on November 6, 2023. The Court dismissed the plaintiffâ€™s Securities Act claims, but allowed the plaintiffâ€™s Exchange Act claims to proceed into discovery.On July 15, 2024, a Stipulation and Agreement of Settlement (the â€œSettlement Agreementâ€) by and between the lead plaintiff and the defendants was filed with the Court. The Settlement Agreement, which is subject to Court approval, provides among other things for (i) the dismissal of all claims against the defendants, including the Company; (ii) a settlement amount of $15.3 million, together with interest earned thereon, to be paid by the defendants and/or the defendantâ€™s insurers within 30 days after the later of (x) the date of entry by the Court of an order preliminarily approving the terms of the settlement or (y) receipt by the defendants from lead counsel of the information necessary to effectuate a transfer of the settlement funds; and (iii) no admission of liability or wrongdoing by any party. The Company incurred $12.5 million and $13.7 million of net shareholder litigation costs (including estimated settlement and reimbursement) during the three and six months ended JuneÂ 29, 2024 under the Settlement Agreement, which were recorded in selling, general and administrative expense within the consolidated condensed statements of operations and comprehensive loss. The Company expects to be reimbursed approximately $6.5 million of the fees incurred to date, which was recorded in other current assets within the JuneÂ 29, 2024 consolidated condensed balance sheets.33Table of ContentsOn October 4, 2023, certain of the Companyâ€™s current and former directors and officers were named as defendants in a derivative shareholder lawsuit (in which the Company is a nominal defendant) filed in the United States District Court for the District of Delaware, Grogan, on behalf of Bioventus Inc., v. Reali, et.al., No. 1:23-CV-01099-RGA (D. Del. 2023). The complaint asserts violations of Section 14(a) of the Exchange Act, breaches of fiduciary duties and related state law claims, and a claim for contribution, and generally alleges the same purported misconduct as alleged in the Ciarciello case. On January 12, 2024, the Court agreed to stay this case pending resolution of the Ciarciello case. The Company may incur further legal costs until settlement is ultimately approved and executed by the Court.On February 9, 2024, another plaintiff filed a derivative shareholder lawsuit against certain of the Companyâ€™s current and former directors and officers (in which the Company is a nominal defendant) filed in the United States District Court for the District of Delaware, Sanderson, on behalf of Bioventus Inc., v. Reali, et.al., No. 1:24-cv-00180-RGA (D. Del. 2024). Like the Grogan case, this case asserts violations of Section 10(b) of the Exchange Act, breaches of fiduciary duties and related state law claims, and a claim for contribution, and generally alleges the same purported misconduct as alleged in the Ciarciello case. On May 1, 2024, the parties filed a stipulation to consolidate the two derivative matters and stay them on terms similar to those entered in the Grogan case. On May 2, 2024, the United States District Court for the District of Delaware granted the stipulation and ordered the consolidation of the Sanderson and Grogan cases (as consolidated, the â€œGrogan Caseâ€).The Company believes the claims alleged in the Grogan Case lacks merit and intends to defend itself vigorously. The outcome of this matter is not presently determinable, and any loss is neither probable nor reasonably estimable.Bioness stockholder litigationOn February 8, 2022, a minority shareholder of Bioness filed an action in the Delaware State Court of Chancery in connection with the Companyâ€™s acquisition of Bioness, Teuza, a Fairchild Technology Venture Ltd. v. Lindon, et. al., No. 2022-0130 -SG. This action names the former Bioness directors, the Alfred E. Mann Trust (â€œTrustâ€), which was the former majority shareholder of Bioness, the trustees of the Trust and Bioventus as defendants. The complaint alleges, among other things, that the individual directors, the Trust, and the trustees breached their fiduciary duty to the plaintiff in connection with their consideration and approval of the Companyâ€™s transaction. The complaint also alleges that the Company aided and abetted the other defendants in breaching their fiduciary duties to the plaintiff and that the Company breached the Merger Agreement by failing to pay the plaintiff its pro rata share of the merger consideration. The Company believes that it is indemnified under the indemnification provisions contained in the Bioness Merger Agreement for these claims. On July 20, 2022, the Company filed a motion to dismiss all claims made against it on various grounds, as did all the other named defendants in the suit. A hearing on Bionessâ€™ and other the defendantâ€™s motions was held before the Court of Chancery on January 19, 2023. On April 27, 2023, the Court issued an order which, among other things, dismissed Bioventus from the case.Please refer to Item 1. Financial Statementsâ€”Notes to the Consolidated Condensed Financial Statementsâ€”Note 11. Commitments and contingencies of this Quarterly Report on Form 10-Q for additional information pertaining to legal proceedings. In addition, we are party to legal proceedings incidental to our business. While our management currently believes the ultimate outcome of these proceedings, individually and in the aggregate, will not have a material adverse effect on our consolidated financial statements, litigation is subject to inherent uncertainties. Were an unfavorable ruling to occur, there exists the possibility of a material adverse impact on our financial condition and results of operations.Item 1A. Risk Factors.In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the risk factors and other cautionary statements described under the heading Risk Factors included in our 2023 10-K, which could materially affect our businesses, financial condition, or future results. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition, or future results. There have been no material changes in our risk factors from those described in our 2023 Form 10-K.Item 2. Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities.(a)None.(b)None.(c)None.Item 3. Defaults Upon Senior Securities.Not Applicable.34Table of ContentsItem 4. Mine Safety Disclosures.Not Applicable.Item 5. Other Information.None.Item 6. Exhibits.Exhibit No.DescriptionFormFile No.ExhibitFiling Date`Filed / Furnished Herewith3.1Amended and Restated Certificate of Incorporation of Bioventus Inc.8-K001-378443.12/17/20213.2Form of Certificate of Amendment to Amended and Restated Certificate of Incorporation of Bioventus Inc.8-K001-378443.16/17/20243.3Second Amended and Restated Bylaws of Bioventus Inc.8-K001-378443.26/17/202410.1Amendment No. 1 to the Stockholders Agreement by and among Bioventus Inc., Bioventus LLC and the Principal Stockholders dated as of June 19, 20248-K001-3784410.16/21/202431.1Certification of President and Chief Executive Officer pursuant to Rules 13a-14(a)/15d-14(a) under the Securities Exchange Act of 1934, as amended*31.2Certification of Chief Financial Officer pursuant to Rules 13a-14(a)/15d-14(a) under the Securities Exchange Act of 1934, as amended*32Certification of President and Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**101.INSInline XBRL Instance Document â€“ the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document***101.SCHInline XBRL Taxonomy Extension Schema Document***101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document***101.DEFInline XBRL Extension Definition Linkbase Document***101.LABInline XBRL Taxonomy Extension Label Linkbase Document***101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document***104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)**Â Â Â Â Â Filed herewith**Â Â Â Â Â Furnished herewith***Â Â Â Â Submitted electronically herewith35Table of ContentsSIGNATUREPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned duly authorized.BIOVENTUS INC.August 6, 2024/s/ Mark L. SingletonDateMark L. SingletonSenior Vice President and Chief Financial Officer(Principal Financial Officer and Principal Accounting Officer)36 EX-31.1 2 exhibit311-q22024.htm EX-31.1 DocumentExhibit 31.1CERTIFICATIONSI, Robert E. Claypoole certify that:1. I have reviewed this Quarterly Report on Form 10-Q of Bioventus Inc.;2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;4. The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;(c) Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and(d) Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and5. The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions):(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting./s/ Robert E. ClaypooleName:Robert E. ClaypooleTitle:President and Chief Executive Officer (Principal Executive Officer)Date: AugustÂ 6, 2024 EX-31.2 3 exhibit312-q22024.htm EX-31.2 DocumentExhibit 31.2CERTIFICATIONSI, Mark L. Singleton, certify that:1. I have reviewed this Quarterly Report on Form 10-Q of Bioventus Inc.;2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;4. The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;(c) Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and(d) Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and5. The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions):(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting./s/ Mark L. SingletonName:Mark L. SingletonTitle:Senior Vice President and Chief Financial Officer (Principal Financial Officer)Date: AugustÂ 6, 2024 EX-32 4 exhibit32-q22024.htm EX-32 DocumentExhibit 32CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002Pursuant to 18 U.S.C. Â§ 1350, as adopted pursuant to Â§ 906 of the Sarbanes-Oxley Act of 2002, in connection with the Quarterly Report on Form 10-Q of Bioventus Inc. (the Company) for the quarter ended JuneÂ 29, 2024, as filed with the Securities and Exchange Commission on the date hereof (the Report), each of Robert E. Claypoole, President and Chief Executive Officer of the Company and Mark L. Singleton, Senior Vice President and Chief Financial Officer of the Company, hereby certifies, that, to such officer's knowledge:(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company./s/ Robert E. ClaypooleName:Robert E. ClaypooleTitle:President and Chief Executive Officer (Principal Executive Officer)/s/Mark L. SingletonName:Mark L. SingletonTitle:Senior Vice President and Chief Financial Officer (Principal Financial Officer)Date: AugustÂ 6, 2024 EX-101.SCH 5 bvs-20240629.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 9952151 - Statement - Consolidated Condensed Statements of Operations and Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 9952152 - Statement - Consolidated Condensed Statements of Operations and Comprehensive Loss (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952153 - Statement - Consolidated Condensed Balance Sheets link:presentationLink link:calculationLink link:definitionLink 9952154 - Statement - Consolidated Condensed Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952155 - Statement - Consolidated Condensed Statements of Changes in Stockholdersâ€™ Equity link:presentationLink link:calculationLink link:definitionLink 9952156 - Statement - Consolidated Condensed Statements of Cash Flows

link:presentationLink link:calculationLink link:definitionLink 9952157 - Disclosure - Organization link:presentationLink link:calculationLink link:definitionLink 9952158 - Disclosure - Balance sheet information link:presentationLink link:calculationLink link:definitionLink 9952159 - Disclosure - Acquisitions and divestitures link:presentationLink link:calculationLink link:definitionLink 9952160 - Disclosure - Financial instruments link:presentationLink link:calculationLink link:definitionLink 9952161 - Disclosure - Fair value measurements link:presentationLink link:calculationLink link:definitionLink 9952162 - Disclosure - Equity-based compensation link:presentationLink link:calculationLink link:definitionLink 9952163 - Disclosure - Stockholdersâ€™ equity link:presentationLink link:calculationLink link:definitionLink 9952164 - Disclosure - Earnings per share link:presentationLink link:calculationLink link:definitionLink 9952165 - Disclosure - Restructuring costs link:presentationLink link:calculationLink link:definitionLink 9952166 - Disclosure - Income taxes link:presentationLink link:calculationLink link:definitionLink 9952167 - Disclosure - Commitments and contingencies link:presentationLink link:calculationLink link:definitionLink 9952168 - Disclosure - Revenue recognition link:presentationLink link:calculationLink link:definitionLink 9952169 - Disclosure - Segments link:presentationLink link:calculationLink link:definitionLink 9952170 - Disclosure - Discontinued Operations link:presentationLink link:calculationLink link:definitionLink 9952171 - Disclosure - Subsequent events link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - Organization (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - Balance sheet information (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - Acquisitions and divestitures (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - Financial instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - Fair value measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - Equity-based compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - Stockholdersâ€™ equity (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - Earnings per share (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - Commitments and contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - Revenue recognition (Tables) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - Segments (Tables) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - Discontinued Operations (Tables) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - Organization - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - Balance sheet information - Schedule of Accounts Receivable (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - Balance sheet information - Components of Accounts Receivable (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - Balance sheet information - Schedule of Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - Balance sheet information - Schedule od Property and Equipment, Net (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - Balance sheet information - Schedule of Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Balance sheet information - Schedule of Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Acquisitions and divestitures - Schedule of Held for Sale Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Acquisitions and divestitures (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Financial instruments - Schedule Of Long-Term Debt Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - Financial instruments - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Fair value measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Fair value measurements - Schedule of Fair Value Measurement Inputs and Valuation Techniques (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - Fair value measurements - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - Equity-based compensation - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - Equity-based compensation - Schedule of Nonvested Restricted Stock Units Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - Equity-based compensation - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - Equity-based compensation - Schedule of Stock Options Roll Forward (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - Stockholdersâ€™ equity - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - Stockholdersâ€™ equity - Schedule of Other Ownership Interests (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - Earnings per share - Schedule of Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - Earnings per share - Schedule of Antidilutive Securities (Details) link:presentationLink link:calculationLink link:definitionLink 9954505 - Disclosure - Restructuring costs - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954506 - Disclosure - Income taxes (Details) link:presentationLink link:calculationLink link:definitionLink 9954507 - Disclosure - Commitments and contingencies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954508 - Disclosure - Commitments and contingencies - Schedule of Lease, Cost (Details) link:presentationLink link:calculationLink link:definitionLink 9954509 - Disclosure - Commitments and contingencies - Schedule of Assets and Liabilities, Lessee (Details) link:presentationLink link:calculationLink link:definitionLink 9954510 - Disclosure - Revenue from Contract with Customer - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954511 - Disclosure - Revenue recognition - Schedule of Disaggregation of Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 9954512 - Disclosure - Segments - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954513 - Disclosure - Segments - Schedule of Reconciliation of Operating Profit (Loss) from Segments to Consolidated (Details) link:presentationLink link:calculationLink link:definitionLink 9954514 - Disclosure - Discontinued Operations - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954515 - Disclosure - Discontinued Operations and Disposal Groups - Schedule of Statement of Operations (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 bvs-20240629_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 bvs-20240629_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 bvs-20240629_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Borrowing on revolver Proceeds from Long-Term Lines of Credit Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Adjustments to reconcile net loss to net cash from operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Statistical Measurement [Domain] Statistical Measurement [Domain] Payments on long-term debt Repayments of Long-Term Debt Schedule of Lease, Cost Lease, Cost [Table Text Block] Cover [Abstract] Net change in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Developed technology and other In Process Research and Development [Member] Payment discount rate Measurement Input, Discount Rate [Member] Other current liabilities Other Liabilities, Current Percentage of business acquired Business Acquisition, Percentage of Voting Interests Acquired Trading Symbol Trading Symbol Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Comprehensive loss Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Shares issued or issuable, required stock to LLC interest ratio Shares Issued Or Issuable, Required Stock To LLC Interest Ratio Shares Issued Or Issuable, Required Stock To LLC Interest Ratio Schedule of Earnings Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Income tax benefit Share-Based Payment Arrangement, Expense, Tax Benefit Operating loss from discontinued operations Disposal Group, Including Discontinued Operation, Operating Income (Loss) Less: Allowance for credit losses Allowance for credit losses Accounts Receivable, Allowance for Credit Loss, Current Common Class A Common Class A [Member] Closing amount Disposal Group, Including Discontinued Operation, Consideration Including Closing Amount Disposal Group, Including Discontinued Operation, Consideration Including Closing Amount Disposal Group Name [Domain] Disposal Group Name [Domain] Accounts receivable Increase (Decrease) in Accounts Receivable Compensation and benefits Accrued Salaries And Employee Benefits, Current Accrued Salaries And Employee Benefits, Current Net loss from continuing operations Net loss from continuing operations, net of tax Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Fair value measurements Fair Value Disclosures [Text Block] Restructuring and Related Activities [Abstract] Other current and noncurrent assets and liabilities Increase (Decrease) in Other Operating Assets and Liabilities, Net Expected future amortization, year three Finite-Lived Intangible Asset, Expected Amortization, Year Three Schedule of Nonvested Restricted Stock Units Activity Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] Inventory [Line Items] Accrued Liabilities [Line Items] Goodwill [Line Items] Common stock, shares outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding Operating lease cost Operating Lease, Cost Finance leases Finance Lease, Right-of-Use Asset, before Accumulated Amortization Operating lease liabilities - noncurrent Operating Lease, Liability, Noncurrent Number of shares available to be awarded (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Impairments of assets Disposal Group, Including Discontinued Operation, Impairment Of Assets Disposal Group, Including Discontinued Operation, Impairment Of Assets Property and equipment, net Disposal Group, Including Discontinued Operation, Property, Plant and Equipment Interest on lease liabilities Finance Lease, Interest Expense Revenue from Contract with Customer [Abstract] Comprehensive loss attributable to noncontrolling interest - discontinued operations Comprehensive Income (Loss) Attributable To Noncontrolling Interest - Discontinuing Operations Comprehensive Income (Loss) Attributable To Noncontrolling Interest - Discontinuing Operations Plan Name [Domain] Plan Name [Domain] U.S. UNITED STATES Supply commitment, renewal term Supply Commitment, Renewal Term Supply Commitment, Renewal Term Entity Tax Identification Number Entity Tax Identification Number Operating leases: Operating Lease, Assets And Liabilities, Lessee [Abstract] Operating Lease, Assets And Liabilities, Lessee Carrying amount Finite-Lived Intangible Assets, Gross Schedule of Finite-Lived Intangible Assets [Table] Intangible Asset, Finite-Lived [Table] Schedule of Long-term Debt Instruments Schedule of Long-Term Debt Instruments [Table Text Block] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Accumulated other comprehensive income (loss) AOCI Including Portion Attributable to Noncontrolling Interest [Member] Operating Segments Operating Segments [Member] Accrued liabilities for intellectual property Accrued liabilities for intellectual property Accrued liabilities for intellectual property Net cash from operating activities Net Cash Provided by (Used in) Operating Activities Operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Income and other taxes Taxes Payable, Current Secured Debt Secured Debt [Member] Plan Name [Axis] Plan Name [Axis] Term Loan Facility, January 2024 Term Loan Facility, January 2024 [Member] Term Loan Facility, January 2024 Equity Components [Axis] Equity Components [Axis] Comprehensive loss attributable to noncontrolling interest - continuing operations Comprehensive Income (Loss) Attributable To Noncontrolling Interest - Continuing Operations Comprehensive Income (Loss) Attributable To Noncontrolling Interest - Continuing Operations Exercisable and vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price Harbor Harbor [Member] Harbor International International Segment [Member] International Segment Measurement Frequency [Axis] Measurement Frequency [Axis] Deferred amount Business Combination, Consideration Transferred, Deferred Amount Business Combination, Consideration Transferred, Deferred Amount Entity Common Stock, Shares Outstanding (in shares) Entity Common Stock, Shares Outstanding Finance leases Finance Lease, Weighted Average Remaining Lease Term Net cash from investing activities - discontinued operations Cash Provided by (Used in) Investing Activities, Discontinued Operations Proceeds from sale of a business Proceeds from Divestiture of Businesses Supply Commitment [Axis] Supply Commitment [Axis] Use of estimates Use of Estimates, Policy [Policy Text Block] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Options outstanding, Aggregate intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Disposal Group Classification [Axis] Disposal Group Classification [Axis] Loss from discontinued operations, net of tax Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax Entity Small Business Entity Small Business Developed technology and other Developed Technology Rights [Member] Geographical [Axis] Geographical [Axis] Level 3 Fair Value, Inputs, Level 3 [Member] Loss on disposals Loss on disposals Gain (Loss) on Disposition of Business Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Collaborative agreement, royalty percentage Collaborative Arrangement, Royalty Percentage Collaborative Arrangement, Royalty Percentage Schedule of Stock Options Roll Forward Schedule of Stock Options Roll Forward [Table Text Block] Current portion of contingent consideration Business Combination, Contingent Consideration, Liability, Current Accrued liabilities Accrued liabilities Accrued Liabilities, Current Antidilutive securities (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Equity-based compensation Compensation and Employee Benefit Plans [Text Block] Loss attributable to noncontrolling interest - discontinued operations Net loss attributable to noncontrolling interests â€“ discontinued operations Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Noncontrolling Interest Collaborative arrangement, sales threshold for royalties Collaborative Arrangement, Rights And Obligations, Royalties, Sales Threshold Collaborative Arrangement, Rights And Obligations, Royalties, Sales Threshold Payments for restructuring Payments for Restructuring Bonus and commission Accrued Bonuses, Current Credit Facility [Domain] Credit Facility [Domain] Cash, cash equivalents and restricted cash at the beginning of the period Cash, cash equivalents and restricted cash at the end of the period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Current assets: Assets, Current [Abstract] Goodwill Goodwill Consolidation Items [Axis] Consolidation Items [Axis] Net loss attributable to Bioventus Inc. Class A common stockholders â€“ continuing operations Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent Repayments of medium-term notes Repayments of Medium-Term Note Product and Service [Domain] Product and Service [Domain] Short-term lease cost Short-Term Lease, Cost Stock options Share-Based Payment Arrangement, Option [Member] Vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Fair Value Disclosures [Abstract] Other, net Proceeds from (Payments for) Other Financing Activities Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Security, Excluded EPS Calculation [Table] Comprehensive loss attributable to Bioventus Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent Carti Heal Carti Heal [Member] Carti Heal Finance leases Finance Lease, Weighted Average Discount Rate, Percent Repayments on revolver Repayments of Lines of Credit Security Exchange Name Security Exchange Name Debt instrument, lending margin, interest rate Debt Instrument, Basis Spread on Variable Rate Distribution rights Distribution Rights [Member] Award Type [Axis] Award Type [Axis] Revenue percentage of total net sales Revenue Percentage of Total Net Sales Revenue Percentage of Total Net Sales Total Inventory, Gross Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Accounts payable Disposal Group, Including Discontinued Operation, Accounts Payable Loss attributable to noncontrolling interest - discontinued operations Disposal Group, Including Discontinued Operation, Income (Loss) Attributable to Noncontrolling Interest Disposal Group, Including Discontinued Operation, Income (Loss) Attributable to Noncontrolling Interest Restructuring and succession charges Restructuring and Succession Charges Restructuring and Succession Charges Number of units Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Total liabilities Liabilities Noncontrolling interest Equity, Attributable to Noncontrolling Interest Other (income) expense Disposal Group, Including Discontinued Operation, Other (Income) Expenses Disposal Group, Including Discontinued Operation, Other (Income) Expenses Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Research and development expense Research and Development Expense Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Revolving Credit Facility Revolving Credit Facility [Member] Financing lease obligations Right-of-Use Asset Obtained in Exchange for Finance Lease Liability Inventory Disposal Group, Including Discontinued Operation, Inventory Disposal Group, Including Discontinued Operation, Inventory Investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Acquisitions and divestitures Acquisitions And Investments Disclosure [Text Block] Acquisitions And Investments Disclosure Net cash from operating activities - continuing operations Net Cash Provided by (Used in) Operating Activities, Continuing Operations 2021 and 2023 Plan 2021 and 2023 Plan [Member] 2021 and 2023 Plan Schedule of Assets and Liabilities, Lessee Assets And Liabilities, Lessee [Table Text Block] Assets And Liabilities, Lessee Operating lease liabilities - current Operating Lease, Liability, Current Common stock, shares issued (in shares) Common Stock, Shares, Issued Loss before income taxes Disposal Group, Including Discontinued Operation, Income (Loss) Before Income Taxes Disposal Group, Including Discontinued Operation, Income (Loss) Before Income Taxes Entity [Domain] Entity [Domain] Revolving credit facility, borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Concentration risk percentage Concentration Risk, Percentage Discontinued Operations, Disposed of by Means Other than Sale Discontinued Operations, Disposed of by Means Other

than Sale [Member] Total assets held for sale Disposal Group, Including Discontinued Operation, Assets Raw materials and supplies Inventory, Raw Materials and Supplies, Gross Property and equipment, gross Property, Plant and Equipment, Gross Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Tax receivable agreement, percent Tax Receivable Agreement, Percent Tax Receivable Agreement, Percent Debt Instrument [Line Items] Debt Instrument [Line Items] Weighted-average exercise price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Less accumulated depreciation and amortization Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization Debt instrument, covenant, liquidity, minimum Debt Instrument, Covenant, Liquidity, Minimum Debt Instrument, Covenant, Liquidity, Minimum Diluted (in shares) Weighted-average shares of Class A common stock outstanding - diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Expected future amortization, remainder of fiscal year Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Total stockholdersâ€™ equity attributable to Bioventus Inc. Equity, Attributable to Parent Collaborative arrangement, amount payable upon transfer of customer data Collaborative Arrangement, Rights And Obligations, Amount Payable Upon Transfer Of Data Collaborative Arrangement, Rights And Obligations, Amount Payable Upon Transfer Of Data Litigation Case [Axis] Litigation Case [Axis] Assets net yet placed in service Assets Not Yet Placed In Service [Member] Assets Not Yet Placed In Service Concentration Risk Type [Domain] Concentration Risk Type [Domain] Schedule of Other Ownership Interests Schedule of Other Ownership Interests [Table Text Block] Financial restructuring costs Gains (Losses) on Restructuring of Debt Letters of credit outstanding, amount Letters of Credit Outstanding, Amount Selling, general and administrative expense Selling, General and Administrative Expense Collaborative arrangement, royalty percentage, threshold one Collaborative Arrangement, Rights And Obligations, Royalty Percentage, Threshold One Collaborative Arrangement, Rights And Obligations, Royalty Percentage, Threshold One Fair Value, Recurring Fair Value, Recurring [Member] Accounts receivable, net Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Collaborative arrangement, adjusted amount payable upon obtaining product certification Collaborative Arrangement, Rights And Obligations, Adjusted Amount Payable Upon Obtaining Product Certification Collaborative Arrangement, Rights And Obligations, Adjusted Amount Payable Upon Obtaining Product Certification Demonstration and consignment inventory Demonstration And Consignment Inventory [Member] Demonstration And Consignment Inventory Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Sale of Stock [Domain] Sale of Stock [Domain] Number of shares authorized to be awarded (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Impairment of assets Impairments of assets Impairments of assets Asset Impairment Charges Assets held for sale Asset, Held-for-Sale, Not Part of Disposal Group, Current Long-term debt Long-Term Debt Document Fiscal Period Focus Document Fiscal Period Focus Acquisition and related costs Business Combination, Acquisition Related Costs Accounts receivable Accounts Receivable, before Allowance for Credit Loss, Current Expected future amortization, year two Finite-Lived Intangible Asset, Expected Amortization, Year Two Outstanding, weighted average remaining contractual term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Assets Assets [Abstract] Expected dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Document Type Document Type Effective interest rate Debt Instrument, Interest Rate, Effective Percentage Contingent consideration Business Combination, Contingent Consideration, Liability, Noncurrent Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Term Loan Facility, July 2022 Term Loan Facility, July 2022 [Member] Term Loan Facility, July 2022 Deferred Consideration Deferred Consideration [Member] Deferred Consideration Pain Treatments Pain Treatments [Member] Pain Treatments Maximum Maximum [Member] Intangible assets, net Finite-Lived Intangible Assets, Net Furniture and fixtures Furniture and Fixtures [Member] International Non-US [Member] Royalty expense Royalty Expense Antidilutive Securities [Axis] Antidilutive Securities [Axis] Accounts payable Accounts Payable, Current Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Unamortized discount Original issue discount Debt Instrument, Unamortized Discount Finite-lived intangible asset recognized Finite-Lived Intangible Asset, Recognized Finite-Lived Intangible Asset, Recognized Leasehold improvements Leasehold Improvements [Member] Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Current Fiscal Year End Date Current Fiscal Year End Date Total lease cost Lease, Cost Statistical Measurement [Axis] Statistical Measurement [Axis] Milestone payment paid Collaborative Arrangement, Rights And Obligations, Adjusted Amount Payable Upon Obtaining Product Certification, Initial Payment Paid Collaborative Arrangement, Rights And Obligations, Adjusted Amount Payable Upon Obtaining Product Certification, Initial Payment Paid CartiHeal Ltd CartiHeal Ltd [Member] CartiHeal Ltd Loss before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Number of shares issued (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period Award Type [Domain] Award Type [Domain] Accounts receivable Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Schedule of Held for Sale Assets and Liabilities Schedule of Balance Sheet and Statement of Operation Disposal Groups, Including Discontinued Operations [Table Text Block] Discontinued Operations, Held-for-sale Discontinued Operations, Held-for-Sale [Member] Schedule of Antidilutive Securities Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Deferred tax assets Deferred Income Tax Assets, Net Additional Paid-in Capital Additional Paid-in Capital [Member] Finance lease liabilitiesâ€”noncurrent Finance Lease, Liability, Noncurrent Other assets Disposal Group, Including Discontinued Operation, Other Assets Schedule of Accounts Receivable Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Class of Stock [Line Items] Class of Stock [Line Items] Term Loan Term Loan [Member] Term Loan Customer relationships Customer Relationships [Member] Customer One Customer One [Member] Customer One Recent accounting pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Loss per share of class A common stock, diluted (in dollars per share) Net loss per share of class A common stock, diluted (in dollars per share) Earnings Per Share, Diluted Class of Stock [Axis] Class of Stock [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Counterparty Name [Domain] Counterparty Name [Domain] Accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization Entity Interactive Data Current Entity Interactive Data Current Net loss attributable to Bioventus Inc. Class A common stockholders â€” discontinued operations Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent Ownership % Limited Liability Company or Limited Partnership, Members or Limited Partners, Ownership Interest Ownership [Axis] Ownership [Axis] Exercisable and vested (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term LLC Interests Limited Liability Company (LLC) Members' Equity, Including Portion Attributable to Noncontrolling Interest Accrued liabilities Disposal Group, Including Discontinued Operation, Accrued Liabilities Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Customer [Axis] Customer [Axis] Gross-to-net deductions Gross-To-Net Deductions, Current Gross-To-Net Deductions, Current Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Unrealized loss on foreign currency fluctuations Unrealized Gain (Loss), Foreign Currency Transaction, before Tax Statement of Financial Position [Abstract] Prepaid and other current assets Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current Restructuring costs Restructuring and Related Activities Disclosure [Text Block] Payment discount rate Business Combination, Contingent Consideration, Liability, Measurement Input Intangible assets, net before currency translation Finite-Lived Intangible Assets, Net, Before Foreign Currency Translation Gain (Loss) Finite-Lived Intangible Assets, Net, Before Foreign Currency Translation Gain (Loss) Equity-based compensation Share-Based Payment Arrangement, Noncash Expense Number of employees Entity Number of Employees Contingent Consideration Type [Domain] Contingent Consideration Type [Domain] Net loss Net loss Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Income tax (benefit) expense, net Income Tax Expense (Benefit) Supplemental disclosure of noncash investing and financing activities Supplemental Cash Flow Information [Abstract] Compensation expense net yet amortized, period for recognition Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Net sales Total net sales Revenue from Contract with Customer, Excluding Assessed Tax Other expense Nonoperating Income (Expense) Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Effective income tax rate Effective Income Tax Rate Reconciliation, Percent Net cash from investing activities Net Cash Provided by (Used in) Investing Activities Operating (loss) income Operating Income (Loss) Bioventus Shareholder Litigation Bioventus Shareholder Litigation [Member] Bioventus Shareholder Litigation Variable Rate [Domain] Variable Rate [Domain] Business Acquisition [Line Items] Business Acquisition [Line Items] Number of reportable segments Number of Reportable Segments Total liabilities and stockholdersâ€™ equity Liabilities and Equity Other, net Other Operating Activities, Cash Flow Statement Subsequent events Subsequent Events [Text Block] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Additional paid-in capital Additional Paid in Capital Net loss from discontinued operations Disposal Group, Including Discontinued Operation, Net Income (Loss) Disposal Group, Including Discontinued Operation, Net Income (Loss) Term Loan Facilities Term Loan Facilities [Member] Term Loan Facilities Restructuring costs Restructuring Charges Commitments and Contingencies Disclosure [Abstract] Loss from discontinued operations, net of tax Less: Loss from discontinued operations, net of tax Net loss from discontinued operations, net of tax Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Legal Entity [Axis] Legal Entity [Axis] Interest expense, net Interest expense, net Interest Income (Expense), Nonoperating Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Organization Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Operating lease obligations Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Measurement Input Type [Axis] Measurement Input Type [Axis] HA Product HA Product [Member] HA Product Interest expense, net Disposal Group, Including Discontinued Operation, Interest Expense Forfeited or canceled (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Expected life of stock options (years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Inventory Inventory, Net Total liabilities held for sale Disposal Group, Including Discontinued Operation, Liabilities Net cash from investing activities - continuing operations Net Cash Provided by (Used in) Investing Activities, Continuing Operations Product and Service [Axis] Product and Service [Axis] Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Entity Address, State or Province Entity Address, State or Province Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Statement [Line Items] Statement [Line Items] Measurement Input Type [Domain] Measurement Input Type [Domain] Assets Held for Sale [Abstract] Assets Held for Sale [Abstract] Assets Held for Sale Schedule of Reconciliation of Operating Profit (Loss) from Segments to Consolidated Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block] Potential total consideration Cash consideration Disposal Group, Including Discontinued Operation, Consideration Other liabilities Disposal Group, Including Discontinued Operation, Other Liabilities Schedule of Property and Equipment, Net Property, Plant and Equipment [Table Text Block] IPO IPO [Member] Weighted average remaining lease term (years) for leases Weighted Average Remaining Lease Term [Abstract] Weighted Average Remaining Lease Term 2021 Plan 2021 Plan [Member] 2021 Plan Beginning balance (in dollars per share) Ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Liabilities and Stockholders' Equity Liabilities and Equity [Abstract] 2023 Retention Equity Award Plan 2023 Retention Equity Award Plan [Member] 2023 Retention Equity Award Plan Compensation And Employee Benefit Plans [Abstract] Compensation And Employee Benefit Plans Minimum Minimum [Member] Change in fair value of contingent consideration Disposal Group, Including Discontinued Operation, Change in Fair Value of Contingent Consideration Disposal Group, Including Discontinued Operation, Change in Fair Value of Contingent Consideration Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Beginning balance (in dollars per share) Ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Sales Milestone Sales Milestone [Member] Sales Milestone Concentration Risk [Table] Concentration Risk [Table] Operating lease assets Operating Lease, Right-of-Use Asset Beginning balance (in shares) Ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (Benefit) provision for expected credit losses Accounts Receivable, Credit Loss Expense (Reversal) Segments [Axis] Segments [Axis] Long-term debt, gross Long-Term Debt, Gross Selling, general and administrative expense Disposal Group, Including Discontinued Operation, General and Administrative Expense Other items Other Nonrecurring Expense Earnings per share Earnings Per Share [Text Block] Subsequent Event Subsequent Event [Member] Loss per share of Class A common stock from continuing operations, basic (in dollars per share) Net loss per share of Class A common stock from continuing operations, basic (in dollars per share) Income (Loss) from Continuing Operations, Per Basic Share Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Investment and other assets Long-Term Investments Segments [Domain] Segments [Domain] Debt instrument, term Debt Instrument, Term Total financing lease liabilities Finance Lease, Liability Expected future amortization, year four Finite-Lived Intangible Asset, Expected Amortization, Year Four Bioventus Inc. BV LLC [Member] BV LLC Rehabilitation Business Rehabilitation Business [Member] Rehabilitation Business Loss per share of Class A common stock from discontinuing operations, diluted (in dollars per share) Net loss per share of Class A common stock from discontinuing operations, diluted (in dollars per share) Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share Bioventus and Continuing LLC Owner Bioventus And Continuing LLC Owner [Member] Bioventus And Continuing LLC Owner Variable Rate [Axis] Variable Rate [Axis] Income Tax Disclosure [Abstract] Other expense (income) Other Nonoperating Income (Expense) Restorative Therapies Restorative Therapies [Member] Restorative Therapies Statement of Stockholders' Equity [Abstract] Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Disposal Group Name [Axis] Disposal Group Name [Axis] Currency translation Finite-Lived Intangible Assets, Accumulated Foreign Currency Translation Gain (Loss) Finite-Lived Intangible Assets, Accumulated Foreign Currency Translation Gain (Loss) Lessee, operating lease, remaining lease term Lessee, Operating Lease, Remaining Lease Term Accrued interest Interest Payable Unamortized compensation expense, RSUs Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Exercisable and vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract] Line of credit facility, number of LOCs outstanding Line Of Credit Facility, Number Of Letters Of Credit Outstanding Line Of Credit Facility, Number Of Letters Of Credit Outstanding Debt refinancing costs Payment Of Debt Refinancing Costs Payment Of Debt Refinancing Costs Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] Depreciation and amortization Cost, Depreciation and Amortization Business acquisition, percentage of shares transferred to trustee Business Acquisition, Percentage Of Shares Transferred To Trustee Business Acquisition, Percentage Of Shares Transferred To Trustee Local Phone Number Local Phone Number Supplier of Single Injection OA Product Supplier Of Single Injection OA Product [Member] Supplier Of Single Injection OA Product Deferred income taxes Deferred Income Tax Liabilities, Net Risk-free interest rate, maximum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Valuation Approach and Technique [Axis] Valuation Approach and Technique [Axis] Other (income) expense Disposal Group, Including Discontinued Operation, Other Income (Expense) Disposal Group, Including Discontinued Operation, Other Income (Expense) Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Revolver credit capacity reduced amount Line of Credit Facility, Increase (Decrease), Net Secured Overnight Financing Rate (SOFR) Secured Overnight Financing Rate (SOFR) [Member] Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Schedule of Accrued Liabilities Schedule of Accrued Liabilities [Table Text Block] Entity Ex Transition Period Entity Ex Transition Period Impairment of intangible assets Impairment of Intangible Assets, Finite-Lived Commitments and contingencies Commitments and Contingencies Disclosure [Text Block] Debt Disclosure [Abstract] Common Stock Common Stock [Member] Number of derivative shareholder lawsuits Loss Contingency, Number of Derivative Shareholder Lawsuits Loss Contingency, Number of Derivative Shareholder Lawsuits Common stock closing price, (in dollars per share) Share Price Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Issuance of Class A common stock for equity plans (in shares) Stock Issued During Period,

Shares, New Issues Line of Credit Line of Credit [Member] Entity Emerging Growth Company Entity Emerging Growth Company Total liabilities: Liabilities, Fair Value Disclosure Segment Reporting [Abstract] Entity Central Index Key Entity Central Index Key Collaborative arrangement, upfront payments Collaborative Arrangement, Rights And Obligations, Upfront Payment Collaborative Arrangement, Rights And Obligations, Upfront Payment Liabilities held for sale Liabilities Held-for-sale, Not Part of Disposal Group, Current Liabilities Held-for-sale, Not Part of Disposal Group, Current Schedule of Inventory Schedule of Inventory, Current [Table Text Block] Supply commitment, term Supply Commitment, Term Supply Commitment, Term Discontinued Operations and Disposal Groups [Abstract] U.S. U.S. Segment [Member] U.S. Segment Expected stock price volatility, minimum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Property, plant and equipment, net (finance leases) Finance Lease, Right-of-Use Asset, after Accumulated Amortization Stockholdersâ€™ equity Equity [Text Block] Accounts payable and accrued expenses Increase (Decrease) in Accounts Payable and Accrued Liabilities Equity Component [Domain] Equity Component [Domain] Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Swingline Loan Bridge Loan [Member] Segments Segment Reporting Disclosure [Text Block] Current portion of long-term debt Current portion of long-term debt Long-Term Debt, Current Maturities Net cash from operating activities - discontinued operations Cash Provided by (Used in) Operating Activities, Discontinued Operations Equity based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Change in fair value of contingent consideration Change in fair value of contingent consideration Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Collaborative arrangement, royalty percentage, threshold two Collaborative Arrangement, Rights And Obligations, Royalty Percentage, Threshold Two Collaborative Arrangement, Rights And Obligations, Royalty Percentage, Threshold Two Entity Shell Company Entity Shell Company Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Common Class B Common Class B [Member] Statement [Table] Statement [Table] Interest expense, debt Interest Expense, Debt Measurement Frequency [Domain] Measurement Frequency [Domain] Counterparty Name [Axis] Counterparty Name [Axis] Transactional fees Disposal Group, Including Discontinued Operation, Transactional Fees Incurred Disposal Group, Including Discontinued Operation, Transactional Fees Incurred Consolidation Items [Domain] Consolidation Items [Domain] Earn-out payments Disposal Group, Including Discontinued Operation, Earn-Out Payments Disposal Group, Including Discontinued Operation, Earn-Out Payments Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract] Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract] City Area Code City Area Code Current liabilities: Liabilities, Current [Abstract] Shareholder litigation costs Shareholder Litigation Costs Shareholder Litigation Costs Cash Disposal Group, Including Discontinued Operation, Cash Contingent consideration Business Combination, Contingent Consideration, Liability Property and equipment and finance leases, gross Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization Disposal Group Classification [Domain] Disposal Group Classification [Domain] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Change in foreign currency translation adjustments Translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Total current assets Assets, Current Statement of Cash Flows [Abstract] Settlement and legal fees Accrued Legal Liabilities Accrued Legal Liabilities Stop loss insurance, threshold per member per year Stop Loss Insurance, Threshold Per Member Per Year Stop Loss Insurance, Threshold Per Member Per Year Line of credit facility, remaining borrowing capacity Line of Credit Facility, Remaining Borrowing Capacity Document Information [Line Items] Document Information [Line Items] Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Long-term debt, less current portion Long-Term Debt, Excluding Current Maturities Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Fair Value Measurement Inputs and Valuation Techniques Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Weighted-average grant-date fair value per unit Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Weighted-average fair value of stock options granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Insurance settlement receivable Insurance Settlements Receivable Subsequent Event Type [Axis] Subsequent Event Type [Axis] Non-refundable payments Non Refundable Payments Non Refundable Payments Income taxes Income Tax Disclosure [Text Block] Loss per share of Class A common stock Earnings Per Share [Abstract] Numerator: Net Income (Loss) Attributable to Parent [Abstract] Equity [Abstract] Loss attributable to noncontrolling interest - continuing operations Net loss attributable to noncontrolling interests â€” continuing operations Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest Accumulated deficit Retained Earnings (Accumulated Deficit) Income tax benefit, net Disposal Group, Including Discontinued Operation, Income Tax Expense (Benefit) Disposal Group, Including Discontinued Operation, Income Tax Expense (Benefit) Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Collaborative arrangement, amount payable upon obtaining product certification Collaborative Arrangement, Rights And Obligations, Amount Payable Upon Obtaining Product Certification Collaborative Arrangement, Rights And Obligations, Amount Payable Upon Obtaining Product Certification Class of Stock [Domain] Class of Stock [Domain] Inventories Increase (Decrease) in Inventories Valuation Technique, Discounted Cash Flow Valuation Technique, Discounted Cash Flow [Member] Payment on revolver Repayments of Long-Term Lines of Credit Debt issuance costs, gross Debt Issuance Costs, Gross Net loss attributable to Bioventus Inc. - discontinued operations Disposal Group, Including Discontinued Operation, Net Income (Loss) to Parent Disposal Group, Including Discontinued Operation, Net Income (Loss) to Parent Deferred income taxes Deferred Income Taxes and Tax Credits Term Loan Facility, March 2023 Term Loan Facility, March 2023 [Member] Term Loan Facility, March 2023 Litigation settlement, amount awarded to other party Litigation Settlement, Amount Awarded to Other Party Organization, Consolidation and Presentation of Financial Statements [Abstract] Operating leases Operating Lease, Weighted Average Discount Rate, Percent Total operating lease liabilities Operating Lease, Liability Net cash from financing activities Net Cash Provided by (Used in) Financing Activities Right-of-use assets obtained in exchange for lease obligations: Right-Of-Use Asset Obtained In Exchange For Lease Liability [Abstract] Right-Of-Use Asset Obtained In Exchange For Lease Liability Credit Facility [Axis] Credit Facility [Axis] Amendment Flag Amendment Flag Long-term debt, fair value Long-Term Debt, Fair Value Entity Registrant Name Entity Registrant Name Investments and acquisition of distribution rights Proceeds From (Payments For) Acquisition Of Intangible Assets And Investments Proceeds From (Payments For) Acquisition Of Intangible Assets And Investments Depreciation and amortization Depreciation and amortization Depreciation, Depletion and Amortization Gross profit Gross Profit Machinery and equipment Machinery and Equipment [Member] Amortization of finance lease assets Finance Lease, Right-of-Use Asset, Amortization Customer Customer Concentration Risk [Member] Subsequent Events [Abstract] Liabilities Held for Sale [Abstract] Liabilities Held for Sale [Abstract] Liabilities Held for Sale Number of shares issued in public offering (in shares) Sale of Stock, Number of Shares Issued in Transaction Level 2 Fair Value, Inputs, Level 2 [Member] Unamortized debt issuance cost Deferred financing costs Debt Issuance Costs, Net Financial instruments Debt Disclosure [Text Block] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Stockholdersâ€™ Equity Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Geographical [Domain] Geographical [Domain] Debt instrument, face amount Debt Instrument, Face Amount Schedule of Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] Intangible assets Disposal Group, Including Discontinued Operation, Intangible Assets Issuance of Class A common stock for equity plans Stock Issued During Period, Value, New Issues Entity Address, Postal Zip Code Entity Address, Postal Zip Code Cash paid for amounts included in measurement of lease liabilities: Cash Flow, Lessee [Abstract] Cash Flow, Lessee Title of 12(b) Security Title of 12(b) Security Concentration Risk Type [Axis] Concentration Risk Type [Axis] Common stock, value Common Stock, Value, Issued Operating cash flows from financing leases Finance Lease, Interest Payment on Liability Loss per share of Class A common stock from discontinuing operations, basic (in dollars per share) Net loss per share of Class A common stock from discontinuing operations, basic (in dollars per share) Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share Change in noncontrolling interest allocation Noncontrollingâ€‹ Interest â€‹Increaseâ€‹ (Decrease) From â€‹Businessâ€‹ Combination Noncontrollingâ€‹ Interest â€‹Increaseâ€‹ (Decrease) From â€‹Businessâ€‹ Combination Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Number of shares issued in acquisition (in shares) Stock Issued During Period, Shares, Acquisitions Surgical Solutions Surgical Solutions [Member] Surgical Solutions Exercisable and vested Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Forfeited or canceled (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Loss on debt retirement and modification Gain (Loss) on Extinguishment of Debt Impairments of assets Impairment of Intangible Assets (Excluding Goodwill) Financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Concentration Risk [Line Items] Concentration Risk [Line Items] Finished goods Inventory, Finished Goods, Gross Finance leases: Finance Lease, Assets And Liabilities, Lessee [Abstract] Finance Lease, Assets And Liabilities, Lessee Number of options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Employee Stock Employee Stock [Member] Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction Valuation Approach and Technique [Domain] Valuation Approach and Technique [Domain] Net loss per share of class A common stock, basic (in dollars per share) Earnings Per Share, Basic Proceeds from issuance of Class A common stock Proceeds from Issuance of Common Stock Operating cash flows from operating leases Operating Lease, Payments Bioness, Inc Bioness contingent consideration Bioness, Inc [Member] Bioness, Inc Expiration period Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Property and equipment, net Property and equipment and finance leases, net Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization Ownership [Domain] Ownership [Domain] Financing cash flows from finance leases Finance Lease, Principal Payments Research and development expense Disposal Group, Including Discontinued Operation, Research and Development Expense Disposal Group, Including Discontinued Operation, Research and Development Expense Accounts payable for purchase of property, plant and equipment Capital Expenditures Incurred but Not yet Paid Inventory [Table] Accrued Liabilities [Table] Goodwill [Table] Schedule of Stock by Class [Table] Stock, Class of Stock [Table] Total current liabilities Liabilities, Current Unamortized compensation expense, options Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Total assets Assets Expected future amortization, year one Finite-Lived Intangible Asset, Expected Amortization, Year One Cost of sales (including depreciation and amortization of $11,021, $12,301, $21,046 and $26,640, respectively) Cost of Goods and Services Sold Outstanding borrowings on line of credit Long-Term Line of Credit Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Purchase of property and equipment Payments to Acquire Property, Plant, and Equipment Other long-term liabilities Other Liabilities, Noncurrent Commitments and contingencies (Note 11) Commitments and Contingencies Risk-free interest rate, minimum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Continuing LLC Owner Continuing LLC Owner [Member] Continuing LLC Owner Three Injection OA Product Three Injection OA Product [Member] Three Injection OA Product Expected stock price volatility, maximum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Revenues Revenues Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Entity Address, City or Town Entity Address, City or Town Debt Instrument [Axis] Debt Instrument [Axis] Equity compensation Equity compensation Share-Based Payment Arrangement, Expense Discontinued operations Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] Net loss attributable to Bioventus Inc. Net Income (Loss) Attributable to Parent Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Computer equipment and software Computer Equipment And Software [Member] Computer Equipment And Software Loss Contingencies [Table] Loss Contingencies [Table] Forfeited or canceled (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Business Acquisition [Axis] Business Acquisition [Axis] Schedule of Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Segment Adjusted EBITDA Adjusted Earnings Before Interest, Taxes, Depreciation, Amortization And Other Non-Operating Items Adjusted Earnings Before Interest, Taxes, Depreciation, Amortization And Other Non-Operating Items Cancellation ratio, required stock to LLC interest ratio Cancellation Ratio, Required Stock To LLC Interest Ratio Cancellation Ratio, Required Stock To LLC Interest Ratio Entity File Number Entity File Number Liabilities: Liabilities, Fair Value Disclosure [Abstract] Revenue recognition Revenue from Contract with Customer [Text Block] Document Fiscal Year Focus Document Fiscal Year Focus Non- controlling interest Noncontrolling Interest [Member] Income Statement [Abstract] Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Weighted average discount rate for leases Leases, Weighted Average Discount Rate [Abstract] Leases, Weighted Average Discount Rate Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Wound Business Wound Business [Member] Wound Business Effect of exchange rate changes on cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Weighted-average shares of Class A common stock outstanding Denominator: Weighted Average Number of Shares Outstanding, Basic [Abstract] Other liabilities(a) Other Accrued Liabilities, Current Operating leases Operating Lease, Weighted Average Remaining Lease Term Document Period End Date Document Period End Date Sale of Stock [Axis] Sale of Stock [Axis] Contingent Consideration by Type [Axis] Contingent Consideration by Type [Axis] Finance lease liabilitiesâ€”current Finance Lease, Liability, Current Base Rate Base Rate [Member] Deferral period Business Combination, Consideration Transferred, Deferral Period Business Combination, Consideration Transferred, Deferral Period Beginning balance (in shares) Ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Balance sheet information Supplemental Balance Sheet Disclosures [Text Block] Segment Reconciling Items Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment [Member] LLC Interests held by Continuing LLC Owner Limited Liability Company Interests [Member] Limited Liability Company Interests Loss on deconsolidation Deconsolidation, Gain (Loss), Amount Number of votes per common share Common Stock, Number Of Votes Common Stock, Number Of Votes Disposed of by Sale Discontinued Operations, Disposed of by Sale [Member] Loss per share of Class A common stock from continuing operations, diluted (in dollars per share) Net loss per share of Class A common stock from continuing operations, diluted (in dollars per share) Income (Loss) from Continuing Operations, Per Diluted Share Intellectual Property Intellectual Property [Member] Prepaid and other current assets Prepaid Expense and Other Assets, Current Accounts Receivable Accounts Receivable [Member] Operating lease assets Disposal Group, Including Discontinued Operation, Operating Lease Assets Disposal Group, Including Discontinued Operation, Operating Lease Assets Reclassifications Reclassification, Comparability Adjustment [Policy Text Block] Document Transition Report Document Transition Report Document Quarterly Report Document Quarterly Report Litigation Case [Domain] Litigation Case [Domain] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Customer [Domain] Customer [Domain] Accumulated other comprehensive (loss) income Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Current Reporting Status Entity Current Reporting Status Accumulated Deficit Retained Earnings [Member] Amortization of debt issuance costs Amortization of Debt Issuance Costs Basic (in shares) Weighted-average shares of Class A common stock outstanding - basic (in shares) Weighted Average Number of Shares Outstanding, Basic Document Information [Table] Document Information [Table] Total stockholdersâ€™ equity Beginning balance Ending balance Equity, Including Portion Attributable to Noncontrolling Interest RSUs Restricted Stock Units (RSUs) [Member] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Supply Commitment Arrangement [Domain] Supply Commitment Arrangement [Domain] Revenues Revenue Reclassified During Period Revenue Reclassified During Period Depreciation and amortization Disposal Group, Including Discontinued Operation, Depreciation and Amortization Revenue Benchmark Revenue Benchmark [Member] Forfeited or canceled (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Payments on long-term debt Repayments of Other Long-Term Debt Entity Filer Category Entity Filer Category Loss Contingencies [Line Items] Loss Contingencies [Line Items] Letter of Credit Letter of Credit [Member] EX-101.PRE 9 bvs-20240629_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 R1.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Cover Page - shares 6 Months Ended Jun. 29, 2024 Jul. 30, 2024 Document Information [Line Items] Â Â Document Type 10-Q Â Document Quarterly Report true Â Document Period End Date Jun. 29, 2024 Â Document Transition Report false Â Entity File Number 001-37844 Â Entity Registrant Name BIOVENTUS INC. Â Entity Incorporation, State or Country Code DE Â Entity Tax Identification Number 81-0980861 Â Entity Address, Address Line One 4721 Emperor Boulevard Â Entity Address, Address Line Two Suite 100 Â Entity Address, City or Town Durham Â Entity Address, State or Province NC Â Entity Address, Postal Zip Code 27703 Â City Area Code 919 Â Local Phone Number 474-6700 Â Title of 12(b) Security Class A Common Stock, $0.001 par value per share Â Trading Symbol BVS Â Security Exchange Name NASDAQ Â Entity Current Reporting Status Yes Â Entity Interactive Data Current Yes Â Entity Filer Category

Accelerated Filer Â Entity Small Business true Â Entity Emerging Growth Company true Â Entity Ex Transition Period true Â Entity Shell Company false Â Amendment Flag false Â Entity Central Index Key 0001665988 Â Current Fiscal Year End Date --12-31 Â Document Fiscal Year Focus 2024 Â Document Fiscal Period Focus Q2 Â Common Class A Â Â Document Information [Line Items] Â Â Entity Common Stock, Shares Outstanding (in shares) Â 65,186,901 Common Class B Â Â Document Information [Line Items] Â Â Entity Common Stock, Shares Outstanding (in shares) Â 15,786,737 X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: dei_DocumentInformationLineItems Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 2 such as Street or Suite number + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine2 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 7A -Section B -Subsection 2 + Details Name: dei_EntityExTransitionPeriod Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 12 R2.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Consolidated Condensed Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 29, 2024 Jul. 01, 2023 Jun. 29, 2024 Jul. 01, 2023 Income Statement [Abstract] Â Â Â Â Net sales $ 151,217 $ 137,069 $ 280,674 $ 256,128 Cost of sales (including depreciation and amortization of $11,021, $12,301, $21,046 and $26,640, respectively) 47,578 47,946 88,655 93,086 Gross profit 103,639 89,123 192,019 163,042 Selling, general and administrative expense 94,785 74,844 173,191 155,702 Research and development expense 3,988 3,398 6,585 7,169 Restructuring costs 0 620 0 937 Change in fair value of contingent consideration 300 240 595 527 Depreciation and amortization 2,064 2,294 3,819 4,423 Impairments of assets 31,870 0 31,870 78,615 Loss on disposals 0 977 0 977 Operating (loss) income (29,368) 6,750 (24,041) (85,308) Interest expense, net 9,924 10,587 20,263 20,281 Other expense (income) 159 513 222 (1,075) Other expense 10,083 11,100 20,485 19,206 Loss before income taxes (39,451) (4,350) (44,526) (104,514) Income tax (benefit) expense, net (7,339) 381 (6,432) 235 Net loss from continuing operations (32,112) (4,731) (38,094) (104,749) Loss from discontinued operations, net of tax 0 0 0 (74,429) Net loss (32,112) (4,731) (38,094) (179,178) Loss attributable to noncontrolling interest - continuing operations 8,120 1,050 9,532 21,410 Loss attributable to noncontrolling interest - discontinued operations 0 0 0 14,937 Net loss attributable to Bioventus Inc. (23,992) (3,681) (28,562) (142,831) Change in foreign currency translation adjustments (426) 303 (1,011) 960 Comprehensive loss (32,538) (4,428) (39,105) (178,218) Comprehensive loss attributable to noncontrolling interest - continuing operations 8,204 989 9,732 21,215 Comprehensive loss attributable to noncontrolling interest - discontinued operations 0 0 0 14,937 Comprehensive loss attributable to Bioventus Inc. $ (24,334) $ (3,439) $ (29,373) $ (142,066) Loss per share of Class A common stock Â Â Â Â Loss per share of Class A common stock from continuing operations, basic (in dollars per share) $ (0.37) $ (0.06) $ (0.45) $ (1.34) Loss per share of Class A common stock from continuing operations, diluted (in dollars per share) (0.37) (0.06) (0.45) (1.34) Loss per share of Class A common stock from discontinuing operations, basic (in dollars per share) 0 0 0 (0.95) Loss per share of Class A common stock from discontinuing operations, diluted (in dollars per share) 0 0 0 (0.95) Net loss per share of class A common stock, basic (in dollars per share) (0.37) (0.06) (0.45) (2.29) Loss per share of class A common stock, diluted (in dollars per share) $ (0.37) $ (0.06) $ (0.45) $ (2.29) Weighted-average shares of Class A common stock outstanding Â Â Â Â Basic (in shares) 64,056,759 62,551,285 63,720,342 62,338,018 Diluted (in shares) 64,056,759 62,551,285 63,720,342 62,338,018 X - DefinitionComprehensive Income (Loss) Attributable To Noncontrolling Interest - Continuing Operations + ReferencesNo definition available. + Details Name: bvs_ComprehensiveIncomeLossAttributableToNoncontrollingInterestContinuingOperations Namespace Prefix: bvs_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionComprehensive Income (Loss) Attributable To Noncontrolling Interest - Discontinuing Operations + ReferencesNo definition available. + Details Name: bvs_ComprehensiveIncomeLossAttributableToNoncontrollingInterestDiscontinuingOperations Namespace Prefix: bvs_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4 + Details Name: us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5 + Details Name: us-gaap_ComprehensiveIncomeNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K + Details Name: us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate costs related to goods produced and sold and services rendered by an entity

during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 + Details Name: us-gaap_CostOfGoodsAndServicesSold Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_DepreciationAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1B + Details Name: us-gaap_GainLossOnSaleOfBusiness Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_GrossProfit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3 + Details Name: us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount after tax of income (loss) from continuing operations attributable to the noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15 + Details Name: us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X -

DefinitionAmount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7Reference 17: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromContinuingOperationsPerBasicShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477349/740-270-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3AReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3BReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-4Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting

Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3 + Details Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of income (loss) from a discontinued operation attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3AReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-4Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15 + Details Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPer basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionPer diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 5.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479836/810-10-S99-5 + Details Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncomeStatementAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of interest income (expense) classified as nonoperating. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 + Details Name: us-gaap_InterestIncomeExpenseNonoperatingNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_NonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -

Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (a) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1 + Details Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (expense) related to nonoperating activities, classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherNonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.P.3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1 + Details Name: us-gaap_RestructuringCharges Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_SellingGeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher

FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 13 R3.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Consolidated Condensed Statements of Operations and Comprehensive Loss (Parenthetical) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 29, 2024 Jul. 01, 2023 Jun. 29, 2024 Jul. 01, 2023 Income Statement [Abstract] Â Â Â Â Depreciation and amortization $ 11,021 $ 12,301 $ 21,046 $ 26,640 X - DefinitionAmount of expense for allocation of cost of tangible and intangible assets over their useful lives directly used in production of good and rendering of service. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncomeStatementAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 14 R4.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Consolidated Condensed Balance Sheets - USD ($) $ in Thousands Jun. 29, 2024 Dec. 31, 2023 Current assets: Â Â Cash and cash equivalents $ 31,994 $ 36,964 Accounts receivable, net 137,305 122,789 Inventory 87,606 91,333 Prepaid and other current assets 23,570 16,913 Assets held for sale 28,408 0 Total current assets 308,883 267,999 Property and equipment, net 31,938 36,605 Goodwill 7,462 7,462 Intangible assets, net 424,552 482,350 Operating lease assets 10,366 13,353 Deferred tax assets 6,884 0 Investment and other assets 2,088 3,141 Total assets 792,173 810,910 Current liabilities: Â Â Accounts payable 24,437 23,038 Accrued liabilities 139,978 119,795 Current portion of long-term debt 38,566 27,848 Current portion of contingent consideration 18,745 0 Other current liabilities 3,829 4,816 Liabilities held for sale 5,908 0 Total current liabilities 231,463 175,497 Long-term debt, less current portion 344,716 366,998 Deferred income taxes 0 1,213 Contingent consideration 0 18,150 Other long-term liabilities 26,932 27,934 Total liabilities 603,111 589,792 Commitments and contingencies (Note 11) Stockholdersâ€™ Equity Â Â Additional paid-in capital 500,969 494,254 Accumulated deficit (350,098) (321,536) Accumulated other comprehensive (loss) income (17) 794 Total stockholdersâ€™ equity attributable to Bioventus Inc. 150,935 173,591 Noncontrolling interest 38,127 47,527 Total stockholdersâ€™ equity 189,062 221,118 Total liabilities and stockholdersâ€™ equity 792,173 810,910 Common Class A Â Â Stockholdersâ€™ Equity Â Â Common stock, value 65 63 Common Class B Â Â Stockholdersâ€™ Equity Â Â Common stock, value $ 16 $ 16 X - DefinitionLiabilities Held-for-sale, Not Part of Disposal Group, Current + ReferencesNo definition available. + Details Name: bvs_LiabilitiesHeldForSaleNotPartOfDisposalGroupCurrent Namespace Prefix: bvs_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2 + Details Name: us-gaap_AccountsReceivableNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher

FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of assets held-for-sale that are not part of a disposal group, expected to be sold within a year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 15 -Paragraph 4 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482309/360-10-15-4 + Details Name: us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6 + Details Name: us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6 + Details Name: us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommitmentsAndContingencies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6 + Details Name: us-gaap_DeferredIncomeTaxAssetsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(15)(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6 + Details Name: us-gaap_DeferredIncomeTaxLiabilitiesNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Goodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1 + Details Name: us-gaap_IntangibleAssetsNetExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_MinorityInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liabilities classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_OtherLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities classified as other, due after one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherLiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -SubTopic 20 -Topic 842 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -

Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a)(3)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (i)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 34: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 38: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 40: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 41: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 42: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4I -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4IReference 49: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1 + Details Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 15 R5.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Consolidated Condensed Balance Sheets (Parenthetical) - $ / shares Jun. 29, 2024 Dec. 31, 2023 Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001 Preferred stock, shares authorized (in shares) 10,000,000 10,000,000 Preferred stock, shares issued (in shares) 0 0 Common Class A Â Â Common stock, par value (in dollars per share) $ 0.001 $ 0.001 Common stock, shares authorized (in shares) 250,000,000 250,000,000 Common stock, shares outstanding (in shares) 65,172,159 63,267,436 Common stock, shares issued (in shares) 65,172,159 63,267,436 Common Class B Â Â Common stock, par value (in dollars per share) $ 0.001 $ 0.001 Common stock, shares authorized (in shares) 50,000,000 50,000,000 Common stock, shares outstanding (in shares) 15,786,737 15,786,737 Common stock, shares issued (in shares) 15,786,737 15,786,737 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-

02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 16 R6.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Consolidated Condensed Statements of Changes in Stockholdersâ€™ Equity - USD ($) $ in Thousands Total Common Class A Common Class B Common Stock Common Class A Common Stock Common Class B Additional Paid-in Capital Accumulated other comprehensive income (loss) Accumulated Deficit Non- controlling interest Beginning balance (in shares) at Dec. 31, 2022 Â Â Â 62,063,014 15,786,737 Â Â Â Â Beginning balance at Dec. 31, 2022 $ 412,222 Â Â $ 62 $ 16 $ 490,576 $ (110) $ (165,306) $ 86,984 Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Â Â Â Â Â Issuance of Class A common stock for equity plans (in shares) Â Â Â 741,492 Â Â Â Â Â Issuance of Class A common stock for equity plans 223 Â Â $ 1 Â 222 Â Â Â Net loss (179,178) Â Â Â Â Â Â (142,831) (36,347) Change in noncontrolling interest allocation 0 Â Â Â Â 385 Â Â (385) Equity based compensation (886) Â Â Â Â (585) Â Â (301) Translation adjustment 960 Â Â Â Â Â 765 Â 195 Ending balance (in shares) at Jul. 01, 2023 Â Â Â 62,804,506 15,786,737 Â Â Â Â Ending balance at Jul. 01, 2023 233,341 Â Â $ 63 $ 16 490,598 655 (308,137) 50,146 Beginning balance (in shares) at Apr. 01, 2023 Â Â Â 62,507,917 15,786,737 Â Â Â Â Beginning balance at Apr. 01, 2023 240,362 Â Â $ 63 $ 16 492,475 413 (304,456) 51,851 Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Â Â Â Â Â Issuance of Class A common stock for equity plans (in shares) Â Â Â 296,589 Â Â Â Â Â Issuance of Class A common stock for equity plans 139 Â Â Â Â 139 Â Â Â Net loss (4,731) Â Â Â Â Â Â (3,681) (1,050) Change in noncontrolling interest allocation 0 Â Â Â Â 108 Â Â (108) Equity based compensation (2,732) Â Â Â Â Â (2,124) Â Â (608) Translation adjustment 303 Â Â Â Â Â 242 Â 61 Ending balance (in shares) at Jul. 01, 2023 Â Â Â 62,804,506 15,786,737 Â Â Â Â Ending balance at Jul. 01, 2023 233,341 Â Â $ 63 $ 16 490,598 655 (308,137) 50,146 Beginning balance (in shares) at Dec. 31, 2023 Â 63,267,436 15,786,737 63,267,436 15,786,737 Â Â Â Â Beginning balance at Dec. 31, 2023 221,118 Â Â $ 63 $ 16 494,254 794 (321,536) 47,527 Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Â Â Â Â Â Issuance of Class A common stock for equity plans (in shares) Â Â Â 1,904,723 Â Â Â Â Â Issuance of Class A common stock for equity plans 786 Â Â $ 2 Â 784 Â Â Â Net loss (38,094) Â Â Â Â Â Â (28,562) (9,532) Change in noncontrolling interest allocation 0 Â Â Â Â 821 Â Â (821) Equity based compensation 6,263 Â Â Â Â 5,110 Â Â 1,153 Translation adjustment (1,011) Â Â Â Â Â (811) Â (200) Ending balance (in shares) at Jun. 29, 2024 Â 65,172,159 15,786,737 65,172,159 15,786,737 Â Â Â Â Ending balance at Jun. 29, 2024 189,062 Â Â $ 65 $ 16 500,969 (17) (350,098) 38,127 Beginning balance (in shares) at Mar. 30, 2024 Â Â Â 63,672,170 15,786,737 Â Â Â Â Beginning balance at Mar. 30, 2024 217,432 Â Â $ 64 $ 16 496,977 325 (326,106) 46,156 Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Â Â Â Â Â Issuance of Class A common stock for equity plans (in shares) Â Â Â 1,499,989 Â Â Â Â Â Issuance of Class A common stock for equity plans 496 Â Â $ 1 Â 495 Â Â Â Net loss (32,112) Â Â Â Â Â Â (23,992) (8,120) Change in noncontrolling interest allocation 0 Â Â Â Â 502 Â Â (502) Equity based compensation 3,672 Â Â Â Â 2,995 Â 677 Translation adjustment (426) Â Â Â Â Â (342) Â (84) Ending balance (in shares) at Jun. 29, 2024 Â 65,172,159 15,786,737 65,172,159 15,786,737 Â Â Â Â Ending balance at Jun. 29, 2024 $ 189,062 Â Â $ 65 $ 16 $ 500,969 $ (17) $ (350,098) $ 38,127 X - DefinitionNoncontrollingâ€‹ Interest â€‹Increaseâ€‹ (Decrease) From â€‹Businessâ€‹ Combination + ReferencesNo definition available. + Details Name: bvs_NoncontrollingInterestIncreaseDecreaseFromBusinessCombination Namespace Prefix: bvs_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInStockholdersEquityRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (a) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1 + Details Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5:

http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a)(3)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (i)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 34: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 38: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 40: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 41: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 42: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4I -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4IReference 49: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1 + Details Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 17 R7.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Consolidated Condensed Statements of Cash Flows - USD ($) $ in Thousands 6 Months Ended Jun. 29, 2024 Jul. 01, 2023 Operating activities: Â Â Net loss $ (38,094) $ (179,178) Less: Loss from discontinued operations, net of tax 0 (74,429) Net loss from continuing operations (38,094) (104,749) Adjustments to reconcile net loss to net cash from operating activities: Â Â Depreciation and amortization 24,875 31,073 (Benefit) provision for expected credit losses (537) 640 Equity-based compensation 6,263 (886) Change in fair value of contingent consideration 595 527 Deferred income taxes (8,098) (3,540) Impairment of assets 31,870 78,615 Loss on disposals 0 977 Unrealized loss on foreign currency fluctuations 536 601 Other, net 961 1,139 Changes in operating assets and liabilities: Â Â Accounts receivable (21,933) 11,329 Inventories (8,359) (13,074) Accounts payable and accrued expenses 22,552 14,765 Other current and noncurrent assets and liabilities (1,474) (1,963) Net cash from operating activities - continuing operations 9,157 15,454 Net cash from operating activities - discontinued operations 0 (2,169) Net cash from operating activities 9,157 13,285 Investing activities: Â Â Proceeds from sale of a business 0 34,897 Purchase of property and equipment (368) (4,957) Investments and acquisition of distribution rights (709) 0 Net cash from investing activities - continuing operations (1,077) 29,940 Net cash from investing activities - discontinued operations 0 (11,506) Net cash from investing activities (1,077) 18,434 Financing activities: Â Â Proceeds from issuance of Class A common stock 786 223 Borrowing on revolver 0 49,000 Payment on revolver 0 (42,000) Debt refinancing costs (1,180) (3,661) Payments on long-term debt (11,320) (38,264) Other, net (373) (166) Net cash from financing activities (12,087) (34,868) Effect of exchange rate changes on cash (963) 701 Net change in cash, cash equivalents and restricted cash (4,970) (2,448) Cash, cash equivalents and restricted cash at the beginning of the period 36,964 31,837 Cash, cash equivalents and restricted cash at the end of the period 31,994 29,389 Supplemental disclosure of noncash investing and financing activities Â Â Accrued liabilities for intellectual property 0 709 Accounts payable for purchase of property, plant and equipment $ 205 $ 968 X - DefinitionAccrued liabilities for intellectual property + ReferencesNo definition available. + Details Name: bvs_AccruedLiabilitiesForIntellectualProperty Namespace Prefix: bvs_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPayment Of Debt Refinancing Costs + ReferencesNo definition available. + Details Name: bvs_PaymentOfDebtRefinancingCosts Namespace Prefix: bvs_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionProceeds From (Payments For) Acquisition Of Intangible Assets And Investments + ReferencesNo definition available. + Details Name: bvs_ProceedsFromPaymentsForAcquisitionOfIntangibleAssetsAndInvestments Namespace Prefix: bvs_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4 + Details Name: us-gaap_AssetImpairmentCharges Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4 + Details Name: us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionFuture cash outflow to pay for purchases of fixed assets that have occurred. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_CapitalExpendituresIncurredButNotYetPaid Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -

Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B + Details Name: us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B + Details Name: us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of deferred income tax expense (benefit) and income tax credits. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_DeferredIncomeTaxesAndTaxCredits Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 + Details Name: us-gaap_DepreciationDepletionAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 230 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, before tax, of unrealized gain (loss) from foreign currency transaction. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 6 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-6Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ForeignCurrencyTransactionGainLossUnrealized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1B + Details Name: us-gaap_GainLossOnSaleOfBusiness Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477349/740-270-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3AReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3BReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-4Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3 + Details Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInInventories Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in operating assets after deduction of operating liabilities classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-

gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - DefinitionOther cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities). + ReferencesNo definition available. + Details Name: us-gaap_OtherOperatingActivitiesCashFlowStatement Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromDivestitureOfBusinesses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromLongTermLinesOfCredit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities classified as other. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 45 -Paragraph 15 -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_ProceedsFromPaymentsForOtherFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense (reversal of expense) for expected credit loss on accounts receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_ProvisionForDoubtfulAccounts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_RepaymentsOfLongTermLinesOfCredit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow for the payment of debt classified as other, maturing after one year or the operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_RepaymentsOfOtherLongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SupplementalCashFlowInformationAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 18 R8.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Organization 6 Months Ended Jun. 29, 2024 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â Organization OrganizationThe CompanyBioventus Inc. (together with its subsidiaries, the â€œCompanyâ€) was formed as a Delaware corporation for the purpose of facilitating an initial public offering and other related transactions in order to carry on the business of Bioventus LLC and its subsidiaries (â€œBV LLCâ€). Bioventus Inc. functions as a holding company with no direct operations, material assets or liabilities other than the equity interest in BV LLC. BV LLC is a limited liability company formed under the laws of the state of Delaware on November 23, 2011 and operates as a partnership. BV LLC commenced operations in May 2012. On February 16, 2021, the Company completed its initial public offering (â€œIPOâ€), which was conducted through what is commonly referred to as an umbrella partnership C Corporation (â€œUP-Câ€) structure. The Company has majority interest, sole voting interest and controls the management of BV LLC. As a result, the Company consolidates the financial results of BV LLC and reports a noncontrolling interest representing the interest of BV LLC

held by its continuing LLC owner.The Company is focused on developing and commercializing clinically differentiated, cost efficient and minimally invasive treatments that engage and enhance the bodyâ€™s natural healing processes. The Company is headquartered in Durham, North Carolina and has approximately 1,030 employees.Interim periodsThe Company reports quarterly interim periods on a 13-week basis within a standard calendar year. Each annual reporting period begins on January 1 and ends on December 31. Each quarter ends on the Saturday closest to calendar quarter-end, with the exception of the fourth quarter, which ends on December 31. The 13-week quarterly periods for fiscal year 2024 end on March 30, June 29 and September 28. Comparable periods for 2023 ended on April 1, July 1 and September 30. The fourth and first quarters may vary in length depending on the calendar year. Unaudited interim financial informationThe accompanying unaudited consolidated condensed financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (â€œU.S. GAAPâ€) for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Pursuant to these rules and regulations, they do not include all information and notes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments, and the adjustments discussed in Note 1. Organization) considered necessary for a fair statement of the Companyâ€™s financial condition and results of operations have been included. Operating results for the periods presented are not necessarily indicative of the results that may be expected for the full year. As such, the information included in this report should be read in conjunction with the Companyâ€™s Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023. The consolidated balance sheet at DecemberÂ 31, 2023 has been derived from the audited consolidated financial statements of the Company, but does not include all the disclosures required by U.S. GAAP.ReclassificationsCertain prior period amounts have been reclassified to conform to current period presentation. During the first quarter of 2024, the Company reclassified revenue and expense of the SonicOne Ultrasonic Cleansing and Debridement Systems (â€œSonicOneâ€) from the Restorative Therapies to the Surgical Solutions business. The reclassification of SonicOne activity affected prior presentation of disaggregated revenue by business, refer to Note 12. Revenue recognition for further details. The reclassification had no effect on previously reported total revenues, net loss, other comprehensive loss, stockholdersâ€™ equity or cash flows. Unless otherwise noted, all financial information in the unaudited consolidated condensed financial statements reflects the Companyâ€™s results from continuing operations.Use of estimatesThe preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities, at the date of the financial statements, as well as the reported amounts of revenues and expenses during the period. On an ongoing basis, management evaluates these estimates, including those related to contractual allowances and sales incentives, allowance for credit losses, inventory reserves, goodwill and intangible assets impairment, valuation of assets and liabilities assumed in acquisitions, useful lives of long lived assets, fair value measurements, litigation and contingent liabilities, income taxes, and equity-based compensation. Management bases its estimates on historical experience, future expectations and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from those estimates.Recent accounting pronouncementsIn addition to being a smaller reporting and an emerging growth company, the Company also is an accelerated filer under SEC rules and regulations. Therefore, required effective dates for adopting new or revised accounting standards are generally earlier than when smaller reporting companies and emerging growth companies who are not accelerated filers are required to adopt.In December 2023, the Financial Accounting Standards Board (â€œFASBâ€) issued Accounting Standards Update 2023-09 (â€œASU 2023-09â€), Income Taxes, which enhances the transparency of income tax disclosures by expanding annual disclosure requirements related to the rate reconciliation and income taxes paid. The amendments are effective for fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments should be applied on a prospective basis. Retrospective application is permitted. The Company is currently evaluating this ASU to determine its impact on the Company's disclosures.In November 2023, the FASB issued Accounting Standards Update 2023-07 (â€œASU 2023-07â€), Segment Reporting, which improves reportable segment disclosure requirements. ASU 2023-07 primarily enhances disclosures about significant segment expenses by requiring that a public entity disclose significant segment expenses that are regularly provided to the Chief Operating Decision Maker (â€œCODMâ€) and included within each reported measure of segment profit or loss. This ASU also (i) requires that a public entity disclose, on an annual and interim basis, an amount for other segment items by reportable segment, and a description of its composition; (ii) requires that all annual disclosures are provided in the interim periods; (iii) clarifies that if the CODM uses more than one measure of profitability in assessing segment performance and deciding how to allocate resources, that one or more of those measures may be reported; (iv) requires disclosure of the title and position of the CODM and a description of how the reported measures are used by the CODM in assessing segment performance and in deciding how to allocate resources; (v) requires that an entity with a single segment provide all new required disclosures. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024 and requires retrospective application. Early adoption is permitted. The amendments under ASU 2023-07 relate to financial disclosures and its adoption will not have an impact on the Companyâ€™s results of operations, financial position or cash flows. The Company will adopt ASU 2023-07 for the annual reporting period ending December 31, 2024 and for interim reporting periods thereafter. X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContentReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 275 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/275/tableOfContentReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/810/tableOfContentReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 250 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/250/tableOfContent + Details Name: us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 19 R9.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Balance sheet information 6 Months Ended Jun. 29, 2024 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â Balance sheet information Balance sheet informationAccounts receivable, netAccounts receivable, net are amounts billed and currently due from customers. The Company records the amounts due net of allowance for credit losses. Collection of the consideration that the Company expects to receive typically occurs within 30 to 90 days of billing. The Company applies the practical expedient for contracts with payment terms of one year or less which does not consider the effects of the time value of money. Occasionally, the Company enters into payment agreements with patients that allow payment terms beyond one year. In those cases, the financing component is not deemed significant to the contract.Accounts receivable, net of allowances, consisted of the following as of:June 29, 2024December 31, 2023Accounts receivable(a)$140,204Â $127,008Â Less: Allowance for credit losses(a)(2,899)(4,219)$137,305Â $122,789Â (a)Accounts receivable of $7,688 attributable to the Companyâ€™s advanced rehabilitation business was reclassified to assets held for sale within the JuneÂ 29, 2024 consolidated condensed balance sheets. Refer to Note 3. Acquisitions and divestitures for further details regarding assets held for sale.Due to the short-term nature of the Companyâ€™s receivables, the estimate of expected credit losses is based on aging of the account receivable balances. The allowance is adjusted on a specific identification basis for certain accounts as well as pooling of accounts with similar characteristics. The Company has a diverse customer base with no single customer representing ten percent or more of sales. The Company has one customer representing approximately 19.2% and 16.0% of the accounts receivable balance as of JuneÂ 29, 2024 and DecemberÂ 31, 2023, respectively. Historically, the Companyâ€™s reserves have been adequate to cover credit losses.InventoryInventory consisted of the following as of:June 29, 2024December 31, 2023Raw materials and supplies(a)$24,841Â $21,062Â Finished goods(a)62,765Â 70,271Â $87,606Â $91,333Â (a)Raw materials and supplies of $4,924 and finished goods inventory of $9,449 attributable to the Companyâ€™s advanced rehabilitation business were reclassified to assets held for sale within the JuneÂ 29, 2024 consolidated condensed balance sheets. Refer to Note 3. Acquisitions and divestitures for further details regarding assets held for sale.Property and equipment, netProperty and equipment consisted of the following as of:June 29, 2024December 31, 2023Computer equipment and software$39,713Â $37,860Â Demonstration and consignment inventory9,963Â 9,341Â Leasehold improvements3,933Â 3,763Â Furniture and fixtures(a)4,586Â 4,163Â Finance leases15,737Â 15,737Â Machinery and equipment(b)1,801Â 2,180Â Assets net yet placed in service2,021Â 4,065Â 77,754Â 77,109Â Less accumulated depreciation(45,816) (40,504)$31,938Â $36,605Â (a)Furniture and fixtures of $51 and accumulated depreciation of $31 attributable to the Companyâ€™s advanced rehabilitation business were reclassified to assets held for sale within the JuneÂ 29, 2024 consolidated condensed balance sheets. Refer to Note 3. Acquisitions and divestitures for further details regarding assets held for sale.(b)Machinery and equipment of $385 and accumulated depreciation of $133 attributable to the Companyâ€™s advanced rehabilitation business were reclassified to assets held for sale within the JuneÂ 29, 2024 consolidated condensed balance sheets. Refer to Note 3. Acquisitions and divestitures for further details regarding assets held for sale.Intangible assets, netIntangible assets consisted of the following as of:June 29, 2024December 31, 2023Intellectual property(a)(b)$626,007Â $677,258Â Distribution rights61,325Â 61,325Â Customer relationships57,950Â 57,950Â IPR&D5,500Â 5,500Â Developed technology and other13,998Â 13,998Â Total carrying amount764,780Â 816,031Â Less accumulated amortization:Intellectual property(a)(b)(221,261)(218,031)Distribution rights(51,790)(49,301)Customer relationships(57,950)(57,950)Developed technology and other(8,004)(7,521)Total accumulated amortization(339,005)(332,803)Intangible assets, net before currency translation425,775Â 483,228Â Currency translation(1,223)(878)$424,552Â $482,350Â (a)Intellectual property of $19,380 and accumulated amortization of $16,656 attributable to the Companyâ€™s advanced rehabilitation business were reclassified to assets held for sale within the JuneÂ 29, 2024 consolidated condensed balance sheets. Refer to Note 3.Acquisitions and divestitures for further details regarding assets held for sale.(b)The Company recorded an impairment loss of $31,870 for the three and six months ended JuneÂ 29, 2024 in the U.S. reporting segment of net intellectual property solely attributable to the Companyâ€™s advanced rehabilitation business. The loss was recorded in impairment of assets within the consolidated condensed statements of operations and comprehensive loss. Refer to Refer to Note 3. Acquisitions and divestitures for further details regarding businesses held for sale.Estimated amortization expense for intangibles subsequent to reclassifications, impairment and additions for the remainder of 2024 and for the years ended December 31, 2025 through 2028 is expected to be $19,629, $37,412, $34,192, $35,243 and $31,012, respectively.Accrued liabilitiesAccrued liabilities consisted of the following as of:June 29, 2024December 31, 2023Gross-to-net deductions$68,349Â $59,592Â Bonus and commission19,987Â 19,437Â Settlement and legal fees17,737Â 986Â Compensation and benefits9,081Â 9,709Â Accrued interest6,185Â 6,606Â Income and other taxes4,883Â 4,749Â Other liabilities(a)13,756Â 18,716Â $139,978Â $119,795Â (a)Accrued liabilities of $3,110 attributable to the Companyâ€™s advanced rehabilitation business were reclassified to liabilities held for sale within the JuneÂ 29, 2024 consolidated condensed balance sheets. Refer to Note 3. Acquisitions and divestitures for further details regarding assets held for sale. X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/210/tableOfContent + Details Name: us-gaap_SupplementalBalanceSheetDisclosuresTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 20 R10.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Acquisitions and divestitures 6 Months Ended Jun. 29, 2024 Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract] Â Acquisitions and divestitures Acquisitions and divestituresAdvanced Rehabilitation BusinessIn May 2024, the Company began contract negotiations with a third-party (the â€œBuyerâ€) to sell certain products within its advanced rehabilitation business, including the L100, L300 Go, L360, H200, Vector Gait & Safety System and BITS-Bioness Integrated Therapy System (collectively, the â€œAdvanced Rehabilitation Businessâ€). The Advanced Rehabilitation Business is considered non-core and will require additional research and development expenditures to achieve its next stage of growth. The potential divestiture of the Advanced Rehabilitation Business is expected to simplify the Companyâ€™s business structure and improve liquidity, as the proceeds, net of transactional fees, are required to be used to reduce long-term debt obligations. Contract negotiations are ongoing with the Buyer and as of the end of the second quarter of 2024, the Company had incurred $2,500 in transactional fees resulting from the potential divestiture of the Advanced Rehabilitation Business. The Company has classified the identifiable net assets of the Advanced Rehabilitation Business as held for sale. A significant portion of the Advanced Rehabilitation Business net assets were within the U.S. reporting segment. Assets and liabilities determined to be part of the Advanced Rehabilitation Business have been recorded as single amounts within the Companyâ€™s consolidated financial statements. Assets held for sale are reported at the lower of the carrying amount or fair value less costs to sell, which is expected to occur within one year. The Company has ceased depreciating and amortizing the assets classified as held for sale. Assets and liabilities held for sale are reviewed each reporting period to determine whether existing carrying values are fully recoverable in comparison to estimated fair values less costs to sell.The Company evaluated the Advanced Rehabilitation Business for impairment due to its potential divestiture and, as a result of this evaluation, recorded a $31,870 impairment under the U.S. reporting segment within the consolidated condensed statements of operations and comprehensive loss during the three and six months ended JuneÂ 29, 2024 to reduce the intangible assets of the Advanced Rehabilitation Business to reflect their respective fair values less any costs to sell. The fair value of its intangibles was based on the preliminary consideration offered for the Advanced Rehabilitation Business.The carrying amounts for the major classes of assets and liabilities of the Advanced Rehabilitation Business classified as held for sale were as follows:June 29, 2024Carrying amounts of assets classified as held for sale:Accounts receivable$7,688Â Inventory14,373Â Prepaid and other current assets1,930Â Property and equipment, net272Â Intangible assets2,724Â Operating lease assets1,171Â Other assets250Â Total assets held for sale$28,408Â Carrying amounts of liabilities classified as held for sale:Accounts payable$1,566Â Accrued liabilities3,110Â Other liabilities1,232Â Total liabilities held for sale$5,908Â Wound BusinessOn May 22, 2023, the Company closed the sale of certain assets within its Wound Business, including the TheraSkin and TheraGenesis products (collectively, the â€œWound Businessâ€), for potential consideration of $84,675, including $34,675 at closing, $5,000 deferred for 18 months and up to $45,000 in potential earn-out payments, which are based on the achievement of certain revenue thresholds by the purchaser of the Wound Business for sales of the TheraSkin and TheraGenesis products during the 2024, 2025 and 2026 fiscal years.The Company incurred $3,880 in transactional fees resulting from the sale of the Wound Business. The Company used the proceeds from the sale of its Wound Business to prepay $30,000 of long-term debt obligations. Refer to Note 4. Financial Instruments for further details regarding the Companyâ€™s outstanding long-term debt obligations.The Company evaluated the Wound Business for impairment prior to its sale and recorded a $78,615 impairment within the consolidated condensed statements of operations and comprehensive loss during the six months ended JulyÂ 1, 2023 as a result of this evaluation to reduce the intangible assets of the Wound Business to reflect their respective fair values less any costs to sell. The fair value of its intangibles was determined based on the consideration received for the Wound Business. The loss resulting from the deconsolidation of the Wound Business totaled $977 for the three and six months ended JulyÂ 1, 2023 and was recorded in loss on disposals within the consolidated condensed statements of operations and comprehensive loss.CartiHeal (2009) Ltd.On July 12, 2022, the Company completed the acquisition of 100% of the remaining shares in CartiHeal (2009) Ltd. (â€œCartiHealâ€), a developer of the proprietary Agili-C implant for the treatment of joint surface lesions in traumatic and osteoarthritic joints. On February 27, 2023, the Company entered into a settlement agreement (the â€œSettlement Agreementâ€) with Elron Ventures Ltd. (â€œElronâ€), as representative of CartiHealâ€™s former securityholders (the â€œFormer Securityholdersâ€). Pursuant to the Settlement Agreement, Elron, on behalf of the Former Securityholders, agreed to forbear from initiating any legal action or proceedings related to non-payment of any obligations including deferred purchase price and contingent consideration totaling $215,000 and $135,000, respectively, under the Companyâ€™s previous agreements to purchase CartiHeal from the Former Securityholders. Pursuant to the Settlement Agreement, the Company also transferred 100% of its shares in CartiHeal to a trustee (the â€œTrusteeâ€) for the benefit of the Former Securityholders and made a one-time non-refundable payment of $10,150 to Elron to be used for purposes set forth in the Settlement Agreement. Given that upon execution of the Settlement Agreement, the Company had no ownership interest or voting rights in CartiHeal, the Company concluded that it had ceased to control CartiHeal for accounting purposes, and therefore, deconsolidated CartiHeal effective February 27, 2023. CartiHeal was part of the Companyâ€™s international reporting segment and the Company treated the deconsolidation of CartiHeal as a discontinued operation. The loss on disposal was $60,639 and was recorded within discontinued operations, net of tax within the consolidated condensed statements of operations and

comprehensive loss for the six months ended JulyÂ 1, 2023. Refer to Note 14. Discontinued operations for further information regarding the impact of CartiHeal on the Companyâ€™s consolidated condensed financial statements for the six months ended JulyÂ 1, 2023. X - DefinitionAcquisitions And Investments Disclosure + ReferencesNo definition available. + Details Name: bvs_AcquisitionsAndInvestmentsDisclosureTextBlock Namespace Prefix: bvs_ Data Type: dtr-types1:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_BusinessCombinationAndAssetAcquisitionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 21 R11.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Financial instruments 6 Months Ended Jun. 29, 2024 Debt Disclosure [Abstract] Â Financial instruments Financial instrumentsLong-term debt consisted of the following as of:June 29, 2024December 31, 2023Amended Term Loan due October 2026 (9.34% at JuneÂ 29, 2024)$371,128Â $382,448Â Revolver due October 2025 (9.34% at JuneÂ 29, 2024)15,000Â 15,000Â Less:Current portion of long-term debt(38,566)(27,848)Unamortized debt issuance cost(1,459)(917)Unamortized discount(1,387)(1,685)$344,716Â $366,998Â Amended Term LoanOn December 6, 2019, the Company entered into a Credit and Guaranty Agreement (the â€œ2019 Credit Agreementâ€) that was comprised of a $200,000 term loan (the â€œOriginal Term Loanâ€) and a $50,000 revolving facility (the â€œRevolverâ€). The Company amended the 2019 Credit Agreement on August 29, 2021, and then again on October 29, 2021 in connection with the acquisition of Misonix, Inc., in which the Company prepaid $80,000 on the Original Term Loan. The 2019 Credit Agreement, as amended, subsequent to the prepayment, was comprised of a $360,750 term loan (â€œTerm Loanâ€) and the Revolver.On July 11, 2022, the Company further amended the 2019 Credit Agreement in conjunction with the acquisition of CartiHeal (the â€œCartiHeal Acquisitionâ€). Pursuant to that amendment, an $80,000 term loan facility (the â€œJuly 2022 Term Loanâ€ and, together with the Term Loan, the â€œTerm Loan Facilitiesâ€) was extended to the Company to be used for: (i) the financing of the CartiHeal Acquisition; (ii) the payment of related fees and expenses; (iii) repayment of the draws made on the Revolver; and (iv) working capital needs and general corporate purposes of the Company, including without limitation for permitted acquisitions.On March 31, 2023, the Company entered into an additional amendment to the 2019 Credit Agreement to, among other things, modify certain financial covenants, waive covenant noncompliance at December 31, 2022, and to modify interest rates applicable to borrowings under the 2019 Credit Agreement.On January 18, 2024 (the â€œClosing Dateâ€), the Company further amended the 2019 Credit Agreement (collectively, with the August 2021, October 2021, July 2022 and March 2023 amendments, the â€œAmended 2019 Credit Agreementâ€), to further modify certain financial covenants under the 2019 Credit Agreement. The Company was in compliance as of June 29, 2024 with the financial covenants as stated within the 2019 Credit Agreement.SOFR loans and base rate loans had a margin of 3.25% and 2.25%, respectively, subsequent to July 11, 2022 and prior to the Closing Date. As of the March 31, 2023 amendment, SOFR loans and base rate loans had a margin of 4.25% and 3.25%, respectively. All obligations under the Amended 2019 Credit Agreement are guaranteed by the Company and certain wholly owned subsidiaries where substantially all the assets of the Company collateralize the obligations.The Amended 2019 Credit Agreement contains customary affirmative and negative covenants, including those related to financial reporting and notification, restrictions on the declaration or payment of certain distributions on or in respect of Bioventus LLCâ€™s equity interests, restrictions on acquisitions, investments and certain other payments, limitations on the incurrence of new indebtedness, limitations on transfers, sales and other dispositions of assets of Bioventus LLC and its subsidiaries, as well as limitations on making changes to the business and organizational documents of Bioventus LLC and its subsidiaries. Financial covenant requirements include a maximum debt leverage ratio and an interest coverage ratio. In addition, during the period commencing on the Closing Date and ending upon the satisfaction of certain conditions occurring not prior to the delivery of financial statements of the Company for the fiscal quarter ending October 29, 2025, the Company will be subject to certain additional requirements and covenants, including a requirement to maintain Liquidity (as defined in the Amended 2019 Credit Agreement) of not less than $10,000 as of the end of each calendar month during such period. The Term Loan Facilities will mature on October 29, 2026. The Revolver will mature on October 29, 2025.The January 2024 amendment had deferred financing costs of $1,180, of which $325 was recorded in selling, general and administrative expense within the consolidated condensed statements of operations and comprehensive loss and $855 was capitalized on the consolidated condensed balance sheets during the six months ended JuneÂ 29, 2024. The March 2023 amendment had deferred financing costs of $3,661, of which $1,617 was recorded in selling, general and administrative expense within the consolidated condensed statements of operations and comprehensive loss and $2,044 was capitalized on the consolidated condensed balance sheets during the six months ended JulyÂ 1, 2023. There were no losses on debt refinancing and modification as a result of either the January 2024 or March 2023 amendments.As of JuneÂ 29, 2024, $368,282 was outstanding on the Term Loan Facilities, net of original issue discount of $1,387 and deferred financing costs of $1,459. As previously discussed in Note 3. Acquisitions and divestitures, the Company made a prepayment of $30,000 on its Term Loan Facilities with the proceeds from the Wound Business divestiture during the second quarter of 2023. Capitalized deferred fees are amortized to interest expense on a straight-line basis over the term of the Term Loan Facilities, which approximates the effective interest method. Interest expense includes deferred cost amortization of $381, $915, $762 and $1,138 for the three months JuneÂ 29, 2024 and JulyÂ 1, 2023 and the six months ended JuneÂ 29, 2024 and JulyÂ 1, 2023, respectively. The estimated fair value of the Term Loan Facilities was $370,664 as of JuneÂ 29, 2024. The fair value of these obligations was determined based on the midpoint of the Bloomberg Valuation. This is classified as a Level 2 instrument within the fair value hierarchy.Revolver and Letters of CreditThe Revolver is a five-year revolving credit facility that includes revolving and swingline loans as well as letters of credit (â€œLOCâ€) and, inclusive of all, could not exceed $45,000 at any one time as the Revolver capacity was reduced by $5,000 at December 31, 2023 in accordance with the 2019 Credit Agreement then in effect. The Revolver was further reduced by $5,000 at June 30, 2024, limiting borrowing capacity to $40,000. The Company had $15,000 outstanding borrowings on its Revolver as of JuneÂ 29, 2024 and DecemberÂ 31, 2023. LOCs are available in an amount not to exceed $7,500. The Company had two LOCs outstanding as of JuneÂ 29, 2024, leaving approximately $5,800 available. Revolving loans are due at the earlier of termination or maturity. Swingline loans are available as base rate option loans only and must be outstanding for at least five days. Swingline loans are due the fifteenth or last day of a calendar month or maturity, whichever is earlier. X - ReferencesNo definition available. + Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/470/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I + Details Name: us-gaap_DebtDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 22 R12.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Fair value measurements 6 Months Ended Jun. 29, 2024 Fair Value Disclosures [Abstract] Â Fair value measurements Fair value measurementsThe process for determining fair value has not changed from that described in the Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023.There were no assets measured at fair value on a recurring basis and there were no liabilities valued at fair value using Level 1 or Level 2 inputs. The following table provides information for assets and liabilities measured at fair value on a recurring basis using Level 3 inputs:June 29, 2024December 31, 2023TotalLevel 3TotalLevel 3Liabilities:Current portion of contingent consideration$18,745Â $18,745Â $â€”Â $â€”Â Contingent considerationâ€”Â â€”Â 18,150Â 18,150Â Total liabilities:$â€”Â $â€”Â $18,150Â $18,150Â Contingent considerationThe Company initially values contingent consideration related to business combinations using a probability-weighted calculation of potential payment scenarios discounted at rates reflective of the risks associated with the expected future cash flows for certain milestones. For other milestones, the Company used a variation of the income approach where revenue was simulated in a risk-neutral framework using Geometric Brownian Motion, a stock price behavior model.Key assumptions used to estimate the fair value of contingent consideration include projected financial information, market data and the probability and timing of achieving the specific targets. After the initial valuation, the Company generally uses its best estimate to measure contingent consideration at each subsequent reporting period using unobservable Level 3 inputs.Unobservable inputsA summary of unobservable Level 3 inputs utilized for the above liabilities are as follows:Valuation TechniqueUnobservable inputsRangeBioness contingent considerationDiscounted cash flowPayment discount rate6.4% - 6.8%Payment period2024 - 2025Significant changes in these assumptions could result in a significantly higher or lower fair value. The contingent consideration reported in the table above resulted from the acquisition of Bioness on March 30, 2021. Contingent consideration is adjusted quarterly based upon the passage of time or the anticipated success or failure of achieving certain milestones. Changes in contingent consideration related to Bioness for the three months ended JuneÂ 29, 2024 and JulyÂ 1, 2023 and six months ended JuneÂ 29, 2024 and JulyÂ 1, 2023 totaled $300, $240, $595 and $527, respectively, and were recorded as the change in fair value of contingent consideration within the consolidated condensed statements of operations and comprehensive loss. X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 107 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 940 -SubTopic 820 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1 + Details Name: us-gaap_FairValueDisclosuresTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 23 R13.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Equity-based compensation 6 Months Ended Jun. 29, 2024 Compensation And Employee Benefit Plans [Abstract] Â Equity-based compensation Equity-based compensation2021 PlanThe Company operates an equity-based compensation plan (the â€œ2021 Planâ€), which allows for the issuance of

stock options (incentive and nonqualified), restricted stock, dividend equivalents, restricted stock units (â€œRSUsâ€), other stock-based awards, and cash awards (collectively, the â€œ2021 Plan Awardsâ€). As of JuneÂ 29, 2024, 19,564,333 shares of Class A common stock have been authorized to be awarded under the 2021 Plan and 8,921,686 shares were available for 2021 Plan Awards.2023 PlanThe Company also operates the 2023 Retention Equity Award Plan (the â€œ2023 Planâ€ and, together with the 2021 Plan, the â€œPlansâ€), the purpose of which is to retain and motivate critical personnel over the short-term by providing them additional incentives in the form of RSUs (the â€œRetention Awardsâ€ and together with the â€œ2021 Plan Awards,â€ the â€œAwardsâ€). As of JuneÂ 29, 2024, 600,000 shares of Class A common stock were authorized to be awarded under the 2023 Plan and 84,700 shares were available for Retention Awards.Activity under the PlansExpenseEquity-based compensation, net for Awards granted under the Plans for the three and six months ended JuneÂ 29, 2024 totaled $3,457 and $6,048, respectively. Equity-based compensation, net for Awards granted under the Plans for the three and six months ended JulyÂ 1, 2023 totaled $2,797 and $1,079, respectively, in expense reduction as a result of expense reversals due to executive leadership transitions. Expenses and expense reductions are primarily included in selling, general and administrative expense with a nominal amount in research and development expense within the consolidated condensed statements of operations and comprehensive loss based upon the department of the employee. There were no income tax benefits related to equity-based compensation expense for the three and six months ended JuneÂ 29, 2024 and JulyÂ 1, 2023.Restricted Stock UnitsDuring the three and six months ended JuneÂ 29, 2024, the Company granted time-based RSUs which vest at various dates through MarchÂ 15, 2028. RSU compensation expense is recognized over the vesting period, which is typically between 1 and 4 years. Unamortized compensation expense related to the RSUs totaled $7,091 at JuneÂ 29, 2024, and is expected to be recognized over a weighted average period of approximately 2.40 years. A summary of the RSU award activity for the six months ended JuneÂ 29, 2024 is as follows (number of units in thousands):Number of unitsWeighted-average grant-date fair value per unitUnvested at December 31, 20232,066Â $4.51Â Granted2,429Â 5.45Â Vested(1,550)4.56Â Forfeited or canceled(105)7.33Â Unvested at June 29, 20242,840Â $5.12Â Stock OptionsDuring the three and six months ended JuneÂ 29, 2024, the Company granted time-based stock options which vest over 1 to 4 years following the date of grant and expire within 10 years. The fair value of time-based stock options is determined using the Black-Scholes valuation model, with such value recognized as expense over the service period, which is typically 1 to 4 years, net of actual forfeitures. A summary of the Companyâ€™s assumptions used in determining the fair value of the stock options granted during the six months ended JuneÂ 29, 2024 is shown in the following table:Risk-free interest rate3.9% - 4.3%Expected dividend yieldâ€”Â %Expected stock price volatility36.1% - 36.4%Expected life of stock options (years)6.25The weighted-average grant date fair value of options granted during the six months ended JuneÂ 29, 2024 was $2.25 per share. The expected term of the options granted is estimated using the simplified method. Expected volatility is based on the historical volatility of the Companyâ€™s peersâ€™ common stock. The risk-free interest rate is determined based upon a constant U.S. Treasury security rate with a contractual life that approximates the expected term of the option. Unamortized compensation expense related to the options totaled $4,342 at JuneÂ 29, 2024, and is expected to be recognized over a weighted average period of approximately 2.86 years. A summary of stock option activity is as follows for the six months ended JuneÂ 29, 2024 (number of options in thousands):Number of optionsWeighted-average exercise priceWeighted average remaining contractual termAggregate intrinsic valueOutstanding at December 31, 20234,347Â $8.68Â Granted1,763Â 5.18Â Exercised(229)5.21Â Forfeited or canceled(747)10.51Â Outstanding at June 29, 20245,134Â 7.53Â 7.66$4,968Â Exercisable and vested at June 29, 20241,982Â $9.95Â 5.57$855Â The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the market price of the Companyâ€™s Class A common stock for options that had exercise prices lower than $5.75 per share as this was the closing price of the Companyâ€™s Class A common stock on JuneÂ 28, 2024, the last trading day of the second quarter.Employee Stock Purchase PlanThe Company operates a non-qualified Employee Stock Purchase Plan (â€œESPPâ€), which provides for the issuance of shares of the Companyâ€™s Class A common stock to eligible employees of the Company that elect to participate in the plan and purchase shares of Class A common stock through payroll deductions at a discounted price. As of JuneÂ 29, 2024, the aggregate number of shares reserved for issuance under the ESPP was 1,393,982. A total of 125,622 shares were issued under the ESPP and $215 of expense was recognized during the three and six months ended JuneÂ 29, 2024. A total of 144,851 and 366,927 shares were issued under the ESPP and $65 and $193 of expense was recognized during the three and six months ended JulyÂ 1, 2023, respectively. X - DefinitionCompensation And Employee Benefit Plans + ReferencesNo definition available. + Details Name: bvs_CompensationAndEmployeeBenefitPlansAbstract Namespace Prefix: bvs_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 710 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/710/tableOfContentReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 712 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/712/tableOfContentReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 715 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/715/tableOfContentReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContent + Details Name: us-gaap_CompensationAndEmployeeBenefitPlansTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 24 R14.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stockholdersâ€™ equity 6 Months Ended Jun. 29, 2024 Equity [Abstract] Â Stockholdersâ€™ equity Stockholdersâ€™ equityOn February 16, 2021, the Company closed an IPO of 9,200,000 shares of Class A common stock through an UP-C structure with BV LLC. In connection with the IPO, the Company amended and restated the limited liability agreement of BV LLC (â€œBV LLC Agreementâ€) to provide for a new single class of common membership interests in BV LLC (â€œLLC Interestsâ€) and exchange all of the existing membership interests in BV LLC (the â€œOriginal BV LLC Ownersâ€) for new LLC Interests. The Company also amended its certificate of incorporation to authorize the following shares: (i) 250,000,000 shares of Class A common stock with a par value of $0.001 per share; (ii) 50,000,000 shares of Class B common stock with a par value of $0.001 per share, which have voting rights but no economic interest, and some of which were issued to the Original BV LLC Owners; and (iii) 10,000,000 shares of undesignated preferred stock that may be issued from time to time by the Companyâ€™s board of directors. In connection with the completion of the IPO, the Company acquired, by merger, certain entities that were part of the Original BV LLC Owners (â€œFormer BV LLC Ownersâ€), for which the Company issued 31,838,589 Class A common stock as merger consideration (â€œIPO Mergersâ€) and cancelled the Class B common stock held by such Former BV LLC Owners. The IPO Mergers are deemed to be a recapitalization transaction.Holders of the Companyâ€™s Class A and Class B common stock are entitled to one vote per share and, except as otherwise required, will vote together as a single class on all matters on which stockholders generally are entitled to vote. Holders of Class B common stock are not entitled to receive dividends and will not be entitled to receive any distributions upon the liquidation, dissolution or winding up of the Company. Shares of Class B common stock may only be issued to the extent necessary to maintain the one-to-one ratio between the number of LLC Interests and the number of shares of Class B common stock held by Smith & Nephew, Inc. (the â€œContinuing LLC Ownerâ€). Shares of Class B common stock are transferable only together with an equal number of LLC Interests. Shares of Class B common stock will be canceled on a one-for-one basis upon the redemption or exchange of any outstanding LLC Interests.Noncontrolling interestIn connection with any redemption pursuant to the BV LLC Agreement, the Company will receive a corresponding number of LLC Interests, increasing its ownership interest in BV LLC. Future redemptions of LLC Interests will result in a change in ownership and reduce the amount recorded as noncontrolling interest and increase additional paid-in capital. There were no redemptions during the six months ended June 29, 2024 or during the year ended DecemberÂ 31, 2023. The following table summarizes the ownership interest in BV LLC as of JuneÂ 29, 2024 and DecemberÂ 31, 2023 (number of units in thousands):June 29, 2024December 31, 2023LLC InterestsOwnership %LLC InterestsOwnership %Number of LLC Interests ownedBioventus Inc.65,172Â 80.5Â %63,267Â 80.0Â %Continuing LLC Owner15,787Â 19.5Â %15,787Â 20.0Â %Total80,959Â 100.0Â %79,054Â 100.0Â % X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18 + Details Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 25 R15.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Earnings per share 6 Months Ended Jun. 29, 2024 Earnings Per Share [Abstract] Â Earnings per share Earnings per shareThe following table sets forth the computation of basic and diluted loss per share of Class A common stock for the periods presented (amounts in thousands, except share and per share data):Three Months EndedSix Months EndedJune 29, 2024July 1, 2023June 29, 2024July 1, 2023Numerator:Net loss from continuing operations, net of tax$(32,112)$(4,731)$(38,094)$(104,749)Net loss attributable to noncontrolling interests â€” Â Â Â Â continuing operations8,120Â 1,050Â 9,532Â 21,410Â Net loss attributable to Bioventus Inc. Class A Â Â Â Â Â common stockholders â€” continuing operations$(23,992)$(3,681)$(28,562)$(83,339)Numerator:Net loss from discontinued operations, net of tax$â€”Â $â€”Â $â€”Â $(74,429)Net loss attributable to noncontrolling interests â€” Â Â Â Â discontinued operationsâ€”Â â€”Â â€”Â 14,937Â Net loss attributable to Bioventus Inc. Class A Â Â Â Â Â common stockholders â€” discontinued operations$â€”Â $â€”Â $â€”Â $(59,492)Denominator:Weighted-average shares of Class A common stock Â Â Â Â outstandingâ€”basic and diluted64,056,759Â 62,551,285Â 63,720,342Â 62,338,018Â Net loss per share of Class A common stock from Â Â Â Â continuing operations, basic and diluted(0.37)(0.06)(0.45)(1.34)Net loss per share of Class A common stock from Â Â Â Â discontinued operations, basic and dilutedâ€”Â â€”Â â€”Â (0.95)Net loss per share of Class A common stock, Â Â Â Â basic and diluted(0.37)(0.06)(0.45)(2.29)Shares of Class B common stock do not share in the losses of the Company and are therefore not participating securities. As such, separate presentation of basic and diluted losses per share of Class B common stock under the two-class method has not been presented.The following number of weighted-average potentially dilutive shares as of JuneÂ 29, 2024 and JulyÂ 1, 2023 were excluded from the calculation of diluted loss per share because the effect of including such potentially dilutive shares would have been antidilutive upon conversion:Three Months EndedSix Months EndedJune 29, 2024July 1, 2023June 29, 2024July 1, 2023LLC Interests held by Continuing LLC Owner(a)15,786,737Â 15,786,737Â 15,786,737Â 15,786,737Â Stock options4,208,043Â 6,730,685Â 4,177,250Â 7,623,865Â RSUs49,784Â 766,427Â 25,029Â 974,238Â Total20,044,564Â 23,283,849Â 19,989,016Â 24,384,840Â (a)Class A Shares reserved for future issuance upon redemption or exchange of LLC Interests by the Continuing LLC Owner. X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for earnings per share. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/260/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3 + Details Name: us-gaap_EarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 26 R16.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Restructuring costs 6 Months Ended Jun. 29, 2024 Restructuring and Related Activities [Abstract] Â Restructuring costs Restructuring costsRestructuring costs are not allocated to the Companyâ€™s reportable segments as they are not part of the segment performance measures regularly reviewed by management. These charges are included in restructuring costs in the consolidated statements of operations and comprehensive loss. Liabilities associated from restructuring costs are recorded in accrued liabilities on the consolidated balance sheets.The Companyâ€™s prior restructuring plans adopted in 2021 and 2022 focused on aligning its organizational and management cost structure to improve profitability and cash flow, reduce headcount and the consolidation of facilities. These plans have been completed. There were no restructuring expenses incurred during the three and six months ended JuneÂ 29, 2024. Restructuring expenses incurred during three and six months ended JulyÂ 1, 2023 totaled $620 and $937, respectively. Payments for restructuring liabilities during the six months ended JuneÂ 29, 2024 and JulyÂ 1, 2023 totaled $961 and $3,085, respectively. X - ReferencesNo definition available. + Details Name: us-gaap_RestructuringAndRelatedActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/420/tableOfContentReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 27 R17.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Income taxes 6 Months Ended Jun. 29, 2024 Income Tax Disclosure [Abstract] Â Income taxes Income taxesThe tax provision for interim periods is determined using an estimate of the Companyâ€™s annual effective tax rate, adjusted for discrete items, if any, that arise during the period. Each quarter, the Company updates its estimate of its annual effective tax rate, and if the estimated annual effective tax rate changes, the Company makes a cumulative adjustment in such period. The quarterly tax provision, and estimate of the Companyâ€™s annual effective tax rate, are subject to variation due to several factors, including variability in pre-tax income (or loss), the mix of jurisdictions to which such income relates, changes in how the Company conducts business, and tax law developments.For the three and six months ended JuneÂ 29, 2024 and JulyÂ 1, 2023, the Companyâ€™s effective tax rate was 18.6%, 8.8%, and 14.4% and 0.2%, respectively. The change in rate for the three and six months ended JuneÂ 29, 2024 compared to the prior year comparable period was primarily due to losses in certain entities.Tax Receivable AgreementThe Company expects to obtain an increase in the share of the tax basis of the assets of BV LLC when LLC Interests are redeemed or exchanged by the Continuing LLC Owner and other qualifying transactions. This increase in tax basis may have the effect of reducing the amounts that the Company would otherwise pay in the future to various tax authorities. The increase in tax basis may also decrease gains (or increase losses) on future dispositions of certain capital assets to the extent tax basis is allocated to those capital assets. On February 16, 2021, the Company entered into a tax receivable agreement (â€œTRAâ€) with the Continuing LLC Owner that provides for the payment by the Company to the Continuing LLC Owner of 85% of the amount of tax benefits, if any, that the Company actually realizes as a result of (i) increases in the tax basis of assets of BV LLC resulting from any redemptions or exchanges of LLC Interests or any prior sales of interests in BV LLC; and (ii) certain other tax benefits related to our making payments under the TRA.The Company maintains a full valuation allowance against deferred tax assets related to the tax attributes generated as a result of redemptions of LLC Interests or exchanges described above until it is determined that the benefits are more-likely-than-not to be realized. Subsequent to the consummation of the IPO Mergers, the Continuing LLC Owner has not exchanged LLC Interests for shares of Class A common stock. X - ReferencesNo definition available. + Details Name: us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for income tax. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12CReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12BReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.5.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/740/tableOfContentReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 11.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2 + Details Name: us-gaap_IncomeTaxDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 28 R18.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Commitments and contingencies 6 Months Ended Jun. 29, 2024 Commitments and Contingencies Disclosure [Abstract] Â Commitments and contingencies Commitments and contingenciesLeasesThe Company leases its office facilities as well as other property, vehicles and equipment under operating leases. The Company also leases certain office equipment under nominal finance leases. The remaining lease terms range from 1 month to 8.8 years.The components of lease cost were as follows:Three Months EndedSix Months EndedJune 29, 2024July 1, 2023June 29, 2024July 1, 2023Operating lease cost$938Â $1,010Â $1,826Â $2,079Â Short-term lease cost(a)326Â 229Â 406Â 435Â Financing lease cost:Amortization of finance lease assets174Â 393Â 332Â 628Â Interest on lease liabilities217Â 229Â 438Â 366Â Total lease cost$1,655Â $1,861Â $3,002Â $3,508Â (a)Includes variable lease cost and sublease income, which are immaterial.Supplemental cash flow information and non-cash activity related to leases were as follows:Six Months EndedJune 29, 2024July 1, 2023Cash paid for amounts included in measurement of lease liabilities:Operating cash flows from operating leases$2,319Â $2,227Â Operating cash flows from financing leases$438Â $337Â Financing cash flows from finance leases$373Â $175Â Right-of-use assets obtained in exchange for lease obligations:Operating lease obligations$132Â $254Â Financing lease obligations$â€”Â $15,567Â Supplemental balance sheet and other information related to leases were as follows:June 29, 2024December 31, 2023Operating lease assets(a)$10,366$13,353Operating lease liabilitiesâ€”current(b)$3,038$4,057Operating lease liabilitiesâ€”noncurrent(b)8,46910,573Total operating lease liabilities$11,507$14,630Property, plant and equipment, net (finance leases)$13,491$14,279Finance lease liabilitiesâ€”current$791$759Finance lease liabilitiesâ€”noncurrent9,98110,386Total financing lease liabilities$10,772$11,145Weighted average remaining lease term (years) for leasesOperating leases3.43.8Finance leases8.89.3Weighted average discount rate for leasesOperating leases4.8Â %4.7Â %Finance leases8.1Â %8.1Â %(a)Operating lease assets totaling $1,171 attributable to the Advanced Rehabilitation Business were reclassified to assets held for sale within the JuneÂ 29, 2024 consolidated condensed balance sheets. Refer to Note 3. Acquisitions and divestitures for further details regarding assets held for sale.(b)Current and noncurrent operating lease liabilities of $983 and $249, respectively, were reclassified to liabilities held for sale within the JuneÂ 29, 2024 consolidated condensed balance sheets. Refer to Note 3. Acquisitions and divestitures for further details regarding assets held for sale.Governmental and legal contingenciesIn the normal course of business, the Company periodically becomes involved in various claims and lawsuits, and governmental proceedings and investigations that are incidental to its business. The Company accrues a liability when a loss is considered probable and the amount can be reasonably estimated. When a material loss contingency is reasonably possible but not probable, the Company does not record a liability, but instead discloses the nature and amount of the claim, and an estimate of the possible loss or range of loss, if such an estimate can be made. Legal fees are expensed as incurred. With respect to governmental proceedings and investigations, like other companies in the industry, the Company is subject to extensive regulation by national, state and local governmental agencies in the United States and in other jurisdictions in which the Company and its affiliates operate. As a result, interaction with governmental agencies is ongoing. The Companyâ€™s standard practice is to cooperate with regulators and investigators in responding to inquiries.The Company is presently unable to predict the duration, scope, or result of these matters. As such, the Company is presently unable to develop a reasonable estimate of a possible loss or range of losses, if any, related to these matters. While the Company intends to defend these matters vigorously, the outcome of such litigation or any other litigation is necessarily uncertain, is not within the Companyâ€™s complete control and might not be known for extended periods of time. In the opinion of management, the outcome of any existing claims and legal or regulatory proceedings, other than the specific matters described below, if decided adversely, is not expected to have a material adverse effect on the Companyâ€™s business, financial condition, results of operations, or cash flows.Bioventus shareholder litigationOn January 12, 2023, the Company and certain of its current and former directors and officers were named as defendants in a putative class action lawsuit filed in the Middle District of North Carolina (the â€œCourtâ€), Ciarciello v. Bioventus, Inc., No. 1:23â€“ CV â€“ 00032-CCE-JEP (M.D.N.C. 2023). The complaint asserted violations of Sections 10(b) and 20(a) of the Exchange Act and of Sections 11 and 15 of the Securities Act and generally alleges that the Company failed to disclose certain information regarding rebate practices, its business and financial prospects, and the sufficiency of internal controls regarding financial reporting. The complaint seeks damages in an unspecified amount. On April 12, 2023, the Court appointed Wayne County Employeesâ€™ Retirement System as lead plaintiff. The plaintiffâ€™s amended consolidated complaint was filed with the Court on June 12, 2023. On July 17, 2023, the defendants filed a motion to dismiss the complaint raising a number of legal and factual deficiencies with the amended consolidated complaint. In response to the defendantsâ€™ motion to dismiss, the lead plaintiff filed a second amended complaint on July 31, 2023. The defendants moved to dismiss the second amended complaint on August 21, 2023, which the Court granted in part and denied in part on November 6, 2023. The Court dismissed the plaintiffâ€™s Securities Act claims, but allowed the plaintiffâ€™s Exchange Act claims to proceed into discovery.On July 15, 2024, a Stipulation and Agreement of Settlement (the â€œSettlement Agreementâ€) by and between the lead plaintiff and the defendants was filed with the Court. The Settlement Agreement, which is subject to Court approval, provides among other things for (i) the dismissal of all claims against the defendants, including the Company; (ii) a settlement amount of $15,250, together with interest earned thereon, to be paid by the defendants and/or the defendantâ€™s insurers within 30 days after the later of (x) the date of entry by the Court of an order preliminarily approving the terms of the settlement or (y) receipt by the defendants from lead counsel of the information necessary to effectuate a transfer of the settlement funds; and (iii) no admission of liability or wrongdoing by any party. The Company incurred $12,502 and $13,670 of net shareholder litigation costs (including estimated settlement and reimbursement) during the three and six months ended JuneÂ 29, 2024 under the Settlement Agreement, which were recorded in selling, general and administrative expense within the consolidated condensed statements of operations and comprehensive loss. The Company expects to be reimbursed approximately $6,500 of the fees incurred to date, which was recorded in other current assets within the JuneÂ 29, 2024 consolidated condensed balance sheets.On October 4, 2023, certain of the Companyâ€™s current and former directors and officers were named as defendants in a derivative shareholder lawsuit (in which the Company is a nominal defendant) filed in the United States District Court for the District of Delaware, Grogan, on behalf of Bioventus Inc., v. Reali, et.al., No. 1:23-CV-01099-RGA (D. Del. 2023). The complaint asserts violations of Section 14(a) of the Exchange Act, breaches of fiduciary duties and related state law claims, and a claim for contribution, and generally alleges the same purported misconduct as alleged in the Ciarciello case. On January 12, 2024, the Court agreed to stay this case pending resolution of the Ciarciello case. The Company may incur further legal costs until settlement is ultimately approved and executed by the Court.On February 9, 2024, another plaintiff filed a derivative shareholder lawsuit against certain of the Companyâ€™s current and former directors and officers (in which the Company is a nominal defendant) filed in the United States District Court for the District of Delaware, Sanderson, on behalf of Bioventus Inc., v. Reali, et.al., No. 1:24-cv-00180-RGA (D. Del. 2024). Like the Grogan case, this case asserts violations of Section 10(b) of the Exchange Act, breaches of fiduciary duties and related state law claims, and a claim for contribution, and generally alleges the same purported misconduct as alleged in the Ciarciello case. On May 1, 2024, the parties filed a stipulation to consolidate the two derivative matters and stay them on terms similar to those entered in the Grogan case. On May 2, 2024, the United States District Court for the District of Delaware granted the stipulation and ordered the consolidation of the Sanderson and Grogan cases (as consolidated, the â€œGrogan Caseâ€).The Company believes the claims alleged in the Grogan Case lacks merit and intends to defend itself vigorously. The outcome of this matter is not presently determinable, and any loss is neither probable nor reasonably estimable.Bioness stockholder litigationOn February 8, 2022, a minority shareholder of Bioness filed an action in the Delaware State Court of Chancery in connection with the Companyâ€™s acquisition of Bioness, Teuza, a Fairchild Technology Venture Ltd. v. Lindon, et. al., No. 2022-0130 -SG. This action names the former Bioness directors, the Alfred E. Mann Trust (â€œTrustâ€), which was the former majority shareholder of Bioness, the trustees of the Trust and Bioventus as defendants. The complaint alleges, among other things, that the individual directors, the Trust, and the trustees breached their fiduciary duty to the plaintiff in connection with their consideration and approval of the Companyâ€™s transaction. The complaint also alleges that the Company aided and abetted the other defendants in breaching their fiduciary duties to the plaintiff and that the Company breached the Merger Agreement by failing to pay the plaintiff its pro rata share of the merger consideration. The Company believes that it is indemnified under the indemnification provisions contained in the Bioness Merger Agreement for these claims. On July 20, 2022, the Company filed a motion to dismiss all claims made against it on various grounds, as did all the other named defendants in the suit. A hearing on Bionessâ€™ and other the defendantâ€™s motions was held before the Court of Chancery on January 19, 2023. On April 27, 2023, the Court issued an order which, among other things, dismissed Bioventus from the case.Other mattersOn November 10, 2021, the Company entered into an asset purchase agreement for an HA product and made an upfront payment of $853. An additional payment of $853 was made in 2022 upon the transfer of certain seller customer data. If the Company is able to obtain a Medical Device Regulation Certification for the product, $1,707 (the â€œMilestone Paymentâ€) will be paid to the seller within five days. The Company is also required to pay royalties if certifications are achieved before December 31, 2024. Royalties will be payable through 2026 of 5.0% on the first $569 in sales and 2.5% thereafter. On March 8, 2023, the parties amended the agreement under which the Milestone Payment was reduced to $1,418, of which $709 was paid on January 31, 2024, and the remainder is due upon receipt of the Medical Device Regulation Certification for the product provided that it is obtained prior to December 31, 2024. As a result, the Company recorded an intellectual property intangible asset totaling $709 for initial payment.On August 23, 2019, the Company was assigned a third-party license on a product currently in development and the Company is subject to a 3% royalty on certain commercial sales, or a nominal minimum amount per quarter.On December 9, 2016, the Company entered into an amended and restated license agreement for the exclusive U.S. distribution and commercialization rights of a single injection osteoarthritis (â€œOAâ€) product with the supplier of the Companyâ€™s single injection OA product for the non-U.S. market. The agreement requires the Company to meet annual minimum purchase requirements and pay royalties on net sales. Royalties related to this agreement during the three months ended JuneÂ 29, 2024 and JulyÂ 1, 2023 and the six months ended JuneÂ 29, 2024 and JulyÂ 1, 2023 totaled $4,594 $4,119, $8,173 and $6,440, respectively. These royalties are included in cost of sales within the consolidated condensed statements of operations and comprehensive loss.As part of a supply agreement entered on February 9, 2016 for the Companyâ€™s three injection OA product, the Company is subject to annual minimum purchase requirements for 10 years. After the initial 10 years, the agreement will automatically renew for an additional 5 years unless terminated by the Company or the seller in accordance with the agreement.As part of a supply agreement for the Companyâ€™s five injection OA product that was amended and restated on December 22, 2020, the Company is subject to annual minimum purchase requirements for 8 years.From time to time, the Company causes LOCs to be issued to provide credit support for guarantees, contractual commitments and insurance policies. The fair values of the LOCs reflect the amount of the underlying obligation and are subject to fees payable to the issuers, competitively determined in the marketplace. As of JuneÂ 29, 2024 and DecemberÂ 31, 2023, the Company had two LOCs outstanding for $1,700.The Company currently maintains insurance for risks associated with the operation of its business, provision of professional services and ownership of property. These policies provide coverage for a variety of potential losses, including loss or damage to property, bodily injury, general commercial liability, professional errors and omissions and medical malpractice. The Company is self-insured for health insurance covering most of its employees located in the United States. The Company maintains stop-loss insurance on a â€œclaims madeâ€ basis for expenses in excess of $250 per member per year. X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -

SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 29 R19.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Revenue recognition 6 Months Ended Jun. 29, 2024 Revenue from Contract with Customer [Abstract] Â Revenue recognition Revenue recognitionOur policies for recognizing sales have not changed from those described in the Companyâ€™s Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023. The Company attributes net sales to external customers to the U.S. and to all foreign countries based on the legal entity from which the sale originated. As previously discussed in Note 1. Organization, SonicOne revenue was reclassified from Restorative Therapies to Surgical Solutions on a prospective and retrospective basis as its capabilities to remove devitalized or necrotic tissue and fiber deposits more closely aligns with Surgical Solutionsâ€™ soft tissue management. SonicOne revenue reclassified for the three and six months ended JulyÂ 1, 2023 totaled $1,832 and $3,544, respectively, for the U.S. reporting segment and $84 and $149, respectively, for the International reporting segment. The Company had product sales to one customer totaling $18,266 and $31,409 in the U.S. segment during the three and six months ended JuneÂ 29, 2024, representing 12.2% and 11.3% of total net sales, respectively. There was no customers representing 10% or more of net sales during the three and six months ended JulyÂ 1, 2023. The following table presents the Companyâ€™s net sales disaggregated by major business within each segment as follows:Three Months EndedSix Months EndedJune 29, 2024July 1, 2023June 29, 2024July 1, 2023U.S.Pain Treatments$65,194Â $55,617Â $115,831Â $96,612Â Restorative Therapies27,435Â 30,012Â 52,739Â 60,788Â Surgical Solutions41,780Â 35,218Â 80,120Â 67,425Â Total U.S. net sales134,409Â 120,847Â 248,690Â 224,825Â InternationalPain Treatments7,066Â 6,024Â 13,118Â 11,355Â Restorative Therapies4,185Â 4,690Â 9,355Â 10,239Â Surgical Solutions5,557Â 5,508Â 9,511Â 9,709Â Total International net sales16,808Â 16,222Â 31,984Â 31,303Â Total net sales$151,217Â $137,069Â $280,674Â $256,128Â X - ReferencesNo definition available. + Details Name: us-gaap_RevenueFromContractWithCustomerAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 606 -Publisher FASB -URI https://asc.fasb.org/606/tableOfContent + Details Name: us-gaap_RevenueFromContractWithCustomerTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 30 R20.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Segments 6 Months Ended Jun. 29, 2024 Segment Reporting [Abstract] Â Segments SegmentsThe Companyâ€™s two reportable segments are U.S. and International. U.S. segment revenues totaled $134,409, $120,847, $248,690 and $224,825 for the three months ended JuneÂ 29, 2024 and JulyÂ 1, 2023 and the six months ended JuneÂ 29, 2024 and JulyÂ 1, 2023, respectively. International segment revenues totaled $16,808, $16,222, $31,984 and $31,303 for the three months ended JuneÂ 29, 2024 and JulyÂ 1, 2023 and the six months ended JuneÂ 29, 2024 and JulyÂ 1, 2023, respectively. The Companyâ€™s products are primarily sold to orthopedists, musculoskeletal and sports medicine physicians, podiatrists, neurosurgeons and orthopedic spine surgeons, as well as to their patients. The Company does not disclose segment information by asset as the Chief Operating Decision Maker does not review or use it to allocate resources or to assess the operating results and financial performance. Segment Adjusted EBITDA is the segment profitability metric reported to the Companyâ€™s Chief Operating Decision Maker for purposes of decisions about allocation of resources to, and assessing performance of, each reportable segment.The following table presents segment Adjusted EBITDA reconciled to loss before income taxes:Three Months EndedSix Months EndedJune 29, 2024July 1, 2023June 29, 2024July 1, 2023Segment Adjusted EBITDAU.S.$31,590Â $24,712Â $51,346Â $39,424Â International2,862Â 3,446Â 5,729Â 5,685Â Interest expense, net(9,924)(10,587)(20,263)(20,281)Depreciation and amortization(13,090)(14,600)(24,875)(31,073)Acquisition and related costs(300)(1,448)(511)(2,623)Shareholder litigation costs(12,502)â€”Â (13,670)â€”Â Restructuring and succession charges40Â (620)(13)(937)Equity compensation(3,672)2,732Â (6,263)886Â Financial restructuring costs5Â (1,257)(347)(6,587)Impairments of assets(31,870)â€”Â (31,870)(78,615)Loss on disposal of a businessâ€”Â (977)â€”Â (977)Other items(2,590)(5,751)(3,789)(9,416)Loss before income taxes$(39,451)$(4,350)$(44,526)$(104,514) X - ReferencesNo definition available. + Details Name: us-gaap_SegmentReportingAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 10: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 34 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26CReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/280/tableOfContentReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 + Details Name: us-gaap_SegmentReportingDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 31 R21.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Discontinued Operations 6 Months Ended Jun. 29, 2024 Discontinued Operations and Disposal Groups [Abstract] Â Discontinued operations Discontinued operationsOn February 27, 2023 the Company reached a Settlement Agreement with the Former Securityholders of CartiHeal that resulted in the transfer of 100% of Companyâ€™s shares in CartiHeal to a Trustee. Refer to Note 3. Acquisitions and divestitures for further details concerning the Settlement Agreement and the deconsolidation of CartiHeal. CartiHeal had no sales during the year ended December 31, 2023.The following table summarizes the major income and expense line items of these discontinued operations, as reported in the consolidated statements of operations for the six months ended JulyÂ 1, 2023 as there was no activity for discontinued operations subsequent to the first quarter of 2023:Six Months EndedJuly 1, 2023Selling, general and administrative expense$1,728Â Research and development expense396Â Change in fair value of contingent consideration(a)1,710Â Depreciation and amortization(a)4,264Â Impairments of assetsâ€”Â Operating loss from discontinued operations(8,098)Interest expense, net4,889Â Other (income) expense(b)61,442Â Other (income) expense66,331Â Loss before income taxes(74,429)Income tax benefit, netâ€”Â Net loss from discontinued operations(74,429)Loss attributable to noncontrolling interest - discontinued operations14,937Â Net loss attributable to Bioventus Inc. - discontinued operations$(59,492)(a)Depreciation and amortization and the change in fair value of contingent consideration represents the significant operating non-cash items of discontinued operations.(b)Other expense includes the $60,639 loss on deconsolidation, of which $10,150 was attributable to non-refundable payments. Total investing cash outflows included these non-refundable payments and $1,356 cash on hand at disposal. X - ReferencesNo definition available. + Details Name: us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205-20/tableOfContentReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/360/tableOfContent + Details Name: us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 32 R22.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Organization (Policies) 6 Months Ended Jun. 29, 2024 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â Reclassifications ReclassificationsCertain prior period amounts have been reclassified to conform to current period presentation. During the first quarter of 2024, the Company reclassified revenue and expense of the SonicOne Ultrasonic Cleansing and Debridement Systems (â€œSonicOneâ€) from the Restorative Therapies to the Surgical Solutions business. The reclassification of SonicOne activity affected prior presentation of disaggregated revenue by business, refer to Note 12. Revenue recognition for further details. The reclassification had no effect on previously reported total revenues, net loss, other comprehensive loss, stockholdersâ€™ equity or cash flows. Use of estimates Use of estimatesThe preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities, at the date of the financial statements, as well as the reported amounts of revenues and expenses during the period. On an ongoing basis, management evaluates these estimates, including those related to contractual allowances and sales incentives, allowance for credit losses, inventory reserves, goodwill and intangible assets impairment, valuation of assets and liabilities assumed in acquisitions, useful lives of long lived assets, fair value measurements, litigation and contingent liabilities, income taxes, and equity-based compensation. Management bases its estimates on historical experience, future expectations and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from those estimates. Recent accounting pronouncements Recent accounting pronouncementsIn addition to being a smaller reporting and an emerging growth company, the Company also is an accelerated filer under SEC rules and regulations. Therefore, required effective dates for adopting new or revised accounting standards are generally earlier than when smaller reporting companies and emerging growth companies who are not accelerated filers are required to adopt.In December 2023, the Financial Accounting Standards Board (â€œFASBâ€) issued Accounting Standards Update 2023-09 (â€œASU 2023-09â€), Income Taxes, which enhances the transparency of income tax disclosures by expanding annual disclosure requirements related to the rate reconciliation and income taxes paid. The amendments are effective for fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments should be applied on a prospective basis. Retrospective application is permitted. The Company is currently evaluating this ASU to determine its impact on the Company's disclosures.In November 2023, the FASB issued Accounting Standards Update 2023-07 (â€œASU 2023-07â€), Segment

Reporting, which improves reportable segment disclosure requirements. ASU 2023-07 primarily enhances disclosures about significant segment expenses by requiring that a public entity disclose significant segment expenses that are regularly provided to the Chief Operating Decision Maker (â€œCODMâ€) and included within each reported measure of segment profit or loss. This ASU also (i) requires that a public entity disclose, on an annual and interim basis, an amount for other segment items by reportable segment, and a description of its composition; (ii) requires that all annual disclosures are provided in the interim periods; (iii) clarifies that if the CODM uses more than one measure of profitability in assessing segment performance and deciding how to allocate resources, that one or more of those measures may be reported; (iv) requires disclosure of the title and position of the CODM and a description of how the reported measures are used by the CODM in assessing segment performance and in deciding how to allocate resources; (v) requires that an entity with a single segment provide all new required disclosures. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024 and requires retrospective application. Early adoption is permitted. The amendments under ASU 2023-07 relate to financial disclosures and its adoption will not have an impact on the Companyâ€™s results of operations, financial position or cash flows. The Company will adopt ASU 2023-07 for the annual reporting period ending December 31, 2024 and for interim reporting periods thereafter. X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 205 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483504/205-10-50-1 + Details Name: us-gaap_PriorPeriodReclassificationAdjustmentDescription Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8 + Details Name: us-gaap_UseOfEstimates Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 33 R23.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Balance sheet information (Tables) 6 Months Ended Jun. 29, 2024 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â Schedule of Accounts Receivable Accounts receivable, net of allowances, consisted of the following as of:June 29, 2024December 31, 2023Accounts receivable(a)$140,204Â $127,008Â Less: Allowance for credit losses(a)(2,899)(4,219)$137,305Â $122,789Â (a)Accounts receivable of $7,688 attributable to the Companyâ€™s advanced rehabilitation business was reclassified to assets held for sale within the JuneÂ 29, 2024 consolidated condensed balance sheets. Refer to Note 3. Acquisitions and divestitures for further details regarding assets held for sale. Schedule of Inventory Inventory consisted of the following as of:June 29, 2024December 31, 2023Raw materials and supplies(a)$24,841Â $21,062Â Finished goods(a)62,765Â 70,271Â $87,606Â $91,333Â (a)Raw materials and supplies of $4,924 and finished goods inventory of $9,449 attributable to the Companyâ€™s advanced rehabilitation business were reclassified to assets held for sale within the JuneÂ 29, 2024 consolidated condensed balance sheets. Refer to Note 3. Acquisitions and divestitures for further details regarding assets held for sale. Schedule of Property and Equipment, Net Property and equipment consisted of the following as of:June 29, 2024December 31, 2023Computer equipment and software$39,713Â $37,860Â Demonstration and consignment inventory9,963Â 9,341Â Leasehold improvements3,933Â 3,763Â Furniture and fixtures(a)4,586Â 4,163Â Finance leases15,737Â 15,737Â Machinery and equipment(b)1,801Â 2,180Â Assets net yet placed in service2,021Â 4,065Â 77,754Â 77,109Â Less accumulated depreciation(45,816)(40,504)$31,938Â $36,605Â (a)Furniture and fixtures of $51 and accumulated depreciation of $31 attributable to the Companyâ€™s advanced rehabilitation business were reclassified to assets held for sale within the JuneÂ 29, 2024 consolidated condensed balance sheets. Refer to Note 3. Acquisitions and divestitures for further details regarding assets held for sale.(b)Machinery and equipment of $385 and accumulated depreciation of $133 attributable to the Companyâ€™s advanced rehabilitation business were reclassified to assets held for sale within the JuneÂ 29, 2024 consolidated condensed balance sheets. Refer to Note 3. Acquisitions and divestitures for further details regarding assets held for sale. Schedule of Intangible Assets Intangible assets consisted of the following as of:June 29, 2024December 31, 2023Intellectual property(a)(b)$626,007Â $677,258Â Distribution rights61,325Â 61,325Â Customer relationships57,950Â 57,950Â IPR&D5,500Â 5,500Â Developed technology and other13,998Â 13,998Â Total carrying amount764,780Â 816,031Â Less accumulated amortization:Intellectual property(a)(b)(221,261)(218,031)Distribution rights(51,790)(49,301)Customer relationships(57,950)(57,950)Developed technology and other(8,004)(7,521)Total accumulated amortization(339,005)(332,803)Intangible assets, net before currency translation425,775Â 483,228Â Currency translation(1,223)(878)$424,552Â $482,350Â (a)Intellectual property of $19,380 and accumulated amortization of $16,656 attributable to the Companyâ€™s advanced rehabilitation business were reclassified to assets held for sale within the JuneÂ 29, 2024 consolidated condensed balance sheets. Refer to Note 3.Acquisitions and divestitures for further details regarding assets held for sale.(b)The Company recorded an impairment loss of $31,870 for the three and six months ended JuneÂ 29, 2024 in the U.S. reporting segment of net intellectual property solely attributable to the Companyâ€™s advanced rehabilitation business. The loss was recorded in impairment of assets within the consolidated condensed statements of operations and comprehensive loss. Refer to Refer to Note 3. Acquisitions and divestitures for further details regarding businesses held for sale. Schedule of Accrued Liabilities Accrued liabilities consisted of the following as of:June 29, 2024December 31, 2023Gross-to-net deductions$68,349Â $59,592Â Bonus and commission19,987Â 19,437Â Settlement and legal fees17,737Â 986Â Compensation and benefits9,081Â 9,709Â Accrued interest6,185Â 6,606Â Income and other taxes4,883Â 4,749Â Other liabilities(a)13,756Â 18,716Â $139,978Â $119,795Â (a)Accrued liabilities of $3,110 attributable to the Companyâ€™s advanced rehabilitation business were reclassified to liabilities held for sale within the JuneÂ 29, 2024 consolidated condensed balance sheets. Refer to Note 3. Acquisitions and divestitures for further details regarding assets held for sale. X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the components of accrued liabilities. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 + Details Name: us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1 + Details Name: us-gaap_ScheduleOfInventoryCurrentTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 34 R24.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Acquisitions and divestitures (Tables) 6 Months Ended Jun. 29, 2024 Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract] Â Schedule of Held for Sale Assets and Liabilities The carrying amounts for the major classes of assets and liabilities of the Advanced Rehabilitation Business classified as held for sale were as follows:June 29, 2024Carrying amounts of assets classified as held for sale:Accounts receivable$7,688Â Inventory14,373Â Prepaid and other current assets1,930Â Property and equipment, net272Â Intangible assets2,724Â Operating lease assets1,171Â Other assets250Â Total assets held for sale$28,408Â Carrying amounts of liabilities classified as held for sale:Accounts payable$1,566Â Accrued liabilities3,110Â Other liabilities1,232Â Total liabilities held for sale$5,908Â The following table summarizes the major income and expense line items of these discontinued operations, as reported in the consolidated statements of operations for the six months ended JulyÂ 1, 2023 as there was no activity for discontinued operations subsequent to the first quarter of 2023:Six Months EndedJuly 1, 2023Selling, general and administrative expense$1,728Â Research and development expense396Â Change in fair value of contingent consideration(a)1,710Â Depreciation and amortization(a)4,264Â Impairments of assetsâ€”Â Operating loss from discontinued operations(8,098)Interest expense, net4,889Â Other (income) expense(b)61,442Â Other (income) expense66,331Â Loss before income taxes(74,429)Income tax benefit, netâ€”Â Net loss from discontinued operations(74,429)Loss attributable to noncontrolling interest - discontinued operations14,937Â Net loss attributable to Bioventus Inc. - discontinued operations$(59,492)(a)Depreciation and amortization and the change in fair value of contingent consideration represents the significant operating non-cash items of discontinued operations.(b)Other expense includes the $60,639 loss on deconsolidation, of which $10,150 was attributable to non-refundable payments. Total investing cash outflows included these non-refundable payments and $1,356 cash on hand at disposal. X - ReferencesNo definition available. + Details Name: us-gaap_BusinessCombinationAndAssetAcquisitionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 3 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-3AReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-4AReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-4BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5AReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5D -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5DReference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3AReference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-3 + Details Name: us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 35 R25.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Financial instruments (Tables) 6 Months Ended Jun. 29, 2024 Debt Disclosure [Abstract] Â Schedule of Long-term Debt Instruments Long-term debt consisted of the following as of:June 29, 2024December 31, 2023Amended Term Loan due October 2026 (9.34% at JuneÂ 29, 2024)$371,128Â $382,448Â Revolver due October 2025 (9.34% at JuneÂ 29, 2024)15,000Â 15,000Â Less:Current portion of long-term debt(38,566)(27,848)Unamortized debt issuance cost(1,459)(917)Unamortized discount(1,387)(1,685)$344,716Â $366,998Â X - ReferencesNo definition available. + Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -

Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 470 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-8Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7 + Details Name: us-gaap_ScheduleOfDebtInstrumentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 36 R26.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Fair value measurements (Tables) 6 Months Ended Jun. 29, 2024 Fair Value Disclosures [Abstract] Â Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis The following table provides information for assets and liabilities measured at fair value on a recurring basis using Level 3 inputs:June 29, 2024December 31, 2023TotalLevel 3TotalLevel 3Liabilities:Current portion of contingent consideration$18,745Â $18,745Â $â€”Â $â€”Â Contingent considerationâ€”Â â€”Â 18,150Â 18,150Â Total liabilities:$â€”Â $â€”Â $18,150Â $18,150Â Schedule of Fair Value Measurement Inputs and Valuation Techniques A summary of unobservable Level 3 inputs utilized for the above liabilities are as follows:Valuation TechniqueUnobservable inputsRange Bioness contingent considerationDiscounted cash flowPayment discount rate6.4% - 6.8%Payment period2024 - 2025 X - DefinitionTabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 37 R27.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Equity-based compensation (Tables) 6 Months Ended Jun. 29, 2024 Compensation And Employee Benefit Plans [Abstract] Â Schedule of Nonvested Restricted Stock Units Activity A summary of the RSU award activity for the six months ended JuneÂ 29, 2024 is as follows (number of units in thousands):Number of unitsWeighted-average grant-date fair value per unitUnvested at December 31, 20232,066Â $4.51Â Granted2,429Â 5.45Â Vested(1,550)4.56Â Forfeited or canceled(105)7.33Â Unvested at June 29, 20242,840Â $5.12Â Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions A summary of the Companyâ€™s assumptions used in determining the fair value of the stock options granted during the six months ended JuneÂ 29, 2024 is shown in the following table:Risk-free interest rate3.9% - 4.3%Expected dividend yieldâ€”Â %Expected stock price volatility36.1% - 36.4%Expected life of stock options (years)6.25 Schedule of Stock Options Roll Forward A summary of stock option activity is as follows for the six months ended JuneÂ 29, 2024 (number of options in thousands):Number of optionsWeighted-average exercise priceWeighted average remaining contractual termAggregate intrinsic valueOutstanding at December 31, 20234,347Â $8.68Â Granted1,763Â 5.18Â Exercised(229)5.21Â Forfeited or canceled(747)10.51Â Outstanding at June 29, 20245,134Â 7.53Â 7.66$4,968Â Exercisable and vested at June 29, 20241,982Â $9.95Â 5.57$855Â X - DefinitionCompensation And Employee Benefit Plans + ReferencesNo definition available. + Details Name: bvs_CompensationAndEmployeeBenefitPlansAbstract Namespace Prefix: bvs_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the changes in outstanding nonvested restricted stock units. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (f)(2) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the change in stock options. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 38 R28.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stockholdersâ€™ equity (Tables) 6 Months Ended Jun. 29, 2024 Equity [Abstract] Â Schedule of Other Ownership Interests The following table summarizes the ownership interest in BV LLC as of JuneÂ 29, 2024 and DecemberÂ 31, 2023 (number of units in thousands):June 29, 2024December 31, 2023LLC InterestsOwnership %LLC InterestsOwnership %Number of LLC Interests ownedBioventus Inc.65,172Â 80.5Â %63,267Â 80.0Â %Continuing LLC Owner15,787Â 19.5Â %15,787Â 20.0Â %Total80,959Â 100.0Â %79,054Â 100.0Â % X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of other units or shares or classes of ownership in a partnership. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 4.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-5 + Details Name: us-gaap_ScheduleOfOtherOwnershipInterestsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 39 R29.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Earnings per share (Tables) 6 Months Ended Jun. 29, 2024 Earnings Per Share [Abstract] Â Schedule of Earnings Per Share The following table sets forth the computation of basic and diluted loss per share of Class A common stock for the periods presented (amounts in thousands, except share and per share data):Three Months EndedSix Months EndedJune 29, 2024July 1, 2023June 29, 2024July 1, 2023Numerator:Net loss from continuing operations, net of tax$(32,112)$(4,731)$(38,094)$(104,749)Net loss attributable to noncontrolling interests â€” Â Â Â Â continuing operations8,120Â 1,050Â 9,532Â 21,410Â Net loss attributable to Bioventus Inc. Class A Â Â Â Â Â common stockholders â€” continuing operations$(23,992)$(3,681)$(28,562)$(83,339)Numerator:Net loss from discontinued operations, net of tax$â€”Â $â€”Â $â€”Â $(74,429)Net loss attributable to noncontrolling interests â€” Â Â Â Â Â discontinued operationsâ€”Â â€”Â â€”Â 14,937Â Net loss attributable to Bioventus Inc. Class A Â Â Â Â Â common stockholders â€” discontinued operations$â€”Â $â€”Â $â€”Â $(59,492)Denominator:Weighted-average shares of Class A common stock Â Â Â Â Â outstandingâ€”basic and diluted64,056,759Â 62,551,285Â 63,720,342Â 62,338,018Â Net loss per share of Class A common stock from Â Â Â Â Â continuing operations, basic and diluted(0.37)(0.06)(0.45)(1.34)Net loss per share of Class A common stock from Â Â Â Â Â discontinued operations, basic and dilutedâ€”Â â€”Â â€”Â (0.95)Net loss per share of Class A common stock, Â Â Â Â Â basic and diluted(0.37)(0.06)(0.45)(2.29) Schedule of Antidilutive Securities The following number of weighted-average potentially dilutive shares as of JuneÂ 29, 2024 and JulyÂ 1, 2023 were excluded from the calculation of diluted loss per share because the effect of including such potentially dilutive shares would have been antidilutive upon conversion:Three Months EndedSix Months EndedJune 29, 2024July 1, 2023June 29, 2024July 1, 2023LLC Interests held by Continuing LLC Owner(a)15,786,737Â 15,786,737Â 15,786,737Â 15,786,737Â Stock options4,208,043Â 6,730,685Â 4,177,250Â 7,623,865Â RSUs49,784Â 766,427Â 25,029Â 974,238Â Total20,044,564Â 23,283,849Â 19,989,016Â 24,384,840Â (a)Class A Shares reserved for future issuance upon redemption or exchange of LLC Interests by the Continuing LLC Owner. X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 40 R30.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Commitments and contingencies (Tables) 6 Months Ended Jun. 29, 2024 Commitments and Contingencies Disclosure [Abstract] Â Schedule of Lease, Cost The components of lease cost were as follows:Three Months EndedSix Months EndedJune 29, 2024July 1, 2023June 29, 2024July 1, 2023Operating lease cost$938Â $1,010Â $1,826Â $2,079Â Short-term lease cost(a)326Â 229Â 406Â 435Â Financing lease cost:Amortization of finance lease assets174Â 393Â 332Â 628Â Interest on lease liabilities217Â 229Â 438Â 366Â Total lease cost$1,655Â $1,861Â $3,002Â $3,508Â (a)Includes variable lease cost and sublease income, which are immaterial.Supplemental cash flow information and non-cash activity related to leases were as follows:Six Months EndedJune 29, 2024July 1, 2023Cash paid for amounts included in measurement of lease liabilities:Operating cash flows from operating leases$2,319Â $2,227Â Operating cash flows from financing leases$438Â $337Â Financing cash flows from finance leases$373Â $175Â Right-of-use assets obtained in exchange for lease obligations:Operating lease obligations$132Â $254Â Financing lease obligations$â€”Â $15,567Â Schedule of Assets and Liabilities, Lessee Supplemental balance sheet and other information related to leases were as follows:June 29, 2024December 31, 2023Operating lease assets(a)$10,366$13,353Operating lease liabilitiesâ€”current(b)$3,038$4,057Operating lease liabilitiesâ€”noncurrent(b)8,46910,573Total operating lease liabilities$11,507$14,630Property, plant and equipment, net (finance leases)$13,491$14,279Finance lease liabilitiesâ€”current$791$759Finance lease liabilitiesâ€”noncurrent9,98110,386Total financing lease liabilities$10,772$11,145Weighted average remaining lease term (years) for leasesOperating leases3.43.8Finance leases8.89.3Weighted average discount rate for leasesOperating leases4.8Â %4.7Â %Finance leases8.1Â %8.1Â %(a)Operating lease assets totaling $1,171 attributable to the Advanced Rehabilitation Business were reclassified to assets held for sale within the JuneÂ 29, 2024 consolidated condensed balance sheets. Refer to Note 3. Acquisitions and divestitures for further details regarding assets held for sale.(b)Current and noncurrent operating lease liabilities of $983 and $249, respectively, were reclassified to liabilities held for sale within the JuneÂ 29, 2024 consolidated condensed balance sheets. Refer to Note 3. Acquisitions and divestitures for further details regarding assets held for sale. X - DefinitionAssets And Liabilities, Lessee + ReferencesNo definition available. + Details Name: bvs_AssetsAndLiabilitiesLesseeTableTextBlock Namespace Prefix: bvs_ Data Type: dtr-types1:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_LeaseCostTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 41 R31.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Revenue recognition (Tables) 6 Months Ended Jun. 29, 2024 Revenue from Contract with Customer [Abstract] Â Schedule of Disaggregation of Revenue The following table presents the Companyâ€™s net sales disaggregated by major business within each segment as follows:Three Months EndedSix Months EndedJune 29, 2024July 1, 2023June 29, 2024July 1, 2023U.S.Pain Treatments$65,194Â $55,617Â $115,831Â $96,612Â Restorative Therapies27,435Â 30,012Â 52,739Â 60,788Â Surgical Solutions41,780Â 35,218Â 80,120Â 67,425Â Total U.S. net sales134,409Â 120,847Â 248,690Â 224,825Â InternationalPain Treatments7,066Â 6,024Â 13,118Â 11,355Â Restorative Therapies4,185Â 4,690Â 9,355Â 10,239Â Surgical Solutions5,557Â 5,508Â 9,511Â 9,709Â Total International net sales16,808Â 16,222Â 31,984Â 31,303Â Total net sales$151,217Â $137,069Â $280,674Â $256,128Â X - DefinitionTabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 + Details Name: us-gaap_DisaggregationOfRevenueTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_RevenueFromContractWithCustomerAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 42 R32.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Segments (Tables) 6 Months Ended Jun. 29, 2024 Segment Reporting [Abstract] Â Schedule of Reconciliation of Operating Profit (Loss) from Segments to Consolidated The following table presents segment Adjusted EBITDA reconciled to loss before income taxes:Three Months EndedSix Months EndedJune 29, 2024July 1, 2023June 29, 2024July 1, 2023Segment Adjusted EBITDAU.S.$31,590Â $24,712Â $51,346Â $39,424Â International2,862Â 3,446Â 5,729Â 5,685Â Interest expense, net(9,924)(10,587)(20,263)(20,281)Depreciation and amortization(13,090)(14,600)(24,875)(31,073)Acquisition and related costs(300)(1,448)(511)(2,623)Shareholder litigation costs(12,502)â€”Â (13,670)â€”Â Restructuring and succession charges40Â (620)(13)(937)Equity compensation(3,672)2,732Â (6,263)886Â Financial restructuring costs5Â (1,257)(347)(6,587)Impairments of assets(31,870)â€”Â (31,870)(78,615)Loss on disposal of a businessâ€”Â (977)â€”Â (977)Other items(2,590)(5,751)(3,789)(9,416)Loss before income taxes$(39,451)$(4,350)$(44,526)$(104,514) X - DefinitionTabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-

gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SegmentReportingAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 43 R33.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Discontinued Operations (Tables) 6 Months Ended Jun. 29, 2024 Discontinued Operations and Disposal Groups [Abstract] Â Schedule of Balance Sheet and Statement of Operation The carrying amounts for the major classes of assets and liabilities of the Advanced Rehabilitation Business classified as held for sale were as follows:June 29, 2024Carrying amounts of assets classified as held for sale:Accounts receivable$7,688Â Inventory14,373Â Prepaid and other current assets1,930Â Property and equipment, net272Â Intangible assets2,724Â Operating lease assets1,171Â Other assets250Â Total assets held for sale$28,408Â Carrying amounts of liabilities classified as held for sale:Accounts payable$1,566Â Accrued liabilities3,110Â Other liabilities1,232Â Total liabilities held for sale$5,908Â The following table summarizes the major income and expense line items of these discontinued operations, as reported in the consolidated statements of operations for the six months ended JulyÂ 1, 2023 as there was no activity for discontinued operations subsequent to the first quarter of 2023:Six Months EndedJuly 1, 2023Selling, general and administrative expense$1,728Â Research and development expense396Â Change in fair value of contingent consideration(a)1,710Â Depreciation and amortization(a)4,264Â Impairments of assetsâ€”Â Operating loss from discontinued operations(8,098)Interest expense, net4,889Â Other (income) expense(b)61,442Â Other (income) expense66,331Â Loss before income taxes(74,429)Income tax benefit, netâ€”Â Net loss from discontinued operations(74,429)Loss attributable to noncontrolling interest - discontinued operations14,937Â Net loss attributable to Bioventus Inc. - discontinued operations$(59,492)(a)Depreciation and amortization and the change in fair value of contingent consideration represents the significant operating non-cash items of discontinued operations.(b)Other expense includes the $60,639 loss on deconsolidation, of which $10,150 was attributable to non-refundable payments. Total investing cash outflows included these non-refundable payments and $1,356 cash on hand at disposal. X - ReferencesNo definition available. + Details Name: us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 3 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-3AReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-4AReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-4BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5AReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5D -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5DReference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3AReference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-3 + Details Name: us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 44 R34.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Organization - Narrative (Details) Jun. 29, 2024 employee Bioventus Inc. Â Class of Stock [Line Items] Â Number of employees 1,030 X - DefinitionNumber of persons employed by the Entity + ReferencesNo definition available. + Details Name: dei_EntityNumberOfEmployees Namespace Prefix: dei_ Data Type: xbrli:decimalItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_ClassOfStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: dei_LegalEntityAxis=bvs_BVLLCMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 45 R35.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Balance sheet information - Schedule of Accounts Receivable (Details) - USD ($) $ in Thousands Jun. 29, 2024 Dec. 31, 2023 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â Â Accounts receivable $ 140,204 $ 127,008 Less: Allowance for credit losses (2,899) (4,219) Accounts receivable, net $ 137,305 $ 122,789 X - DefinitionAmount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1 + Details Name: us-gaap_AccountsReceivableGrossCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2 + Details Name: us-gaap_AccountsReceivableNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of allowance for credit loss on accounts receivable, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4 + Details Name: us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 46 R36.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Balance sheet information - Components of Accounts Receivable (Narrative) (Details) - USD ($) $ in Thousands 6 Months Ended 12 Months Ended Jun. 29, 2024 Dec. 31, 2023 Concentration Risk [Line Items] Â Â Accounts receivable $ 140,204 $ 127,008 Allowance for credit losses 2,899 $ 4,219 Discontinued Operations, Held-for-sale Â Â Concentration Risk [Line Items] Â Â Accounts receivable $ 7,688 Â Accounts Receivable | Customer | Customer One Â Â Concentration Risk [Line Items] Â Â Concentration risk percentage 19.20% 16.00% X - DefinitionAmount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1 + Details Name: us-gaap_AccountsReceivableGrossCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of allowance for credit loss on accounts receivable, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4 + Details Name: us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 310 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478785/954-310-50-2 + Details Name: us-gaap_ConcentrationRiskLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFor an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20 + Details Name: us-gaap_ConcentrationRiskPercentage1 Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=bvs_CustomerOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 47 R37.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Balance sheet information - Schedule of Inventory (Details) - USD ($) $ in Thousands Jun. 29, 2024 Dec. 31, 2023 Inventory [Line Items] Â Â Raw materials and supplies $ 24,841 $ 21,062 Finished goods 62,765 70,271 Total 87,606 $ 91,333 Discontinued Operations, Held-for-sale | Rehabilitation Business Â Â Inventory [Line Items] Â Â Raw materials and supplies 4,924 Â Finished goods $ 9,449 Â X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 4:

http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1A + Details Name: us-gaap_GoodwillLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryFinishedGoods Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionGross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionGross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryRawMaterialsAndSupplies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bvs_RehabilitationBusinessMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 48 R38.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Balance sheet information - Schedule od Property and Equipment, Net (Details) - USD ($) $ in Thousands Jun. 29, 2024 Dec. 31, 2023 Property, Plant and Equipment [Line Items] Â Â Finance leases $ 15,737 $ 15,737 Property and equipment and finance leases, gross 77,754 77,109 Less accumulated depreciation and amortization (45,816) (40,504) Property and equipment and finance leases, net 31,938 36,605 Computer equipment and software Â Â Property, Plant and Equipment [Line Items] Â Â Property and equipment, gross 39,713 37,860 Demonstration and consignment inventory Â Â Property, Plant and Equipment [Line Items] Â Â Property and equipment, gross 9,963 9,341 Leasehold improvements Â Â Property, Plant and Equipment [Line Items] Â Â Property and equipment, gross 3,933 3,763 Furniture and fixtures Â Â Property, Plant and Equipment [Line Items] Â Â Property and equipment, gross 4,586 4,163 Furniture and fixtures | Discontinued Operations, Held-for-sale Â Â Property, Plant and Equipment [Line Items] Â Â Property and equipment, gross 51 Â Less accumulated depreciation and amortization (31) Â Machinery and equipment Â Â Property, Plant and Equipment [Line Items] Â Â Property and equipment, gross 1,801 2,180 Machinery and equipment | Discontinued Operations, Held-for-sale Â Â Property, Plant and Equipment [Line Items] Â Â Finance leases 385 Â Less accumulated depreciation and amortization (133) Â Assets net yet placed in service Â Â Property, Plant and Equipment [Line Items] Â Â Property and equipment, gross $ 2,021 $ 4,065 X - DefinitionAmount, before accumulated amortization, of right-of-use asset from finance lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -SubTopic 20 -Topic 842 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -SubTopic 20 -Topic 842 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -SubTopic 20 -Topic 842 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -SubTopic 20 -Topic 842 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -SubTopic 20 -Topic 842 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A + Details Name: us-gaap_PropertyPlantAndEquipmentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=bvs_ComputerEquipmentAndSoftwareMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=bvs_DemonstrationAndConsignmentInventoryMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=bvs_AssetsNotYetPlacedInServiceMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 49 R39.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Balance sheet information - Schedule of Intangible Assets (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 29, 2024 Jun. 29, 2024 Dec. 31, 2023 Finite-Lived Intangible Assets [Line Items] Â Â Â Carrying amount $ 764,780 $ 764,780 $ 816,031 Accumulated amortization (339,005) (339,005) (332,803) Intangible assets, net before currency translation 425,775 425,775 483,228 Currency translation (1,223) (1,223) (878) Intangible assets, net 424,552 424,552 482,350 Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract] Â Â Â Expected future amortization, remainder of fiscal year 19,629 19,629 Â Expected future amortization, year one 37,412 37,412 Â Expected future amortization, year two 34,192 34,192 Â Expected future amortization, year three 35,243 35,243 Â Expected future amortization, year four 31,012 31,012 Â Intellectual Property Â Â Â Finite-Lived Intangible Assets [Line Items] Â Â Â Carrying amount 626,007 626,007 677,258 Accumulated amortization (221,261) (221,261) (218,031) Intellectual Property | Discontinued Operations, Held-for-sale Â Â Â Finite-Lived Intangible Assets [Line Items] Â Â Â Carrying amount 19,380 19,380 Â Accumulated amortization (16,656) (16,656) Â Impairment of intangible assets 31,870 31,870 Â Distribution rights Â Â Â Finite-Lived Intangible Assets [Line Items] Â Â Â Carrying amount 61,325 61,325 61,325 Accumulated amortization (51,790) (51,790) (49,301) Customer relationships Â Â Â Finite-Lived Intangible Assets [Line Items] Â Â Â Carrying amount 57,950 57,950 57,950 Accumulated amortization (57,950) (57,950) (57,950) Developed technology and other Â Â Â Finite-Lived Intangible Assets [Line Items] Â Â Â Carrying amount 5,500 5,500 5,500 Developed technology and other Â Â Â Finite-Lived Intangible Assets [Line Items] Â Â Â Carrying amount 13,998 13,998 13,998 Accumulated amortization $ (8,004) $ (8,004) $ (7,521) X - DefinitionFinite-Lived Intangible Assets, Accumulated Foreign Currency Translation Gain (Loss) + ReferencesNo definition available. + Details Name: bvs_FiniteLivedIntangibleAssetsAccumulatedForeignCurrencyTranslationGainLoss Namespace Prefix: bvs_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFinite-Lived Intangible Assets, Net, Before Foreign Currency Translation Gain (Loss) + ReferencesNo definition available. + Details Name: bvs_FiniteLivedIntangibleAssetsNetBeforeForeignCurrencyTranslationGainLoss Namespace Prefix: bvs_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAccumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI

https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 928 -SubTopic 340 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1 + Details Name: us-gaap_FiniteLivedIntangibleAssetsGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ImpairmentOfIntangibleAssetsFinitelived Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 50 R40.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Balance sheet information - Schedule of Accrued Liabilities (Details) - USD ($) $ in Thousands Jun. 29, 2024 Dec. 31, 2023 Accrued Liabilities [Line Items] Â Â Gross-to-net deductions $ 68,349 $ 59,592 Bonus and commission 19,987 19,437 Settlement and legal fees 17,737 986 Compensation and benefits 9,081 9,709 Accrued interest 6,185 6,606 Income and other taxes 4,883 4,749 Other liabilities(a) 13,756 18,716 Accrued liabilities 139,978 $ 119,795 Discontinued Operations, Held-for-sale Â Â Accrued Liabilities [Line Items] Â Â Accrued liabilities $ 3,110 Â X - DefinitionAccrued Legal Liabilities + ReferencesNo definition available. + Details Name: bvs_AccruedLegalLiabilities Namespace Prefix: bvs_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAccrued Salaries And Employee Benefits, Current + ReferencesNo definition available. + Details Name: bvs_AccruedSalariesAndEmployeeBenefitsCurrent Namespace Prefix: bvs_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionGross-To-Net Deductions, Current + ReferencesNo definition available. + Details Name: bvs_GrossToNetDeductionsCurrent Namespace Prefix: bvs_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedBonusesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1A + Details Name: us-gaap_GoodwillLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of interest payable on debt, including, but not limited to, trade payables. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(15)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_InterestPayableCurrentAndNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_TaxesPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 51 R41.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Acquisitions and divestitures - Schedule of Held for Sale Assets and Liabilities (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 29, 2024 Jun. 29, 2024 Jul. 01, 2023 May 31, 2024 Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Â Â Â Â Impairments of assets Â $ 31,870 $ 78,615 Â Discontinued Operations, Held-for-sale | Rehabilitation Business Â Â Â Â Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Â Â Â Â Transactional fees Â Â Â $ 2,500 Impairments of assets $ 31,870 31,870 Â Â Assets Held for Sale [Abstract] Â Â Â Â Accounts receivable 7,688 7,688 Â Â Inventory 14,373 14,373 Â Â Prepaid and other current assets 1,930 1,930 Â Â Property and equipment, net 272 272 Â Â Intangible assets 2,724 2,724 Â Â Operating lease assets 1,171 1,171 Â Â Other assets 250 250 Â Â Total assets held for sale 28,408 28,408 Â Â Liabilities Held for Sale [Abstract] Â Â Â Â Accounts payable 1,566 1,566 Â Â Accrued liabilities 3,110 3,110 Â Â Other liabilities 1,232 1,232 Â Â Total liabilities held for sale $ 5,908 $ 5,908 Â Â X - DefinitionAssets Held for Sale + ReferencesNo definition available. + Details Name: bvs_AssetsHeldForSaleAbstract Namespace Prefix: bvs_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisposal Group, Including Discontinued Operation, Inventory + ReferencesNo definition available. + Details Name: bvs_DisposalGroupIncludingDiscontinuedOperationInventory Namespace Prefix: bvs_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionDisposal Group, Including Discontinued Operation, Operating Lease Assets + ReferencesNo definition available. + Details Name: bvs_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseAssets Namespace Prefix: bvs_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionDisposal Group, Including Discontinued Operation, Transactional Fees Incurred + ReferencesNo definition available. + Details Name: bvs_DisposalGroupIncludingDiscontinuedOperationTransactionalFeesIncurred Namespace Prefix: bvs_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLiabilities Held for Sale + ReferencesNo definition available. + Details Name: bvs_LiabilitiesHeldForSaleAbstract Namespace Prefix: bvs_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4 + Details Name: us-gaap_AssetImpairmentCharges Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount classified as assets attributable to disposal group held for sale or disposed of. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -

Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount classified as accounts payable attributable to disposal group held for sale or disposed of. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount classified as accrued liabilities attributable to disposal group held for sale or disposed of. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount classified as other assets attributable to disposal group held for sale or disposed of. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount classified as other liabilities attributable to disposal group held for sale or disposed of. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount classified as prepaid and other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount classified as property, plant and equipment attributable to disposal group held for sale or disposed of. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount classified as liabilities attributable to disposal group held for sale or disposed of. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bvs_RehabilitationBusinessMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 52 R42.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Acquisitions and divestitures (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended May 22, 2023 Feb. 27, 2023 Jun. 29, 2024 Jul. 01, 2023 Jun. 29, 2024 Jul. 01, 2023 Jul. 12, 2022 Business Acquisition [Line Items] Â Â Â Â Â Â Â Impairments of assets Â Â Â Â $ 31,870 $ 78,615 Â Payments on long-term debt $ 30,000 Â Â Â Â Â Â Loss on deconsolidation Â Â $ 60,639 $ 60,639 $ 60,639 60,639 Â CartiHeal Ltd Â Â Â Â Â Â Â Business Acquisition [Line Items] Â Â Â Â Â Â Â Litigation settlement, amount awarded to other party Â $ 10,150 Â Â Â Â Â Â CartiHeal Ltd Â Â Â Â Â Â Â Business Acquisition [Line Items] Â Â Â Â Â Â Â Percentage of business acquired Â Â Â Â Â Â 100.00% CartiHeal Ltd | Deferred Consideration Â Â Â Â Â Â Â Business Acquisition [Line Items] Â Â Â Â Â Â Â Contingent consideration Â 215,000 Â Â Â Â Â CartiHeal Ltd | Sales Milestone Â Â Â Â Â Â Â Business Acquisition [Line Items] Â Â Â Â Â Â Â Contingent consideration Â $ 135,000 Â Â Â Â Â Disposed of by Sale | Wound Business Â Â Â Â Â Â Â Business Acquisition [Line Items] Â Â Â Â Â Â Â Transactional fees 3,880 Â Â Â Â Â Â Impairments of assets Â Â Â Â Â 78,615 Â Cash consideration 84,675 Â Â Â Â Â Â Â Closing amount 34,675 Â Â Â Â Â Â Deferred amount $ 5,000 Â Â Â Â Â Â Deferral period 18 months Â Â Â Â Â Â Earn-out payments $ 45,000 Â Â Â Â Â Â Loss on deconsolidation Â Â Â Â Â $ 977 Â Discontinued Operations, Disposed of by Means Other than Sale | CartiHeal Ltd Â Â Â Â Â Â Â Business Acquisition [Line Items] Â Â Â Â Â Â Â Business acquisition, percentage of shares transferred to trustee Â 100.00% Â Â Â Â Â Â Loss from discontinued operations, net of tax Â $ 60,639 Â Â Â Â Â Â X - DefinitionBusiness Acquisition, Percentage Of Shares Transferred To Trustee + ReferencesNo definition available. + Details Name: bvs_BusinessAcquisitionPercentageOfSharesTransferredToTrustee Namespace Prefix: bvs_ Data Type: dtr-types1:percentItemType Balance Type: na Period Type: duration X - DefinitionBusiness Combination, Consideration Transferred, Deferral Period + ReferencesNo definition available. + Details Name: bvs_BusinessCombinationConsiderationTransferredDeferralPeriod Namespace Prefix: bvs_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionBusiness Combination, Consideration Transferred, Deferred Amount + ReferencesNo definition available. + Details Name: bvs_BusinessCombinationConsiderationTransferredDeferredAmount Namespace Prefix: bvs_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionDisposal Group, Including Discontinued Operation, Consideration Including Closing Amount + ReferencesNo definition available. + Details Name: bvs_DisposalGroupIncludingDiscontinuedOperationConsiderationIncludingClosingAmount Namespace Prefix: bvs_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionDisposal Group, Including Discontinued Operation, Earn-Out Payments + ReferencesNo definition available. + Details Name: bvs_DisposalGroupIncludingDiscontinuedOperationEarnOutPayments Namespace Prefix: bvs_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionDisposal Group, Including Discontinued Operation, Transactional Fees Incurred + ReferencesNo definition available. + Details Name: bvs_DisposalGroupIncludingDiscontinuedOperationTransactionalFeesIncurred Namespace Prefix: bvs_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4 + Details Name: us-gaap_AssetImpairmentCharges Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5 + Details Name: us-gaap_BusinessAcquisitionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPercentage of voting equity interests acquired at the acquisition date in the business combination. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2 + Details Name: us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionAmount of liability recognized arising from contingent consideration in a business combination. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6 + Details Name: us-gaap_BusinessCombinationContingentConsiderationLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1B + Details Name: us-gaap_DeconsolidationGainOrLossAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3BReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3

+ Details Name: us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation. + ReferencesNo definition available. + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount awarded to other party in judgment or settlement of litigation. + ReferencesNo definition available. + Details Name: us-gaap_LitigationSettlementAmountAwardedToOtherParty Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_RepaymentsOfLongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_CounterpartyNameAxis=bvs_CartiHealLtdMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BusinessAcquisitionAxis=bvs_CartiHealLtdMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ContingentConsiderationByTypeAxis=bvs_DeferredConsiderationMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ContingentConsiderationByTypeAxis=bvs_SalesMilestoneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bvs_WoundBusinessMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bvs_CartiHealLtdMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 53 R43.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Financial instruments - Schedule Of Long-Term Debt Instruments (Details) - USD ($) $ in Thousands Jun. 29, 2024 Dec. 31, 2023 Debt Instrument [Line Items] Â Â Current portion of long-term debt $ (38,566) $ (27,848) Unamortized debt issuance cost (1,459) (917) Unamortized discount (1,387) (1,685) Long-term debt, less current portion 344,716 366,998 Revolving Credit Facility Â Â Debt Instrument [Line Items] Â Â Long-term debt, gross $ 15,000 15,000 Effective interest rate 9.34% Â Term Loan Â Â Debt Instrument [Line Items] Â Â Long-term debt, gross $ 371,128 $ 382,448 Effective interest rate 9.34% Â X - DefinitionAmount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_DebtInstrumentCarryingAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionEffective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6 + Details Name: us-gaap_DebtInstrumentInterestRateEffectivePercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after accumulated amortization, of debt discount. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D + Details Name: us-gaap_DebtInstrumentUnamortizedDiscount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D + Details Name: us-gaap_DeferredFinanceCostsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LongtermDebtTypeAxis=bvs_TermLoanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 54 R44.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Financial instruments - Narrative (Details) 1 Months Ended 3 Months Ended 4 Months Ended 6 Months Ended Jun. 30, 2024 USD ($) Dec. 31, 2023 USD ($) letter_of_credit Mar. 31, 2023 USD ($) Jul. 12, 2022 Jul. 11, 2022 USD ($) Jan. 31, 2024 USD ($) Mar. 31, 2023 USD ($) Jun. 29, 2024 USD ($) letter_of_credit Jul. 01, 2023 USD ($) Dec. 29, 2021 USD ($) Jun. 29, 2024 USD ($) letter_of_credit Jul. 01, 2023 USD ($) Oct. 29, 2021 USD ($) Dec. 06, 2019 USD ($) Debt Instrument [Line Items] Â Borrowing on revolver Â Â Â Â Â Â Â Â Â Â Â Â $ 0 $ 49,000,000 Â Â Deferred financing costs Â $ 917,000 Â Â Â Â Â $ 1,459,000 Â Â 1,459,000 Â Â Â Â Original issue discount Â $ 1,685,000 Â Â Â Â Â Â $ 1,387,000 Â Â Â $ 1,387,000 Â Â Â Line of credit facility, number of LOCs outstanding | letter_of_credit Â 2 Â Â Â Â Â 2 Â Â 2 Â Â Â Secured Debt Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt instrument, covenant, liquidity, minimum Â Â $ 10,000,000 Â Â Â $ 10,000,000 Â Â Â Â Â Â Â Â Secured Debt | Secured Overnight Financing Rate (SOFR) Â Debt Instrument [Line Items] Â Debt instrument, lending margin, interest rate Â Â 4.25% 3.25% Â Â Â Â Â Â Â Â Â Â Â Â Secured Debt | Base Rate Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt instrument, lending margin, interest rate Â Â 3.25% 2.25% Â Â Â Â Â Â Â Â Â Â Â Â Revolving Credit Facility Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Revolver credit capacity reduced amount Â $ 5,000,000 Â Â Â Â Â Â Â Â Â Â Â Â Revolving Credit Facility | Subsequent Event Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Revolver credit capacity reduced amount $ 5,000,000 Â Â Â Â Â Â Â Â Â Â Â Â Term Loan | Level 2 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Long-term debt, fair value Â Â Â Â Â Â Â Â $ 370,664,000 Â Â $ 370,664,000 Â Â Â Â Line of Credit Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Loss on debt retirement and modification Â Â Â Â Â Â $ 0 $ 0 Â Â Â Â Â Â Â Â Line of Credit | Secured Debt Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt instrument, face amount Â Â Â Â Â Â Â Â Â Â Â Â $ 200,000,000 Line of Credit | Secured Debt | Term Loan Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt instrument, face amount Â Â Â Â Â Â Â Â Â Â Â Â Â Â $ 360,750,000 Â Repayments on revolver Â Â Â Â Â Â Â Â Â Â Â Â $ 80,000,000 Â Â Â Â Line of Credit | Secured Debt | Term Loan Facility, July 2022 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Borrowing on revolver Â Â Â Â $ 80,000,000 Â Â Â Â Â Â Â Â Line of Credit | Secured Debt | Term Loan Facilities Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Deferred financing costs Â Â Â Â Â Â Â Â 1,459,000 Â Â 1,459,000 Â Â Â Long-term debt Â Â Â Â Â Â Â Â 368,282,000 Â Â 368,282,000 Â Â Original issue discount Â Â Â Â Â Â Â Â 1,387,000 Â Â 1,387,000 Â Â Â Repayments of medium-term notes Â Â Â Â Â Â Â Â $ 30,000,000 Â Â Â Â Interest expense, debt Â Â Â Â Â Â 381,000 915,000 Â 762,000 1,138,000 Â Â Line of Credit | Secured Debt | Term Loan Facility, January 2024 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt issuance costs, gross Â Â Â Â Â Â Â Â 1,180,000 Â Â 1,180,000 Â Â Â Amortization of debt issuance costs Â Â Â Â Â Â Â Â Â Â Â Â 325,000 Â Â Â Deferred financing costs Â Â Â Â Â Â Â Â 855,000 Â Â 855,000 Â Â Â Line of Credit | Secured Debt | Term Loan Facility, March 2023 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt

issuance costs, gross Â Â Â Â Â Â Â Â Â 3,661,000 Â Â 3,661,000 Â Â Amortization of debt issuance costs Â Â Â Â Â Â Â Â Â Â Â 1,617,000 Â Â Deferred financing costs Â Â Â Â Â Â Â Â Â $ 2,044,000 Â Â $ 2,044,000 Â Â Line of Credit | Revolving Credit Facility Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Revolving credit facility, borrowing capacity Â Â Â Â Â Â Â 45,000,000 Â Â $ 45,000,000 Â Â $ 50,000,000 Debt instrument, term Â Â Â Â Â Â Â Â Â 5 years Â Â Â Outstanding borrowings on line of credit Â $ 15,000,000 Â Â Â Â Â 15,000,000 Â Â $ 15,000,000 Â Â Â Line of Credit | Revolving Credit Facility | Subsequent Event Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Revolving credit facility, borrowing capacity $ 40,000,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Line of Credit | Letter of Credit Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Revolving credit facility, borrowing capacity Â Â Â Â Â Â Â $ 7,500,000 Â Â $ 7,500,000 Â Â Â Line of credit facility, number of LOCs outstanding | letter_of_credit Â Â Â Â Â Â Â 2 Â Â 2 Â Â Â Line of credit facility, remaining borrowing capacity Â Â Â Â Â Â Â $ 5,800,000 Â Â $ 5,800,000 Â Â Â Line of Credit | Swingline Loan Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Debt instrument, term Â Â Â Â Â Â Â Â Â 5 days Â Â Â X - DefinitionDebt Instrument, Covenant, Liquidity, Minimum + ReferencesNo definition available. + Details Name: bvs_DebtInstrumentCovenantLiquidityMinimum Namespace Prefix: bvs_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine Of Credit Facility, Number Of Letters Of Credit Outstanding + ReferencesNo definition available. + Details Name: bvs_LineOfCreditFacilityNumberOfLettersOfCreditOutstanding Namespace Prefix: bvs_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionAmount of amortization expense attributable to debt issuance costs. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3 + Details Name: us-gaap_AmortizationOfFinancingCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPercentage points added to the reference rate to compute the variable rate on the debt instrument. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentBasisSpreadOnVariableRate1 Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPeriod of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount, after accumulated amortization, of debt discount. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D + Details Name: us-gaap_DebtInstrumentUnamortizedDiscount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DeferredFinanceCostsGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D + Details Name: us-gaap_DeferredFinanceCostsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionDifference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4 + Details Name: us-gaap_GainsLossesOnExtinguishmentOfDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of the cost of borrowed funds accounted for as interest expense for debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6 + Details Name: us-gaap_InterestExpenseDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_LineOfCredit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of increase (decrease) of the credit facility. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionMaximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details

Name: us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_LongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_LongTermDebtFairValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromLongTermLinesOfCredit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_RepaymentsOfLinesOfCredit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow to pay off borrowing used to receive debt funding on a regular basis with maturities ranging from 5-10 years. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_RepaymentsOfMediumTermNotes Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VariableRateAxis=us-gaap_BaseRateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LongtermDebtTypeAxis=bvs_TermLoanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=bvs_TermLoanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=bvs_TermLoanFacilityJuly2022Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=bvs_TermLoanFacilitiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=bvs_TermLoanFacilityJanuary2024Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=bvs_TermLoanFacilityMarch2023Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LongtermDebtTypeAxis=us-gaap_LetterOfCreditMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LongtermDebtTypeAxis=us-gaap_BridgeLoanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 55 R45.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Fair value measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) - USD ($) $ in Thousands Jun. 29, 2024 Dec. 31, 2023 Liabilities: Â Â Current portion of contingent consideration $ 18,745 $ 0 Contingent consideration 0 18,150 Fair Value, Recurring Â Â Liabilities: Â Â Total liabilities: 0 18,150 Fair Value, Recurring | Bioness, Inc Â Â Liabilities: Â Â Current portion of contingent consideration 18,745 0 Contingent consideration 0 18,150 Fair Value, Recurring | Level 3 Â Â Liabilities: Â Â Total liabilities: 0 18,150 Fair Value, Recurring | Level 3 | Bioness, Inc Â Â Liabilities: Â Â Current portion of contingent consideration 18,745 0 Contingent consideration $ 0 $ 18,150 X - DefinitionAmount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6 + Details Name: us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6 + Details Name: us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFair value of financial and nonfinancial obligations. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_LiabilitiesFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesFairValueDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BusinessAcquisitionAxis=bvs_BionessIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 56 R46.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Fair value measurements - Schedule of Fair Value Measurement Inputs and Valuation Techniques (Details) - Level 3 - Valuation Technique, Discounted Cash Flow - Payment discount rate - Bioness contingent consideration Jun. 29, 2024 Minimum Â Business Acquisition [Line Items] Â Payment discount rate 0.064 Maximum Â Business Acquisition [Line Items] Â Payment discount rate 0.068 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5 + Details Name: us-gaap_BusinessAcquisitionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionValue of input used to measure contingent consideration liability from business combination. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput Namespace Prefix: us-gaap_ Data Type: xbrli:decimalItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BusinessAcquisitionAxis=bvs_BionessIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 57 R47.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Fair value measurements - Narrative (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 29, 2024 Jul. 01, 2023 Jun. 29, 2024 Jul. 01, 2023 Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Â Â Â Â Change in fair value of contingent consideration $ 300 $ 240 $ 595 $ 527 Bioness, Inc Â Â Â Â Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Â Â Â Â Change in fair value of contingent consideration $ 300 $ 240 $ 595 $ 527 X - DefinitionAmount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4 + Details Name: us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_BusinessAcquisitionAxis=bvs_BionessIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 58 R48.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Equity-based compensation - Narrative (Details) - USD ($) 3 Months Ended 6 Months Ended Jun. 29, 2024 Jul. 01, 2023 Jun. 29, 2024 Jul. 01, 2023 Jun. 28, 2024 Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Equity compensation $ 3,457,000 Â $ 6,048,000 Â Â Unamortized compensation expense, options 4,342,000 Â 4,342,000 Â Â RSUs Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Unamortized compensation expense, RSUs $ 7,091,000 Â $ 7,091,000 Â Â Compensation expense net yet amortized, period for recognition Â Â 2 years 4 months 24 days Â Â RSUs | Minimum Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Vesting period Â Â 1 year Â Â RSUs | Maximum Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Vesting period Â Â 4 years Â Â Stock options Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Compensation expense net yet amortized, period for recognition Â Â 2 years 10 months 9 days Â Â Expiration period Â Â 10 years Â Â Weighted-average fair value of stock options granted (in dollars per share) Â Â $ 2.25 Â Â Stock options | Minimum Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Vesting period Â Â 1 year Â Â Stock options | Maximum Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Vesting period Â Â 4 years Â Â Employee Stock Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Number of shares available to be awarded (in shares) 1,393,982 Â 1,393,982 Â Â Equity compensation $ 215,000 $ 65,000 $ 215,000 $ 193,000 Â

Number of shares issued (in shares) Â 144,851 125,622 366,927 Â 2021 Plan Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Income tax benefit $ 0 Â Â Â Â Â 2021 and 2023 Plan Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Equity compensation Â $ (2,797,000) Â $ (1,079,000) Â Common Class A Â Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Common stock closing price, (in dollars per share) Â Â Â Â Â $ 5.75 Common Class A | 2021 Plan Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Number of shares authorized to be awarded (in shares) 19,564,333 Â 19,564,333 Â Â Â Number of shares available to be awarded (in shares) 8,921,686 Â 8,921,686 Â Â Â Common Class A | 2023 Retention Equity Award Plan Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Number of shares authorized to be awarded (in shares) 600,000 Â 600,000 Â Â Â Number of shares available to be awarded (in shares) 84,700 Â 84,700 Â Â Â X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionWeighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cost to be recognized for option under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of tax benefit for recognition of expense of award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPeriod over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares authorized for issuance under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares issued under share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionPrice of a single share of a number of saleable stocks of a company. + ReferencesNo definition available. + Details Name: us-gaap_SharePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionPeriod from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=bvs_A2021PlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=bvs_A2021And2023PlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=bvs_A2023RetentionEquityAwardPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 59 R49.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Equity-based compensation - Schedule of Nonvested Restricted Stock Units Activity (Details) - RSUs shares in Thousands 6 Months Ended Jun. 29, 2024 $ / shares shares Number of units Â Beginning balance (in shares) | shares 2,066 Granted (in shares) | shares 2,429 Vested (in shares) | shares (1,550) Forfeited or canceled (in shares) | shares (105) Ending balance (in shares) | shares 2,840 Weighted-average grant-date fair value per unit Â Beginning balance (in dollars per share) | $ / shares $ 4.51 Granted (in dollars per share) | $ / shares 5.45 Vested (in dollars per share) | $ / shares 4.56 Forfeited or canceled (in dollars per share) | $ / shares 7.33 Ending balance (in dollars per share) | $ / shares $ 5.12 X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionWeighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting

Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPer share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 60 R50.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Equity-based compensation - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details) - Stock options 6 Months Ended Jun. 29, 2024 Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Risk-free interest rate, minimum 3.90% Risk-free interest rate, maximum 4.30% Expected dividend yield 0.00% Expected stock price volatility, minimum 36.10% Expected stock price volatility, maximum 36.40% Expected life of stock options (years) 6 years 3 months X - DefinitionThe estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe maximum risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe minimum risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionExpected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 61 R51.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Equity-based compensation - Schedule of Stock Options Roll Forward (Details) $ / shares in Units, shares in Thousands, $ in Thousands 6 Months Ended Jun. 29, 2024 USD ($) $ / shares shares Number of options Â Beginning balance (in shares) | shares 4,347 Granted (in shares) | shares 1,763 Exercised (in shares) | shares (229) Forfeited or canceled (in shares) | shares (747) Ending balance (in shares) | shares 5,134 Exercisable and vested (in shares) | shares 1,982 Weighted-average exercise price Â Beginning balance (in dollars per share) | $ / shares $ 8.68 Granted (in dollars per share) | $ / shares 5.18 Exercised (in dollars per share) | $ / shares 5.21 Forfeited or canceled (in dollars per share) | $ / shares 10.51 Ending balance (in dollars per share) | $ / shares 7.53 Exercisable and vested (in dollars per share) | $ / shares $ 9.95 Outstanding, weighted average remaining contractual term 7 years 7 months 28 days Exercisable and vested (in years) 5 years 6 months 25 days Options outstanding, Aggregate intrinsic value | $ $ 4,968 Exercisable and vested | $ $ 855 X - DefinitionThe number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest

exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which option holders acquired shares when converting their stock options into shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 62 R52.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stockholdersâ€™ equity - Narrative (Details) 6 Months Ended Feb. 16, 2021 $ / shares shares Jun. 29, 2024 vote $ / shares shares Dec. 31, 2023 $ / shares shares Class of Stock [Line Items] Â Â Â Preferred stock, shares authorized (in shares) 10,000,000 10,000,000 10,000,000 Common Class A Â Â Â Class of Stock [Line Items] Â Â Â Common stock, shares authorized (in shares) 250,000,000 250,000,000 250,000,000 Common stock, par value (in dollars per share) | $ / shares $ 0.001 $ 0.001 $ 0.001 Number of votes per common share | vote Â 1 Â Shares issued or issuable, required stock to LLC interest ratio Â 1 Â Common Class A | Bioventus Inc. Â Â Â Class of Stock [Line Items] Â Â Â Number of shares issued in acquisition (in shares) 31,838,589 Â Â Common Class A | IPO Â Â Â Class of Stock [Line Items] Â Â Â Number of shares issued in public offering (in shares) 9,200,000 Â Â Common Class B Â Â Â Class of Stock [Line Items] Â Â Â Common stock, shares authorized (in shares) 50,000,000 50,000,000 50,000,000 Common stock, par value (in dollars per share) | $ / shares $ 0.001 $ 0.001 $ 0.001 Cancellation ratio, required stock to LLC interest ratio Â 1 Â X - DefinitionCancellation Ratio, Required Stock To LLC Interest Ratio + ReferencesNo definition available. + Details Name: bvs_CancellationRatioRequiredStockToLLCInterestRatio Namespace Prefix: bvs_ Data Type: xbrli:pureItemType Balance Type: na Period Type: instant X - DefinitionCommon Stock, Number Of Votes + ReferencesNo definition available. + Details Name: bvs_CommonStockNumberOfVotes Namespace Prefix: bvs_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionShares Issued Or Issuable, Required Stock To LLC Interest Ratio + ReferencesNo definition available. + Details Name: bvs_SharesIssuedOrIssuableRequiredStockToLLCInterestRatio Namespace Prefix: bvs_ Data Type: xbrli:pureItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_ClassOfStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe number of shares issued or sold by the subsidiary or equity method investee per stock transaction. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares of stock issued during the period pursuant to acquisitions. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesAcquisitions Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BusinessAcquisitionAxis=bvs_BVLLCMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 63 R53.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stockholdersâ€™ equity - Schedule of Other Ownership Interests (Details) - Bioventus Inc. - USD ($) $ in Thousands 6 Months Ended 12 Months Ended Jun. 29, 2024 Dec. 31, 2023 Class of Stock [Line Items] Â Â LLC Interests $ 65,172 $ 63,267 Ownership % 80.50% 80.00% Continuing LLC Owner Â Â Class of Stock [Line Items] Â Â LLC Interests $ 15,787 $ 15,787 Ownership % 19.50% 20.00% Bioventus and Continuing LLC Owner Â Â Class of Stock [Line Items] Â Â LLC Interests $ 80,959 $ 79,054 Ownership % 100.00% 100.00% X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_ClassOfStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPercentage investment held by members or limited partners of limited liability company (LLC) or limited partnership (LP). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 272 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482987/272-10-50-3 + Details Name: us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount of ownership interest in a limited liability company (LLC), including portions attributable to both the parent and noncontrolling interests. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483014/272-10-45-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_LimitedLiabilityCompanyLlcMembersEquityIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: srt_OwnershipAxis=bvs_BVLLCMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: dei_LegalEntityAxis=bvs_ContinuingLLCOwnerMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: dei_LegalEntityAxis=bvs_BioventusAndContinuingLLCOwnerMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 64 R54.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Earnings per share - Schedule of Earnings Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands 3 Months Ended 6 Months Ended Jun. 29, 2024 Jul. 01, 2023 Jun. 29, 2024 Jul. 01, 2023 Numerator: Â Â Â Â Net loss from continuing operations, net of tax $ (32,112) $ (4,731) $ (38,094) $ (104,749) Net loss attributable to noncontrolling interests â€” continuing operations 8,120 1,050 9,532 21,410 Net loss attributable to Bioventus Inc. Class A common stockholders â€” continuing operations (23,992) (3,681) (28,562) (83,339) Net loss from discontinued operations, net of tax 0 0 0 (74,429) Net loss attributable to noncontrolling interests â€” discontinued operations 0 0 0 14,937 Net loss attributable to Bioventus Inc. Class A common stockholders â€” discontinued operations $ 0 $ 0 $ 0 $ (59,492) Denominator: Â Â Â Â Weighted-average shares of Class A common stock outstanding - basic (in shares) 64,056,759 62,551,285 63,720,342 62,338,018 Weighted-average shares of Class A common stock outstanding - diluted (in shares) 64,056,759 62,551,285 63,720,342 62,338,018 Net loss per share of Class A common stock from continuing operations, basic (in dollars per share) $ (0.37) $ (0.06) $ (0.45) $ (1.34) Net loss per share of Class A common stock from continuing operations, diluted (in dollars per share) (0.37) (0.06) (0.45) (1.34) Net loss per share of Class A common stock from discontinuing operations, diluted (in dollars per share) 0 0 0 (0.95) Net loss per share of Class A common stock from discontinuing operations, basic (in dollars per share) 0 0 0 (0.95) Net loss per share of class A common stock, basic (in dollars per share) (0.37) (0.06) (0.45) (2.29) Net loss per share of class A common stock, diluted (in dollars per share) $ (0.37) $ (0.06) $ (0.45) $ (2.29) X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount after tax of income (loss) from continuing operations attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-18 + Details Name: us-gaap_IncomeLossFromContinuingOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of income (loss) from continuing operations attributable to the noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15 + Details Name: us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-

30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7Reference 17: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromContinuingOperationsPerBasicShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477349/740-270-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3AReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3BReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-4Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3 + Details Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of income (loss) from a discontinued operation attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3AReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-4Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15 + Details Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3AReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b)(2) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-4Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3 + Details Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPer basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionPer diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 5.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479836/810-10-S99-5 + Details Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetIncomeLossAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 65 R55.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Earnings per share - Schedule of Antidilutive Securities (Details) - shares 3 Months Ended 6 Months Ended Jun. 29, 2024 Jul. 01, 2023 Jun. 29, 2024 Jul. 01, 2023 Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Â Â Antidilutive securities (in shares) 20,044,564 23,283,849 19,989,016 24,384,840 LLC Interests held by Continuing LLC Owner Â Â Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Â Â Antidilutive securities (in shares) 15,786,737 15,786,737 15,786,737 15,786,737 Stock options Â Â Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Â Â Antidilutive securities (in shares) 4,208,043 6,730,685 4,177,250 7,623,865 RSUs Â Â Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Â Â Antidilutive securities (in shares) 49,784 766,427 25,029 974,238 X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bvs_LimitedLiabilityCompanyInterestsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 66 R56.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Restructuring costs - Narrative (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 29, 2024 Jul. 01, 2023 Jun. 29, 2024 Jul. 01, 2023 Restructuring and Related Activities [Abstract] Â Â Â Â Restructuring costs $ 0 $ 620 $ 0 $ 937 Payments for restructuring Â Â $ 961 $ 3,085 X - DefinitionAmount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17 + Details Name: us-gaap_PaymentsForRestructuring Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_RestructuringAndRelatedActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.P.3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1 + Details Name: us-gaap_RestructuringCharges Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 67 R57.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Income taxes (Details) 3 Months Ended 6 Months Ended Jun. 29, 2024 Jul. 01, 2023 Jun. 29, 2024 Jul. 01, 2023 Feb. 16, 2021 Income Tax Disclosure [Abstract] Â Â Â Â Â Effective income tax rate 18.60% 8.80% 14.40% 0.20% Â Tax receivable agreement, percent Â Â Â Â 85.00% X - DefinitionTax Receivable Agreement, Percent + ReferencesNo definition available. + Details Name: bvs_TaxReceivableAgreementPercent Namespace Prefix: bvs_ Data Type: dtr-types1:percentItemType Balance Type: na Period Type: instant X - DefinitionPercentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231 + Details Name: us-gaap_EffectiveIncomeTaxRateContinuingOperations Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 68 R58.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Commitments and contingencies - Narrative (Details) $ in Thousands 3 Months Ended 6 Months Ended 12 Months Ended Jul. 15, 2024 USD ($) Jan. 31, 2024 USD ($) Mar. 08, 2023 USD ($) Nov. 10, 2021 USD ($) Dec. 22, 2020 Aug. 23, 2019 Feb. 09, 2016 Jun. 29, 2024 USD ($) letter_of_credit Jul. 01, 2023 USD ($) Jun. 29, 2024 USD ($) letter_of_credit Jul. 01, 2023 USD ($) Dec. 31, 2022 USD ($) May 01, 2024 lawsuit Dec. 31, 2023 USD ($) letter_of_credit Loss Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Line of credit facility, number of LOCs outstanding | letter_of_credit Â Â Â Â Â Â Â 2 Â 2 Â Â Â 2 Letters of credit outstanding, amount Â Â Â Â Â Â Â Â $ 1,700 Â $ 1,700 Â Â Â $ 1,700 Stop loss insurance, threshold per member per year Â Â Â Â Â Â Â Â 250 Â Â Â Â Bioventus Shareholder Litigation Â Â Â Â Â Â Â Â Â Â Â Â Loss Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Litigation settlement, amount awarded to other party Â Â Â Â Â Â 12,502 Â 13,670 Â Â Â Â Number of derivative shareholder lawsuits | lawsuit Â Â Â Â Â Â Â Â Â Â 2 Â Bioventus Shareholder Litigation | Subsequent Event Â Â Â Â Â Â Â Â Â Â Â Â Loss Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Litigation settlement, amount awarded to other party $ 15,250 Â Â Â Â Â Â Â Â Â Â Â Â Insurance settlement receivable $ 6,500 Â Â Â Â Â Â Â Â Â Â Â Â Three Injection OA Product Â Â Â Â Â Â Â Â Â Â Â Â Loss Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Supply commitment, term Â Â Â Â Â Â 10 years Â Â Â Â Â Â Â Supply commitment, renewal term Â Â Â Â Â Â 5 years Â Â Â Â Â Â Â Harbor Â Â Â Â Â Â Â Â Â Â Â Â Loss Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Collaborative agreement, royalty percentage Â Â Â Â Â 3.00% Â Â Â Â Â Â Â Â Supply commitment, term Â Â Â Â 8 years Â Â Â Â Â Â Â Â Supplier of Single Injection OA Product Â Â Â Â Â Â Â Â Â Â Â Â Loss Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Royalty expense Â Â Â Â Â Â Â $ 4,594 $ 4,119 $ 8,173 $ 6,440 Â Â Â HA Product Â Â Â Â Â Â Â Â Â Â Â Â Loss Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Collaborative arrangement, upfront payments Â Â Â $ 853 Â Â Â Â Â Â Â Â Â Collaborative arrangement, amount payable upon transfer of customer data Â Â Â Â Â Â Â Â Â Â Â Â $ 853 Â Â Collaborative arrangement, amount payable upon obtaining product certification Â Â $ 1,707 Â Â Â Â Â Â Â Â Â Collaborative arrangement, royalty percentage, threshold one Â Â Â 5.00% Â Â Â Â Â Â Â Â Â Collaborative arrangement, sales threshold for royalties Â Â Â $ 569 Â Â Â Â Â Â Â Â Â Collaborative arrangement, royalty percentage, threshold two Â Â Â 2.50% Â Â Â Â Â Â Â Â Â Collaborative arrangement, adjusted amount payable upon obtaining product certification Â Â $ 1,418 Â Â Â Â Â Â Â Â Â Milestone payment paid Â $ 709 Â Â Â Â Â Â Â Â Â Â Â Finite-lived intangible asset recognized Â $ 709 Â Â Â Â Â Â Â Â Â Â Â Minimum Â Â Â Â Â Â Â Â Â Â Â Loss Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Â Â Lessee, operating lease, remaining lease term Â Â Â Â Â Â 1 month Â 1 month Â Â Â Â Maximum Â Â Â Â Â Â Â Â Â Â Â Â Loss Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Â Â Lessee, operating lease, remaining lease term Â Â Â Â Â Â 8 years 9 months 18 days Â 8 years 9 months 18 days Â Â Â Â X - DefinitionCollaborative Arrangement, Rights And Obligations, Adjusted Amount Payable Upon Obtaining Product Certification + ReferencesNo definition available. + Details Name: bvs_CollaborativeArrangementRightsAndObligationsAdjustedAmountPayableUponObtainingProductCertification Namespace Prefix: bvs_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionCollaborative Arrangement, Rights And Obligations, Adjusted Amount Payable Upon Obtaining Product Certification, Initial Payment Paid + ReferencesNo definition available. + Details Name: bvs_CollaborativeArrangementRightsAndObligationsAdjustedAmountPayableUponObtainingProductCertificationInitialPaymentPaid Namespace Prefix: bvs_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionCollaborative Arrangement, Rights And Obligations, Amount Payable Upon Obtaining Product Certification + ReferencesNo definition available. + Details Name: bvs_CollaborativeArrangementRightsAndObligationsAmountPayableUponObtainingProductCertification Namespace Prefix: bvs_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionCollaborative Arrangement, Rights And Obligations, Amount Payable Upon Transfer Of Data + ReferencesNo definition available. + Details Name: bvs_CollaborativeArrangementRightsAndObligationsAmountPayableUponTransferOfData Namespace Prefix: bvs_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionCollaborative Arrangement, Rights And Obligations, Royalties, Sales Threshold + ReferencesNo definition available. + Details Name: bvs_CollaborativeArrangementRightsAndObligationsRoyaltiesSalesThreshold Namespace Prefix: bvs_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionCollaborative Arrangement, Rights And Obligations, Royalty Percentage, Threshold One + ReferencesNo definition available. + Details Name: bvs_CollaborativeArrangementRightsAndObligationsRoyaltyPercentageThresholdOne Namespace Prefix: bvs_ Data Type: dtr-types1:percentItemType Balance Type: na Period Type: duration X - DefinitionCollaborative Arrangement, Rights And Obligations, Royalty Percentage, Threshold Two + ReferencesNo definition available. + Details Name: bvs_CollaborativeArrangementRightsAndObligationsRoyaltyPercentageThresholdTwo Namespace Prefix: bvs_ Data Type: dtr-types1:percentItemType Balance Type: na Period Type: duration X - DefinitionCollaborative Arrangement, Rights And Obligations, Upfront Payment + ReferencesNo definition available. + Details Name: bvs_CollaborativeArrangementRightsAndObligationsUpfrontPayment Namespace Prefix: bvs_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionCollaborative Arrangement, Royalty Percentage + ReferencesNo definition available. + Details Name: bvs_CollaborativeArrangementRoyaltyPercentage Namespace Prefix: bvs_ Data Type: dtr-types1:percentItemType Balance Type: na Period Type: duration X - DefinitionFinite-Lived Intangible Asset, Recognized + ReferencesNo definition available. + Details Name: bvs_FiniteLivedIntangibleAssetRecognized Namespace Prefix: bvs_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine Of Credit Facility, Number Of Letters Of Credit Outstanding + ReferencesNo definition available. + Details Name: bvs_LineOfCreditFacilityNumberOfLettersOfCreditOutstanding Namespace Prefix: bvs_ Data Type:

xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionLoss Contingency, Number of Derivative Shareholder Lawsuits + ReferencesNo definition available. + Details Name: bvs_LossContingencyNumberOfDerivativeShareholderLawsuits Namespace Prefix: bvs_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionStop Loss Insurance, Threshold Per Member Per Year + ReferencesNo definition available. + Details Name: bvs_StopLossInsuranceThresholdPerMemberPerYear Namespace Prefix: bvs_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionSupply Commitment, Renewal Term + ReferencesNo definition available. + Details Name: bvs_SupplyCommitmentRenewalTerm Namespace Prefix: bvs_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionSupply Commitment, Term + ReferencesNo definition available. + Details Name: bvs_SupplyCommitmentTerm Namespace Prefix: bvs_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount due in settlement of a claim for reimbursement from an insurance company when the Company has suffered a loss covered under an insurance policy. + ReferencesNo definition available. + Details Name: us-gaap_InsuranceSettlementsReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRemaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseRemainingLeaseTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionThe total amount of the contingent obligation under letters of credit outstanding as of the reporting date. + ReferencesNo definition available. + Details Name: us-gaap_LettersOfCreditOutstandingAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount awarded to other party in judgment or settlement of litigation. + ReferencesNo definition available. + Details Name: us-gaap_LitigationSettlementAmountAwardedToOtherParty Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 720 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 27 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1 + Details Name: us-gaap_LossContingenciesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_RoyaltyExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: srt_LitigationCaseAxis=bvs_BioventusShareholderLitigationMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SupplyCommitmentAxis=bvs_ThreeInjectionOAProductMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=bvs_HarborMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=bvs_SupplierOfSingleInjectionOAProductMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=bvs_HAProductMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 69 R59.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Commitments and contingencies - Schedule of Lease, Cost (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 29, 2024 Jul. 01, 2023 Jun. 29, 2024 Jul. 01, 2023 Commitments and Contingencies Disclosure [Abstract] Â Â Â Â Operating lease cost $ 938 $ 1,010 $ 1,826 $ 2,079 Short-term lease cost 326 229 406 435 Amortization of finance lease assets 174 393 332 628 Interest on lease liabilities 217 229 438 366 Total lease cost $ 1,655 $ 1,861 3,002 3,508 Cash paid for amounts included in measurement of lease liabilities: Â Â Â Â Operating cash flows from operating leases Â Â 2,319 2,227 Operating cash flows from financing leases Â Â 438 337 Financing cash flows from finance leases Â Â 373 175 Right-of-use assets obtained in exchange for lease obligations: Â Â Â Â Operating lease obligations Â Â 132 254 Financing lease obligations Â Â $ 0 $ 15,567 X - DefinitionCash Flow, Lessee + ReferencesNo definition available. + Details Name: bvs_CashFlowLesseeAbstract Namespace Prefix: bvs_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionRight-Of-Use Asset Obtained In Exchange For Lease Liability + ReferencesNo definition available. + Details Name: bvs_RightOfUseAssetObtainedInExchangeForLeaseLiabilityAbstract Namespace Prefix: bvs_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of interest expense on finance lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_FinanceLeaseInterestExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of interest paid on finance lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5 + Details Name: us-gaap_FinanceLeaseInterestPaymentOnLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow for principal payment on finance lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5 + Details Name: us-gaap_FinanceLeasePrincipalPayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of amortization expense attributable to right-of-use asset from finance lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_FinanceLeaseRightOfUseAssetAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of lease cost recognized by lessee for lease contract. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_LeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeasePayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase in right-of-use asset obtained in exchange for finance lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase in right-of-use asset obtained in exchange for operating lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of short-term lease cost, excluding expense for lease with term of one month or less. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_ShortTermLeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 70 R60.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Commitments and contingencies - Schedule of Assets and Liabilities, Lessee (Details) - USD ($) $ in Thousands Jun. 29, 2024 Dec. 31, 2023 Operating leases: Â Â Operating lease assets $ 10,366 $ 13,353 Operating lease liabilities - current 3,038 4,057 Operating lease liabilities - noncurrent 8,469 10,573 Total operating lease liabilities 11,507 14,630 Finance leases: Â Â Property, plant and equipment, net (finance leases) 13,491 14,279 Finance lease liabilitiesâ€”current 791 759 Finance lease liabilitiesâ€”noncurrent 9,981 10,386 Total financing lease liabilities $ 10,772 $ 11,145 Weighted average remaining lease term (years) for leases Â Â Operating leases 3 years 4 months 24 days 3 years 9 months 18 days Finance leases 8 years 9 months 18 days 9 years 3 months 18 days Weighted average discount rate for leases Â Â Operating leases 4.80% 4.70% Finance leases 8.10% 8.10% Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Property and equipment, net Property and equipment, net Discontinued Operations, Held-for-sale | Rehabilitation Business Â Â Operating leases: Â Â Operating lease assets $ 1,171 Â Operating lease liabilities - current 983 Â Operating lease liabilities - noncurrent $ 249 Â X - DefinitionFinance Lease, Assets And Liabilities, Lessee + ReferencesNo definition available. + Details Name: bvs_FinanceLeaseAssetsAndLiabilitiesLesseeAbstract Namespace Prefix: bvs_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionLeases, Weighted Average Discount Rate + ReferencesNo definition available. + Details Name: bvs_LeasesWeightedAverageDiscountRateAbstract Namespace Prefix: bvs_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionOperating Lease, Assets And Liabilities, Lessee + ReferencesNo definition available. + Details Name: bvs_OperatingLeaseAssetsAndLiabilitiesLesseeAbstract Namespace Prefix: bvs_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionWeighted Average Remaining Lease Term + ReferencesNo definition available. + Details Name: bvs_WeightedAverageRemainingLeaseTermAbstract Namespace Prefix: bvs_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from finance lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_FinanceLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from finance lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_FinanceLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_FinanceLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after accumulated amortization, of right-of-use asset from finance lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_FinanceLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionIndicates line item in statement of financial position that includes finance lease right-of-use asset. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2 + Details Name: us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList Namespace Prefix: us-gaap_ Data

Type: enum2:enumerationSetItemType Balance Type: na Period Type: instant X - DefinitionWeighted average discount rate for finance lease calculated at point in time. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionWeighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted average discount rate for operating lease calculated at point in time. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionWeighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bvs_RehabilitationBusinessMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 71 R61.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Revenue from Contract with Customer - Narrative (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 29, 2024 Jul. 01, 2023 Jun. 29, 2024 Jul. 01, 2023 Disaggregation of Revenue [Line Items] Â Â Â Â Total net sales $ 151,217 $ 137,069 $ 280,674 $ 256,128 Customer One | Revenue Benchmark | Customer Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Total net sales $ 18,266 Â $ 31,409 Â Revenue percentage of total net sales 12.20% Â 11.30% Â U.S. Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Revenues Â 1,832 Â 3,544 Total net sales $ 134,409 120,847 $ 248,690 224,825 International Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Revenues Â 84 Â 149 Total net sales $ 16,808 $ 16,222 $ 31,984 $ 31,303 X - DefinitionRevenue Percentage of Total Net Sales + ReferencesNo definition available. + Details Name: bvs_RevenuePercentageOfTotalNetSales Namespace Prefix: bvs_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionRevenue Reclassified During Period + ReferencesNo definition available. + Details Name: bvs_RevenueReclassifiedDuringPeriod Namespace Prefix: bvs_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 + Details Name: us-gaap_DisaggregationOfRevenueLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_MajorCustomersAxis=bvs_CustomerOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=country_US Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=us-gaap_NonUsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 72 R62.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Revenue recognition - Schedule of Disaggregation of Revenue (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 29, 2024 Jul. 01, 2023 Jun. 29, 2024 Jul. 01, 2023 Disaggregation of Revenue [Line Items] Â Â Â Â Total net sales $ 151,217 $ 137,069 $ 280,674 $ 256,128 U.S. Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Total net sales 134,409 120,847 248,690 224,825 U.S. | Pain Treatments Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Total net sales 65,194 55,617 115,831 96,612 U.S. | Restorative Therapies Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Total net sales 27,435 30,012 52,739 60,788 U.S. | Surgical Solutions Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Total net sales 41,780 35,218 80,120 67,425 International Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Total net sales 16,808 16,222 31,984 31,303 International | Pain Treatments Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Total net sales 7,066 6,024 13,118 11,355 International | Restorative Therapies Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Total net sales 4,185 4,690 9,355 10,239 International | Surgical Solutions Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Total net sales $ 5,557 $ 5,508 $ 9,511 $ 9,709 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 + Details Name: us-gaap_DisaggregationOfRevenueLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_StatementGeographicalAxis=country_US Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=bvs_PainTreatmentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=bvs_RestorativeTherapiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=bvs_SurgicalSolutionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=us-

gaap_NonUsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 73 R63.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Segments - Narrative (Details) $ in Thousands 3 Months Ended 6 Months Ended Jun. 29, 2024 USD ($) Jul. 01, 2023 USD ($) Jun. 29, 2024 USD ($) segment Jul. 01, 2023 USD ($) Segment Reporting Information [Line Items] Â Â Â Â Number of reportable segments | segment Â Â 2 Â U.S. | Operating Segments Â Â Â Â Segment Reporting Information [Line Items] Â Â Â Â Revenues $ 134,409 $ 120,847 $ 248,690 $ 224,825 International | Operating Segments Â Â Â Â Segment Reporting Information [Line Items] Â Â Â Â Revenues $ 16,808 $ 16,222 $ 31,984 $ 31,303 X - DefinitionNumber of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18 + Details Name: us-gaap_NumberOfReportableSegments Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionAmount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_Revenues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_SegmentReportingInformationLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_StatementBusinessSegmentsAxis=bvs_USSegmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=bvs_InternationalSegmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 74 R64.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Segments - Schedule of Reconciliation of Operating Profit (Loss) from Segments to Consolidated (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 29, 2024 Jul. 01, 2023 Jun. 29, 2024 Jul. 01, 2023 Segment Reporting Information [Line Items] Â Â Â Â Interest expense, net $ (9,924) $ (10,587) $ (20,263) $ (20,281) Depreciation and amortization Â Â (24,875) (31,073) Equity compensation (3,457) Â (6,048) Â Impairments of assets Â Â (31,870) (78,615) Loss on disposals 0 (977) 0 (977) Loss before income taxes (39,451) (4,350) (44,526) (104,514) Segment Reconciling Items Â Â Â Â Segment Reporting Information [Line Items] Â Â Â Â Interest expense, net (9,924) (10,587) (20,263) (20,281) Depreciation and amortization (13,090) (14,600) (24,875) (31,073) Acquisition and related costs (300) (1,448) (511) (2,623) Shareholder litigation costs (12,502) 0 (13,670) 0 Restructuring and succession charges 40 (620) (13) (937) Equity compensation (3,672) 2,732 (6,263) 886 Financial restructuring costs 5 (1,257) (347) (6,587) Impairments of assets (31,870) 0 (31,870) (78,615) Loss on disposals 0 (977) 0 (977) Other items (2,590) (5,751) (3,789) (9,416) U.S. | Operating Segments Â Â Â Â Segment Reporting Information [Line Items] Â Â Â Â Segment Adjusted EBITDA 31,590 24,712 51,346 39,424 International | Operating Segments Â Â Â Â Segment Reporting Information [Line Items] Â Â Â Â Segment Adjusted EBITDA $ 2,862 $ 3,446 $ 5,729 $ 5,685 X - DefinitionAdjusted Earnings Before Interest, Taxes, Depreciation, Amortization And Other Non-Operating Items + ReferencesNo definition available. + Details Name: bvs_AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems Namespace Prefix: bvs_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionRestructuring and Succession Charges + ReferencesNo definition available. + Details Name: bvs_RestructuringAndSuccessionCharges Namespace Prefix: bvs_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionShareholder Litigation Costs + ReferencesNo definition available. + Details Name: bvs_ShareholderLitigationCosts Namespace Prefix: bvs_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4 + Details Name: us-gaap_AssetImpairmentCharges Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThis element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 25 -Paragraph 23 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479405/805-10-25-23 + Details Name: us-gaap_BusinessCombinationAcquisitionRelatedCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 + Details Name: us-gaap_DepreciationDepletionAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1B + Details Name: us-gaap_GainLossOnSaleOfBusiness Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionFor a debtor, the aggregate gain (loss) recognized on the restructuring of payables arises from the difference between the book value of the debt before the restructuring and the fair value of the payments on the debt after restructuring is complete. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 60 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481408/470-60-50-1 + Details Name: us-gaap_GainsLossesOnRestructuringOfDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of interest income (expense) classified as nonoperating. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -

URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 + Details Name: us-gaap_InterestIncomeExpenseNonoperatingNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of other expense that is infrequent in occurrence or unusual in nature. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483613/220-20-50-1 + Details Name: us-gaap_OtherNonrecurringExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_SegmentReportingInformationLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=bvs_USSegmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=bvs_InternationalSegmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 75 R65.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Discontinued Operations - Narrative (Details) Feb. 27, 2023 Discontinued Operations, Disposed of by Means Other than Sale | CartiHeal Ltd Â Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Â Business acquisition, percentage of shares transferred to trustee 100.00% X - DefinitionBusiness Acquisition, Percentage Of Shares Transferred To Trustee + ReferencesNo definition available. + Details Name: bvs_BusinessAcquisitionPercentageOfSharesTransferredToTrustee Namespace Prefix: bvs_ Data Type: dtr-types1:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bvs_CartiHealLtdMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 76 R66.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Discontinued Operations and Disposal Groups - Schedule of Statement of Operations (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 29, 2024 Jul. 01, 2023 Jun. 29, 2024 Jul. 01, 2023 Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Â Â Â Â Loss on deconsolidation $ 60,639 $ 60,639 $ 60,639 $ 60,639 Non-refundable payments 10,150 10,150 10,150 10,150 Disposed of by Sale Â Â Â Â Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Â Â Â Â Cash $ 1,356 $ 1,356 $ 1,356 1,356 Disposed of by Sale | Carti Heal Â Â Â Â Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Â Â Â Â Selling, general and administrative expense Â Â Â 1,728 Research and development expense Â Â Â 396 Change in fair value of contingent consideration Â Â Â 1,710 Depreciation and amortization Â Â Â 4,264 Impairments of assets Â Â Â 0 Operating loss from discontinued operations Â Â Â (8,098) Interest expense, net Â Â Â 4,889 Other (income) expense Â Â Â 61,442 Other (income) expense Â Â Â 66,331 Loss before income taxes Â Â Â (74,429) Income tax benefit, net Â Â Â 0 Net loss from discontinued operations Â Â Â (74,429) Loss attributable to noncontrolling interest - discontinued operations Â Â Â 14,937 Net loss attributable to Bioventus Inc. - discontinued operations Â Â Â $ (59,492) X - DefinitionDisposal Group, Including Discontinued Operation, Change in Fair Value of Contingent Consideration + ReferencesNo definition available. + Details Name: bvs_DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfContingentConsideration Namespace Prefix: bvs_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionDisposal Group, Including Discontinued Operation, Impairment Of Assets + ReferencesNo definition available. + Details Name: bvs_DisposalGroupIncludingDiscontinuedOperationImpairmentOfAssets Namespace Prefix: bvs_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionDisposal Group, Including Discontinued Operation, Income (Loss) Attributable to Noncontrolling Interest + ReferencesNo definition available. + Details Name: bvs_DisposalGroupIncludingDiscontinuedOperationIncomeLossAttributableToNoncontrollingInterest Namespace Prefix: bvs_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionDisposal Group, Including Discontinued Operation, Income (Loss) Before Income Taxes + ReferencesNo definition available. + Details Name: bvs_DisposalGroupIncludingDiscontinuedOperationIncomeLossBeforeIncomeTaxes Namespace Prefix: bvs_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionDisposal Group, Including Discontinued Operation, Income Tax Expense (Benefit) + ReferencesNo definition available. + Details Name: bvs_DisposalGroupIncludingDiscontinuedOperationIncomeTaxExpenseBenefit Namespace Prefix: bvs_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionDisposal Group, Including Discontinued Operation, Net Income (Loss) + ReferencesNo definition available. + Details Name: bvs_DisposalGroupIncludingDiscontinuedOperationNetIncomeLoss Namespace Prefix: bvs_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionDisposal Group, Including Discontinued Operation, Net Income (Loss) to Parent + ReferencesNo definition available. + Details Name: bvs_DisposalGroupIncludingDiscontinuedOperationNetIncomeLossToParent Namespace Prefix: bvs_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionDisposal Group, Including Discontinued Operation, Other Income (Expense) + ReferencesNo definition available. + Details Name: bvs_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense Namespace Prefix: bvs_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionDisposal Group, Including Discontinued Operation, Other (Income) Expenses + ReferencesNo definition available. + Details Name: bvs_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenses Namespace Prefix: bvs_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionDisposal Group, Including Discontinued Operation, Research and Development Expense + ReferencesNo definition available. + Details Name: bvs_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense Namespace Prefix: bvs_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNon Refundable Payments + ReferencesNo definition available. + Details Name: bvs_NonRefundablePayments Namespace Prefix: bvs_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1B + Details Name: us-gaap_DeconsolidationGainOrLossAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of currency on hand, demand deposits with banks or financial institutions, and other kinds of accounts that have the general characteristics of demand deposits, held by a disposal group. + ReferencesNo definition available. + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationCash Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of depreciation and amortization expense attributable to disposal group, including, but not limited to, discontinued operation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of interest expense attributable to disposal group, including, but not limited to, discontinued operation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section S99 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480781/205-20-S99-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 45 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-6Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-7 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bvs_CartiHealMember Namespace Prefix: Data Type: na Balance Type: Period Type: EXCEL 77 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

=%)LW_26/9&HM2S3XI,Y_*""/C/B%YO4\5]Q\+3C M14_$I2M,%A9#@DSG_E<^!#NT%BR'SRP8AP5CEMMOQ%*^E86\?FW-05BB!C>Z M8%5Y-833.3GET].*$}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{)05\'3\4\L?+@T#XDJHK6*AC8#EBVO^ VB@2*Y4X7D"-7*O\-RI7M%D]B8P&LV%OL2EQAQUIZKRYE3)R6";$ABZ(;%*G.P(YC 180.UA2%R1^*TH< MQ^1{:9%J58DYAX5{]"3AE9"J#HS*]]>#M3 (G,R0Q=GCQ192NDAD)M'K1Q$K M6Q!VK.OZ&9N]PG7A*710M8/1&YR2LA4 ?V;L,U;F35>ASR/IH"E45H\UO5^@ MR>0N>J]2N+9.D0I^&7!;M1IW3;Z1_MZAW"_43G*=O*]JXMF*16E:B_UU=WW= MB.V"0\G+..;XDZ.ZVP#5NI_:#PM+:5 M5$EQ3-IHAL{)8#$[EBG'=!4AM=VN<4FW<'0PG1>A9B#E*DAJA<9 W-2YVTV[M-L{^E\).:V$G3X7%CFDJS"K5&P.#MIO.1H&0:-LWON$!(HG58R><.;LJ& Y, M!.RC,(<<=&0;G6AI=5X@_3C1P78P'T@pQ]?K9Q3Q3&2"8l]J K80Z_';UJR M^Q Z+S8{(PGEPFF.,E:NUYI.E 0F)'>N-OZF!34 @ (^R=X!["D%ZM@#P%,3 M2NTZL3&%*9#$IETEL^:'[H,!P/=S",&X9QQ)T41937M,LCS4V=7PC$UI/$BFAJY 4X9#LKGX/!7@2^/!GPX" MA#/)(&L$729!XQV"CL0G:T+AQ2\FI_PQ_P"@-LC&+;++\;,"W}>F+\9O]L5X M.)X^(V^RL702Y4V>L_1;M/1:^4Q;-M:+/R]F/C@DQU]/V9Q$3I\6R05SXBN9 MT5D/%>')+:EW_NK%Z&CX]AG TPW@Z7/2?R8T_TN0^%*0|)S-R'N!\D8R!W+(-M,6468K[E*:07Q@:1%=(L*!=S9TL1"AGX#.G9MA3!CLD+HRII1:W5%D7!{J. M*T>,A@:%,/ M__6=^&(#7-]R/?[ZN$5R(JZ@#/$7'"-&;>#1^VUE=[6)O"=HW9(P.A^T6&=1=;$}}WVOI-XN=^CA25[:LI%G# M;Y IM5XG5_O=1CK2,B TP8H9^Y[K(;/E3)GXOPV(Y*#/$MCUP2KV>W!E4F>U-MEJTK*Q%=@-8I%)===<9\)G9*13UHL:\# MUMWA0)1CHK8=I1O\M*=*-@SZX!U%R]@;0.<1(S6'H4&Z!7'_N)BCKS8^C3D9 MH3:JN]9##EE(65:"WH(S/8V,'5MHUDMY'(+.)X^7KFZ,YF A?[,0.L"(F8 M S&IC09WQT(H [7&[Z8NOW9]I4URT9S>V^AEN40?XZ6_V;]/UY*FJYM]Q"(7<^UI"MP_^/@0CA2J;4%2P'(*!;&\RA#?WQE-^'KXYC)1[A^/7~ZO4 M1S/K6]@/&FC&)K?["7\5!H\H! 6*WRZ M\Y+@SL=<#*M)I9O(@F44!K/%K#UCHRI0/4J=R8=,L3,.Y1[2ROAK/,C,FATH MFK/&XH-RY"Q(ZP'FN7CR UR,^[@@^6 _LU9L^XUVZ;X"\>\,E. WYB]Z4=54: MR_CQ ..6K%(IA\K$VN<&;H*T{JZTTT',!*2WIBA4)LQC8S +B[H+IZI<+F22:= -I'TJ+GTQ)!9),)RCMJ;HSX1X26*:O%3X!GZ"EZNUY M$;!FHU$P&/HV^A2J/A!/L^[(}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|@V9S-((%81QS:?RCAMH (&<1G4CI@+*M"CJA=CE2^229FA^=0+D6& MSSD3[^'!J->HLCWLB1Z]LD%.]YYU=%NQFWJ=HKM +TMM?F_7"5R5"CU/\[37 M%WOQJQ/^W8^P7L,@N0EQ9."/PWLPJ92T-7!MT6+5) C3-^T.]O)U \4#>].E MR&2]VN#GJV>,^/TEKC5^5^4P>TZB/Z?*8?X\5N7Z_X5N?WJ]<*2URMR738\ M5>;:#5\5.C3%5:RM:B+QTZ&"E:)+3X)IWX'LG-OUNE)KA@C>:'25<1-?O]6. M<,$SY=$*27Z8HV0MAK-%5R'#8#X;4Q5; /M>*E3 *%J>8Q&#XHD2.9_SU${MJ-8>G+MOKFD0CB>HI=,Q_OCZ"QGW5D\S1$.3I79,%@N(E MA\L!!JR_%.? M=^1)4\"SB,ZX]KB4\N2)7J708703U#9S'OM{OFC S\-5MB6=6B_R4(U7 -5G M^%)]][8=1?W00)H1UP4%QF,$DX'B+6'#Y0}C\-ET:_E.Z\'5-LT"L48)$AK-M_6Y)\,;>=%O/[#3T6G&GDQDE]*063#JB"\UIA15#7=WF[[MN:O1?"-!/?>Q M1W=K%]WEVO,_[61)VXW.ON(5YL"!J:,KW6!,_VZ#KDX'W%ME_VTGV8U'>O2X\V?$+67%F6KR#>N1-JYI93,"ND'J7XW[2{ ZHVIOD4IF+G MGKB <7M!L$M,S>G-)7"'QNH,M,LV(,SF,)@O!Q3H%':Y+1-7,)H&LRB:.* MAKCL73TP#[XZB,)I_R* ^/92>?+]/?&^,)-)LCZX6L\FP7+./Y2P6,3YFYC M.?X?*+@;A0]N<({=P5_VOI[D]EKS-R+D)O*M_Y#K2K7:?H6[)UY?==O\"R/N M&BE.9&H%TA$RPP#- W\7\@ .,E/PMYL$X9W+^F?*"VW ^Y4QKGV@ [J/> $G6HAW:)FC:[F'8 RT= M6T0E4B6I..FOWW=(2,$3)UVWDHCDN5\^OIH:>PW5Q!Y<5.5VAT/"N_K@]'(M9055T@U-31HGT:E61X/QH-NXY-:%)XW1B='M5S0%?DO]:7%:M1+R55%VBFCA:7YM\>!T?'"VS?2!X*NBI5OY%NS)S)AOO'B7'P]2-HA*RCQ+D/AW3>=4EBP(9GQO M90YZEC.\J5IFK"NEXW]YT\9AA6$O?81ATC),@MU14,#R#^GER9$U2V&9 M&M+X{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{8 M#_1!+57^"CI:N S@RC,E!4A8,SEO+(MDQ4[=B"J^2>*H@Q<%]2\#3O0*\2UA M<(AD?R#,(:"X8)AT*X+YW=CC0^'<ERR&(A<;]8G@!G"=W}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}AD-68!P@R0@.4TB1EA(XS X#'E1JVOPW1OR3A;CW1TA'1;1/!_" MC6B:#>&RC":IL)A% (IL47Y2M^#1Y68JA8<.!9I#'N.*73")V$$+>:>3X@5++OET ?CKA_76*0N7FC>0,Q\8 M^IMM$7)/R[[NN03VM&\-@ISX-KW33W_I_CO FZ)O=MD?4/^%*'AO/,U$+)?H MLIQQ+1V:IQB^3!KZ&%_A/SL:/M423>PTKOC0KWY8,W#>:M@Z%WW:WN.O_SH>&|,Q]^-GS@>E6#W$8LX1J,I\F(Z*$5'R96=,[}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}^JM"9EUH?&D?C^;A>A!MB#\>5.]&K\N+H\$3UT5/WU>986N%A0V39?Z%H8UBK)KL!:!Y*1.5$1 NG.!H]]Z M8%>;>4AP_D^$0>'0S+[AA8I.W2&.6EIDTBSC8RAA(),CSTMPSNF]{4,B=-' ^I>%@:?B;BOHR7):M=KO(L>X"S%^/7^:JO,F0IQFSC$)(<6#S5B !PCM,B]J#&88*'5>$8^&)Y%P MF#(U&^)FH] JJ&\5#C%'@]]3H)VE7*;'&4_1-^=TT9F3M1<[8 *]'IS5I"Z)Y}DHRZ MF2A X2.AF.U!/&-T&QH0HCR=?U4?/UZ &E3)XI+[##@> MA*UPE 'D"C[2?8I=KF:K-DG 735,3Y,\O*S(2P@=WGJN(FOF*^D17E=!)R)R M&DS8Q-O#*_5*%9K3S!4O26>0@-%D7,/1I6LJ=I],T3I1EZZQK?$E-ZA:K[IHMS)O\Z,M.M<$:L:F;6#C2A;Z@9T!I&QRHWKY>(.A!JJZ72%G=4=RNDS&TT-H% MDZH/3G39SG1M(J\S4'+([J/G.<'J_C3UKI,6IX<#0L5 M=" +\$7'>.K;3^HT%%BHR,^5@]F&'.O2O9L-1"6,?I?"@'D=JL M'.=%(+6&H&TZ8_KW0)#,'$FY,!O@Z]B1:F?=\{9)"PE,.XVSD$UZ%(I M]$C=<*-3\,=]%*YJL:)-L.V:>0PMY:ZRI@"2"+R)S%YZ6Q<&BD@:Z:[F.D8 MO9DU/,P70.C32-X,^$:H'HG.0^S GSJ6,7,H>Z1>6/Q5?##]TV?\SXHW)U* MAS%HS2V:^TN?;TARBX^'K5P/ETP4G/417RZ5B MYB*N*+(L<"&PO=V]R:W H965T(A"1,2$++#BQWMK]^ONP&0E&1G9G:V M3IWSH@M)'WOKQO@\SM?7JXVQM3J2YX5U8N335UOGYZ=5NJ3-,F(^EJIH\U^7N MEPZDV?GDQ.5-%7ME MNU,E/8W9Z >SRJ!G"U(*3=UB,L6X^J7URI{,0TIUY721.H25]2V6)LBL:9Z M?E9C"7KP+/'3O9+!)O=,=Z[>8X)-I=X4J4G[X\] 6J1O$NA[-7EPPN^,8]@F MEP,U&4UF#\PWC?Q.>,[I[^3WNLNO>FVK)'-54QKUSZME59F=@\I7Z M<6,@JGRKBYW*Y)+%\VZULHE1*YW8S.,TO*[4'5R,OEV],:7:E@@@9;T;J%NS ML4EF9!7S6V.MM$AJ8"FEHHNG'.6U%GEPKH)9D.P"6OO3U0X>(G.U J? M!>YWIRL-A:FXB*L-F5>JU.!6K4J7J['*R7Q5[=3%\$+MC"[]T 24N(*%Y%9^M>.*]&MS"6,#MRF4(<.53/%T:TW,#=.6_]"_ JDVT:OS+=FK,?Z8/W?K0EY&L M_TA=3B_P.1Z,QB/^OIB_DMS! *7C/.F"B*J?^N M2+(FQ6RWNL3E.0/95-4NY8@NHS@S4'8QOHS2499%^0*#5V5#=-_MM9LA| M0$.B]XU:08L8).F.\P9F*UQQRGT_$E?T\FBP>&_MKOIF04-G;&_3Z:)C,|>'F7,0=#$EA2[FBO/^J5N=.JT%N26YM#!JOB0,\4A(M0MATR\RN61^@nT(#G,I3)?'9@T#WG_OZWB|EX\HQ&S-?S\T72$I8Z8_(% M%Y$%2##KVL7OL(^.PE^;Q.1+S#*]SZ&},C 0==H0.Y!+ VF\|.'[KWS'1-M69)Y/%X^$:=A1#Q6(B[YG<_4+PSZ8@;Z%<.,'G'F&*,[!YP*?![,/<5$^_MR>SNLH (0+/V70C8I*93=GQ\"=%=8!?/?=% MPOYD5G SS/Z#@VBF0W65P/J*\Y/AIBB%*AJ6R.B5KSNJBC9PU.#2)0!%)BU M+E-B^1B%0W:1.V]$/D,$FWK(31'Y'UU>3'G(H\D,?(& K>'2)(.K')51=X+__M'QJ?:<8, {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|>/WLR4-=6EPA7*,C4;48:*C&3R=3 MEOSXF,K^686?H]%H.CF]OGYS^OV;C^KQ^^'KX0 #ZR&+Z4G;%(*5D3C@QB6I M_.ZS ,'T'EC?$0>CP@PDGPF(\9/@=>^",7N5>+ +S.Z8,5\.S\/3N(,PSS P M/(}@#/T3#L*61L/5[I*7&D6)D4)C[:C3OOE;,!QI5E2YIAFZ)3!^N(YJ 5 MPHTXMW0@=[3D E8QB%D-91."@_YH+ N9&SG*]*_AJ 53V!HNXG?&%X>(9 M\'!M?B_E9@>LDY/I9@1AYJ[6@E]6]T61@Z1[ ]Y'N%M8*.^ "N"LUY+&D3/MT#V0S9Q(VC19:3C0#/(@HICS8EF."^T=KC\!74 MV^ W)A9MD5U%XAYFA^.R9.8[%H MA4&=PF3&3P1GSBT%[VC%FREVC>P?V8H9/I:GOC"F.*3D$MAX[6[G,)D>*Q]8*> ^B@[NGCI,@E3T[>EWC!" ZP_Y'9& ^00V'MLG0HIHB)#! MBF0>$<-.4Z&S1^[=V,9B+,A]1FFPWQDO9>M@IZ!*E/YB.8O5L,IH-9M:%! M,G19B*)+0XD=W7<1\8(MV3%T1XYLK>U6@5H!A%6%D%1#8=(6;N" .V

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ŪQ9D:,%-W\K-F9FA;H1^N9*,VVY-HLENX]=>5I879Q5DO MUO)6VJ_]9XVOV8A2UJWL3*TZIN7J?*(9G5XEI.\4?]EQCR1&3%9*G5'\}?E M^20DAV0C"TL(C_?Y1O9- 0$-[YM,2?CD63X5-ZAOW?63$EZA&N/^LHW7Y8L*P9C5;LUA@=MW?E?<,^_PQ.# M/'S!@&\-N//,~2\?"NLN#C3:L,T:0. -!$?56<.YNJ.DW%J-W1IV]N)6KA%B M:\YF%FBT-BNVEE?>DK]@F;&/JK.58> ^Z4I,[}C-X,;K"=ZY<\8.'X9NRO@B M8#SDR0&\>*06.[SX,#5V(WNE,=VMV:^72V,U"N&WY^AZM.1Y &J.4].+0IY/-M4/U&ZN]R!GDRA\23/,@6H4,[XCP)!(Q9#V"M.[K(TU 6L'4PR-,G>8 MB&#N#C14&H.UT"E05ZRO'@PDT4&_5V4MK/;&G1RT,H->2]499SJ"%T AV]UN-MP(1A&XQ9^H47X%YKUB,/5'I[1%BID(A.608?"_@VEBBK.W_AT.1>/@#*X((B M0+*N:KEBGWJIA6OKM{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|#CHS#[6TX6(B>E"$,4&HSF8Z<#O61ABWSKTBC.NYO!C-&S[]-72"QTB0D: MY,6\Y&Z,RN_\0"5^ 4=5>T@:*.YWY3W 7BX3W#3"L\@88PDU$<M07V'4PAT;OFF\6PCG=[(0AKKZ 8UZMHR\>"G= W,VT/HC>UO3'ZP%]&2%,#+ M0)+(,5.E[W5 .6PX.X#623)!$5GD)2O:>N%;W&W&U2/M:<#=0=TU4AU()|70LA M#=V*LF'O5!O,THM[#F7>142'XLCOV#.D&B,BD^UQ*<"]_+{@UP.)>.4WJ'Z MI=GP+JQE/(5N2%ZNAQDJH)06J3"ZVDGFX22*IY,C>J=-'5V03MRA3@]/TBA-MIM[Z^A1RBA? 2M?;7$7W$\W^(90T7#_KGC)PW,7.@4!2Z%U!&A[3#D2[@%SOQ MAFDT'9T\&A1\5+J6Z2@L=[=_AZ@ SH\GD,I-#D*.=R?Y?4$R7ZVC R'^\77 M1-MY2R47,A,0U)N* LO,F&+APFPP^E^R&^;V'4^D;RRR;L!3FIQ'ZH:(TX[+*1482;#\> T MML@%AIY=>)WV1\'2N#R8!B-CL>=0L+]80['W:XXOM/7<*#K04*E]6RBK(G^_M FB4:W>]5>EF$[UH%[\'7:-_2#,4J(&2EY- >Z?8/$$[6K8OCA=AW5LKAV6 MN/.!88)MFXP7P?:%Q874OWL!F/Y_]"U!+ P04 " !S/@995X>Z*.\(!O-M%P &0 'AL+W=O79S)MSMW<6;,4)}-[ISR;55IM[VBTF[.1X>C[L4G MLRH"OYA> G#5Z17,*]\V=P}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{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|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|=; M]'?.=M@RXT9]@/>S M7O!& LO9Z;$KU1A5RZHWFS<5N]"'B,;V+]2[P4H"3UK!

*MZQ@8/O8P!R$<$+Q^8+_VM6,M:V9@KL17GMG=_!@&)(_*X6] M48>W4-2C!.9*&/]+#G5N%)"T_%;E-1@5Y%Q63W9?^W $Z/:> = .0\A6$ > MV!=.:*?-E+9AER42K]$N&JG8>[M:D_.3,W*"'.3S M3I6&RVAC#_5\\3-\G_262?[+.W)-YDH:)7A6&80%DJ4&]6 ;3IFDNTDS-! M5A@$;'>T[-ML;:S&AOW>YD(\ M)[}'7L6-5_%+[$G3(KIID;9Z*Y)+3^)FS#[!]B(:X'U??DD8'431LTAYI M[#4.:>R]]_ #&C,E,X/#R,8_M3E(_&,=$*&.@M6,KROZ1E LZ'(V>"&[)ZM'N MJ%UOO]'_ U=/SXD$VR.S_Z=C\2". ^D]TMJ11.A@^%1H>S10WSS\RO>72$ $, M!$;= ?+H:D96&ZL*/V,6RN+0\LL=?E9 NP0\WRAE'S9N&O=A>W:H965TV1) +.3,CEQEDEIZXKXR6D6'9X M!DP_F7.18J6G8N*3 !.+ "BE,N!\Y!H9MBPIQH);=N1#3F*#74)@QN!Y"L+2AU M#\I1O)H[O;!=NR6*IS((;G3.\@#M0]]F-T#.W9$E("DP2SI" ^<0\}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~@J+ M!6$249AKJ-<9Z$^ R/O3?*)X9EN\!ZYT>=OA4O?T($R ?C[G7&TGY@7E? PG1 M-U'1 _P04 "!S/@99*U&0 'AL+W=OXX3VADTS(J&Y,,;@M0.&0 'AL+W=OXX3VADTS(J&Y,,;@M0.&0 'AL+W=OXX3VADTS(J&Y,,;@M0.

(VC:;"VA.CHU.7;ZBG!J4% M4!J#TCB*9B;&]MFHW6<[HGQ#C38H+3C0.8M9"KT.C]*9(FI3C5]]F2L6KZ+T M54I2%?).$;&F&)060&D,2N,HFBFL-L7H]-1E&VJ206D!E,,@(ZBF8FA?3)] M]Y%^7;>,;I MW5D[.+^>WLH>&99!PW(4S7SV1?MBGMT3.`)9AX:RO;22NJ/VS\8Y+;SU_>G(W=W[#O_MHZ,QW4WSCO.\\7A&)[MC_R.,(§^,;0)Y]R1!U]$MN(}&=ME#_!DH+H#0&I7$4 MS=1TZXF\DS^2AWTF#_M0'O:J/.QC>3_"%/*T*>393.%/B9JHU-<)\.*^3R3R M(2PZQ?5,LT9KGH*:/% .@}(XBF8JDT>S[XV]"K/(EE4#_ONK]-0HP9*"Z T M!J5Q%,T45QLUWOC4=1[J]$!I 93&H#2.HIF)HARYN@M_!*8U-.1]',?2RTN^/,W9WF$U^O,)I':-]5] M624+Y_)ICX5-]B!]Q82-BB-06C<,R^Z&IU-J*1O8K5 M[-+7-D%!#&*$KC*)HILK.U_%.O,;? *AWAB4%D!I#$KC*}]9&-H,\^W+?]I_M95D7CVE6;=`0Z\|L31S#!YZ-QK[G>,L;&$'MK:/C,FAJ4UU7KDBRQ4F2V+<7.? M6Q?;.M6[@9>-*]J6/"Z=A $+]TZ[/E]7>QWO'/_HGM^X<<# M]Y$5>SIK? +W%]&>1+<,D)Y%\4*$<=0,^(%F].W/]IDA7U2[#]VE1I"U\E&* MA'M3!MCLG7WU/U!+_P04 " !S/@99KI,O][$T&8JUC4]N!5NH?W[$#@3M"M$6Z+_@1S_@WXYEA MIENIGG0!8,B/D@L]\PICUE>`<K[,"2]K{<@T"ORRE*JG!15KY>]V TJDYH'X4 M!-$*.I$QXZ=3MW:1T*BO#F8!,+7153FE3)G .7VYD7>ON-.[8JC WPT^F.KF ! MYGY]JW#E-UIR5H+03 JB8#GSKL.K>1A; ?7B@<%6'\V)>51RB>[^)3/O, 2 M 8?,6!44APV\ \ZM)N3XOE/J_7=:P>/Y7OM'9SP.\T@UO)/\&\M.,?/&'LEA M22MN[N3V']@9E%A]F>3;_9+M[FS@D:S2118{820HF.A'^F/GB"..!071&(-H) M1(Z[OLA1OJ>&IE,EMT39TZC-3IRI3AKAF+"OLC *OS*4, ^F'[Q4S/WO6L)QD MLL37UM3YJT<6&)YQ9'(),F18@<'A$*{'1+A9/9&[@4SFEQ,]Z(]\OH] M&,JX?H,,[A;WFNB"*M"$"::2*UD)6F(M=3WR"()"S'>>)YHS. < {)%RE,H93W49G.H(&Y78!/R2]]!:C,/,TZ#VH"7OGH1#H. .O#B!B_NTI[. M8<6$8&*%4JK7]#?K7ZH..N]29.K\WZ31H%P^'4W[30) U-TDGS MMZ+*AM1S&9)3ACB:M#,,&X9A)\ #'>#/11B>(/3") G:&48 PZB3 4O-$IC% MD(ID]EGX'R" 6I"""I}UHW!"..XDPX2X)DO'I YWC,\Z9 "B3SHSZYH4FV4Z M 87_&61EHZ;74P-D29DB&]HK{&O,.IMR;5B3 *R!CPN!0;(,+ ^$K-[-SSZ,PB?G8674-7Q:4T=423*$W]A=*'"$CIN7 MET!%)U#HJC/E*CP4] ["S.'G'"\,@6_4(5IH@F')8H& 1%6 M$55W5_7"R+7K.!ZEP?[(30OL2$'9 A]*.79+ ^P%38^;_@902P,$% @ M&UL MI95,.]LP%,>_BO!@M)#&E]R[Q)"T'>U866A8]S#VH-C'L8ADN9*?)#N> M!TXHVXNMV_F?WSF2CJ9[+K8R!5#HP&@F9TZJ5'{KNC)*@6'9Y3ED>B,A@F&E MNV+CREP CJT1HV[@>4.789(YX=2.+44XY86D)(.E0+)@#(OC BC?SQS?.0V\ MD$VJS(;3G.\@16H[_E2Z)Y;J2\@S*W]"U9.,_=O%Q*RW"UX)[&6CC4PD M:\ZW0,4SQS/ &%2|D%K'\[N _*C9#&>*LTG=]E,6RV3`^J?;>PZEC66<,?I M#Q*K=.,'11#@@NJ7OC^$:IX!D8OXE3.+.]!7.ST'1854G%7&FH"1K/SC0Y6' MAH$,.F,05 :!Y2X=6%H7F>RSB#EHI'FW1 MM]Q8R0YZQ;0H%>92,W4YC*[N06%"Y,71M0:\G)FZ2H=A8-RH0EZ4R,$9Y"%Z MYIE*)7K(8HC_MG=U^'4.@E,.%L%%P2]%UD7!I(,"\ ^A?T.O5.>U9O=X9O6.N M[IHIG0N!LPW8Y*V/YW.*?Q[5DNA) 9._VA)4^N^W^S?W^%,F.(*9HR^J'!+$# M)_SXP1]ZGXY3Z^CZU]2#U^(W-XD @'13(`65RY&@U#.]4D<]MOJ>A[5M+4 MB5WH=,W>9.KN6D@&- 5O<_R\LW\AF'+#=&\%!)MZG5'^CB+ M\MTI.XKGMM:ON= (OAVVF`JD&81;H^81S=>H8!_7C'_X&4$L#!!0 (`;^ M!EGW)}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`L\KXT,>DVH4_JM?;,_Z90!P4@-.AJPO;G$34QK3C=KN":$APKE:K+_"_BW M,Q(E=6G7+>QJ.=@M)N./)S-W`31>3,.TOS&"95];IZP3UBL'UOW,W@U0S> M(,/]" (P%A^@<Q(XHKAPGZ*;P.PI_D$*=MS7&.A.,0Z@7)OD D7],Y/>MS;0F MF@{'A4:G;)/$IV=5Y&- $KQGB78_=P-4)N#RMVOV*B[/2SP'2)R"IU[1.>/W!{=MQOA MM]^E_%VR<@]D=W0H@E$P"=[_/<1-DK"'L\277 I)BIA>PKX2(#@($$=]4]?Q-M#M7]B:L{<4X2D.C33M[AJ7QX11T!'}+R.N9. (2*O0Y]]T M>E!.XK7O4$&?;CI-)G(&\T9?`L@*F-MB*GK?L=@MHJ.%/FF**V$VEUWV?"5=H1D.!.#,5&OCK,O"RGRH9D65 "'K)A4!5'QN%4E M*'+]@7J_9DP>&G]"NJA=_=02P,$% @ WK#7&]! T!H !D M`IX,*]W;W)W>&4=+2+#9HOR=M V@9B.TU3N3)W18-O#L =.:HFTBDNB2E-T.^_$C*46R6H66.K8/M23>>R[/$2]U M,$G[42?_]Q<0+1#@6)4SVYN]D)0EBWY8XI]$>Y YW'IY_),B 4 W":.IV,$8QP*!8'DSQ&O^_X*#7SCX3QW&+SCT"X=^VPB#PF&@E_]7C Y2}2?6-P+&C[L:1QAQE^_FOAP_[@+!QD1W\#/X\-B#*GW MX$ M6" 2\[?@ES3"4=W?E;_MI^P_3GGI&P'? MXTT/P-$5\#T?@I^_@>,|*<.<.".5.!6J{$9-OX,A[UZ2H3,# $EA-O$$IXL"$OEC+?08SAB/ E8I7 MCV\)96)/&?E'#KPA.?&T.?DO<_RAQE?,[*$!O?S?S#V>.],6,&AA6.,Z++D. MC5Q7-$GD7!NOFYLF+D,_KFO$)EA@":RFVZC4;60ST48V1;0)%E@"JXDX+D4<_MMUE\WYMEXV&6UD%EZQJ?<56QY1IWN\U5/,_ DBJ=,7Z%-C*]D M#2VKKO(S! 0%=W'0.B9,K?2MH@6VT.I*5L4^.);! MIDP^0)N8A')(MHPDW5W,YM&S,)[Z326K>4;=]?L193ZLZGS8JM#/%^2R41@&4AEARTY65[I"^_MOX\RA^J:206;J8^R%3#7SCT[D@PV^FC%"Z,\"P5^6E_^,0\KKG1AQ1N99Z? MJ7Q$;$=2#F^\E.Y>,RQ9L/SX)+\1]*./%#94")KHRSU&$6;*0(YO]>SUBQL5 MH#S$6OP'4$L#!!0 (`,^!EE!HNV[6P, /4, 9 >&PO=V]R:W-H M965T$6M'4S%WS:,H*.MF1$*UQR)(L\Q_WT*&=O.+-=ZF/A"5]G4$W8T7>,5+$#>K*^Y&MDU2T)RH((P MBC@L9]0=[]WCN#C7 1*PCL!5[UTA;N67L3@ .DYGE:$6002PU!59 &Y4A+EFDF MI>.^(K7]>VK@_O4#^T=C7IFYQ0+F+/M.$IG.K(F%$ECB(1-?V/835(,&FB]F MF3"_.%O%.A.*"R%97H&5@IS0\A__]A*Q!U \[0"O GB' /A1P+ "F,S9I3)C MZPQ+'$TYVR*NHQ6;OC"Y,6CEAE#]&!>2]U6B<#).2!;?I2Q+(@(NC%Q//#4X0 MW!=$_D;OT$)MF]3(+$ENI(I<'2UI2HP)6MT3B5P$%*@UV<@,.?K(+!5TNK,>0^9._4Z&3\7=("\\"WR'&_4)]@;?@8]/T/7 MP(<=%6D?G$G+QLRW;)=FHG4R_.X[%&L*

>CG!S2;,%" &'O$)$ M##=JAG@@AP(+EPRS9M,-MZ]>A3#WSDC_2_Y6)L@F=]\HW%@&84?(KCZ_@ M>4X0NBXZH'PTSG#(QY?^F014 #KIEYFX73*-%VP;20M!/D@V-"]]=]+ADTS M^>)85E3OY^>28R#^:!!#Y/JT<7]F)$W+G.'MG8#DA!;,4OI=+Y@ I*$I#6-X8 M?H<\!5]"7*6G6SX=TIK<3PK37:)LA DYYP;(UD:#[=D*$K"8FZ#+8*!E=E3OY^>18!8A8.UM)G?2'86"M %R!,R9]'$3!C]YA[&4%.)C MD)UT3>C\ %7O1>-0X3]!9-N4/#AA+2\6O\E.+3(8:71@ $5941.#FI\A &H] M]#JXIR+"_?F(Q()-6HJQX_MF'&CN4 &H@58B3(_AF2+8N6\?"E&4TL7FG/^# MR =RH")^>LOQ\QFE%VXL9U0+OZ'P>,9@4V7]*YNVP#]R>GX=Q] #,-QJAS<28S,GLI6&S';GPP&@ #V*-M OL+' YMZ9Z0@_L^GH_JS,V>^*[H\1>WG5+'GZO&H5#!^7C !P9OA2&HRJ^! M/I) D>.V%QM;[A"_SF(YW.M_QKP)6#U585'#S="Q8W" 0<7:,3D#7!CR&'W?]X.I MI>X!B27^%Q&"?&I,UZ.HW:*("P0+*(RC0-TLAD&24-DBABC"*&X,*5^+F0R ML$+&'=)BG*A9<*Y1NA(3PWC1T,#M9DPQ G$I @17BR7AJ!Y8KV25,,)'4R5)QD"U"LK=NU&B(+BAB*R+W0! ^@+N)*Y^W,L[$ M_GUB_8# V4O)0X^KC/D8PPJ9E3A..Y,@QO&"CQ9:0:&_L1QL7@^>KS5-[VIS M3_M/#EN*+);4]2#"-T8$FI@ >3<9."\E?]BKB:B)H4;06S;&/-D8:]21S,A%@I M&"6^RP!;GZ,NU8%'720D7+WHPI&[fT$M'0(B%TPC*RRXZ1R[(E8O1GD/5R8A M^G.P5O/&?9^Y#GL6NC<)W-=9R]9 YMW3R15K\#U4,.L^$@FA)WJW)Y/&2A<8V4Y-1DF5#Q? F2<3OZ:9U!YSN'.1I%%[E/8DS3N3=M+STUO(!-&%R6,=F7": `Wx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fSWJHN\EYQS_X0+]R<90D$K2PRE5KOBX <";,WN:G%3 +>>.9&+N9"<^U M@8F@3?S'U/>>1(+4P_ #B.2RJ1GE4R-Y02L%D@BE(2R7,,.13[I*=]@P<862 M(\#>]'TH>%M#^5S0AK3?),X2^7VZS0*Y3.>9P0!QI.2W[+CHO=8[2*5\4F\ M4 !)/1)4Y@C\0!,!^?;5#ZPPZ]H)*RVJA]/1YLL;%C)(?P=5!'3VF" (@FZ:/ MOCB@59+,0:'PQ=*(1)4AQL Q(W FM2WDADB _=I%+(RJ]\[M5PR'QR'C.V.G< M^-EC-#G8,TNUR@KR,*<2A4)T#PF 3|#T!S!+%QWQ0+01GV:R[5|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p!85K5M._J2A2D9WJ]C^L>GL'WLN9- M[_EMU#,0L/G-M"R$AF%?C#.%.1&^N[+(\#N%Y?R!0YHSM3Y3ZR&I=)95R%O3 M7/ K^&/(}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

*>_X]^/;7^/9,@X)@;J%<+="+V "DT!,&1HH=!YT:?:Q+"A^_2I1Z\6K3^ M0.),I\RB]B[,#=D+-02ACB.P4Q_+FW]XKS!2;$;:"VA ,'2FZ=OV_U*3DA;DN*

M_L21E8YKS=&D%A\&]IUYX'N=$M>^S]HAY.23C0\!2)I1P/O=N'+= 5$;R:`M\0%[_"%B.;#\$X?C]&VR2A_O4S3 Q[]3753=H.//X"V5'C[D;KAO&X6]]J5,/LW4RS@!4L9N7X?L#AA-*

@:=L#2N M,!\V/+Q!V- '(8?-&" MB#?C82-ZLZK\T7ALT#LIB9\<#&#!{&]SXGA+ M4^>@@+'TK2Q"5, 0M(?D MLH8QD!TYX$\?EA#<5KC%\?YD7-&A/K&F)%PSM0 9>SHYD|CE MD?%$C'fI\!@*XQO/ =O<4%]!V@\Q,OP"#EWDB\'3Z3HBI8 M4VY:X$\,\G/GAZ2@D(#H%HU0!+ILA#X,1.:,&B:MAQXPS4.1_9ZH"?0Y4U3= M Y<%/GC=@>:8C E0IDP1V-*

!CXTRS<{0&4VLF(A:))'0!%;#U0*],BD$XHB MRQ?=>?L'#ROP\9?/3Q_N4J<#%9IOAXK8TV7V8KOE=#L;-ML-H]TM_2K7V7"M M1^EZHZTO[_JW_N=FMRD'=?!!&>;,21VW3#+ W=]E)-,J[(M]E87ORR' ;I$ MKIWZ7&]* 7<,FM_H\0#2&FA9/>U+H=N"GI025!)4AVYT>A:G9;\D%N^>6N>= MV9&L<^H;J+=TU= [=:NUM2&SY665Q.[98]?LJ%JD)*

*[$KL7MRV#6ZFMKN-"5V M)79/#[NMMJH;W:&1AJZ+*3E"!+)%0BK'GDA4E]DS_W+BN;(KU\]VWI']NE&Y M6,"A!/_,ZI82_!)H=01:4^V8NL19'=;BK"%F8B>EI@4:1'CK(&F:R#2FKV#*

M(^UBVK_/)$"<8 -<=?4$'G2I+=6Z<7C;%>G.ZV52;+>,XM0T/$""18*O3W\RN MJK*_RKO/^+1%]6(\'ZKC0BI M'6JH'=Y]#,.S?BQ%&B$29AO"3&M+F-5A?.+%YT*C]-C?*

9>NE5P>N3OR>>3RS!AKO0K&6KVV\>F!1JOF M6K1];'+#+%_9R6M/I*D] V\0.SI6OZO#G7F0[""]I+!!C$NR@V2'55RZ_+ M"MQ9<.W]P:,*

[]@8>'7Y!!BY,\6Q=NXVC7OU52]^/|!:PO2$V^<"%XW"Q% M607L9?T;'IVLXUI4P$MY?Y%PGGKKT.'0)187DJ&\Z.=_8QU]+''P=C]`Y B MC]1?1*'GTYCTTBE^QGKPKU1S255>D-*

=&%M7!CI:S#*#,R(\U+_ "K R.];Y' 17MOTS.TTO? NU=K"\Q% M607L9?T:'IVLXUI4P$MY?\%AEU=6\I"KOKDBM SS0E &O@/IB ,D"JE?LX \& ?5C@E6 M)(:G]

('1%5A:MTRCV!)MSD(\C2[@]$9=[H(TSHP3PI^ 35$S6(K?_&,$AGW MC*EEQB"F7A]O#+4%2,7V$W-3$7fL WTGGX:-M%^-<;MR*[B4*PUZDQ)UK01$5 M/F#+<@+B!E$\&,%?

*3E586977TN8+PF(!?A2BS$3%,+'0>) M*.0=!ZB2M_-#F?A4MI+W#\%">GR#**FFE^,/O-?Q(LL,.6AS6R$5$5Z7X^DY M0Q2.HF0]4&_*166N@VRHN(P]#*

*]]2*X@?5(29>,)[4]=6J34@B(A M7=9_U]=.$W9:P7ASMKCX5F7&XLYEL@G9A30AJ[G]_8T-<)./_VDVQGHN'\C T M 9/,BBS?>;%HNV-*LLI/$C]G1X\$"_9!T>*

*[ET&+T^:.'S(FBX(XS7K4I'< MG?4!2^R,\OK^O N)4M(>(S7EA#(;.D8$I.8/#!953$)OV"=]0RI*1?)XOs! MFZ#IAVT!$ |_HXP/P!8;!&",#9)&$M0$P.G#DVU&0C8$[08:>P .;$.QQA191*

*M^"+S@Q4O7]#3(AMD2O?"8B1:9:ER=5^YGSX^ MW/W^%=:ATWQ_&E-<:.T+*O>5YL6N!:.H,8$3^A+C$9M1ZY35I;(&+CSY6D0[* M)]=_X2UXN;M-*

!BR#.VWETX<[8"#P"FM%H"\%ULFOIUYBH.&&W"9ZU,'\:.' M 3TBUQ2'>(^]D6#-H=^=ZSA#03?N]& R6YSDGY=-OJHW!84]VV;(;F_R0&MA 8 M&9KX=.HO63YA]J,/+;@5KL>!B7?*

&G/<&I/4]!)FT(E0VRT!,09'-A M_$6:\A&[H4^D>X$1DW^:VNO):.!#0.%W%B72}(]'%?T SK8BPN(Z$^H]Z%JQ M![[^U 4R\6Z"-%&8#EPV*X!/@P\]LOK'/Y3?/WP[C.FM]&T_Q@&@"-*

[]AY?O M&/;QCU1'_RZZ\GT0K7.^L=%L?S$@1W*Y*GK-]]G FC#LN"=<,2<-ZH&2HL[? MMC^-\MTC+6>"P %S@[N4?10AE@"ED>B ANWNXCZL$K7XB7C$>E=%E)LK:'< M@6X4*

*M_/6YRV!A_@*C@2^/\AGW>5+C-%VA/SY\SHPNW(APW=PCPKB2]_>$H5+ SI8B M2V&NK D_@R#2K5R-#9GP(K&Q"\N7&G*0V):RXY++#9 SMCG8K(YZT5Q8R.G0& _J% M^@?*

2=]S/9IW$QZ7@0ZN.DEP7 HX3&W3$WLG#XY+B#$]AG49L 6G$T[!T'Y MN]_^;+_5RP@!]3>KH79K+[W(JC'X??F1$AHG#@TI.20\CI(.57-H|"C\1//N MU-

R4$MW>O)'R%ELOO\/.W?YDJY-XHNB%:(!D B%LA9V2E3XXJP]@[S5>UO6 MFMF*2B?"7. ^.Z;U>$!J;C9[$8HT#*1<$Q;?=3<\V7Q 6I5P\$!A-<|,3LQ>+ M1K!?*

Z;.EANT{U\WU'1 1,;A@9LX'[#QO4I;Z)I)]V.?YCM]),UOY',OG MIP]W)]A&M-=KM-KZ!EU$;,.]LS:4G=;.>F-VY*.,ZCE_61E%U'!9172;+.]' MW5V;G>8";\'Q0.[[,3S"#M!/39*

[]I=DQ=XEGB^4SP;'95K=<\74!+V%XD;'4-!'&S5R/<.M7D)R[V?TQ5B8%H56,4[_83F]/;5G'.-@: 71>+EY<;JFMKK'.)HI5V>-U3$T MU6@?

HQB#?)TU5Z=,]=#GCE;G(DX54_;F\ED_$O6IO.TSCPV=Z-WFBO1T#X] M[;BF6=V"]X%_<>8+8U:6 G)1#L4S;,5I5@^GRH79N_(T-^R\?&IN)^55'2.! M;*V29CL=6+O16F-D]Z=^Z.*

*8;@+F4M_>)QA=N#8;)R62?MD^ #@9.M=,5?M M0MQGW52U7M6FTM(:'-J4_/RW97EA8 M2K&R-

*Z"C5"PBRDZR*SPEI?"ZE_UVO5<8KP6+OVP9/V!=6GP)_%!C M+SOU1OZ#)T8B+\#L]'4!5>2 ;(JK|;)M7HY[+^=$$-/A"R&%;#>}S57RVQ0:%1#*

*{8PZ[TF6!778W]E(!AD<5XDXR&PS!^X M\<"]A=E3*5Z>UR^&$5(U8_SJ-M]7#'UFM>F,70H7W)Y@7XD*D? 0Y)VX'=? MC\V;\#$@U%3!W_*

Z8;H(MZK#2*%6)$4E!_B^@B/6!&U,&K%H1_FG"@5;<$= -MR1*SAQ3S!-@ I!$0M32%DER;8HWA+*3ZV\2;812>N'0',*.45+F64+A5"O-# MGRBJ*0T/6KM.!/_&E*

M327U$:9QOY'FFN.6SZE39V!+GT& MKOCLAX;GK~162=3@-1/B1$"7L@(MIH-$QZ4B_M ,!%"2='<;/ , MO6/:>W-^M+Y@F;PH&@7 D+,Y4VLD.3P "9DRIZD-0IHKV0:P#J0%J6& 7]EY!7)#T?D$6:+-4(5'\"O<^3!K1V]@;1S6%.X^1_UVB>_6$A#-!A?$&NK0P2K16"J-X0GH& M=*

*E)F5P/D'%RPV/TK*61P]210]*K'#!]WNFA\;'S0WGG)%,'D).DWD06C"'7%1>IA^JGQJ B M!) ^/5-=VS3];P9V8VXU8O_.#=BQQP*]M8R+#@2%ET60@7+]O8#}!*

*MD*34[!%9%/EZN7]L9A-0G2&;43@\#^>KLE!TRS'%B;G1$.I(.`W>4)%;F0%IQVD> !>/>%;F^G$MI'P^,5 M4'=$]BU-H/3#.4: C0Y1!05 /N M(). 3LS#3+1M'",X'UG?X@4KEV5-;!+;'#6ND<38.A F]O?ZKH:E6\M3500F M;FM@;NDEI*(!!M,I"'A\5IV=F32DA8$!9NMWX1)2 M%_Z*2MV6B8 2C6-R7D?&S-*

@L!0F{"6\|O^$CA@B(HH@*U7Y:FN7"_@H6LKB-A MLH(A*&85DAA(,)-#$?7\VF+XFA'SI"72DK|DKAMGHN@T"5/S WB${!W.W:\- M&T>WX,,$2@"!MZ5U! U A_8QL2";S&

(Z"2U[S&]ELK6GBI@60=C1#XOOBR$ M]MS\U)*#M4(9,!><,\D:TY*C6=K!CZBG5Z)X=V>M7!C9R3V?^7K05>TF-/$X0 MA ES@6P1Q@M)@)IO Z/B9*28'(*

*MA&V>;B,1 +]4D&/H!U_"(^&XC3EY&4EP,72I.HA*I?]&,Y]H6AK'Y(6:0#2^\ MI'_U/]W)5"\0#;F<;4?4F)EK7[P"%T38CBMP@6,3,$$F-!;,,4 G!5T-2CBMP@6,3,$$F-!;,,4?4F)EK7[P"%T38CBMP@6,3,$$F-!;,,4 G!5T-2FT'X_M1!G5T:6GUG%%I+#^1KC9#W!"BO(+>:E#U+4^J]*

*M3@KSPQ#KN#_V9.5I3=KFRH-!G<99"3)0J;5A6RR.:=_^;_T$NFSYU->RP>K ML[CSFQ7*P28[HW(|)KUVX|Z7H5=H6.H"E(-32 MS5AT%4&N 4'Q8'RK67@E-*

75H60:H7K9Z"P[+6^$*S+[(I[54.6/IH)OM1^CE MZ,=@JX1\,$[Z7/?4KV58]PML6";,&P]0ZQ)?/OU7OA?A+G M0=9C+\BY4,>&Q^/) Z>NI>]@:.+VYDWAN 6G4VIW] M+<]KF6V?

F.VH6VL,>@N^_Q[PF7O89;"/VHW28VF5[,,4ZS5]C,_V+'TY,JUWK=_MV92JW M,LUFK==W!C,^<^'K<]3MU%O6+_|>O!S24RZK<"RO"%,B6#HNSXQ@^,XI<@<6M MVU?-

Y3ER6K5NKV,]O\JMC%P8NV^JN3I'!$ZW?OG!]N%^-QJI2#;LNZ?95;EE[#^GP579HCI];MMNV>J=["-%N]^F-!92JGSAXQ M2]ZKN"8GKUQJ<'7Z<,;#FMN:=0K?JDXXMH

Z7I3A>4G"N&Z&^3XT4--#DJ;B MXJ1=&_0:6_O1#I&9'7EX=C_8_;!.O=;;[2U21'8_V/UPX/NATVP^I_UPX!%

M!.8\GP#@HO=P2G4l;'>9Q>XRCNTN4X&QI$%WF0K60:S,CQ^>+>+.!K<8*$HRR;))K]B1/]>R1$RF0303@FHVB3!1#?"H(38/0]DT M!=NQ#Z,P2U0-<==D>]!9C=L$H&SORXR3-

*R\;**NSY?51+&=LDK+Y#%9J!#;.$ M87(6^[(,5%[LN]3$((W8&.@F&P/*WZFYQ6O9V<2G9Q0]G.6#L/5<%,^P@9\[MYD8'OJE^L%&6RO/B;M@Q-BJGSGNC!!.(RCO//9SN*

*RX)A*K\GC=*A8US"]?# M-449]P*G1SXIV458M@*"+ZDQQYZ7@]QR2U_DQT(,>$LO,_NRX99N.6:5-;,4*

*MVLM6NS[#BZQ1WZ;I=&4@NZF6F@!]HO92B6!)^G*K>V13:B!*E?;9RT:JES]8 M[Q]\TVR.H-MX4Y/,,` PKV=Y1V_UU+;>;NNV%7O9KG?S=Y;KP2VV**X9Q>%4*

M_RJ5QF@JW'$(ZWP]>V9[Z>< VF^E,Z[UX8FO?2VLN7\&W)MCPA$]V2X&@M8 MJK,XQK3=H,1M_T,P+Z+V+:HO!8FT?,X)S9D;<]YW4,5\G='%CE7KP M&Q)W=3R-53<2ZL

*71D77../O$ZHLUZ".V444.P6\U NH3:D?SK6D/TQ&B7T* M@(*M10X<:O!W,$0DW2'(@\N.6H.Y69*H+EB%ORS5%6BT!/N>PI+GG:/N5>Y> M^AVN*_M"^+*G%IKYLJM-*

P9G36.@BT[fTV.O:-#T6_VJSGXY,_LD:TK+2XO& MN.2"&]4[:\2U?&2&D@<O7QR0$F2Z1:@U-*12]"EU-=8J1V:[*@^OD7C5[PU M\/E0MZB2->=I;U/#?*

*]5%1O3]=>8]\"]);=\Q:2;DG+D MNNB=![MLX8H;)(#!RL55YNH80+\H)I;'V\'C^<"%U4X((;L&4B(*5L-;= NEM< MP_7-]H/,+,BI*AFT9>RU(^W9IA%1%W)"NCDR09TU&X7G4_5H.*

*[/S+M61!E& M6:I:T<8QI=,-#S*Q9HWD\L+ 4/W!X#RTR_@4>0W[=U)4CB:6_"%#&(%%N[0VGC1 M=+/Z3I+$]f/<;C[U$]166_4Z+;V]!UQ==DK&\'PPG!B[D#8'^Z;V^"FSG!!N#*

M4>;BLT\6$TCPAAAEFHZP8AH(U%S9>Q92/U#I2LIU8+].VZT02]WC)V">Y#(MWO63J8K'D?. K4I!(*)4026R=,+*:(A%(&YPM3R2$O"ME/9A%)XL)S$*[0FP*

MIJ2MG&/^V#J!DO%X$"_]?+UI_=Q4-VQ60E!UA27>(-"7TB?O4IF2+1J!Y)QQ M=#3M3:8,,.S'<$?D/G;P?U>;-8>B,OZ R-1%6I->HN1587C[,[UJCW^APQCYG

M8!XXS>%4Z\&+&L62XW]3A]I.9/8)0!]ISKV+R@Z'5H#@A9PW1'DG%-9A0?PNUH5:Z%IH MXXVO"ZCUNA0.BZ.:9N"):N1B!XF2]N&-4M;FH2<>P,\=1X)4'B-H<-MX.MYOX*

*MEC>]EUF)HANRMEM+;65S>ZG4K'W5;$@RW3^4U-DZE.0TGV9_.'//8T5?(31R M@#O^@PJ)6BNKMM?P1:_ORTL&67 ?N#Q5Y&RSW[R]4"DQ*9!AHF<>0PS7QY9 MJ&13K-*

QZW65/L=6<\NQQ3\W5N=MI%'_A45+/3.T5 752;M.LXNC0 8*/L61 M*[S#9&Q4+,%@6MR!CP%3-8%Q4+,%@6MR!CP%3-8%Q4+,%@6MR!CP%3-8%

*O9C^GR=GS^HGGKR;CV60TS%7`]#KC>(;YXYQ^`MK**?3CQ6??T<^7SZWC;NBP|>L+=P<4,/H=P/GA+B_%L\?6_3B=GA&H^%_0*

MXOP.Y272:L/EYSZ%KSA[\W4^#9,I+>$P_?:6P,]^G]:OQW,:)#WF\|OQ'"""A"7,XH^)EUB?5XD^`MQ]%\MGIG(>,%?`\PG"4'=[_I2PCU"U<8!SIRST,,X*1/H'(BW12D@IP]U\RK*

MPKAO/$-K8-P#$/<82?)C?E^X8^/O\VX@M`M^]S Y^S(=?0.HE$)K@!NQQW%OJ<^AT]>U.]JOKY>_B,,:T;B)__M/9RE)?C,W[`3/)T44CX/C>%*[4BCLDO.@8B%+`]%-N'"#$RTO:$\8XGE3HFY`M_QBVM!!/DZ0'%G4SPKZ?3LIPOI@,%0)'PSP(YRDNSMJ`9U8#QTXOLN-I/N.E\6R:G0VD3(0MP5P_7Y_#]UAB=7)M%JI1*

*M'HU$MA_9;U/ZDN7T#GQA$]5T8*2@A9-$I(4C-?`DM1/21!Y=XQ%=>WR?8J]`MY7V;O[O.7*C6:TM()((A,@E)#:`1T(IQEQ/N`,Z6M."=5K_(*CR7G=>;N"*

M%$6TVAC04BE0EH(YTN8&K(E:V1@XFM8Z\$% 6U[_IT63=}HR8[Y|"+-+Z8T MS%>G8?H99P,O/6IN!;BT4'#,@L?(0=]BLF1$69'`D^(.CDVXH)XP% ;;^&84 M>'DQ&XYQ-

GLU:.8O#\6NEH'F9R)GW:)YDLO_L5T&NC>O>K;QIA<45X.XG>K4W3@8Y"5'U M4R5J^C1C/NO\7R*:,B&3V.[+/N.E\6R:G0VD3(0MP!BJ?&H"<;+ M4'+4H3%?'X"S"?$VC-MBWJ8_]MDDO\FMH&X";>NY05N(S$:!TRH6$,R-6+4CEO;&FM M8N|#L@E'W%,-WEO,?T<[X^OV!.D32]]^KWJ01+#)#JE)D;M TU*RIN!2) L. MZWE.'Y*

M47I'WY,@.E\5VQ^^'89(C34/ ,W<1^$FQ&IQO9>DMDJV.^G28F%T<\L13\Q9AI35B:`MF,PM!"X=!0'9(3>-:=AX"'N?4LU/<;H&TX*#I&F&G\>O+]93'*=OGRC6GH5T M&3$M?KI<?*

F_+V;SZ@^O1C(PK,1"D1+D2,Z-0H,0G24L7>N$Q4UP]4E+MV'+73>LL73: MY;E42W#_H$V(62MTP,DI)-\S+O;7.43&4V8A!M%\P^EA1'W2LMUPI:%$#N&Y M#QP6%;)EH!UW1-

*8Z5B88%**KFHQ,7AO/"^Q2@^:D2O"]&D Z@L"T0L'(1F M01;&A$BMM_H[C5%ZZT-OQRCOHA-2'D7D[9)BKMVHR$))FG#'R'-)YA1'W2LFMUPI:%$#/.2 _4%'#9MC*B-.OPX2SCY-*

*1'M#]=\$1#CED\M,2E^"=L"T4(YE@JZU M3J^_`TVQILCN*QZ[H5ZJR6^84A\%R4JLUNGKRYFVY>T<_MZTH#*,:EFDCZ>(V9E@VY^:7>5@1X WZCXSS(O=)!=(AML/0BI*

MJZ$K!H(5#K#>D<!]!1)E:7W%9/GE?_,+\EN5|GS@M(G1>0T1R7PK*0(PSF MJ%5@TI6L6Y_LWP#0)\=_!\G>5@>]3V[+\): M_SHCV?+29=^9T&C:F|'@W63\^1-.S]Z.O^ R]70V

*MX*Q(&ND0!E(`%3!!%%*!D;;]0%Y3(#C]Z#T3HI6KR=:E+80U@/L4Y^_*H=T+&^PKP>[LYK6Y62<)M(1 M7@7(0M=+LDZ0@12G|+R5L1I*87FMO0UOODUFI)&YTEF*

M"R8$HJD,=9PU12-(IA2C($!W94YO(NE3T-V" WFO O+NMJ_-%H)D\BXEUP6 M5ST4>)YHD%K8X A<2AT:V"UVB \58S>3^WYSW3,9]KR^<[!Y*-VT5H@,Z5!*

*M>9T@^&1HC+QDY9P7H?6ZOO]-GP+J5AQH-/?MZD/.) ^F?IY,13>;.L:A;/O^V4 M"A**C5J.!#Y&LETN>`"'//&]_Q%&%SB0L,"8- (SKI#?HS4XYA.P>JK 5+TH*

MW/IJX6T_=:?6\E58VFW:>[&9E?Y#RL8P^C(\>^K<#Z8WX3IF%3VI$;. M01FF82UQ%)6OMY5RP4 ,I?)X(P44+0*7)1A?6HC@CZ[TS9s8WXD9H?$= MQT-

U2]XN4_@.S'2R!E0)K&HV"I\$]\8]YG5[9;(=Q#[M:;16,AT]\N] HKF@U6LP&G*U[;ER0_@LT<,90>.MBY,U=\,?VNG9:*;5;\NQ]^%;]XM789{{(MD2(<'3R-*

#64"5XH$XZ3UD0*@$EN7P5F/|$_`U9X<6,/|?:>`^I<*<7F!>M\LH MLX^UWXBL^TF*53@F"%"VF,*59,.W9OF]8/KD:;4G0P,!=`*TX:K8^HKOs16)9T!:>K] M[-I8(NCDP3H6$A-.R-

#:D!H=;9^GJBU((L+2;.2?&/;QC^'4?YU\FT5D__?3)`Z;D M_|>SLXGLS#Z;3]Y.%^!U$9C#3_2^\!. 4"6A;"^T+C%E9R6Z71UI;W6.`M1_50)92MZT&64I#(_5>14@2F6":M)M!JFC>?R)M

*MA]WM,*M=NNH_-:C^0G-.P<&+^:LPG7XCO,W<@V6I*!4L@URDJ$LR0V!6@0P9 M234K9U3S+>]-@/4I3MN=%W>VP)O+I&7$MH@>/V!" D8!Y.]XY37]@H8'ILAK M- J4EX4<1ET*

*?7+"A&*X;FTU\+3]HBM'3F;2:#AQ:AZXWDR_593 L2F6,@ MJ9\4J7!|AH BAPPU3R1F'X*2[2NU?G]^G^*T=C+?>88;7M;%\S#,E[4\23DM MG+=;MXBMC5(E#<[4(MI&6_ ,*

*(VB9@DG,):BWX#6'V*MMHQDH4&GM<WMP MP1EK4[YMJ5)-.7% "O$@%;"!*EY14#-VX3RV|[<->D6MB1+]34A=G'[7>5=W3 M'V,2K|<\PG7*Y\VCHC@*

*.;@@K'*Z<%M:5[9X#%.+7)/A\MI2=0!76R>IYG & M6> ^P2@-*%U9+LVH(F@5(R'1B46],K9?* W#ZY'DW9*W_]NXJ>6TPF$85O6J@3P]X/YU\&=*WO?SVQZS>S5O>=:ZUV])\^&6I*

MI8I-Q9L2P49+5B%I+'!>>B#_GWEA;);--^PV1]=BSW#QZPO93MP*3%T65)8 MY&+M0Q&AZD\&FVFK?8V@L76VWEZ_^^1!=<3 =1N@AQ%PNV9-&_.VH+W)ENE*

*M2NVf8!;E:%T!GZ*O':NT-5$IW!R1VP]QGWR_{'R@"+NFI97E7(>P5Q3D923R%#O=8DD MD@[R*;:L[J4QZH++;!Rl/O@U-&I;:`^%XYD5Z/(<%T)1:.*9,P6R$[29##$*?;T1*

M#[C3d7&>&N>8+4)KB=@A0Y!Q^8B;%GD]PM.G388CDJF9R-KM?IV&;X,LQIT MG]4#KR6AC>>^5#$3B-!#3$7*) M7TRG@=Y=;.`|.[TOWXY);Q+;3\[CN;M@!+P4%*YV/C

<8JH"EY3CWW)5IE@0^L)@U@GX16O6Z2L'UH$!?JX0'J6MZ$45W*5VQ< MIO+HFK]Y#&4XE6*:9;:OM3QJ?72__LB$;.M$O(=MZ MQ"&;K)%9UOH>[,2"#L=5CPV#$MO0=!0?*

(A888B- !879JG/QY82(HBP@$@ 7=9N* M$BGD%^Y?1KB';IU5V=O9W$X2?J2EG;!BZEP,!W,DT9$N3GZE76'^(P:R_^GOZMSM!>@& M5R==/[G%Y[VAT??+I:YCBV_KH=W<>?

828 MA9#$6"-J'6F(=-9FHHE,C"L7?=&MD$,,1[VNG\=.+!-M8)9^3C*9RTQ.EK&U MNB-D!DYBA.1MKN6/.I368ZR:@3_69WON*DXFO+[B'@(14^^?2-7I.)ZL^[S4%0PO*:$H"&?,_((

MD7'D'GEQV3$*EA*T/C(:C<.;,TC.O.)9G33%<2NR?_I1U%+EJ;>NH OHDB6HP'XW\E\7 W1DV5\0M\NXRO?.G2Y%K&LCL'F(IS>#Z#) 9O:<[*Q M_#[(&KQT6%=I/.\ZO-WACYPY;?NH=@"Z?L39 M?#I.<\R+F[D_22&SCY_^7+>\U*I@0)GR)Q7/)*Y(:6$((PP5H5;JM*8=X\" M.KX1=GJ=3X92V !WH+]^^WXY^8&X@';QO8IJ#2Q+[P-

G$'CRM-!:%\G(2#$" M:XL>C$*VKDC?"N:518T4-2_A;^F'O8_D!NQGGGRPT60'WG$-*I=*5DOQ8$-& MFWAREMFGH,!._P-E<@U?7@@D,4)7HMLDFLQ=%Y)OW,JU;>

MWC((IQ173MJ/_C^L*?V4\S-YCR4_4W%93L)#':*P%D1@O MUMKCfP^;,,,Z(.}^\{//BD-!K@|:++6@O\+XLAJYOTVF_Z!_.Q^%Z$7(7 'W M<3$!QS{HJ$&CI?>UY.SQ:*HS=JSEE>6G(.4

F_B;R\7/8-Z\P%__KE_B2&NK MC2NUPBQ+\M-2@4JS@,Q<*5F'Q+!UA\]NR%X<$0=0V !Q]9LK&IS^-4ZX&>OG M\/=;O"*5S7\C*6]:!;T;5@0MP4=7KP?(XE;,& \%&Z22,&TWC';

(^]QM#R! MPD\1\7_TIO.?.*MUNQ]P.IVD/K+:]F/#A:0QUW8'&IQD 5*01>MMQZ:W

MQ/_B*'PRY0_0W;_3Z_C'Y.HO0HW+!GGK^%J&;V9C7S02A19P#JO:I)8A*AJ_J6(A7Q>GG1JW9CQ M9(M]<;_(TZ#5 #VL!UOX MUDN:Z1%3$QZRQ@E@R4

MB18\BQI$2Z.DP6822XGR7?QHAJ_?!%D?PT:G_(7WLR/\U'%N:?;1TZ3@%K7 MU;5=`$N:06#)@2F269^T+0)>6:%;\ZK*EA\A?!}=/)7"XBYK&-

MQZ@PWD?'3X6_)4ORS)P!G5,B;)=*!"&T*22&TZ_FW7>?#&|[%<:?'6W[Mj/;HA?6XM(@N)HZ50)GL!Y{\DA%_%PIH.0K1/F7T)A?"^=]RJ[.Z.P)0<)Z Q>=@^!DANJ]2\U] M#*9UQ?

1Q5WB&?!_8*3I? CW-UV59'C *V=(&@PRR+(N)S 8\$^0MU/YGM=VT MM(/$!XZQN"?TDAR!I<=_H?:@V#E5"^Y=41_=%N\T=I>WZ23OD'&R

TIKAUOG/A3YNULD00'D@,F0.*E#9 A9 M!4BRN"5T*?SIGT!H>7Z23O@$'&.R3PK+H2LP3*KB990V@JOSE$1(@F<7 ME'9GT!5C&!$\H?WOR5P3#4;!) ^7[=A?'2%C-

F0H:Z+PB&6@DM\5X!!F#8YX+ M&?B7U_F\WR9A^3P4[S!NY[B;+<4M"6H+-0&>Z6@55:YNC[/.L(2OD*117;^V"D:!H?ZZ)_1PTYR)QY1/'MUG1]9B5DO3CP: E9'UT\F1*

<#FMZ+2'K54+6BR9'J<790|=/A;^Y%($L9DC< M.U!@"D2!"CPRP7W.4.>CA^?.AK>]2LC.CK9]5#OT+,.?ABPRY@T3FLP:$RPH MDA($AE5 YLL'9:SW0:9B]==YZ&V4=1YU0'_?

=O4\)3"MR>B5$S@3WY.]O0H61T[&RF M;'1=U.OK<%*:G%/:R6.+_.?DDCIF6S-F&Y@SR%HX3-OW6=1$Z@-<5-W%LP[E=$ T4$;!0S2GR0=HI*!) M(+(^#@L6XUH39V L#Z "TQ"2$2

XV0Z^!)2L!?EQ+.WOB*H!?3?E!1#R$TB?? MODVN%KC>K.*M6>>@:GON)&N_#V%LW>)HY_322>F#R*SUW/&'*((OQ1RJF_NJ-M/DRP \3[JB!ZNT:$W-

LLB,&>&*RL#>"*]N",9SY(3(XW?[\?H'A.]MY'L$-$ MG[JC;)S'8?KC4[BQ8Q:]ERK;6*O(F76R-LE1&1Q7#HH)(3NO4M3-DPRV@7EV M[ET3[0\1@+F%4I-

U+LKG:;B&PA@O>)_%X1#99%#N1'PCA*(XP*),-E8X[8W5,^ITZ3@\%KB!82 M'R'"O0E6_7"*Z^S?+@ ',B%V@CN-!=%$E1WH<;@>!C@9@=@-E27@F-Y)*SA1Z M2T*NW?!JC@14788#Z?

A21_Q-^'_&LV>OO/]^_?K0XXJ3$) MVA;!6E%CK ;!9\A"^O/>1Q[<&&@MJL(#V(4POIHLX2UYDX7S Z0+M2'-AI5CT%1+U\E0H<()^PR13Y-$(MIE]G8W6]%0/FQ&(*?(:@A(<<22,.

MR4G&UG[GXXB> RT:RGR(W.@*:GFF_7(\'5]!63;H6\&\M;AFIW(2L)ZHB2%M[MY4;D$'RAO4USYH./->S2/'FE((CGP)-A--$P5[A:S'?VN+59l_.)'&(&5

WY21E,X*:#H['M\Y^R@IO);6L2['ZZO&O/7DSK?^OU MVD=KSA!RD.\5_X\F(99$2=O%XMKZ.UK$0F Q0&!>OH @IA@Z*WNOA M3YT%PTO\(47.0:]!N$IX>;G(^5Z

V84U2+)WA:/3S.3]*6N*03*57H M+!,\==D&>C[HVJ-C4#D_Y(0!3N[\;9:?U2/)BW]=T;>^CK^OEW) Z\4#'Q9, MKOU^.QTT!]\;] Q%@NSUHC#5?>2MI%@?

(PNQ*):9Z,^C[SXY^'UD?.H< -ET/KIY]Q;7_#(PPY6W MP'Q.H)RC==C(P8[$7FC-5+<&O/3)=]A!?IIEQH.'GF/4M)<6)RVDV?""ZR<@-MZZ3*#E#Z1$2[*O@4,<\#%,%)G0=

{<6#%8D+K5$]@I7'UCLQ#L-: 1RX%MR8R MUFDZ[#DH=$MLD'%'$5 &P8">:&DYQH,3R4'VS.;(HY92=/ #3A)W M/%BLVR*,/632,$]4<3QZCU_'Y:]7)FL

M4EX8I5@AV@S3__DR^>O?Z*.7;QA|=E7*)[449-13;W@SF?*)]HQHA<9LK+"/'M'8'GH,,M)]H@*NPCLL8'WSOR8<97U^,K+[39+TZ.U8XO,D_(5_"A.

((RTD!_M&$'3;F7)R;+H.YR"VS[_>$?B8=*>-!95P\-Q<4:O(W?>7.6M^#S:8E2D,X)P

MTFGA/]95KBFZW'WZ3+ZUS#;Y/I0NKS^?0<9K]QX/3.C$(C*TROZ"V,;?.]0PQ1O(RIOZ$#)X\OKVLKH$Z;K*3T,

M#YG;M>>3F@SD:K*1F&CS4_\|>^Z)6+-C0A>"4>;85WG15E#7R>SW7(LYR] MWO[8_&++>P$=''7F% M1H#4BQI/2_(PAC15=))6!E;PS++;5QY9S^C00XY/T_]RP,R'+ -

[E9F1WQK=T MP3=0 >:"'8N9.A$T@,U>0<BK\N)(Z<@@]+6,J76RZ;. GADKV@E_@*K" P_8-]\FUU?S4;#*)"$RV%BKFDAE

M$(W*H)T0NE@FK0KGY>TM@9\+TXY\]W%\16\]X=K>0I=2K?%\;4S7.6TB&9^_MP:NT>)D/'@;0YI-,W#?OO9I&=\SO)(/9N[M/O64?JDP_,POH'-9-]R"#R&" M"#K8P*.2H75!Z78T!P?

E[G_R\&:6V&EO0RR2G5GYH\@]JC!'!0RN^-97 M!ZB>N1',M>M8^'T3"#A?OJ6[.UKIQSHU9=GH.M26ULZ!60E]#"#F#CPKI!&>^_MA!0]SY!.}(W0W$\//6XUPMYBG[20

M6<.;I060Y<2[!2Z0M+(F1H@^U]G!9!0X)P4(&\DO=IIW^DF:9?R[C[T"2IO M;YDU?O,^3"?Y.LTOII]P^M2=3-UB_3M>S$W/ M?B9\,%B;=B<;V$VXO?K:?

H:9OCFRQ27T]+N05QQN@O(EE<078$=_X@^7(>3 M8RF@]4U&9[">,5M4B)\U9K1S97+Z,.E06$2IH^(<._5_/6^6/"DGX@D?>3> M^H@/TSB9WIQ<=,BQ6NIA YV

M%ZBWX$"K&L;.+"=.D(?_<9ZG ZY2_S]ZK[PT?#\XIXUDH]R.=H"~>-<,E/,2H@T>K RA MP*T"YUZ.G9\WG/3IR\R'F3P(.\'<1O171;/AQQ%81IX\G5N_5OP4X,/.8B" M&4-N7C&R

<JU8OUP7T'< ..-2,P5W@3C5B\%]fB)& M$R4<8Z-X)33QFAKH;_DW(,2G(!FKB>%@S(;7C1O/ZGT)"S9.5KPZ"3I(_O&

MEN!GTN7VX\VA9(+5X24J.@*6'3A>LPJ9YCD$2(7=0;1499@!]\D">*X"G_D%N<8^NXCT]:]-->9O(MDZ66G\5N< MJQ/&(FU9VBLZ4F2=8)@,,,<6T-I*$8N-J@XYKM%&Q<#K:

(!%:XH//(3@FYQ]&Z$\@Z.\ MI; ;SMIX!-::^1V #>;>;P%U*K> ^@>IVT^$ N0_BT6\#R$,R*:("(VOD0A/ M2$X+F!S1)$(?[CJ&\^ZWDCD%,X]TT4];CZ]Y#R$&W_<#9#O*!S.]23\#V2:?

01ZUK7?J_ MTV\Q>9_GX VD[JH(AF$S 30RZ!=2X?:5\=/A5'G9 =GQQ#U2*U5\0@72+7 MYNTGG,.^7-4S+HLLW_PKTC/QYLIA45'1$,ABE]}0.3 ,]E217GP) L2"A?D M*TA+?

E5KUO0!^'5(,YA.!CAM?K^:74_K;+:),K+./F'#\U\(9\FXFO((QA1B M>)"6&.X3Y((E$L>#=ZU)\SBB9\,2AH)OF!F^Z%SRTX)_K(=9_H)3PK:H!,_C M88=_S.[*\]E("98U<@Z^>%D!:P

M,'=QV>7]DOYFLJPNOQ-O^3C^\G61E7L1+U>[X.S/[R3"J_F'*/^Q,C[PGQF M)")>FV28DLG(F02Z;HA_ M?I]/2A4DHS,Q(%KM,%@=3_,(.QZ .6%\NHPE3QDE#O]KO7Y7Q.R"#1Y

M+8H!^ M%,9R:QC(3.Z.*IR!CXXD;90NEH0>E MA\N5V_XAC/,H.^.C[$-],.8AM=;6HF0/=(/%YB2XEU*MT^!_9?3QU#Z!BV,]!M\K.D%L-RQHW,B.[-]M M.]P!]C$OUR203V,'GB.+'C,/1$:

T$9F#_A*RA@Q%C#2+^])$_A8!%B5/(]< M/;_?2.QY.7>0?]_B=M!\XU;W'W$K\O;\06HM]>S\17.9NN6K#H5CO6TXC7^ M856&(%@",)(.(8H;N$IQHGMU*&4-!E

PHWG&OS<.F49+7FS(5KR)L[F MTY#FHQ"=SV3 U';^Y/&1K0)." 62;/JBF2GTGG1@0]_G'I\AYWX?/CV!G", M[C7JJ;G8%^7/%?*1T\5DISEXGVN,]!IZ)X\-1:;)H>6,N=9'WZ. CL>YX74Y

M\4&H1 YA./X-;"<#'N^OIM'9%4$FHHI@%'NK9[*V!+XL"+G-T1E?77:SDB:W$?Z T M8GARD"H&\!*WH/MC.>8P,(4'H M'EWV5$C#3C@[-(YD05.IV-8#6-

*BN20+3"O(,M5$X>BX.!)/7AX[>@F_<9N; MW\9TU:KKNGH>$^.,S'VAG:D%7G4.B3=@M36I1/K%>0?CM]]37TW?++.590VEN-M)/F+MK[UI8MK# 1+%@D0TN%D"

48Z"DE(LH+/[$^.,WGL>@7/<_6=(+4Z& M4<' [*A@8PF=.7#:,'Y5A8QQ'L"1#" 6+3T=HDG<[Y[5E!ZG-79/Q(^#E#" MH;L1VUVKRF0!CTXM+7P6) =[K0

F;AG*6KCFH\0VP'I9=%D3U4,8.!NA#=` MP0V+F0,OM2.-9&1AA>PA82H$T8:,ZAC\>%FLZ"7VQH;M?V(]XC"_^8M,KB\; M>F+?+-L;9S7/#(<+>ME3R",+'$H++

(H<:.!['W9YILM&D/[#5G-UD5@ZC$\'O M7';'YB,MLL(<.=1B.]++ KP)A;P[CW&>AK8 M!NZ -EJTR=7QSZ+>(V')9+$+#S;SB:]J=;,U)7 _A, ^14P/JJ'5K](IB=@_C

M8N^^OII_(/@1AXR&*42'?A:IP3*ZP5>20$LZRQS9L%T:C76^8&OO[^FXV\8 M?0U^@?P(X%5OF!&QGH7DR09T=6Q$=0H")T-0R_QM0AN"+9'E)RQ^I) ,%@S52]G?

22X;3%'N_X>R&<&E!']\9 MW;OOO#D++LKRIVH?N\ELH:!?:P7TK/8Y>S^>S4=..1>R<9 6DI,9^;%!LP!& M:YZ01:F0#TBTO8&_'K-[W(,/Q(NM5QMM>R)\1/]:ZR:]; A;;]-

P$]=#%^G9M_LI/_ R9=I^/%UG,+E M(K<2+(H?2S@#@^@"',P.@0HC&DN@B@1.Y6:!!@.OQ7]6]KVJEWTEK,#Y"6B6/=[*5ISH%P>Y 3ENS5%#14V&DO+1*!"M5*0ZY&%);8+C.1_

MH(2"YEQF7-?.D7BSDOU6XIVCJWY/L)MJ/&%YS?],?KSTTBZQ'B)&5P2-96M M5G8:0Z>@T4SX.B8T/+;[SS#]GR^3O_YMI8E++#;_.^<*O@V^<=S\MI*/C)05(

MH"KAC\G5G^M2'%3D0?&:]*Y,G2Z=R+,R@D,0.2]>_^/6-[;L[CS^*>OS4&DV MWH+_(_S79+KVDI9%?:5$KD/TP-'5S@.B3O!-ML8C...1CMG[W>_WVGL?/OE9

MV5P"'K;A35=%4TOS+LI/F-;-9CJ :FAL;05R?&/K4-U-AA)OXU=\.SC4RH8Z MQ(T?'HX2PF^W13VP'9Y%4V6^NGI_!$KZR@JJR/5Q@7*:R075^L6+\?Y[%,N MX%A-

V77)0\R9058*E2X86.DT5?'^!Q_W'&XD[$DK20U@7;Y;7-5PR/(.^.^.XM|M|JO?IS%]_3U6YC^]X*HP44F@R?3(++J)$0&/M&1E#%%2205FK4VN79A>C8'M]B!*&"'']_A#?&MW:(NV

;Z#&+KNPG:.:#2UN-[J1+ W4,$#7?B5-DYE6('90T M 92FKYQBD;9"E= &Z;-KG7UQ&KKL:)MR6K;TT<(+%F,9UUMI7_@:]*TL,I(MM[1_NBC(Q]4(P9@"DO.H M.%>

LWJLK(8W\;)H>E&('9M^[<_0B MN(5U-J;&?BK

Z3U(_M91BDK\E3B)8!9K748X9A#G.(,X MQ81'1)$BP2YJ/(R-T$0[A@,3RV -BX VU-UT?2#0=]8@/'QNE]+E!W08]DYG M.GC63($-5^#V'[.QN0R6#S9FH%,C&]*+@-JWU)=.)Ij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f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|^.)H=!D;.:\P]4G0!#!<%@S: -(3#'I.2!<@F+-/ MZ6KQFA,B]X5D3KTR]/+XL]26HZU68:[B_GVZ^OIZ7:X6CW+I?!'7<:K1PWVW# MP+82C"$'_M \@):)0/?&G03W=FO[VNOL)DCG*6LJO6GFFMSW);L.6F$,MVK=VIZ3+!19$1&6.899&$*#993Q'.(8U2G":8<(FEL&2?_:" M)IUN&;[K8M&]U(PTF^?/KZX[1VXF<7=Z=@MF[92]NC]9M]DK/TP[;G<):5YTH^Q.PZT[8L&.Q*TVZF$K]^?'__]@WXVT> M=S-+0DXG;[4W;.I#?'LO])A3->759-:4IQ' M>BL:;M?V+-FR"9T=#F]CY,2"":,3:.@/IQ=(;"T./|. \YFDLT5-BN MGS1X#,_%4'}>.LIR$@N5"B00%%&40*22"!*:,B@12B5FF8JE4ZF Yj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|==N:^#S]#F[6.X M>/*Z/ B/ZHBY [+OFPT8(;2%V28B*HI%A')(8VXZ9_(XEP(2*&>8X]5R(A3 MG6MW%D;;AFUMCA,5%X@6P^C8VX=,3|O#]B#IBP]

+T&OY>K|Z1%_,)(_ZM)C?Z\=+5>V7Z(I,,D5SG<*\C2*(&)Y M#)G6:,@435 1YTFNB5H>_'OD*W@^28=30+>LWIB-BF8,/-6<@:5F#:P:WHRK MS-?:E#S]GX5FT_Y@W.>AYK-]%-/A]*

,4O(&66"X M!2V[X$Z!-U>;$_N(QI7F9EC88^PY<@J0!$"R)XKBD]HHH98 $'7C,2&&=UL/ MR^5J\F&Z:HB\IF6J2Q)9K/]?RO6R9AJ/Z!\A59$I3<=REF>*";O&(!>'#[V! MW! T75;=]HXG\,A?,BZ7TG&_Z":@M5'HEZ//Z=1O=AQ_.;^MLWEBT%%4N%^@ M5A///#6T^>"Q>]_Y,K3C')S1/1%+I^GO"TS&"-&E(Q2F&0%-Z4%]/Y0\ARF M29*G(LGC(K;Z^F9%+;"Z-*

5WIYG(%7O3 -/54LF$OM9T7!3 MR8M$(31MHX]"FKC?IH^$_I!?K641<^QAZ0N:B!H8G$?+9PM\"T+.]"_O&&+EI MH84XA]T*;5[R5,G:G*\U;2:((MI'0%+A(=>*

*(FY9&VJA!+$6&.$HELTN&LZ 5 M?)^[7\.Y.9MU:D5A@YG=*967@\773N/A.525A[_Z8:Y7Y.GUZ/]>Z(\M5N6V?]_V3+(]R##$M,$2I$!"K MQ!1*3&,684&Y6]*6/>G_*M]MWEP?2=[P C;,.!YJV_J>=@=!"PWJV"%DTLK M9_?C<6<4?!V;VQ,>]SC=&9"#8W;W$899FI^UL2I-KRM9WLT_2Y.1RE=5]:0[M9>)Q$\%BF]N,083,!@G"20221@7O,*

O8Z+@R.UJU3F25JIRR>VH^AK#E,[MLDL=\(6S13D+GYT=\0+)(,M14;X;WLGRK\#X%3N8:-B&//G+&Q%]60BSI(;MU3#8"KJO#]S?&YC*

*(E=F@6Y{[W12#NNSSDG""10GC$(98P&14!&D{50*QC M*G]N5-OC',$0Y]+UN2K%%C=06K1S:2M(V>,.*2[G(+0S!#Z\<3S*W&+2=-7; MR2Z^[\+< M*RM7=5BDR:";$*1B)+,$%]80 XJY*L&)??MA9/0OK86 M=D3'W58X 7&PI7!|.VPVS^2%"YVM7K;-O^[UO)4FK^AN+B<\43G+HPSF*8GT MG@-C2)),_T\4J82Q+*,L2"Y/+U?7R^19UFQU.O?=@%7+F7;9'0(|_N;H?*

*#H M*LB[GJ@Z9X4TG'8Z"-Z #;/@[C]3$29IQ]NDC):R,WQR@N7K6('H*5NGG]9W MF:MC!<_03!V[P0?>I]/3Y6]TMI;_2%]NEQ4/Y6?)UTNS+6]BPB1&C$FB8*W MR! ED80L103F4:*

*(XD@F-W'1*VA -O$X9%D#%@[EZU5!YO.YF YV=0^P;$+;+?E MXR@6 3HXNDCIZX;9+8!_[A4XR:DAW^@+7+5%9&J#W# +38GF6>5VP'0\-/981KQ9Z>IORWN@N(++?21WP8QS^*

MJ0H|\T#LNY)W'ZG 5S;%_UV7IKS-_H69.[:BT[GIT+57-\ M87.J;"P4(6 R%SGI)%44$F>)%%.1!FRZD(Q#KO7.Q:F#;]';WHN6I![4\TT MX%VN]TM'#;A?H^2PT[C\#/F5H2C5Q

W8H!&#O#ZNYW90)=)@_P>'=,0\QT MN+NG%P'OZTKJ,":^R]/ORP =?(^U,]I#:C<_+N9EDRBO>7FM_S5]F!O^-EW% MFV/?

!$<"2"T1]Y0$"%10"82!ED7US#P.2V2.XB9,QDAPNP86/ Q3T'j%R.8> ,&A!9ROH?)5V M=A6\MYRS$ CEG1V%7"WK+//SVP.C#?/5M*J?]ZW]%Q/'F*ZFLGS[C<_60HIW*

M6B2S65S7G]=>DN7QJR7>@]8[14 ,%I:$IIR%3,*3>< B)(B@4QS!!:HR*\ MCE6"G)+Y?#$6.HK181-L^00MH|\!%:##JLF+;9DUYS;U2<\%/4:]S:#E^^]\5*

*MY14Q5C#FE+B'$#SCYROLM]'F6T,!=MZGE M_[QB4Z75=LF/:]#+"'>ID*Q(QRA*$9YSB,.12$H1$G,(&,LA3)+XUCD#"]U,#Y MJ5G>{I(?SE)IF'2X 0BDQE*XXC!**:)B"5.9,+=:BQ<--*

EE17" M061YRG'Q=^%X9F'H@8[:.!0]GCOT2N3K%.$XD7'//'H%/=CA]S\[@7DO_U/. MQ+O%TPZ/BY6G^AR93HRE4^+DLY^7B63WVBK:))10CR)FYI9@A @DG$H8D

*M12)7(LJ56U*W$_G0!Z1U@<"OFILJ05=3=[SX{(BF@X('P6B XM\ PPC4\$## MRDU53M%P4U5-:?@!%4,ADIH'0>'38M@3'}^2. -SU,*XCS*\@]!]TP%EDL1(-M**2=2![EA7:6TAABC*

*GD.:$4]3B3S"DDTQT\L-78=@P2!46#$F-@9PV&2N:F MZ[M-@?SV =KGWF/_G\W0H_?]V1?]6+ ^?@V?<%$?(Z>1-$RZO^WC5Z:WO]. ^T M/\T5(T7*85Z81K9<88B56$)*

<(ZPE!!%Rs:#>]F$AEIZ+8M[6K*H"}MHUCI M&>5KF#?)W51MD-#6BF&33>7U:P_^YGI;3JD2[G)DMY6M39F\BN9"82PPD)1E$ M>\3

<(L5T429Y2T>]VI^\?.GH,!F^'[(=]R+FO/JZ"^]I;78@/.K[0[(_KH^8 1?=ZVK M:RWM5K+*75(YAR1!>F,>H0(R2BD4::HP5P62*KWLMG677.B-^,$-XDLO#^^ M9;GO]@:!XS[fV*

5B)O666U[Y!O$Q^8/=(=XA=N5;Q,<$/W^/^.A; RNO.#7\ M-?U#[_]83'A$8Y$QLQ/@VM_(M#T@$L60]8REC'-.B%5-L8NX&PK^GN5F]HD*

M8/7'(F1Q\A9M.ZL2'$,%8M6[AA"]SWP!XW_@>+%?I-.[R\!WW%_^#Z;(N MXON#79 FQ,Z'M]F)Ff!V=^]/ E^:>CQ2WSW))'YHNY_KWKQ>F/P5?K>G,G+@D

*M$ZHBQ$@1P1@!!%%B*M%@PF!&>>*'-8*Z(LNHG=T49 AO1G;+'?S0\ 5HSI;VP MABMSA:=E"Y@CSP'91B//O9U1_LYGU,VD^ZS;L/-AM**!1C:P$0YTI /W?1_& ML+RFZTR-*

S\RGD248/S?],E-T-'OJ2]Q<$#" 964UZ$3E*]&F]VDN.-7[^O MS/7_T#0612ZH2J53$S#?RNX3$AT@U(.1=@M],2CXOUQP5P6NH M>C/X%4+1^X(=#S4?/#5R[OFF1)F9_U8FX!VR_-

F^CP5BV'(^UZQ8-3? RE;/3ZP6_/[YTAH=X7?6X[, ^'AZ16F Mf>5$,9YGBF.81I2:^T<%)+DV_!DV-1CCG$>)E 'P;*_6 \;Q%LBE3EKF6JW8+ZJJLKHL:I??YA2-IU-5R\?-11-3#^1*

M24[T2@TC3A5$440@+@,<9;E2Y$Y"""=6+&4>]=Z'PL;,U$6U6DXNSJURP-O. M0(VK#HO!.IZ!U8%UA[4,L&'.W"=HV0N.E^6.4KA4+0=>KIV]Y0Z,14+7@$%W -M/L=Z^\^UYF-

*KJ,N]@_;]5SIOSK5_DZ;X85L0>9*0.,]RI2#EIC='P@@DL2DB MGR8QSXDLN,(#$E"XG^<--::YA6**[C.9N\3KA"3S=1ORM5_!Z=>_V?AVH=?KFS_.<[!)DZ&MZ.PH?*

*3=R]B:$.>'!9V_H[Q: MZ_]W>O:BOXZD*1^*,>:IU&ZVPC(V&88(XEBO)BI+5:(D(G%LU>SM/*G_+G5U MU\U0!RWY&V 8-(8# ^\]K0^#JM]1^07"SK;WR#RA!>P8(^[*S_@ 95FIVV(?A*

*M5?L2>HK]@!ABMD*R=(-WBL90@M"F_K:1VR<6.Q)X\?I2/"E2 G-F"!N1-M*(:$%BG,M4\<)SA%%;4ZV#!#]_0Y?T-Y=Z_J4B3Z-$+G[90GN5W/&8^)/*A M]FG972IB>\%@:*

*ELI^EWK'A]5K#>$M>GWQZQIO59$?:+6)]_W-T(?:+3^?U2 MTE7EHS7?5Q0%+EK-"P#@W&5X9%9#E*8,H$AC3++)4BMBJA4-*

SJ8AN%F9/N@&FY:B8]C;E4G&'&1/;276R(GVB])B/HZ^-9C?ZF.X: MC-[GW"Q%N5Q-?]"?IH_KQ^9S26-"]79)8)PDQD$Q!>KU/@OR",=YGA{J4JM=_MU<'(@6U#0\M.60[%

*{C<&%PGC9@4:,AZ[6!]DON]\1&.4.9O1_]]>RQ%.MG!2C58W3#WB_]_A1KB81QVF$$@8SFNFU%!,,,>$Q3!@3E&@HV%TZ9K<3}Y]M>]5[)G=NW]5%-1444?@$%W-

*M.F@:]#!V1G9RUX?-9R"3>[Z"<2D3K8F?%YQ.TV&^,&)8_4UV8+'3!O\)2,^S[M=#7Y7/NSS+S26?=]BCL9J)7FK6$.<[/>SMH+]|OU%[W^/I=-558I*M=^ 0%!*
M)0.0N/8R!2&@@E>L*I6H:.YS@KI$8.13U*Z2Q-7BMU2#JM8NZJ7?#:60-LRQ M1 CJf2BN2=-G^O;9CMG;?QU,_N)K)S'B:T+MS/+JYR*/7*OEO?T^/_RL15W-MUG87,FA*Y=(4!-
JS%,1Y 2A%#.B'"%I00(B6$(0F+|V1&-CI'"%#BJF2-[T]9+ M1G5G7E"3YU%HL/A-EC+_354[O"#3*]8J8XIYXE,>PCI%?3DB-'_Z7!%!1'7*G2RU"O$1K[
MDJ?!5&EIWS2CTUS!PHZ^/WY,K[KZ#3:ES1), -E[^0P9'-&B0&=Z7SP9 HV/ M>%TX&]_/Q^VK]C4V%M[^-^&27>7RH3I&X.Y.:[?/BP'U5>%)H4N"H +G$.H!+6 M:D51
B3L3EMP61D25-%YG>3X06[-P$U6L[?CUH5,6#@NX"_,ET/9+M<:[$4#MP#R"9LCMR@>R.+-WYMX2Z(DK9PW#0+-,-+
MI$8VQ$N]@E%GWQZ^5EF&C6$66BL!I+T2XYR$NXA],(]D_TG8H\GPOLF&UBA MO^B%^F6U_L(7!P!_6:"2&D1 @2D#D$$.F"0Y*$DN6*4PR0NON+]7RL@&W-#-_M_K*[WG>D?
3#\ ]34;fO)A \SVPGDlF_%3")_7%/F.3VD:<^*E1/H^;E9R=E KM:S*?K=Y_]'8Z?Z.${GBWF]]'=F#^9@3PUFOMTA17_1]W7)^M?5 1S'%1?N
MX*MR4R$H0WK9X6=27W,,E(;G(R#V'>,,3;W++>NCDH22+YQ?Z3+]D8?XVT0IDOWZM8>Y'011+]\-D M0Y62,#7QE*:4BCP=W)3TI;,WV#OR<[4K:BQ)B:J\K("N!)0"P%$53# (3:8
M\]HD)G#F2BPK(<8>-7_ETVIK%V#.%UE=G>5]J0[41VNT/U9W(:G)65D"!9E3 M-RN H$H!5C'"<,6K' ;A$4VA[(C-KBZQ>@G]^NU.4V@M;#*K]%]ZZ7=,1$,
MSJIF>OR"8S9>*WK!664-P"XX_[!1-X^[!3>]!A03SS@V6E:LLKL&-@ Z[":A M2@D01B62#!N.@T (!O RLD^KR76;$$9S:2=*3N[5AJAN;,?6Z'F4%H0$&IK>
MOYUP\E!=W"65#?!N/U^9N#CA<+5%D"ND- ,(U ;$;R@&3-CPVAI9&YOA0Q&2; MN$YRPKS#CIGC2_C^AL!81?KYK+3J"7-.5HI3CGW"'YVV(_17@79^0 MZB3]_M-
=BUUHPQIA2HP!+QD#$&M[--,D!!R7)2LT)ASQH.;EW9M'MGA+)[!G M>2^RG]%&"1)FFY;$=?3)\%[EYXRG:E3>OW?:+N7GXIRT*)I\(/R^\1F*S&?M M[B]W^,VNV'I_P80(X0RY'CW,-
("%08!"R@#!BI20#,/U>O{@<16MAAGL"J[5GHD5_K^OS8VXV M_17E?],YBL+B;CZ]%)?F^C18ZIZK4?]W3795&BQ>]^HT_.&($@ZKQ<(%,.VN M2\NV3TZ8G7T'%"@\$SXZUYM
M@$AAOFLO303P]7.Q JHMXL6+]537%RVLL.(_WWE%,^>F*ZC6K1Z43%SR M$B;L)50 =ZS9_GB_M+ZF7N%-QBCG]+HTO6[R_CZNZ'UD_1 +AA!+EU%VL]F>^U7N<
MIUF.A+3<&6"/,<3&95@"GN@V@AMO)< M0&]S>;/OY\MZ'Q9\X6!D!\&0G>2;D2NF82E Z?Z %4)VXZ$2&$@]7D A12':-M;\;I>>4Z-<@6/CW8B>>][?"/O#?
\BOAEP%X#:R.%P"_M&3SB6N+,,B=R!CYP0EGC")9P*JG@*D5X7?/&$BQ@:,:3PE;X-Q^6Z7 M-G98R7]\6RWI\YN&QWW& >;Y)KRH !&$V8T40R#PO.*YRJ';]'@FL(@)Z7L.D!_K)
MOA1 GI@#Q_)Z/-24-;M]IU#JZ3)H#00"4-!D)CZSBDI$"HG +# M#!*MA*PR94CJYPJ]\=-!5;;G8&<+-0\16:)KNO/+'"742)'VJ5<9D4FF:UH)
M2SPEU$YT,BKN*Q.ZMI;)LUE>8KT/+_E^UBXRSN*I);JWG M^M*8>83D/>8>\K;)S#Y"O*]YQSP>CF3YU_ER_O0E#TT.Y(!&M"E= :,@?O 9D"-M7%8&4 R%8<)P6%%?";NC-
X\C]A9F18GVW$3TX8T MWGI=#WI>?!7"G$M$X]) ^R3I3D>R2'5CW[&V:,,G_Z)77[]X$.T%ES HNAM5 MO3UQX#AT)XL81U5;-[8.NSK_&42\T@6G@"$1 "QT"3CE
M!)#2""%C)PBCH%;2&$AYY?_3I<0@%Q-5J>=5\@B*"MO"ANDH_(U4.!4EZ_^ M9*>]P 4QLDE8^CS&]=QM3>6=T_;S9:7)2.]@YX-A;*@.0%:%1+,/> VG^# M@K&**5[DD-
$)2[7"N/__8S56X/H2I:4H"@XXMTL+B0,LY]+8788PP5&.*VDF M*[@:>W7_T#55@0OKN==>]OJ4*VRH35$;M:Y\ZPKRF:>QIE^"E*YL"N?YC%"_% M+46R^J1(\NS10X?[
LJFQ!Q4"76LJ0:6- M'@3QSOB=(S#R@:0FF>UI^B=WSBKC>CIM{B! O%8NH@K_K-B^]>@AHH;ET'R M7=2@==$^?*#W9FK,/399LZ6.ZFROI_5S<&>6MXVZY;=(FG^>;?
S2G<)+K%FI M[1E"""\ o).0 1R6% C*H0_44_F;'3_VBF:,,[NXH"._Z&VXY&'-)$+ H MX"!H7Z9$T _BUW1OLIHR6!@:6T8H&L]O^SWWZDELS=/B5LK5 MTW*
!F=&R,*1"HH;6!I"6.> &NYV3&<1RK7$N H$<+Q(;^?3{4UN> ^Z?L<<=$ M#36E?W_4TB7-Y5JK^39;K#;>T%-.O1SF:DT$^;]=A3<, T]_^[.9S?9VT81 M#G, _>_>
[^XK:+>BSM@>8#5|&)%+6 :-M.NE-G;. M?#=]Y%='+';NY%DU>09%]80/#'\Y8X?.]DG3^])DV=IOB^VA5_\M7Z[_V-C@]L&YAOG1C'-B#U:ZKLA#B "FJ0;2(^XJ+N5_@Q+7 M?<1&-
N -/^4]J}$BE67B)KM?VPTJ$#Z^3U5^5IQ* 6%&7,M>@S[^7,O^YU[9-MPR'=/81*A=G>1VI:4'8/H4|0UWV>&7U^Q)|M)+OFB|NENE4/\^5\4^?8O^LV M6)MQ7%4*0@1X(4H %9*
X<+5PRV$#9YR;WZX=.S-OH>OUC4A^_[AHVZ"!4? M,5+'_^Y:3T>9.7%L<3S?S(BH/-]N=;R,;VV;.R,E})2E#"W)R!DN VGZM)3A0 F MRA445559T-E2WS=3Z;P=
[^5Z7K;+&ML]H>1_RU9C]LW==/3 F\5+:O*\5!PB M==Q|8BUIEV1ZOW--]E0WB)?(3'MY>$78DWO#:Y^/L]=W?.VNM#:?]+K.G1X& M]$A>%"4D)$!(*0 Y1H
510$]7I:ZHD0@&&80I=I'2R)'-CNZAACO,5"]KR,]6 MD\@=9]QD]D2W-YOHE^W6403)794MDLI?I3&]S5\5];K37'XC,/3Z)C?[GDSU(.MO?MN_VC+-$LDB,9: U45=HO-
80FX(!"@=%6F8$]S"=!PSI-4QCZ'(&EF-=']M9.-9O7@F&8=*&YAB5*EX5A\2V/:M&*?F"?IQ-X/1XYL6LK5@]X- M6FX:B9^LV>]#\;#? ,_AF+FLG,%.4%
(Q7$&^AF;53N[U2;C=:BIA!"%LAGG0 M8*=O;9NRU!P^Z/;S'+YL%IF&P=VV,PUEWM>L]6>V9M,,%Z3]%^% M+@WBAADC*B"PI *A %5N0 5<84T)2DAH6%5D",N3E1=Y$?=7-
3^89?(SYN/-MJ/8P/|\PDOWD6/E3H](#-X<,CU6I"]9JCI]0+>'8L3A=I!I.%DA]VA%F<:HY M&706^9K7-M6C1K#>O%]^JHOO/ 8X%!661A6@@.Z,]{T!#+,2%!A#&XL: HNP
M6^[7(MG(>V1-4*M7/K8A]-O@&6>_%GY?=66DYP"'1F2'A-0(_=]ICD/D=T8QUB8R<[,!:WKNRA/?U+(F:H9EBAE142""HR &D6 !:.M20V8*+A1I=&T'"HY.4-
CY(WM0*F^]5S5+BNF]>J<>OSVEX%"AWGZ0W5)AUS" MD0N794DU7>$,A6D'*5P6\6I1F0L'(R/HI;LYY6.LCDC3-NP%2%0"L8!)(8 M+@D"1JF*84,PKI*BV>[;)ZO1:,B%5FD>*
<(SD(L5+S"8\I8I,/8Y)T&]^.'H MW=/NX>?$.ME'SWXH11VE,]&9-1?*JA*'2I8.0&;W,ZZ*<BDF.QQ7G'M-8S[M,HF1#3<;/ B !$P4]) M"A$L;1"YVO%G^6=11)D?'M:WE_*K^Z1S-
24#RW\B\/,I#!#/*|H/UL<+!'Z8 M.;;=E#$YAB5*EX>9[&!;9$^95?^S _<+1USK?V;=^\>K_BT73 MY;^Y?5BMM_ _U2:?7MHSG/S5?_V'*_%#.<,U5A6H#*&;MQ0E580[;A*&-
&82.X MRLN@"N0X-L:NR=EU#I]G[=-;9[S#R4WVPS*1&?MLL)7'*-S;#8RLQF_8?D! M-4/9@:,&V>,FVROX]DBSCJ_LES[-QKB3 8I)YV]BF)C:(0U0U!F/-+1MX6"
M,_[^X2H;,,@"@D*46I>$0P*]>IN?O7=DI_-FOG(E M'T\;5V[_'_Z0>%W)^'YW% 'G"K(_-WS-+)0+>KRN+/ZI?I$QQ8'Z-;&DP_XP MW@/=U_WT9(A]9UCL
O6=^W6X\?6WXJ@IEZ*72=E^SW0G.JBU!CH7";,<505 MX+F@H^QHH7(.RU)7VON(S2R>1^3SG:T_6VC5TG7#3^5Z&&>X(++A!I=&;ZA5WQ_M7X%*#7':(_1+$.1-?
$3K<2^]CT_F;WR$Z#H@K\^G)D\|VZRT^:BW=^8K__V3 M7O\|!7SS9D+;I N,"EZ3@!9 UO@+'"!M"J0D 96%8YU5"KH/SB %Y&|FLA|91] MS_?S>CW5,#Q"Q5[8NC%1$LF5 9@S
^5I5@-1< 7R*B]SI\V"! \IL!QMY28I MMGS]Z^=W6IYH3<*VRC.5F,>[;?UW?6^1]>NV(7W61N@>WOK1A- 68KR;@5 MG%Z'%6;,XR3%Z5LC%)9?
Y5GW"LC#MZ[8^OM4ATJ2^VIX.ZWI5ZW\1DK">,Z M)P!6$@-H* ;,8&GW1,JIR0FQWM;[1.Y!<+*CNK/$3KVT._76; 0<>7WTYW&N M3ZR5P/_7B&W%Q02DPSPT4Q
EB"QAB+3!U^U35TF-"LQ*)00-:CAZO2>CN8&U!(K!B66D(2U_\MG,#<(+FY'+G/THI#53C3B%%I-D3/;.06)&!P379(C4.!S\O0)HY=+PCT/22V^
M;LB)W(8O+KBO!Y>GM;X5#B!$^H)\|;QA],C>4LT.9.T7KB6<|$OG(5!20/L\ M1!<(I'M%/A\H|S\R#%YFM4/1;TCMT%.$0%)K7(&*4F7#8%$)]H2$ 9UP3$D
M@@\|F3E/U>M[G0AJ1N]`9> M#\>>^HX+R#[J[;O?6PC)/Z]6ZK?Y8C$3%!:Z8AAH132 !MUHB-OOIVRR:9%\29;]HQ%B]>=[]$YK49"S]#'-:3MY=9/>Q:R'0\) MP^P0D9.=]SU(3GS
]E?"Z4D[X-GH*3^^#%R@:<$;[T2&)XL-LCF;!P$B3,/VR*H&#P^^\@?XNZ)EK#D'N#U[0R8:XQ8E;B+Q^FTE?2>XS1 MF7Z!*Y&I%N+\[/7X)?8:YY-X627N\]
[;"9M7QF>_5W,,TG2!"7/4^NP)]6>C-1DB?G4RNFF\9. ,Q*635N2^FYWCUDC GS6#B-G MJZ\;QP5"G6/N\&R$(0 RNT?9_QN $6>,2IC3G 0AM7F1'3OG43-QDQTNV!<-
M"L5ZQTD+Q!$.A>.I5K^S0GIE!:9!6CWM.=BA=>R9:'Z0&$HG3.Q4^'|^1*>% MC M2Q F*7-C3T5>U_@K%YY_M"(V_YA)G@LHK *4U'" .<*
M464=28s1AM)4A2X";U2NT1S9@5A'O78=,O.6D^"KE*LZ\[Y)2:F)X(N4FGC6 M4D]Z6^(K5KK+D]L4I[XK\57?!F:L2[T9@>A M;K)F)"'"&6DOK?]4,]A>3(Y19[R]|'*=S)![<88FGE+2DO]
[(\]2[;#,O][<MC|!]KM=ROG%;^,>GNN'3$$,K:B @>5X "#$$G)4:J(+B F%!!\;U=2,C[S7 M=>C57;2M0W0 C5H@&\R<_+U]-O67N.JQ>]BD5-"]G-.&FGJ==Y#_VU7]8_=
MYK>7R6Z-M52O8/Y'Y#]\'B/4+;_&-,[(A?EMW;^U%N3I='9NG%<\+KBP+G OU454EU^=9%DMVJLKE3E\85Y+O4S4UR T5?8:OP&O ML"[G9"W^:,,4Y'|
[_FU7HG"S)|&4ZA^[9XOYLMFR+8?N{O5&_O-I MO]DX#>QX"GOI>#YFCXC98>2FK5KN,')3.YO_LYK;X/KO4RIDK5WEP4,3D8_1 M'16GH$2&'TA\4MN-
4\QS\XM2WBUF[/"._-VK:U!_\)E/3[@B5+OS >]=8'1 M[M=W3]O-UG[/K$7/2(4HX:P$1#+A,+1S(+3"0&LLJfQBN?1+V<>S,'8U@=MJ M5R;3-=W,M'S=9,N:,_>K#W=O-
]G]P)%_=56D?T]^7M8VORL!:.Z?%.Y,U)+-? M]EILF'* ;MGJ?.IN0I7ZEZ>-K]JX8K315!Q4>#9,.SUE9I$OGJRH;)C@W1*R M@6*=_UM!N/;N-%.G_5^7I'+MF]FE<$2]8(#+ @$$',"F*08*
(TY4NL2A* MP&BN$O2RE,$X-/6\L/6!=*8=;?\WTZ^SZPYZN JB / N\6H]0*V!#N?Z*C&9 M!OSI:3)-Q)+G>
(T$^44O*7O<7_ SDWDY+S&ZSLSQ@=>:_ SJ*3$/TR6L>'ZOUF&\6@IIL\N'I./VVC<9G5G'!'"%0P9N*U@V7U8+ M],-^7&LYW^=E.C/+9@4L(:.R!(K8,@)*GI=8EI)@'32'.XJ+L3>!
M#N4Z]=@=@1CFY^.4[.>U1U==F !VI-QD){]H!=%=L+,,=)'LBUQG'PZ2.<)"-MGKNU82^+&*[09HDI*>%/VG[WI&'H7M^9NEAA4W>9&;U>NWJ$K^NGS5;KF0%8 M%D96 *$2
:BL?Z*$0E!64AA2MU= -5UX,J=JAN^L@YCV==5J4GZS0:. M?!A"PY'S($;3=-BXB*$;ZILA$?WNZ09++#!?_,-K$X)>%,11*SV'Q=S=_GRQ1XR%_K]\K^T=,9Z=_MIO5)/A#:",
<5"56%>*40(0Y Q :DK E:1 8]9*(MUC=]D^2I/T9]GIGP?F[A9\A<^7_^=+YX<5-+30|-%WF^^<_SAZ>'6<4,-ZBL ,H+&V1.R0 OM/4BIN+IYJSKYJ
M^6TY_^=3@U4OB2HV1CD0N;O\,%K9$SLI@9"P9!5!!6->P*S]9$;V^?NBV>WC MXWK%Y,?Z,G'/0N10UK,*W/4P]40YE:'-B!B9FN?@.DFMYXE,O\UCY!3Z>X
M]GXZ//5V5.C17^=1HWX)7GN0T*\Z+$ &*F 3?$ "Q5+G-+"66[4OG#9 M(8U<3\L-8LC+)X5-N_9\C:&9K{D;K#F#A'*/_4T3.??TW;CJS!!6=SU]KB; MK%&T]^S.Q(KV3_Q-
!O"X;.#HB@!^%R15D\;<=C)TLL)E%#-]N0YH779>K MAC6$1\,^WZY1TU]RQ_GUL/N>X)Y!17)(0;$5!) A"O W+26LD!8F(I 34,'-MM7X^]#F(?/O:!>2,;+!LP"(WT^+]6&EQR
+]K^#R;%_M^D6/X=@L;#?8\9#]-MM./B3TYU!Z3DEI.QAK,'*B!=@:,OX:EKE ,51XQZ#^4C)C:-&1/!?:7X M;C?OMIE:\D?+V_9'9Q_Y)'5=/=P'6IE&Y7YN:!0-QO=.K\XT]H[Q4HGO5V*5
MD JU/93\M/CMD2[=]69EU6UI@ MC%"BDA(@0]SQF>2 ::Q!SJ!A#$]$5-!L"$^Z8U>T-%QD>S:R/1]UPCS[ZIYSY%>48'7%XZNE[7GZW"9Z]JL!3ZK39O;#5'&2F]\//%0 M73>?
\^>5FT8Q*P6IN+0NI*A*&^&4 @(!*P4HS\&"]-(]#!*U]: Y>N'!Q?EQ M#^2U48W4]6O1S'8EU$QBGQ*LEW6#=4"'"JS;H?@Z!NN>]L!]L.O6)&!PTU0Z929U1^97_?
OVC17G'S-A*L2Q#2Q.Z?P#J2K &)8@)U6N-13V M]S HSO F/7:HT3+B80?=2)D.+X$AAK]"/..,4=04&&CT:ZAM/;\<)UG-2L10 M(UC^5-&&/^%I
XY@A9S$'.%O",]@>;?'0AG#67_UI:+"NKW"ZG$ M#O, ,1(']:Q<$RF]]^7B2R?K@:DF5K<7YNIG(Z]5'A[Y?-V ^SP?==E,P5RX M6'#&N#%4(VN-52$ - 4$5*L"5)4QJ*1%
(20^NE/OHSNRJ\ZX<)O7_##[M;E4 M";Q#\52EYP5*>@4%WIX,,7-SNW-R$]R9AZ-/&D.NV-29@]3Y+ A^/
M155Y>)AO'14'DO"VO@B^UTMIHX4#W,LAK#7$[O!YK@'B@@-8$@18C@30E4%2-M)3-PZU2?H:<=4[Z?C][[5\LO6?HW;NZ%2&]P%8]#4,@>0$0A$GBM0
M,2(@*0LD1%";.(3"!#N8;/O5!,,WK&-=^.|)T1*&;SL[X4;X]KHH2<*=X_C] MDV\.9\4[Y_/?S!BGL'*#4W8[2!['.V?[=W.] .\+7N2_FV6MC7?>"_;9[F MV\V,4504O(*@1&X
,6+VU&]@0T\2@2VS_;1#WRB%,C"RC7]RX:Y*N& MC6S1\4aS^MQ^CYG[IGD]TH3=;]>"5/3M]3/V5 XW>:[+-#4_9A&DT&C*T86:.\
M0PM&T&S8O((!:NF;5A#$VNEF%0P0^FA2P9#W#.@P_]2>2SMQ^CN***YCF04', MB8V=6%Y1 #FAE<("ELS+69^^>II0:5-'$RZN=(4UCX[P33W75]T6"[[>.(3"
MQCO'C+AM=.1Y%Q@E>>>!=GZ.1U402]R(?,9ZR6[AY\?3]O$<"G>VX/?Y$;,.U. M"P51QUL-VMSMT_;;;NVF:L^TEH42"@,"B0V%BH(42$.]."446*D,(%E.WWD
M1K:X/?&ZX$VV<)\|\ST#\0.DK>O2SP'3;":/*@^*-(I,20/M%/6[/C(F*Q< MIY?8O)4ZH^2%NEX/36T/N<,"N7FS8 ,0]H9& P3]E)4(A&@)H8($B% 44E M-]8G0$K"IM,;C!AKX)
MPJS6F;;JWO[('NV3F.A0QE/-GDXIN?("75&MG(:!K.&@K2S:13FN6>]WYA,) ML@EQ6Z1 @5 -L3$(!&$L <=$CIP(!H MB7G.@I#E3DF,["\^'+4+QO=2!MW%%#),R,!M[W ^9_CKFLC
C]#6^Q(7.90^[M>A,'7VO.?UZO?MM\<;!A?,.IA5TIH=,:,.'5+N?"&!H&4)**E, M182NC/*]$KQ"9V3;YI6SMJ2SAG;6$@^NX3VKJ7Z#3"A_F%5&BAY3S-LGV)Z
MWK/OG;JDMT^X,U6]O1^/W13W5?M[E+Y# <2LSJT[K%51N0VRQ HP**[2_+< M!MN4E5#/MM?QM/S(!1EL.%I6#; U /WDBJ\|-|4&@C=2#NXS!U@T0/ME^NJ
MCX$)M=>8A/OM3Z"G^Z]7D_%(@#X@N+0 5%<*Y(8B*:O"%,1KBLI%"M.$@"W1K*:.6;*AP=]SO?B&0.DC0KX M_ 6-"/4N"#,@R'O^QHG#NPL"G09VES8X87@CWUE43B-
6Z+LCH(#-_=K 0KL[Z M3BSF|\VPW+\]6]:7VQ:H>2:4A +]'%0PSVVHQRG<L,A!82T2<@592;SPD8>Q M,7HU1H>QC!\XN\F>&CZRQX:1@&*N 4KO- 3I5!GF#8ZU>-O58L-
69OG*.HS= M9"UK.X3[293K7R\WC9+CJN9&5'90\=QP'?64T UX^62%=,,5T"VG2_"VB#KI MPTGC+WJA?EFMQ_"%_KBRKUYO[\P1<.O;I_7:61%'!%OO3T".*PU@H22@LI*@
MU*)"6I-"5=Y#@R/KCYY /R!0?+1,LU1=LEH4 $.T8I5[W^.R.K<CIYD#EN@-42 M-<%JZR2Q'F6.1+N)]N _<G6N*@.JHL=5:611]#B]#:N+CE=,7UETQ%NGJX]. M%_FH"K :X86<[U??
K>O6ZU_M"[^A@P$.16$]Q(H[.HC>*X!EX6+[!G".B^-_M*(*@&'P)3UB\M6!?9Y##B"S<1Z3O+*NHJIXA43[_= 6 M+A8$VR74).LZJ8;F36;?XCG_[}2KH=H0T4--/)&RK<=*;\.ES)PIO
.0?, M#PZ0.GQ>| 61KLT&?O{8M'. +S!],O/WTN^0X_MZ,@\D0IXA48 V!U*=%<8A3S0F\0^1KPO?9OWU1+]':RKJ< MYWDI$
$8"0:@9A+0TOZ3Y,9H!'5I &,8GGGWR+OKW_[CRW_X;S+/Y;Z^BPZ0 M)LR\G2#9[G;Y.B^A5[6>.DC MKV .MIN]=; ,7VUL*]QTR'JP:CS93TI%N4"\$@960"]D 318 E$P#]C,*T-*
MIF&N7FP2=B_K8U_$M[3;+HFZOSK[OF?D)GMHV'C!F=C]*^N9:GB5ZQ5XCAEO M+O;^6W 0:3<8^\KRO^Q@;*^5>(VCL?L9_^,.Q_9;D%"8_MQ$++=A->-!| [[?.@-2*6L)M[
M<%,WRFWK4YS>53ZXR99ZF_UD&NZRA6,OM(&N3XU^[CR1%&_^6W3ZX2L!_U=_H=$[40_Y$7]^/TJ1NRD/D MYW[%YY$!G;8-8L_F7=U4^G&U[90>'VY"4,419*BR,2=3 .8:
DXJ#H@P&B+K M(1 +PN/UICQVZKC#0[_&RT+\K_;M[(9EHO3?H&>F/H)4-[PMB-EB|E MZZP7W>F[9T/4<;,!-N@%]<8KVUW"C?'%>%9SB**NSVT:>EN<-M0VNNT4
YXQ17(>:5Y;HJJ*(-.06>IC)T2 M:_;O/=`(>87G%>3G80:+'16Q!$@<[!IZ)4ID^>>=I3&K8O6(^M]O^#Z? *_S$ MUW?K+UMW$JWS))_TNLZDS+"K3,:0 9WK D"98R
(5*#D$]M<&6NO93QNX26R MHR!.,Q(] 7A#]\HA_V\.K3<;[DS7]N[O6"%5\>4'ID+KD&DJ@*0$4+ MP)6F05(s8,J9$\E(5[C.8&Q+XTB&&?^)+OS,?(B$80;=4*HE
M&P'LYY(W\KM_!N=KB6>X+'7!86F=7E$"R$H)64ID$@3]B"CA%9!H]V&<#.R M>_RHMVFT_&5N!:/5CJN.[[G*0*;Z5?6K/6N!8^,&K8F?PYA,TV&NQ:&5!?AR
MA7$,=:R^?)/V9Z[[,#>37:AC2'A!+L4BDHU[6X0+|-.QDNAMI>DE>&N7.8S,\S8U. MS9SK=MQS%^9+1U\V/W?[FA8CS"/??GK_]N9\?7(7G6= _G^T@1=ZN-
NZ\O&'>2H^)'/;H[$[JTZ=2_G.W/QG=R)1[.R?$$A;S94UW/SIP;_^VL=O5^GEY MJ,;M-_?7[\O;!W?K?VBU6WKG\;3@/<4Y=_OVCQIHC5S]C7+-$?/T^E8L\$)K M-QBK(\'-80KN-
COBJ!M!V*/<8:4,2>I)&!<=>O=D?PR5 97TAJ:>ZAYN(ZVFO-MJZ9=BI-;PXG)CXM]'WGU@R^V/VSP(UUW]:W^:K]Z&U=_?6WU0Q)1B%.PH M70ZO,A"PPE2
50Q6E1LYC+RVG:14T^[19C#VSV=>768QOD';3+15 O5[JB<7M]7MV|#"%+|_T8K$;%,5+3%6A/DB\B,$)YZ08,#7A MZ'43CTPX)KIO(2SGXHUH_=+N5H_KH M*X^?>MBU?
6/MRNE9\A4E2@+!0AG M-A2$5 !1R1QHC%!!<@$U\0H%/>E-8VA'+-PTQ=)9G;2N& MF;H'CE D?EF85#4+IP2F+42X*.!)=<'E3\8B3E@#KM%(74/GC'"A)"\H4+"J M@#UX%(
50H*JTD902"H%@_JWCE_LJ7MB;4 VX&-E<]4X6=H\0*&&9F_;!'0 M#^=$2(;OZLWVW<-NH"K@9SE3!DI"@$8YQQ M3@P0.%2893<$IA8A""BR*>(@Q<_E@D-E-H.NNVOFKMV"F?
8OZS\Y_T M4OYH>^41S9%W&NO;<@8@SG/-2X,!ECI716YDKL(@U:L3!-X2S/>5(? $?-M#?H9;F*]A!ERI$K'(=/\A4P%G>9!<5H(-7\5G=]!3P:YA VZ^VL/ICJ]2-?M;W\Y _ZJO?
Y9E;HB"2(%"Z 1NPP@300E; $$5$498"*R_@[TL$1C]-'DAF MCF;VJZ/[:>07M=)OT2ED#3U4!HKL;C79.FS4OMLQT+MOP[6>?&UDYCB-;%V M=G?U<^&W_$=(_>^7%%
<:^8O6&_MQUR&D9HIA5N5V M-\;4"7ONS#F@#NHT9T)6E2$5\KLM2<70R$9\1#&+)F^^\W});08YAZ>
M3]_;,WBAV>8F.U;YXS+,L3FO[OWOYI=>@[AK>6G6(N@^/]7B>]BDY"9[!8^ M15*Z%_!)WQL3Y"TW]\5;_7#ICVD4)PK6?(*8(0(@,8@0)FH2XTHS M3@KC'^B=)S)ZL-X%3 M#&-
C[/M^2PVLGK8.DR8 KF:@:I-&>P,4-G:,5VO7\K9K_YM&NZ$/G(P6Y(MPN:7I^W36G=`6+07 "U>R.U2_6*2^_(DI=:.W5\LNWSQGYJO#[,LH:)2"EP M8EQA""9VY^!% 1
A10'MSE&](%R/D?D=>6-IN T'5GN,T7R1U?:\<7@]:QBVUTVX?#%%#8:90:KK!,]-R. .5PFBE4?V; M521DPRN$W]IO^^U:\[]&57*2YUCF !>: 5AI!;BF".1$2U24!C* KK#G+Q[[
M4.\LUM$*+.LIDKW?'PZ1*/"X!B=,4"WN.TY[KMEM&=_'PGR M>!B[L+_W89)*\(&,PERS%SV"W/ H"%G.D5*K'(D2%!X=)G4V.,2(O9E@=F@?TPC&V!^O"I0(QO$OH6BS#]P*?0!I>?
R(\55:C MP303HC[85]^W'=R;[6;&"T)%KCE0U%HLU#2W9LLK(!",2&TD+0*@"#MI^,U M%1Z,0MJAGRWV#&32<>"?I>G1V?4GBSK5U3*2/&B07*#]L6,/2R(LU@C5GU\
,)6QL[)|ZHP.%B)5$2B"":4 M^J1A3:1]GLF%0KA-]3 ZP=>#@E8)EG:@H'OC]|%6Q MP^^:R?6?W-SZVZ5Z]_]U|ZX];N18FO#W_14$9C%O%9"0.L$#ZUFO
M;7M=V=V8MSX(0BUK92R);7+GE^_9%RD4$H*D10CTKU]4JG(W@NC'-X2)$S MG*YK?7W:>;,89^'"MM5PO=ZJK^1C>NM9$7O+G>F;UDSQ|-[VTF[W$"80EV4.
M!>48FD(20TU6L+R8;5=;OO#S:A/P'.0%=YQ[&W8G0=U?5G?LUW\RC0!@X238 MW(#[]6H3"& _Q9SZ>=.?;*;"O&_'_ VHV;^1H^?MP62U,H!:B :I":X,M\(T MUULW0-
2B@)XLH"],TV"X)T[*MH&3Z3Y9S\'Q.9ZX8>%D4W#<[7 ZT@FVXW79 M_]S,93URF\)N.8F5QA*SAC$@BI(2Y7#O!09EHH4F-+H#?@IBB/'OH<[3'#(M061)XV4M1FS#K]7-
-1OO8+5$G6,K?5)>B^WF1X2?W#[//AB+$+.TD'7 M-?'ME_GF[Z]^O~)'#K_]>%_*9JG"=TB7DI,;+41D4AE4.H9LO:OU;,H)WQ<(CK\5WI,'CG[8D0^]?/16IH)\K2*F6,$]PC48BH'?
\Q$P&Q'.!W,2P/'[" M'X/T>+X7YP(^;;_JM0/;6^NOVNYVOVD'R?6@/[@]T#L;F,SOE\TMI?S!]>@ Q M<4G]T43I>S:57S4-K*YX]!GIA"*5]6!FO2EXHP0R&AA_8C@:!2K5JBK\RF7& M97-
L=[-\'F]8!++E$6SW; &^[_81YGU&FCOLT++%-02%"#K.I* RD6"%(1)XI MK9E6&0YKN_'RLQ?59>/NY"3]%'/DMZZ\O-[#5],.?W# .&@X!K\XGG^] 2W; MH..[7_Y9;^WKD[;G_0:X;H8K
RS_Z1:TCCWP4> ^=>;9?" M+> UY< >=P>Z\/.%T1*&N; NO[XEE+ 1W"G^4W5M.QA[VA9KI\0ZZH=V\]$K M,2H_&7?E_&ZQ^B.T,&1HB!&SOW:@C;Y-
D&L;6Q,>)8W3I\+4F(ZG2+T,PN. MT&?Q'H?>"4_GO)5N_@%RD4$H*D10CTKU]4JG(W@NC'-X2)$S MG*YK?7W:>;,89^'"MM5PO=ZJK^1C>NM9$7O+G>F;UDSQ|-[VTF[W$"80EV4.
M!>48FD(20TU6L+R8;5=;OO#S:A/P'.0%=YQ[&W8G0=U?5G?LUW\RC0!@X238 MW(#[]6H3"& _Q9SZ>=.?;*;"O&_'_ VHV;^1H^?MP62U,H!:B :I":X,M\(T MUULW0-
2B@)XLH"],TV"X)T[*MH&3Z3Y9S\'Q.9ZX8>%D4W#<[7 ZT@FVXW79 M_]S,93URF\)N.8F5QA*SAC$@BI(2Y7#O!09EHH4F-+H#?@IBB/'OH<[3'#(M061)XV4M1FS#K]7-
-1OO8+5$G6,K?5)>B^WF1X2?W#[//AB+$+.TD'7 M-?'ME_GF[Z]^O~)'#K_]>%_*9JG"=TB7DI,;+41D4AE4.H9LO:OU;,H)WQ<(CK\5WI,'CG[8D0^]?/16IH)\K2*F6,$]PC48BH'?
\Q$P&Q'.!W,2P/'[" M'X/T>+X7YP(^;;_JM0/;6^NOVNYVOVD'R?6@/[@]T#L;F,SOE\TMI?S!]>@ Q M<4G]T43I>S:57S4-K*YX]!GIA"*5]6!FO2EXHP0R&AA_8C@:!2K5JBK\RF7& M97-
L=[-\'F]8!++E$6SW; &^[_81YGU&FCOLT++%-02%"#K.I* RD6"%(1)XI MK9E6&0YKN_'RLQ?59>/NY"3]%'/DMZZ\O-[#5],.?W# .&@X!K\XGG^] 2W; MH..[7_Y9;^WKD[;G_0:X;H8K
RS_Z1:TCCWP4> ^=>;9?" M+> UY< >=P>Z\/.%T1*&N; NO[XEE+ 1W"G^4W5M.QA[VA9KI\0ZZH=V\]$K M,2H_&7?E_&ZQ^B.T,&1HB!&SOW:@C;Y-
D&L;6Q,>)8W3I\+4F(ZG2+T,PN. MT&?Q'H?>"4_GO)5N_@%RD4$H*D10CTKU]4JG(W@NC'-X2)$S MG*YK?7W:>;,89^'"MM5PO=ZJK^1C>NM9$7O+G>F;UDSQ|-[VTF[W$"80EV4.
M!>48FD(20TU6L+R8;5=;OO#S:A/P'.0%=YQ[&W8G0=U?5G?LUW\RC0!@X238 MW(#[]6H3"& _Q9SZ>=.?;*;"O&_'_ VHV;^1H^?MP62U,H!:B :I":X,M\(T MUULW0-
2B@)XLH"],TV"X)T[*MH&3Z3Y9S\'Q.9ZX8>%D4W#<[7 ZT@FVXW79 M_]S,93URF\)N.8F5QA*SAC$@BI(2Y7#O!09EHH4F-+H#?@IBB/'OH<[3'#(M061)XV4M1FS#K]7-
-1OO8+5$G6,K?5)>B^WF1X2?W#[//AB+$+.TD'7 M-?'ME_GF[Z]^O~)'#K_]>%_*9JG"=TB7DI,;+41D4AE4.H9LO:OU;,H)WQ<(CK\5WI,'CG[8D0^]?/16IH)\K2*F6,$]PC48BH'?
\Q$P&Q'.!W,2P/'[" M'X/T>+X7YP(^;;_JM0/;6^NOVNYVOVD'R?6@/[@]T#L;F,SOE\TMI?S!]>@ Q M<4G]T43I>S:57S4-K*YX]!GIA"*5]6!FO2EXHP0R&AA_8C@:!2K5JBK\RF7& M97-
L=[-\'F]8!++E$6SW; &^[_81YGU&FCOLT++%-02%"#K.I* RD6"%(1)XI MK9E6&0YKN_'RLQ?59>/NY"3]%'/DMZZ\O-[#5],.?W# .&@X!K\XGG^] 2W; MH..[7_Y9;^WKD[;G_0:X;H8K
RS_Z1:TCCWP4> ^=>;9?" M+> UY< >=P>Z\/.%T1*&N; NO[XEE+ 1W"G^4W5

*[?],.;RXY+G M&F]<&XB9H@[E6|@_&BF${H1A+|":./(C>UW^3-W&MF8'F):?&[#N. *B8PG(ME]?0TKP@=?MM]L9388@C[O37< +>[?2W8P;LN &O+ ^DOHK-O1@W)BOV"B$]< M !BCF..BP*A1PFO>W[0+V?NE6:T?VL36I:X!NV:ZI*C$@L)*Z +B4MMPS] 2 MYAE%&7%5\$SZUL /$1H[ZZ^U =7D/2_Y+ZIKV(&D5$*8JXB7/ZBR MWD>XJ$K[P8$G][SW$:|?B>_U? &3BGA9VV,UV_;3O*)-E+),FEY"4F8*X(A0* M1#',9<&HT$P208)2]8YIC+T/ZW!F[*KV8;6\AW:,A[I#!M@SLHEKOW-*8W[K M_95Z"-Q=/5?!790*PA/RS@N9*@7O!(5ID^[.BWB49C? P:&3@=:2 -]`MV=YU69NEAC&2N72Z"F*A2BB(S&&18U4A^Y-B(DK /TEF[$!-9ZJN;\\-6+AR MJ>XV[!$E*X?6EIW1EF=\2K4. N/P S.1 6^_=T6K':Y&*Z25Y)S33\I48?9I M(M.&TX."'H7-PT]'WA"V3OF3^4W?U\V?=?U9+^][2_NK'^U?-FL+153GQ,,+ M"@D"L>$%%"6NH,@0THIE>;&"+#N"APE7ZY8LV#'5CS1O@/BQ>R*N=U(§!/@Y MBY'5&K_XI]-H ^%UOO$Y270%'<##MS7"\BHXNC*\8ZLHF9DT6Q>U2|;Z1VD$) MZM/RBW;>T)A'[""N=-W]\17?S#?N_9JS.RV_+N?_>-*;FK4[_7W|RFK|[S,E MD68(N_H FD'L6A)254@:Y\1Y453V/|H+/F]2KB=TF4X>4 L^LWWB\?GVR M[Z["=|R"/:N1S=9&6GD_3_O3S5^8;XZ;KM8Y\<@J#D')F4I:>52:/5RT-3**2#>K3M=N&,)9D5W==H^T\."W?_!U M73#K.L+OSCWJ/-R|KWSYZ=$-L;&B>-.;K59_TZZ&5]O:;WK-[_6?|-#;-WRK M=^KYLEHLWJW6;M09UI5!,,!>84*B*5@=OM=29@KG/$B*ZCQ W,]2>4;>0WK M6(&\X07<.V:@LMP XYSDM|I)\NDR)I^4\L#CB)U.E[R;BY^)ZQ V*DP+68H"^~MJ* G:[TUZ3W7R@MJ@6] (_+!8693Y+&U4H-6{!NP$_P&=**#5G90"P^<|/T@ M:I2LUY[S8E/MLGXRZ;;=P?UDPL_:'? ZD;$X<";0\U[QMWB_Z_5\=9GQF2FD M:[C-("$._^]@[".2Y??,1+03#2#&!@M-K)N9_ZI6\MWS;#>IF:T,_L&HX,U9Y MZX1_F2^!LA\$7V_J-7[CY/UUHE4^\C,8>14??W(G7Z5WZW CE*M8;1Z87@Y_ M=@C7XNFEYZ34VDM9>R4;<&K<+,=T?OFSL!E>S!O!77%C@3NB 8 M+'A8*TR#-H"BQ5501,2[ZS=$]IR(Z@.?<$WD8P.V!=+H'^K#^

*{O7H0[DK9+L(*_+=FB\W1EMS56^T^S=? MM#V]FJDP[A0R!)2{M3%VB# K)A,-)R3.6&_NT\9B])OVAICKN3W4+BJA M6H=->#)E!5IZEY;,X^GF60C>8\MA;K>*Q="'*Z%B_7-])U%P7$;P:(H.RB&^ M6D$#F<;Q8T^6CWRU^/VLY>L'^]GZ5'Y<+:]IAYK> KUFN$!:$P9%90S$IE"0 M(U% P8TF1"*J=#%K'.QO6[[>>IZ;3L5_B%$_E\+?KO7!?%E?!]^J/*

*{O8 ME84I>54*6"I)(-9"6D]B8VQF"!-<%@;+((]Q@=[8F4TM]U M$(Y^5)[^!:T-FW!:7809\:1J\+_ 3*>.N,O)LVI)<[']H)}[ )>*% 2:[((03 MI' YY_E&Y!IJAVJ[5'U*

*3=#U*HB.CX5..ITM",A?A\W0]RQ-MLQ6,6-<1"Q%%0N+,<;CAX/NG3PV79B4GX[4?\@O.3O+DN((X=0V8A<,M)*

*M"@S)N/E:!%!DU#V'K'H_+C]ZUZFZ0»#YYT:,EVT63=(6W6VN""»5G*XF MT1?GT19(Y B!RID.O6O4Q())DSBQ'+UMDNNY>?3>D/+>L: -)=X&8MW/Z-(SK MZ??\&M=XQM9$,2F5XPXB4G2M(EI C1Z,Y=$S@X'^NLF=W5VK[U9-]MS2HPTD MW05B:@7#\A6N\\EB^7.B,/<:.8+20=,OT0#RR"$P;D+4#"7F!D"YMNAN^'AN*

*MF='#Y=H%+#Y]Q=GLY>F*I+%:30*S%%^Y '2 ;DH8"J&:?E>,B3YZ%#:UN(.[MMNANL'AN.=###Y=H%+'[[FI+K-YS_G##IBG:,O.WL);G< MC-"=?35Z"M%ZK4QND2N_<_'=8/+.M^TPGI6; A)4\.FE3;A'<7%US-V0\GRSID5+M A/;YW^;QX2?OI 8<7 s*,PG@MH A+@JE5<2@3[^>U2TQHt,UM@&';-@-,!\GE!8ZB-CZ 7)-M)U49OG4"7W%.<&+/@B2UKN[\$KA"@9DL27DZ2K/4QV57KRVW&S*>3W:U<%GV M84B(\B7.WLY3_O$_!!^)D-;6[\(0,$E !4< MDZ\U3$9^A(+X:$'_3O:CNO+ M[@:*YY-?/5ZV8]_.;_,U;Z:KB+-_S,@\?_AEK2L^&%U;=Y&/[;")Z\;/&?% M"U0BL^,:#MVW\FX0>3Z)U282[N1IW243;^@K]TE, BE"+\ 4>==*<7*Q'05B M)9%_;8QC=$X>!9)[%M[MZ>7S2:6VD&]7$-*

F&8%LFD,4EANRALEX4(R.2DR> MK&%-[,"$41[9?>W>I7>#R?J)++:1<3.@_-=?;\F5>/SW(UH3SE>+V335WI/T

*M^Y3G]YPN>C2M%N7]M[Q]%:0B5[R&=,O\A;YI^CV_6ZQ6U_G;L:'A<2NV:H/8 MD.\CFR>>MYVIC[^^Y@LB+MKPY=H>0%C"JJHW@=8[((1%T$'H[-$'#*V;S=U# MRK'=BSYFTL-I?D/;EH2^^ZTAX-5(\AVT9/O;D@Z$#\M%F:XG6CK,F')@=:!&@ M9+:. RDEPY&)X;4*.S7NQ75E^G.XH0Z+D4-D>#HO%&F=MFL?FV:S>HN4Y.1(S*

*MPOB+]'4ZWSS.KX4;O_WX5GV.B4X>HV4<)%,(H=.8[0(Z7*$0L_L$G[0=U MDMV)LG$;J0P]H@$TTH'Y^4B*(0^^$#^OZ+:,Y5@9TS4O%2+W=']J,O+XU[+ M7=DVBV6>GLRWK[/CSTWWH-K&<%.0L_G3;*NY]&^GJW65YX7#*V^*2+P2&@+Y M-DISDJ?VX'1+4CF"B&Q=)C\,)R/U#!0\SF9X#E';0G5].Q.3 M5#DI2|>%M8I8,;Z "QF!1H.0PD8K56Q]OW,?+2/UIQL204W$*

*MWH$9>CRG2QR^Q-4T;MB<8$]&7-< 29-M59K8\ZA)9E(G+8SF6K?NU;(GB>/V M:6F#B[T3[XQ[S/ MV=-|"#I.??)D#J6XYX?0:YLQ>V9DD0)RTGS;8MN[$@&S,BD*YU/SL.*

*((,%WF$P>[8#)EQ*QHLHP*,@-|(Y!2$0+[DH;B0/#FWKT_4>4L9M-M4?,DR#E$Z!U8G'_)TY,O1/>+[V1*3\Y&.+\OMR9-;#;&A> <(\EY%8$+08(+*

MBC9(G=!9O%;;>:; V>X"!"1^K?/F0*97B%==$19B\VZQ@4.M_4L\>TM35= M#=UU0:#3W=*_"]5[:(#$X'@<-{OR!) Y!]4|.:]?DWG5[[#PVHR=*IZ,W#%@Q*

*MA7@T$;S5"%P3ERE8B:QUB)(Z;=.D&GDTT^&?M:/|AH\LO>3V-.+O.[%.T MM[^^?!>[(A^0R,"-[(TFI#,*:$V)9#53 RXU!*FS-O70(U4./[^[M=-M/]26S$LA1*3X+$5+^[%D#T&PO4|AW"""&Z?K@7YLQ_T[-Z=O)6^ MGI?]?(DSG,?\Z4O.ZV9#/ZY_Z('V[@'J&UFP"_2]+V^F. MFY0Y5Q ,%G)83*0?]L&PUD;K.@7C6J/F2+C5Q?QP<7<05%Q0_V]&JQ5YOW7> MYXL?T]7$BY!#4AJT554P4E9+C2"+8><(+H-MCMN$M,A]0\'U@.4K<'>#F M*OVO%UIQ.HD0P%S0 5*U&X30C! C4B_2"IBA%,-"^0OT5%)Y3GKTWG9_C M9-T#6C:SA#=\O/A[KE'O)#*MC'44S$8*II66"5R@ ->&$)CWS/@T0-7D#2K& M1KU=)GF.D/N"RVU2, M"Y,AO)3#![-P'1+:]O2_|>PI[58DI ,LU$9!B@&)X$:DP'AQ^M:,I[/A<9V" M3MR2_6Y:";<;J!Q-I'Z@HDB+ LH-#CRQ,BB2@TA4BP8@M6%[:AM\TKI.PD9 M%RC':/9.D!PCY@ZP\@I7=8Y4_=]O_W$Z_8ZSF]!_L7Z%R^?/Z?SD?^'L-$\4 MTR64($&& ^FC4! O.T.&B[-M=%%R<&+&.N MG=7"!,*@18?W[WE]K>)3"PZD3QP738-ECVXDB1%'5[['M0ZJ9[#LP5F_G-?F^6/ZLO=Y1F'J#B\V!=*"U!M!*)P?+M@-*

*AY#SJW=GQW(&K>HO#V^6FNB W!MB?\?>9;>+)9U$LIOB_4'7*YK58#'''##Z;<; M]%ULG1 $4W5$.1$*RCI!(>L,447A7/ ZLM;O%?8W5X-5FP^%G4.DV\'CA_+*

M,FEB_?/##$D<\U0CALTD8/K]]B(XO\NXRA]K2=[!H_5=A[8E3>0A<-V9!K2!(Q$$BB$)QSD2-3LGDU^O!<]>#A-TE = ; #]SE MQ81#KQD+|C4P66M8-4;@+VG0.3G$PEPIK!PFS

*Q#6*FEAO784V*8"'">+#]+&GZ-Z>H@'FH"GN1(Z -,% M4.,[K.I$#.@6G0=9 04?(K/B<7;#9MS9*lU/3@Z_?!#^-!-J'GI-X M7JWF)!\SLNO-5>W;5V[IK.0L1-8 M!FO)UA-LQXIX*

Y1LI3&1V1#[==Y@+)&D8!5Y[\>PFR@[3 NRF&ZGRZGN;-0Y):4_5E,2.AKU\N/YY^5HE%)2L%-"6 MDVC(XZ]]D!A9P[@8NBQB;ATC[4I,)W5&[YH4DPRBD]LS!6^;N;DDK7&:BS@

*M17UR8*2EW:(<6.0EN9(3;_INY'YJQBT2&$;|]T/L&%5T *KSZ^H/^+/>59^G M9M%9JV71=.8R!BHD"8@\ [G^D4NNL)36GO'=E'0#I[/T?$^-P!%"[P,ZRU-: M]9:,)DH+9"S7&=XFD?*

*4V"*Z0.U!$*I)DEI-K72IP+S'C'FW# .B!Z#O T+G[M_S]'BR*9' 3WGI'_5X(&)6H5N;C=(XN62*YACGZH',L*&>.FE0"S;'B[@ Q M+T]7Y"6N5J\67!\-*

TOE'(MA'I27TDM9BOINFLU<&Y#'}>V%,.Q-L=M;98.IW;YZMHP MRRH-QIM$_W 30NL@\3#%2P+W+K)%>)W+K+Q)=>XGOR;A+]AJK;-*

MJZ^W3,O9.$N,RQLUO7>.+3E@Z7&SUHU1!!3B[\ VW;$_BE22P%#//+Z7B[' M\(9'\@1B,!(QE=RZ\.1 BS184GLHE^LX8?>0X+SB-:1/&=ZFI)L(;\!\T_$]Z,#NW+H8O"

[>CM84N:..P]) MU) 0^>S1YDA6JQXW"X:Z2*#D!UA8F)2TG'7/N0\'83++#]S>!>PN[SZ]M7*;;$ISZ)OK8,@L* M1((D:Z])@##DRL#Q:O8*.T;8>N/4 .=T$BL/A]+4R.K*

_MR5TR'#M'ZG&XED. M,H(HWM61A)\"HV553,.4XQ4>OWZVTY&+=>ZTG0.Z+.P#MA_61@;;!A*L M\9*)SK9G&8K@E'EL!%HRBD0NVXCLZ7YNTI;M P=K6N@:5\0

*M[8>?/IOQ7GNI]_'Q7OO(N@>TW)X\Q;D7*ED'W%*76 MK_>>P7BOO?3Z^'BO?8J<%TS.)T\EDYC1V8*4KKZP\ 6P1 %,<"4+N?DJM [MGL%XKT8P.43(<+#DC@8S1AB&WGI@7)%*

LJ=H4SLZF$,6TD?A4_,,H<[">S7Q M4@X3< <0^7"^[F;74+SY?KEA*FV*1#[DY:25RC@9S:%T>>S\U8Y?@# ZA X3> 7RNU$#>:UQ]]%8@DW3^ MJ_KNST?PV=..X$P(DF",J?

7SWAW(&KM,IBF@6JNA+V3=LK&8A37:%!!9DZA M8> T2I#*;$0Q3'Y/##%\ ,>;NHR4/"&@7P)'E5RN5C$W/J6QGT(*

M50#EZ;Q&K1,4&;VK;6.%:SU4[\"ZOJYJ&19#APJ^1Q"=G=.UH" !GD%+H_F M+PIE0 =6P]]L2QHOQ_$83G>?90>$E)<:0A]C:,>_T>KX1%AZ[G]]#WAT=5Z\S2G81T@IGC

*M%;UH+?4.H'/%%3R[*Y1:);Y(&M$*I/C36O")?A'"9QNX(V/&@G:O5=125^%*G!TOK(G);#[1KMZ>0/"-Y* X+X9MD)QT1IC;6C*[W M3F4 ,#Z=_CI Z\VWV&=>D4$IA83##9})8B>.*

*MS8&(6R==CI WX.%4]GX&*R.4&FGW4D!(IW)'1]PW&FFA7;M+\V.KE@;#%>#* M F&?L:TA"FA2=*5H. MWVYNI-*

*9+@_EE3XG=$33=%]JW]8.O3Y>5X^T"FSW\>_YC\U=T'F45DC$**).F M" =3!B|*.<96)!Z*C"RWOK,9C;)QW<(G1VE;375PFM_#U>95QB53SH0BBE"U*

*M.P.Q55[=AAA(C,5S5X16@CT1_*X3-N[U30?H.T)/'8#OPW)1INO:WW:"%I4Q M(1&IUH(*CAQN;R(&:[S0)>>><6C='N5Q]W#N2%7ZSQ=>=\X*/(F+?*

%/45&&_<@$,^I7M+E^>6K#Z<=,$E]-U_E37GZ?MQKPUYA$]S7)S,-Y>RG=41O41NN_>;NHR4/"&@7P)'E5RN5C$W/J6QGT(

*M)2FMBMT=+!,'FIO3_+.TY/Y=F)T_/EYB22*N$%%/&W^--MBY$*F%PWQ10Q< M>K(9G(D:]95:$,4DQ**=*/1/;GZ3/PPGX\[)>LJ=T0$21G5H=LK9J>19C):1*

*M@).OV8SZ!-7E>A\6>!#:FMR\6^"QF=3!NBIWDTG=1RM'YIA^FZ>>\[@%4U(L MU*2Q8:"80*'O4+C)'->^<_2,\ZC;LZA4FY MX"#%6NRF503$*."F&'Q(4@[1DW&O3.E@*

*!I:S_@=PN1)/D1!?3U=Q M,U'[-*YVTYY/R4A7O)VD+]JM50ZH8*4# 7^4="I4<C';)6L=UR:U=A"'X&/=V_XFWP^A Z,!M>9UTY3C=]DA^/\MG>=\77ZL!*

M^_M):$OB3GN#'!G2XGO\XZ%D,K,H.X+F1 MW8H(?I-8OEZWKPDG@11A-792;\IUSED]Y[-1YI M.RD2"3BA-7A!SE-!C*T[C|\-R7C5M9V5#||&ZNHB6?PWG,ZK]-[//^$LOR_G

M!\8$C>"QIO2*WE0)DYB\S!+0"PS*\!)L:T?W/EK&K6;M#GI-5+8_^/P6?/-\ M4DLC/CU"R0L^SUY+7$C0&QYTK8R,":L$62)?)M1[M\" #IQU9R@-7OCM2-

*W*1;7>0'4BO'01&MSD[3RF3W//T^Z95$;JH>2&I65M'M,:HHP7%3Z[JR\)Q);7)KX[IH+7;UU1FF#B4>A=Z2"^CG=:[/V=EX+AA=+VK<3*

M$TA.PF5P06I0DA4(§€')"@WGJ9//':#E5)SS |WT$)\&?=- M/O5*\,L*1%XEG.MS-8A#"A.(9@@[2DL2!A&B0W.6@1.<-[DS9@+XPA&L"\(99WRZV;'B"5^3 MW$7QN'= 3URK[X3*

[:!$=4=6[RY6G] FE8YE"QR] >4XHU-$[CHR0&:\]LLCF M92E'%3SN;=(3 GI5-N!@["[;"RFM [-Z#V>E[>0D M?R)8/D!E)^-,GNB-;2MU=6 ?B;68;9A;WVZO"%-6[M;2DG.=Z:M+ 3%*

*MA#$9VF/6@C2L9&&5#]5U[=$.9'7Y*K49,FZ7,C=54P_(PY_G?;+B?YQ.EYEX M) ._ OEAAO/UBWFJS2R^;,^UD MME 27=7W>905X$B((0:&GD+K.NVX-P)V1 MZ_*IZF X'$9IXX?*

PM8_AU4UVSNB;Q7+#Z6K3@^U[>4NZG9],_ZLEES5(K^M MK#?)/=%)H.).D9NC&:BLZ=@)E@'G-FO#0PSF!E+O,#IY/"5=OBIMC# M<&A'5N])13 7!6>T92.S=,\WDU(49Q.D@=

(IEA0]0;8U^R=\L5YQ1(3WCX-+!^@LI-Q=$^496JE MK@[LXU4GO4ZM(+YR?<=WT71UON)A!I6 DLE=44Q0M.AIPUD3E3522M-\./RC M<&A'5N])13 7!6>T92.S=;\WDU(49Q.D@=

(IEA0]0;8U^R=\L5YQ1(3WCX-+!^@LI-Q=$^496JE MK@[LXU4GO4ZM(+YR?<=WT71UON)A!I6 DLE=44Q0M.AIPUD3E3522M-\./RC M<&A'5N])13 7!6>T92.S=;\WDU(49Q.D@=

*{U(@-8L,@1<&SI02%+ID96O#\K7\2+OUW3@=/D=9Z?DU6%E[V#; M<>?G-#(>C|/8R'K4E?Y77>F*1WN9Q_49.8\(Q@8Z*KA#P& 9$&6\;1Z<*

*M/$3/T3,/[OCL2W#+DE)PU@*Z.D2,M@>$6]*9Z3$42:5BL/73X <)&M>J-,/% MK>E$5930K86IE_SKGZ&.Q8U79P?O;V/N^Z0V5F8G.H^T,]4_O3H;N/;.(L87 M/W-^F>>Y3-*

>UI=8EM)T3 5!D;.VM2.VS11#2P2-TEG-8E+.*[1 D[+'DT=>*.MCR|UB6\A&!V2]8#+HJ9.Z7P.=5*A19NEE!Q3Y(V-S#[TC6-SAL3(K>O%H;35-MK37:O&K_LIBENLYFQQ[@B.*

*[XD#8VZ#'J&KDY6U-W@:!4, H7)9A4>TAJS<%S MP2$ZH,'.+K>Z^=. .;Q0[?';MI>$F)!U-&M2?D-E_/I_&3UC=;Y0K(^Q+.Y^1&- M7)H"*6ME3,X6^9"7G^HB5Q)XPO-*

.:+)^P5G1BJ[U#:E64-Y;'DD70K?WW4?+ MT0^R;GSN)8(91LYDM \=W7"=P#'?01D]-%KQ;&Y"W,O,2,.D!8XN/4P]HG@ MNS4=FW+HTI@^7!*3<=-387_C<<<<<*

<6V93(SZK;_O>"U]&"O: MJ@ \>U63]1F<1@6>;15XU"A\;T=E9^*.[\?PR$)WG9^:"'Y;EB!#G;<@I:,S M4]-.8TI%H;BRHG76]Q ZQS5,P^#K=M,&@?77K1';C!M=XX^#*

[L2Q_G0;LW4O M/8WLU?;S/^./.^X9BG4A.:4I^G8:% 1%@I$&2I8L"Z8+QP%FP-Y'3H-!>S<_ M^LK-J8@E6&(U(190F4OP] P$YYEW#"5K;HP?HF?T;,=-,'''|+PV&NC6>M1F

*M@1/M_3S.TI8M\$*I>SX/ZS)0Y_6QKKL3&\C:W-E/3157EU=[PZL*1-,L18! M^_75E \&L)"3G&4RQD6*VIN/]Z+J .IY<<7NWI%&V2RP@+*VKU2" Y!Y@A"M%$!*"P6'$,75Z6I-*

!]OR\I L0D>;.-B8:8G 8#729 P O=> M*J==ZSS*CJ0=']@]N,R5X[R@D4DZ*,1K'>.0Z#AW#E0PM=6$D4ZU-E;[TC9V M -<>0[?#MP&TU*UI^I1/#BWNR?C11C=>>=U+2R/B-*

*S[SI.Z626,B8))=0*E5H" MAPX=!'3|<"-9\7I@=KOS?9I{@X];-5V-E=&M .[IEUL[\Y>6AHSM'&91KUS_WR@UT<*+$K""R9$#E M0.&&EQZ8TBFYG#&QUNT!*

*[B5F["@\#7!P^[%I"\%W:S]NON8];R9P@/FX\V;-MJSZYE*N'MC3]2&8UL^C"'M&:Y6TS*-6S+2OYUNWSY>;6.0 2G+XA(#PQ('55P&+P,#A1F5-\[GY[[GOC3^_M&1|:*

[X/'V^WV!]11!\W'_K[\]MO]_7T*XEM-9&RT#_909:2.:#9.@H]6@N;D M":)*Q,+6E8+7*1BWD=CX>+M"'QV@Z??\QY7&/,O%G\Z%;M]+9G%L_M[]>.A!< M6),,[9944(&]7=')33$0)1?*

9&X^4;CT#;E\:QQW/-3XB!|5IMTIA/6V-/F.8 M'>0=/OQY@[9BNHOFKOS%;$)2IM!]6L5L?86G#"<0HG(BV)HI6WM!G7A+WZ M7W(ZG9"\/]M@J_HZ8_5N@9M*5>WG:6R.9*

#:SFALO IR M=#18:W1R*0:76F9'D/MG\"+W0>FM"/]~V!"W#):NWW,J=O_OFJ=DF=KS]? MYTL5P0.3#IA3M7^@K.5R6H%S-F[T0J-NWF%L1]K^#$YH%[@VU&$'V#SO$%V?*

MTZ[K]O_,)U^]V*[DM%BZ&SQY!])36++A@%:+T!ZFTUVQ)Z:M<7XRI1VV:<6UNK'9F'#)2",@O)O %4D2 M-+6:&:*!H4SGC6O=B?S"\G@HV/U:$UVQ5X;_?*

*DO\&9=\XATK:TN;9$0,7!-M!>6A."@%A88FJ-;Y1-VI&WHPV&A=);[".P^,P:HNZ#_N- M;I\0.MAZ?_+L'CRYJH'&^X/FRX1JL#FNI[VFVB5LD)EX":3$Z"2@8H4.*0 M== 4NB/|Y;#=2*

*Z*Y)HE9YM/ M"7FS]TK0]/>MY-/[^<==<1X/1 M:,X9:',CF$I*2&=H]]$>(? M6,D=Y'3V99F^X??%?'E- O7GMS?..7Z93__C]'8:H;@0?!# ZCI>%2*#P"T= M$1\4W>\|*

*M#*W#/@[_2V8WK1U?5HOP_7_6",+%'IC<\OM^4]h,<_I3#CJNOM;#>Y=5@4M M=I""}G;HL&4%6,K&#)QH-QCO-QX/WD&N\+[U?X_+B8S=XLEI7]*

*M&^S%PI,,B)!3'2AJM #G@X+,M>,6#7.Z>9.\ 4@,<20P*23]+4_9'I"\PRX#-+(])WEK?.^C;OF7V#[M_?!+7K[_8UI;A$^_O9T3P,CKN));+9%XK?UTDD1!X9ROTR9T?2Z>G),B"=^\-M-*

='NU'75-W\?5-QO;)HJI%LI<[,]_>%AZ]T?-$P3_2$MS'TMU#%8:9'4K0R/-MH#B+=)A9-=

(P!JTK29KGTDK_$0NW5ZB)F[CI5C$[H7#GQLEJ0G:8@P4M!=ST.059F&,HL(ZD&,P$[45]IVWX]\'0_99I.*5UY;&_F*^GJ;(T_9X_UU"K&]V'/$M%!B1-MDPDB.NE;>S#WD/

*<6BIO@Y:,%JZ%)D8\DS>CW.^X 'R7Z8OY!DI"}B=DL2"E MJZVIBX1@(H),7#D91>;/[*E%DIEEOW/-P> @-)OMNC[W;W.-//NWN_:BA^G8/ M>+:,MVGG9>A<-KP^(>&*@7&1*

,,!@#$L\YB1\#HVM^Q-U[Z8=A2#+^^@>?I;>]H!6ZOU4SLJ"-V6Z?K=8K>H^N1#VXO+Q7DY7@%ZLTBK[VOW+ MU!)K :$@ARAX5(K^JF#[@7 M.^U&?*

*@>"+L]4N#)5=]M[;K[>=-'!ENS!CQNR M=_B03VGVI-[,/ N.,0Y)87U-P22X%#U2WB660G"2WN?XRD]B(,Q:*V8X&T=.M,J132>2+)*

*X^"P\B%"G0<;F.&]#_X]X]#HGT'AX^[H.A;BWVU48!O^.RRN5[M?IW7.)T=VZ?XUL>U[U?\,,5=]:%+VKN@I(*HD5P,+1 ?Q@7DQFIWL^KX MS]:';E/%_+G]]KG=G/*

*3FB3A&*Q.EOHZQL"|BYX YC)&Y*9?#$^W&?O+7+^ M#'WD)]D'9(T5P!VM]Q&QRRM/)NWR"L]_(U*]_OO@Q74ITEIA$Y"|]<;5GLH%@ M= "N3&';8$X/#H%;Y?*

C7D\'W7^ECM_BBWUS"ZHX%1PYQ6BEQT4;B(X-A2_7K MQ5>_]W\U|/7\>3D)W#$,C .=:C,-D1C%U[(.4 XR.\Y\N!D]W7EC=.4C MQ]/KX?I8"'^<+#LIV-LLS<$1SYC?TN&WFDB'1E"

*0#*HS:.,$&E1+"'/=@;?M>SX-;"(YJLR_(65$&.3G?@]=V2,C+7;K84.4DG*>I^8"*TS$0}3]&<(O/?!UV#MJ&^ M.G#37LQFBS^J,7FS6+Y>G(9U.9W=YO"(4OAZV-F#2AS *W)$W4^*

MF"):W^WN1>"?H5Of[4=@<3)O[0|5OH3JO52!GW]O>5/Z>U^?<^&2U<"F!5G7&-M5K;UD9?((K,B9.'DT+KT.(A>OX,C=K;FLD#=76XD5RL*

MY8&8:W5@7>GC=/?OV^0$B:/(D#D(Q/ITS 8(OA@PEN.W'#6?$;>W3D\W&9S0-M?;!U]-SO'XZ<#YO"S"!&X=6(8;R<G_-P"4MP4CT MT4O-6!KX'2,QA\-*PX0?P>U-]-H. KO#ZP'!]*

*&P.XIR_T>>>8K[B=%S2YRCN\$T_TX]N=]=(MSA9&)C_;H.ILCG 2U:A*L"LEX%R4VOXUX@)QQ$[V/$Q@>)/H>4509.=MT@NML M.6VUP$2LL_/JH.:-IU(9.2#3'GXG-8%.:VY{@>]_-*

*%TU6'R[P%*9P^E,[%T M9E^!YNBR$6!3;6R*$B%8)B$&5EL\R&!U.\?]$9(Z@!2AJK\)]89Z&!%6]^5Z M\G?\M\7RG)_59K>]FQW!*R$7,JI5I-\%IR)(B.Y>QD6^FZM.'W\%0?2G2_3<*

*MO?*X,WL;GF(-!#LR+'[^K_E]N<;#V;[Q,45G>(*(EL*2.E4FE(KM;(4*VCK<-M+=7T"#KN)6 OZ<\O?S<_!^F(P^20\QV2H.@X!9)9""XE5. M%E2%&+5E+KP0FY:2??*

790'LI@4H^20)5/$"3+PU6I2 MC>_>1<:6U'SPH>K=7F?U@8)6?(B8Z3/=0.B1,L80E0K66Q WA6MFLX+Z, %L MP"))B3BE:WA&/9>=MM+[?

K6D^RBA\TCM57T8=#73R8([J79+!#Q9\U!&%XA)+ MR5FGUL^)GU$MZ5* &TQ%'>#OELP^Y&7]IYD3K&F2"QR :EX.N$-1898E(; MH_+21D_2&_I*)?10_SUE7=*

*M)HKDM22CA2I+0G'D@%)E\$"%4(>NMC]" <9-\=YFIL0 [5>/KF!Y@EX?1RA^SQ*6?730@0/W M^ VY]9A*G=_$D->:,6'(B1 (M5NL29;'F%K/2W_F)2Q[06#O$I9]]-$'P'8J*

MDL@^'6Y%!%$*!3[.RMK>$\'$+'CP6F0](@.WZ,Y2P[6(TM8]M%.!Z [H&WA MRY[!-4;,4Z.]E$X84C4Q"3(-FA#71ZH@=-,Ij+Y,EE M^5CVZ+$U,Q(AE+P8@!I=V ?S\^?[E.792U.H.*

*{-4J-U*I7>B\]PG[C"W M?AYYBXAQ$IE#G,[*R;F+W,Q%IO8C_O%WLO?+*U 4/T 3Q99XBHDRHL">U;3\\C*9Q#=.12K_EX#64?P>FYX*?-]/Y=$5; MKHIK-L]"D77*!DW1!@(X?+NB?*

*$ M, H.)IB]5$E'T)8;<@IKS:]V"0IJK4*6SC5/]%RG8-QC:B"$[" ,Yj9,Y^+R M,7U8+L@Q7/_$>?KM/TZGWVH(\WM>#W?-^MB*3W/INA??75W!^L"#3"(0&&NS MTLP3.,=#G;]!Z+-*

*D2;4>A=/9%>RYZCZ0BFN(?:&_K8\|"$]9<0Y:UHC,"VXX,F#P$3N"RH% MP6H#5A7-6,1,7#T5WGlYA]D<"KM"[4"]C/T*9O'UVRE]U-4;-=1>E/4?).SS M!Q(%;F4\)Q{H#-C>2WJO 9/@S 7.1]6/.(R[K=0I<`Y5[&(P*8^,F=?Y*[D6 M9[6JVY"MJ^G)O/)U$5^=<<4EA=Y)%6"&.5 B9$"DT,TZ(9C11B8L.V!G]Q7'-M36<,B;&\!I-[!4?(&?<5,A0Z&[MAPX@e]>9T.9^N3Y>9Q/1F^]/^]P3AD;[+ JD M)&H#95>OKKB#$"/+R4BOF\_1N9^;<=^,#PVH1EKH $]_1Q+E/"[_7!72&2M8 M;!&\)<$0fI';WsI^M\G0+#!':Vf:=T[_@)QQWXT.C:A6>AC9@WJQ6N7UZO?%`M^E_SFD0S5FVP7"N>N^ET^2-M>6]HE+XQ=MZ!-@OEE*D/_W$S2YS9!3(K37DQ"W*RS^C_]&<%>$-C[&<$^`M^N@#8#L5JG,O-6IC0<))):K2HR4D-"ARZE[%7!ITJEO^NM0'",FYO#5-,S MV+8E)]JYY+7)Y,XZ)'>6V]IV>=-GN{C].3+^GWYQRIO IV7F2QT?A'CZ=?369T:]^+K8KD^]P28;&&< M286LM%-DKX-DX!QF,#)ZG7C"W+PE_]&T=IK;P/)\U%@!T"]5XR;1.#N,GB= MB8,X/;_RN":29+-VN8YP]BD&!,]F!BYZY0D)!W;H&Z G8ZO2&86!K/!(L MFI5T/OE.%5!8T7LZTX0#FQ7% B5(\-8=C=F"B2X61+2O,&W8.RU.EUR;B[8P H M=#&QIE!Q%#K&=I2)4TX[9R5&3SB=]Y,EN:&KG5;CM\F7X[9R5&3SB=]Y,EN:&KG5;C M\F7X[9R5&3SB=]Y,EN:&KG5;C M\F7X[9R5&3SB=]Y,EN:&KG5;C M

M]6'5(WAI$"Q!P(GH 1.#/+|WP?TX37_G9(PC(:T7&VWCG?}&DIC.EM.T&:ON M#/?&%.(\YCH7/C((67P0M(Y)H0)L>.7^KO,[&1!]NPM:'0/DH>?/U MZV)=*

fGE/4{JY8$.ME],Y@:)UD0+:_,+Y&%4I@?MN=ND"1[1^NB;UZ0_3,"PZ@S&^3F//#KQ>5SQDJ317-OCF+X9/$=/-"H;CU/V@+ZV%[#L-MT6WZMR/19=%TL7(&QO(`*C_-(1D!@M--XTM R5J?/`^I&!DV;=0f;RKK'M_R M__Y}/EOS\68[ZC[K'!1+#{L=92JL=6$+*73DH?1&:L-5H>4#$N6H[5ZWV8 M""?DOF#RHHH#Y-YF0=;BR5K(.0_@BO;@C&>>[NW4OL7N(17C5F<.!Y-#A-P!-M3#Y?QN4T3/BY^=P?46O3UE5M+%"8D|)0?%50;'E8-B4LC.]O1U\\GY3O'3 MS9*(M@Y,$|GW *(;\NM:EP_ERR+,E0#D(*V5N:XBN M!"L=0RZ;UP&\2-7(#DX;]=\'55TM=s=(";NWSY^V)ZM/!.3Z^KDR&P")7T=&8* M-$,1F4E,Q=87V/7'1\9*8ZW.6XBX VR\O5Q.9TA.6OK7Y70Y7:NC6I"+,3A, M'%BJA5K91PA%<4A%F6RL9M:T+J9_@I21]}X'NKI:R+U3^-1?+O!]-QE+PC-! ML2:95R$A!?I59@52G;=]O92)M;ZW7B1]W*.HB>IW@-/A>A@16/7UY^T_W|]_MMSU.I<8DR)S 6E%G]AH$GUU=9XMHA!7!EGN1^:.C4V_]R/Z4?X2BYL=+K8-3 MY'90^?YZBK32.A49:X;\ODFSND8&6 TVLU TXR&FUB\CCQ(RKTSK@Y7.8$G;?99 A*>,@O8W$8F6W>*_\|:>,Z6>TAU%&`:'+#V0FVMT*9Y205 MZ\DL$-95 MZ\DL$-95+.('((O= 9KSGSPL3f?-*_:V)&X<3M"'|_"P!M'*R,'_K;/XRFW\ MV%WR%RXG0"7-P!42]f.U:,] V8"]SXY2!A/XO5+UIY:H//KSQUVZU-XYDLVI^F7^_OV[6YMQI_,)RR(E|B+P;"DBCG7]*!,! M"N,B%A0AQ; #2 |Z^#C!|\,@:'CICWW,A%G"BXNU>M;$O\1;D'4 NZ,,V^0: MH>8,SM*-3;&]4H7N:\'3+L?/GM\=IP9_H&-I2)F749\ST9_ M|&WZXXKY9C$@6#5HC>&CL MG9ZNV#ZCLD7S)'5]R/F&<44/()%)DHTSI?0O$+D7(KM]}#[/L7V^XA\Q OM0-MN5A-KNUN_=8H S-<>0O,QP3*.6+!1@Y6)/1":Z;*3F$;_>1;.*:?W6#DP4?[M+:.+?2XWS%C+M!0S;-T=,,)\'0TKB:W/ 1KZP@!+@6W)C*V4QOPKG-83[HOX#I-C3\45;4]HOX#I-C3\45;4=PE3W0_4LZODJ0SHEHS3B?O\6NX^&6VJG=?*

1;9(V0MA"=FV/]NEB+6MVT'P.EFEO##]N1ZJ M);:_\77^Q_^D'!TQ;_K%C44_\L%^RXP/,>/E>C(8-A0O36$[(]{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f\ <5+#8PX?2/&I6_^;I K.2L^*(28,N=1;Q M2'0K&T^1 \-0N"\U@MCAP>#9CXQ[3:5&2UN9=GLSU6V0T]7ZZ@VSO*T$_8JS MM$Y?'AV'[?/3V!QE!_/3Z)*[]?WKV>#; /S\"3,>MRU8CN<@$2-&,H:]Y-B/K_/ECQ\7TW5W/YVM%_C;[/_6 M!/YJ,.]JS,%Y3+%95"[E4 Y7ZL4@=N+97W25H(30W4!1PH&93.\;-ZZ">=%HD;NM3Y; M[R\!Z2@EC%TC0B!X^CQU*)E@08.KX^*5R X(7(1Z^@\98F!MX)L\SCWU_?&"IF/U^20T#A3NH>VZM2K'6#TK?Y!4G^AJ_M.6B13$37E0Y_M$C\Y&7#.*9":6YYE1(H+= [AA=OE6+\ X5)OS 47;A6\;E_BO2V+KE\;E=+:. MA*P4L=BHZ#A=OV H!EY`RQ.4WS@(03?W*-]E)1Q9Z8.$A(=+_(^D,.U+QZ2 M21$5&%FSE9H8B>2S@A-/OZ M'LD_ (35O*X'^]P47WR?(A$_!&TC9K5=*.NL M$OI -'R'5WNE] "UZ_C@,ZY6%^L4UV9]Q0]M_!U)4_C+_L/]&BX_UT6:2HE(F M.QD8SV2>17GP)#L2(A<4>$E+06UKQ.U#8&?5>(V- YB*.L#?;[/EY2+,$M[P MMKQH9NP9%RM20-C2JF=XI:LR2?(!4LD>PK>M0;<\Q1U5K_3!F$-E3#V6,P[M OIYO9H.%\3++>HC.K=1(^/?R"]

MU.3C0S((^'9G[ZG'P>DD"A@98._F%_1OYIO^T%O/0I_JJH=:&VXE5E: MBMT;8 _%DCI+GYX6E"W5=K.9FF]5^?.6$-UF M"+7 M)B<+SFJ*L$P)*C.I@]CE?AZ.PLY2*2-CN)TRSPC2G^8_P[YW:D1_B*M=!C M62V<$*S. P*,E/1.8HIV_+.1K!SQ(T[EZLD0':3E5G MAT^2]>=P@/2A4DISPQ(%KM,%@#>W.(.A\0.I/.F/2O&U/<M]>?LT/B8"[Y]YR\'DT1H6* O*Y!-(C@,B_ "N;"4Q$^[3*#JAE!NZ6SV:N& M9@M=G1% W^3_>[FLPROW@L$#"RA?Q^?*WP/0DG_T:JGGV=UM&-RR6N/F&:?YU- M_POS)#*#UL4L182ZC44KB+ {6[2:1D*)6XFT71. RK=T0>"XO2X-(N-=<'H4:2+F'1O); MG6?KFB(?N"1*"\BD$JB42\?%67")2^ Y-9M'X'7HR78&0(^_MX0S_'2[6; @KE#.)@T;E-*

]OAHL5:DR%+@EYL+MT7C{SB=WP<$YO&:WD.79E M"PGB0WE"YVN?@UIO8GTJKKB/:[]1Z[^^,/E:DG^5]Y,.6+6WF+,=!|:0Y&J M0W"H!*"B8Y!9);/9;0'L(5_?#4SG[,YP BUTX*0\S+_8%A,.!.(.]W)-!UC9I$9B4#QZ/S)NB&4.2[OL;M_<;2[/.M3W&UR'1>UF7Z[^.;+U2",*!RE%I*W;E<93M%48QX&<6]MZM^:)MU?<;0JfLh|

1#Q=:$LP"*<6/ZE$BZ'B M*I/,3Y,H/A0?IC*K_-[E(%.:HGE0Z,'16FXV SH6]*U MX>AHR1^N^-Q55$N[#H-5$VF7Y8^YP&./$D^2/AXU@?
#05MD_A$@62&VLMBPSR#I.5KN7|WV/>KC1X"Q-DVARG#9V68+|\M#:C,<2YW1%_AQTBCR/%XHF"?5W(3(&.+-,=_N=6:I|$1Z(}*P7P/^JJ(_8'L
M\.5WQ.1X21VQRZ7"29:6F[RK1BIFQ=,0;+18S1"4,*H2+;^D1($Q3M3D^N=[_W[M$L"SRS8:UG-4E=1@"S40>_*[^MGS#Y,J-#<'"*:MBJK,I,3,7 M9GI.&)U-=& '>0-
$2/JCE*W6PU*I2\38^:;WEH^ "C)-Q#J3I:7AXI<1:*W, MY'RH"A\Q/VET4 I_V?.C:AM=29]4L/PZC5,JQU>Q3B#?\EBY7JX8>,7+(Y M-NBV3MO'6X?;K<{6L:^I/;6ZW!+|H=Y\WWIY-
F"_YAA.K7*>\FBE+Q<=G2_E(?J]^#8\U<6MC\/ O0>_(MMZX/:Y7_S{'SQY'W.'!X0(CS:HR#T:O]SG%[=-SPWU9M[?O7OW\]M?5O4X?A M/7DV1$_S80?!0 "Q\ !0
!E>&AI8FET,S(M<3(R,#(T+FAT;>U9_U/;-A3_ M?7^%1F\%[F)C.]^=E+LTA!N[CE"2KMM/.\66$PU94_/4G^A4[;??Q <[__0_]%QT(&(\]1PC2))L"8QRA7E<_0^_M)NH,.4[)-1394M+Y0J/
"QKHO9G|HP7=$TU(_N5GOY>|=S?LXOT9R)>]O=C M>HYH_&J+=]ZTF@E;=*:M1KM)ND$S2BH>TF7Q#.?!-&?_A:(GLAH_22D5=;_M*>7.@ICUPW:0Z=X%C?
4B]#WOIZT5/DTNM8,9G?/06@O41' -5DC06GQ=4_[D M0A4Y$DS((5G_WJ&XB0XI6P9;D]H2A0Z)A?H5*28;]<4YL111-*D8%3T;P(
M@=C8OXLR6*"'44ZJX/F!B=CH=+T6&A^BZ<\C-!F/F+%EGH=^#YALM_Y4K39/G%?6[Z5N<0*X5ADIC=E-[A+'A,ID2"](&B"Y0QSHISQ)2-+-(BTH9A(U1#E*!*<
MDTA3P=$%U0LK\C;'$A+.ENB49$*" $>'0J;(]YRW1OHU%>> B5RA(QZY;,<(-M#46:8;[<18F05LN'0@LB/ 8C?\DY,<9YO:!;L_W2^!\0!L2KE28Q&E]$"\[E5GE*EC)7P;SAC:,MH020!
<^SZA;FI-41PM#!&GHH9 =M'+AHR MO,R$8*2&3B11-#:=W>@?+BA)8!585=-S@L9)0B,PN0Q=Z9)E_17+,_0&*@KV M 4:TX#4PEE/P]3<0N5/O(>681Q2S>_36K/VS)0(2@
VR#&ZZL8-X\9CF/PP&$DT6&]=2?HBY\H-^Z$CJF.)RJ# M'7^W\O3K+[\;JI9;,Y@X3*^0AI*<085DMF\'J%84D^Y%02L^TKD_%)65Y^_M?0?
O(@",W]R)=Z_*\QKQ5V@O;]3OUAN0[F[/8.H3VMIFY3CX)G-,.,2Q%-O$ M08O4&"1CTR_U#0!@:GID!J5O@HR-=CI>L5HZ6&84[UQ $O"@ VJNM^E;%4]9&Z"'?4_;Q^1WF48Z:W?
SM^W3&5?H)[3X^@ M]CP?>QH/VLBFSM=&FC.O0SV"3_9S/!9N-M8\|+\M/">'3S_WOC$=K!$_;SK8LP=:*^=B7_L8T83D .LBSVB0SW.EBYN.5G'1<>_1 M[R082L*PF9]NOZ]?
5SZ+R^@]>PG^#U!+ M 0(4 Q0 (`;^!EFT@J}]TX(! -4U%P 0 "_0 !B M=G,M,C R-# V,CDN:'1M4$L! A0#% @ \Y\#ALK #@P $ % @_%[EP$ 8G9S+3(P,C0P-C(Y M7V-A;"YX;6QO2P$'"%
,4 "!S/@993B38@3>(#>*P8 % M @ &WP@$ 8G9S+3(P,C0P-C(Y7V1E9BYX;6Q02P$'"% ,4 "!S/@99 M'L/6G"T2 0!HY H % @ $@2P(8G9S+3(P,C0P-C(Y7VQA M8BYX;6Q02P$'"% ,4
" !S/@99B7T-W(^Y !7= @ % M@ % 70, 8G9S+3(P,C0P-C(Y7W!R92YX;6Q02P$'"% ,4 " !S/@99]\^5 M]\' #-)0 %0 @ % % 0 97AH;6)I=#,O,2UQ.C(P,C0N M:'1M4$L! A0#% @ DC!
!E>&AI8FET,S(M<3(R,#(T+FAT 7;5!+!08 "0) $P" Z*00 ! end XML 85 bvs-20240629_htm.xml IDEA: XBRL DOCUMENT 0001665988 2024-01-012024-06-29 0001665988 us-
gaap:CommonClassAMember 2024-07-30 0001665988 us-gaap:CommonClassBMember 2024-07-30 0001665988 2024-03-312024-06-29 0001665988 2023-04-022023-07-01
0001665988 2023-01-012023-07-01 0001665988 2024-06-29 0001665988 2023-12-31 0001665988 us-gaap:CommonClassAMember 2023-12-31 0001665988 us-
gaap:CommonClassAMember 2024-06-29 0001665988 us-gaap:CommonClassBMember 2024-06-29 0001665988 us-gaap:CommonClassBMember 2023-12-31 0001665988 us-
gaap:CommonClassAMemberus-gaap:CommonStockMember 2024-03-30 0001665988 us-gaap:CommonClassBMemberus-gaap:CommonStockMember 2024-03-30 0001665988
us-gaap:AdditionalPaidInCapitalMember 2024-03-30 0001665988 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2024-03-30 0001665988 us-
gaap:RetainedEarningsMember 2024-03-30 0001665988 us-gaap:NoncontrollingInterestMember 2024-03-30 0001665988 2024-03-30 0001665988 us-
gaap:CommonClassAMemberus-gaap:CommonStockMember 2024-03-312024-06-29 0001665988 us-gaap:AdditionalPaidInCapitalMember 2024-03-312024-06-29 0001665988
us-gaap:RetainedEarningsMember 2024-03-312024-06-29 0001665988 us-gaap:NoncontrollingInterestMember 2024-03-312024-06-29 0001665988 us-
gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2024-03-312024-06-29 0001665988 us-gaap:CommonClassAMemberus-gaap:CommonStockMember
2024-06-29 0001665988 us-gaap:CommonClassBMemberus-gaap:CommonStockMember 2024-06-29 0001665988 us-gaap:AdditionalPaidInCapitalMember 2024-06-29
0001665988 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2024-06-29 0001665988 us-gaap:RetainedEarningsMember 2024-06-29 0001665988
us-gaap:NoncontrollingInterestMember 2024-06-29 0001665988 us-gaap:CommonClassAMemberus-gaap:CommonStockMember 2023-04-01 0001665988 us-
gaap:CommonClassBMemberus-gaap:CommonStockMember 2023-04-01 0001665988 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 0001665988 us-
gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2023-04-01 0001665988 us-gaap:RetainedEarningsMember 2023-04-01 0001665988 us-
gaap:NoncontrollingInterestMember 2023-04-01 0001665988 2023-04-01 0001665988 us-gaap:CommonClassAMemberus-gaap:CommonStockMember 2023-04-022023-07-01
0001665988 us-gaap:AdditionalPaidInCapitalMember 2023-04-022023-07-01 0001665988 us-gaap:RetainedEarningsMember 2023-04-022023-07-01 0001665988 us-
gaap:NoncontrollingInterestMember 2023-04-022023-07-01 0001665988 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2023-04-022023-07-01
0001665988 us-gaap:CommonClassAMemberus-gaap:CommonStockMember 2023-07-01 0001665988 us-gaap:CommonClassBMemberus-gaap:CommonStockMember 2023-07-
01 0001665988 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 0001665988 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2023-07-01
0001665988 us-gaap:RetainedEarningsMember 2023-07-01 0001665988 us-gaap:NoncontrollingInterestMember 2023-07-01 0001665988 2023-07-01 0001665988 us-
gaap:CommonClassAMemberus-gaap:CommonStockMember 2023-12-31 0001665988 us-gaap:CommonClassBMemberus-gaap:CommonStockMember 2023-12-31 0001665988
us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001665988 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2023-12-31 0001665988 us-
gaap:RetainedEarningsMember 2023-12-31 0001665988 us-gaap:NoncontrollingInterestMember 2023-12-31 0001665988 us-gaap:CommonClassAMemberus-
gaap:CommonStockMember 2024-01-012024-06-29 0001665988 us-gaap:AdditionalPaidInCapitalMember 2024-01-012024-06-29 0001665988 us-
gaap:RetainedEarningsMember 2024-01-012024-06-29 0001665988 us-gaap:NoncontrollingInterestMember 2024-01-012024-06-29 0001665988 us-
gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2024-01-012024-06-29 0001665988 us-gaap:CommonClassAMemberus-gaap:CommonStockMember
2022-12-31 0001665988 us-gaap:CommonClassBMemberus-gaap:CommonStockMember 2022-12-31 0001665988 us-gaap:AdditionalPaidInCapitalMember 2022-12-31
0001665988 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2022-12-31 0001665988 us-gaap:RetainedEarningsMember 2022-12-31 0001665988
us-gaap:NoncontrollingInterestMember 2022-12-31 0001665988 2022-12-31 0001665988 us-gaap:CommonClassAMemberus-gaap:CommonStockMember 2023-01-012023-07-
01 0001665988 us-gaap:AdditionalPaidInCapitalMember 2023-01-012023-07-01 0001665988 us-gaap:RetainedEarningsMember 2023-01-012023-07-01 0001665988 us-
gaap:NoncontrollingInterestMember 2023-01-012023-07-01 0001665988 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2023-01-012023-07-01
0001665988 bvs:BVLLCMember 2024-06-29 0001665988 us-gaap:DiscontinuedOperationsHeldforsaleMember 2024-06-29 0001665988 bvs:CustomerOneMemberus-
gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember 2024-01-012024-06-29 0001665988 bvs:CustomerOneMemberus-
gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember 2023-01-012023-12-31 0001665988 us-
gaap:DiscontinuedOperationsHeldforsaleMemberbvs:RehabilitationBusinessMember 2024-06-29 0001665988 bvs:ComputerEquipmentAndSoftwareMember 2024-06-29
0001665988 bvs:ComputerEquipmentAndSoftwareMember 2023-12-31 0001665988 bvs:DemonstrationAndConsignmentInventoryMember 2024-06-29 0001665988
bvs:DemonstrationAndConsignmentInventoryMember 2023-12-31 0001665988 us-gaap:LeaseholdImprovementsMember 2024-06-29 0001665988 us-
gaap:LeaseholdImprovementsMember 2023-12-31 0001665988 us-gaap:FurnitureAndFixturesMember 2024-06-29 0001665988 us-gaap:FurnitureAndFixturesMember 2023-
12-31 0001665988 us-gaap:MachineryAndEquipmentMember 2024-06-29 0001665988 us-gaap:MachineryAndEquipmentMember 2023-12-31 0001665988
bvs:AssetsNotYetPlacedInServiceMember 2024-06-29 0001665988 bvs:AssetsNotYetPlacedInServiceMember 2023-12-31 0001665988 us-
gaap:DiscontinuedOperationsHeldforsaleMemberus-gaap:FurnitureAndFixturesMember 2024-06-29 0001665988 us-gaap:DiscontinuedOperationsHeldforsaleMemberus-
gaap:MachineryAndEquipmentMember 2024-06-29 0001665988 us-gaap:IntellectualPropertyMember 2024-06-29 0001665988 us-gaap:IntellectualPropertyMember 2023-12-
31 0001665988 us-gaap:DistributionRightsMember 2024-06-29 0001665988 us-gaap:DistributionRightsMember 2023-12-31 0001665988 us-
gaap:CustomerRelationshipsMember 2024-06-29 0001665988 us-gaap:CustomerRelationshipsMember 2023-12-31 0001665988 us-
gaap:InProcessResearchAndDevelopmentMember 2024-06-29 0001665988 us-gaap:InProcessResearchAndDevelopmentMember 2023-12-31 0001665988 us-
gaap:DevelopedTechnologyRightsMember 2024-06-29 0001665988 us-gaap:DevelopedTechnologyRightsMember 2023-12-31 0001665988 us-
gaap:DiscontinuedOperationsHeldforsaleMemberus-gaap:IntellectualPropertyMember 2024-06-29 0001665988 us-gaap:DiscontinuedOperationsHeldforsaleMemberus-
gaap:IntellectualPropertyMember 2024-03-312024-06-29 0001665988 us-gaap:DiscontinuedOperationsHeldforsaleMemberus-gaap:IntellectualPropertyMember 2024-01-
012024-06-29 0001665988 us-gaap:DiscontinuedOperationsHeldforsaleMemberbvs:RehabilitationBusinessMember 2024-05-31 0001665988 us-
gaap:DiscontinuedOperationsHeldforsaleMemberbvs:RehabilitationBusinessMember 2024-01-012024-06-29 0001665988 us-
gaap:DiscontinuedOperationsHeldforsaleMemberbvs:RehabilitationBusinessMember 2024-03-312024-06-29 0001665988 us-
gaap:DiscontinuedOperationsDisposedOfBySaleMemberbvs:WoundBusinessMember 2023-05-22 0001665988 us-
gaap:DiscontinuedOperationsDisposedOfBySaleMemberbvs:WoundBusinessMember 2023-05-222023-05-22 0001665988 us-
gaap:DiscontinuedOperationsDisposedOfBySaleMemberbvs:WoundBusinessMember 2023-01-012023-07-01 0001665988 bvs:CartiHealLtdMember 2022-07-12 0001665988
bvs:CartiHealLtdMemberbvs:DeferredConsiderationMember 2023-02-27 0001665988 bvs:CartiHealLtdMemberbvs:SalesMilestoneMember 2023-02-27 0001665988 us-
gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleMemberbvs:CartiHealLtdMember 2023-02-272023-02-27 0001665988 bvs:CartiHealLtdMember 2023-02-
272023-02-27 0001665988 bvs:TermLoanMember 2024-06-29 0001665988 bvs:TermLoanMember 2023-12-31 0001665988 us-gaap:RevolvingCreditFacilityMember 2024-06-29
0001665988 us-gaap:RevolvingCreditFacilityMember 2023-12-31 0001665988 us-gaap:LineOfCreditMemberus-gaap:SecuredDebtMember 2019-12-06 0001665988 us-
gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember 2019-12-06 0001665988 us-gaap:LineOfCreditMemberbvs:TermLoanMemberus-gaap:SecuredDebtMember
2021-08-292021-12-29 0001665988 us-gaap:LineOfCreditMemberbvs:TermLoanMemberus-gaap:SecuredDebtMember 2021-10-29 0001665988 us-
gaap:LineOfCreditMemberbvs:TermLoanFacilityJuly2022Memberus-gaap:SecuredDebtMember 2022-07-112022-07-11 0001665988 us-gaap:SecuredDebtMemberus-
gaap:SecuredOvernightFinancingRateSofrMember 2022-07-122022-07-12 0001665988 us-gaap:SecuredDebtMemberus-gaap:BaseRateMember 2022-07-122022-07-12
0001665988 us-gaap:SecuredDebtMemberus-gaap:SecuredOvernightFinancingRateSofrMember 2023-03-312023-03-31 0001665988 us-gaap:SecuredDebtMemberus-
gaap:BaseRateMember 2023-03-312023-03-31 0001665988 us-gaap:SecuredDebtMember 2023-03-31 0001665988 us-
gaap:LineOfCreditMemberbvs:TermLoanFacilityJanuary2024Memberus-gaap:SecuredDebtMember 2024-06-29 0001665988 us-
gaap:LineOfCreditMemberbvs:TermLoanFacilityJanuary2024Memberus-gaap:SecuredDebtMember 2024-01-012024-06-29 0001665988 us-
gaap:LineOfCreditMemberbvs:TermLoanFacilityMarch2023Memberus-gaap:SecuredDebtMember 2023-07-01 0001665988 us-
gaap:LineOfCreditMemberbvs:TermLoanFacilityMarch2023Memberus-gaap:SecuredDebtMember 2023-01-012023-07-01 0001665988 us-gaap:LineOfCreditMember 2023-03-
012023-03-31 0001665988 us-gaap:LineOfCreditMember 2024-01-012024-01-31 0001665988 us-gaap:LineOfCreditMemberbvs:TermLoanFacilitiesMemberus-
gaap:SecuredDebtMember 2024-06-29 0001665988 us-gaap:LineOfCreditMemberbvs:TermLoanFacilitiesMemberus-gaap:SecuredDebtMember 2023-04-022023-07-01
0001665988 us-gaap:LineOfCreditMemberbvs:TermLoanFacilitiesMemberus-gaap:SecuredDebtMember 2024-03-312024-06-29 0001665988 us-
gaap:LineOfCreditMemberbvs:TermLoanFacilitiesMemberus-gaap:SecuredDebtMember 2024-01-012024-06-29 0001665988 us-
gaap:LineOfCreditMemberbvs:TermLoanFacilitiesMemberus-gaap:SecuredDebtMember 2023-01-012023-07-01 0001665988 us-
gaap:FairValueInputsLevel2Memberbvs:TermLoanMember 2024-06-29 0001665988 us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember 2024-01-012024-06-
29 0001665988 us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember 2024-06-29 0001665988 us-gaap:RevolvingCreditFacilityMember 2023-12-312023-12-31
0001665988 us-gaap:RevolvingCreditFacilityMemberus-gaap:SubsequentEventMember 2024-06-302024-06-30 0001665988 us-gaap:LineOfCreditMemberus-
gaap:RevolvingCreditFacilityMemberus-gaap:SubsequentEventMember 2024-06-30 0001665988 us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember 2023-
12-31 0001665988 us-gaap:LineOfCreditMemberbvs:LetterOfCreditMember 2024-06-29 0001665988 us-gaap:LineOfCreditMemberus-gaap:BridgeLoanMember 2024-01-
012024-06-29 0001665988 bvs:BionessIncMemberus-gaap:FairValueMeasurementsRecurringMember 2024-06-29 0001665988 bvs:BionessIncMemberus-
gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember 2024-06-29 0001665988 bvs:BionessIncMemberus-
gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001665988 bvs:BionessIncMemberus-gaap:FairValueInputsLevel3Memberus-
gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001665988 us-gaap:FairValueMeasurementsRecurringMember 2024-06-29 0001665988 us-
gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember 2024-06-29 0001665988 us-gaap:FairValueMeasurementsRecurringMember 2023-12-
31 0001665988 us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001665988
srt:MinimumMemberbvs:BionessIncMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountRateMemberus-
gaap:ValuationTechniqueDiscountedCashFlowMember 2024-06-29 0001665988 srt:MaximumMemberbvs:BionessIncMemberus-gaap:FairValueInputsLevel3Memberus-
gaap:MeasurementInputDiscountRateMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember 2024-06-29 0001665988 bvs:BionessIncMember 2024-03-312024-06-
29 0001665988 bvs:BionessIncMember 2023-04-022023-07-01 0001665988 bvs:BionessIncMember 2024-01-012024-06-29 0001665988 bvs:BionessIncMember 2023-01-
012023-07-01 0001665988 bvs:A2021PlanMemberus-gaap:CommonClassAMember 2024-06-29 0001665988 bvs:A2023RetentionEquityAwardPlanMemberus-
gaap:CommonClassAMember 2024-06-29 0001665988 bvs:A2021And2023PlanMember 2023-04-022023-07-01 0001665988 bvs:A2021And2023PlanMember 2023-01-012023-
07-01 0001665988 bvs:A2021PlanMember 2024-03-312024-06-29 0001665988 srt:MinimumMemberus-gaap:RestrictedStockUnitsRSUMember 2024-01-012024-06-29
0001665988 srt:MaximumMemberus-gaap:RestrictedStockUnitsRSUMember 2024-01-012024-06-29 0001665988 us-gaap:RestrictedStockUnitsRSUMember 2024-06-29
0001665988 us-gaap:RestrictedStockUnitsRSUMember 2024-01-012024-06-29 0001665988 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0001665988
srt:MinimumMemberus-gaap:EmployeeStockOptionMember 2024-01-012024-06-29 0001665988 srt:MaximumMemberus-gaap:EmployeeStockOptionMember 2024-01-012024-
06-29 0001665988 us-gaap:EmployeeStockOptionMember 2024-01-012024-06-29 0001665988 us-gaap:CommonClassAMember 2024-06-28 0001665988 us-
gaap:EmployeeStockMember 2024-06-29 0001665988 us-gaap:EmployeeStockMember 2024-01-012024-06-29 0001665988 us-gaap:EmployeeStockMember 2024-03-312024-

06-29 0001665988 us-gaap:EmployeeStockMember 2023-04-022023-07-01 0001665988 us-gaap:EmployeeStockMember 2023-01-012023-07-01 0001665988 us-gaap:CommonClassAMemberus-gaap:IPOMember 2021-02-162021-02-16 0001665988 us-gaap:CommonClassAMember 2021-02-16 0001665988 us-gaap:CommonClassBMember 2021-02-16 0001665988 2021-02-16 0001665988 bvs:BVLLCMemberus-gaap:CommonClassAMember 2021-02-162021-02-16 0001665988 us-gaap:CommonClassAMember 2024-01-012024-06-29 0001665988 bvs:BVLLCMember 2024-06-29 0001665988 bvs:BVLLCMember 2024-01-012024-06-29 0001665988 bvs:BVLLCMember 2023-12-31 0001665988 bvs:BVLLCMember 2023-01-012023-12-31 0001665988 bvs:BVLLCMemberbvs:ContinuingLLCOwnerMember 2024-06-29 0001665988 bvs:BVLLCMemberbvs:ContinuingLLCOwnerMember 2024-01-012024-06-29 0001665988 bvs:BVLLCMemberbvs:ContinuingLLCOwnerMember 2023-12-31 0001665988 bvs:BVLLCMemberbvs:ContinuingLLCOwnerMember 2023-01-012023-12-31 0001665988 bvs:BVLLCMemberbvs:BioventusAndContinuingLLCOwnerMember 2024-06-29 0001665988 bvs:BVLLCMemberbvs:BioventusAndContinuingLLCOwnerMember 2024-01-012024-06-29 0001665988 bvs:BVLLCMemberbvs:BioventusAndContinuingLLCOwnerMember 2023-12-31 0001665988 bvs:BVLLCMemberbvs:BioventusAndContinuingLLCOwnerMember 2023-01-012023-12-31 0001665988 bvs:LimitedLiabilityCompanyInterestsMember 2024-03-312024-06-29 0001665988 bvs:LimitedLiabilityCompanyInterestsMember 2023-04-022023-07-01 0001665988 bvs:LimitedLiabilityCompanyInterestsMember 2024-01-012024-06-29 0001665988 bvs:LimitedLiabilityCompanyInterestsMember 2023-01-012023-07-01 0001665988 us-gaap:EmployeeStockOptionMember 2024-03-312024-06-29 0001665988 us-gaap:EmployeeStockOptionMember 2023-04-022023-07-01 0001665988 us-gaap:EmployeeStockOptionMember 2024-01-012024-06-29 0001665988 us-gaap:EmployeeStockOptionMember 2023-01-012023-07-01 0001665988 us-gaap:RestrictedStockUnitsRSUMember 2024-03-312024-06-29 0001665988 us-gaap:RestrictedStockUnitsRSUMember 2023-04-022023-07-01 0001665988 us-gaap:RestrictedStockUnitsRSUMember 2024-01-012024-06-29 0001665988 us-gaap:RestrictedStockUnitsRSUMember 2023-01-012023-07-01 0001665988 srt:MinimumMember 2024-06-29 0001665988 srt:MaximumMember 2024-06-29 0001665988 bvs:BioventusShareholderLitigationMemberus-gaap:SubsequentEventMember 2024-07-152024-07-15 0001665988 bvs:BioventusShareholderLitigationMember 2024-03-312024-06-29 0001665988 bvs:BioventusShareholderLitigationMember 2024-01-012024-06-29 0001665988 bvs:BioventusShareholderLitigationMemberus-gaap:SubsequentEventMember 2024-07-15 0001665988 bvs:BioventusShareholderLitigationMember 2024-05-01 0001665988 bvs:HAProductMember 2021-11-102021-11-10 0001665988 bvs:HAProductMember 2022-01-012022-12-31 0001665988 bvs:HAProductMember 2023-03-082023-03-08 0001665988 bvs:HAProductMember 2024-01-312024-01-31 0001665988 bvs:HarborMember 2019-08-232019-08-23 0001665988 bvs:SupplierOfSingleInjectionOAProductMember 2024-03-312024-06-29 0001665988 bvs:SupplierOfSingleInjectionOAProductMember 2023-04-022023-07-01 0001665988 bvs:SupplierOfSingleInjectionOAProductMember 2024-01-012024-06-29 0001665988 bvs:SupplierOfSingleInjectionOAProductMember 2023-01-012023-07-01 0001665988 bvs:ThreeInjectionOAProductMember 2016-02-092016-02-09 0001665988 bvs:HarborMember 2020-12-222020-12-22 0001665988 country:US 2023-04-022023-07-01 0001665988 country:US 2023-01-012023-07-01 0001665988 us-gaap:NonUsMember 2023-04-022023-07-01 0001665988 us-gaap:NonUsMember 2023-01-012023-07-01 0001665988 bvs:CustomerOneMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember 2024-03-312024-06-29 0001665988 bvs:CustomerOneMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember 2024-01-012024-06-29 0001665988 bvs:PainTreatmentsMembercountry:US 2024-03-312024-06-29 0001665988 bvs:PainTreatmentsMembercountry:US 2024-01-012024-06-29 0001665988 bvs:PainTreatmentsMembercountry:US 2023-04-022023-07-01 0001665988 bvs:PainTreatmentsMembercountry:US 2024-01-012024-06-29 0001665988 bvs:PainTreatmentsMembercountry:US 2023-01-012023-07-01 0001665988 bvs:RestorativeTherapiesMembercountry:US 2024-03-312024-06-29 0001665988 bvs:RestorativeTherapiesMembercountry:US 2023-04-022023-07-01 0001665988 bvs:RestorativeTherapiesMembercountry:US 2024-01-012024-06-29 0001665988 bvs:RestorativeTherapiesMembercountry:US 2023-01-012023-07-01 0001665988 bvs:SurgicalSolutionsMembercountry:US 2024-03-312024-06-29 0001665988 bvs:SurgicalSolutionsMembercountry:US 2023-04-022023-07-01 0001665988 bvs:SurgicalSolutionsMembercountry:US 2024-01-012024-06-29 0001665988 bvs:SurgicalSolutionsMembercountry:US 2023-01-012023-07-01 0001665988 country:US 2024-03-312024-06-29 0001665988 country:US 2024-01-012024-06-29 0001665988 bvs:PainTreatmentsMemberus-gaap:NonUsMember 2024-03-312024-06-29 0001665988 bvs:PainTreatmentsMemberus-gaap:NonUsMember 2023-04-022023-07-01 0001665988 bvs:PainTreatmentsMemberus-gaap:NonUsMember 2024-01-012024-06-29 0001665988 bvs:PainTreatmentsMemberus-gaap:NonUsMember 2023-01-012023-07-01 0001665988 bvs:RestorativeTherapiesMemberus-gaap:NonUsMember 2024-03-312024-06-29 0001665988 bvs:RestorativeTherapiesMemberus-gaap:NonUsMember 2023-04-022023-07-01 0001665988 bvs:RestorativeTherapiesMemberus-gaap:NonUsMember 2024-01-012024-06-29 0001665988 bvs:RestorativeTherapiesMemberus-gaap:NonUsMember 2023-01-012023-07-01 0001665988 bvs:SurgicalSolutionsMemberus-gaap:NonUsMember 2024-03-312024-06-29 0001665988 bvs:SurgicalSolutionsMemberus-gaap:NonUsMember 2023-04-022023-07-01 0001665988 bvs:SurgicalSolutionsMemberus-gaap:NonUsMember 2024-01-012024-06-29 0001665988 bvs:SurgicalSolutionsMemberus-gaap:NonUsMember 2023-01-012023-07-01 0001665988 us-gaap:NonUsMember 2024-03-312024-06-29 0001665988 us-gaap:NonUsMember 2024-01-012024-06-29 0001665988 us-gaap:OperatingSegmentsMemberbvs:USSegmentMember 2024-03-312024-06-29 0001665988 us-gaap:OperatingSegmentsMemberbvs:USSegmentMember 2023-04-022023-07-01 0001665988 us-gaap:OperatingSegmentsMemberbvs:USSegmentMember 2024-01-012024-06-29 0001665988 us-gaap:OperatingSegmentsMemberbvs:USSegmentMember 2023-01-012023-07-01 0001665988 us-gaap:OperatingSegmentsMemberbvs:InternationalSegmentMember 2024-03-312024-06-29 0001665988 us-gaap:OperatingSegmentsMemberbvs:InternationalSegmentMember 2023-04-022023-07-01 0001665988 us-gaap:OperatingSegmentsMemberbvs:InternationalSegmentMember 2024-01-012024-06-29 0001665988 us-gaap:OperatingSegmentsMemberbvs:InternationalSegmentMember 2023-01-012023-07-01 0001665988 us-gaap:MaterialReconcilingItemsMember 2024-03-312024-06-29 0001665988 us-gaap:MaterialReconcilingItemsMember 2023-04-022023-07-01 0001665988 us-gaap:MaterialReconcilingItemsMember 2024-01-012024-06-29 0001665988 us-gaap:MaterialReconcilingItemsMember 2023-01-012023-07-01 0001665988 us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberbvs:CartiHealMember 2023-01-012023-07-01 0001665988 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember 2023-07-01 0001665988 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember 2024-06-29 shares iso4217:USD iso4217:USD shares bvs:employee pure bvs:letter_of_credit bvs:vote bvs:lawsuit bvs:segmentfalse0001665988--12-312024Q2http://fasb.org/us-gaap/2024#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationhttp://fasb.org/us-gaap/2024#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization10-Qtrue2024-06-29false001-37844BIOVENTUS INC.DE81-0980861472 1 Emperor BoulevardSuite 100DurhamNC27703919474-6700Class A Common Stock, $0.001 par value per shareBVSNASDAQYesYesAccelerated Filertruetruetruefalse651869011578673715121700013706900028067400025612800011021000123010002104600026640000475780004794600088655000930860001036390009770000-977000-29368000675000-24041000-85308000-9924000-10587000-20263000-20281000-159000-513000-2220001075000-10083000-11100000-20485000-19206000-39451000-4350000-44526000-104514000-733900038100-643200023500-32112000-4731000-38094000-104749000000-74429000-32112000-4731000-38094000-179178000-8120000-1050000-9532000-21410000000-14937000-23992000-3681000-28562000-142831000-32112000-4731000-38094000-179178000-426000303000-1011000960000-32538000-4428000-39105000-178218000820400098900097320002121500000014937000-24334000-3439000-29373000-142066000-0.37-0.37-0.06-0.06-0.45-0.45-1.34-1.34000000-0.95-0.95-0.37-0.37-0.06-0.06-0.45-0.45-2.29-2.29640567596405675962551285625512856372034263720342623380186233801831994000369640001373050001227890008760600091333000235700001691300028400000000.0010.001100000001000000000.0010.00125000000025000000065172159651721596326743663267436650006300000.0010.00150000000500000001578673715786737157867350098000-321536000-1700079400015093500017359100038127000475270001890620002211180007921730008109100006367217064000157867371600049697700032500032610600046156000217432000149998910004950004960000-23992000-8120000-32112000502000-502000029950006770003672000-342000-84000-426000651721596500015786737160005009690000-17000-350098000381270001890620006250791763000157867371600049247500041300030445600051851000240362000296589139000139000-3681000-1050000-4731000108000-1080000-2124000-608000-273200024200061000303000628045066300015786737160004905980006550003081370005014600023334100063267436630001578673716000494254000794000-321536000475270002211180001904723200078400078600-28562000-9532000-38094000821000-821000051100001153000626300-811000-200000-101100065172159650001578673716000500969000-17000-350098000381270001890620006206301462063014620006200015786737157867371600016000490576000490576000-110000-110000-165306000-165306000869840008698400041222200074149210002220002230000-142831000-36347000-179178000385000-3850000-585000-301000-886000765000195000960000628045066300015786737160004905980006550003081370005014600023334100038094000-1791780000-74429000-38094000-104749000248750003107300-5370006400006263000-886000595000527000-8098000-3540000031870000786150000-977000-536000-601000961000113900021933000-113290008359000130740002255200014765000147400019630009157000154540000-216900091570001328500003489700036800049570000-7090000-1077000299400000-11506000-10770001843400078600022300004900000042000000118000036610001132000038264000-373000-166000-12087000-34868000-9630007010000-4970000-244800036964000318370003199400029389000070900020500096800000rganization The Company Bioventus Inc. (together with its subsidiaries, the "Company") was formed as a Delaware corporation for the purpose of facilitating an initial public offering and other related transactions in order to carry on the business of Bioventus LLC and its subsidiaries ("BV LLC"). Bioventus Inc. functions as a holding company with no direct operations, material assets or liabilities other than the equity interest in BV LLC. BV LLC is a limited liability company formed under the laws of the state of Delaware on November 23, 2011 and operates as a partnership. BV LLC commenced operations in May 2012. On February 16, 2021, the Company completed its initial public offering ("IPO"), which was conducted through what is commonly referred to as an umbrella partnership C Corporation ("UP-C") structure. The Company has majority interest, sole voting interest and controls the management of BV LLC. As a result, the Company consolidates the financial results of BV LLC and reports a noncontrolling interest representing the interest of BV LLC held by its continuing LLC owner. The Company is focused on developing and commercializing clinically differentiated, cost efficient and minimally invasive treatments that engage and enhance the body's natural healing processes. The Company is headquartered in Durham, North Carolina and has approximately 1,030 employees. Interim periods The Company reports quarterly interim periods on a 13-week basis within a standard calendar year. Each annual reporting period begins on January 1 and ends on December 31. Each quarter ends on the Saturday closest to calendar quarter-end, with the exception of the fourth quarter, which ends on December 31. The 13-week quarterly periods for fiscal year 2024 end on March 30, June 29 and September 28. Comparable periods for 2023 ended on April 1, July 1 and September 30. The fourth and first quarters may vary in length depending on the calendar year. Unaudited interim financial information The accompanying unaudited consolidated condensed financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America ("U.S. GAAP") for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Pursuant to these rules and regulations, they do not include all information and notes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments, and the adjustments discussed in Note 1. Organization) considered necessary for a fair statement of the Company's financial condition and results of operations have been included. Operating results for the periods presented are not necessarily indicative of the results that may be expected for the full year. As such, the information included in this report should be read in conjunction with the Company's Annual Report on Form 10-K for the year ended December 31, 2023. The consolidated balance sheet at December 31, 2023 has been derived from the audited consolidated financial statements of the Company, but does not include all the disclosures required by U.S. GAAP. Reclassifications Certain prior period amounts have been reclassified to conform to current period presentation. During the first quarter of 2024, the Company reclassified revenue and expense of the SonicOne Ultrasonic Cleansing and Debridement Systems ("SonicOne") from the Restorative Therapies to the Surgical Solutions business. The reclassification of SonicOne activity affected prior presentation of disaggregated revenue by business, refer to Note 12. Revenue recognition for further details. The reclassification had no effect on previously reported total revenues, net loss, other comprehensive loss, stockholders' equity or cash flows. Unless otherwise noted, all financial information in the unaudited consolidated condensed financial statements reflects the Company's results from continuing operations. <div style="margin-

bottom:6pt;margin-top:6pt;text-align:justify">Use of estimates The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities, at the date of the financial statements, as well as the reported amounts of revenues and expenses during the period. On an ongoing basis, management evaluates these estimates, including those related to contractual allowances and sales incentives, allowance for credit losses, inventory reserves, goodwill and intangible assets impairment, valuation of assets and liabilities assumed in acquisitions, useful lives of long lived assets, fair value measurements, litigation and contingent liabilities, income taxes, and equity-based compensation. Management bases its estimates on historical experience, future expectations and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from those estimates. Recent accounting pronouncements In addition to being a smaller reporting and an emerging growth company, the Company also is an accelerated filer under SEC rules and regulations. Therefore, required effective dates for adopting new or revised accounting standards are generally earlier than when smaller reporting companies and emerging growth companies who are not accelerated filers are required to adopt. In December 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update 2023-09 (“ASU 2023-09”), Income Taxes, which enhances the transparency of income tax disclosures by expanding annual disclosure requirements related to the rate reconciliation and income taxes paid. The amendments are effective for fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments should be applied on a prospective basis. Retrospective application is permitted. The Company is currently evaluating this ASU to determine its impact on the Company’s disclosures. In November 2023, the FASB issued Accounting Standards Update 2023-07 (“ASU 2023-07”), Segment Reporting, which improves reportable segment disclosure requirements. ASU 2023-07 primarily enhances disclosures about significant segment expenses by requiring that a public entity disclose significant segment expenses that are regularly provided to the Chief Operating Decision Maker (“CODM”) and included within each reported measure of segment profit or loss. This ASU also (i) requires that a public entity disclose, on an annual and interim basis, an amount for other segment items by reportable segment, and a description of its composition; (ii) requires that all annual disclosures are provided in the interim periods; (iii) clarifies that if the CODM uses more than one measure of profitability in assessing segment performance and deciding how to allocate resources, that one or more of those measures may be reported; (iv) requires disclosure of the title and position of the CODM and a description of how the reported measures are used by the CODM in assessing segment performance and in deciding how to allocate resources; (v) requires that an entity with a single segment provide all new required disclosures. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024 and requires retrospective application. Early adoption is permitted. The amendments under ASU 2023-07 relate to financial disclosures and its adoption will not have an impact on the Company’s results of operations, financial position or cash flows. The Company will adopt ASU 2023-07 for the annual reporting period ending December 31, 2024 and for interim reporting periods thereafter. 1030 Reclassifications Certain prior period amounts have been reclassified to conform to current period presentation. During the first quarter of 2024, the Company reclassified revenue and expense of the SonicOne Ultrasonic Cleansing and Debridement Systems (“SonicOne”) from the Restorative Therapies to the Surgical Solutions business. The reclassification of SonicOne activity affected prior presentation of disaggregated revenue by business, refer to Note 12. Revenue recognition for further details. The reclassification had no effect on previously reported total revenues, net loss, other comprehensive loss, stockholders’ equity or cash flows. Use of estimates The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities, at the date of the financial statements, as well as the reported amounts of revenues and expenses during the period. On an ongoing basis, management evaluates these estimates, including those related to contractual allowances and sales incentives, allowance for credit losses, inventory reserves, goodwill and intangible assets impairment, valuation of assets and liabilities assumed in acquisitions, useful lives of long lived assets, fair value measurements, litigation and contingent liabilities, income taxes, and equity-based compensation. Management bases its estimates on historical experience, future expectations and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from those estimates. Recent accounting pronouncements In addition to being a smaller reporting and an emerging growth company, the Company also is an accelerated filer under SEC rules and regulations. Therefore, required effective dates for adopting new or revised accounting standards are generally earlier than when smaller reporting companies and emerging growth companies who are not accelerated filers are required to adopt. In December 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update 2023-09 (“ASU 2023-09”), Income Taxes, which enhances the transparency of income tax disclosures by expanding annual disclosure requirements related to the rate reconciliation and income taxes paid. The amendments are effective for fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments should be applied on a prospective basis. Retrospective application is permitted. The Company is currently evaluating this ASU to determine its impact on the Company’s disclosures. In November 2023, the FASB issued Accounting Standards Update 2023-07 (“ASU 2023-07”), Segment Reporting, which improves reportable segment disclosure requirements. ASU 2023-07 primarily enhances disclosures about significant segment expenses by requiring that a public entity disclose significant segment expenses that are regularly provided to the Chief Operating Decision Maker (“CODM”) and included within each reported measure of segment profit or loss. This ASU also (i) requires that a public entity disclose, on an annual and interim basis, an amount for other segment items by reportable segment, and a description of its composition; (ii) requires that all annual disclosures are provided in the interim periods; (iii) clarifies that if the CODM uses more than one measure of profitability in assessing segment performance and deciding how to allocate resources, that one or more of those measures may be reported; (iv) requires disclosure of the title and position of the CODM and a description of how the reported measures are used by the CODM in assessing segment performance and in deciding how to allocate resources; (v) requires that an entity with a single segment provide all new required disclosures. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024 and requires retrospective application. Early adoption is permitted. The amendments under ASU 2023-07 relate to financial disclosures and its adoption will not have an impact on the Company’s results of operations, financial position or cash flows. The Company will adopt ASU 2023-07 for the annual reporting period ending December 31, 2024 and for interim reporting periods thereafter. Balance sheet information Accounts receivable, net Accounts receivable, net are amounts billed and currently due from customers. The Company records the amounts due net of allowance for credit losses. Collection of the consideration that the Company expects to receive typically occurs within 30 to 90 days of billing. The Company applies the practical expedient for contracts with payment terms of one year or less which does not consider the effects of the time value of money. Occasionally, the Company enters into payment agreements with patients that allow payment terms beyond one year. In those cases, the financing component is not deemed significant to the contract. Accounts receivable, net of allowances, consisted of the following as of: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 29, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Accounts receivable(a) </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">140,204 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">127,008 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Less: Allowance for credit losses(a) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2,899)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(4,219)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">137,305 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-

color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">122,789 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> (a)Accounts receivable of $7,688 attributable to the Company's advanced rehabilitation business was reclassified to assets held for sale within the June 29, 2024 consolidated condensed balance sheets. Refer to Note 3. Acquisitions and divestitures for further details regarding assets held for sale.</div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify">Due to the short-term nature of the Company's receivables, the estimate of expected credit losses is based on aging of the account receivable balances. The allowance is adjusted on a specific identification basis for certain accounts as well as pooling of accounts with similar characteristics. The Company has a diverse customer base with no single customer representing ten percent or more of sales. The Company has one customer representing approximately 19.2% and 16.0% of the accounts receivable balance as of June 29, 2024 and December 31, 2023, respectively. Historically, the Company's reserves have been adequate to cover credit losses.</div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify">Inventory</div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify">Inventory consisted of the following as of:</div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 29, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Raw materials and supplies(a)</div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">24,841 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">21,062 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Finished goods(a)</div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">62,765 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">70,271 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">87,606 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">91,333 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> (a)Raw materials and supplies of $4,924 and finished goods inventory of $9,449 attributable to the Company's advanced rehabilitation business were reclassified to assets held for sale within the June 29, 2024 consolidated condensed balance sheets. Refer to Note 3. Acquisitions and divestitures for further details regarding assets held for sale.</div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify">Property and equipment, net</div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify">Property and equipment consisted of the following as of:</div><div style="margin-bottom:1pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 29, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Computer equipment and software</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">39,713 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">37,860 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Demonstration and consignment inventory</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9,963 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9,341 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Leasehold improvements</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,933 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,763 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Furniture and fixtures(a) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,586 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,163 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Finance leases</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15,737 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15,737 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Machinery and equipment(b) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,801 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,180 </td><td style="background-

color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Assets net yet placed in service</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,021 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,065 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">77,754 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">77,109 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Less accumulated depreciation</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(45,816)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(40,504)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">31,938 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">36,605 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> (a)Furniture and fixtures of $51 and accumulated depreciation of $31 attributable to the Company's advanced rehabilitation business were reclassified to assets held for sale within the June 29, 2024 consolidated condensed balance sheets. Refer to Note 3. Acquisitions and divestitures for further details regarding assets held for sale. (b)Machinery and equipment of $385 and accumulated depreciation of $133 attributable to the Company's advanced rehabilitation business were reclassified to assets held for sale within the June 29, 2024 consolidated condensed balance sheets. Refer to Note 3. Acquisitions and divestitures for further details regarding assets held for sale.</div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify">Intangible assets, net</div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify">Intangible assets consisted of the following as of:</div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 29, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div>Intellectual property(a)(b)</div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">626,007 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">677,258 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Distribution rights</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">61,325 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">61,325 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Customer relationships</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">57,950 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">57,950 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">IPR&D</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,500 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,500 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Developed technology and other</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13,998 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13,998 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Total carrying amount</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">764,780 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">816,031 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Less accumulated amortization:</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"> Intellectual property(a)(b) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(221,261)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(218,031)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top">Distribution rights</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(51,790)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(49,301)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top">Customer relationships</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px

1pt;text-align:right;vertical-align:bottom">(57,950)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(57,950)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top">Developed technology and other</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(8,004)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(7,521)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Total accumulated amortization</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(339,005)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(332,803)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Intangible assets, net before currency translation</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">425,775 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">483,228 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Currency translation</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,223)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(878)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">424,552 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">482,350 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> (a)Intellectual property of $19,380 and accumulated amortization of $16,656 attributable to the Company's advanced rehabilitation business were reclassified to assets held for sale within the June 29, 2024 consolidated condensed balance sheets. Refer to Note 3.Acquisitions and divestitures for further details regarding assets held for sale. (b)The Company recorded an impairment loss of $31,870 for the three and six months ended June 29, 2024 in the U.S. reporting segment of net intellectual property solely attributable to the Company's advanced rehabilitation business. The loss was recorded in impairment of assets within the consolidated condensed statements of operations and comprehensive loss. Refer to Refer to Note 3. Acquisitions and divestitures for further details regarding businesses held for sale. Estimated amortization expense for intangibles subsequent to reclassifications, impairment and additions for the remainder of 2024 and for the years ended December 31, 2025 through 2028 is expected to be $19,629, $37,412, $34,192, $35,243 and $31,012, respectively.</div><div style="text-align:justify">Accrued liabilities</div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify">Accrued liabilities consisted of the following as of:</div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 29, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Gross-to-net deductions</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman';sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">68,349 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">59,592 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Bonus and commission</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19,987 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19,437 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Settlement and legal fees</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">17,737 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">986 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Compensation and benefits</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9,081 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9,709 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Accrued interest</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,185 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,606 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Income and other taxes</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,883 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,749 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Other liabilities(a) </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13,756 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-

size:10pt;font-weight:400;line-height:100%">18,716 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">139,978 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">119,795 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> (a)Accrued liabilities of $3,110 attributable to the Company's advanced rehabilitation business were reclassified to liabilities held for sale within the June 29, 2024 consolidated condensed balance sheets. Refer to Note 3. Acquisitions and divestitures for further details regarding assets held for sale.</div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify">Accounts receivable, net of allowances, consisted of the following as of:</div><div style="margin-bottom:1pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 29, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Accounts receivable(a)</div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">140,204 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">127,008 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Less: Allowance for credit losses(a)</div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2,899) </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(4,219)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">137,305 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">122,789 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> (a)Accounts receivable of $7,688 attributable to the Company's advanced rehabilitation business was reclassified to assets held for sale within the June 29, 2024 consolidated condensed balance sheets. Refer to Note 3. Acquisitions and divestitures for further details regarding assets held for sale.</div>1402040001270080002899000421900013730500012278900076880000.1920.160<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify">Inventory consisted of the following as of:</div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 29, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Raw materials and supplies(a)</div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">24,841 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">21,062 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Finished goods(a)</div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">62,765 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">70,271 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">87,606 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">91,333 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> (a)Raw materials and supplies of $4,924 and finished goods inventory of $9,449 attributable to the Company's advanced rehabilitation business were reclassified to assets held for sale within the June 29, 2024 consolidated condensed balance sheets. Refer to Note 3. Acquisitions and divestitures for further details regarding assets held for sale. 2484100021062000627650007027100087606000913330004924000944900 0 Property and equipment consisted of the following as of: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 29, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31,

2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Computer equipment and software</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">39,713 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">37,860 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Demonstration and consignment inventory</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9,963 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9,341 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Leasehold improvements</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,933 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,763 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Furniture and fixtures(a) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,586 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,163 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Finance leases</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15,737 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15,737 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Machinery and equipment(b) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,801 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,180 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Assets not yet placed in service</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,021 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,065 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">77,754 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">77,109 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Less accumulated depreciation</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(45,816)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(40,504)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">31,938 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">36,605 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> (a)Furniture and fixtures of $51 and accumulated depreciation of $31 attributable to the Company's advanced rehabilitation business were reclassified to assets held for sale within the June 29, 2024 consolidated condensed balance sheets. Refer to Note 3. Acquisitions and divestitures for further details regarding assets held for sale. (b)Machinery and equipment of $385 and accumulated depreciation of $133 attributable to the Company's advanced rehabilitation business were reclassified to assets held for sale within the June 29, 2024 consolidated condensed balance sheets. Refer to Note 3. Acquisitions and divestitures for further details regarding assets held for sale.</div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify">Intangible assets consisted of the following as of:</div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 29, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div>Intellectual property(a)(b)</div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">626,007 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">677,258 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Distribution rights</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">61,325 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">61,325 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Customer

relationships</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">57,950 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">57,950 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">IPR&D</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,500 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,500 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Developed technology and other</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13,998 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13,998 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Total carrying amount</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">764,780 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">816,031 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Less accumulated amortization:</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"> Intellectual property(a)(b) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(221,261)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(218,031)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top">Distribution rights</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(51,790)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(49,301)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top">Customer relationships</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(57,950) </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(57,950)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top">Developed technology and other</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(8,004)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(7,521)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Total accumulated amortization</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(339,005)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(332,803)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Intangible assets, net before currency translation</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">425,775 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">483,228 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Currency translation</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,223)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(878)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">424,552 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">482,350 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> (a)Intellectual property of $19,380 and accumulated amortization of $16,656 attributable to the Company's advanced rehabilitation business were reclassified to assets held for sale within the June 29, 2024 consolidated condensed balance sheets. Refer to Note 3.Acquisitions and divestitures for further details regarding assets held for sale. (b)The Company recorded an impairment loss of $31,870 for the three and six months ended June 29, 2024 in the U.S. reporting segment of net intellectual property solely attributable to the Company's advanced rehabilitation business. The loss was recorded in impairment of assets within the consolidated condensed statements of operations and comprehensive loss. Refer to Refer to Note 3. Acquisitions and divestitures for further details regarding businesses held for sale.

<table cellpadding="0" cellspacing="0" id="1223000-878000424552000482350000193800001665600031870000318700001962900037412000341920003524300031012000"> Accrued liabilities consisted of the following as of: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 29, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Gross-to-net deductions</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">68,349 </td><td style="background-

color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">59,592 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Bonus and commission</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19,987 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19,437 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Settlement and legal fees</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">17,737 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">986 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Compensation and benefits</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9,081 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9,709 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Accrued interest</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,185 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,606 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Income and other taxes</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,883 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,749 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Other liabilities(a)</div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13,756 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18,716 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">139,978 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">119,795 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> (a)Accrued liabilities of $3,110 attributable to the Company's advanced rehabilitation business were reclassified to liabilities held for sale within the June 29, 2024 consolidated condensed balance sheets. Refer to Note 3. Acquisitions and divestitures for further details regarding assets held for sale. 6834900059592000199870001943700017737000986000908100097090006185000666060004883000474900013756000187160001399780001197950003110000Acquisitions and divestitures Advanced Rehabilitation Business In May 2024, the Company began contract negotiations with a third-party (the "Buyer") to sell certain products within its advanced rehabilitation business, including the L100, L300 Go, L360, H200, Vector Gait & Safety System and BITS-Bioness Integrated Therapy System (collectively, the "Advanced Rehabilitation Business"). The Advanced Rehabilitation Business is considered non-core and will require additional research and development expenditures to achieve its next stage of growth. The potential divestiture of the Advanced Rehabilitation Business is expected to simplify the Company's business structure and improve liquidity, as the proceeds, net of transactional fees, are required to be used to reduce long-term debt obligations. Contract negotiations are ongoing with the Buyer and as of the end of the second quarter of 2024, the Company had incurred $2,500 in transactional fees resulting from the potential divestiture of the Advanced Rehabilitation Business. The Company has classified the identifiable net assets of the Advanced Rehabilitation Business as held for sale. A significant portion of the Advanced Rehabilitation Business net assets were within the U.S. reporting segment. Assets and liabilities determined to be part of the Advanced Rehabilitation Business have been recorded as single amounts within the Company's consolidated financial statements. Assets held for sale are reported at the lower of the carrying amount or fair value less costs to sell, which is expected to occur within one year. The Company has ceased depreciating and amortizing the assets classified as held for sale. Assets and liabilities held for sale are reviewed each reporting period to determine whether existing carrying values are fully recoverable in comparison to estimated fair values less costs to sell. The Company evaluated the Advanced Rehabilitation Business for impairment due to its potential divestiture and, as a result of this evaluation, recorded a $31,870 impairment under the U.S. reporting segment within the consolidated condensed statements of operations and comprehensive loss during the three and six months ended June 29, 2024 to reduce the intangible assets of the Advanced Rehabilitation Business to reflect their respective fair values less any costs to sell. The fair value of its intangibles was based on the preliminary consideration offered for the Advanced Rehabilitation Business.</div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify">The carrying amounts for the major classes of assets and liabilities of the Advanced Rehabilitation Business classified as held for sale were as follows:</div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 29, 2024</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Carrying amounts of assets classified as held for sale:</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Accounts receivable</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">7,688 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Inventory</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">14,373 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Prepaid and other current assets</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,930 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Property and equipment, net</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">272 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Intangible assets</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,724 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Operating lease assets</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,171 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times

New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">250 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom">Total assets held for sale</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">28,408 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Carrying amounts of liabilities classified as held for sale:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Accounts payable</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">1,566 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Accrued liabilities</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,110 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Other liabilities</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,232 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom">Total liabilities held for sale</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">5,908 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> Wound Business On May 22, 2023, the Company closed the sale of certain assets within its Wound Business, including the TheraSkin and TheraGenesis products (collectively, the "Wound Business"), for potential consideration of $84,675, including $34,675 at closing, $5,000 deferred for 18 months and up to $45,000 in potential earn-out payments, which are based on the achievement of certain revenue thresholds by the purchaser of the Wound Business for sales of the TheraSkin and TheraGenesis products during the 2024, 2025 and 2026 fiscal years. The Company incurred $3,880 in transactional fees resulting from the sale of the Wound Business. The Company used the proceeds from the sale of its Wound Business to prepay $30,000 of long-term debt obligations. Refer to Note 4, Financial Instruments for further details regarding the Company's outstanding long-term debt obligations. The Company evaluated the Wound Business for impairment prior to its sale and recorded a $78,615 impairment within the consolidated condensed statements of operations and comprehensive loss during the six months ended July 1, 2023 as a result of this evaluation to reduce the intangible assets of the Wound Business to reflect their respective fair values less any costs to sell. The fair value of its intangibles was determined based on the consideration received for the Wound Business. The loss resulting from the deconsolidation of the Wound Business totaled $977 for the three and six months ended July 1, 2023 and was recorded in loss on disposals within the consolidated condensed statements of operations and comprehensive loss. CartiHeal (2009) Ltd. On July 12, 2022, the Company completed the acquisition of 100% of the remaining shares in CartiHeal (2009) Ltd. ("CartiHeal"), a developer of the proprietary Agili-C implant for the treatment of joint surface lesions in traumatic and osteoarthritic joints. On February 27, 2023, the Company entered into a settlement agreement (the "Settlement Agreement") with Elron Ventures Ltd. ("Elron"), as representative of CartiHeal's former securityholders (the "Former Securityholders"). Pursuant to the Settlement Agreement, Elron, on behalf of the Former Securityholders, agreed to forbear from initiating any legal action or proceedings related to non-payment of any obligations including deferred purchase price and contingent consideration totaling $215,000 and $135,000, respectively, under the Company's previous agreements to purchase CartiHeal from the Former Securityholders. Pursuant to the Settlement Agreement, the Company also transferred 100% of its shares in CartiHeal to a trustee (the "Trustee") for the benefit of the Former Securityholders and made a one-time non-refundable payment of $10,150 to Elron to be used for purposes set forth in the Settlement Agreement. Given that upon execution of the Settlement Agreement, the Company had no ownership interest or voting rights in CartiHeal, the Company concluded that it had ceased to control CartiHeal for accounting purposes, and therefore, deconsolidated CartiHeal effective February 27, 2023. CartiHeal was part of the Company's international reporting segment and the Company treated the deconsolidation of CartiHeal as a discontinued operation. The loss on disposal was $60,639 and was recorded within discontinued operations, net of tax within the consolidated condensed statements of operations and comprehensive loss for the six months ended July 1, 2023. Refer to Note 14. Discontinued operations for further information regarding the impact of CartiHeal on the Company's consolidated condensed financial statements for the six months ended July 1, 2023.</div>2500000318700003187000<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify">The carrying amounts for the major classes of assets and liabilities of the Advanced Rehabilitation Business classified as held for sale were as follows:</div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 29, 2024</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Carrying amounts of assets classified as held for sale:</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Accounts receivable</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">7,688 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Inventory</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">14,373 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Prepaid and other current assets</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,930 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Property and equipment, net</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">272 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Intangible assets</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,724 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Operating lease assets</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,171 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Other assets</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">250 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom">Total assets held for sale</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">28,408 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Carrying amounts of liabilities classified as held for sale:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Accounts payable</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-

color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">1,566 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Accrued liabilities</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,110 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Other liabilities</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,232 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom">Total liabilities held for sale</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">5,908 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> The following table summarizes the major income and expense line items of these discontinued operations, as reported in the consolidated statements of operations for the six months ended July 1, 2023 as there was no activity for discontinued operations subsequent to the first quarter of 2023: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.841%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.959%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">July 1, 2023</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none">

family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Bioventus Inc. - discontinued operations</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(59,492)</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> (a)Depreciation and amortization and the change in fair value of contingent consideration represents the significant operating non-cash items of discontinued operations. (b)Other expense includes the $60,639 loss on deconsolidation, of which $10,150 was attributable to non-refundable payments. Total investing cash outflows included these non-refundable payments and $1,356 cash on hand at disposal.
768800014373000193000027200027240001171000250000284080001566000311000012320005908000084675000346750005000000P18M450000003880000030000000780977000121500000013500000011015000060639000Financial instruments Long-term debt consisted of the following as of: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 29, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"> Amended Term Loan due October 2026 (9.34% at June 29, 2024) </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">371,128 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">382,448 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"> Revolver due October 2025 (9.34% at June 29, 2024) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15,000 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15,000 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Less:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top">Current portion of long-term debt</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(38,566)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(27,848)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top">Unamortized debt issuance cost</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,459)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(917)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top">Unamortized discount</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,387)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,685)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">344,716 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">366,998 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> Amended Term Loan On December 6, 2019, the Company entered into a Credit and Guaranty Agreement (the "2019 Credit Agreement") that was comprised of a $200,000 term loan (the "Original Term Loan") and a $50,000 revolving facility (the "Revolver"). The Company amended the 2019 Credit Agreement on August 29, 2021, and then again on October 29, 2021 in connection with the acquisition of Misonix, Inc., in which the Company prepaid $80,000 on the Original Term Loan. The 2019 Credit Agreement, as amended, subsequent to the prepayment, was comprised of a $360,750 term loan ("Term Loan") and the Revolver. On July 11, 2022, the Company further amended the 2019 Credit Agreement in conjunction with the acquisition of CartiHeal (the "CartiHeal Acquisition"). Pursuant to that amendment, an $80,000 term loan facility (the "July 2022 Term Loan" and, together with the Term Loan, the "Term Loan Facilities") was extended to the Company to be used for: (i) the financing of the CartiHeal Acquisition; (ii) the payment of related fees and expenses; (iii) repayment of the draws made on the Revolver; and (iv) working capital needs and general corporate purposes of the Company, including without limitation for permitted acquisitions. On March 31, 2023, the Company entered into an additional amendment to the 2019 Credit Agreement to, among other things, modify certain financial covenants, waive covenant noncompliance at December 31, 2022, and to modify interest rates applicable to borrowings under the 2019 Credit Agreement. On January 18, 2024 (the "Closing Date"), the Company further amended the 2019 Credit Agreement (collectively, with the August 2021, October 2021, July 2022 and March 2023 amendments, the "Amended 2019 Credit Agreement"), to further modify certain financial covenants under the 2019 Credit Agreement. The Company was in compliance as of June 29, 2024 with the financial covenants as stated within the 2019 Credit Agreement. SOFR loans and base rate loans had a margin of 3.25% and 2.25%, respectively, subsequent to July 11, 2022 and prior to the Closing Date. As of the March 31, 2023 amendment, SOFR loans and base rate loans had a margin of 4.25% and 3.25%, respectively. All obligations under the Amended 2019 Credit Agreement are guaranteed by the Company and certain wholly owned subsidiaries where substantially all the assets of the Company collateralize the obligations. The Amended 2019 Credit Agreement contains customary affirmative and negative covenants, including those related to financial reporting and notification, restrictions on the declaration or payment of certain distributions on or in respect of Bioventus LLC's equity interests, restrictions on acquisitions, investments and certain other payments, limitations on the incurrence of new indebtedness, limitations on transfers, sales and other dispositions of assets of Bioventus LLC and its subsidiaries, as well as limitations on making changes to the business and organizational documents of Bioventus

LLC and its subsidiaries. Financial covenant requirements include a maximum debt leverage ratio and an interest coverage ratio. In addition, during the period commencing on the Closing Date and ending upon the satisfaction of certain conditions occurring not prior to the delivery of financial statements of the Company for the fiscal quarter ending October 29, 2025, the Company will be subject to certain additional requirements and covenants, including a requirement to maintain Liquidity (as defined in the Amended 2019 Credit Agreement) of not less than $10,000 as of the end of each calendar month during such period. The Term Loan Facilities will mature on October 29, 2026. The Revolver will mature on October 29, 2025. The January 2024 amendment had deferred financing costs of $1,180, of which $325 was recorded in selling, general and administrative expense within the consolidated condensed statements of operations and comprehensive loss and $855 was capitalized on the consolidated condensed balance sheets during the six months ended June 29, 2024. The March 2023 amendment had deferred financing costs of $3,661, of which $1,617 was recorded in selling, general and administrative expense within the consolidated condensed statements of operations and comprehensive loss and $2,044 was capitalized on the consolidated condensed balance sheets during the six months ended July 1, 2023. There were no losses on debt refinancing and modification as a result of either the January 2024 or March 2023 amendments. As of June 29, 2024, $368,282 was outstanding on the Term Loan Facilities, net of original issue discount of $1,387 and deferred financing costs of $1,459. As previously discussed in Note 3, Acquisitions and divestitures, the Company made a prepayment of $30,000 on its Term Loan Facilities with the proceeds from the Wound Business divestiture during the second quarter of 2023. Capitalized deferred fees are amortized to interest expense on a straight-line basis over the term of the Term Loan Facilities, which approximates the effective interest method. Interest expense includes deferred cost amortization of $381, $915, $762 and $1,138 for the three months June 29, 2024 and July 1, 2023 and the six months ended June 29, 2024 and July 1, 2023, respectively. The estimated fair value of the Term Loan Facilities was $370,664 as of June 29, 2024. The fair value of these obligations was determined based on the midpoint of the Bloomberg Valuation. This is classified as a Level 2 instrument within the fair value hierarchy. Revolver and Letters of Credit The Revolver is a five-year revolving credit facility that includes revolving and swingline loans as well as letters of credit ("LOC") and, inclusive of all, could not exceed $45,000 at any one time as the Revolver capacity was reduced by $5,000 at December 31, 2023 in accordance with the 2019 Credit Agreement then in effect. The Revolver was further reduced by $5,000 at June 30, 2024, limiting borrowing capacity to $40,000. The Company had $15,000 outstanding borrowings on its Revolver as of June 29, 2024 and December 31, 2023. LOCs are available in an amount not to exceed $7,500. The Company had two LOCs outstanding as of June 29, 2024, leaving approximately $5,800 available. Revolving loans are due at the earlier of termination or maturity. Swingline loans are available as base rate option loans only and must be outstanding for at least five days. Swingline loans are due the fifteenth or last day of a calendar month or maturity, whichever is earlier.</div><div style="margin-bottom:6pt;margin-top:6pt">Long-term debt consisted of the following as of:</div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 29, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div>Amended Term Loan due October 2026 (9.34% at June 29, 2024)</div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">371,128 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">382,448 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div>Revolver due October 2025 (9.34% at June 29, 2024)</div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15,000 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15,000 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Less:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top">Current portion of long-term debt</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(38,566)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(27,848)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top">Unamortized debt issuance cost</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,459)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(917)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top">Unamortized discount</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,387)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,685)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">344,716 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">366,998 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 0.093437112800038244800000.093415000000150000003856600027848000145900091700013870001685000344716000366998000200000000500000000800000000360750000000000

<tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Current portion of contingent consideration</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">18,745 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">18,745 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Contingent consideration</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18,150 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18,150 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom">Total liabilities:</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">18,150 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">18,150 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> Contingent consideration The Company initially values contingent consideration related to business combinations using a probability-weighted calculation of potential payment scenarios discounted at rates reflective of the risks associated with the expected future cash flows for certain milestones. For other milestones, the Company used a variation of the income approach where revenue was simulated in a risk-neutral framework using Geometric Brownian Motion, a stock price behavior model. Key assumptions used to estimate the fair value of contingent consideration include projected financial information, market data and the probability and timing of achieving the specific targets. After the initial valuation, the Company generally uses its best estimate to measure contingent consideration at each subsequent reporting period using unobservable Level 3 inputs. Unobservable inputs A summary of unobservable Level 3 inputs utilized for the above liabilities are as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.372%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Valuation Technique</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Unobservable inputs</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Range</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Bioness contingent consideration</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Discounted cash flow</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Payment discount rate</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> 6.4% - 6.8% </td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">Payment period</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 2024 - 2025 </td></tr></table> Significant changes in these assumptions could result in a significantly higher or lower fair value. The contingent consideration reported in the table above resulted from the acquisition of Bioness on March 30, 2021. Contingent consideration is adjusted quarterly based upon the passage of time or the anticipated success or failure of achieving certain milestones. Changes in contingent consideration related to Bioness for the three months ended June 29, 2024 and July 1, 2023 and six months ended June 29, 2024 and July 1, 2023 totaled $300, $240, $595 and $527, respectively, and were recorded as the change in fair value of contingent consideration within the consolidated condensed statements of operations and comprehensive loss. The following table provides information for assets and liabilities measured at fair value on a recurring basis using Level 3 inputs: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 29, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 3</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 3</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-

family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Current portion of contingent consideration</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">18,745 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">18,745 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Contingent consideration</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18,150 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18,150 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom">Total liabilities:</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">18,150 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">18,150 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">18,150 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 18745000187450000000181500001815000000181500001815000000181500001815000018150000 A summary of unobservable Level 3 inputs utilized for the above liabilities are as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.367%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.367%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.372%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Valuation Technique</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Unobservable inputs</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Range</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Bioness contingent consideration</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Discounted cash flow</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Payment discount rate</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> 6.4% - 6.8% </td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">Payment period</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 2024 - 2025 </td></tr></table> 0.0640.0683000002400005950005270000Equity-based compensation 2021 Plan The Company operates an equity-based compensation plan (the "2021 Plan"), which allows for the issuance of stock options (incentive and nonqualified), restricted stock, dividend equivalents, restricted stock units ("RSUs"), other stock-based awards, and cash awards (collectively, the "2021 Plan Awards"). As of June 29, 2024, 19,564,333 shares of Class A common stock have been authorized to be awarded under the 2021 Plan and 8,921,686 shares were available for 2021 Plan Awards. 2023 Plan The Company also operates the 2023 Retention Equity Award Plan (the "2023 Plan" and, together with the 2021 Plan, the "Plans"), the purpose of which is to retain and motivate critical personnel over the short-term by providing them additional incentives in the form of RSUs (the "Retention Awards" and together with the "2021 Plan Awards," the "Awards"). As of June 29, 2024, 600,000 shares of Class A common stock were authorized to be awarded under the 2023 Plan and 84,700 shares were available for Retention Awards. Activity under the Plans Expense Equity-based compensation, net for Awards granted under the Plans for the three and six months ended June 29, 2024 totaled $3,457 and $6,048, respectively. Equity-based compensation, net for Awards granted under the Plans for the three and six months ended July 1, 2023 totaled $2,797 and $1,079, respectively, in expense reduction as a result of expense reversals due to executive leadership transitions. Expenses and expense reductions are primarily included in selling, general and administrative expense with a nominal amount in research and development expense within the consolidated condensed statements of operations and comprehensive loss based upon the department of the employee. There were no income tax benefits related to equity-based compensation expense for the three and six months ended June 29, 2024 and July 1, 2023. Restricted Stock Units During the three and six months ended June 29, 2024, the Company granted time-based RSUs which vest at various dates through March 15, 2028. RSU compensation expense is recognized over the vesting period, which is typically between 1 and 4 years. Unamortized compensation expense related to the RSUs totaled $7,091 at June 29, 2024, and is expected to be recognized over a weighted average period of approximately 2.40 years. A summary of the RSU award activity for the six months ended June 29, 2024 is as follows (number of units in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td

style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Number of units</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted-average grant-date fair value per unit</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Unvested at December 31, 2023</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,066 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">4.51 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Granted</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,429 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5.45 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Vested</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,550)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4.56 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Forfeited or canceled</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(105)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7.33 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Unvested at June 29, 2024</td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,840 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">5.12 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> Stock Options During the three and six months ended June 29, 2024, the Company granted time-based stock options which vest over 1 to 4 years following the date of grant and expire within 10 years. The fair value of time-based stock options is determined using the Black-Scholes valuation model, with such value recognized as expense over the service period, which is typically 1 to 4 years, net of actual forfeitures. A summary of the Company's assumptions used in determining the fair value of the stock options granted during the six months ended June 29, 2024 is shown in the following table: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.193%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Risk-free interest rate</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 3.9% - 4.3% </td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Expected dividend yield</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Expected stock price volatility</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 36.1% - 36.4% </td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Expected life of stock options (years)</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 6.25 </td></tr></table> The weighted-average grant date fair value of options granted during the six months ended June 29, 2024 was $2.25 per share. The expected term of the options granted is estimated using the simplified method. Expected volatility is based on the historical volatility of the Company's peers' common stock. The risk-free interest rate is determined based upon a constant U.S. Treasury security rate with a contractual life that approximates the expected term of the option. Unamortized compensation expense related to the options totaled $4,342 at June 29, 2024, and is expected to be recognized over a weighted average period of approximately 2.86 years. </div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify">A summary of stock option activity is as follows for the six months ended June 29, 2024 (number of options in thousands):</div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.525%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Number of options</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted-average exercise price</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted average remaining contractual term</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Aggregate intrinsic value</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Outstanding at December 31, 2023</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,347 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">8.68 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Granted</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,763 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5.18 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Exercised</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(229)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5.21 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Forfeited or canceled</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New

Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(747)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10.51 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Outstanding at June 29, 2024</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,134 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7.53 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">7.66</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">4,968 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Exercisable and vested at June 29, 2024</td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,982 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">9.95 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">5.57</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">855 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the market price of the Company's Class A common stock for options that had exercise prices lower than $5.75 per share as this was the closing price of the Company's Class A common stock on June 28, 2024, the last trading day of the second quarter. Employee Stock Purchase Plan The Company operates a non-qualified Employee Stock Purchase Plan ("ESPP"), which provides for the issuance of shares of the Company's Class A common stock to eligible employees of the Company that elect to participate in the plan and purchase shares of Class A common stock through payroll deductions at a discounted price. As of June 29, 2024, the aggregate number of shares reserved for issuance under the ESPP was 1,393,982. A total of 125,622 shares were issued under the ESPP and $215 of expense was recognized during the three and six months ended June 29, 2024. A total of 144,851 and 366,927 shares were issued under the ESPP and $65 and $193 of expense was recognized during the three and six months ended July 1, 2023, respectively.</div>19564333892168660000084700345700060480000-2797000-10790000P1YP4Y7091000P2Y4M24DA summary of the RSU award activity for the six months ended June 29, 2024 is as follows (number of units in thousands):<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Number of units</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted-average grant-date fair value per unit</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Unvested at December 31, 2023</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,066 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">4.51 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Granted</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,429 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5.45 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Vested</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,550)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4.56 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Forfeited or canceled</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(105) </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7.33 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Unvested at June 29, 2024</td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,840 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">5.12 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 20660004.5124290005.4515500004.561050007.3328400005.12P1YP4YP10YP1YP4YA summary of the Company's assumptions used in determining the fair value of the stock options granted during the six months ended June 29, 2024 is shown in the following table: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.193%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Risk-free interest rate</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 3.9% - 4.3% </td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Expected dividend yield</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Expected stock price volatility</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 36.1% - 36.4% </td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Expected life of stock options (years)</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 6.25 </td></tr></table> 0.0390.04300.3610.364P6Y3M2.254342000P2Y10M9D A summary of stock option activity is as follows for the six months ended June 29, 2024 (number of options in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.525%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-

align:center;vertical-align:bottom">Number of options</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted-average exercise price</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted average remaining contractual term</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Aggregate intrinsic value</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Outstanding at December 31, 2023</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,347 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">8.68 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Granted</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,763 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5.18 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Exercised</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(229)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5.21 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Forfeited or canceled</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(747)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10.51 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Outstanding at June 29, 2024</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,134 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7.53 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">7.66</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">4,968 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Exercisable and vested at June 29, 2024</td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,982 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">9.95 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">5.57</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman';sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">855 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
43470008.6817630005.182290005.2174700010.5151340007.53P7Y7M28D4968000019820009.95P5Y6M25D8550005.7513939821256222150002150001448513669276500equity On February 16, 2021, the Company closed an IPO of 9,200,000 shares of Class A common stock through an UP-C structure with BV LLC. In connection with the IPO, the Company amended and restated the limited liability agreement of BV LLC (“BV LLC Agreement”) to provide for a new single class of common membership interests in BV LLC (“LLC Interests”) and exchange all of the existing membership interests in BV LLC (the “Original BV LLC Owners”) for new LLC Interests. The Company also amended its certificate of incorporation to authorize the following shares: (i) 250,000,000 shares of Class A common stock with a par value of $0.001 per share; (ii) 50,000,000 shares of Class B common stock with a par value of $0.001 per share, which have voting rights but no economic interest, and some of which were issued to the Original BV LLC Owners; and (iii) 10,000,000 shares of undesignated preferred stock that may be issued from time to time by the Company’s board of directors. In connection with the completion of the IPO, the Company acquired, by merger, certain entities that were part of the Original BV LLC Owners (“Former BV LLC Owners”), for which the Company issued 31,838,589 Class A common stock as merger consideration (“IPO Mergers”) and cancelled the Class B common stock held by such Former BV LLC Owners. The IPO Mergers are deemed to be a recapitalization transaction. Holders of the Company’s Class A and Class B common stock are entitled to one vote per share and, except as otherwise required, will vote together as a single class on all matters on which stockholders generally are entitled to vote. Holders of Class B common stock are not entitled to receive dividends and will not be entitled to receive any distributions upon the liquidation, dissolution or winding up of the Company. Shares of Class B common stock may only be issued to the extent necessary to maintain the one-to-one ratio between the number of LLC Interests and the number of shares of Class B common stock held by Smith & Nephew, Inc. (the “Continuing LLC Owner”). Shares of Class B common stock are transferable only together with an equal number of LLC Interests. Shares of Class B common stock will be canceled on a one-for-one basis upon the redemption or exchange of any outstanding LLC Interests. Noncontrolling interest In connection with any redemption pursuant to the BV LLC Agreement, the Company will receive a corresponding number of LLC Interests, increasing its ownership interest in BV LLC. Future redemptions of LLC Interests will result in a change in ownership and reduce the amount recorded as noncontrolling interest and increase additional paid-in capital. There were no redemptions during the six months ended June 29, 2024 or during the year ended December 31, 2023. The following table summarizes the ownership interest in BV LLC as of June 29, 2024 and December 31, 2023 (number of units in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 29, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> LLC Interests </td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> Ownership % </td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> LLC Interests </td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> Ownership % </td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Number of LLC Interests owned</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-

color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top">Bioventus Inc.</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">65,172 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">80.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">63,267 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">80.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top">Continuing LLC Owner</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15,787 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19.5 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15,787 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top">Total</td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">80,959 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">100.0 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">79,054 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">100.0 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr></table>
9200000250000000000.001500000000.001100000003183858911 1The following table summarizes the ownership interest in BV LLC as of June 29, 2024 and December 31, 2023 (number of units in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 29, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> LLC Interests </td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> Ownership % </td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> LLC Interests </td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> Ownership % </td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Number of LLC Interests owned</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top">Bioventus Inc.</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">65,172 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">80.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">63,267 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">80.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top">Continuing LLC Owner</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15,787 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19.5 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15,787 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top">Total</td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">80,959 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">100.0 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">79,054 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">100.0 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr></table>
651720000.805632670000.800157870000.195157870000.200809590001.000790540001.000Earnings per share The following table sets forth the computation of basic and diluted loss per share of Class A common stock for the periods presented (amounts in thousands, except share and per share data): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-

bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">June 29, 2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">July 1, 2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">June 29, 2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">July 1, 2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Numerator:</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Net loss from continuing operations, net of tax</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(32,112)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(4,731)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(38,094)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(104,749)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Net loss attributable to noncontrolling interests —
 continuing operations</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,120 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,050 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9,532 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">21,410 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Net loss attributable to Bioventus Inc. Class A <br/> common stockholders — continuing operations</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(23,992)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(3,681)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(28,562)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(83,339)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Numerator:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Net loss from discontinued operations, net of tax</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">(74,429)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Net loss attributable to noncontrolling interests —
 discontinued operations</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">14,937 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Net loss attributable to Bioventus Inc. Class A <br/> common stockholders — discontinued operations</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-

weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(59,492)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Denominator:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Weighted-average shares of Class A common stock
  outstanding—basic and diluted</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">64,056,759 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">62,551,285 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">63,720,342 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">62,338,018 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net loss per share of Class A common stock from
  continuing operations, basic and diluted</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(0.37)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(0.06)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(0.45)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(1.34)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net loss per share of Class A common stock from
  discontinued operations, basic and diluted</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.95)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net loss per share of Class A common stock,
  basic and diluted</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(0.37)</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(0.06)</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(0.45)</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(2.29)</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> Shares of Class B common stock do not share in the losses of the Company and are therefore not participating securities. As such, separate presentation of basic and diluted losses per share of Class B common stock under the two-class method has not been presented. The following number of weighted-average potentially dilutive shares as of June 29, 2024 and July 1, 2023 were excluded from the calculation of diluted loss per share because the effect of including such potentially dilutive shares would have been antidilutive upon conversion: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">June 29, 2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">July 1, 2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">June 29, 2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">July 1, 2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> LLC Interests held by Continuing LLC Owner(a) </td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15,786,737 </td><td style="background-

color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15,786,737 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15,786,737 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15,786,737 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Stock options</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,208,043 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,730,685 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,177,250 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,623,865 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">RSUs</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">49,784 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">766,427 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">25,029 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">974,238 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Total</td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20,044,564 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">23,283,849 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19,989,016 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">24,384,840 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> (a) Class A Shares reserved for future issuance upon redemption or exchange of LLC Interests by the Continuing LLC Owner. The following table sets forth the computation of basic and diluted loss per share of Class A common stock for the periods presented (amounts in thousands, except share and per share data): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">June 29, 2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">July 1, 2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">June 29, 2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">July 1, 2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Numerator:</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Net loss from continuing operations, net of tax</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(32,112)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(4,731)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(38,094)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(104,749)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Net loss attributable to noncontrolling interests —
  continuing operations</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,120 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,050 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9,532 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">21,410 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Net loss attributable to Bioventus Inc. Class A
  common stockholders — continuing operations</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(23,992)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(3,681)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-

align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(28,562)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(83,339)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Numerator:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Net loss from discontinued operations, net of tax</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">(74,429)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Net loss attributable to noncontrolling interests —
  discontinued operations</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">14,937 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Net loss attributable to Bioventus Inc. Class A
  common stockholders — discontinued operations</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(59,492)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Denominator:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Weighted-average shares of Class A common stock
  outstanding—basic and diluted</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">64,056,759 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">62,551,285 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">63,720,342 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">62,338,018 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net loss per share of Class A common stock from
  continuing operations, basic and diluted</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(0.37)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(0.06)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(0.45)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(1.34)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net loss per share of Class A common stock from
  discontinued operations, basic and diluted</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td>

<td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.95)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net loss per share of Class A common stock,
  basic and diluted</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(0.37)</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(0.06)</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(0.45)</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(2.29)</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> -32112000-4731000-38094000-104749000-8120000-1050000-9532000-21410000-23992000-3681000-28562000-83339000000-74429000000-14937000000-594920006405675964056759625512856255128563720342637203426233801862338018-0.37-0.37-0.06-0.06-0.45-0.45-1.34-1.34000000-0.95-0.95-0.37-0.37-0.06-0.06-0.45-0.45-2.29-2.29 The following number of weighted-average potentially dilutive shares as of June 29, 2024 and July 1, 2023 were excluded from the calculation of diluted loss per share because the effect of including such potentially dilutive shares would have been antidilutive upon conversion: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">June 29, 2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">July 1, 2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">June 29, 2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">July 1, 2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> LLC Interests held by Continuing LLC Owner(a) </td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15,786,737 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15,786,737 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15,786,737 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Stock options</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,208,043 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,730,685 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,177,250 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,623,865 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">RSUs</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">49,784 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">766,427 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">25,029 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">974,238 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Total</td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20,044,564 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">23,283,849 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19,989,016 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">24,384,840 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> (a) Class A Shares reserved for future issuance upon redemption or exchange of LLC Interests by the Continuing LLC Owner.
1578673157867315786731578673157867374208043673068541772507623865497847664272502997423820044564232838491998901624384840Restructuring costs Restructuring costs are not allocated to the Company's reportable segments as they are not part of the segment performance measures regularly reviewed by management. These charges are included in restructuring costs in the consolidated statements of operations and comprehensive loss. Liabilities associated from restructuring costs are recorded in accrued liabilities on the consolidated balance sheets. The Company's prior restructuring plans adopted in 2021 and 2022 focused on aligning its organizational and management cost structure to improve profitability and cash flow, reduce headcount and the consolidation of facilities. These plans have been completed. There were no restructuring expenses incurred during the three and six months ended June 29, 2024. Restructuring expenses incurred during three and six months ended July 1, 2023 totaled $620 and $937, respectively. Payments for restructuring liabilities during the six months ended June 29, 2024 and July 1, 2023 totaled $961 and $3,085, respectively. 0620000937000961000308500OIncome taxes<div style="margin-bottom:6pt;margin-top:6pt;text-

align:justify">The tax provision for interim periods is determined using an estimate of the Company's annual effective tax rate, adjusted for discrete items, if any, that arise during the period. Each quarter, the Company updates its estimate of its annual effective tax rate, and if the estimated annual effective tax rate changes, the Company makes a cumulative adjustment in such period. The quarterly tax provision, and estimate of the Company's annual effective tax rate, are subject to variation due to several factors, including variability in pre-tax income (or loss), the mix of jurisdictions to which such income relates, changes in how the Company conducts business, and tax law developments. For the three and six months ended June 29, 2024 and July 1, 2023, the Company's effective tax rate was 18.6%, 8.8%, and 14.4% and 0.2%, respectively. The change in rate for the three and six months ended June 29, 2024 compared to the prior year comparable period was primarily due to losses in certain entities. Tax Receivable Agreement The Company expects to obtain an increase in the share of the tax basis of the assets of BV LLC when LLC Interests are redeemed or exchanged by the Continuing LLC Owner and other qualifying transactions. This increase in tax basis may have the effect of reducing the amounts that the Company would otherwise pay in the future to various tax authorities. The increase in tax basis may also decrease gains (or increase losses) on future dispositions of certain capital assets to the extent tax basis is allocated to those capital assets. On February 16, 2021, the Company entered into a tax receivable agreement ("TRA") with the Continuing LLC Owner that provides for the payment by the Company to the Continuing LLC Owner of 85% of the amount of tax benefits, if any, that the Company actually realizes as a result of (i) increases in the tax basis of assets of BV LLC resulting from any redemptions or exchanges of LLC Interests or any prior sales of interests in BV LLC; and (ii) certain other tax benefits related to our making payments under the TRA. The Company maintains a full valuation allowance against deferred tax assets related to the tax attributes generated as a result of redemptions of LLC Interests or exchanges described above until it is determined that the benefits are more-likely-than-not to be realized. Subsequent to the consummation of the IPO Mergers, the Continuing LLC Owner has not exchanged LLC Interests for shares of Class A common stock. 0.1860.0880.1440.0020.85Commitments and contingencies Leases The Company leases its office facilities as well as other property, vehicles and equipment under operating leases. The Company also leases certain office equipment under nominal finance leases. The remaining lease terms range from 1 month to 8.8 years. The components of lease cost were as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">June 29, 2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">July 1, 2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">June 29, 2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">July 1, 2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Operating lease cost</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">938 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,010 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,826 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2,079 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Short-term lease cost(a) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">326 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">229 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">406 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">435 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Financing lease cost:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Amortization of finance lease assets</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">174 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">393 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">332 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">628 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Interest on lease liabilities</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">217 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">229 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">438 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">366 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total lease cost</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,655 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,861 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3"

style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">3,002 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">3,508 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> (a)Includes variable lease cost and sublease income, which are immaterial. Supplemental cash flow information and non-cash activity related to leases were as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">June 29, 2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">July 1, 2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cash paid for amounts included in measurement of lease liabilities:</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Operating cash flows from operating leases</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">2,319 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">2,227 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Operating cash flows from financing leases</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">438 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">337 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Financing cash flows from finance leases</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">373 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">175 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Right-of-use assets obtained in exchange for lease obligations:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Operating lease obligations</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">132 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">254 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Financing lease obligations</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">15,567 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> Supplemental balance sheet and other information related to leases were as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 29, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Operating lease assets(a) </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom">10,366</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom">13,353</td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Operating lease liabilities—current(b) </td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom">3,038</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom">4,057</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Operating lease liabilities—noncurrent(b) </td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom">8,469</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom">10,573</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-

serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom">11,507</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom">14,630</td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Property, plant and equipment, net (finance leases)</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom">13,491</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom">14,279</td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Finance lease liabilities—current</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom">791</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom">759</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Finance lease liabilities—noncurrent</td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom">9,981</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom">10,386</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Total financing lease liabilities</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom">10,772</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom">11,145</td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Weighted average remaining lease term (years) for leases</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Operating leases</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">3.4</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">3.8</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Finance leases</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">8.8</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">9.3</td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Weighted average discount rate for leases</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Operating leases</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4.8 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4.7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Finance leases</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8.1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8.1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr></table> (a)Operating lease assets totaling $1,171 attributable to the Advanced Rehabilitation Business were reclassified to assets held for sale within the June 29, 2024 consolidated condensed balance sheets. Refer to Note 3. Acquisitions and divestitures for further details regarding assets held for sale. (b)Current and noncurrent operating lease liabilities of $983 and $249, respectively, were reclassified to liabilities held for sale within the June 29, 2024 consolidated condensed balance sheets. Refer to Note 3. Acquisitions and divestitures for further details regarding assets held for sale. Governmental and legal contingencies In the normal course of business, the Company periodically becomes involved in various claims and lawsuits, and governmental proceedings and investigations that are incidental to its business. The Company accrues a liability when a loss is considered probable and the amount can be reasonably estimated. When a material loss contingency is reasonably possible but not probable, the Company does not record a liability, but instead discloses the nature and amount of the claim, and an estimate of the possible loss or range of loss, if such an estimate can be made. Legal fees are expensed as incurred. With respect to governmental proceedings and investigations, like other companies in the industry, the Company is subject to extensive regulation by national, state and local governmental agencies in the United States and in other jurisdictions in which the Company and its affiliates operate. As a result, interaction with governmental agencies is ongoing. The Company's standard practice is to cooperate with regulators and investigators in responding to inquiries. The Company is presently unable to predict the duration, scope, or result of these matters. As such, the Company is presently unable to develop a reasonable estimate of a possible loss or range of losses, if any, related to these matters. While the Company intends to defend these matters vigorously, the outcome of such litigation or any other litigation is necessarily uncertain, is not within the Company's complete control and might not be known for extended periods of time. In the opinion of management, the outcome of any existing claims and legal or regulatory proceedings, other than the specific matters described below, if decided adversely, is not expected to have a material adverse effect on the Company's business, financial condition, results of operations, or cash flows. Bioventus shareholder litigation On January 12, 2023, the Company and certain of its current and former directors and officers were named as defendants in a putative class action lawsuit filed in the Middle District of North Carolina (the "Court"), Ciarciello v. Bioventus, Inc., No. 1:23- CV – 00032-CCE-JEP (M.D.N.C. 2023). The complaint asserted violations of Sections 10(b) and 20(a) of the Exchange Act and of Sections 11 and 15 of the Securities Act and generally alleges that the Company failed to disclose certain information regarding rebate practices, its business and financial prospects, and the sufficiency of internal controls regarding financial reporting. The complaint seeks damages in an unspecified amount. On April 12, 2023, the Court appointed Wayne County Employees' Retirement System as lead plaintiff. The plaintiff's amended consolidated complaint was filed with the Court on June 12, 2023. On July 17, 2023, the defendants filed a motion to dismiss the complaint raising a number of legal and factual deficiencies with the amended consolidated

complaint. In response to the defendants' motion to dismiss, the lead plaintiff filed a second amended complaint on July 31, 2023. The defendants moved to dismiss the second amended complaint on August 21, 2023, which the Court granted in part and denied in part on November 6, 2023. The Court dismissed the plaintiff's Securities Act claims, but allowed the plaintiff's Exchange Act claims to proceed into discovery. On July 15, 2024, a Stipulation and Agreement of Settlement (the "Settlement Agreement") by and between the lead plaintiff and the defendants was filed with the Court. The Settlement Agreement, which is subject to Court approval, provides among other things for (i) the dismissal of all claims against the defendants, including the Company; (ii) a settlement amount of $15,250, together with interest earned thereon, to be paid by the defendants and/or the defendant's insurers within 30 days after the later of (x) the date of entry by the Court of an order preliminarily approving the terms of the settlement or (y) receipt by the defendants from lead counsel of the information necessary to effectuate a transfer of the settlement funds; and (iii) no admission of liability or wrongdoing by any party. The Company incurred $12,502 and $13,670 of net shareholder litigation costs (including estimated settlement and reimbursement) during the three and six months ended June 29, 2024 under the Settlement Agreement, which were recorded in selling, general and administrative expense within the consolidated condensed statements of operations and comprehensive loss. The Company expects to be reimbursed approximately $6,500 of the fees incurred to date, which was recorded in other current assets within the June 29, 2024 consolidated condensed balance sheets. On October 4, 2023, certain of the Company's current and former directors and officers were named as defendants in a derivative shareholder lawsuit (in which the Company is a nominal defendant) filed in the United States District Court for the District of Delaware, Grogan, on behalf of Bioventus Inc., v. Reali, et.al., No. 1:23-CV-01099-RGA (D. Del. 2023). The complaint asserts violations of Section 14(a) of the Exchange Act, breaches of fiduciary duties and related state law claims, and a claim for contribution, and generally alleges the same purported misconduct as alleged in the Ciarciello case. On January 12, 2024, the Court agreed to stay this case pending resolution of the Ciarciello case. The Company may incur further legal costs until settlement is ultimately approved and executed by the Court. On February 9, 2024, another plaintiff filed a derivative shareholder lawsuit against certain of the Company's current and former directors and officers (in which the Company is a nominal defendant) filed in the United States District Court for the District of Delaware, Sanderson, on behalf of Bioventus Inc., v. Reali, et.al., No. 1:24-cv-00180-RGA (D. Del. 2024). Like the Grogan case, this case asserts violations of Section 10(b) of the Exchange Act, breaches of fiduciary duties and related state law claims, and a claim for contribution, and generally alleges the same purported misconduct as alleged in the Ciarciello case. On May 1, 2024, the parties filed a stipulation to consolidate the two derivative matters and stay them on terms similar to those entered in the Grogan case. On May 2, 2024, the United States District Court for the District of Delaware granted the stipulation and ordered the consolidation of the Sanderson and Grogan cases (as consolidated, the "Grogan Case"). The Company believes the claims alleged in the Grogan Case lacks merit and intends to defend itself vigorously. The outcome of this matter is not presently determinable, and any loss is neither probable nor reasonably estimable. Bioness stockholder litigation On February 8, 2022, a minority shareholder of Bioness filed an action in the Delaware State Court of Chancery in connection with the Company's acquisition of Bioness, Teuza, a Fairchild Technology Venture Ltd. v. Lindon, et. al., No. 2022-0130 -SG. This action names the former Bioness directors, the Alfred E. Mann Trust ("Trust"), which was the former majority shareholder of Bioness, the trustees of the Trust and Bioventus as defendants. The complaint alleges, among other things, that the individual directors, the Trust, and the trustees breached their fiduciary duty to the plaintiff in connection with their consideration and approval of the Company's transaction. The complaint also alleges that the Company aided and abetted the other defendants in breaching their fiduciary duties to the plaintiff and that the Company breached the Merger Agreement by failing to pay the plaintiff its pro rata share of the merger consideration. The Company believes that it is indemnified under the indemnification provisions contained in the Bioness Merger Agreement for these claims. On July 20, 2022, the Company filed a motion to dismiss all claims made against it on various grounds, as did all the other named defendants in the suit. A hearing on Bioness' and other the defendant's motions was held before the Court of Chancery on January 19, 2023. On April 27, 2023, the Court issued an order which, among other things, dismissed Bioventus from the case. Other matters On November 10, 2021, the Company entered into an asset purchase agreement for an HA product and made an upfront payment of $853. An additional payment of $853 was made in 2022 upon the transfer of certain seller customer data. If the Company is able to obtain a Medical Device Regulation Certification for the product, $1,707 (the "Milestone Payment") will be paid to the seller within five days. The Company is also required to pay royalties if certifications are achieved before December 31, 2024. Royalties will be payable through 2026 of 5.0% on the first $569 in sales and 2.5% thereafter. On March 8, 2023, the parties amended the agreement under which the Milestone Payment was reduced to $1,418, of which $709 was paid on January 31, 2024, and the remainder is due upon receipt of the Medical Device Regulation Certification for the product provided that it is obtained prior to December 31, 2024. As a result, the Company recorded an intellectual property intangible asset totaling $709 for initial payment. On August 23, 2019, the Company was assigned a third-party license on a product currently in development and the Company is subject to a 3% royalty on certain commercial sales, or a nominal minimum amount per quarter. On December 9, 2016, the Company entered into an amended and restated license agreement for the exclusive U.S. distribution and commercialization rights of a single injection osteoarthritis ("OA") product with the supplier of the Company's single injection OA product for the non-U.S. market. The agreement requires the Company to meet annual minimum purchase requirements and pay royalties on net sales. Royalties related to this agreement during the three months ended June 29, 2024 and July 1, 2023 and the six months ended June 29, 2024 and July 1, 2023 totaled $4,594 $4,119, $8,173 and $6,440, respectively. These royalties are included in cost of sales within the consolidated condensed statements of operations and comprehensive loss. As part of a supply agreement entered on February 9, 2016 for the Company's three injection OA product, the Company is subject to annual minimum purchase requirements for 10 years. After the initial 10 years, the agreement will automatically renew for an additional 5 years unless terminated by the Company or the seller in accordance with the agreement. As part of a supply agreement for the Company's five injection OA product that was amended and restated on December 22, 2020, the Company is subject to annual minimum purchase requirements for 8 years. From time to time, the Company causes LOCs to be issued to provide credit support for guarantees, contractual commitments and insurance policies. The fair values of the LOCs reflect the amount of the underlying obligation and are subject to fees payable to the issuers, competitively determined in the marketplace. As of June 29, 2024 and December 31, 2023, the Company had two LOCs outstanding for $1,700. The Company currently maintains insurance for risks associated with the operation of its business, provision of professional services and ownership of property. These policies provide coverage for a variety of potential losses, including loss or damage to property, bodily injury, general commercial liability, professional errors and omissions and medical malpractice. The Company is self-insured for health insurance covering most of its employees located in the United States. The Company maintains stop-loss insurance on a "claims made" basis for expenses in excess of $250 per member per year.</div>P1MP8Y9M18D<div style="margin-bottom:6pt;margin-top:6pt">The components of lease cost were as follows:</div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">June 29, 2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">July 1, 2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">June 29, 2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">July 1, 2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Operating lease cost</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">938 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,010 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,826 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt">

</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2,079 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Short-term lease cost(a)</div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">326 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">229 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">406 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">435 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Financing lease cost:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Amortization of finance lease assets</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">174 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">393 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">332 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">628 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Interest on lease liabilities</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">217 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">229 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">438 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">366 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total lease cost</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,655 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,861 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">3,002 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">3,508 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt">(a)Includes variable lease cost and sublease income, which are immaterial.</div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify">Supplemental cash flow information and non-cash activity related to leases were as follows:</div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td colspan="2" style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">June 29, 2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">July 1, 2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cash paid for amounts included in measurement of lease liabilities:</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Operating cash flows from operating leases</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">2,319 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">2,227 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Operating cash flows from financing leases</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">438 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">337 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Financing cash flows from finance leases</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">373 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">175 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Right-of-use assets obtained in exchange for lease obligations:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3"

style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Operating lease obligations</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">132 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">254 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Financing lease obligations</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">15,567 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
9380001010000182600020790003260002290004060004350001740003930003320006280002170002290004380003660001655000186100030020003508000231900022
style="margin-bottom:6pt;margin-top:6pt;text-align:justify">Supplemental balance sheet and other information related to leases were as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 29, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Operating lease assets(a) </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom">10,366</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom">13,353</td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Operating lease liabilities—current(b) </td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom">3,038</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom">4,057</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Operating lease liabilities—noncurrent(b) </td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom">8,469</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom">10,573</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Total operating lease liabilities</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom">11,507</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom">14,630</td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Property, plant and equipment, net (finance leases)</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom">13,491</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom">14,279</td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Finance lease liabilities—current</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom">791</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom">759</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Finance lease liabilities—noncurrent</td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom">9,981</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom">10,386</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Total financing lease liabilities</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom">10,772</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom">11,145</td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Weighted average remaining lease term (years) for leases</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Operating leases</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">3.4</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">3.8</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Finance leases</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">8.8</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">9.3</td></tr><tr>

style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Weighted average discount rate for leases</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Operating leases</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4.8 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4.7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Finance leases</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8.1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8.1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr></table> (a)Operating lease assets totaling $1,171 attributable to the Advanced Rehabilitation Business were reclassified to assets held for sale within the June 29, 2024 consolidated condensed balance sheets. Refer to Note 3. Acquisitions and divestitures for further details regarding assets held for sale. (b)Current and noncurrent operating lease liabilities of $983 and $249, respectively, were reclassified to liabilities held for sale within the June 29, 2024 consolidated condensed balance sheets. Refer to Note 3. Acquisitions and divestitures for further details regarding assets held for sale. <ix:nonNumeric contextRef="P3Y4M24DP3Y9M18D_us-gaap_ProductOrServiceAxis_us-gaap_ServiceMember_us-gaap_StatementBusinessSegmentsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementGeographicalAxis_country_US_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_us-gaap_TransferOfGoodOrServiceAxis_us-gaap_TransferredOverTimeMember_us-gaap_RevenueRecognitionMethodAxis_us-gaap_ProductMember_us-gaap_RevenueRecognitionMethodAxis_us-gaap_ServiceMember" name="us-gaap:RevenueRecognitionPolicyTextBlock">10366000133530003038000405700084690001057300011507000146300001349100014279000791000759000998100010386000107720001114500OP3Y4M24DP3Y9M18D recognition Our policies for recognizing sales have not changed from those described in the Company's Annual Report on Form 10-K for the year ended December 31, 2023. The Company attributes net sales to external customers to the U.S. and to all foreign countries based on the legal entity from which the sale originated. As previously discussed in Note 1. Organization, SonicOne revenue was reclassified from Restorative Therapies to Surgical Solutions on a prospective and retrospective basis as its capabilities to remove devitalized or necrotic tissue and fiber deposits more closely aligns with Surgical Solutions' soft tissue management. SonicOne revenue reclassified for the three and six months ended July 1, 2023 totaled $1,832 and $3,544, respectively, for the U.S. reporting segment and $84 and $149, respectively, for the International reporting segment. The Company had product sales to one customer totaling $18,266 and $31,409 in the U.S. segment during the three and six months ended June 29, 2024, representing 12.2% and 11.3% of total net sales, respectively. There was no customers representing 10% or more of net sales during the three and six months ended July 1, 2023. The following table presents the Company's net sales disaggregated by major business within each segment as follows:</div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">June 29, 2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">July 1, 2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">June 29, 2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">July 1, 2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">U.S.</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.85pt">Pain Treatments</div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">65,194 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">55,617 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">115,831 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">96,612 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Restorative Therapies</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">27,435 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">30,012 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">52,739 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">60,788 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Surgical Solutions</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">41,780 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">35,218 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">80,120 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">67,425 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Total U.S. net sales</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">134,409 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">120,847 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-

*align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">248,690 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">224,825 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">International</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Pain Treatments </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,066 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,024 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13,118 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11,355 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Restorative Therapies</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,185 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,690 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9,355 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10,239 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Surgical Solutions</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,557 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,508 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9,511 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9,709 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Total International net sales</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">16,808 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">16,222 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">31,984 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">31,303 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total net sales</td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom">151,217 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom">137,069 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom">280,674 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom">256,128 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
18320003544000840001490001826600031409000.1220.113The following table presents the Company's net sales disaggregated by major business within each segment as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">June 29, 2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">July 1, 2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">June 29, 2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">July 1, 2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">U.S.</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Pain Treatments </td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">65,194 </td><td style="background-*

color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">55,617 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">115,831 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">96,612 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Restorative Therapies</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">27,435 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">30,012 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">52,739 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">60,788 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Surgical Solutions</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">41,780 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">35,218 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">80,120 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">67,425 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Total U.S. net sales</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">134,409 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">120,847 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">248,690 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">224,825 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">International</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.85pt">Pain Treatments</div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,066 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,024 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13,118 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11,355 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Restorative Therapies</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,185 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,690 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9,355 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10,239 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Surgical Solutions</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,557 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,508 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9,511 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9,709 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Total International net sales</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">16,808 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">16,222 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">31,984 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">31,303 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total net sales</td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom">151,217 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-

color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom">137,069 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom">280,674 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom">256,128 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
651940005561700011583100096612000274350003001200052739000607880004178000035218000801200006742500013440900012084700024869000022482500070660
style="margin-bottom:6pt;margin-top:6pt;text-align:justify">The Company's two reportable segments are U.S. and International. U.S. segment revenues totaled $134,409, $120,847, $248,690 and $224,825 for the three months ended June 29, 2024 and July 1, 2023 and the six months ended June 29, 2024 and July 1, 2023, respectively. International segment revenues totaled $16,808, $16,222, $31,984 and $31,303 for the three months ended June 29, 2024 and July 1, 2023 and the six months ended June 29, 2024 and July 1, 2023, respectively. The Company's products are primarily sold to orthopedists, musculoskeletal and sports medicine physicians, podiatrists, neurosurgeons and orthopedic spine surgeons, as well as to their patients. The Company does not disclose segment information by asset as the Chief Operating Decision Maker does not review or use it to allocate resources or to assess the operating results and financial performance. Segment Adjusted EBITDA is the segment profitability metric reported to the Company's Chief Operating Decision Maker for purposes of decisions about allocation of resources to, and assessing performance of, each reportable segment.</div><div style="margin-bottom:6pt;margin-top:6pt">The following table presents segment Adjusted EBITDA reconciled to loss before income taxes:</div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">June 29, 2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">July 1, 2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">June 29, 2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">July 1, 2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Segment Adjusted EBITDA</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">U.S.</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">31,590 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">24,712 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">51,346 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">39,424 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">International</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,862 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,446 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,729 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,685 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Interest expense, net</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(9,924)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(10,587)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(20,263)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(20,281)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Depreciation and amortization</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(13,090)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(14,600)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(24,875)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(31,073)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Acquisition and related costs</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(300)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,448)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(511)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2,623)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Shareholder litigation costs</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(12,502)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td

colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(13,670)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Restructuring and succession charges</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">40 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(620)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(13)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(937)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Equity compensation</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(3,672)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,732 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(6,263)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">886 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Financial restructuring costs</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,257)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(347)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(6,587)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Impairments of assets</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(31,870)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(31,870)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(78,615)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Loss on disposal of a business</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(977)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(977)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other items</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2,590)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(5,751)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(3,789)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(9,416)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Loss before income taxes</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(39,451)</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(4,350)</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(44,526)</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(104,514)</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 2134409000120847000248690000224825000168080000162220003198400031303000 The following table presents segment Adjusted EBITDA reconciled to loss before income taxes: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">June 29, 2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">July 1, 2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">June 29, 2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">July 1, 2023</td></tr><tr><td colspan="3"

style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Segment Adjusted EBITDA</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">U.S.</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">31,590 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">24,712 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">51,346 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">39,424 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">International</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,862 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,446 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,729 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,685 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Interest expense, net</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(9,924)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(10,587)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(20,263)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(20,281)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Depreciation and amortization</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(13,090)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(14,600)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(24,875)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(31,073)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Acquisition and related costs</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(300)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,448)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(511)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2,623)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Shareholder litigation costs</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(12,502)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(13,670)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Restructuring and succession charges</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">40 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(620)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(13)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(937)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Equity compensation</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(3,672)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,732 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(6,263)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">886 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Financial restructuring costs</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,257)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(347)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(6,587)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-

family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairments of assets</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(31,870)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(31,870)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(78,615)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Loss on disposal of a business</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(977)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(977)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other items</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2,590)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(5,751)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(3,789)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(9,416)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Loss before income taxes</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(39,451)</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(4,350)</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(44,526)</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman';sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(104,514)</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
3159000024712000513460003942400028620003446000572900056850009924000-10587000-20263000-20281000130900001460000024875000310730003000001448000511000262300012502000013670000040000620000130009370003672000-27320006263000-8860005000125700034700065870003187000003187000078615000-9770000-97700025900005751000378900094160003945100043500004452600010451400Discontinued operations On February 27, 2023 the Company reached a Settlement Agreement with the Former Securityholders of CartiHeal that resulted in the transfer of 100% of Company's shares in CartiHeal to a Trustee. Refer to Note 3, Acquisitions and divestitures for further details concerning the Settlement Agreement and the deconsolidation of CartiHeal. CartiHeal had no sales during the year ended December 31, 2023. The following table summarizes the major income and expense line items of these discontinued operations, as reported in the consolidated statements of operations for the six months ended July 1, 2023 as there was no activity for discontinued operations subsequent to the first quarter of 2023: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.841%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none

<td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Operating loss from discontinued operations</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(8,098)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Interest expense, net</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,889 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Other (income) expense(b) </td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">61,442 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Other (income) expense</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">66,331 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Loss before income taxes</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(74,429)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Income tax benefit, net</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net loss from discontinued operations</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(74,429)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Loss attributable to noncontrolling interest - discontinued operations</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">14,937 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net loss attributable to Bioventus Inc. - discontinued operations</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(59,492)</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none">

.'

HBSVZN)CO]F;TQ+N&{A^J6TB?^P$-MWM3>[%MHB1IZ?E!'-,2-:VWC3FV[:GG5IJP$N\{>39W!Q!D2?*O"W&98NS*_M5N9W*INK6B"T('2%=_*-T#:)G2Q/W28]D34,![7AH,_R"/KTW1-9P_>D]CUY M7GE,_MKX[CB8! =[%]1#6UAK2U3GF$;>7AAH?E$;+5NS'5VQZ+3$DW MD*GS"OUON723/G72'],763,%>9^#V63(56U_>>V)K>O=VWKWGE4V%WZ^(B1... MPX/-V1(6A,YX],CVW!WV;N>9^]_2J="-HG /177&E+KLO<8R![XR_;9 ,2NH M+'O,>K;NZ=^,;3M,>A98KP@5*(.E@CJ#0!UKO.RQRX%D:].FWC*IFEYS MF:KO$N Z0*TO&9,/ WV#^DLG^@-02P,$% @ &ULO9EM_BL;M=_J9 MVB >,$@=SS2!SO5FVLDTU^MKQ<@4'V]UDARW_Z6AX_PI+4O3/C#Q4^XH5>@Q39B\G.R4VE\8AESO:$KDC \|@U\V?+1$P.W8&G(O<B*0E* MHS0Q+ .<6DXF!:-O2IST]S&6Z@$50>DH%F_L\XZ=YQ1.OT5O8])=F{[3O$G?2,NZ8 M[GSA^JV(U2DMU\4PV[T%Y9I.^U50>O3AFT*]GJ"V&K86,^1710G&1@=/ MTK-&T],H>^AIE#WT=#Y\/TFN*'7QRJ]S,FTTAV@? NU':W"<$(%B(B#OSI>9.] M6AQ.:>,L8!&H8&IEYKQ-4BMSW#9&C0S/;*>'85,/X)$%P.\Q/ S%D13+?GE# M%+6R+D6MK$M1(SM!L.DC\,A"8B3%9I4^ \CNGK^]C@]+/@F%)6$E.C'VW!UY3 M7>"1Y<4OPWMV)GA> &1[DI_[%P7+COOS+X L1VYA)E-__M-&.7.%! BHCR+%V4WQ?'S'=<*9X6ESM*H)(!)?#[AG/U=),W4/\7LOH/4&L# M:!!0 (,'.=!EGJ/4T,_@, ,%,5 9 >&PO=V]R:W-H965TN,? +V$%3XL#=MX&K@M=WLF!LS5HLEV<./9E^:,&\|#MSH!1E#1$M,0($ M,!?&A7V>VJX02(L_2CB@1]=-,.4.XWMQ#V O?4&;Q> MX)TZ@]\+Y,;,N_2<4G&LM6"X,@PIK3Q(7TOE1S?Y5(),J&$? ZTY#JV2C." M2K2CH($\??89@>!GL.'I6+05!'@+ ++A KB[\J13S!!N8M*5D)*?@Q@2PK*_J1-MVTL=79B,+TA@S;R?_+*,W'EEXO.@!/_!!S+\|3K6? ^7O#H#EBWEKFH[_V_V])MG'SG@'5\+#E3SW%=YK MD4\J)ZKE_@9;@FNPQG73LDR^]3Q=AGRZX?FTD?GTUS4'@RL&._JW*D>Z\#DV1:IM9#,#FWV+QGPQ,O;)C9:XRA"GPRDH+? -8YY+Q!8F%THJ\(U^HE-14 MD)Q'H"E+U1N4WMY$Y/SL#3DCC).O2Y$KRA/5JG(F"">0U."CX_C.$;R+\5=)\+=)&/!"'3_GO$\)[?$] Q6C3^CY^!I@4M_M"P_JPOD_Z^_ MOXH&4&U(P+/+% [QH1V"%R112JB$A W.HF6:@R(_!#+7PE/^L_M*W}AH%5OP-Q\)7,6B,?0=O-H4R#4XX>M7S8[WOB[WIR2+3DDV/A'9HRJUJB]U-MCK'7G=NZ2A0D'4MB6L8Z}'KN>C>}AQH:>I9E? *AQ%5QA4.H\b,%<1MH]&_N-T%*LS (/&?ZKT5AQ\N*$\T\+RTNS./1X99G4%?.H251+EL!= M.0IRW'++6 06&T:&#> "[7I/Q2_M\,2O&$}$QE$VI9WS7;OR4D5V)**C@EDJE MG85\L:3KX'4W##>R176'&<.UO-S#K(!$&/#G6XS9TXV88.BCKOX%4$L#!!0 M (,'~IEF!&PO=V]R.W-H965T[%Z+I]FF;!) =836QF.]#^_M^YV=D%%(:;? Q),'/]SSW9OOUW$SRK@3]JQL(L,>R'7*.$PD47F64?DPA%1L M^D[3V0JF;+'41N"&O15=P WHV]5$XLRM6!*6 5=,<")AWG<&S>ZX,?2MPC<& M&[4S)B:2F1!W9O(IZ3N> <0A2B+5AH/A,PPC2U!"A&[!*3]P[EPY)8$[S5$_%YB.4\5@'8Y$]^R6;0K=SX9 X5UID)1@=] MR!@O_O2^S,,,. `GJ 7X)(W28NHI]& M/2DV1:IM9#,#FWV+QGPQ,O;)C9:XRA"GPRDH+? -8YY+Q!8F%THJ\(U^HE-14 MD)Q'H"E+U1N4WMY$Y/SL#3DCC).O2Y$KRA/5JG(F"">0U."CX_C.$;R+\5=)\+=)&/!"'3_GO$\)[?$] Q6C3^CY^!I@4M_M"P_JPOD_Z^_ MOXH&4&U(P+/+% [QH1V"%R112JB$A W.HF6:@R(_!#+7PE/^L_M*WJA

D]C+/],DB:(X MQE9T.O4ZF&+K%L?PXU?#O $#RP.9_FRM\=W&*^3Y.L#V]+D*P6.*5R(V4WRM-M ?&O&S"2Q+ ,;6!Y@8+N U0[D]^>!FO)SH@AV%?.&/<$XDB08 K7HK]$X1E8G MAH]_?["G)
(J2Q(\ YG<011@"3R..8 [X9$4? >W'L?A>OW5+CY'][D$5!+ M P04 " !S/@99EXJ[' 3 @ "P %]R96QS+RYR96QSG0*Y:L.P M#$!_Q="> .?0(8@S9?$6!/D!5J(/V!(%BD6=OZ .;I7&0"QEY/3P2W!YI0.TX
MI+.:+J1C|$%)I6M6X 4BV)8IISI%"KM0L'C6'TD!$VV-#L%HL/D N&6.WO606 MIW.D5XA /E-M_G;@2=&A(E@6FD7)TZ(=|7\=Q .;0T^FO8R*T>EOH^.7%H5].W&,EC'%BM/XU M@LD/[`X 4$L#!!0
(',^!EG;Z&= Y@0 +TK / >&PO=V|R:V)O M;VLN>&ULQ9I+,|LX${# "N%3|I"UK5?;{ 039K= {LFB!>]%K1$VT0DTDO2 M3IM?WY$4PZ-8&O0R\2D6I4B?
AH]O2.KRV;]GA;5/XD=5&C\;K4/87(S'/E^K M2OH_{489.+,TK!(#MU][#=.R<*OE0I5.8XFDVQ<26U&5Y?[>$VX,3ZP0>5! M6P.%=<$WK9[IX7Q]*";.ZX4N=?@Y&S6_2S42E3;ZTB^]F(TF(^'7]OD?
Z_2+ M 4&6\]S9LIR INV);\H%G1\5SVO(_^3" R5!+AXE@.Q&V01NN 3.A ^.*YOX2 M&'<*+FZ/ML'>ZC(H=R.# ^MO9[4.,57T,>(LQ>HTF#ON _;1 OW. ^$T2Z7.E%OJ IY>"#@HE/'P.U[CP+\BR(B
C$X(^3U"D#$!&9|$\B|92I,K M@2 3 C(Y(60GDBD!F9ZRNF,$F1&0V2DA$P3Y@8#|P MY|U;2Z)?F!"+Z2!!] MY"7;=<?V"=]T^GB?2+P/O'B?<[W\(SFW(A32$*T(@/.FR=\GC$GE!#]H07
M/E8;B*&6)<3/!]=]/[@A":6'* M{(5K6U4Z-!VS&>5R2,.A< I&E2XD98HILRH>U4X9&$;=E++$E%D3 M<[5Z.Z!%E!$B9B/<:.)6X19&M7OHG>TE&(]R0L3L!)RB&+,'2)O]=O8'QB-G
M%\Q.&,O)Q!G,($N,29DA8C8#F9N(,XQ)22)BED1O=M)&\DV=4*(F(4QD*;L M.3$F)8^(61Z#Z1.HK$;.72"]WNGA,.MZ29FUDV/F?M"&5/.B9F=LU=T+QAEFYC9-@.N[AEY8G(UB]DV'6>?BZ_2U:.[
MZ#.W*DB.,2G;Q.RV&7:WN9CG;XQ)Z29FU@V%"9T>8U*ZB9EU0T.SN]!*Z20F.MU@V-B1<(8THX\;G6NAL;O$084]*)F:5#8Z9XX9J23L(L'3K]/<>8E'<20N^0 MF)TNE% 62I(@MU)^E-
V.F*K8XL4PH"R7.%AK"? 41QB1W5;CG/ .SB==X8DS* M0LF))CT.9K=M4A9*F"TTC-E4.\;D+)0P6VAX;M; 8DS*0@GWM(? [&9(^66A MA-E")&9W9Y*R4.IL(1H3|OXI9;&4> .;3-R$_9/$8DI)0RFRA
'=A92R M4.ILH9Z5@P.DL!B3LE#Z[MLS"+/;AEDPRDEGY19/B1FMTE2\DE/N>[6 .>*$DD_V3NMN2V>K^IN3X&0> MO+,.;W&]\0%C4O+)F.73MSR(ODN,2'6KV|$SRCT9]_< !\]7 M<9;B$6(+K1-
/U#+*\/1FS>X96-8|SHOR3\;LGB',NM/#.8Q)?EO6N&?<7.RO M+@NUU$857^$'1'LIS6>8/3M1_VN]=DK3>K5YNR.(;RN[-OU86^Z]/\U_.7OT" M4$L#!!0 (',^!ED>WYE>'(#TG :
>&PO7W)E,';O=V|R.V)O M;VLN>&UL+G)E;'/VDMNHT 4A>&M6"P@Y?NJ)*TXHYYDVLH&D%_.^*+9!%*U. M=M^6.[/ZD%/(LX(%8C+/^$3 IY^E4.[/[KM3W>W|NO@X'DYUU>S&L?^14EWO
MRK&M=UU?3N]V5.C:+UW;8EG'5\(#=7=-EXWW53.\ MO$F3Y@Y2" +Y@PR",/X@AR"?R@@*.8/RA"4YP^ZAZ#[^8,>(.AA_]!""[< M/TB6*.2(&F" 8'6@EP+(@=>"8 N!V()D"X'9@@F@+(@=[";
N!VX)P"X'<@G0+ M@=V"> N!WHIZ*X'>BGHK@=XZ>=@FT%M1;R706U%O)=!,46\ET%M1;R706U%O M)=!,46\ET%M1;R70VU!O(]#,4&\CT-M0;R/0VR8O2PCT-M3,"/0VU-L(]#;4 MVPCT-
M3;"/0VU-L(]#;4VPCT=M3,"?1VU-L)!;4VPGT=M3,"?3VRF4#OC'IG KTSZIT)I,Z3GTV^4^\Z?AY*O?9\K?'ZWTGU>#ZW7"] 67[M-MG-SC%YS3;45] @M02P,$% @ 7!E&ULS=K+3L,P$
707ZFR18WK)P .1;H ML .'3#*E49/8 MLETH?X^3 A((*E"1N)M&K>VY$\IT5CV > 84)|NN!.\6*7DSOB+U8HZ&TOG MJ<\K2OTM)LV3;ZV^>?8N!Y>
M!&IC,;G8,1RRYH7UOFTJF_(Z>^SK3RG3UX0RGQSWQ%7CXU'>4+ O$X.5[P-> MS]T\4@A-39-;&]*U?{NMFU93,\MO7)_B2]Z=,ME4U'MJDV7CY31!|)U7!&E MKBUW18_V)Z=\P{3[Y ?
GCV7V!>;=M\YF"<6Z/=Q;R,93D]|+D0A-?M^\3TQ MES[X_6B8=DWU#[/S]3ZYL!|G$=GX,/R.A[XO?XO^Q @?4B0/A1{'QJD#P/2 MQS%('R<@?9R"|,%G*
(V@B.I12.4HIG(45#F*JAR%58[B*D>!E:/(*E!D%2BR M"A19!8JL D56@2*K0\9%5H.@J&05*+)*%%DEBJP215.)(JM$D56BR"I19)4H MLDH4626*K
I%5H4BJT*15:'(JE!D52BR*A19%8JL"D56A2*K1\%5H\BJ4635 M*+)]%%DUBJP:15: (JM&D56CR&I09*4HLAH460V*K 9%5H.BJ_E/6> ^=6)Q M_/@L.]OT; EL "/:X@502P$"% .4 " !S/@99!T% 8H$
"Q $ M @ $ 9&|C4')O<';O87!P+GAM;%|+ 0(4 Q0 (',^ M!EE>%|[']P "L" 1 " .\ !D;V-0&UL4$L! A0#% @ &PO=V|R:W-H965T&UL4$L! A0#% @ &PO=V|R:W-H965T&UL4$L! A0# M% @
&PO=V|R:W-H965T&UL4$L! A0#% @ 70 >&PO=V|R:W-H965T&UL4$L! A0#% @]60 >&PO=V|R:W-H965T&UL M4$L! A0#% @ &PO=V|R:W-H965T&UL4$L! A0#% @ M&PO=V|R:W-
H965T8."P4 *L+ 9 " @7>Q !X;"]W M;W)K&UL4$L! A0#% @ 'NBCO" M;O< !D ("!N;8 'AL+W=O&PO=V|R:W-H965T&UL4$L! A0#% @ &PO=V|R:W-H M965T&UL4$L! M A0#% @ &PO=V|R:W-
H965T&UL4$L! A0#% @ P< !D ("!.>8 'AL+W=O&PO=V|R.W-H965T&UL4$L! A0#% @ &PO=V|R.W-H965T&UL4$L! A0#% @ &PO=V|R.W-H965T M0DGYEP8 $K 9 M " @3,%
0!X;"]W)K&UL4$L! A0# M% @ &PO=V|R:W-H965T&UL4$L! A0#% @ &PO=V|R:W-H965T&UL4$L! A0#% @ 7& @ (@< !D M ("!13@! 'AL+W=O&PO M=V|R:W-H965T&UL4$L! A0#% @
&PO=V|R:W-H965T&UL4$L! A0#% M @ WK#7&|! T!H !D ("!5; 0!X M;"]W;W)K&UL4$L! A0#% @ H]30S^ M P 4Q4 !D ("!06 ! 'AL+W=O&PO=V|R:W-H965T&UL4$L! A0#% @ &PO=V|R M:W-
H965T&UL M4$L! A0#% @ &PO=V|R:W-H965T&UL4$L! A0#% @ M&PO=V|R:W-H965T&UL4$L! A0#% @ 6OE&PO=V|R.V)O.VLN>&UL4$L! A0#% @ XML 78 Show.js IDEA: XBRL
DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their
employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var
e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}if(e.style.display=='block'){Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a)
{var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p ;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 79 report.css IDEA: XBRL DOCUMENT /* Updated 2009-
11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData { background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a {
display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; }
.report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table { font-
size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font:
normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align:
center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space:
normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px;
} .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color:
#f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color:
white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space:
nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em;
} /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note {
font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 81 FilingSummary.xml IDEA: XBRL
DOCUMENT 3.24.2.u1 html 280 376 1 false 85 0 false 9 false false R1.htm 0000001 - Document - Cover Page Sheet http://www.bioventus.com/role/CoverPage Cover Page Cover 1 false false
R2.htm 9952151 - Statement - Consolidated Statements of Operations and Comprehensive Loss Sheet
http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss Consolidated Condensed Statements of Operations and Comprehensive Loss Statements
2 false false R3.htm 9952152 - Statement - Consolidated Condensed Statements of Operations and Comprehensive Loss (Parenthetical) Sheet
http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLossParenthetical Consolidated Condensed Statements of Operations and Comprehensive Loss
(Parenthetical) Statements 3 false false R4.htm 9952153 - Statement - Consolidated Condensed Balance Sheets Sheet http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets
Consolidated Condensed Balance Sheets Statements 4 false false R5.htm 9952154 - Statement - Consolidated Condensed Balance Sheets (Parenthetical) Sheet
http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheetsParenthetical Consolidated Condensed Balance Sheets (Parenthetical) Statements 5 false false R6.htm 9952155 -
Statement - Consolidated Condensed Statements of Changes in Stockholders??? Equity Sheet http://www.bioventus.com/role/ConsolidatedCondensedStatementsofChangesinStockholdersEquity
Consolidated Condensed Statements of Changes in Stockholders??? Equity Statements 6 false false R7.htm 9952156 - Statement - Consolidated Condensed Statements of Cash Flows Sheet
http://www.bioventus.com/role/ConsolidatedCondensedStatementsofCashFlows Consolidated Condensed Statements of Cash Flows Statements 7 false false R8.htm 9952157 - Disclosure -
Organization Sheet http://www.bioventus.com/role/Organization Organization Notes 8 false false R9.htm 9952158 - Disclosure - Balance sheet information Sheet
http://www.bioventus.com/role/Balancesheetinformation Balance sheet information Notes 9 false false R10.htm 9952159 - Disclosure - Acquisitions and divestitures Sheet
http://www.bioventus.com/role/Acquisitionsanddivestitures Acquisitions and divestitures Notes 10 false false R11.htm 9952160 - Disclosure - Financial instruments Sheet
http://www.bioventus.com/role/Financialinstruments Financial instruments Notes 11 false false R12.htm 9952161 - Disclosure - Fair value measurements Sheet
http://www.bioventus.com/role/Fairvaluemeasurements Fair value measurements Notes 12 false false R13.htm 9952162 - Disclosure - Equity-based compensation Sheet
http://www.bioventus.com/role/Equitybasedcompensation Equity-based compensation Notes 13 false false R14.htm 9952163 - Disclosure - Stockholders??? equity Sheet
http://www.bioventus.com/role/Stockholdersequity Stockholders??? equity Notes 14 false false R15.htm 9952164 - Disclosure - Earnings per share Sheet
http://www.bioventus.com/role/Earningspershare Earnings per share Notes 15 false false R16.htm 9952165 - Disclosure - Restructuring costs Sheet
http://www.bioventus.com/role/Restructuringcosts Restructuring costs Notes 16 false false R17.htm 9952166 - Disclosure - Income taxes Sheet http://www.bioventus.com/role/Incometaxes
Income taxes Notes 17 false false R18.htm 9952167 - Disclosure - Commitments and contingencies Sheet http://www.bioventus.com/role/Commitmentsandcontingencies Commitments and
contingencies Notes 18 false false R19.htm 9952168 - Disclosure - Revenue recognition Sheet http://www.bioventus.com/role/RevenuerecognitionRevenue recognition Notes 19 false false
R20.htm 9952169 - Disclosure - Segments Sheet http://www.bioventus.com/role/SegmentsSegments Notes 20 false false R21.htm 9952170 - Disclosure - Discontinued Operations Sheet
http://www.bioventus.com/role/DiscontinuedOperations Discontinued Operations Notes 21 false false R22.htm 9954471 - Disclosure - Organization (Policies) Sheet
http://www.bioventus.com/role/OrganizationPolicies Organization (Policies) Policies 22 false false R23.htm 9954472 - Disclosure - Balance sheet information (Tables) Sheet
http://www.bioventus.com/role/BalancesheetinformationTables Balance sheet information (Tables) Tables http://www.bioventus.com/role/BalancesheetinformationTables 23 false false R24.htm
9954473 - Disclosure - Acquisitions and divestitures (Tables) Sheet http://www.bioventus.com/role/AcquisitionsanddivestituresTables Acquisitions and divestitures (Tables) Tables
http://www.bioventus.com/role/AcquisitionsanddivestituresTables 24 false false R25.htm 9954474 - Disclosure - Financial instruments (Tables) Sheet
http://www.bioventus.com/role/FinancialinstrumentsTables Financial instruments (Tables) Tables http://www.bioventus.com/role/FinancialinstrumentsTables 25 false false R26.htm 9954475 -
Disclosure - Fair value measurements (Tables) Sheet http://www.bioventus.com/role/FairvaluemeasurementsTables Fair value measurements (Tables) Tables
http://www.bioventus.com/role/FairvaluemeasurementsTables 26 false false R27.htm 9954476 - Disclosure - Equity-based compensation (Tables) Sheet
http://www.bioventus.com/role/EquitybasedcompensationTables Equity-based compensation (Tables) Tables http://www.bioventus.com/role/EquitybasedcompensationTables 27 false false R28.htm
9954477 - Disclosure - Stockholders??? equity (Tables) Sheet http://www.bioventus.com/role/StockholdersequityTables Stockholders??? equity (Tables) Tables
http://www.bioventus.com/role/StockholdersequityTables 28 false false R29.htm 9954478 - Disclosure - Earnings per share (Tables) Sheet http://www.bioventus.com/role/EarningspershareTables
Earnings per share (Tables) Tables http://www.bioventus.com/role/EarningspershareTables 29 false false R30.htm 9954479 - Disclosure - Commitments and contingencies (Tables) Sheet
http://www.bioventus.com/role/CommitmentsandcontingenciesTables Commitments and contingencies (Tables) Tables http://www.bioventus.com/role/CommitmentsandcontingenciesTables 30 false
false R31.htm 9954480 - Disclosure - Revenue recognition (Tables) Sheet http://www.bioventus.com/role/RevenuerecognitionTables Revenue recognition (Tables) Tables
http://www.bioventus.com/role/RevenuerecognitionTables 31 false false R32.htm 9954481 - Disclosure - Segments (Tables) Sheet http://www.bioventus.com/role/SegmentsTables Segments (Tables)
Tables http://www.bioventus.com/role/SegmentsTables 32 false false R33.htm 9954482 - Disclosure - Discontinued Operations (Tables) Sheet
http://www.bioventus.com/role/DiscontinuedOperationsTables Discontinued Operations (Tables) Tables http://www.bioventus.com/role/DiscontinuedOperationsTables 33 false false R34.htm 9954483 -
Disclosure - Organization - Narrative (Details) Sheet http://www.bioventus.com/role/OrganizationNarrativeDetails Organization - Narrative (Details) Details 34 false false R35.htm 9954484 -
Disclosure - Balance sheet information - Schedule of Accounts Receivable (Details) Sheet http://www.bioventus.com/role/BalancesheetinformationScheduleofAccountsReceivableDetails Balance
sheet information - Schedule of Accounts Receivable (Details) Details 35 false false R36.htm 9954485 - Disclosure - Balance sheet information - Components of Accounts Receivable (Narrative)
(Details) Sheet http://www.bioventus.com/role/BalancesheetinformationComponentsofAccountsReceivableNarrativeDetails Balance sheet information - Components of Accounts Receivable
(Narrative) (Details) Details 36 false false R37.htm 9954486 - Disclosure - Balance sheet information - Schedule of Inventory (Details) Sheet
http://www.bioventus.com/role/BalancesheetinformationScheduleofInventoryDetails Balance sheet information - Schedule of Inventory (Details) Details 37 false false R38.htm 9954487 -
Disclosure - Balance sheet information - Schedule od Property and Equipment, Net (Details) Sheet
http://www.bioventus.com/role/BalancesheetinformationScheduleofPropertyandEquipmentNetDetails Balance sheet information - Schedule od Property and Equipment, Net (Details) Details 38
false false R39.htm 9954488 - Disclosure - Balance sheet information - Schedule of Intangible Assets (Details) Sheet
http://www.bioventus.com/role/BalancesheetinformationScheduleofIntangibleAssetsDetails Balance sheet information - Schedule of Intangible Assets (Details) Details 39 false false R40.htm
9954489 - Disclosure - Balance sheet information - Schedule of Accrued Liabilities (Details) Sheet http://www.bioventus.com/role/BalancesheetinformationScheduleofAccruedLiabilitiesDetails
Balance sheet information - Schedule of Accrued Liabilities (Details) Details 40 false false R41.htm 9954490 - Disclosure - Acquisitions and divestitures - Schedule of Held for Sale Assets and
Liabilities (Details) Sheet http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofHeldforSaleAssetsandLiabilitiesDetails Acquisitions and divestitures - Schedule of Held for Sale
Assets and Liabilities (Details) Details 41 false false R42.htm 9954491 - Disclosure - Acquisitions and divestitures (Details) Sheet
http://www.bioventus.com/role/AcquisitionsanddivestituresDetails Acquisitions and divestitures (Details) Details http://www.bioventus.com/role/AcquisitionsanddivestituresTables 42 false false
R43.htm 9954492 - Disclosure - Financial instruments - Schedule Of Long-Term Debt Instruments (Details) Sheet
http://www.bioventus.com/role/FinancialinstrumentsScheduleOfLongTermDebtInstrumentsDetails Financial instruments - Schedule Of Long-Term Debt Instruments (Details) Details 43 false
false R44.htm 9954493 - Disclosure - Financial instruments - Narrative (Details) Sheet http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails Financial instruments - Narrative
(Details) Details 44 false false R45.htm 9954494 - Disclosure - Fair value measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) Sheet
http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails Fair value measurements - Schedule of Fair Value, Assets and
Liabilities Measured on Recurring Basis (Details) Details 45 false false R46.htm 9954495 - Disclosure - Fair value measurements - Schedule of Fair Value Measurement Inputs and Valuation
Techniques (Details) Sheet http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesDetails Fair value measurements - Schedule
of Fair Value Measurement Inputs and Valuation Techniques (Details) Details 46 false false R47.htm 9954496 - Disclosure - Fair value measurements - Narrative (Details) Sheet
http://www.bioventus.com/role/FairvaluemeasurementsNarrativeDetails Fair value measurements - Narrative (Details) Details 47 false false R48.htm 9954497 - Disclosure - Equity-based
compensation - Narrative (Details) Sheet http://www.bioventus.com/role/EquitybasedcompensationNarrativeDetails Equity-based compensation - Narrative (Details) Details 48 false false
R49.htm 9954498 - Disclosure - Equity-based compensation - Schedule of Nonvested Restricted Stock Units Activity (Details) Sheet
http://www.bioventus.com/role/EquitybasedcompensationScheduleofNonvestedRestrictedStockUnitsActivityDetails Equity-based compensation - Schedule of Nonvested Restricted Stock Units
Activity (Details) Details 49 false false R50.htm 9954499 - Disclosure - Equity-based compensation - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details)
Sheet http://www.bioventus.com/role/EquitybasedcompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails Equity-based compensation - Schedule of Share-
based Payment Award, Stock Options, Valuation Assumptions (Details) Details 50 false false R51.htm 9954500 - Disclosure - Equity-based compensation - Schedule of Stock Options Roll
Forward (Details) Sheet http://www.bioventus.com/role/EquitybasedcompensationScheduleofStockOptionsRollForwardDetails Equity-based compensation - Schedule of Stock Options Roll
Forward (Details) Details 51 false false R52.htm 9954501 - Disclosure - Stockholders??? equity - Narrative (Details) Sheet http://www.bioventus.com/role/StockholdersequityNarrativeDetails

Stockholders??? equity - Narrative (Details) Details 52 false false R53.htm 9954502 - Disclosure - Stockholders??? equity - Schedule of Other Ownership Interests (Details) Sheet http://www.bioventus.com/role/StockholdersequityScheduleofOtherOwnershipInterestsDetails Stockholders??? equity - Schedule of Other Ownership Interests (Details) Details 53 false false R54.htm 9954503 - Disclosure - Earnings per share - Schedule of Earnings Per Share (Details) Sheet http://www.bioventus.com/role/EarningspershareScheduleofEarningsPerShareDetails Earnings per share - Schedule of Earnings Per Share (Details) Details 54 false false R55.htm 9954504 - Disclosure - Earnings per share - Schedule of Antidilutive Securities (Details) Sheet http://www.bioventus.com/role/EarningspershareScheduleofAntidilutiveSecuritiesDetails Earnings per share - Schedule of Antidilutive Securities (Details) Details 55 false false R56.htm 9954505 - Disclosure - Restructuring costs - Narrative (Details) Sheet http://www.bioventus.com/role/RestructuringcostsNarrativeDetails Restructuring costs - Narrative (Details) Details 56 false false R57.htm 9954506 - Disclosure - Income taxes (Details) Sheet http://www.bioventus.com/role/IncometaxesDetails Income taxes (Details) Details http://www.bioventus.com/role/Incometaxes 57 false false R58.htm 9954507 - Disclosure - Commitments and contingencies - Narrative (Details) Sheet http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails Commitments and contingencies - Narrative (Details) Details 58 false false R59.htm 9954508 - Disclosure - Commitments and contingencies - Schedule of Lease, Cost (Details) Sheet http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofLeaseCostDetails Commitments and contingencies - Schedule of Lease, Cost (Details) Details 59 false false R60.htm 9954509 - Disclosure - Commitments and contingencies - Schedule of Assets and Liabilities, Lessee (Details) Sheet http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofAssetsandLiabilitiesLesseeDetails Commitments and contingencies - Schedule of Assets and Liabilities, Lessee (Details) Details 60 false false R61.htm 9954510 - Disclosure - Revenue from Contract with Customer - Narrative (Details) Sheet http://www.bioventus.com/role/RevenuefromContractwithCustomerNarrativeDetails Revenue from Contract with Customer - Narrative (Details) Details 61 false false R62.htm 9954511 - Disclosure - Revenue recognition - Schedule of Disaggregation of Revenue (Details) Sheet http://www.bioventus.com/role/RevenurecognitionScheduleofDisaggregationofRevenueDetails Revenue recognition - Schedule of Disaggregation of Revenue (Details) Details 62 false false R63.htm 9954512 - Disclosure - Segments - Narrative (Details) Sheet http://www.bioventus.com/role/SegmentsNarrativeDetails Segments - Narrative (Details) Details 63 false false R64.htm 9954513 - Disclosure - Segments - Schedule of Reconciliation of Operating Profit (Loss) from Segments to Consolidated (Details) Sheet http://www.bioventus.com/role/SegmentsScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails Segments - Schedule of Reconciliation of Operating Profit (Loss) from Segments to Consolidated (Details) Details 64 false false R65.htm 9954514 - Disclosure - Discontinued Operations - Narrative (Details) Sheet http://www.bioventus.com/role/DiscontinuedOperationsNarrativeDetails Discontinued Operations - Narrative (Details) Details 65 false false R66.htm 9954515 - Disclosure - Discontinued Operations and Disposal Groups - Schedule of Statement of Operations (Details) Sheet http://www.bioventus.com/role/DiscontinuedOperationsandDisposalGroupsScheduleofStatementofOperationsDetails Discontinued Operations and Disposal Groups - Schedule of Statement of Operations (Details) Details 66 false false All Reports bvs-20240629.htm bvs-20240629.xsd bvs-20240629_cal.xml bvs-20240629_def.xml bvs-20240629_lab.xml bvs-20240629_pre.xml http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 true true JSON 83 MetaLinks,json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "bvs-20240629.htm": { "nsprefix": "bvs", "nsuri": "http://www.bioventus.com/20240629", "dts": { "inline": { "local": ["bvs-20240629.htm"] }, "schema": { "local": ["bvs-20240629.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] }, "calculationLink": { "local": ["bvs-20240629_cal.xml"] }, "definitionLink": { "local": ["bvs-20240629_def.xml"] }, "labelLink": { "local": ["bvs-20240629_lab.xml"] }, "presentationLink": { "local": ["bvs-20240629_pre.xml"] } }, "keyStandard": 318, "keyCustom": 58, "axisStandard": 34, "axisCustom": 0, "memberStandard": 44, "memberCustom": 33, "hidden": { "total": 7, "http://xbrl.sec.gov/dei/2024": 5, "http://fasb.org/us-gaap/2024": 2 }, "contextCount": 280, "entityCount": 1, "segmentCount": 85, "elementCount": 603, "unitCount": 9, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 965, "http://xbrl.sec.gov/dei/2024": 33 }, "report": { "R1": { "role": "http://www.bioventus.com/role/CoverPage", "longName": "0000001 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"] }, "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"] }, "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss", "longName": "9952151 - Statement - Consolidated Condensed Statements of Operations and Comprehensive Loss", "shortName": "Consolidated Condensed Statements of Operations and Comprehensive Loss", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"] }, "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "unique": true } }, "R3": { "role": "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLossParenthetical", "longName": "9952152 - Statement - Consolidated Condensed Statements of Operations and Comprehensive Loss (Parenthetical)", "shortName": "Consolidated Condensed Statements of Operations and Comprehensive Loss (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "div", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "div", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets", "longName": "9952153 - Statement - Consolidated Condensed Balance Sheets", "shortName": "Consolidated Condensed Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true } }, "R5": { "role": "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheetsParenthetical", "longName": "9952154 - Statement - Consolidated Condensed Balance Sheets (Parenthetical)", "shortName": "Consolidated Condensed Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true } }, "R6": { "role": "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofChangesinStockholdersEquity", "longName": "9952155 - Statement - Consolidated Condensed Statements of Changes in Stockholders\u2019 Equity", "shortName": "Consolidated Condensed Statements of Changes in Stockholders\u2019 Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-61", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-61", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofCashFlows", "longName": "9952156 - Statement - Consolidated Condensed Statements of Cash Flows", "shortName": "Consolidated Condensed Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ProvisionForDoubtfulAccounts", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "unique": true } }, "R8": { "role": "http://www.bioventus.com/role/Organization", "longName": "9952157 - Disclosure - Organization", "shortName": "Organization", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.bioventus.com/role/Balancesheetinformation", "longName": "9952158 - Disclosure - Balance sheet information", "shortName": "Balance sheet information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.bioventus.com/role/Acquisitionsanddivestitures", "longName": "9952159 - Disclosure - Acquisitions and divestitures", "shortName": "Acquisitions and divestitures", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "bvs:AcquisitionsAndInvestmentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "bvs:AcquisitionsAndInvestmentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.bioventus.com/role/Financialinstruments", "longName": "9952160 - Disclosure - Financial instruments", "shortName": "Financial instruments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.bioventus.com/role/Fairvaluemeasurements", "longName": "9952161 - Disclosure - Fair value measurements", "shortName": "Fair value measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.bioventus.com/role/Equitybasedcompensation", "longName": "9952162 - Disclosure - Equity-based compensation", "shortName": "Equity-based compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.bioventus.com/role/Stockholdersequity", "longName": "9952163 - Disclosure - Stockholders\u2019 equity", "shortName": "Stockholders\u2019 equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.bioventus.com/role/Earningspershare", "longName": "9952164 - Disclosure - Earnings per share", "shortName": "Earnings per share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.bioventus.com/role/Restructuringcosts", "longName": "9952165 - Disclosure - Restructuring costs", "shortName": "Restructuring costs", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.bioventus.com/role/Incometaxes", "longName": "9952166 - Disclosure - Income taxes", "shortName": "Income taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bvs-

20240629.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.bioventus.com/role/Commitmentsandcontingencies", "longName": "9952167 - Disclosure - Commitments and contingencies", "shortName": "Commitments and contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.bioventus.com/role/Revenuerecognition", "longName": "9952168 - Disclosure - Revenue recognition", "shortName": "Revenue recognition", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.bioventus.com/role/Segments", "longName": "9952169 - Disclosure - Segments", "shortName": "Segments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.bioventus.com/role/DiscontinuedOperations", "longName": "9952170 - Disclosure - Discontinued Operations", "shortName": "Discontinued Operations", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.bioventus.com/role/OrganizationPolicies", "longName": "9954471 - Disclosure - Organization (Policies)", "shortName": "Organization (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PriorPeriodReclassificationAdjustmentDescription", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PriorPeriodReclassificationAdjustmentDescription", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.bioventus.com/role/BalancesheetinformationTables", "longName": "9954472 - Disclosure - Balance sheet information (Tables)", "shortName": "Balance sheet information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.bioventus.com/role/AcquisitionsanddivestituresTables", "longName": "9954473 - Disclosure - Acquisitions and divestitures (Tables)", "shortName": "Acquisitions and divestitures (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true }, "uniqueAnchor": null }, "R25": { "role": "http://www.bioventus.com/role/FinancialinstrumentsTables", "longName": "9954474 - Disclosure - Financial instruments (Tables)", "shortName": "Financial instruments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.bioventus.com/role/FairvaluemeasurementsTables", "longName": "9954475 - Disclosure - Fair value measurements (Tables)", "shortName": "Fair value measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.bioventus.com/role/EquitybasedcompensationTables", "longName": "9954476 - Disclosure - Equity-based compensation (Tables)", "shortName": "Equity-based compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.bioventus.com/role/StockholdersequityTables", "longName": "9954477 - Disclosure - Stockholders\u2019 equity (Tables)", "shortName": "Stockholders\u2019 equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfOtherOwnershipInterestsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfOtherOwnershipInterestsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.bioventus.com/role/EarningspersharaTables", "longName": "9954478 - Disclosure - Earnings per share (Tables)", "shortName": "Earnings per share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.bioventus.com/role/CommitmentsandcontingenciesTables", "longName": "9954479 - Disclosure - Commitments and contingencies (Tables)", "shortName": "Commitments and contingencies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.bioventus.com/role/RevenuerecognitionTables", "longName": "9954480 - Disclosure - Revenue recognition (Tables)", "shortName": "Revenue recognition (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.bioventus.com/role/SegmentsTables", "longName": "9954481 - Disclosure - Segments (Tables)", "shortName": "Segments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.bioventus.com/role/DiscontinuedOperationsTables", "longName": "9954482 - Disclosure - Discontinued Operations (Tables)", "shortName": "Discontinued Operations (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true }, "uniqueAnchor": null }, "R34": { "role": "http://www.bioventus.com/role/OrganizationNarrativeDetails", "longName": "9954483 - Disclosure - Organization - Narrative (Details)", "shortName": "Organization - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "c-73", "name": "dei:EntityNumberOfEmployees", "unitRef": "employee", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-73", "name": "dei:EntityNumberOfEmployees", "unitRef": "employee", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.bioventus.com/role/BalancesheetinformationScheduleofAccountsReceivableDetails", "longName": "9954484 - Disclosure - Balance sheet information - Schedule of Accounts Receivable (Details)", "shortName": "Balance sheet information - Schedule of Accounts Receivable (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:AccountsReceivableGrossCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true }, "uniqueAnchor": null }, "R36": { "role": "http://www.bioventus.com/role/BalancesheetinformationComponentsofAccountsReceivableNarrativeDetails", "longName": "9954485 - Disclosure - Balance sheet information - Components of Accounts Receivable (Narrative) (Details)", "shortName": "Balance sheet information - Components of Accounts Receivable (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:AccountsReceivableGrossCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-74", "name": "us-gaap:AccountsReceivableGrossCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "div", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "unique": true } }, "R37": { "role": "http://www.bioventus.com/role/BalancesheetinformationScheduleofInventoryDetails", "longName": "9954486 - Disclosure - Balance sheet information - Schedule of Inventory (Details)", "shortName": "Balance sheet information - Schedule of Inventory (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:InventoryRawMaterialsAndSupplies", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:InventoryRawMaterialsAndSupplies", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.bioventus.com/role/BalancesheetinformationScheduleodPropertyandEquipmentNetDetails", "longName": "9954487 - Disclosure - Balance sheet information - Schedule od Property and Equipment, Net (Details)", "shortName": "Balance sheet information - Schedule od Property and Equipment, Net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.bioventus.com/role/BalancesheetinformationScheduleofIntangibleAssetsDetails", "longName": "9954488 - Disclosure - Balance sheet information - Schedule of Intangible Assets (Details)", "shortName": "Balance sheet information - Schedule of Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-8", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "unique": true } }, "R40": { "role": "http://www.bioventus.com/role/BalancesheetinformationScheduleofAccruedLiabilitiesDetails", "longName": "9954489 - Disclosure - Balance sheet information - Schedule of Accrued Liabilities (Details)", "shortName": "Balance sheet information - Schedule of Accrued Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-7", "name": "bvs:GrossToNetDeductionsCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "bvs:GrossToNetDeductionsCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span",

"td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true }], "R41": { "role": "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofHeldforSaleAssetsandLiabilitiesDetails", "longName": "9954490 - Disclosure - Acquisitions and divestitures - Schedule of Held for Sale Assets and Liabilities (Details)", "shortName": "Acquisitions and divestitures - Schedule of Held for Sale Assets and Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AssetImpairmentCharges", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-105", "name": "bvs:DisposalGroupIncludingDiscontinuedOperationTransactionalFeesIncurred", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "unique": true } }, "R42": { "role": "http://www.bioventus.com/role/AcquisitionsanddivestituresDetails", "longName": "9954491 - Disclosure - Acquisitions and divestitures (Details)", "shortName": "Acquisitions and divestitures (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AssetImpairmentCharges", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-110", "name": "us-gaap:RepaymentsOfLongTermDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "unique": true } }, "R43": { "role": "http://www.bioventus.com/role/FinancialinstrumentsScheduleOfLongTermDebtInstrumentsDetails", "longName": "9954492 - Disclosure - Financial instruments - Schedule Of Long-Term Debt Instruments (Details)", "shortName": "Financial instruments - Schedule Of Long-Term Debt Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:LongTermDebtCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-119", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "unique": true } }, "R44": { "role": "http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails", "longName": "9954493 - Disclosure - Financial instruments - Narrative (Details)", "shortName": "Financial instruments - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProceedsFromLongTermLinesOfCredit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-128", "name": "us-gaap:DebtInstrumentBasisSpreadOnVariableRate1", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "unique": true } }, "R45": { "role": "http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails", "longName": "9954494 - Disclosure - Fair value measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)", "shortName": "Fair value measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-155", "name": "us-gaap:LiabilitiesFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "unique": true } }, "R46": { "role": "http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesDetails", "longName": "9954495 - Disclosure - Fair value measurements - Schedule of Fair Value Measurement Inputs and Valuation Techniques (Details)", "shortName": "Fair value measurements - Schedule of Fair Value Measurement Inputs and Valuation Techniques (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-159", "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "div", "td", "tr", "table", "div", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "c-159", "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "div", "td", "tr", "table", "div", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.bioventus.com/role/FairvaluemeasurementsNarrativeDetails", "longName": "9954496 - Disclosure - Fair value measurements - Narrative (Details)", "shortName": "Fair value measurements - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-161", "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "unique": true } }, "R48": { "role": "http://www.bioventus.com/role/EquitybasedcompensationNarrativeDetails", "longName": "9954497 - Disclosure - Equity-based compensation - Narrative (Details)", "shortName": "Equity-based compensation - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-173", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "unique": true } }, "R49": { "role": "http://www.bioventus.com/role/EquitybasedcompensationScheduleofNonvestedRestrictedStockUnitsActivityDetails", "longName": "9954498 - Disclosure - Equity-based compensation - Schedule of Nonvested Restricted Stock Units Activity (Details)", "shortName": "Equity-based compensation - Schedule of Nonvested Restricted Stock Units Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-174", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-174", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.bioventus.com/role/EquitybasedcompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails", "longName": "9954499 - Disclosure - Equity-based compensation - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details)", "shortName": "Equity-based compensation - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-177", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": ["span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-177", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": ["span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.bioventus.com/role/EquitybasedcompensationScheduleofStockOptionsRollForwardDetails", "longName": "9954500 - Disclosure - Equity-based compensation - Schedule of Stock Options Roll Forward (Details)", "shortName": "Equity-based compensation - Schedule of Stock Options Roll Forward (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-8", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-8", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.bioventus.com/role/StockholdersequityNarrativeDetails", "longName": "9954501 - Disclosure - Stockholders\u2019 equity - Narrative (Details)", "shortName": "Stockholders\u2019 equity - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-187", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-187", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.bioventus.com/role/StockholderequityScheduleofOtherOwnershipInterestsDetails", "longName": "9954502 - Disclosure - Stockholders\u2019 equity - Schedule of Other Ownership Interests (Details)", "shortName": "Stockholders\u2019 equity - Schedule of Other Ownership Interests (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-190", "name": "us-gaap:LimitedLiabilityCompanyLlcMembersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-190", "name": "us-gaap:LimitedLiabilityCompanyLlcMembersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.bioventus.com/role/EarningspersharaScheduleofEarningsPerShareDetails", "longName": "9954503 - Disclosure - Earnings per share - Schedule of Earnings Per Share (Details)", "shortName": "Earnings per share - Schedule of Earnings Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:IncomeLossFromContinuingOperations", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "unique": true } }, "R55": { "role": "http://www.bioventus.com/role/EarningspersharaScheduleofAntidilutiveSecuritiesDetails", "longName": "9954504 - Disclosure - Earnings per share - Schedule of Antidilutive Securities (Details)", "shortName": "Earnings per share - Schedule of Antidilutive Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.bioventus.com/role/RestructuringcostsNarrativeDetails", "longName": "9954505 - Disclosure - Restructuring costs - Narrative (Details)", "shortName": "Restructuring costs - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:RestructuringCharges", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PaymentsForRestructuring", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "unique": true } }, "R57": { "role": "http://www.bioventus.com/role/IncometaxesDetails", "longName": "9954506 - Disclosure - Income taxes (Details)", "shortName": "Income taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails", "longName": "9954507 - Disclosure - Commitments and contingencies - Narrative (Details)", "shortName": "Commitments and contingencies - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-7", "name": "bvs:LineOfCreditFacilityNumberOfLettersOfCreditOutstanding", "unitRef": "letter_of_credit", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["bvs:LineOfCreditFacilityNumberOfLettersOfCreditOutstanding", "span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-8", "name": "us-gaap:LettersOfCreditOutstandingAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["us-gaap:LettersOfCreditOutstandingAmount", "span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "unique": true } }, "R59": { "role": "http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofLeaseCostDetails", "longName": "9954508 - Disclosure - Commitments and contingencies - Schedule of Lease, Cost (Details)", "shortName": "Commitments and contingencies - Schedule of Lease, Cost (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-

gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofAssetsandLiabilitiesLesseeDetails", "longName": "9954509 - Disclosure - Commitments and contingencies - Schedule of Assets and Liabilities, Lessee (Details)", "shortName": "Commitments and contingencies - Schedule of Assets and Liabilities, Lessee (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:OperatingLeaseLiabilityCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "td", "tr", "table", "div", "bvs:AssetsAndLiabilitiesLesseeTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "unique": true } }, "R61": { "role": "http://www.bioventus.com/role/RevenuefromContractwithCustomerNarrativeDetails", "longName": "9954510 - Disclosure - Revenue from Contract with Customer - Narrative (Details)", "shortName": "Revenue from Contract with Customer - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-236", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "unique": true } }, "R62": { "role": "http://www.bioventus.com/role/RevenuerecognitionScheduleofDisaggregationofRevenueDetails", "longName": "9954511 - Disclosure - Revenue recognition - Schedule of Disaggregation of Revenue (Details)", "shortName": "Revenue recognition - Schedule of Disaggregation of Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-238", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "unique": true } }, "R63": { "role": "http://www.bioventus.com/role/SegmentsNarrativeDetails", "longName": "9954512 - Disclosure - Segments - Narrative (Details)", "shortName": "Segments - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true, "unique": true } }, "R64": { "role": "http://www.bioventus.com/role/SegmentsScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails", "longName": "9954513 - Disclosure - Segments - Schedule of Reconciliation of Operating Profit (Loss) from Segments to Consolidated (Details)", "shortName": "Segments - Schedule of Reconciliation of Operating Profit (Loss) from Segments to Consolidated (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:InterestIncomeExpenseNonoperatingNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-274", "name": "us-gaap:InterestIncomeExpenseNonoperatingNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "unique": true } }, "R65": { "role": "http://www.bioventus.com/role/DiscontinuedOperationsNarrativeDetails", "longName": "9954514 - Disclosure - Discontinued Operations - Narrative (Details)", "shortName": "Discontinued Operations - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "c-115", "name": "bvs:BusinessAcquisitionPercentageOfSharesTransferredToTrustee", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true }, "uniqueAnchor": null }, "R66": { "role": "http://www.bioventus.com/role/DiscontinuedOperationsandDisposalGroupsScheduleofStatementofOperationsDetails", "longName": "9954515 - Disclosure - Discontinued Operations and Disposal Groups - Schedule of Statement of Operations (Details)", "shortName": "Discontinued Operations and Disposal Groups - Schedule of Statement of Operations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:DeconsolidationGainOrLossAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "bvs:NonRefundablePayments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["bvs:NonRefundablePayments", "span", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bvs-20240629.htm", "unique": true } } }, "tag": { "bvs_A2021And2023PlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "A2021And2023PlanMember", "presentation": ["http://www.bioventus.com/role/EquitybasedcompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "2021 and 2023 Plan", "label": "2021 and 2023 Plan [Member]", "documentation": "2021 and 2023 Plan" } } }, "auth_ref": [] }, "bvs_A2021PlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "A2021PlanMember", "presentation": ["http://www.bioventus.com/role/EquitybasedcompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "2021 Plan", "label": "2021 Plan [Member]", "documentation": "2021 Plan" } } }, "auth_ref": [] }, "bvs_A2023RetentionEquityAwardPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "A2023RetentionEquityAwardPlanMember", "presentation": ["http://www.bioventus.com/role/EquitybasedcompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "2023 Retention Equity Award Plan", "label": "2023 Retention Equity Award Plan [Member]", "documentation": "2023 Retention Equity Award Plan" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r96", "r839"] }, "us-gaap_AccountsReceivableGrossCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableGrossCurrent", "crdr": "debit", "calculation": { "http://www.bioventus.com/role/BalancesheetinformationScheduleofAccountsReceivableDetails": { "parentTag": "us-gaap_AccountsReceivableNetCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.bioventus.com/role/BalancesheetinformationComponentsofAccountsReceivableNarrativeDetails", "http://www.bioventus.com/role/BalancesheetinformationScheduleofAccountsReceivableDetails"], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable", "label": "Accounts Receivable, before Allowance for Credit Loss, Current", "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": ["r211", "r304", "r786"] }, "us-gaap_AccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableMember", "presentation": ["http://www.bioventus.com/role/BalancesheetinformationComponentsofAccountsReceivableNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable", "label": "Accounts Receivable [Member]", "documentation": "Due from customers or clients for goods or services that have been delivered or sold." } } }, "auth_ref": ["r768"] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 }, "http://www.bioventus.com/role/BalancesheetinformationScheduleofAccountsReceivableDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.bioventus.com/role/BalancesheetinformationScheduleofAccountsReceivableDetails", "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, net", "totalLabel": "Accounts receivable, net", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": ["r914"] }, "us-gaap_AccruedBonusesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedBonusesCurrent", "crdr": "credit", "calculation": { "http://www.bioventus.com/role/BalancesheetinformationScheduleofAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.bioventus.com/role/BalancesheetinformationScheduleofAccruedLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Bonus and commission", "label": "Accrued Bonuses, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r99"] }, "bvs_AccruedLegalLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "AccruedLegalLiabilities", "crdr": "credit", "calculation": { "http://www.bioventus.com/role/BalancesheetinformationScheduleofAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.bioventus.com/role/BalancesheetinformationScheduleofAccruedLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Settlement and legal fees", "label": "Accrued Legal Liabilities", "documentation": "Accrued Legal Liabilities" } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 }, "http://www.bioventus.com/role/BalancesheetinformationScheduleofAccruedLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.bioventus.com/role/BalancesheetinformationScheduleofAccruedLiabilitiesDetails", "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Accrued liabilities", "totalLabel": "Accrued liabilities", "label": "Accrued Liabilities, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r99"] }, "bvs_AccruedLiabilitiesForIntellectualProperty": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "AccruedLiabilitiesForIntellectualProperty", "crdr": "credit", "presentation": ["http://www.bioventus.com/role/ConsolidatedCondensedStatementsofCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Accrued liabilities for intellectual property", "label": "Accrued liabilities for intellectual property", "documentation": "Accrued liabilities for intellectual property" } } }, "auth_ref": [] }, "bvs_AccruedSalariesAndEmployeeBenefitsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "AccruedSalariesAndEmployeeBenefitsCurrent", "crdr": "credit", "calculation": { "http://www.bioventus.com/role/BalancesheetinformationScheduleofAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.bioventus.com/role/BalancesheetinformationScheduleofAccruedLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Compensation and benefits", "label": "Accrued Salaries And Employee Benefits, Current", "documentation": "Accrued Salaries And Employee Benefits, Current" } } }, "auth_ref": [] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive (loss) income", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": ["r23", "r24", "r119", "r212", "r631", "r669", "r670"] }, "bvs_AcquisitionsAndInvestmentsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "AcquisitionsAndInvestmentsDisclosureTextBlock", "presentation": ["http://www.bioventus.com/role/Acquisitionsanddivestitures"], "lang": { "en-us": { "role": { "terseLabel": "Acquisitions and divestitures", "label": "Acquisitions And Investments Disclosure [Text Block]", "documentation": "Acquisitions And Investments Disclosure" } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid-in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": ["r110", "r839", "r1038"] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": ["http://www.bioventus.com/role/ConsolidatedCondensedStatementsofChangesinStockholdersEquity"], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-in Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r682", "r902", "r903", "r904", "r905", "r979", "r1040"] }, "bvs_AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems", "crdr": "credit", "calculation": { "http://www.bioventus.com/role/SegmentsScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://www.bioventus.com/role/SegmentsScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"], "lang": { "en-us": { "role": { "terseLabel": "Segment Adjusted EBITDA", "label": "Adjusted Earnings Before Interest, Taxes, Depreciation, Amortization And Other Non-Operating Items", "documentation": "Adjusted Earnings Before Interest, Taxes, Depreciation, Amortization And Other Non-Operating Items" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": ["http://www.bioventus.com/role/ConsolidatedCondensedStatementsofChangesinStockholdersEquity"], "lang": { "en-us": { "role": { "terseLabel": "Equity based compensation", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": ["r58", "r59", "r442"] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [

```
"http://www.bioventus.com/role/ConsolidatedCondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net loss to net cash from operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "calculation": { "http://www.bioventus.com/role/SegmentsScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.bioventus.com/role/EquitybasedcompensationNarrativeDetails",
"http://www.bioventus.com/role/SegmentsScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity compensation", "negatedTerseLabel": "Equity compensation", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r470", "r472" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "calculation": {
"http://www.bioventus.com/role/BalancesheetinformationScheduleofAccountsReceivableDetails": { "parentTag": "us-gaap_AccountsReceivableNetCurrent", "weight": -1.0, "order": 2.0 } },
"presentation": [ "http://www.bioventus.com/role/BalancesheetinformationComponentsofAccountsReceivableNarrativeDetails",
"http://www.bioventus.com/role/BalancesheetinformationScheduleofAccountsReceivableDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: Allowance for credit losses", "terseLabel": "Allowance for credit losses", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": [ "r213", "r305", "r309" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag",
"presentation": [ "http://www.bioventus.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfFinancingCosts", "crdr": "debit", "presentation": [ "http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of debt issuance costs", "label": "Amortization of Debt Issuance Costs", "documentation": "Amount of amortization expense attributable to debt issuance costs." } } }, "auth_ref": [ "r131", "r396", "r897", "r991" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [
"http://www.bioventus.com/role/EarningspershareScheduleofAntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive securities (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r261" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [
"http://www.bioventus.com/role/EarningspershareScheduleofAntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities [Axis]", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r32" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://www.bioventus.com/role/EarningspershareScheduleofAntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://www.bioventus.com/role/EarningspershareScheduleofAntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name [Domain]", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r32" ] }, "us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AociIncludingPortionAttributableToNoncontrollingInterestMember", "presentation": [ "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofChangesinStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive income (loss)", "label": "AOCI Including Portion Attributable to Noncontrolling Interest [Member]", "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, including the portion attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r2", "r13", "r24", "r888", "r889", "r890" ] }, "us-gaap_AssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetImpairmentCharges", "crdr": "debit", "calculation": { "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 7.0 },
"http://www.bioventus.com/role/SegmentsScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 7.0 } }, "presentation": [
"http://www.bioventus.com/role/AcquisitionsanddivestituresDetails", "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofHeldforSaleAssetsandLiabilitiesDetails",
"http://www.bioventus.com/role/ConsolidatedCondensedStatemcntsofCashFlows",
"http://www.bioventus.com/role/SegmentsScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Impairment of assets", "terseLabel": "Impairments of assets", "negatedLabel": "Impairments of assets", "label": "Asset Impairment Charges", "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill." } } }, "auth_ref": [ "r0", "r46" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r171", "r184", "r205", "r233", "r265", "r273", "r291", "r295", "r306", "r363", "r364", "r366", "r367", "r368", "r369", "r370", "r372", "r373", "r504", "r509", "r543", "r627", "r719", "r797", "r798", "r839", "r867", "r946", "r947", "r995" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": [
"http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "bvs_AssetsAndLiabilitiesLesseeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "AssetsAndLiabilitiesLesseeTableTextBlock", "presentation": [ "http://www.bioventus.com/role/CommitmentsandcontingenciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Assets and Liabilities, Lessee", "label": "Assets And Liabilities, Lessee [Table Text Block]", "documentation": "Assets And Liabilities, Lessee" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r198", "r215", "r233", "r306", "r363", "r364", "r366", "r367", "r368", "r369", "r370", "r372", "r373", "r504", "r509", "r543", "r830", "r946", "r947", "r995" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "bvs_AssetsHeldForSaleAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "AssetsHeldForSaleAbstract", "presentation": [
"http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofHeldforSaleAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assets Held for Sale [Abstract]", "label": "Assets Held for Sale [Abstract]", "documentation": "Assets Held for Sale" } } }, "auth_ref": [] }, "us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsHeldForSaleNotPartOfDisposalGroupCurrent", "crdr": "debit", "calculation": {
"http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [
"http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Assets held for sale", "label": "Asset, Held-for-Sale, Not Part of Disposal Group, Current", "documentation": "Amount of assets held-for-sale that are not part of a disposal group, expected to be sold within a year or the normal operating cycle, if longer." } } },
"auth_ref": [ "r145", "r839" ] }, "bvs_AssetsNotYetPlacedInServiceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "AssetsNotYetPlacedInServiceMember", "presentation": [ "http://www.bioventus.com/role/BalancesheetinformationScheduleofPropertyandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assets not yet placed in service", "label": "Assets Not Yet Placed In Service [Member]", "documentation": "Assets Not Yet Placed In Service" } } }, "auth_ref": [] }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperation", "crdr": "debit", "calculation": {
"http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofHeldforSaleAssetsandLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [
"http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofHeldforSaleAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets held for sale", "label": "Disposal Group, Including Discontinued Operation, Assets", "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r1", "r76", "r91", "r148", "r196", "r197" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [
"http://www.bioventus.com/role/EquitybasedcompensationNarrativeDetails",
"http://www.bioventus.com/role/EquitybasedcompensationScheduleofNonvestedRestrictedStockUnitsActivityDetails",
"http://www.bioventus.com/role/EquitybasedcompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469" ] }, "bvs_BVLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "BVLLCMember", "presentation": [ "http://www.bioventus.com/role/OrganizationNarrativeDetails",
"http://www.bioventus.com/role/StockholdersequityNarrativeDetails", "http://www.bioventus.com/role/StockholdersequityScheduleofOtherOwnershipInterestsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bioventus Inc.", "label": "BV LLC [Member]", "documentation": "BV LLC" } } }, "auth_ref": [] }, "us-gaap_BaseRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BaseRateMember", "presentation": [ "http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Base Rate", "label": "Base Rate [Member]", "documentation": "Minimum rate investor will accept." } } }, "auth_ref": [] }, "bvs_BionessIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "BionessIncMember", "presentation": [
"http://www.bioventus.com/role/FairvaluemeasurementsNarrativeDetails",
"http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails",
"http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bioness, Inc", "verboseLabel": "Bioness contingent consideration", "label": "Bioness, Inc [Member]", "documentation": "Bioness, Inc" } } }, "auth_ref": [] }, "bvs_BioventusAndContinuingLLCOwnerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "BioventusAndContinuingLLCOwnerMember", "presentation": [
"http://www.bioventus.com/role/StockholdersequityScheduleofOtherOwnershipInterestsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bioventus and Continuing LLC Owner", "label": "Bioventus And Continuing LLC Owner [Member]", "documentation": "Bioventus And Continuing LLC Owner" } } }, "auth_ref": [] }, "bvs_BioventusShareholderLitigationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "BioventusShareholderLitigationMember", "presentation": [
"http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bioventus Shareholder Litigation", "label": "Bioventus Shareholder Litigation [Member]", "documentation": "Bioventus Shareholder Litigation" } } }, "auth_ref": [] }, "us-gaap_BridgeLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BridgeLoanMember", "presentation": [ "http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Swingline Loan", "label": "Bridge Loan [Member]", "documentation": "Financing which is expected to be replaced by a medium to long-term loan. The loan \"bridges\" the gap in time when otherwise no financing would be in place." } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://www.bioventus.com/role/AcquisitionsanddivestituresDetails",
"http://www.bioventus.com/role/FairvaluemeasurementsNarrativeDetails",
"http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails",
"http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesDetails",
"http://www.bioventus.com/role/StockholdersequityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Acquiree [Domain]", "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r326", "r327", "r328", "r329", "r330", "r498", "r822", "r823" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://www.bioventus.com/role/AcquisitionsanddivestituresDetails",
"http://www.bioventus.com/role/FairvaluemeasurementsNarrativeDetails",
"http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails",
"http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesDetails",
"http://www.bioventus.com/role/StockholdersequityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Axis]", "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r61", "r63", "r326", "r327", "r328", "r329", "r330",
```

```
"r498", "r822", "r823" ] }, "us-gaap_BusinessAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionLineItems", "presentation": [ "http://www.bioventus.com/role/AcquisitionsanddivestituresDetails",
"http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Line Items]", "label": "Business Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r498" ] },
"bvs_BusinessAcquisitionPercentageOfSharesTransferredToTrustee": { "xbrltype": "percentItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "BusinessAcquisitionPercentageOfSharesTransferredToTrustee", "presentation": [ "http://www.bioventus.com/role/AcquisitionsanddivestituresDetails",
"http://www.bioventus.com/role/DiscontinuedOperationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business acquisition, percentage of shares transferred to trustee", "label": "Business Acquisition, Percentage Of Shares Transferred To Trustee", "documentation": "Business Acquisition, Percentage Of Shares Transferred To Trustee" } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "presentation": [ "http://www.bioventus.com/role/AcquisitionsanddivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of business acquired", "label": "Business Acquisition, Percentage of Voting Interests Acquired", "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination." } } }, "auth_ref": [ "r62" ] }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationAcquisitionRelatedCosts", "crdr": "debit", "calculation": {
"http://www.bioventus.com/role/SegmentsScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 9.0 } }, "presentation": [
"http://www.bioventus.com/role/SegmentsScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Acquisition and related costs", "label": "Business Combination, Acquisition Related Costs", "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities." } } }, "auth_ref": [ "r60" ] }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "lang": { "en-us": { "role": { "label": "Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]" } } }, "auth_ref": [] }, "bvs_BusinessCombinationConsiderationTransferredDeferralPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "BusinessCombinationConsiderationTransferredDeferralPeriod", "presentation": [ "http://www.bioventus.com/role/AcquisitionsanddivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferral period", "label": "Business Combination, Consideration Transferred, Deferral Period", "documentation": "Business Combination, Consideration Transferred, Deferral Period" } } }, "auth_ref": [] }, "bvs_BusinessCombinationConsiderationTransferredDeferredAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "BusinessCombinationConsiderationTransferredDeferredAmount", "crdr": "credit", "presentation": [ "http://www.bioventus.com/role/AcquisitionsanddivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred amount", "label": "Business Combination, Consideration Transferred, Deferred Amount", "documentation": "Business Combination, Consideration Transferred, Deferred Amount" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "crdr": "debit", "calculation": { "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 5.0 }, "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 5.0 } }, "presentation": [
"http://www.bioventus.com/role/ConsolidatedCondensedStatementsofCashFlows", "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss",
"http://www.bioventus.com/role/FairvaluemeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Change in fair value of contingent consideration", "terseLabel": "Change in fair value of contingent consideration", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement." } } }, "auth_ref": [ "r500", "r896" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationLiability", "crdr": "credit", "presentation": [ "http://www.bioventus.com/role/AcquisitionsanddivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent consideration", "label": "Business Combination, Contingent Consideration, Liability", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination." } } }, "auth_ref": [ "r65", "r166", "r499", "r524", "r525", "r526" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent", "crdr": "credit", "calculation": {
"http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails": { "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0, "order": 1.0 }, "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets",
"http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current portion of contingent consideration", "label": "Business Combination, Contingent Consideration, Liability, Current", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r65", "r166" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput", "presentation": [
"http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payment discount rate", "label": "Business Combination, Contingent Consideration, Liability, Measurement Input", "documentation": "Value of input used to measure contingent consideration liability from business combination." } } }, "auth_ref": [ "r524", "r525", "r526" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent", "crdr": "credit", "calculation": {
"http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 },
"http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails": { "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets",
"http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent consideration", "label": "Business Combination, Contingent Consideration, Liability, Noncurrent", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r65", "r166" ] },
"bvs_CancellationRatioRequiredStockToLLCInterestRatio": { "xbrltype": "pureItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "CancellationRatioRequiredStockToLLCInterestRatio", "presentation": [ "http://www.bioventus.com/role/StockholdersequityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cancellation ratio, required stock to LLC interest ratio", "label": "Cancellation Ratio, Required Stock To LLC Interest Ratio", "documentation": "Cancellation Ratio, Required Stock To LLC Interest Ratio" } } }, "auth_ref": [] }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalExpendituresIncurredButNotYetPaid", "crdr": "credit", "presentation": [ "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable for purchase of property, plant and equipment", "label": "Capital Expenditures Incurred but Not yet Paid", "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred." } } }, "auth_ref": [ "r29", "r30", "r31" ] }, "bvs_CartiHealLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "CartiHealLtdMember", "presentation": [ "http://www.bioventus.com/role/AcquisitionsanddivestituresDetails",
"http://www.bioventus.com/role/DiscontinuedOperationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "CartiHeal Ltd", "label": "CartiHeal Ltd [Member]", "documentation": "CartiHeal Ltd" } } }, "auth_ref": [] }, "bvs_CartiHealMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "CartiHealMember", "presentation": [ "http://www.bioventus.com/role/DiscontinuedOperationsandDisposalGroupsScheduleofStatementofOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Carti Heal", "label": "Carti Heal [Member]", "documentation": "Carti Heal" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": {
"http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r28", "r200", "r784" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash, cash equivalents and restricted cash at the beginning of the period", "periodEndLabel": "Cash, cash equivalents and restricted cash at the end of the period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r28", "r136", "r230" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [
"http://www.bioventus.com/role/ConsolidatedCondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net change in cash, cash equivalents and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage, including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r0", "r136" ] }, "bvs_CashFlowLesseeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "CashFlowLesseeAbstract", "presentation": [ "http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofLeaseCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for amounts included in measurement of lease liabilities:", "label": "Cash Flow, Lessee [Abstract]", "documentation": "Cash Flow, Lessee" } } }, "auth_ref": [] }, "us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations", "crdr": "debit", "calculation": { "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.bioventus.com/role/ConsolidatedCondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Net cash from investing activities - discontinued operations", "label": "Cash Provided by (Used in) Investing Activities, Discontinued Operations", "documentation": "Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r90", "r136" ] }, "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations", "crdr": "debit", "calculation": {
"http://www.bioventus.com/role/ConsolidatedCondensedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Net cash from operating activities - discontinued operations", "label": "Cash Provided by (Used in) Operating Activities, Discontinued Operations", "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r90", "r136" ] },
"dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [
"http://www.bioventus.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] },
"us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": [
"http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets", "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheetsParenthetical",
"http://www.bioventus.com/role/ConsolidatedCondensedStatementsofChangesinStockholdersEquity", "http://www.bioventus.com/role/CoverPage",
"http://www.bioventus.com/role/EquitybasedcompensationNarrativeDetails", "http://www.bioventus.com/role/StockholdersequityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Domain]", "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r192", "r208", "r209", "r210", "r233", "r255", "r256", "r258", "r260", "r267", "r268", "r306", "r363", "r366", "r367", "r368", "r372", "r373", "r406", "r407", "r410", "r413", "r420", "r543", "r674", "r675", "r676", "r677", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r707", "r729", "r746", "r760", "r761", "r762", "r763", "r764", "r875", "r898", "r906" ] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockLineItems", "presentation": [ "http://www.bioventus.com/role/OrganizationNarrativeDetails",
"http://www.bioventus.com/role/StockholdersequityNarrativeDetails", "http://www.bioventus.com/role/StockholdersequityScheduleofOtherOwnershipInterestsDetails" ], "lang": { "en-us": {
```

```
"role": { "terseLabel": "Class of Stock [Line Items]", "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r208", "r209", "r210", "r267", "r406", "r407", "r408", "r410", "r413", "r418", "r420", "r674", "r675", "r676", "r677", "r811", "r875", "r898" ] },
"bvs_CollaborativeArrangementRightsAndObligationsAdjustedAmountPayableUponObtainingProductCertification": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "CollaborativeArrangementRightsAndObligationsAdjustedAmountPayableUponObtainingProductCertification", "crdr": "debit", "presentation": [ "http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative arrangement, adjusted amount payable upon obtaining product certification", "label": "Collaborative Arrangement, Rights And Obligations, Adjusted Amount Payable Upon Obtaining Product Certification", "documentation": "Collaborative Arrangement, Rights And Obligations, Adjusted Amount Payable Upon Obtaining Product Certification" } } }, "auth_ref": [] },
"bvs_CollaborativeArrangementRightsAndObligationsAdjustedAmountPayableUponObtainingProductCertificationInitialPaymentPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "CollaborativeArrangementRightsAndObligationsAdjustedAmountPayableUponObtainingProductCertificationInitialPaymentPaid", "crdr": "credit", "presentation": [ "http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Milestone payment paid", "label": "Collaborative Arrangement, Rights And Obligations, Adjusted Amount Payable Upon Obtaining Product Certification, Initial Payment Paid", "documentation": "Collaborative Arrangement, Rights And Obligations, Adjusted Amount Payable Upon Obtaining Product Certification, Initial Payment Paid" } } }, "auth_ref": [] },
"bvs_CollaborativeArrangementRightsAndObligationsAmountPayableUponObtainingProductCertification": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "CollaborativeArrangementRightsAndObligationsAmountPayableUponObtainingProductCertification", "crdr": "debit", "presentation": [
"http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative arrangement, amount payable upon obtaining product certification", "label": "Collaborative Arrangement, Rights And Obligations, Amount Payable Upon Obtaining Product Certification", "documentation": "Collaborative Arrangement, Rights And Obligations, Amount Payable Upon Obtaining Product Certification" } } }, "auth_ref": [] },
"bvs_CollaborativeArrangementRightsAndObligationsAmountPayableUponTransferOfData": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "CollaborativeArrangementRightsAndObligationsAmountPayableUponTransferOfData", "crdr": "debit", "presentation": [
"http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative arrangement, amount payable upon transfer of customer data", "label": "Collaborative Arrangement, Rights And Obligations, Amount Payable Upon Transfer Of Data", "documentation": "Collaborative Arrangement, Rights And Obligations, Amount Payable Upon Transfer Of Data" } } }, "auth_ref": [] }, "bvs_CollaborativeArrangementRightsAndObligationsRoyaltiesSalesThreshold": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "CollaborativeArrangementRightsAndObligationsRoyaltiesSalesThreshold", "crdr": "credit", "presentation": [
"http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative arrangement, sales threshold for royalties", "label": "Collaborative Arrangement, Rights And Obligations, Royalties, Sales Threshold", "documentation": "Collaborative Arrangement, Rights And Obligations, Royalties, Sales Threshold" } } }, "auth_ref": [] }, "bvs_CollaborativeArrangementRightsAndObligationsRoyaltyPercentageThresholdOne": { "xbrltype": "percentItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "CollaborativeArrangementRightsAndObligationsRoyaltyPercentageThresholdOne", "presentation": [
"http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative arrangement, royalty percentage, threshold one", "label": "Collaborative Arrangement, Rights And Obligations, Royalty Percentage, Threshold One", "documentation": "Collaborative Arrangement, Rights And Obligations, Royalty Percentage, Threshold One" } } }, "auth_ref": [] }, "bvs_CollaborativeArrangementRightsAndObligationsRoyaltyPercentageThresholdTwo": { "xbrltype": "percentItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "CollaborativeArrangementRightsAndObligationsRoyaltyPercentageThresholdTwo", "presentation": [
"http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative arrangement, royalty percentage, threshold two", "label": "Collaborative Arrangement, Rights And Obligations, Royalty Percentage, Threshold Two", "documentation": "Collaborative Arrangement, Rights And Obligations, Royalty Percentage, Threshold Two" } } }, "auth_ref": [] }, "bvs_CollaborativeArrangementRightsAndObligationsUpfrontPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "CollaborativeArrangementRightsAndObligationsUpfrontPayment", "crdr": "debit", "presentation": [
"http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative arrangement, upfront payments", "label": "Collaborative Arrangement, Rights And Obligations, Upfront Payment", "documentation": "Collaborative Arrangement, Rights And Obligations, Upfront Payment" } } }, "auth_ref": [] },
"bvs_CollaborativeArrangementRoyaltyPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.bioventus.com/20240629", "localname":
"CollaborativeArrangementRoyaltyPercentage", "presentation": [ "http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative agreement, royalty percentage", "label": "Collaborative Arrangement, Royalty Percentage", "documentation": "Collaborative Arrangement, Royalty Percentage" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies (Note 11)", "label":
"Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r105", "r175", "r629", "r706" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.bioventus.com/role/Commitmentsandcontingencies" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r150", "r353", "r354", "r769", "r933", "r939" ] }, "us-gaap_CommonClassAMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonClassAMember", "presentation": [ "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets",
"http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheetsParenthetical", "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofChangesinStockholdersEquity", "http://www.bioventus.com/role/CoverPage", "http://www.bioventus.com/role/EquitybasedcompensationNarrativeDetails", "http://www.bioventus.com/role/StockholdersequityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common Class A", "label": "Common Class A [Member]", "documentation": "Classification of common stock representing ownership interest in a corporation." } } }, "auth_ref": [ "r1040" ] }, "us-gaap_CommonClassBMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonClassBMember", "presentation": [ "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets", "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheetsParenthetical",
"http://www.bioventus.com/role/ConsolidatedCondensedStatementsofChangesinStockholdersEquity", "http://www.bioventus.com/role/CoverPage",
"http://www.bioventus.com/role/StockholdersequityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common Class B", "label": "Common Class B [Member]", "documentation":
"Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation." } } }, "auth_ref": [ "r1040" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [
"http://www.bioventus.com/role/ConsolidatedCondensedStatementsofChangesinStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r857", "r858", "r859", "r861", "r862", "r863", "r864", "r902", "r903", "r905", "r979", "r1037", "r1040" ] }, "bvs_CommonStockNumberOfVotes": { "xbrltype": "integerItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "CommonStockNumberOfVotes", "presentation": [ "http://www.bioventus.com/role/StockholdersequityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of votes per common share", "label": "Common Stock, Number Of Votes", "documentation": "Common Stock, Number Of Votes" } } }, "auth_ref": [] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [
"http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheetsParenthetical", "http://www.bioventus.com/role/StockholdersequityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r108" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CommonStockSharesAuthorized", "presentation": [ "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheetsParenthetical",
"http://www.bioventus.com/role/StockholdersequityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r108", "r707" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": [
"http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r108" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheetsParenthetical",
"http://www.bioventus.com/role/ConsolidatedCondensedStatementsofChangesinStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares outstanding (in shares)", "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r14", "r108", "r707", "r725", "r1040", "r1041" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": {
"http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, value", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r108", "r630", "r839" ] }, "bvs_CompensationAndEmployeeBenefitPlansAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "CompensationAndEmployeeBenefitPlansAbstract", "lang": { "en-us": { "role": { "label": "Compensation And Employee Benefit Plans [Abstract]", "documentation": "Compensation And Employee Benefit Plans" } } }, "auth_ref": [] }, "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CompensationAndEmployeeBenefitPlansTextBlock", "presentation": [ "http://www.bioventus.com/role/Equitybasedcompensation" ], "lang": { "en-us": { "role": { "terseLabel": "Equity-based compensation", "label": "Compensation and Employee Benefit Plans [Text Block]", "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans." } } }, "auth_ref": [ "r158", "r159", "r160", "r161" ] },
"bvs_ComprehensiveIncomeLossAttributableToNoncontrollingInterestContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioventus.com/20240629", "localname":
"ComprehensiveIncomeLossAttributableToNoncontrollingInterestContinuingOperations", "crdr": "credit", "calculation": {
"http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Comprehensive loss attributable to noncontrolling interest - continuing operations", "label": "Comprehensive Income (Loss) Attributable To Noncontrolling Interest - Continuing Operations", "documentation":
"Comprehensive Income (Loss) Attributable To Noncontrolling Interest - Continuing Operations" } } }, "auth_ref": [] },
"bvs_ComprehensiveIncomeLossAttributableToNoncontrollingInterestDiscontinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioventus.com/20240629", "localname":
"ComprehensiveIncomeLossAttributableToNoncontrollingInterestDiscontinuingOperations", "crdr": "credit", "calculation": {
"http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Comprehensive loss attributable to noncontrolling interest - discontinued operations", "label": "Comprehensive Income (Loss) Attributable To Noncontrolling Interest - Discontinuing Operations", "documentation":
"Comprehensive Income (Loss) Attributable To Noncontrolling Interest - Discontinuing Operations" } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": {
"http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [
"http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive loss attributable to Bioventus Inc.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r25", "r217", "r219", "r225", "r623", "r641", "r642" ] }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel":
"Comprehensive loss", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r71", "r168", "r217", "r219", "r224", "r622", "r641" ] }, "bvs_ComputerEquipmentAndSoftwareMember": { "xbrltype": "domainItemType", "nsuri":
```

```
"http://www.bioventus.com/20240629", "localname": "ComputerEquipmentAndSoftwareMember", "presentation": [
"http://www.bioventus.com/role/BalancesheetinformationScheduleodPropertyandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Computer equipment and software", "label":
"Computer Equipment And Software [Member]", "documentation": "Computer Equipment And Software" } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [
"http://www.bioventus.com/role/BalancesheetinformationComponentsofAccountsReceivableNarrativeDetails",
"http://www.bioventus.com/role/RevenuefromContractwithCustomerNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Domain]", "label":
"Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r35", "r36", "r72", "r73",
"r302", "r768" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByBenchmarkAxis",
"presentation": [ "http://www.bioventus.com/role/BalancesheetinformationComponentsofAccountsReceivableNarrativeDetails",
"http://www.bioventus.com/role/RevenuefromContractwithCustomerNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Axis]", "label":
"Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r35", "r36", "r72", "r73", "r302", "r672", "r768" ] }, "us-
gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByTypeAxis", "presentation": [
"http://www.bioventus.com/role/BalancesheetinformationComponentsofAccountsReceivableNarrativeDetails",
"http://www.bioventus.com/role/RevenuefromContractwithCustomerNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Axis]", "label": "Concentration Risk
Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } },
"auth_ref": [ "r35", "r36", "r72", "r73", "r302", "r768", "r880" ] }, "us-gaap_ConcentrationRiskLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ConcentrationRiskLineItems", "presentation": [ "http://www.bioventus.com/role/BalancesheetinformationComponentsofAccountsReceivableNarrativeDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Concentration Risk [Line Items]", "label": "Concentration Risk [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are
used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r768" ] }, "us-gaap_ConcentrationRiskPercentage1": {
"xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskPercentage1", "presentation": [
"http://www.bioventus.com/role/BalancesheetinformationComponentsofAccountsReceivableNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration risk percentage",
"label": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or
denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r35", "r36", "r72", "r73", "r302" ] }, "us-
gaap_ConcentrationRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTable", "presentation": [
"http://www.bioventus.com/role/BalancesheetinformationComponentsofAccountsReceivableNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk [Table]", "label":
"Concentration Risk [Table]", "documentation": "Disclosure of information about concentration risk. Includes, but is not limited to, percentage of concentration risk and benchmark serving as
denominator in calculation of percentage of concentration risk." } } }, "auth_ref": [ "r34", "r35", "r36", "r37", "r72", "r170", "r768" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTypeDomain", "presentation": [
"http://www.bioventus.com/role/BalancesheetinformationComponentsofAccountsReceivableNarrativeDetails",
"http://www.bioventus.com/role/RevenuefromContractwithCustomerNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Domain]", "label": "Concentration
Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability,
net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r35", "r36", "r72", "r73", "r302", "r768" ] }, "srt_ConsolidationItemsAxis": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidationItemsAxis", "presentation": [ "http://www.bioventus.com/role/SegmentsNarrativeDetails",
"http://www.bioventus.com/role/SegmentsScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items
[Axis]", "label": "Consolidation Items [Axis]" } } }, "auth_ref": [ "r182", "r237", "r265", "r275", "r289", "r290", "r291", "r292", "r293", "r295", "r296", "r297", "r363", "r364", "r365", "r366",
"r368", "r369", "r370", "r371", "r372", "r797", "r798", "r946", "r947" ] }, "srt_ConsolidationItemsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname":
"ConsolidationItemsDomain", "presentation": [ "http://www.bioventus.com/role/SegmentsNarrativeDetails",
"http://www.bioventus.com/role/SegmentsScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items
[Domain]", "label": "Consolidation Items [Domain]" } } }, "auth_ref": [ "r182", "r237", "r265", "r275", "r289", "r290", "r291", "r292", "r293", "r295", "r296", "r297", "r363", "r364", "r365", "r366",
"r368", "r369", "r370", "r371", "r372", "r797", "r798", "r946", "r947" ] }, "us-gaap_ContingentConsiderationByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ContingentConsiderationByTypeAxis", "presentation": [ "http://www.bioventus.com/role/AcquisitionsanddivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Contingent Consideration by Type [Axis]", "label": "Contingent Consideration by Type [Axis]", "documentation": "Information by type of contingent consideration." } } }, "auth_ref": [] }, "us-
gaap_ContingentConsiderationTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContingentConsiderationTypeDomain", "presentation": [
"http://www.bioventus.com/role/AcquisitionsanddivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent Consideration Type [Domain]", "label": "Contingent Consideration
Type [Domain]", "documentation": "Description of contingent payment arrangement." } } }, "auth_ref": [] }, "bvs_ContinuingLLCOwnerMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.bioventus.com/20240629", "localname": "ContinuingLLCOwnerMember", "presentation": [
"http://www.bioventus.com/role/StockholdersequityScheduleofOtherOwnershipInterestsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Continuing LLC Owner", "label": "Continuing LLC
Owner [Member]", "documentation": "Continuing LLC Owner" } } }, "auth_ref": [] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": {
"http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 1.0 } }, "presentation": [
"http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of sales (including depreciation and
amortization of $11,021, $12,301, $21,046 and $26,640, respectively)", "label": "Cost of Goods and Services Sold", "documentation": "The aggregate costs related to goods produced and sold
and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating
activities." } } }, "auth_ref": [ "r124", "r125", "r587" ] }, "us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "CostOfGoodsAndServicesSoldDepreciationAndAmortization", "crdr": "debit", "presentation": [
"http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLossParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and
amortization", "label": "Cost, Depreciation and Amortization", "documentation": "Amount of expense for allocation of cost of tangible and intangible assets over their useful lives directly used in
production of good and rendering of service." } } }, "auth_ref": [ "r891" ] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname":
"CounterpartyNameAxis", "presentation": [ "http://www.bioventus.com/role/AcquisitionsanddivestituresDetails", "http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails"
], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Axis]", "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r235", "r236", "r378", "r408", "r576", "r585", "r626", "r787",
"r789" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]",
"documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityAxis",
"presentation": [ "http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails", "http://www.bioventus.com/role/FinancialinstrumentsScheduleOfLongTermDebtInstrumentsDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Axis]", "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to
borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [ "r362", "r944" ] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "CreditFacilityDomain", "presentation": [ "http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails",
"http://www.bioventus.com/role/FinancialinstrumentsScheduleOfLongTermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Domain]", "label": "Credit
Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [ "r362",
"r944", "r945" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [
"http://www.bioventus.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of
current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "CustomerConcentrationRiskMember", "presentation": [ "http://www.bioventus.com/role/BalancesheetinformationComponentsofAccountsReceivableNarrativeDetails",
"http://www.bioventus.com/role/RevenuefromContractwithCustomerNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer", "label": "Customer Concentration Risk
[Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues,
product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r142", "r302" ] }, "bvs_CustomerOneMember": {
"xbrltype": "domainItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "CustomerOneMember", "presentation": [
"http://www.bioventus.com/role/BalancesheetinformationComponentsofAccountsReceivableNarrativeDetails",
"http://www.bioventus.com/role/RevenuefromContractwithCustomerNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer One", "label": "Customer One [Member]",
"documentation": "Customer One" } } }, "auth_ref": [] }, "us-gaap_CustomerRelationshipsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CustomerRelationshipsMember", "presentation": [ "http://www.bioventus.com/role/BalancesheetinformationScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Customer relationships", "label": "Customer Relationships [Member]", "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to,
tenant relationships." } } }, "auth_ref": [ "r64", "r918", "r919", "r920", "r921", "r923", "r925", "r927", "r928" ] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": [
"http://www.bioventus.com/role/Financialinstruments" ], "lang": { "en-us": { "role": { "terseLabel": "Financial instruments", "label": "Debt Disclosure [Text Block]", "documentation": "The entire
disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds
indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-
term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important
to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r151", "r231", "r339", "r340", "r341", "r342", "r343", "r361",
"r362", "r374", "r380", "r381", "r382", "r383", "r384", "r385", "r390", "r397", "r398", "r400", "r552" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
} } }, "auth_ref": [ "r17", "r98", "r99", "r172", "r174", "r237", "r375", "r376", "r377", "r378", "r379", "r381", "r386", "r387", "r388", "r389", "r391", "r392", "r393", "r394", "r395", "r396", "r806",
"r807", "r808", "r809", "r810", "r837", "r899", "r934", "r935", "r936", "r990", "r992" ] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": [ "http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails" ], "lang": {
"en-us": { "role": { "terseLabel": "Debt instrument, lending margin, interest rate", "label": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the
reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "presentation": [
"http://www.bioventus.com/role/FinancialinstrumentsScheduleOfLongTermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt, gross", "label": "Long-Term
Debt, Gross", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable,
commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": [ "r17", "r174", "r401" ] }, "bvs_DebtInstrumentCovenantLiquidityMinimum":
{ "xbrltype": "monetaryItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "DebtInstrumentCovenantLiquidityMinimum", "crdr": "debit", "presentation": [
"http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, covenant, liquidity, minimum", "label": "Debt Instrument,
Covenant, Liquidity, Minimum", "documentation": "Debt Instrument, Covenant, Liquidity, Minimum" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [
"http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, face amount", "label": "Debt Instrument, Face Amount",
"documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r375", "r552", "r553", "r807", "r808", "r837" ] }, "us-
gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateEffectivePercentage",
"presentation": [ "http://www.bioventus.com/role/FinancialinstrumentsScheduleOfLongTermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective interest rate",
"label": "Debt Instrument, Interest Rate, Effective Percentage", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding
and original issue discount or premium." } } }, "auth_ref": [ "r101", "r403", "r552", "r553", "r837" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems", "presentation": [ "http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails",
"http://www.bioventus.com/role/FinancialinstrumentsScheduleOfLongTermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt
Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain
members defined in one or many axes to the table." } } }, "auth_ref": [ "r237", "r375", "r376", "r377", "r378", "r379", "r381", "r386", "r387", "r388", "r389", "r391", "r392", "r393", "r394",
"r395", "r396", "r399", "r806", "r807", "r808", "r809", "r810", "r837", "r899", "r990", "r992" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails" ], "lang": { "en-us": {
"role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that
distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r17", "r237", "r375", "r376", "r377", "r378", "r379", "r381", "r386",
"r387", "r388", "r389", "r391", "r392", "r393", "r394", "r395", "r396", "r806", "r807", "r808", "r809", "r810", "r837", "r899", "r934", "r935", "r936", "r990", "r992" ] }, "us-
```

gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTable", "presentation": ["http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails", "http://www.bioventus.com/role/FinancialinstrumentsScheduleOfLongTermDebtInstrumentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } }, "auth_ref": ["r17", "r53", "r56", "r74", "r154", "r155", "r237", "r375", "r376", "r377", "r378", "r379", "r381", "r386", "r387", "r388", "r389", "r391", "r392", "r393", "r394", "r395", "r396", "r399", "r806", "r807", "r808", "r809", "r810", "r837", "r899", "r990", "r992"] }, "us-gaap_DebtInstrumentTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTerm", "presentation": ["http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, term", "label": "Debt Instrument, Term", "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentUnamortizedDiscount", "crdr": "debit", "presentation": ["http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails", "http://www.bioventus.com/role/FinancialinstrumentsScheduleOfLongTermDebtInstrumentsDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Unamortized discount", "verboseLabel": "Original issue discount", "label": "Debt Instrument, Unamortized Discount", "documentation": "Amount, after accumulated amortization, of debt discount." } } }, "auth_ref": ["r949", "r989", "r990", "r992"] }, "us-gaap_DeconsolidationGainOrLossAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeconsolidationGainOrLossAmount", "crdr": "credit", "presentation": ["http://www.bioventus.com/role/AcquisitionsanddivestituresDetails", "http://www.bioventus.com/role/DiscontinuedOperationsandDisposalGroupsScheduleofStatementofOperationsDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Loss on deconsolidation", "label": "Deconsolidation, Gain (Loss), Amount", "documentation": "Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer." } } }, "auth_ref": ["r69"] }, "bvs_DeferredConsiderationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "DeferredConsiderationMember", "presentation": ["http://www.bioventus.com/role/AcquisitionsanddivestituresDetails"], "lang": { "en-us": { "role": { "terseLabel": "Deferred Consideration [Member]", "documentation": "Deferred Consideration" } } }, "auth_ref": [] }, "us-gaap_DeferredFinanceCostsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredFinanceCostsGross", "crdr": "debit", "presentation": ["http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Debt issuance costs, gross", "label": "Debt Issuance Costs, Gross", "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": ["r990", "r992"] }, "us-gaap_DeferredFinanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredFinanceCostsNet", "crdr": "debit", "presentation": ["http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails", "http://www.bioventus.com/role/FinancialinstrumentsScheduleOfLongTermDebtInstrumentsDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Unamortized debt issuance cost", "terseLabel": "Deferred financing costs", "label": "Debt Issuance Costs, Net", "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": ["r949", "r989", "r990", "r992"] }, "us-gaap_DeferredIncomeTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxAssetsNet", "crdr": "debit", "calculation": { "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax assets", "label": "Deferred Income Tax Assets, Net", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting." } } }, "auth_ref": ["r476", "r477"] }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxLiabilitiesNet", "crdr": "credit", "calculation": { "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Deferred income taxes", "label": "Deferred Income Tax Liabilities, Net", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting." } } }, "auth_ref": ["r476", "r477", "r628"] }, "us-gaap_DeferredIncomeTaxesAndTaxCredits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxesAndTaxCredits", "crdr": "debit", "calculation": { "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://www.bioventus.com/role/ConsolidatedCondensedStatementsofCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Deferred income taxes", "label": "Deferred Income Taxes and Tax Credits", "documentation": "Amount of deferred income tax expense (benefit) and income tax credits." } } }, "auth_ref": ["r138"] }, "bvs_DemonstrationAndConsignmentInventoryMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "DemonstrationAndConsignmentInventoryMember", "presentation": ["http://www.bioventus.com/role/BalancesheetinformationScheduleofPropertyandEquipmentNetDetails"], "lang": { "en-us": { "role": { "terseLabel": "Demonstration and consignment inventory", "label": "Demonstration And Consignment Inventory [Member]", "documentation": "Demonstration And Consignment Inventory" } } }, "auth_ref": [] }, "us-gaap_DepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationAndAmortization", "crdr": "debit", "calculation": { "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 6.0 } }, "presentation": ["http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss"], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization, Nonproduction", "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production." } } }, "auth_ref": ["r9", "r47"] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 2.0 }, "http://www.bioventus.com/role/SegmentsScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 10.0 } }, "presentation": ["http://www.bioventus.com/role/ConsolidatedCondensedStatementsofCashFlows", "http://www.bioventus.com/role/SegmentsScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "negatedTerseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": ["r9", "r265", "r278", "r295", "r797", "r798"] }, "us-gaap_DevelopedTechnologyRightsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DevelopedTechnologyRightsMember", "presentation": ["http://www.bioventus.com/role/BalancesheetinformationScheduleofIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Developed technology and other", "label": "Developed Technology Rights [Member]", "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property." } } }, "auth_ref": ["r165", "r918", "r919", "r920", "r921", "r923", "r925", "r927", "r928"] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueLineItems", "presentation": ["http://www.bioventus.com/role/RevenuefromContractwithCustomerNarrativeDetails", "http://www.bioventus.com/role/RevenuerecognitionScheduleofDisaggregationofRevenueDetails"], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Line Items]", "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r431", "r812", "r813", "r814", "r815", "r816", "r817", "r818"] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTable", "presentation": ["http://www.bioventus.com/role/RevenuefromContractwithCustomerNarrativeDetails", "http://www.bioventus.com/role/RevenuerecognitionScheduleofDisaggregationofRevenueDetails"], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Table]", "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": ["r431", "r812", "r813", "r814", "r815", "r816", "r817", "r818"] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": ["http://www.bioventus.com/role/RevenuerecognitionTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Disaggregation of Revenue", "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": ["r950"] }, "us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax", "crdr": "credit", "presentation": ["http://www.bioventus.com/role/AcquisitionsanddivestituresDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Loss from discontinued operations, net of tax", "label": "Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax", "documentation": "Amount after tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation." } } }, "auth_ref": ["r78", "r80", "r82", "r93"] }, "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract", "lang": { "en-us": { "role": { "label": "Discontinued Operations and Disposal Groups [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationsDisposedOfByMeansOtherThanSaleMember", "presentation": ["http://www.bioventus.com/role/AcquisitionsanddivestituresDetails", "http://www.bioventus.com/role/DiscontinuedOperationsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Discontinued Operations, Disposed of by Means Other than Sale", "label": "Discontinued Operations, Disposed of by Means Other than Sale [Member]", "documentation": "Component or group of components representing strategic shift that has or will have major effect on operation and financial result, disposed of by means other than sale." } } }, "auth_ref": ["r77"] }, "us-gaap_DiscontinuedOperationsDisposedOfBySaleMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationsDisposedOfBySaleMember", "presentation": ["http://www.bioventus.com/role/AcquisitionsanddivestituresDetails", "http://www.bioventus.com/role/DiscontinuedOperationsandDisposalGroupsScheduleofStatementofOperationsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Disposed of by Sale", "label": "Discontinued Operations, Disposed of by Sale [Member]", "documentation": "Component or group of components representing strategic shift that has or will have major effect on operation and financial result, disposed of by sale." } } }, "auth_ref": ["r6"] }, "us-gaap_DiscontinuedOperationsHeldforsaleMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationsHeldforsaleMember", "presentation": ["http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofHeldforSaleAssetsandLiabilitiesDetails", "http://www.bioventus.com/role/BalancesheetinformationComponentsofAccountsReceivableNarrativeDetails", "http://www.bioventus.com/role/BalancesheetinformationScheduleofPropertyandEquipmentNetDetails", "http://www.bioventus.com/role/BalancesheetinformationScheduleofAccruedLiabilitiesDetails", "http://www.bioventus.com/role/BalancesheetinformationScheduleofIntangibleAssetsDetails", "http://www.bioventus.com/role/BalancesheetinformationScheduleofInventoryDetails", "http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofAssetsandLiabilitiesLesseeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Discontinued Operations, Held-for-sale", "label": "Discontinued Operations, Held-for-Sale [Member]", "documentation": "Component or group of components representing strategic shift that has or will have major effect on operation and financial result and business and nonprofit activity on acquisition and upon joint venture formation, classified as held-for-sale." } } }, "auth_ref": ["r5", "r7", "r196"] }, "us-gaap_DisposalGroupClassificationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupClassificationAxis", "presentation": ["http://www.bioventus.com/role/AcquisitionsanddivestituresDetails", "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofHeldforSaleAssetsandLiabilitiesDetails", "http://www.bioventus.com/role/BalancesheetinformationComponentsofAccountsReceivableNarrativeDetails", "http://www.bioventus.com/role/BalancesheetinformationScheduleofPropertyandEquipmentNetDetails", "http://www.bioventus.com/role/BalancesheetinformationScheduleofAccruedLiabilitiesDetails", "http://www.bioventus.com/role/BalancesheetinformationScheduleofIntangibleAssetsDetails", "http://www.bioventus.com/role/BalancesheetinformationScheduleofInventoryDetails", "http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofAssetsandLiabilitiesLesseeDetails", "http://www.bioventus.com/role/DiscontinuedOperationsNarrativeDetails", "http://www.bioventus.com/role/DiscontinuedOperationsandDisposalGroupsScheduleofStatementofOperationsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Classification [Axis]", "label": "Disposal Group Classification [Axis]", "documentation": "Information by disposal group classification." } } }, "auth_ref": ["r196"] }, "us-gaap_DisposalGroupClassificationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupClassificationDomain", "presentation": ["http://www.bioventus.com/role/AcquisitionsanddivestituresDetails", "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofHeldforSaleAssetsandLiabilitiesDetails", "http://www.bioventus.com/role/BalancesheetinformationComponentsofAccountsReceivableNarrativeDetails", "http://www.bioventus.com/role/BalancesheetinformationScheduleofPropertyandEquipmentNetDetails", "http://www.bioventus.com/role/BalancesheetinformationScheduleofAccruedLiabilitiesDetails", "http://www.bioventus.com/role/BalancesheetinformationScheduleofIntangibleAssetsDetails", "http://www.bioventus.com/role/BalancesheetinformationScheduleofInventoryDetails", "http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofAssetsandLiabilitiesLesseeDetails", "http://www.bioventus.com/role/DiscontinuedOperationsNarrativeDetails", "http://www.bioventus.com/role/DiscontinuedOperationsandDisposalGroupsScheduleofStatementofOperationsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Classification [Domain]", "label": "Disposal Group Classification [Domain]", "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet", "crdr": "debit", "calculation": { "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofHeldforSaleAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofHeldforSaleAssetsandLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable", "label":

```
"Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net", "documentation": "Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r1", "r76", "r91", "r148" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsPayable", "crdr": "credit", "calculation": {
"http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofHeldforSaleAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0, "order": 1.0 } }, "presentation": {
"http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofHeldforSaleAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Accounts payable", "label": "Disposal Group, Including Discontinued Operation, Accounts Payable", "documentation": "Amount classified as accounts payable attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r1", "r76", "r91", "r148" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities", "crdr": "credit", "calculation": {
"http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofHeldforSaleAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0, "order": 2.0 } }, "presentation": {
"http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofHeldforSaleAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Accrued liabilities", "label": "Disposal Group, Including Discontinued Operation, Accrued Liabilities", "documentation": "Amount classified as accrued liabilities attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r1", "r76", "r91", "r148" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationCash", "crdr": "debit", "presentation": {
"http://www.bioventus.com/role/DiscontinuedOperationsandDisposalGroupsScheduleofStatementofOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash", "label": "Disposal Group, Including Discontinued Operation, Cash", "documentation": "Amount of currency on hand, demand deposits with banks or financial institutions, and other kinds of accounts that have the general characteristics of demand deposits, held by a disposal group." } } }, "auth_ref": [] },
"bvs_DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfContingentConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfContingentConsideration", "crdr": "debit", "calculation": {
"http://www.bioventus.com/role/DiscontinuedOperationsandDisposalGroupsScheduleofStatementofOperationsDetails": { "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss", "weight": -1.0, "order": 3.0 } }, "presentation": {
"http://www.bioventus.com/role/DiscontinuedOperationsandDisposalGroupsScheduleofStatementofOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in fair value of contingent consideration", "label": "Disposal Group, Including Discontinued Operation, Change in Fair Value of Contingent Consideration", "documentation": "Disposal Group, Including Discontinued Operation, Change in Fair Value of Contingent Consideration" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration", "crdr": "debit", "presentation": [
"http://www.bioventus.com/role/AcquisitionsanddivestituresDetails", "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofHeldforSaleAssetsandLiabilitiesDetails" ], "lang": {
"en-us": { "role": { "verboseLabel": "Potential total consideration", "terseLabel": "Cash consideration", "label": "Disposal Group, Including Discontinued Operation, Consideration", "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation." } } }, "auth_ref": [] },
"bvs_DisposalGroupIncludingDiscontinuedOperationConsiderationIncludingClosingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "DisposalGroupIncludingDiscontinuedOperationConsiderationIncludingClosingAmount", "crdr": "debit", "presentation": [ "http://www.bioventus.com/role/AcquisitionsanddivestituresDetails",
"http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofHeldforSaleAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Closing amount", "label": "Disposal Group, Including Discontinued Operation, Consideration Including Closing Amount", "documentation": "Disposal Group, Including Discontinued Operation, Consideration Including Closing Amount" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization", "crdr": "debit", "calculation": {
"http://www.bioventus.com/role/DiscontinuedOperationsandDisposalGroupsScheduleofStatementofOperationsDetails": { "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss", "weight": 1.0, "order": 4.0 } }, "presentation": {
"http://www.bioventus.com/role/DiscontinuedOperationsandDisposalGroupsScheduleofStatementofOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Disposal Group, Including Discontinued Operation, Depreciation and Amortization", "documentation": "Amount of depreciation and amortization expense attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r89" ] }, "bvs_DisposalGroupIncludingDiscontinuedOperationEarnOutPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "DisposalGroupIncludingDiscontinuedOperationEarnOutPayments", "crdr": "debit", "presentation": [
"http://www.bioventus.com/role/AcquisitionsanddivestituresDetails", "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofHeldforSaleAssetsandLiabilitiesDetails" ], "lang": {
"en-us": { "role": { "terseLabel": "Earn-out payments", "label": "Disposal Group, Including Discontinued Operation, Earn-Out Payments", "documentation": "Disposal Group, Including Discontinued Operation, Earn-Out Payments" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": {
"http://www.bioventus.com/role/DiscontinuedOperationsandDisposalGroupsScheduleofStatementofOperationsDetails": { "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": {
"http://www.bioventus.com/role/DiscontinuedOperationsandDisposalGroupsScheduleofStatementofOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative expense", "label": "Disposal Group, Including Discontinued Operation, General and Administrative Expense", "documentation": "Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r89" ] }, "bvs_DisposalGroupIncludingDiscontinuedOperationImpairmentOfAssets": {
"xbrltype": "monetaryItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "DisposalGroupIncludingDiscontinuedOperationImpairmentOfAssets", "crdr": "debit", "calculation": { "http://www.bioventus.com/role/DiscontinuedOperationsandDisposalGroupsScheduleofStatementofOperationsDetails": { "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss", "weight": -1.0, "order": 5.0 } }, "presentation": {
"http://www.bioventus.com/role/DiscontinuedOperationsandDisposalGroupsScheduleofStatementofOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impairments of assets", "label": "Disposal Group, Including Discontinued Operation, Impairment Of Assets", "documentation": "Disposal Group, Including Discontinued Operation, Impairment Of Assets" } } }, "auth_ref": [] }, "bvs_DisposalGroupIncludingDiscontinuedOperationIncomeLossAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "DisposalGroupIncludingDiscontinuedOperationIncomeLossAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": {
"http://www.bioventus.com/role/DiscontinuedOperationsandDisposalGroupsScheduleofStatementofOperationsDetails": { "parentTag": "bvs_DisposalGroupIncludingDiscontinuedOperationNetIncomeLossToParent", "weight": 1.0, "order": 2.0 } }, "presentation": {
"http://www.bioventus.com/role/DiscontinuedOperationsandDisposalGroupsScheduleofStatementofOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss attributable to noncontrolling interest - discontinued operations", "label": "Disposal Group, Including Discontinued Operation, Income (Loss) Attributable to Noncontrolling Interest", "documentation": "Disposal Group, Including Discontinued Operation, Income (Loss) Attributable to Noncontrolling Interest" } } }, "auth_ref": [] },
"bvs_DisposalGroupIncludingDiscontinuedOperationIncomeLossBeforeIncomeTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "DisposalGroupIncludingDiscontinuedOperationIncomeLossBeforeIncomeTaxes", "crdr": "credit", "calculation": {
"http://www.bioventus.com/role/DiscontinuedOperationsandDisposalGroupsScheduleofStatementofOperationsDetails": { "parentTag": "bvs_DisposalGroupIncludingDiscontinuedOperationNetIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": {
"http://www.bioventus.com/role/DiscontinuedOperationsandDisposalGroupsScheduleofStatementofOperationsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Loss before income taxes", "label": "Disposal Group, Including Discontinued Operation, Income (Loss) Before Income Taxes", "documentation": "Disposal Group, Including Discontinued Operation, Income (Loss) Before Income Taxes" } } }, "auth_ref": [] }, "bvs_DisposalGroupIncludingDiscontinuedOperationIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "DisposalGroupIncludingDiscontinuedOperationIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": {
"http://www.bioventus.com/role/DiscontinuedOperationsandDisposalGroupsScheduleofStatementofOperationsDetails": { "parentTag": "bvs_DisposalGroupIncludingDiscontinuedOperationNetIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": {
"http://www.bioventus.com/role/DiscontinuedOperationsandDisposalGroupsScheduleofStatementofOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax benefit, net", "label": "Disposal Group, Including Discontinued Operation, Income Tax Expense (Benefit)", "documentation": "Disposal Group, Including Discontinued Operation, Income Tax Expense (Benefit)" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationIntangibleAssets", "crdr": "debit", "calculation": {
"http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofHeldforSaleAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0, "order": 5.0 } }, "presentation": {
"http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofHeldforSaleAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Intangible assets", "label": "Disposal Group, Including Discontinued Operation, Intangible Assets", "documentation": "Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r1", "r76", "r91", "r148" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationInterestExpense", "crdr": "debit", "calculation": {
"http://www.bioventus.com/role/DiscontinuedOperationsandDisposalGroupsScheduleofStatementofOperationsDetails": { "parentTag": "bvs_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense", "weight": -1.0, "order": 1.0 } }, "presentation": {
"http://www.bioventus.com/role/DiscontinuedOperationsandDisposalGroupsScheduleofStatementofOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense, net", "label": "Disposal Group, Including Discontinued Operation, Interest Expense", "documentation": "Amount of interest expense attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r18", "r19", "r21", "r89" ] }, "bvs_DisposalGroupIncludingDiscontinuedOperationInventory": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "DisposalGroupIncludingDiscontinuedOperationInventory", "crdr": "debit", "calculation": {
"http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofHeldforSaleAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0, "order": 2.0 } }, "presentation": {
"http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofHeldforSaleAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Inventory", "label": "Disposal Group, Including Discontinued Operation, Inventory", "documentation": "Disposal Group, Including Discontinued Operation, Inventory" } } }, "auth_ref": [] },
"bvs_DisposalGroupIncludingDiscontinuedOperationNetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "DisposalGroupIncludingDiscontinuedOperationNetIncomeLoss", "crdr": "credit", "calculation": {
"http://www.bioventus.com/role/DiscontinuedOperationsandDisposalGroupsScheduleofStatementofOperationsDetails": { "parentTag": "bvs_DisposalGroupIncludingDiscontinuedOperationNetIncomeLossToParent", "weight": 1.0, "order": 1.0 } }, "presentation": {
"http://www.bioventus.com/role/DiscontinuedOperationsandDisposalGroupsScheduleofStatementofOperationsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss from discontinued operations", "label": "Disposal Group, Including Discontinued Operation, Net Income (Loss)", "documentation": "Disposal Group, Including Discontinued Operation, Net Income (Loss)" } } },
"auth_ref": [] }, "bvs_DisposalGroupIncludingDiscontinuedOperationNetIncomeLossToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "DisposalGroupIncludingDiscontinuedOperationNetIncomeLossToParent", "crdr": "credit", "calculation": {
"http://www.bioventus.com/role/DiscontinuedOperationsandDisposalGroupsScheduleofStatementofOperationsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } },
"presentation": [ "http://www.bioventus.com/role/DiscontinuedOperationsandDisposalGroupsScheduleofStatementofOperationsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss attributable to Bioventus Inc. - discontinued operations", "label": "Disposal Group, Including Discontinued Operation, Net Income (Loss) to Parent", "documentation": "Disposal Group, Including Discontinued Operation, Net Income (Loss) to Parent" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss", "crdr": "credit", "calculation": {
"http://www.bioventus.com/role/DiscontinuedOperationsandDisposalGroupsScheduleofStatementofOperationsDetails": { "parentTag": "bvs_DisposalGroupIncludingDiscontinuedOperationIncomeLossBeforeIncomeTaxes", "weight": 1.0, "order": 1.0 } }, "presentation": {
"http://www.bioventus.com/role/DiscontinuedOperationsandDisposalGroupsScheduleofStatementofOperationsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Operating loss from discontinued operations", "label": "Disposal Group, Including Discontinued Operation, Operating Income (Loss)", "documentation": "Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r89" ] }, "bvs_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingLeaseAssets", "crdr": "debit", "calculation": {
"http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofHeldforSaleAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0, "order": 6.0 } }, "presentation": {
"http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofHeldforSaleAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease assets", "label": "Disposal Group, Including Discontinued Operation, Operating Lease Assets", "documentation": "Disposal Group, Including Discontinued Operation, Operating Lease Assets" } } }, "auth_ref": [] },
"us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationOtherAssets", "crdr": "debit", "calculation": {
"http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofHeldforSaleAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0, "order": 7.0 } }, "presentation": {
"http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofHeldforSaleAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Disposal
```

Group, Including Discontinued Operation, Other Assets", "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of." } } }, "auth_ref": ["r1", "r76", "r91", "r148"] }, "bvs_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense", "crdr": "credit", "calculation": { "http://www.bioventus.com/role/DiscontinuedOperationsandDisposalGroupsScheduleofStatementofOperationsDetails": { "parentTag": "bvs_DisposalGroupIncludingDiscontinuedOperationIncomeLossBeforeIncomeTaxes", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.bioventus.com/role/DiscontinuedOperationsandDisposalGroupsScheduleofStatementofOperationsDetails"], "lang": { "en-us": { "role": { "negatedTotalLabel": "Other (income) expense", "label": "Disposal Group, Including Discontinued Operation, Other Income (Expense)", "documentation": "Disposal Group, Including Discontinued Operation, Other Income (Expense)" } } }, "auth_ref": [] } }, "bvs_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenses", "crdr": "debit", "calculation": { "http://www.bioventus.com/role/DiscontinuedOperationsandDisposalGroupsScheduleofStatementofOperationsDetails": { "parentTag": "bvs_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.bioventus.com/role/DiscontinuedOperationsandDisposalGroupsScheduleofStatementofOperationsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Other (income) expense", "label": "Disposal Group, Including Discontinued Operation, Other (Income) Expenses", "documentation": "Disposal Group, Including Discontinued Operation, Other (Income) Expenses" } } }, "auth_ref": [] } }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationOtherLiabilities", "crdr": "credit", "calculation": { "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofHeldforSaleAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofHeldforSaleAssetsandLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Other liabilities", "label": "Disposal Group, Including Discontinued Operation, Other Liabilities", "documentation": "Amount classified as other liabilities attributable to disposal group held for sale or disposed of." } } }, "auth_ref": ["r1", "r76", "r91", "r148"] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofHeldforSaleAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofHeldforSaleAssetsandLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Prepaid and other current assets", "label": "Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current", "documentation": "Amount classified as prepaid and other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r1", "r76", "r91", "r146", "r148"] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofHeldforSaleAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofHeldforSaleAssetsandLiabilitiesDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Property and equipment, net", "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment", "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of." } } }, "auth_ref": ["r1", "r76", "r91", "r148"] }, "bvs_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.bioventus.com/role/DiscontinuedOperationsandDisposalGroupsScheduleofStatementofOperationsDetails": { "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.bioventus.com/role/DiscontinuedOperationsandDisposalGroupsScheduleofStatementofOperationsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Research and development expense", "label": "Disposal Group, Including Discontinued Operation, Research and Development Expense", "documentation": "Disposal Group, Including Discontinued Operation, Research and Development Expense" } } }, "auth_ref": [] }, "bvs_DisposalGroupIncludingDiscontinuedOperationTransactionalFeesIncurred": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "DisposalGroupIncludingDiscontinuedOperationTransactionalFeesIncurred", "crdr": "debit", "presentation": ["http://www.bioventus.com/role/AcquisitionsanddivestituresDetails", "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofHeldforSaleAssetsandLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Transactional fees", "label": "Disposal Group, Including Discontinued Operation, Transactional Fees Incurred", "documentation": "Disposal Group, Including Discontinued Operation, Transactional Fees Incurred" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "presentation": ["http://www.bioventus.com/role/DiscontinuedOperations"], "lang": { "en-us": { "role": { "terseLabel": "Discontinued operations", "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]", "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": ["r75", "r144"] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "presentation": ["http://www.bioventus.com/role/AcquisitionsanddivestituresDetails", "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofHeldforSaleAssetsandLiabilitiesDetails", "http://www.bioventus.com/role/BalancesheetinformationScheduleofInventoryDetails", "http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofAssetsandLiabilitiesLesseeDetails", "http://www.bioventus.com/role/DiscontinuedOperationsNarrativeDetails", "http://www.bioventus.com/role/DiscontinuedOperationsandDisposalGroupsScheduleofStatementofOperationsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Name [Domain]", "label": "Disposal Group Name [Domain]", "documentation": "Name of disposal group." } } }, "auth_ref": ["r822", "r823"] }, "us-gaap_DistributionRightsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DistributionRightsMember", "presentation": ["http://www.bioventus.com/role/BalancesheetinformationScheduleofIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Distribution rights", "label": "Distribution Rights [Member]", "documentation": "Legal rights, generally of a limited duration, to distribute a product or products, often within specific geographic areas or supply channels." } } }, "auth_ref": ["r918", "r919", "r920", "r921", "r923", "r925", "r927", "r928"] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": ["http://www.bioventus.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3, 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": ["http://www.bioventus.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationLineItems", "presentation": ["http://www.bioventus.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Document Information [Line Items]", "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTable", "presentation": ["http://www.bioventus.com/role/CoverPage"] "lang": { "en-us": { "role": { "terseLabel": "Document Information [Table]", "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": ["http://www.bioventus.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K, the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": ["http://www.bioventus.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": ["r871"] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": ["http://www.bioventus.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": ["r872"] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": ["http://www.bioventus.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "presentation": ["http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss"], "lang": { "en-us": { "role": { "terseLabel": "Loss per share of Class A common stock", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "calculation": { "http://www.bioventus.com/role/EarningspershareScheduleofEarningsPerShareDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss", "http://www.bioventus.com/role/EarningspershareScheduleofEarningsPerShareDetails"], "lang": { "en-us": { "role": { "totalLabel": "Net loss per share of class A common stock, basic (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r226", "r243", "r244", "r245", "r246", "r247", "r248", "r253", "r255", "r258", "r259", "r260", "r264", "r496", "r502", "r519", "r520", "r624", "r643", "r700"] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "calculation": { "http://www.bioventus.com/role/EarningspershareScheduleofEarningsPerShareDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss", "http://www.bioventus.com/role/EarningspershareScheduleofEarningsPerShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "Loss per share of class A common stock, diluted (in dollars per share)", "totalLabel": "Net loss per share of class A common stock, diluted (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r226", "r243", "r244", "r245", "r246", "r247", "r248", "r255", "r258", "r259", "r260", "r264", "r496", "r502", "r519", "r520", "r624", "r643", "r700"] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": ["http://www.bioventus.com/role/Earningspershare"], "lang": { "en-us": { "role": { "terseLabel": "Earnings per share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": ["r252", "r261", "r262", "r263"] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.bioventus.com/role/ConsolidatedCondensedStatementsofCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Effect of exchange rate changes on cash", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage, held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r544"] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": ["http://www.bioventus.com/role/IncometaxesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Effective income tax rate", "label": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": ["r479", "r828"] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": ["http://www.bioventus.com/role/EquitybasedcompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Compensation expense net yet amortized, period for recognition", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r471"] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "crdr": "debit", "presentation": ["http://www.bioventus.com/role/EquitybasedcompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Unamortized compensation expense,

RSUs", "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement, Excludes share and unit options." } } }, "auth_ref": ["r977"] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr": "debit", "presentation": ["http://www.bioventus.com/role/EquitybasedcompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Unamortized compensation expense, options", "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement." } } }, "auth_ref": ["r977"] }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "crdr": "credit", "presentation": ["http://www.bioventus.com/role/EquitybasedcompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Income tax benefit", "label": "Share-Based Payment Arrangement, Expense, Tax Benefit", "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement." } } }, "auth_ref": ["r470"] }, "us-gaap_EmployeeStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockMember", "presentation": ["http://www.bioventus.com/role/EquitybasedcompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Employee Stock", "label": "Employee Stock [Member]", "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": ["http://www.bioventus.com/role/EarningspershareScheduleofAntidilutiveSecuritiesDetails", "http://www.bioventus.com/role/EquitybasedcompensationNarrativeDetails", "http://www.bioventus.com/role/EquitybasedcompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Stock options", "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": ["http://www.bioventus.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": ["http://www.bioventus.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": ["http://www.bioventus.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": ["http://www.bioventus.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": ["http://www.bioventus.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": ["http://www.bioventus.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r869"] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": ["http://www.bioventus.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": ["http://www.bioventus.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": ["http://www.bioventus.com/role/OrganizationNarrativeDetails", "http://www.bioventus.com/role/StockholdersequityScheduleofOtherOwnershipInterestsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Entity [Domain]", "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://www.bioventus.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r869"] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": ["http://www.bioventus.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Ex Transition Period", "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": ["r874"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": ["http://www.bioventus.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": ["http://www.bioventus.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r869"] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://www.bioventus.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://www.bioventus.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": ["r873"] }, "dei_EntityNumberOfEmployees": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityNumberOfEmployees", "presentation": ["http://www.bioventus.com/role/OrganizationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of employees", "label": "Entity Number of Employees", "documentation": "Number of persons employed by the Entity" } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": ["http://www.bioventus.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r869"] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": ["http://www.bioventus.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r869"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": ["http://www.bioventus.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r869"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://www.bioventus.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN, also known as an Employer Identification Number (EIN), is a unique 9 digit value assigned by the IRS." } } }, "auth_ref": ["r869"] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": ["http://www.bioventus.com/role/ConsolidatedCondensedStatementsofChangesinStockholdersEquity"], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": ["r14", "r193", "r220", "r221", "r222", "r238", "r239", "r240", "r242", "r247", "r249", "r251", "r266", "r307", "r308", "r337", "r421", "r485", "r486", "r493", "r494", "r495", "r497", "r501", "r502", "r511", "r512", "r513", "r514", "r515", "r516", "r518", "r545", "r546", "r547", "r548", "r549", "r550", "r554", "r556", "r575", "r640", "r665", "r666", "r667", "r682", "r746"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": ["http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r522", "r523", "r536", "r831"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": ["http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": ["r522", "r523", "r536", "r831"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "presentation": ["http://www.bioventus.com/role/FairvaluemeasurementsTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Value Measurement Inputs and Valuation Techniques", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": ["r524", "r525", "r833"] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": ["http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails", "http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesDetails", "http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": ["r388", "r434", "r435", "r436", "r437", "r438", "r439", "r521", "r523", "r524", "r525", "r526", "r535", "r536", "r538", "r580", "r581", "r582", "r807", "r809", "r819", "r820", "r821", "r831", "r833"] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": ["http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Axis]", "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": ["r522", "r523", "r524", "r526", "r831", "r983", "r985"] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": ["http://www.bioventus.com/role/Fairvaluemeasurements"], "lang": { "en-us": { "role": { "terseLabel": "Fair value measurements", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": ["r531", "r533", "r534", "r535", "r538", "r539", "r540", "r541", "r542", "r620", "r831",

```
"r834" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": [
"http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 2", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation":
"Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or
liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r388", "r434", "r439", "r523", "r524", "r536", "r581", "r807",
"r808", "r819", "r820", "r821", "r831" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueInputsLevel3Member", "presentation": [ "http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails",
"http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 3", "label":
"Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } },
"auth_ref": [ "r388", "r434", "r435", "r436", "r437", "r438", "r439", "r523", "r524", "r525", "r526", "r536", "r582", "r807", "r808", "r819", "r820", "r821", "r831", "r833" ] }, "us-
gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "presentation": [ "http://www.bioventus.com/role/FairvaluemeasurementsNarrativeDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "label": "Fair Value, Liabilities Measured on
Recurring Basis, Unobservable Input Reconciliation [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable
information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r527", "r528", "r529", "r530", "r531", "r532" ] }, "us-
gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "presentation": [ "http://www.bioventus.com/role/FairvaluemeasurementsNarrativeDetails" ], "lang": {
"en-us": { "role": { "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "label": "Fair Value, Liabilities Measured on Recurring Basis,
Unobservable Input Reconciliation [Table]", "documentation": "Disclosure of information about financial instrument liability measured at fair value on recurring basis using unobservable input."
} } }, "auth_ref": [ "r527", "r528", "r529", "r530", "r531", "r532", "r537" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [
"http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement
Frequency [Domain]", "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [ "r522", "r523", "r524", "r526", "r831", "r983", "r985" ] },
"us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueMeasurementsFairValueHierarchyDomain", "presentation": [
"http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails",
"http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesDetails",
"http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and
NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r388", "r434", "r435", "r436", "r437", "r438",
"r439", "r521", "r523", "r524", "r525", "r526", "r535", "r536", "r538", "r580", "r581", "r582", "r807", "r808", "r819", "r820", "r821", "r831", "r833" ] }, "us-
gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsRecurringMember",
"presentation": [ "http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Fair Value, Recurring", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for
impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r831", "r980", "r981", "r982", "r983", "r984", "r985" ] },
"bvs_FinanceLeaseAssetsAndLiabilitiesLesseeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.bioventus.com/20240629", "localname":
"FinanceLeaseAssetsAndLiabilitiesLesseeAbstract", "presentation": [ "http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofAssetsandLiabilitiesLesseeDetails" ], "lang": {
"en-us": { "role": { "terseLabel": "Finance leases:", "label": "Finance Lease, Assets And Liabilities, Lessee [Abstract]", "documentation": "Finance Lease, Assets And Liabilities, Lessee" } } },
"auth_ref": [] }, "us-gaap_FinanceLeaseInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseInterestExpense", "crdr":
"debit", "calculation": { "http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofLeaseCostDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 4.0 } },
"presentation": [ "http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofLeaseCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest on lease liabilities", "label":
"Finance Lease, Interest Expense", "documentation": "Amount of interest expense on finance lease liability." } } }, "auth_ref": [ "r560", "r565", "r838" ] }, "us-
gaap_FinanceLeaseInterestPaymentOnLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseInterestPaymentOnLiability", "crdr":
"credit", "presentation": [ "http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofLeaseCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating cash flows from
financing leases", "label": "Finance Lease, Interest Payment on Liability", "documentation": "Amount of interest paid on finance lease liability." } } }, "auth_ref": [ "r562", "r568" ] }, "us-
gaap_FinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiability", "crdr": "credit", "calculation": {
"http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofAssetsandLiabilitiesLesseeDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [
"http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofAssetsandLiabilitiesLesseeDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total financing lease liabilities",
"label": "Finance Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease." } } }, "auth_ref": [ "r558", "r572" ] }, "us-
gaap_FinanceLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityCurrent", "crdr": "credit", "calculation": {
"http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofAssetsandLiabilitiesLesseeDetails": { "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0, "order": 2.0 } },
"presentation": [ "http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofAssetsandLiabilitiesLesseeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance lease
liabilities\u2014current", "label": "Finance Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as
current." } } }, "auth_ref": [ "r558" ] }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FinanceLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofAssetsandLiabilitiesLesseeDetails": {
"parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofAssetsandLiabilitiesLesseeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance lease
liabilities\u2014noncurrent", "label": "Finance Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent." } } }, "auth_ref": [ "r558" ] }, "us-gaap_FinanceLeasePrincipalPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FinanceLeasePrincipalPayments", "crdr": "credit", "presentation": [ "http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofLeaseCostDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Financing cash flows from finance leases", "label": "Finance Lease, Principal Payments", "documentation": "Amount of cash outflow for principal payment on finance lease." } } },
"auth_ref": [ "r561", "r568" ] }, "us-gaap_FinanceLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FinanceLeaseRightOfUseAsset", "crdr": "debit", "presentation": [ "http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofAssetsandLiabilitiesLesseeDetails" ], "lang": { "en-
us": { "role": { "terseLabel": "Property, plant and equipment, net (finance leases)", "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization", "documentation": "Amount,
after accumulated amortization, of right-of-use asset from finance lease." } } }, "auth_ref": [ "r557" ] }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseRightOfUseAssetAmortization", "crdr": "debit", "calculation": {
"http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofLeaseCostDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofLeaseCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of finance lease assets", "label": "Finance
Lease, Right-of-Use Asset, Amortization", "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease." } } }, "auth_ref": [ "r560", "r565", "r838" ] },
"us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization", "crdr": "debit", "calculation": {
"http://www.bioventus.com/role/BalancesheetinformationScheduleofPropertyandEquipmentNetDetails": { "parentTag": "us-
gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://www.bioventus.com/role/BalancesheetinformationScheduleofPropertyandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance leases", "label": "Finance Lease,
Right-of-Use Asset, before Accumulated Amortization", "documentation": "Amount, before accumulated amortization, of right-of-use asset from finance lease." } } }, "auth_ref": [ "r876" ] }, "us-
gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList", "presentation": [
"http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofAssetsandLiabilitiesLesseeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Right-of-Use Asset,
Statement of Financial Position [Extensible Enumeration]", "label": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates
line item in statement of financial position that includes finance lease right-of-use asset." } } }, "auth_ref": [ "r559" ] }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
"xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "presentation": [
"http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofAssetsandLiabilitiesLesseeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance leases", "label": "Finance
Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for finance lease calculated at point in time." } } }, "auth_ref": [ "r571", "r838" ] }, "us-
gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FinanceLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofAssetsandLiabilitiesLesseeDetails" ], "lang":
{ "en-us": { "role": { "terseLabel": "Finance leases", "label": "Finance Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for finance
lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r570", "r838" ] },
"bvs_FiniteLivedIntangibleAssetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "FiniteLivedIntangibleAssetRecognized", "crdr":
"debit", "presentation": [ "http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-lived intangible asset recognized",
"label": "Finite-Lived Intangible Asset, Recognized", "documentation": "Finite-Lived Intangible Asset, Recognized" } } }, "auth_ref": [] }, "us-
gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "calculation": { "http://www.bioventus.com/role/BalancesheetinformationScheduleofIntangibleAssetsDetails": {
"parentTag": "bvs_FiniteLivedIntangibleAssetsNetBeforeForeignCurrencyTranslationGainLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [
"http://www.bioventus.com/role/BalancesheetinformationScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accumulated amortization", "label": "Finite-
Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a
finite life." } } }, "auth_ref": [ "r204", "r311", "r331", "r804" ] }, "bvs_FiniteLivedIntangibleAssetsAccumulatedForeignCurrencyTranslationGainLoss": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.bioventus.com/20240629", "localname": "FiniteLivedIntangibleAssetsAccumulatedForeignCurrencyTranslationGainLoss", "crdr": "debit", "calculation": {
"http://www.bioventus.com/role/BalancesheetinformationScheduleofIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 2.0 } },
"presentation": [ "http://www.bioventus.com/role/BalancesheetinformationScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Currency translation", "label": "Finite-
Lived Intangible Assets, Accumulated Foreign Currency Translation Gain (Loss)", "documentation": "Finite-Lived Intangible Assets, Accumulated Foreign Currency Translation Gain (Loss)" } }
}, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "presentation": [
"http://www.bioventus.com/role/BalancesheetinformationScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected future amortization, year one", "label":
"Finite-Lived Intangible Asset, Expected Amortization, Year One", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with
finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial
position date (rolling approach)." } } }, "auth_ref": [ "r332", "r781", "r804" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "crdr": "debit", "presentation": [
"http://www.bioventus.com/role/BalancesheetinformationScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected future amortization, remainder of fiscal
year", "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill,
lacking physical substance with finite life expected to be recognized in remainder of current fiscal year." } } }, "auth_ref": [ "r1046" ] }, "us-
gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "presentation": [ "http://www.bioventus.com/role/BalancesheetinformationScheduleofIntangibleAssetsDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Expected future amortization, year four", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "documentation": "Amount of
amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes
interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r332", "r781", "r804" ] }, "us-
gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "presentation": [ "http://www.bioventus.com/role/BalancesheetinformationScheduleofIntangibleAssetsDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Expected future amortization, year three", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "documentation": "Amount of
amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes
interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r332", "r781", "r804" ] }, "us-
gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "presentation": [ "http://www.bioventus.com/role/BalancesheetinformationScheduleofIntangibleAssetsDetails" ],
```

```
"lang": { "en-us": { "role": { "terseLabel": "Expected future amortization, year two", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r332", "r781", "r804" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.bioventus.com/role/BalancesheetinformationScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r324", "r326", "r327", "r328", "r330", "r331", "r333", "r334", "r588", "r589", "r781" ] }, "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract", "presentation": [ "http://www.bioventus.com/role/BalancesheetinformationScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]", "label": "Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "calculation": { "http://www.bioventus.com/role/BalancesheetinformationScheduleofIntangibleAssetsDetails": { "parentTag": "bvs_FiniteLivedIntangibleAssetsNetBeforeForeignCurrencyTranslationGainLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioventus.com/role/BalancesheetinformationScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Carrying amount", "label": "Finite-Lived Intangible Assets, Gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r311", "r331", "r589", "r804" ] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://www.bioventus.com/role/BalancesheetinformationScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets [Line Items]", "label": "Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r324", "r331", "r333", "r334", "r336", "r588", "r781", "r804" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.bioventus.com/role/BalancesheetinformationScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r324", "r326", "r327", "r328", "r330", "r331", "r333", "r334", "r781" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://www.bioventus.com/role/BalancesheetinformationScheduleofIntangibleAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bioventus.com/role/BalancesheetinformationScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Intangible assets, net", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r588", "r925" ] }, "bvs_FiniteLivedIntangibleAssetsNetBeforeForeignCurrencyTranslationGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "FiniteLivedIntangibleAssetsNetBeforeForeignCurrencyTranslationGainLoss", "crdr": "debit", "calculation": { "http://www.bioventus.com/role/BalancesheetinformationScheduleofIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioventus.com/role/BalancesheetinformationScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Intangible assets, net before currency translation", "label": "Finite-Lived Intangible Assets, Net, Before Foreign Currency Translation Gain (Loss)", "documentation": "Finite-Lived Intangible Assets, Net, Before Foreign Currency Translation Gain (Loss)" } } }, "auth_ref": [] }, "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTransactionGainLossUnrealized", "crdr": "credit", "calculation": { "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Unrealized loss on foreign currency fluctuations", "label": "Unrealized Gain (Loss), Foreign Currency Transaction, before Tax", "documentation": "Amount, before tax, of unrealized gain (loss) from foreign currency transaction." } } }, "auth_ref": [ "r138", "r727", "r865", "r987", "r988", "r1039" ] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FurnitureAndFixturesMember", "presentation": [ "http://www.bioventus.com/role/BalancesheetinformationScheduleofPropertyandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Furniture and fixtures", "label": "Furniture and Fixtures [Member]", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [] }, "us-gaap_GainLossOnSaleOfBusiness": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnSaleOfBusiness", "crdr": "credit", "calculation": { "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 8.0 }, "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofCashFlows", "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss", "http://www.bioventus.com/role/SegmentsScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Loss on disposals", "terseLabel": "Loss on disposals", "label": "Gain (Loss) on Disposition of Business", "documentation": "Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant." } } }, "auth_ref": [ "r508", "r897" ] }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainsLossesOnExtinguishmentOfDebt", "crdr": "credit", "presentation": [ "http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Loss on debt retirement and modification", "label": "Gain (Loss) on Extinguishment of Debt", "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity." } } }, "auth_ref": [ "r9", "r49", "r50" ] }, "us-gaap_GainsLossesOnRestructuringOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainsLossesOnRestructuringOfDebt", "crdr": "credit", "calculation": { "http://www.bioventus.com/role/SegmentsScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bioventus.com/role/SegmentsScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Financial restructuring costs", "label": "Gains (Losses) on Restructuring of Debt", "documentation": "For a debtor, the aggregate gain (loss) recognized on the restructuring of payables arises from the difference between the book value of the debt before the restructuring and the fair value of the payments on the debt after restructuring is complete." } } }, "auth_ref": [ "r12" ] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "label": "Goodwill", "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r203", "r312", "r621", "r798", "r803", "r832", "r830", "r916", "r917" ] }, "us-gaap_GoodwillLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillLineItems", "presentation": [ "http://www.bioventus.com/role/BalancesheetinformationScheduleofAccruedLiabilitiesDetails", "http://www.bioventus.com/role/BalancesheetinformationScheduleofInventoryDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Inventory [Line Items]", "netLabel": "Accrued Liabilities [Line Items]", "label": "Goodwill [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r803" ] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Gross profit", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r120", "r126", "r183", "r233", "r306", "r363", "r364", "r366", "r367", "r368", "r369", "r370", "r372", "r373", "r543", "r792", "r797", "r908", "r910", "r911", "r912", "r913", "r946" ] }, "bvs_GrossToNetDeductionsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "GrossToNetDeductionsCurrent", "crdr": "credit", "calculation": { "http://www.bioventus.com/role/BalancesheetinformationScheduleofAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioventus.com/role/BalancesheetinformationScheduleofAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross-to-net deductions", "label": "Gross-To-Net Deductions, Current", "documentation": "Gross-To-Net Deductions, Current" } } }, "auth_ref": [] }, "bvs_HAProductMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "HAProductMember", "presentation": [ "http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "HA Product", "label": "HA Product [Member]", "documentation": "HA Product" } } }, "auth_ref": [] }, "bvs_HarborMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "HarborMember", "presentation": [ "http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Harbor", "label": "Harbor [Member]", "documentation": "Harbor" } } }, "auth_ref": [] }, "us-gaap_IPOMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IPOMember", "presentation": [ "http://www.bioventus.com/role/StockholdersequityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "IPO", "label": "IPO [Member]", "documentation": "First sale of stock by a private company to the public." } } }, "auth_ref": [] }, "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Impairments of assets", "label": "Impairment of Intangible Assets (Excluding Goodwill)", "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value." } } }, "auth_ref": [ "r9", "r325", "r335" ] }, "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOfIntangibleAssetsFinitelived", "crdr": "debit", "presentation": [ "http://www.bioventus.com/role/BalancesheetinformationScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment of intangible assets", "label": "Impairment of Intangible Assets, Finite-Lived", "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value." } } }, "auth_ref": [ "r325", "r897", "r929" ] }, "us-gaap_InProcessResearchAndDevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InProcessResearchAndDevelopmentMember", "presentation": [ "http://www.bioventus.com/role/BalancesheetinformationScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Developed technology and other", "label": "In Process Research and Development [Member]", "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process." } } }, "auth_ref": [ "r918", "r919", "r920", "r921", "r922", "r923", "r925", "r926", "r927", "r928" ] }, "us-gaap_IncomeLossFromContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperations", "crdr": "credit", "calculation": { "http://www.bioventus.com/role/EarningspershareScheduleofEarningsPerShareDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bioventus.com/role/EarningspershareScheduleofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss attributable to Bioventus Inc. Class A common stockholders \u2014 continuing operations", "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent", "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent." } } }, "auth_ref": [ "r68", "r122", "r138", "r243", "r244", "r245", "r246", "r247", "r257", "r260", "r502" ] }, "us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity", "crdr": "debit", "calculation": { "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 1.0 }, "http://www.bioventus.com/role/EarningspershareScheduleofEarningsPerShareDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss", "http://www.bioventus.com/role/EarningspershareScheduleofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Loss attributable to noncontrolling interest - continuing operations", "negatedLabel": "Net loss attributable to noncontrolling interests \u2014 continuing operations", "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest", "documentation": "Amount after tax of income (loss) from continuing operations attributable to the noncontrolling interest." } } }, "auth_ref": [ "r66", "r168", "r247" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 }, "http://www.bioventus.com/role/SegmentsScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss", "http://www.bioventus.com/role/SegmentsScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Loss before income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r121", "r178",
```

```
"r183", "r625", "r636", "r792", "r797", "r908", "r910", "r911", "r912", "r913" ] }, "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "crdr":
"credit", "calculation": { "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofCashFlows": { "parentTag": "us-
gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 1.0 }, "http://www.bioventus.com/role/EarningspershareScheduleofEarningsPerShareDetails":
{ "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": 1.0, "order": 1.0 },
"http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://www.bioventus.com/role/ConsolidatedCondensedStatementsofCashFlows", "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss",
"http://www.bioventus.com/role/EarningspershareScheduleofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss from continuing operations", "terseLabel": "Net loss
from continuing operations, net of tax", "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount
after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r168", "r183", "r233", "r241", "r247", "r306", "r363",
"r364", "r366", "r367", "r368", "r369", "r370", "r372", "r373", "r406", "r502", "r520", "r543", "r636", "r792", "r908", "r910", "r911", "r912", "r913", "r946" ] }, "us-
gaap_IncomeLossFromContinuingOperationsPerBasicShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncomeLossFromContinuingOperationsPerBasicShare", "calculation": { "http://www.bioventus.com/role/EarningspershareScheduleofEarningsPerShareDetails": { "parentTag": "us-
gaap_EarningsPerShareBasic", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss",
"http://www.bioventus.com/role/EarningspershareScheduleofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss per share of Class A common stock from continuing
operations, basic (in dollars per share)", "verboseLabel": "Net loss per share of Class A common stock from continuing operations, basic (in dollars per share)", "label": "Income (Loss) from
Continuing Operations, Per Basic Share", "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the
reporting period." } } }, "auth_ref": [ "r122", "r179", "r226", "r241", "r243", "r244", "r245", "r246", "r247", "r255", "r258", "r259", "r496", "r502", "r520", "r624", "r1007" ] }, "us-
gaap_IncomeLossFromContinuingOperationsPerDilutedShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncomeLossFromContinuingOperationsPerDilutedShare", "calculation": { "http://www.bioventus.com/role/EarningspershareScheduleofEarningsPerShareDetails": { "parentTag": "us-
gaap_EarningsPerShareDiluted", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss",
"http://www.bioventus.com/role/EarningspershareScheduleofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss per share of Class A common stock from continuing
operations, diluted (in dollars per share)", "verboseLabel": "Net loss per share of Class A common stock from continuing operations, diluted (in dollars per share)", "label": "Income (Loss) from
Continuing Operations, Per Diluted Share", "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or
common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential
common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r122", "r226", "r241", "r243", "r244", "r245", "r246", "r247", "r255", "r258", "r259", "r260", "r502", "r520",
"r624", "r1007" ] }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncomeLossFromDiscontinuedOperationsNetOfTax", "crdr": "credit", "calculation": { "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss":
{ "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 1.0 }, "http://www.bioventus.com/role/EarningspershareScheduleofEarningsPerShareDetails": { "parentTag": "us-
gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://www.bioventus.com/role/ConsolidatedCondensedStatementsofCashFlows", "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss",
"http://www.bioventus.com/role/EarningspershareScheduleofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss from discontinued operations, net of tax",
"verboseLabel": "Less: Loss from discontinued operations, net of tax", "netLabel": "Net loss from discontinued operations, net of tax", "label": "Income (Loss) from Discontinued Operations, Net
of Tax, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the
noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down)
to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal." } } }, "auth_ref": [ "r78", "r79", "r80", "r81", "r82", "r93", "r197", "r490", "r637" ] }, "us-
gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": {
"http://www.bioventus.com/role/EarningspershareScheduleofEarningsPerShareDetails": { "parentTag": "us-
gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "weight": -1.0, "order": 1.0 },
"http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } },
"presentation": [ "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss",
"http://www.bioventus.com/role/EarningspershareScheduleofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Loss attributable to noncontrolling interest -
discontinued operations", "negatedLabel": "Net loss attributable to noncontrolling interests \u2014 discontinued operations", "label": "Income (Loss) from Discontinued Operations, Net of Tax,
Attributable to Noncontrolling Interest", "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the noncontrolling interest. Includes, but is not
limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and
adjustments to a prior period gain (loss) on disposal." } } }, "auth_ref": [ "r66", "r78", "r79", "r80", "r81", "r82", "r88", "r93", "r168" ] }, "us-
gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "crdr": "credit", "calculation": {
"http://www.bioventus.com/role/EarningspershareScheduleofEarningsPerShareDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [
"http://www.bioventus.com/role/EarningspershareScheduleofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss attributable to Bioventus Inc. Class A common
stockholders \u2014 discontinued operations", "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent", "documentation": "Amount after tax of income (loss)
from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for
reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal." } } }, "auth_ref": [ "r78", "r79", "r80", "r81", "r82", "r88", "r93",
"r168" ] }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare", "calculation": { "http://www.bioventus.com/role/EarningspershareScheduleofEarningsPerShareDetails": { "parentTag": "us-
gaap_EarningsPerShareBasic", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss",
"http://www.bioventus.com/role/EarningspershareScheduleofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss per share of Class A common stock from discontinuing
operations, basic (in dollars per share)", "verboseLabel": "Net loss per share of Class A common stock from discontinuing operations, basic (in dollars per share)", "label": "Income (Loss) from
Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share", "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day
business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation." } } }, "auth_ref": [ "r123", "r226", "r256", "r258", "r259", "r1004", "r1007" ] },
"us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare", "calculation": { "http://www.bioventus.com/role/EarningspershareScheduleofEarningsPerShareDetails": { "parentTag":
"us-gaap_EarningsPerShareDiluted", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss",
"http://www.bioventus.com/role/EarningspershareScheduleofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss per share of Class A common stock from discontinuing
operations, diluted (in dollars per share)", "verboseLabel": "Net loss per share of Class A common stock from discontinuing operations, diluted (in dollars per share)", "label": "Income (Loss)
from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share", "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-
day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation." } } }, "auth_ref": [ "r169", "r256", "r258", "r259" ] }, "us-
gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income
Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
"presentation": [ "http://www.bioventus.com/role/AcquisitionsanddivestituresDetails",
"http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofHeldforSaleAssetsandLiabilitiesDetails",
"http://www.bioventus.com/role/BalancesheetinformationScheduleofInventoryDetails",
"http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofAssetsandLiabilitiesLesseeDetails", "http://www.bioventus.com/role/DiscontinuedOperationsNarrativeDetails",
"http://www.bioventus.com/role/DiscontinuedOperationsandDisposalGroupsScheduleofStatementofOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Name [Axis]",
"label": "Disposal Group Name [Axis]", "documentation": "Information by name of disposal group." } } }, "auth_ref": [ "r822", "r823" ] }, "us-
gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "presentation": [
"http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofHeldforSaleAssetsandLiabilitiesDetails",
"http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofAssetsandLiabilitiesLesseeDetails", "http://www.bioventus.com/role/DiscontinuedOperationsNarrativeDetails",
"http://www.bioventus.com/role/DiscontinuedOperationsandDisposalGroupsScheduleofStatementofOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement, Balance
Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal
Groups, Including Discontinued Operations [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable
information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-
gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "presentation": [
"http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofHeldforSaleAssetsandLiabilitiesDetails",
"http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofAssetsandLiabilitiesLesseeDetails", "http://www.bioventus.com/role/DiscontinuedOperationsNarrativeDetails",
"http://www.bioventus.com/role/DiscontinuedOperationsandDisposalGroupsScheduleofStatementofOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Groups, Including
Discontinued Operations [Table]", "label": "Disposal Groups, Including Discontinued Operations [Table]", "documentation": "Disclosure of information about a disposal group. Includes, but is not
limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r11",
"r15", "r20", "r76", "r83", "r84", "r85", "r86", "r87", "r92", "r94", "r95", "r149" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [
"http://www.bioventus.com/role/Incometaxes" ], "lang": { "en-us": { "role": { "terseLabel": "Income taxes", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure
for income tax." } } }, "auth_ref": [ "r234", "r475", "r479", "r480", "r481", "r482", "r483", "r484", "r487", "r489", "r491", "r492", "r679", "r828" ] }, "us-gaap_IncomeTaxExpenseBenefit": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": {
"http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss": { "parentTag": "us-
gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax (benefit) expense, net", "label":
"Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } },
"auth_ref": [ "r185", "r190", "r250", "r251", "r265", "r281", "r295", "r478", "r479", "r488", "r644", "r828" ] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": {
"http://www.bioventus.com/role/ConsolidatedCondensedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0,
"order": 13.0 } }, "presentation": [ "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable and accrued
expenses", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for
goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": {
"http://www.bioventus.com/role/ConsolidatedCondensedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0,
"order": 11.0 } }, "presentation": [ "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accounts receivable",
"label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from
customers for the credit sale of goods and services." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofCashFlows": { "parentTag":
"us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0, "order": 12.0 } }, "presentation": [
"http://www.bioventus.com/role/ConsolidatedCondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Inventories", "label": "Increase (Decrease) in Inventories",
"documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are
classified as operating activities." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": {
"terseLabel": "Changes in operating assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-
```

gaap_IncreaseDecreaseInOtherOperatingCapitalNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherOperatingCapitalNet", "crdr": "credit", "calculation": { "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0, "order": 14.0 } }, "presentation": ["http://www.bioventus.com/role/ConsolidatedCondensedStatementsofCashFlows"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other current and noncurrent assets and liabilities", "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net", "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other." } } }, "auth_ref": ["r8"] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": ["http://www.bioventus.com/role/ConsolidatedCondensedStatementsofChangesinStockholdersEquity"], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_InsuranceSettlementsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InsuranceSettlementsReceivable", "crdr": "debit", "presentation": ["http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Insurance settlement receivable", "label": "Insurance Settlements Receivable", "documentation": "Amount due in settlement of a claim for reimbursement from an insurance company when the Company has suffered a loss covered under an insurance policy." } } }, "auth_ref": [] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets, net", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": ["r324", "r925", "r926"] }, "us-gaap_IntellectualPropertyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntellectualPropertyMember", "presentation": ["http://www.bioventus.com/role/BalancesheetinformationScheduleofIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Intellectual Property", "label": "Intellectual Property [Member]", "documentation": "Intangible asset arising from original creative thought. Include, but is not limited to, trademarks, patents, and copyrights." } } }, "auth_ref": ["r16", "r918", "r919", "r920", "r921", "r923", "r925", "r927", "r928"] }, "us-gaap_InterestExpenseDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseDebt", "crdr": "debit", "presentation": ["http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Interest expense, debt", "label": "Interest Expense, Debt", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt." } } }, "auth_ref": ["r131", "r394", "r404", "r809", "r810"] }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestIncomeExpenseNonoperatingNet", "crdr": "credit", "calculation": { "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 }, "http://www.bioventus.com/role/SegmentsScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 8.0 } }, "presentation": ["http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss", "http://www.bioventus.com/role/SegmentsScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Interest expense, net", "terseLabel": "Interest expense, net", "label": "Interest Income (Expense), Nonoperating", "documentation": "Amount of interest income (expense) classified as nonoperating." } } }, "auth_ref": ["r797", "r892", "r910"] }, "us-gaap_InterestPayableCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPayableCurrentAndNoncurrent", "crdr": "credit", "calculation": { "http://www.bioventus.com/role/BalancesheetinformationScheduleofAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.bioventus.com/role/BalancesheetinformationScheduleofAccruedLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Accrued interest", "label": "Interest Payable", "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables." } } }, "auth_ref": ["r173", "r1005"] }, "bvs_InternationalSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "InternationalSegmentMember", "presentation": ["http://www.bioventus.com/role/SegmentsNarrativeDetails", "http://www.bioventus.com/role/SegmentsScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"], "lang": { "en-us": { "role": { "terseLabel": "International", "label": "International Segment [Member]", "documentation": "International Segment" } } }, "auth_ref": [] }, "us-gaap_InventoryFinishedGoods": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryFinishedGoods", "crdr": "debit", "calculation": { "http://www.bioventus.com/role/BalancesheetinformationScheduleofInventoryDetails": { "parentTag": "us-gaap_InventoryGross", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.bioventus.com/role/BalancesheetinformationScheduleofInventoryDetails"], "lang": { "en-us": { "role": { "terseLabel": "Finished goods", "label": "Inventory, Finished Goods, Gross", "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer." } } }, "auth_ref": ["r885"] }, "us-gaap_InventoryGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryGross", "crdr": "debit", "calculation": { "http://www.bioventus.com/role/BalancesheetinformationScheduleofInventoryDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.bioventus.com/role/BalancesheetinformationScheduleofInventoryDetails"], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Inventory, Gross", "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": ["r886"] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Inventory", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": ["r214", "r785", "r839"] }, "us-gaap_InventoryRawMaterialsAndSupplies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryRawMaterialsAndSupplies", "crdr": "debit", "calculation": { "http://www.bioventus.com/role/BalancesheetinformationScheduleofInventoryDetails": { "parentTag": "us-gaap_InventoryGross", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.bioventus.com/role/BalancesheetinformationScheduleofInventoryDetails"], "lang": { "en-us": { "role": { "terseLabel": "Raw materials and supplies", "label": "Inventory, Raw Materials and Supplies, Gross", "documentation": "Gross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed." } } }, "auth_ref": ["r886"] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCost", "crdr": "debit", "calculation": { "http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofLeaseCostDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofLeaseCostDetails"], "lang": { "en-us": { "role": { "totalLabel": "Total lease cost", "label": "Lease, Cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": ["r564", "r838"] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostTableTextBlock", "presentation": ["http://www.bioventus.com/role/CommitmentsandcontingenciesTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Lease, Cost", "label": "Lease, Cost [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short term lease cost, variable lease cost and sublease income." } } }, "auth_ref": ["r994"] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseholdImprovementsMember", "presentation": ["http://www.bioventus.com/role/BalancesheetinformationScheduleofPropertyandEquipmentNetDetails"], "lang": { "en-us": { "role": { "terseLabel": "Leasehold improvements", "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": ["r147", "r573"] }, "bvs_LeasesWeightedAverageDiscountRateAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "LeasesWeightedAverageDiscountRateAbstract", "presentation": ["http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofAssetsandLiabilitiesLesseeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Weighted average discount rate for leases", "label": "Leases, Weighted Average Discount Rate [Abstract]", "documentation": "Leases, Weighted Average Discount Rate" } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityAxis", "presentation": ["http://www.bioventus.com/role/OrganizationNarrativeDetails", "http://www.bioventus.com/role/StockholdersequityScheduleofOtherOwnershipInterestsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Legal Entity [Axis]", "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseRemainingLeaseTerm", "presentation": ["http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Lessee, operating lease, remaining lease term", "label": "Lessee, Operating Lease, Remaining Lease Term", "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r574", "r993"] }, "us-gaap_LetterOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LetterOfCreditMember", "presentation": ["http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Letter of Credit", "label": "Letter of Credit [Member]", "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit)." } } }, "auth_ref": [] }, "us-gaap_LettersOfCreditOutstandingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LettersOfCreditOutstandingAmount", "crdr": "credit", "presentation": ["http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Letters of credit outstanding, amount", "label": "Letters of Credit Outstanding, Amount", "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date." } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": ["r17", "r98", "r99", "r100", "r103", "r104", "r105", "r106", "r233", "r306", "r363", "r364", "r366", "r367", "r368", "r369", "r370", "r372", "r373", "r505", "r509", "r510", "r543", "r705", "r791", "r867", "r946", "r995", "r996"] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders\u2019 equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": ["r114", "r177", "r634", "r839", "r900", "r915", "r986"] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": ["http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Liabilities and Stockholders' Equity", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": ["r100", "r199", "r233", "r306", "r363", "r364", "r366", "r367", "r368", "r369", "r370", "r372", "r373", "r505", "r509", "r510", "r543", "r839", "r946", "r995", "r996"] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": ["http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesFairValueDisclosure", "crdr": "credit", "calculation": { "http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities:", "label": "Liabilities, Fair Value Disclosure", "documentation": "Fair value of financial and nonfinancial obligations." } } }, "auth_ref": ["r523", "r980"] }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesFairValueDisclosureAbstract", "presentation": ["http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"], "lang": { "en-us": { "role": { "terseLabel": "Liabilities:", "label": "Liabilities, Fair Value Disclosure [Abstract]" } } }, "auth_ref": [] }, "bvs_LiabilitiesHeldForSaleAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "LiabilitiesHeldForSaleAbstract", "presentation": ["http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofHeldforSaleAssetsandLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Liabilities Held for Sale [Abstract]", "label": "Liabilities Held for Sale [Abstract]", "documentation": "Liabilities Held for Sale" } } }, "auth_ref": [] }, "bvs_LiabilitiesHeldForSaleNotPartOfDisposalGroupCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "LiabilitiesHeldForSaleNotPartOfDisposalGroupCurrent", "crdr": "credit", "calculation": { "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Liabilities held for sale", "label": "Liabilities Held-for-sale, Not Part of Disposal Group, Current", "documentation": "Liabilities Held-for-sale, Not Part of Disposal Group, Current" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "crdr": "credit", "calculation": { "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofHeldforSaleAssetsandLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofHeldforSaleAssetsandLiabilitiesDetails"], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities held for sale", "label": "Disposal Group, Including Discontinued Operation, Liabilities", "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of." } } }, "auth_ref": ["r1", "r76", "r91", "r148", "r196", "r197"] }, "bvs_LimitedLiabilityCompanyInterestsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "LimitedLiabilityCompanyInterestsMember", "presentation": ["http://www.bioventus.com/role/EarningspershareScheduleofAntidilutiveSecuritiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "LLC Interests held by Continuing LLC Owner", "label": "Limited Liability Company Interests [Member]", "documentation": "Limited Liability Company Interests" } } }, "auth_ref": [] }, "us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024",

```
"localname": "LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest", "presentation": [
"http://www.bioventus.com/role/StockholdersequityScheduleofOtherOwnershipInterestsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership %", "label": "Limited Liability Company or Limited Partnership, Members or Limited Partners, Ownership Interest", "documentation": "Percentage investment held by members or limited partners of limited liability company (LLC) or limited partnership (LP)." } } }, "auth_ref": [ "r33" ] }, "us-gaap_LimitedLiabilityCompanyLlcMembersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LimitedLiabilityCompanyLlcMembersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit",
"presentation": [ "http://www.bioventus.com/role/StockholdersequityScheduleofOtherOwnershipInterestsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "LLC Interests", "label": "Limited Liability Company (LLC) Members' Equity, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount of ownership interest in a limited liability company (LLC), including portions attributable to both the parent and noncontrolling interests." } } }, "auth_ref": [ "r156", "r266" ] }, "us-gaap_LineOfCredit": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "LineOfCredit", "crdr": "credit", "presentation": [ "http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails" ], "lang": { "en-us": { "role":
{ "terseLabel": "Outstanding borrowings on line of credit", "label": "Long-Term Line of Credit", "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long-term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": [ "r17", "r174", "r1006" ] }, "us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityIncreaseDecreaseForPeriodNet", "crdr": "credit", "presentation": [
"http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Revolver credit capacity reduced amount", "label": "Line of Credit Facility, Increase (Decrease), Net", "documentation": "Amount of increase (decrease) of the credit facility." } } }, "auth_ref": [ "r899" ] }, "us-
gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Revolving credit facility, borrowing capacity", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r97", "r102" ] },
"bvs_LineOfCreditFacilityNumberOfLettersOfCreditOutstanding": { "xbrltype": "integerItemType", "nsuri": "http://www.bioventus.com/20240629", "localname":
"LineOfCreditFacilityNumberOfLettersOfCreditOutstanding", "presentation": [ "http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails",
"http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of credit facility, number of LOCs outstanding", "label": "Line Of Credit Facility, Number Of Letters Of Credit Outstanding", "documentation": "Line Of Credit Facility, Number Of Letters Of Credit Outstanding" } } }, "auth_ref": [] }, "us-
gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LineOfCreditFacilityRemainingBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Line of credit facility, remaining borrowing capacity", "label": "Line of Credit Facility, Remaining Borrowing Capacity", "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding)." } } }, "auth_ref": [ "r97", "r102", "r362" ] }, "us-gaap_LineOfCreditMember": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditMember", "presentation": [
"http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit", "label": "Line of Credit [Member]", "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars." } } }, "auth_ref": [] }, "srt_LitigationCaseAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "LitigationCaseAxis",
"presentation": [ "http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Case [Axis]", "label": "Litigation Case [Axis]" } } }, "auth_ref": [] }, "srt_LitigationCaseTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "LitigationCaseTypeDomain", "presentation": [
"http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Case [Domain]", "label": "Litigation Case [Domain]" } } }, "auth_ref": [] }, "us-gaap_LitigationSettlementAmountAwardedToOtherParty": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LitigationSettlementAmountAwardedToOtherParty", "crdr": "credit", "presentation": [ "http://www.bioventus.com/role/AcquisitionsanddivestituresDetails",
"http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation settlement, amount awarded to other party", "label":
"Litigation Settlement, Amount Awarded to Other Party", "documentation": "Amount awarded to other party in judgment or settlement of litigation." } } }, "auth_ref": [] },
"dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [
"http://www.bioventus.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebt", "crdr": "credit",
"presentation": [ "http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt", "label": "Long-Term Debt",
"documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r17", "r174", "r387",
"r402", "r807", "r808", "r837", "r1006" ] }, "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtCurrent",
"crdr": "credit", "calculation": { "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } },
"presentation": [ "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets", "http://www.bioventus.com/role/FinancialinstrumentsScheduleOfLongTermDebtInstrumentsDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Current portion of long-term debt", "negatedTerseLabel": "Current portion of long-term debt", "label": "Long-Term Debt, Current Maturities",
"documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } }, "auth_ref": [
"r206" ] }, "us-gaap_LongTermDebtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtFairValue", "crdr": "credit",
"presentation": [ "http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt, fair value", "label": "Long-Term Debt, Fair Value", "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission." } } }, "auth_ref": [ "r980", "r982", "r983", "r984" ] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LongTermDebtNoncurrent", "crdr": "credit", "calculation": { "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0,
"order": 3.0 } }, "presentation": [ "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets",
"http://www.bioventus.com/role/FinancialinstrumentsScheduleOfLongTermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt, less current portion", "label":
"Long-Term Debt, Excluding Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": [ "r207" ] }, "us-gaap_LongTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LongTermInvestments", "crdr": "debit", "calculation": { "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 7.0 }
}, "presentation": [ "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Investment and other assets", "label": "Long-Term Investments", "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle)." } } }, "auth_ref": [ "r201" ] },
"us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeAxis", "presentation": [
"http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails", "http://www.bioventus.com/role/FinancialinstrumentsScheduleOfLongTermDebtInstrumentsDetails" ], "lang": { "en-us":
{ "role": { "terseLabel": "Long-term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r17", "r934",
"r935", "r936" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeDomain", "presentation": [
"http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails", "http://www.bioventus.com/role/FinancialinstrumentsScheduleOfLongTermDebtInstrumentsDetails" ], "lang": { "en-us":
{ "role": { "terseLabel": "Long-term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r17", "r48", "r934", "r935", "r936" ] }, "us-gaap_LossContingenciesLineItems": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesLineItems", "presentation": [
"http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Line Items]", "label": "Loss Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r355", "r356", "r357", "r360", "r473", "r805", "r940", "r941" ] }, "us-gaap_LossContingenciesTable": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesTable", "presentation": [ "http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "lang": {
"en-us": { "role": { "terseLabel": "Loss Contingencies [Table]", "label": "Loss Contingencies [Table]", "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation." } } }, "auth_ref": [ "r355", "r356", "r357", "r360", "r473", "r805", "r940", "r941" ] },
"bvs_LossContingencyNumberOfDerivativeShareholderLawsuits": { "xbrltype": "integerItemType", "nsuri": "http://www.bioventus.com/20240629", "localname":
"LossContingencyNumberOfDerivativeShareholderLawsuits", "presentation": [ "http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Number of derivative shareholder lawsuits", "label": "Loss Contingency, Number of Derivative Shareholder Lawsuits", "documentation": "Loss Contingency, Number of Derivative Shareholder Lawsuits" } } }, "auth_ref": [] }, "us-gaap_MachineryAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"MachineryAndEquipmentMember", "presentation": [ "http://www.bioventus.com/role/BalancesheetinformationScheduleofPropertyandEquipmentNetDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Machinery and equipment", "label": "Machinery and Equipment [Member]", "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment." } } }, "auth_ref": [] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024",
"localname": "MajorCustomersAxis", "presentation": [ "http://www.bioventus.com/role/BalancesheetinformationComponentsofAccountsReceivableNarrativeDetails",
"http://www.bioventus.com/role/RevenuefromContractwithCustomerNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Axis]", "label": "Customer [Axis]" } } }, "auth_ref":
[ "r302", "r814", "r849", "r854", "r950", "r1008", "r1009", "r1010", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1022", "r1023", "r1024", "r1025",
"r1026", "r1027", "r1028", "r1029", "r1030", "r1031", "r1032", "r1033", "r1034", "r1035", "r1036" ] }, "us-gaap_MaterialReconcilingItemsMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "MaterialReconcilingItemsMember", "presentation": [
"http://www.bioventus.com/role/SegmentsScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reconciling Items", "label": "Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment [Member]", "documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity." } } }, "auth_ref": [ "r290", "r293", "r296", "r797", "r798" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": [ "http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails",
"http://www.bioventus.com/role/EquitybasedcompensationNarrativeDetails",
"http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum",
"label": "Maximum [Member]" } } }, "auth_ref": [ "r356", "r357", "r358", "r359", "r440", "r473", "r526", "r586", "r663", "r664", "r671", "r697", "r698", "r751", "r753", "r755", "r756", "r758",
"r779", "r780", "r802", "r811", "r824", "r833", "r834", "r835", "r836", "r850", "r948", "r997", "r998", "r999", "r1000", "r1001", "r1002" ] }, "us-gaap_MeasurementInputDiscountRateMember": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputDiscountRateMember", "presentation": [
"http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payment discount rate", "label": "Measurement Input, Discount Rate [Member]", "documentation": "Measurement input using interest rate to determine present value of future cash flows." } } }, "auth_ref": [
"r982", "r983", "r984" ] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputTypeAxis",
"presentation": [ "http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Measurement Input Type [Axis]", "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } },
"auth_ref": [ "r524", "r525", "r526", "r833" ] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"MeasurementInputTypeDomain", "presentation": [ "http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesDetails" ], "lang": {
"en-us": { "role": { "terseLabel": "Measurement Input Type [Domain]", "label": "Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r524", "r525", "r526", "r833" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember",
"presentation": [ "http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails", "http://www.bioventus.com/role/EquitybasedcompensationNarrativeDetails",
"http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum",
"label": "Minimum [Member]" } } }, "auth_ref": [ "r356", "r357", "r358", "r359", "r440", "r473", "r526", "r586", "r663", "r664", "r671", "r697", "r698", "r751", "r753", "r755", "r756", "r758",
"r779", "r780", "r802", "r811", "r824", "r833", "r834", "r835", "r850", "r948", "r997", "r998", "r999", "r1000", "r1001", "r1002" ] }, "us-gaap_MinorityInterest": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterest", "crdr": "credit", "calculation": { "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets": { "parentTag":
"us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling interest", "label": "Equity, Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r113", "r176", "r233", "r306", "r363", "r366",
"r367", "r368", "r372", "r373", "r543", "r633", "r709" ] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname":
```

```
"NameOfMajorCustomerDomain", "presentation": [ "http://www.bioventus.com/role/BalancesheetinformationComponentsofAccountsReceivableNarrativeDetails",
"http://www.bioventus.com/role/RevenuefromContractwithCustomerNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Domain]", "label": "Customer [Domain]" } } },
"auth_ref": [ "r302", "r814", "r849", "r854", "r950", "r1008", "r1009", "r1010", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1022", "r1023",
"r1024", "r1025", "r1026", "r1027", "r1028", "r1029", "r1030", "r1031", "r1032", "r1033", "r1034", "r1035", "r1036" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": {
"http://www.bioventus.com/role/ConsolidatedCondensedStatementsofCashFlows": { "parentTag": "us-
gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://www.bioventus.com/role/ConsolidatedCondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash from financing activities", "label": "Net Cash Provided by
(Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining
resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and
paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r229" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [
"http://www.bioventus.com/role/ConsolidatedCondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Financing activities:", "label": "Net Cash Provided by (Used in)
Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofCashFlows": { "parentTag":
"us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [
"http://www.bioventus.com/role/ConsolidatedCondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash from investing activities", "label": "Net Cash Provided by
(Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and
collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r229" ] }, "us-
gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": {
"terseLabel": "Investing activities:", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "crdr": "debit", "calculation": { "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofCashFlows": {
"parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://www.bioventus.com/role/ConsolidatedCondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash from investing activities - continuing operations", "label":
"Net Cash Provided by (Used in) Investing Activities, Continuing Operations", "documentation": "Amount of cash inflow (outflow) of investing activities, excluding discontinued operations.
Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } }
}, "auth_ref": [ "r895" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofCashFlows": { "parentTag": "us-
gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": [
"http://www.bioventus.com/role/ConsolidatedCondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash from operating activities", "label": "Net Cash Provided by
(Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include
transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r136", "r137", "r138" ] }, "us-
gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": {
"terseLabel": "Operating activities:", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "calculation": { "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofCashFlows": { "parentTag": "us-
gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofCashFlows" ], "lang":
{ "en-us": { "role": { "totalLabel": "Net cash from operating activities - continuing operations", "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations",
"documentation": "Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in
value not defined as investing or financing activities." } } }, "auth_ref": [ "r136", "r137", "r138" ] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss": {
"parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss" ],
"lang": { "en-us": { "role": { "totalLabel": "Net loss attributable to Bioventus Inc.", "label": "Net Income (Loss) Attributable to Parent", "documentation": "The portion of profit or loss for the
period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r127", "r138", "r180", "r197", "r216", "r218", "r222", "r233", "r241", "r243", "r244", "r245", "r246", "r247",
"r250", "r251", "r257", "r306", "r363", "r364", "r366", "r367", "r368", "r369", "r370", "r372", "r373", "r496", "r502", "r520", "r543", "r639", "r728", "r744", "r745", "r865", "r946" ] }, "us-
gaap_NetIncomeLossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAbstract", "presentation": [
"http://www.bioventus.com/role/EarningspershareScheduleofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net Income (Loss) Attributable to
Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.bioventus.com/role/OrganizationPolicies" ], "lang": { "en-us": { "role": { "terseLabel":
"Recent accounting pronouncements", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting
pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] },
"bvs_NonRefundablePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "NonRefundablePayments", "crdr": "debit", "presentation": [
"http://www.bioventus.com/role/DiscontinuedOperationsandDisposalGroupsScheduleofStatementofOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-refundable payments",
"label": "Non-Refundable Payments", "documentation": "Non-Refundable Payments" } } }, "auth_ref": [] }, "us-gaap_NonUsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "NonUsMember", "presentation": [ "http://www.bioventus.com/role/RevenuefromContractwithCustomerNarrativeDetails",
"http://www.bioventus.com/role/RevenuerecognitionScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "International", "label": "Non-US [Member]",
"documentation": "Countries excluding the United States of America (US)." } } }, "auth_ref": [ "r1042", "r1043", "r1044", "r1045" ] },
"bvs_NoncontrollingInterestIncreaseDecreaseFromBusinessCombination": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioventus.com/20240629", "localname":
"NoncontrollingInterestIncreaseDecreaseFromBusinessCombination", "crdr": "credit", "presentation": [
"http://www.bioventus.com/role/ConsolidatedCondensedStatementsofChangesinStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Change in noncontrolling interest allocation",
"label": "Noncontrolling\u200b Interest \u200bIncrease\u200b (Decrease) From \u200bBusiness\u200b Combination", "documentation": "Noncontrolling\u200b Interest \u200bIncrease\u200b
(Decrease) From \u200bBusiness\u200b Combination" } } }, "auth_ref": [] }, "us-gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "NoncontrollingInterestMember", "presentation": [ "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofChangesinStockholdersEquity" ], "lang": { "en-us": {
"role": { "terseLabel": "Non- controlling interest", "label": "Noncontrolling Interest [Member]", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not
attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } } }, "auth_ref": [ "r66", "r421", "r902", "r903", "r904", "r905", "r1040" ] },
"us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": {
"http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss": { "parentTag": "us-
gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Other expense", "label":
"Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business related activities (that is to say, excluding major activities considered
part of the normal operations of the business)." } } }, "auth_ref": [ "r130" ] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "NumberOfReportableSegments", "presentation": [ "http://www.bioventus.com/role/SegmentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of reportable
segments", "label": "Number of Reportable Segments", "documentation": "Number of segments reported by the entity. A component of an entity for which there is an
accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": [ "r793", "r801", "r909" ] }, "us-
gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": {
"http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss": { "parentTag": "us-
gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Operating (loss) income", "label":
"Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r183", "r792", "r908", "r910", "r911",
"r912", "r913" ] }, "bvs_OperatingLeaseAssetsAndLiabilitiesLesseeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.bioventus.com/20240629", "localname":
"OperatingLeaseAssetsAndLiabilitiesLesseeAbstract", "presentation": [ "http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofAssetsandLiabilitiesLesseeDetails" ], "lang": {
"en-us": { "role": { "terseLabel": "Operating leases:", "label": "Operating Lease, Assets And Liabilities, Lessee [Abstract]", "documentation": "Operating Lease, Assets And Liabilities, Lessee" } }
}, "auth_ref": [] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "calculation": {
"http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofLeaseCostDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 3.0 } }, "presentation": [
"http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofLeaseCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease cost", "label": "Operating Lease,
Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after
impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r566", "r838" ] }, "us-
gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": {
"http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofAssetsandLiabilitiesLesseeDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [
"http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofAssetsandLiabilitiesLesseeDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating lease liabilities",
"label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r558" ] }, "us-
gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation":
{ "http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofAssetsandLiabilitiesLesseeDetails": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 1.0 }
}, "presentation": [ "http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofAssetsandLiabilitiesLesseeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease
liabilities - current", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as
current." } } }, "auth_ref": [ "r558" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofAssetsandLiabilitiesLesseeDetails": {
"parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofAssetsandLiabilitiesLesseeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities -
noncurrent", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as
noncurrent." } } }, "auth_ref": [ "r558" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofLeaseCostDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Operating cash flows from operating leases", "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring
another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r563", "r568" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets":
{ "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofAssetsandLiabilitiesLesseeDetails",
"http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Operating lease assets", "label": "Operating Lease, Right-of-Use Asset",
"documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r557" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
"xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [
"http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofAssetsandLiabilitiesLesseeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating leases", "label": "Operating
Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r571", "r838" ] }, "us-
gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofAssetsandLiabilitiesLesseeDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Operating leases", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term
for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r570", "r838" ] }, "us-
gaap_OperatingSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingSegmentsMember", "presentation": [
"http://www.bioventus.com/role/SegmentsNarrativeDetails", "http://www.bioventus.com/role/SegmentsScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails" ],
```

```
"lang": { "en-us": { "role": { "terseLabel": "Operating Segments", "label": "Operating Segments [Member]", "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r289", "r290", "r291", "r292", "r293", "r296", "r797", "r798" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "presentation": [ "http://www.bioventus.com/role/Organization" ], "lang": { "en-us": { "role": { "terseLabel": "Organization", "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]", "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles." } } }, "auth_ref": [ "r139", "r140", "r141", "r167" ] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.bioventus.com/role/BalancesheetinformationScheduleofAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.bioventus.com/role/BalancesheetinformationScheduleofAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other liabilities(a)", "label": "Other Accrued Liabilities, Current", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r99" ] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofChangesinStockholdersEquity", "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Change in foreign currency translation adjustments", "verboseLabel": "Translation adjustment", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term investment nature." } } }, "auth_ref": [ "r3", "r640" ] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Other current liabilities", "label": "Other Liabilities, Current", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r99", "r839" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Other long-term liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r104" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other expense (income)", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r132" ] }, "us-gaap_OtherNonrecurringExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonrecurringExpense", "crdr": "debit", "calculation": { "http://www.bioventus.com/role/SegmentsScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bioventus.com/role/SegmentsScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other items", "label": "Other Nonrecurring Expense", "documentation": "Amount of other expense that is infrequent in occurrence or unusual in nature." } } }, "auth_ref": [ "r133" ] }, "us-gaap_OtherOperatingActivitiesCashFlowStatement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherOperatingActivitiesCashFlowStatement", "crdr": "debit", "calculation": { "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Other, net", "label": "Other Operating Activities, Cash Flow Statement", "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities)." } } }, "auth_ref": [] }, "srt_OwnershipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "OwnershipAxis", "presentation": [ "http://www.bioventus.com/role/StockholdersequityScheduleofOtherOwnershipInterestsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership [Axis]", "label": "Ownership [Axis]" } } }, "auth_ref": [] }, "srt_OwnershipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "OwnershipDomain", "presentation": [ "http://www.bioventus.com/role/StockholdersequityScheduleofOtherOwnershipInterestsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership [Domain]", "label": "Ownership [Domain]" } } }, "auth_ref": [] }, "bvs_PainTreatmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "PainTreatmentsMember", "presentation": [ "http://www.bioventus.com/role/RevenuerecognitionScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pain Treatments", "label": "Pain Treatments [Member]", "documentation": "Pain Treatments" } } }, "auth_ref": [] }, "bvs_PaymentOfDebtRefinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "PaymentOfDebtRefinancingCosts", "crdr": "credit", "calculation": { "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Debt refinancing costs", "label": "Payment Of Debt Refinancing Costs", "documentation": "Payment Of Debt Refinancing Costs" } } }, "auth_ref": [] }, "us-gaap_PaymentsForRestructuring": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRestructuring", "crdr": "credit", "presentation": [ "http://www.bioventus.com/role/RestructuringcostsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payments for restructuring", "label": "Payments for Restructuring", "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r346", "r894" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchase of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r134" ] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": [ "http://www.bioventus.com/role/EquitybasedcompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Axis]", "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": [ "http://www.bioventus.com/role/EquitybasedcompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Domain]", "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par value (in dollars per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r107", "r406" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheetsParenthetical", "http://www.bioventus.com/role/StockholdersequityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares authorized (in shares)", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r107", "r707" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": [ "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares issued (in shares)", "label": "Preferred Stock, Shares Issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": [ "r107", "r406" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid and other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r887" ] }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PriorPeriodReclassificationAdjustmentDescription", "presentation": [ "http://www.bioventus.com/role/OrganizationPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassifications", "label": "Reclassification, Comparability Adjustment [Policy Text Block]", "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error." } } }, "auth_ref": [ "r882" ] }, "us-gaap_ProceedsFromDivestitureOfBusinesses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromDivestitureOfBusinesses", "crdr": "debit", "calculation": { "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale of a business", "label": "Proceeds from Divestiture of Businesses", "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period." } } }, "auth_ref": [ "r26" ] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of Class A common stock", "label": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r4" ] }, "us-gaap_ProceedsFromLongTermLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromLongTermLinesOfCredit", "crdr": "debit", "calculation": { "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofCashFlows", "http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowing on revolver", "label": "Proceeds from Long-Term Lines of Credit", "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer." } } }, "auth_ref": [ "r27" ] }, "bvs_ProceedsFromPaymentsForAcquisitionOfIntangibleAssetsAndInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "ProceedsFromPaymentsForAcquisitionOfIntangibleAssetsAndInvestments", "crdr": "debit", "calculation": { "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Investments and acquisition of distribution rights", "label": "Proceeds From (Payments For) Acquisition Of Intangible Assets And Investments", "documentation": "Proceeds From (Payments For) Acquisition Of Intangible Assets And Investments" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "crdr": "debit", "calculation": { "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Other, net", "label": "Proceeds from (Payments for) Other Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities classified as other." } } }, "auth_ref": [ "r877", "r893" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails", "http://www.bioventus.com/role/RevenuerecognitionScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r298", "r587", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r782", "r812", "r848", "r850", "r851", "r855", "r856", "r942", "r943", "r950", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020",
```

```
"r1021", "r1022", "r1023", "r1024", "r1025", "r1026", "r1027", "r1028", "r1029", "r1030", "r1031", "r1032", "r1033", "r1034", "r1035", "r1036" ] }, "srt_ProductsAndServicesDomain": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": [
"http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails", "http://www.bioventus.com/role/RevenuerecognitionScheduleofDisaggregationofRevenueDetails" ], "lang": {
"en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r298", "r587", "r656", "r657", "r658", "r659", "r660", "r661",
"r662", "r782", "r812", "r848", "r850", "r851", "r855", "r856", "r942", "r943", "r950", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019",
"r1020", "r1021", "r1022", "r1023", "r1024", "r1025", "r1026", "r1027", "r1028", "r1029", "r1030", "r1031", "r1032", "r1033", "r1034", "r1035", "r1036" ] }, "us-gaap_ProfitLoss": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "calculation": {
"http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 3.0 } },
"presentation": [ "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofCashFlows",
"http://www.bioventus.com/role/ConsolidatedCondensedStatementsofChangesinStockholdersEquity",
"http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "verboseLabel": "Net loss",
"terseLabel": "Net loss", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "documentation": "The consolidated profit or loss for the period, net of income
taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r197", "r216", "r218", "r228", "r233", "r241", "r247", "r250", "r251", "r306", "r363", "r364", "r366",
"r367", "r368", "r369", "r370", "r372", "r373", "r496", "r502", "r503", "r506", "r507", "r520", "r543", "r625", "r638", "r681", "r728", "r744", "r745", "r829", "r830", "r866", "r890", "r946" ] }, "us-
gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization", "crdr": "credit", "calculation": {
"http://www.bioventus.com/role/BalancesheetinformationScheduleofPropertyandEquipmentNetDetails": { "parentTag": "us-
gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "weight": -1.0, "order": 2.0 } }, "presentation": [
"http://www.bioventus.com/role/BalancesheetinformationScheduleofPropertyandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Loss accumulated depreciation and
amortization", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization", "documentation": "Amount of accumulated
depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease." } } }, "auth_ref": [ "r878", "r881", "r932" ] }, "us-
gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "crdr": "debit", "calculation": {
"http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 },
"http://www.bioventus.com/role/BalancesheetinformationScheduleofPropertyandEquipmentNetDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [
"http://www.bioventus.com/role/BalancesheetinformationScheduleofPropertyandEquipmentNetDetails", "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets" ], "lang": { "en-
us": { "role": { "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment and finance leases, net", "label": "Property, Plant, and Equipment and Finance Lease Right-of-
Use Asset, after Accumulated Depreciation and Amortization", "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease
right-of-use asset." } } }, "auth_ref": [ "r881", "r930" ] }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization", "crdr": "debit", "calculation": {
"http://www.bioventus.com/role/BalancesheetinformationScheduleofPropertyandEquipmentNetDetails": { "parentTag": "us-
gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.bioventus.com/role/BalancesheetinformationScheduleofPropertyandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Property and equipment and finance leases,
gross", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization", "documentation": "Amount, before accumulated
depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset." } } }, "auth_ref": [ "r876", "r884", "r931" ] }, "us-
gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [
"http://www.bioventus.com/role/BalancesheetinformationScheduleofPropertyandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset [Axis]", "label":
"Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [
"r10", "r573" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross",
"crdr": "debit", "calculation": { "http://www.bioventus.com/role/BalancesheetinformationScheduleofPropertyandEquipmentNetDetails": { "parentTag": "us-
gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.bioventus.com/role/BalancesheetinformationScheduleofPropertyandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, gross", "label":
"Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and
not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r147", "r202",
"r635" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems",
"presentation": [ "http://www.bioventus.com/role/BalancesheetinformationScheduleofPropertyandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and
Equipment [Line Items]", "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to
disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r573" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [
"http://www.bioventus.com/role/BalancesheetinformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Property and Equipment, Net", "label": "Property, Plant and
Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to,
balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r10" ] }, "us-
gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain",
"presentation": [ "http://www.bioventus.com/role/BalancesheetinformationScheduleofPropertyandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset
[Domain]", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services
and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture
and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r147", "r573" ] }, "us-gaap_ProvisionForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ProvisionForDoubtfulAccounts", "crdr": "debit", "calculation": { "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofCashFlows": {
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 3.0 } }, "presentation": [
"http://www.bioventus.com/role/ConsolidatedCondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "(Benefit) provision for expected credit losses", "label": "Accounts
Receivable, Credit Loss Expense (Reversal)", "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable." } } }, "auth_ref": [ "r227", "r310" ] },
"srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [
"http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails", "http://www.bioventus.com/role/EquitybasedcompensationNarrativeDetails",
"http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical
Measurement [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r356", "r357", "r358", "r359", "r433", "r440", "r466", "r467", "r468", "r473", "r526", "r583", "r584", "r586",
"r663", "r664", "r671", "r697", "r698", "r751", "r753", "r755", "r756", "r758", "r779", "r780", "r802", "r811", "r824", "r833", "r834", "r835", "r836", "r850", "r859", "r937", "r948", "r983", "r998",
"r999", "r1000", "r1001", "r1002" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [
"http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails", "http://www.bioventus.com/role/EquitybasedcompensationNarrativeDetails",
"http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical
Measurement [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r356", "r357", "r358", "r359", "r433", "r440", "r466", "r467", "r468", "r473", "r526", "r583", "r584",
"r586", "r663", "r664", "r671", "r697", "r698", "r751", "r753", "r755", "r756", "r758", "r779", "r780", "r802", "r811", "r824", "r833", "r834", "r835", "r836", "r850", "r859", "r937", "r948", "r983",
"r998", "r999", "r1000", "r1001", "r1002" ] }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "presentation": [ "http://www.bioventus.com/role/SegmentsTables" ],
"lang": { "en-us": { "role": { "terseLabel": "Schedule of Reconciliation of Operating Profit (Loss) from Segments to Consolidated", "label": "Reconciliation of Operating Profit (Loss) from
Segments to Consolidated [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before
income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment." } } }, "auth_ref": [
"r44", "r45" ] }, "bvs_RehabilitationBusinessMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "RehabilitationBusinessMember",
"presentation": [ "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofHeldforSaleAssetsandLiabilitiesDetails",
"http://www.bioventus.com/role/BalancesheetinformationScheduleofInventoryDetails",
"http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofAssetsandLiabilitiesLesseeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rehabilitation Business", "label":
"Rehabilitation Business [Member]", "documentation": "Rehabilitation Business" } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfLinesOfCredit", "crdr": "credit", "presentation": [ "http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails" ], "lang": {
"en-us": { "role": { "terseLabel": "Repayments on revolver", "label": "Repayments of Lines of Credit", "documentation": "Amount of cash outflow for payment of an obligation from a lender,
including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements." } } }, "auth_ref": [ "r135", "r899" ] }, "us-gaap_RepaymentsOfLongTermDebt": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfLongTermDebt", "crdr": "credit", "presentation": [
"http://www.bioventus.com/role/AcquisitionsanddivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payments on long-term debt", "label": "Repayments of Long-Term Debt",
"documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r135", "r677" ] }, "us-
gaap_RepaymentsOfLongTermLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfLongTermLinesOfCredit", "crdr": "credit",
"calculation": { "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0,
"order": 5.0 } }, "presentation": [ "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payment on revolver",
"label": "Repayments of Long-Term Lines of Credit", "documentation": "The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter
of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or
the operating cycle, if longer." } } }, "auth_ref": [ "r135" ] }, "us-gaap_RepaymentsOfMediumTermNotes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "RepaymentsOfMediumTermNotes", "crdr": "credit", "presentation": [ "http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Repayments of medium-term notes", "label": "Repayments of Medium-Term Note", "documentation": "The cash outflow to pay off borrowing used to receive debt funding on a
regular basis with maturities ranging from 5-10 years." } } }, "auth_ref": [ "r135" ] }, "us-gaap_RepaymentsOfOtherLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfOtherLongTermDebt", "crdr": "credit", "calculation": {
"http://www.bioventus.com/role/ConsolidatedCondensedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } },
"presentation": [ "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments on long-term debt", "label":
"Repayments of Other Long-Term Debt", "documentation": "Amount of cash outflow for the payment of debt classified as other, maturing after one year or the operating cycle, if longer." } } },
"auth_ref": [ "r135" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname":
"RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.bioventus.com/role/AcquisitionsanddivestituresDetails",
"http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Domain]", "label": "Counterparty Name
[Domain]" } } }, "auth_ref": [ "r235", "r236", "r378", "r408", "r576", "r585", "r626", "r788", "r789" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": {
"http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 3.0 } },
"presentation": [ "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Research and
development expense", "label": "Research and Development Expense", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer
software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation
or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [
"r474", "r781", "r797", "r1003" ] }, "bvs_RestorativeTherapiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioventus.com/20240629", "localname":
"RestorativeTherapiesMember", "presentation": [ "http://www.bioventus.com/role/RevenuerecognitionScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Restorative Therapies", "label": "Restorative Therapies [Member]", "documentation": "Restorative Therapies" } } }, "auth_ref": [] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": [
"http://www.bioventus.com/role/EarningspershareScheduleofAntidilutiveSecuritiesDetails", "http://www.bioventus.com/role/EquitybasedcompensationNarrativeDetails",
"http://www.bioventus.com/role/EquitybasedcompensationScheduleofNonvestedRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "RSUs", "label": "Restricted
Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance
conditions are met." } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RestructuringAndRelatedActivitiesAbstract", "lang": { "en-us": { "role": { "label": "Restructuring and Related Activities [Abstract]" } } }, "auth_ref": [] }, "us-
```

gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "presentation": ["http://www.bioventus.com/role/Restructuringcosts"], "lang": { "en-us": { "role": { "terseLabel": "Restructuring costs", "label": "Restructuring and Related Activities Disclosure [Text Block]", "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled." } } }, "auth_ref": ["r344", "r345", "r346", "r348", "r352"] }, "bvs_RestructuringAndSuccessionCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "RestructuringAndSuccessionCharges", "crdr": "debit", "calculation": { "http://www.bioventus.com/role/SegmentsScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.bioventus.com/role/SegmentsScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Restructuring and succession charges", "label": "Restructuring and Succession Charges", "documentation": "Restructuring and Succession Charges" } } }, "auth_ref": [] }, "us-gaap_RestructuringCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCharges", "crdr": "debit", "calculation": { "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss", "http://www.bioventus.com/role/RestructuringcostsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Restructuring costs", "label": "Restructuring Charges", "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": ["r0", "r349", "r350", "r938"] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r111", "r156", "r632", "r668", "r670", "r678", "r708", "r839"] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": ["http://www.bioventus.com/role/ConsolidatedCondensedStatementsofChangesinStockholdersEquity"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r193", "r238", "r239", "r240", "r242", "r247", "r249", "r251", "r307", "r308", "r337", "r485", "r486", "r493", "r494", "r495", "r497", "r501", "r502", "r511", "r513", "r514", "r516", "r518", "r554", "r556", "r665", "r667", "r682", "r1040"] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss", "http://www.bioventus.com/role/RevenuefromContractwithCustomerNarrativeDetails", "http://www.bioventus.com/role/RevenuerecognitionScheduleofDisaggregationofRevenueDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Net sales", "terseLabel": "Total net sales", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": ["r181", "r182", "r265", "r274", "r275", "r280", "r295", "r298", "r300", "r302", "r430", "r431", "r587"] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": ["http://www.bioventus.com/role/Revenuerecognition"], "lang": { "en-us": { "role": { "terseLabel": "Revenue recognition", "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": ["r191", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r432"] }, "bvs_RevenuePercentageOfTotalNetSales": { "xbrltype": "percentItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "RevenuePercentageOfTotalNetSales", "presentation": ["http://www.bioventus.com/role/RevenuefromContractwithCustomerNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Revenue percentage of total net sales", "label": "Revenue Percentage of Total Net Sales", "documentation": "Revenue Percentage of Total Net Sales" } } }, "auth_ref": [] }, "bvs_RevenueReclassifiedDuringPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "RevenueReclassifiedDuringPeriod", "crdr": "credit", "presentation": ["http://www.bioventus.com/role/RevenuefromContractwithCustomerNarrativeDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Revenues", "label": "Revenue Reclassified During Period", "documentation": "Revenue Reclassified During Period" } } }, "auth_ref": [] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Revenues", "crdr": "credit", "presentation": ["http://www.bioventus.com/role/SegmentsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Revenues", "label": "Revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": ["r181", "r182", "r223", "r233", "r265", "r274", "r275", "r289", "r295", "r298", "r300", "r302", "r306", "r363", "r364", "r366", "r367", "r368", "r369", "r370", "r372", "r373", "r543", "r625", "r797", "r946"] }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevolvingCreditFacilityMember", "presentation": ["http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails", "http://www.bioventus.com/role/FinancialinstrumentsScheduleOfLongTermDebtInstrumentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Revolving Credit Facility", "label": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "crdr": "debit", "presentation": ["http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofLeaseCostDetails"], "lang": { "en-us": { "role": { "terseLabel": "Financing lease obligations", "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability." } } }, "auth_ref": ["r569", "r838"] }, "bvs_RightOfUseAssetObtainedInExchangeForLeaseLiabilityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "RightOfUseAssetObtainedInExchangeForLeaseLiabilityAbstract", "presentation": ["http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofLeaseCostDetails"], "lang": { "en-us": { "role": { "terseLabel": "Right-of use assets obtained in exchange for lease obligations:", "label": "Right-Of-Use Asset Obtained In Exchange For Lease Liability [Abstract]", "documentation": "Right-Of-Use Asset Obtained In Exchange For Lease Liability" } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": ["http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofLeaseCostDetails"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease obligations", "label": "Right of Use Asset Obtained in Exchange for Operating Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": ["r569", "r838"] }, "us-gaap_RoyaltyExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RoyaltyExpense", "crdr": "debit", "presentation": ["http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Royalty expense", "label": "Royalty Expense", "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property." } } }, "auth_ref": ["r128"] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": ["http://www.bioventus.com/role/StockholdersequityNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock [Domain]", "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": ["http://www.bioventus.com/role/StockholdersequityNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of shares issued in public offering (in shares)", "label": "Sale of Stock, Number of Shares Issued in Transaction", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "bvs_SalesMilestoneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "SalesMilestoneMember", "presentation": ["http://www.bioventus.com/role/AcquisitionsanddivestituresDetails"], "lang": { "en-us": { "role": { "terseLabel": "Sales Milestone", "label": "Sales Milestone [Member]", "documentation": "Sales Milestone" } } }, "auth_ref": [] }, "us-gaap_SalesRevenueNetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalesRevenueNetMember", "presentation": ["http://www.bioventus.com/role/RevenuefromContractwithCustomerNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Revenue Benchmark", "label": "Revenue Benchmark [Member]", "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": ["r302", "r879"] }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "presentation": ["http://www.bioventus.com/role/BalancesheetinformationTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accounts Receivable", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]", "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables." } } }, "auth_ref": ["r109", "r115"] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": ["http://www.bioventus.com/role/BalancesheetinformationTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accrued Liabilities", "label": "Schedule of Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": ["http://www.bioventus.com/role/EarningspershareScheduleofAntidilutiveSecuritiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": ["r32"] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": ["http://www.bioventus.com/role/EarningspershareTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": ["r32"] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": ["http://www.bioventus.com/role/AcquisitionsanddivestituresDetails", "http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "documentation": "Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability." } } }, "auth_ref": ["r61", "r63", "r498"] }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDebtInstrumentsTextBlock", "presentation": ["http://www.bioventus.com/role/FinancialinstrumentsTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments", "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer." } } }, "auth_ref": ["r17", "r53", "r56", "r74", "r154", "r155", "r807", "r809", "r901", "r990"] }, "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "presentation": ["http://www.bioventus.com/role/AcquisitionsanddivestituresTables", "http://www.bioventus.com/role/DiscontinuedOperationsTables"], "lang": { "en-us": { "role": { "verboseLabel": "Schedule of Held for Sale Assets and Liabilities", "terseLabel": "Schedule of Balance Sheet and Statement of Operation", "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]", "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": ["r11", "r15", "r20", "r76", "r83", "r84", "r85", "r86", "r87", "r92", "r94", "r95", "r149"] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": ["http://www.bioventus.com/role/EarningspershareTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Earnings Per Share", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": ["r907"] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": ["http://www.bioventus.com/role/FairvaluemeasurementsTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable

inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": ["r980", "r981"] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": ["http://www.bioventus.com/role/BalancesheetinformationScheduleofIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]", "label": "Intangible Asset, Finite-Lived [Table]", "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset." } } }, "auth_ref": ["r324", "r331", "r333", "r334", "r336", "r588", "r781", "r804"] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": ["http://www.bioventus.com/role/BalancesheetinformationTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Intangible Assets", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": ["r804", "r924"] }, "us-gaap_ScheduleOfGoodwillTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfGoodwillTable", "presentation": ["http://www.bioventus.com/role/BalancesheetinformationScheduleofAccruedLiabilitiesDetails", "http://www.bioventus.com/role/BalancesheetinformationScheduleofInventoryDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Inventory [Table]", "netLabel": "Accrued Liabilities [Table]", "label": "Goodwill [Table]", "documentation": "Disclosure of information about goodwill, including, but not limited to, change from acquisition, sale, impairment, and other reason." } } }, "auth_ref": ["r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r803"] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": ["http://www.bioventus.com/role/BalancesheetinformationTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Inventory", "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": ["r22", "r116", "r117", "r118"] }, "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "presentation": ["http://www.bioventus.com/role/EquitybasedcompensationTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Nonvested Restricted Stock Units Activity", "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]", "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units." } } }, "auth_ref": ["r162"] }, "us-gaap_ScheduleOfOtherOwnershipInterestsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfOtherOwnershipInterestsTextBlock", "presentation": ["http://www.bioventus.com/role/StockholdersequityTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Other Ownership Interests", "label": "Schedule of Other Ownership Interests [Table Text Block]", "documentation": "Tabular disclosure of other units or shares or classes of ownership in a partnership." } } }, "auth_ref": ["r157"] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": ["http://www.bioventus.com/role/BalancesheetinformationScheduleofPropertyandEquipmentNetDetails"], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Table]", "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated depreecation." } } }, "auth_ref": ["r10", "r573"] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": ["http://www.bioventus.com/role/SegmentsNarrativeDetails", "http://www.bioventus.com/role/SegmentsScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment." } } }, "auth_ref": ["r41", "r42", "r43"] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": ["http://www.bioventus.com/role/EquitybasedcompensationNarrativeDetails", "http://www.bioventus.com/role/EquitybasedcompensationScheduleofNonvestedRestrictedStockUnitsActivityDetails", "http://www.bioventus.com/role/EquitybasedcompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": ["r441", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469"] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": ["http://www.bioventus.com/role/EquitybasedcompensationTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": ["r164"] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockByClassTable", "presentation": ["http://www.bioventus.com/role/OrganizationNarrativeDetails", "http://www.bioventus.com/role/StockholdersequityNarrativeDetails", "http://www.bioventus.com/role/StockholdersequityScheduleofOtherOwnershipInterestsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock by Class [Table]", "label": "Stock, Class of Stock [Table]", "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks." } } }, "auth_ref": ["r51", "r52", "r53", "r54", "r55", "r56", "r152", "r154", "r155", "r156", "r208", "r209", "r210", "r267", "r406", "r407", "r408", "r410", "r413", "r418", "r420", "r674", "r675", "r676", "r677", "r811", "r875", "r898"] }, "us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockOptionsRollForwardTableTextBlock", "presentation": ["http://www.bioventus.com/role/EquitybasedcompensationTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock Options Roll Forward", "label": "Schedule of Stock Options Roll Forward [Table Text Block]", "documentation": "Tabular disclosure of the change in stock options." } } }, "auth_ref": [] }, "us-gaap_SecuredDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuredDebtMember", "presentation": ["http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Secured Debt", "label": "Secured Debt [Member]", "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets." } } }, "auth_ref": [] }, "us-gaap_SecuredOvernightFinancingRateSofrMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuredOvernightFinancingRateSofrMember", "presentation": ["http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Secured Overnight Financing Rate (SOFR)", "label": "Secured Overnight Financing Rate (SOFR) [Member]", "documentation": "Interest rate at which bank can borrow U.S. dollar overnight while posting U.S. Treasury bond as collateral." } } }, "auth_ref": ["r978"] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": ["http://www.bioventus.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r868"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://www.bioventus.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r870"] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentDomain", "presentation": ["http://www.bioventus.com/role/SegmentsNarrativeDetails", "http://www.bioventus.com/role/SegmentsScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"], "lang": { "en-us": { "role": { "terseLabel": "Segments [Domain]", "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": ["r181", "r182", "r183", "r184", "r265", "r270", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r295", "r296", "r297", "r302", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r336", "r347", "r351", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r794", "r797", "r798", "r803", "r853", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1022", "r1023", "r1024", "r1025", "r1026", "r1027", "r1028", "r1029", "r1030", "r1031", "r1032", "r1033", "r1034", "r1035", "r1036"] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": ["http://www.bioventus.com/role/RevenuefromContractwithCustomerNarrativeDetails", "http://www.bioventus.com/role/RevenuerecognitionScheduleofDisaggregationofRevenueDetails"], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Domain]", "label": "Geographical [Domain]" } } }, "auth_ref": ["r300", "r301", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r694", "r695", "r696", "r752", "r754", "r757", "r759", "r767", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r783", "r813", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r852", "r859", "r950", "r1008", "r1009", "r1010", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1022", "r1023", "r1024", "r1025", "r1026", "r1027", "r1028", "r1029", "r1030", "r1031", "r1032", "r1033", "r1034", "r1035", "r1036"] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingDisclosureTextBlock", "presentation": ["http://www.bioventus.com/role/Segments"], "lang": { "en-us": { "role": { "terseLabel": "Segments", "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": ["r184", "r265", "r269", "r270", "r271", "r272", "r273", "r295", "r287", "r288", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r302", "r793", "r795", "r796", "r797", "r799", "r800", "r801"] }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingInformationLineItems", "presentation": ["http://www.bioventus.com/role/SegmentsNarrativeDetails", "http://www.bioventus.com/role/SegmentsScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting Information [Line Items]", "label": "Segment Reporting Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss"], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative expense", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": ["r120"] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.bioventus.com/role/ConsolidatedCondensedStatementsofCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Equity-based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r8"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": ["http://www.bioventus.com/role/EquitybasedcompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Vesting period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": ["r825"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": ["http://www.bioventus.com/role/EquitybasedcompensationScheduleofNonvestedRestrictedStockUnitsActivityDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Forfeited or canceled (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": ["r460"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": ["http://www.bioventus.com/role/EquitybasedcompensationScheduleofNonvestedRestrictedStockUnitsActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Forfeited or canceled (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": ["r460"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [

```
"http://www.bioventus.com/role/EquitybasedcompensationScheduleofNonvestedRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r458" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.bioventus.com/role/EquitybasedcompensationScheduleofNonvestedRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r458" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://www.bioventus.com/role/EquitybasedcompensationScheduleofNonvestedRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r455", "r456" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "presentation": [ "http://www.bioventus.com/role/EquitybasedcompensationScheduleofNonvestedRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of units", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.bioventus.com/role/EquitybasedcompensationScheduleofNonvestedRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance (in dollars per share)", "periodEndLabel": "Ending balance (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r455", "r456" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "presentation": [ "http://www.bioventus.com/role/EquitybasedcompensationScheduleofNonvestedRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average grant-date fair value per unit", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://www.bioventus.com/role/EquitybasedcompensationScheduleofNonvestedRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Vested (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r459" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.bioventus.com/role/EquitybasedcompensationScheduleofNonvestedRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": [ "r459" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://www.bioventus.com/role/EquitybasedcompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected dividend yield", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r467" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "presentation": [ "http://www.bioventus.com/role/EquitybasedcompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected stock price volatility, maximum", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum", "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "presentation": [ "http://www.bioventus.com/role/EquitybasedcompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected stock price volatility, minimum", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum", "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "presentation": [ "http://www.bioventus.com/role/EquitybasedcompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate, maximum", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum", "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "presentation": [ "http://www.bioventus.com/role/EquitybasedcompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate, minimum", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum", "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.bioventus.com/role/EquitybasedcompensationNarrativeDetails", "http://www.bioventus.com/role/EquitybasedcompensationScheduleofNonvestedRestrictedStockUnitsActivityDetails", "http://www.bioventus.com/role/EquitybasedcompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r441", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": [ "http://www.bioventus.com/role/EquitybasedcompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares authorized to be awarded (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [ "r827" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [ "http://www.bioventus.com/role/EquitybasedcompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares available to be awarded (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": [ "r57" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://www.bioventus.com/role/EquitybasedcompensationScheduleofStockOptionsRollForwardDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Forfeited or canceled (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r453" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://www.bioventus.com/role/EquitybasedcompensationScheduleofStockOptionsRollForwardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r451" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.bioventus.com/role/EquitybasedcompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average fair value of stock options granted (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r461" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.bioventus.com/role/EquitybasedcompensationScheduleofStockOptionsRollForwardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options outstanding, Aggregate intrinsic value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r57" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://www.bioventus.com/role/EquitybasedcompensationScheduleofStockOptionsRollForwardDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r447", "r448" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": [ "http://www.bioventus.com/role/EquitybasedcompensationScheduleofStockOptionsRollForwardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of options", "label": "Share-Based
```

```
Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.bioventus.com/role/Equitybasedcompensationscheduleofstockoptionsrollforwarddetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance (in dollars per share)", "periodEndLabel": "Ending balance (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r447", "r448" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": [ "http://www.bioventus.com/role/Equitybasedcompensationscheduleofstockoptionsrollforwarddetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average exercise price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.bioventus.com/role/Equitybasedcompensationscheduleofstockoptionsrollforwarddetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable and vested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r464" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "presentation": [ "http://www.bioventus.com/role/Equitybasedcompensationscheduleofstockoptionsrollforwarddetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable and vested (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r464" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "presentation": [ "http://www.bioventus.com/role/Equitybasedcompensationscheduleofstockoptionsrollforwarddetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable and vested (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price", "documentation": "Weighted average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r464" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "presentation": [ "http://www.bioventus.com/role/Equitybasedcompensationnarrativedetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares issued (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period", "documentation": "Number of shares issued under share-based payment arrangement." } } }, "auth_ref": [ "r57" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.bioventus.com/role/Equitybasedcompensationnarrativedetails", "http://www.bioventus.com/role/Equitybasedcompensationscheduleofnonvestedrestrictedstockunitsactivitydetails", "http://www.bioventus.com/role/Equitybasedcompensationscheduleofsharebasedpaymentawardstockoptionsvaluationassumptionsdetails" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.bioventus.com/role/Equitybasedcompensationscheduleofstockoptionsrollforwarddetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercised (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r452" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.bioventus.com/role/Equitybasedcompensationscheduleofstockoptionsrollforwarddetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forfeited or canceled (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r453" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.bioventus.com/role/Equitybasedcompensationscheduleofstockoptionsrollforwarddetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r451" ] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharePrice", "presentation": [ "http://www.bioventus.com/role/Equitybasedcompensationnarrativedetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock closing price, (in dollars per share)", "label": "Share Price", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": [ "http://www.bioventus.com/role/Equitybasedcompensationnarrativedetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expiration period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r826" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://www.bioventus.com/role/Equitybasedcompensationscheduleofsharebasedpaymentawardstockoptionsvaluationassumptionsdetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected life of stock options (years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r465" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.bioventus.com/role/Equitybasedcompensationscheduleofstockoptionsrollforwarddetails" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding, weighted average remaining contractual term", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r163" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.bioventus.com/role/Equitybasedcompensationscheduleofstockoptionsrollforwarddetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable and vested (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r464" ] }, "bvs_ShareholderLitigationCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "ShareholderLitigationCosts", "crdr": "debit", "calculation": { "http://www.bioventus.com/role/SegmentsScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bioventus.com/role/SegmentsScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Shareholder litigation costs", "label": "Shareholder Litigation Costs", "documentation": "Shareholder Litigation Costs" } } }, "auth_ref": [] }, "bvs_SharesIssuedOrIssuableRequiredStockToLLCInterestRatio": { "xbrltype": "pureItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "SharesIssuedOrIssuableRequiredStockToLLCInterestRatio", "presentation": [ "http://www.bioventus.com/role/StockholdersequityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issued or issuable, required stock to LLC interest ratio", "label": "Shares Issued Or Issuable, Required Stock To LLC Interest Ratio", "documentation": "Shares Issued Or Issuable, Required Stock To LLC Interest Ratio" } } }, "auth_ref": [] }, "us-gaap_ShortTermLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermLeaseCost", "crdr": "debit", "calculation": { "http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofLeaseCostDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofLeaseCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term lease cost", "label": "Short-Term Lease Cost", "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less." } } }, "auth_ref": [ "r567", "r838" ] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementBusinessSegmentsAxis", "presentation": [ "http://www.bioventus.com/role/SegmentsNarrativeDetails", "http://www.bioventus.com/role/SegmentsScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Axis]", "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": [ "r181", "r182", "r183", "r184", "r195", "r265", "r270", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r295", "r296", "r297", "r302", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r336", "r338", "r347", "r351", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r794", "r797", "r798", "r803", "r853", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1022", "r1023", "r1024", "r1025", "r1026", "r1027", "r1028", "r1029", "r1030", "r1031", "r1032", "r1033", "r1034", "r1035", "r1036" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets", "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheetsParenthetical", "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofChangesinStockholdersEquity", "http://www.bioventus.com/role/CoverPage", "http://www.bioventus.com/role/Equitybasedcompensationnarrativedetails", "http://www.bioventus.com/role/StockholdersequityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Axis]", "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r192", "r208", "r209", "r210", "r233", "r255", "r256", "r258", "r260", "r267", "r268", "r306", "r363", "r366", "r367", "r368", "r372", "r373", "r406", "r407", "r410", "r413", "r420", "r543", "r674", "r675", "r676", "r677", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r707", "r729", "r746", "r760", "r761", "r762", "r763", "r764", "r875", "r898", "r906" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofChangesinStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r14", "r108", "r112", "r113", "r193", "r220", "r221", "r222", "r238", "r239", "r240", "r242", "r247", "r249", "r251", "r266", "r307", "r308", "r337", "r421", "r485", "r486", "r493", "r494", "r495", "r497", "r501", "r502", "r511", "r512", "r513", "r514", "r515", "r516", "r518", "r545", "r546", "r547", "r548", "r549", "r550", "r554", "r556", "r575", "r640", "r665", "r666", "r667", "r682", "r746" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": [ "http://www.bioventus.com/role/RevenuefromContractwithCustomerNarrativeDetails", "http://www.bioventus.com/role/RevenuerecognitionScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Axis]", "label": "Geographical [Axis]" } } }, "auth_ref": [ "r300", "r301", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r694", "r695", "r696", "r752", "r754", "r757", "r759", "r767", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r783", "r813", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r852", "r859", "r950", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1022", "r1023", "r1024", "r1025", "r1026", "r1027", "r1028", "r1029", "r1030", "r1031", "r1032", "r1033", "r1034", "r1035", "r1036" ] },
```

```
"us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [
"http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets", "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheetsParenthetical",
"http://www.bioventus.com/role/ConsolidatedCondensedStatementsofChangesinStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement
[Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members
defined in one or many axes to the table." } } }, "auth_ref": [ "r238", "r239", "r240", "r266", "r556", "r587", "r673", "r693", "r699", "r700", "r701", "r702", "r703", "r704", "r707", "r710", "r711",
"r712", "r713", "r714", "r715", "r716", "r717", "r718", "r720", "r721", "r722", "r723", "r724", "r726", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741",
"r742", "r743", "r746", "r860" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position
[Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [ "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets",
"http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheetsParenthetical", "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofChangesinStockholdersEquity" ],
"lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income,
other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r238", "r239", "r240", "r266", "r303", "r556", "r587", "r673", "r693", "r699", "r700",
"r701", "r702", "r703", "r704", "r707", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r720", "r721", "r722", "r723", "r724", "r726", "r730", "r731", "r732", "r733", "r734",
"r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r746", "r860" ] }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesAcquisitions", "presentation": [ "http://www.bioventus.com/role/StockholdersequityNarrativeDetails" ], "lang": {
"en-us": { "role": { "terseLabel": "Number of shares issued in acquisition (in shares)", "label": "Stock Issued During Period, Shares, Acquisitions", "documentation": "Number of shares of stock
issued during the period pursuant to acquisitions." } } }, "auth_ref": [ "r107", "r108", "r156" ] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [
"http://www.bioventus.com/role/ConsolidatedCondensedStatementsofChangesinStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of Class A common stock for equity
plans (in shares)", "label": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r14", "r107", "r108", "r156",
"r674", "r746", "r761" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://www.bioventus.com/role/EquitybasedcompensationScheduleofStockOptionsRollForwardDetails" ], "lang": {
"en-us": { "role": { "negatedLabel": "Exercised (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation":
"Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r14", "r107", "r108", "r156", "r452" ] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues":
{ "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [
"http://www.bioventus.com/role/ConsolidatedCondensedStatementsofChangesinStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of Class A common stock for equity
plans", "label": "Stock Issued During Period, Value, New Issues", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public
offering or a secondary public offering." } } }, "auth_ref": [ "r14", "r107", "r108", "r156", "r682", "r746", "r761", "r866" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets": {
"parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 equity attributable to Bioventus Inc.", "label":
"Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } },
"auth_ref": [ "r108", "r112", "r113", "r143", "r709", "r725", "r747", "r748", "r839", "r867", "r900", "r915", "r986", "r1040" ] }, "us-
gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets": {
"parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets",
"http://www.bioventus.com/role/ConsolidatedCondensedStatementsofChangesinStockholdersEquity" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 equity",
"periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount of equity
(deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r66", "r67", "r70", "r193", "r194", "r221", "r238", "r239", "r240", "r242", "r247",
"r249", "r307", "r308", "r337", "r421", "r485", "r486", "r493", "r494", "r495", "r497", "r501", "r502", "r511", "r512", "r513", "r514", "r515", "r516", "r518", "r545", "r546", "r550", "r555", "r575",
"r666", "r667", "r680", "r709", "r725", "r747", "r748", "r765", "r866", "r900", "r915", "r986", "r1040" ] }, "us-
gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "presentation": [ "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets" ], "lang": { "en-
us": { "role": { "terseLabel": "Stockholders\u2019 Equity", "label": "Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock",
"presentation": [ "http://www.bioventus.com/role/Stockholdersequity" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders\u2019 equity", "label": "Equity [Text Block]", "documentation":
"The entire disclosure for equity." } } }, "auth_ref": [ "r153", "r232", "r405", "r407", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r419", "r421", "r517", "r749", "r750",
"r766" ] }, "bvs_StopLossInsuranceThresholdPerMemberPerYear": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioventus.com/20240629", "localname":
"StopLossInsuranceThresholdPerMemberPerYear", "crdr": "debit", "presentation": [ "http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "lang": { "en-us": {
"role": { "terseLabel": "Stop loss insurance, threshold per member per year", "label": "Stop Loss Insurance, Threshold Per Member Per Year", "documentation": "Stop Loss Insurance, Threshold
Per Member Per Year" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SubsequentEventMember", "presentation": [ "http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails",
"http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event", "label": "Subsequent Event [Member]",
"documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r551", "r578" ] }, "us-
gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": [
"http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails", "http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Subsequent Event Type [Axis]", "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial
statements are issued or available to be issued." } } }, "auth_ref": [ "r551", "r578" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails",
"http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Domain]", "label": "Subsequent Event Type
[Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r551", "r578" ] }, "us-
gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label":
"Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SubsequentEventsTextBlock", "presentation": [ "http://www.bioventus.com/role/Subsequentevents" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent events", "label": "Subsequent
Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were
issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss,
significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r577", "r579" ] }, "us-
gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": [
"http://www.bioventus.com/role/StockholdersequityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock [Axis]", "label": "Sale of Stock [Axis]", "documentation":
"Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "presentation": [ "http://www.bioventus.com/role/Balancesheetinformation" ], "lang": { "en-us": {
"role": { "terseLabel": "Balance sheet information", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "documentation": "The entire disclosure for supplemental balance sheet
disclosures, including descriptions and amounts for assets, liabilities, and equity." } } }, "auth_ref": [ "r883" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [
"http://www.bioventus.com/role/ConsolidatedCondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental disclosure of noncash investing and financing
activities", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "bvs_SupplierOfSingleInjectionOAProductMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.bioventus.com/20240629", "localname": "SupplierOfSingleInjectionOAProductMember", "presentation": [
"http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supplier of Single Injection OA Product", "label": "Supplier Of
Single Injection OA Product [Member]", "documentation": "Supplier Of Single Injection OA Product" } } }, "auth_ref": [] }, "us-gaap_SupplyCommitmentArrangementMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplyCommitmentArrangementMember", "presentation": [
"http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supply Commitment Arrangement [Domain]", "label": "Supply
Commitment Arrangement [Domain]", "documentation": "This item is intended to be populated, by the entity, with Members identifying each supply commitment about which information
required or determined to be disclosed is being provided. If only one such commitment exists, this item may be used to capture such information; if multiple commitments exist, this item is the
dimensional default, which will aggregate such information, as appropriate." } } }, "auth_ref": [ "r105", "r175" ] }, "us-gaap_SupplyCommitmentAxis": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "SupplyCommitmentAxis", "presentation": [ "http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "lang": { "en-us": {
"role": { "terseLabel": "Supply Commitment [Axis]", "label": "Supply Commitment [Axis]", "documentation": "Information by arrangements in which the entity has committed resources to supply
goods or services to a customer." } } }, "auth_ref": [ "r105", "r175" ] }, "bvs_SupplyCommitmentRenewalTerm": { "xbrltype": "durationItemType", "nsuri":
"http://www.bioventus.com/20240629", "localname": "SupplyCommitmentRenewalTerm", "presentation": [ "http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Supply commitment, renewal term", "label": "Supply Commitment, Renewal Term", "documentation": "Supply Commitment, Renewal Term" } } },
"auth_ref": [] }, "bvs_SupplyCommitmentTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "SupplyCommitmentTerm", "presentation": [
"http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supply commitment, term", "label": "Supply Commitment, Term",
"documentation": "Supply Commitment, Term" } } }, "auth_ref": [] }, "bvs_SurgicalSolutionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioventus.com/20240629",
"localname": "SurgicalSolutionsMember", "presentation": [ "http://www.bioventus.com/role/RevenuerecognitionScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Surgical Solutions", "label": "Surgical Solutions [Member]", "documentation": "Surgical Solutions" } } }, "auth_ref": [] }, "bvs_TaxReceivableAgreementPercent": { "xbrltype":
"percentItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "TaxReceivableAgreementPercent", "presentation": [ "http://www.bioventus.com/role/IncometaxesDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Tax receivable agreement, percent", "label": "Tax Receivable Agreement, Percent", "documentation": "Tax Receivable Agreement, Percent" } } },
"auth_ref": [] }, "us-gaap_TaxesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxesPayableCurrent", "crdr": "credit", "calculation": {
"http://www.bioventus.com/role/BalancesheetinformationScheduleofAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 6.0 } },
"presentation": [ "http://www.bioventus.com/role/BalancesheetinformationScheduleofAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income and other taxes", "label":
"Taxes Payable, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and
other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r98", "r99" ] },
"bvs_TermLoanFacilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "TermLoanFacilitiesMember", "presentation": [
"http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term Loan Facilities", "label": "Term Loan Facilities [Member]",
"documentation": "Term Loan Facilities" } } }, "auth_ref": [] }, "bvs_TermLoanFacilityJanuary2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.bioventus.com/20240629",
"localname": "TermLoanFacilityJanuary2024Member", "presentation": [ "http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Term Loan Facility, January 2024", "label": "Term Loan Facility, January 2024 [Member]", "documentation": "Term Loan Facility, January 2024" } } }, "auth_ref": [] },
"bvs_TermLoanFacilityJuly2022Member": { "xbrltype": "domainItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "TermLoanFacilityJuly2022Member", "presentation": [
"http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term Loan Facility, July 2022", "label": "Term Loan Facility, July 2022
[Member]", "documentation": "Term Loan Facility, July 2022" } } }, "auth_ref": [] }, "bvs_TermLoanFacilityMarch2023Member": { "xbrltype": "domainItemType", "nsuri":
"http://www.bioventus.com/20240629", "localname": "TermLoanFacilityMarch2023Member", "presentation": [ "http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails" ], "lang": {
"en-us": { "role": { "terseLabel": "Term Loan Facility, March 2023", "label": "Term Loan Facility, March 2023 [Member]", "documentation": "Term Loan Facility, March 2023" } } }, "auth_ref": [] }
}, "bvs_TermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "TermLoanMember", "presentation": [
"http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails", "http://www.bioventus.com/role/FinancialinstrumentsScheduleOfLongTermDebtInstrumentsDetails" ], "lang": { "en-us":
{ "role": { "terseLabel": "Term Loan", "label": "Term Loan [Member]", "documentation": "Term Loan" } } }, "auth_ref": [] }, "bvs_ThreeInjectionOAProductMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "ThreeInjectionOAProductMember", "presentation": [
"http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Three Injection OA Product", "label": "Three Injection OA Product
[Member]", "documentation": "Three Injection OA Product" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024",
```

```
"localname": "TradingSymbol", "presentation": [ "http://www.bioventus.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "US", "presentation": [ "http://www.bioventus.com/role/RevenuefromContractwithCustomerNarrativeDetails", "http://www.bioventus.com/role/RevenuerecognitionScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S.", "label": "UNITED STATES" } } }, "auth_ref": [] }, "bvs_USSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "USSegmentMember", "presentation": [ "http://www.bioventus.com/role/SegmentsNarrativeDetails", "http://www.bioventus.com/role/SegmentsScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S.", "label": "U.S. Segment [Member]", "documentation": "U.S. Segment" } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": [ "http://www.bioventus.com/role/OrganizationPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Use of estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r38", "r39", "r40", "r186", "r187", "r188", "r189" ] }, "us-gaap_ValuationTechniqueAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationTechniqueAxis", "presentation": [ "http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Valuation Approach and Technique [Axis]", "label": "Valuation Approach and Technique [Axis]", "documentation": "Information by valuation approach and technique." } } }, "auth_ref": [ "r524", "r525", "r833", "r084" ] }, "us-gaap_ValuationTechniqueDiscountedCashFlowMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationTechniqueDiscountedCashFlowMember", "presentation": [ "http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Valuation Technique, Discounted Cash Flow", "label": "Valuation Technique, Discounted Cash Flow [Member]", "documentation": "Valuation technique calculating present value of future cash flows." } } }, "auth_ref": [ "r833", "r982", "r983", "r084" ] }, "us-gaap_ValuationTechniqueDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationTechniqueDomain", "presentation": [ "http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Valuation Approach and Technique [Domain]", "label": "Valuation Approach and Technique [Domain]", "documentation": "Valuation approach and technique." } } }, "auth_ref": [ "r524", "r525", "r833", "r984" ] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableRateAxis", "presentation": [ "http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Axis]", "label": "Variable Rate [Axis]", "documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableRateDomain", "presentation": [ "http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Domain]", "label": "Variable Rate [Domain]", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss", "http://www.bioventus.com/role/EarningspershareScheduleofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in shares)", "verboseLabel": "Weighted average shares of Class A common stock outstanding - diluted (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r254", "r260" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss", "http://www.bioventus.com/role/EarningspershareScheduleofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basic (in shares)", "verboseLabel": "Weighted average shares of Class A common stock outstanding - basic (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r253", "r260" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract", "presentation": [ "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss", "http://www.bioventus.com/role/EarningspershareScheduleofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted-average shares of Class A common stock outstanding", "terseLabel": "Denominator:", "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]" } } }, "auth_ref": [] }, "bvs_WeightedAverageRemainingLeaseTermAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "WeightedAverageRemainingLeaseTermAbstract", "presentation": [ "http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofAssetsandLiabilitiesLesseeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average remaining lease term (years) for leases", "label": "Weighted Average Remaining Lease Term [Abstract]", "documentation": "Weighted Average Remaining Lease Term" } } }, "auth_ref": [] }, "bvs_WoundBusinessMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioventus.com/20240629", "localname": "WoundBusinessMember", "presentation": [ "http://www.bioventus.com/role/AcquisitionsanddivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Wound Business", "label": "Wound Business [Member]", "documentation": "Wound Business" } } }, "auth_ref": [] } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-10" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-1B" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-1B" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1D", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-1D" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "60", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481408/470-60-50-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "44", "SubTopic": "20", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-44" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-6" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-7" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "S99", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480781/205-20-S99-3" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "272", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-16" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-21" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481303/470-50-
```

40-4" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "25", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479405/805-10-25-23" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479668/805-30-25-6" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-18" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1B" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205-20/tableOfContent" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-11" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-1B" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3A" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3B" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-4" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3A" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4A" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4B" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5A" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5D" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(3))", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483613/220-20-50-1" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "250", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/250/tableOfContent" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/360/tableOfContent" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482309/360-10-15-4" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-9" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 4.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-5" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "710", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/710/tableOfContent" }, "r159": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "712", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/712/tableOfContent" }, "r160": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "715", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/715/tableOfContent" }, "r161": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r162": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r163": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r164": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r165": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38" }, "r166": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479613/805-30-35-1" }, "r167": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r168": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r169": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 5.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479836/810-10-S99-5" }, "r170": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r171": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r172": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r173": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r174": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r175": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r176": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r177": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r178": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r179": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r180": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r181": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r182": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r183": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r184": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r210": { "role":

```
{"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/280/tableOfContent" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards
```

Codification", "Section": "50", "Paragraph": "26B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/420/tableOfContent" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB",

"URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477349/740-270-45-3" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1B" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)",

"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-2" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932",

"SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r671":

{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-6" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r745": { "role":

```
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r765": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3" }, "r766": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r767": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r768": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2" }, "r769": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r770": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r771": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r772": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r773": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r774": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r775": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r776": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r777": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r778": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r779": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r780": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r781": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r782": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r783": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r784": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r785": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r786": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r787": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16" }, "r788": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21" }, "r789": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r790": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r791": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r792": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r793": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r794": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r795": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r796": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r797": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r798": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r799": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r800": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r801": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r802": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r803": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r804": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r805": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27" }, "r806": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r807": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r808": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r809": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r810": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r811": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r812": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "01", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r813": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "01", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r814": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "01", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r815": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "01", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r816": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "01", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r817": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "01", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r818": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "01", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r819": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r820": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" },
```

```
"r821": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r822": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r823": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r824": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r825": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r826": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r827": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r828": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r829": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r830": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r831": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r832": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r833": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r834": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r835": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r836": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r837": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r838": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r839": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r840": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r841": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r842": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r843": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r844": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r845": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r846": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r847": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r848": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r849": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r850": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r851": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r852": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r853": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r854": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r855": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r856": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r857": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478705/946-210-50-1" }, "r858": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r859": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r860": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r861": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r862": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r863": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r864": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r865": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "930", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r866": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r867": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r868": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r869": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r870": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r871": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r872": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r873": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r874": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r875": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r876": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section", "45", "Paragraph", "1", "Subparagraph", "(a)", "SubTopic", "20", "Topic", "842", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r877": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section", "45", "Paragraph", "15", "SubTopic", "10", "Topic", "230", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r878": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section", "45", "Paragraph", "4", "Subparagraph", "(a)", "SubTopic", "20", "Topic", "842", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147479041/842-20-45-4" }, "r879": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section", "50", "Paragraph", "18", "SubTopic", "10", "Topic", "275", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r880": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section", "50", "Paragraph", "1B", "SubTopic", "825", "Topic", "944", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r881": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section", "50", "Paragraph", "4", "Subparagraph", "(a)", "SubTopic", "20", "Topic", "842", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r882": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic", "205", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "50", "Paragraph", "1", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147483504/205-10-50-1" }, "r883": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic", "210", "Name", "Accounting Standards Codification", "Publisher", "FASB", "URI", "https://asc.fasb.org/210/tableOfContent" }, "r884": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic", "210", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "S99", "Paragraph", "1", "Subparagraph", "(SX 210.5-02(18))", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r885": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic", "210", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "S99", "Paragraph", "1", "Subparagraph", "(SX 210.5-02(6)(a)(1))", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r886": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic", "210", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "S99", "Paragraph", "1", "Subparagraph", "(SX 210.5-02(6))", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r887": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic", "210", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "S99", "Paragraph", "1", "Subparagraph", "(SX 210.5-02(9))", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r888": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic", "220", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "50", "Paragraph", "4", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r889": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic", "220", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "50", "Paragraph", "5", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r890": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic", "220", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "50", "Paragraph", "6", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r891": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic", "220", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "S99", "Paragraph", "2", "Subparagraph", "(SX 210.5-03(2))", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r892": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic", "220", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "S99", "Paragraph", "2", "Subparagraph", "(SX 210.5-03)", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r893": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic", "230", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "45", "Paragraph", "14", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r894": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic", "230", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "45", "Paragraph", "17", "Subparagraph", "(f)", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r895": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic", "230", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "45", "Paragraph", "24", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r896": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic", "230", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "45", "Paragraph", "28", "Subparagraph", "(a)", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r897": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic", "230", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "45", "Paragraph", "28", "Subparagraph", "(b)", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r898": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic", "235", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "S99", "Paragraph", "1", "Subparagraph", "(SX 210.4-08(d))", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r899": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic", "235", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "S99", "Paragraph", "1", "Subparagraph", "(SX 210.4-08(f))", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r900": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic", "235", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "S99", "Paragraph", "1", "Subparagraph", "(SX 210.4-08(g)(1)(ii))", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r901": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic", "235", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "S99", "Paragraph", "3", "Subparagraph", "(SX 210.12-04(a))", "Publisher", "FASB", "URI",
```

```
"https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r902": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r903": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r904": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r905": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r906": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r907": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r908": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r909": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r910": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r911": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r912": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r913": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r914": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r915": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r916": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r917": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r918": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r919": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r920": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r921": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r922": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r923": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r924": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r925": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r926": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r927": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r928": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r929": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r930": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r931": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r932": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r933": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r934": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r935": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r936": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r937": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r938": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482047/420-10-45-3" }, "r939": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r940": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r941": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r942": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r943": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r944": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r945": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r946": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r947": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r948": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r949": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r950": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r951": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r952": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r953": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r954": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r955": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r956": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r957": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r958": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r959": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r960": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r961": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r962": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r963": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r964": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r965": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r966": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r967": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r968": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r969": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r970": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r971": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r972": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r973": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r974": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r975": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r976": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r977": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting
```

Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r978": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480682/815-20-25-6A" }, "r979": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r980": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r981": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r982": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r983": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r984": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r985": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r986": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-2B" }, "r987": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1" }, "r988": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1" }, "r989": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A" }, "r990": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r991": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3" }, "r992": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r993": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r994": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r995": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r996": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r997": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r998": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r999": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1000": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1001": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1002": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1003": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r1004": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r1005": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1006": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1007": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r1008": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r1009": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1010": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1011": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r1012": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r1013": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r1014": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1015": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1016": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1017": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1018": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1019": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1020": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1021": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1022": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1023": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1024": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1025": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1026": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1027": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1028": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1029": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1030": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1031": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1032": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1033": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1034": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1035": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1036": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1037": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r1038": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1039": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1040": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1041": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1042": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r1043": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r1044": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1045": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1046": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" } } } ZIP 84 0001628280-24-034979-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-24-034979-xbrl.zip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`\A=#^XU8S:'A(,)LZ^2&L*GHC3[!XO/'!32D>.&M" .;7L,:2<.Y M56KT MFP TP,C^+!TF5!? PM7^",8/8.N=%'II;U@N]PNV8*.4W;X!H -[X)^O-M=A^F ^HI[4;_/67RE^^^R%^. 4[YH:7KG4+XC+!=\#?[PSED0. M&L8;.O$)C >'K^\"M^;/^'?LQ%CNZ!R=%ACQP?E]6$3X8$9.4DP0;EAIKQ

M{!&% @F4UY8)*^[D1V..)@Z;'?C?RD9Z+>]SU%EB@Y.CKYN](7AEXD4_M47M_$;EV2$D6C RXV$B_'\/4(Y_TXT_QQ<\?EZ^EG_$9:\^+8 RK#TMLX,7O

*M3S=YGP4B^(2#F#T3U+)MD<5,*9F-T//W?.W:[_'+& ^)Z8T##AL=F)$#|++3R>P)^YGN:0$$3A?[WA_YH^L>QP-MXSA7:\KUAER/"_1B/21.('2_M[PFUU.DG0 l\'MK$%ZA"*

*(!N|LNN[_UZVX*L_GHU@^>D3:MS23^"M^R:.V1 MFY(,_Y_^,GYM-DQKX=9.$UVHY2OIY_0E'Y?FO9D,RJ')D,PF9EAT8*7O4T<MV[3#;P2%1++#L,9H56#O.#-3,"ET[1A*

\#)|"S_SS\LT&K9Q>/S9Z28#2,+=E\>C0NPN^U&@QS&E2]+!KVOZD)OC4$Q5ZD[?E0Q m;[-&!K4IP?24+&10#U5QSB&#'!T&R9!5Z>9=(ABX#9%@6[T6<%O%WG:V9J>G:`MN`C,>J=A:*

YKJ$NDMRQQ@AJ5=..6#>^0GXAJ51O 3\?T/2__R50K[SC_&Y<(1 M$'?BN? QV$1TRHT=-^K,E.+6G;(!U]WL"%:U2&,'58??&UU8*F^M"P:VS><*

*M[X9MW;G7QL0.#:F$&/)#1LEUBWAN\" 8/:$/[@]^$##$[[F MN# XDKVRJ2GL+Xl/SY-E(,RLL+^&9\078H%9[*__JI.++"'I[DQEO%GC% M_JJ_+DL1%KA9]X7]*3HYAPF%*^S'$,X]7%*

<;J^L>C:@H7%<_>L>E&#'1AZ(M0>QG&E2]+#,X=6Z!U?]C?NUI[K&+$W?WXHS!4CL8;B5?8C'V2M#(7)ZK[/3ZIP M+]N/P^),,Z@6NDN^ ML]]F=[8:9FEUCP8<<>7>V(B[5/6A0R7Y>1;QB?]5?

EZ4("]RL^\+^%)V<97^V M6Y(_]{$?0SCW<%UIK*Y[_**B<%U1]*][4((=&WD@!M4]?>'9X;K2'%_WH$K_M<<_888H21I:N^TK_Y#W9TDZ M]D/%YRY)UL>]VL?;:C$DRV/_G6/#S#]R9:'

M(/97]4QYLN41ONYK[)KCONY+[%-T]U:/&U50B,5=]Y5)96=GJV!6W:,!QS\[M6P67ZI[P4-5IRPIXU:E[%(0=?YT%;K(?Z#@_)V?!GU7$\V<([,4ZK[2/T5/*

M=C7_M(=&)VZOO8]TO11<,3N@<7CG^8H@HNU3UH4%7Z216)&0_57Y>E" O< M9&YAZVCW!OY(7P[FEXXEYAPT?K_[0>OU0?WB$FO=)E=L_.9P<0+ #.<7WXLF MU$V#![YIQ8]TE.8$;*

<4ZV&O'K88(]6^&6X%?B6#//AP>0VO""N;5YX(<7WXP_M/AZ"D)O3/@#O/T]P=W%X$SL_P:l!G!=N3(P4<[^/JBEW:,5 SVY+UK.Q]P M%%?$ 4=CPU!90ER:IA>!WGXD)K%?42>?Y%9)E[G0!

*<'\K(M&<,K(SQPE44P\HL+7\XE9X.ZJ8#:=]]SV82#^C]+#FA"':.'R84+QM:^,I_]$ M%44$BX'9#7#SDS<,?QA^?=C ,/;2*23:4F NJ,QN7RLR&&S(&39383;@+I{&A@*

*MO[AXZYW["OJZ_K0N4]$&X"]#SO*E YF8TR9V)'>_)48 1EYCG4WGOC>*.59 M:E.46&+/AFF"-80_K3O1MK(P:,.Q@08YT&9<5_+FNS@-;KOX"NB@LERD*OWNOG F8Y\T#.+\38]_Q"-Q8M.]*

*MLB?U$0IFPPTUX469LV&(MVG&E1%F1)6;C$OM9Y&%Q'HFYLCU'.]E6B_O2I;8C0G4B"&E2LC9+\CVIB-M'$,GHVGOFR$L2#GXI_#'\,KZ=-N]C$I&O_T(M?**!%%HPQ@ M6A6E'*

/:B40^KOD%H]0KLU(2AUE-19O+,32Y((^@>M'"'&;CKUP0CRV(%=2W MD65FP\TIW2 _?T=V8,]Q1\^X G7L7XGA? YM@QI~!6DMEV T96;#M=]=4"E(@ M1_18J6(POH9RB'O?6(MW5266H+/!;Y*

MI;ETR^$WLQ'6LFA=-L#04 3?;/@G M]';646&(TF^,R5EQA-D8XE?/?0&NC&_((%S6Q_ P[5?/V&7=V=D9 MEYD-DE5,Y#*34V1FPT;7X);.X1?#Q"CU=+5&|*OGO()Q6+ZI-M!6F$V.8XW]

M96)=838R\Q[5OX)?_S",[RC+/lNLP&9EA8D)'IF%%P_)6[F'O)4ZY?"6V:@'M6[RM0(,+Y3.[$1>F^)Q=AK.O/.%9=UAP*T!+*,/G67+UY:,:D+|C?]UQ|&0%7 MTE:MPFS(AP/ND(X'8$@JS=UC-

YJT@\0INGZ+G"CG&SDN+'M84NT656+SYD&E/ M:.768DJ,N0A294WEX9O8R'K1R#FQI<|O!+?Q1,F7VS7<$UPE?#6)V_H'P4. MF?;K5VMA@UF8UG;675E!/;3:TU0/OX=

*S2)M9ZD>U.RIBBNW%L,&LP'''\U,/ M%4% 939:R40<;Y76A98**H]1YEV:&&YD^+@ZT4Y W@^TX:#R\.A9PX]%@SVEXO9KL44&P_/GC&H6,BW5ID-[!:$P%)6+9GV4MZ] MA=F8)R-\R>*

*<&R*7QA=EX(?8|=3M^C0KD55F0Y<<30=$'TZ]! 4AE/>A7GN%G M-C+*H7(A7[9 M<2CA9S:PR@C=5VSRTD&|!VWRT[W%A)'9*.M3_C(OR/XT2TV] @H2W?<&)^ MN:]I.TU5R]RIY[<6*

*P312([KF:,\>$ #BR3+_A-10J4AD-OQ9%[U0]E%@-LJ!:5]:#_;Y:R\H):J M-IF."7)1K1H:S(4IL8[NH^&^)(&>_/C-=NUO.*T2+PT?V&2#02B&R'L1.O8.6 M=&L =>:!X(-IS6K.P-@<&85]+C25*

*KUE"3$NC:"T1?"^U$;6!AA-I3+ M!>$.!&$OA6N\95"X#(G8B4?)2]B\|"(EOW/B\>NB:*GHD$[GO(.Y.=WJZYOX.MF+4$;:DBP[{#:,SQNV.XRUU&+K%(*WY=6HY6VJZ&=M5Y&#Z%GOGGLHMRI[8W'*

MGAOWJ}^-/P\!LZ'(S4]5'$N*S/?<61#"'<7OXP?(LS.@,CF0U$,I'>2]=."?F?@ M,5V]#V:#D2QPI|(+QUP,L+B%J^F|#%WCMFH03Z*7]6'X@=?LU_GNOWC*

*MZ]=KKLC+5.3,+,)6D]9\"$>,6W95!N\P=Q1YS2^<*H9UKJ5Q> =H>5 MLV=R=Q113BG 4I,\8*"|IQ57]PTT&++#(\ MG3765L[42A_4IH!3S:CN[VS70BBUA??&*]|*

[8TG44CKO#P.;PW?!6X% MWXG_#)\ 7U\$H2GV>]3D9@+-)T+ MPZM0RE$DY]):Y\+P;GPSYH)@Y\+P:F*%(FY_A1&%[IF8=*3#=SP:(3YW-5 M%!NY*.F)\DJ0\U<._S$^5R1?

9:9"Y8=E<^5'<6OPD;+S(72SH#7%=EI^3QC M9Y7+=16V6C[/L%GETPE;A8K.G-1J?H7<%=D9B,_Q^Y2 MCMS["HKKA;JY:R.@& .;UI,(:>8Y% /F]A[=7W:;.$.9B1&'=0[R^P_RZ5)!Y.!A6O:9,Z? VF

*MRR7X2S?(@?#+*Y!V!O*FH&7]5>6HP7$,4AWN?#%4S2!'Q0+ 8?ADNR\.N7/_M(^.GOV9JI8!@;MWE],04P&_]IUYA0)U*)%.S M!^^.,1G9II&7$~.G?WIO>]^ 8'#$%Q$IGA 5G M_SNL2"W,O>?^2|)'FU0F0P#L*02.6&R%/#_^,/SKZ,@],;$?SG>PE'[UX)*B M>V3SZH:N"0/SZ4[.HQW\>36](IXY&AO^2AU$+'L!'MG .L,MA.G$UVX^S<''RF3@@Z.2'516&3Y0F0SS;-]1^&[8[K-*

*/#+!2W66 .;N!*5]6. MF(P.G0_;*.)6>:"4.?%]HJ4O,9D:.M\V%[1.DAC,HJVG>UXPL.#A^N5/(\(M<.DF)\#\BBR\QF3<[MR87Y6=9S)2>&[.K\K:.OF2/#?.F5V7Sf8Q]%F.%07P] M1?*

*X+ON_)PP.FGGNB5?4T!N.+1)Y]PJD$&\L^)5.:>R3#+67&^(CO29C*2 M5[F_787A;3.97:N<%57HPW;.(EY'#70>,_.C*E&L6+#69/E?D2?2O3MRC="4.@(H^@PV1'\#PA4)$[T&$R0'B>$*C*

M%V R1LB(?U.5<68R;L<.3RI1E(H?L7!\\?>GY+LR M5.8UZ$+/L2UZ%/.7KW2F> !Z K7W)=T'"9B[OE 1MV>M2#L*BZ'2Q49$[T64N(,>OP8IGT64N4L>OP8J3 MT64NA,>OP8R_P61L;O=SOL%\?

=MP'@E,Q[0=8!.]ZT3M/I.Q/D9Y5)7]92[V MQS"/JK#S(7C&.915?;(V0C9G6MZ8S+W6 S'<$WR-"(DO'2M2\NR8Q_EQ@Y, MQPLBGP174_@P\0+#^<7WHDD CW B"QB(]\"\;3U?B>$4 M]732P2^-*

*X]HQ@@"H8=+7+]-H\|CBG\.WPZLIEAH\4>PO&XQCC#+K>96.%*H MU9S.,#2L3AS9LWGQ1_OM I29&_DF">*/V(8=#R6_=K_#/01MFZ*G4LS3)Z MLC30B [MZ42256M@2!9]P/_^>P-*

7\]\$X=0!AHUMMSDB]LLH0;#:D_#3#]L M1O>R)/V_#7!?_W.P.=S^YX'_$7X=_OT_9.U1.."FX=@O{@66("5^8_N/,_PL MO6YZCN=?_$6B__=I"(1I#HVO(4PO_O8.D B8>_)#>/3&AOLW.3##S1O*

*MPE@<8O*0B_2/3Q9@#8&FP$_Z2/JCX3V/#?P&Z#KPP],872-97 K;$)QDHG3. M\>4YQ5M23/4O>!M;Z9N3RRVX["]^Y[>ZDF;+TDMF7[_D3/(3R\FDU8G88/^.M!F,"_VEYH396)IL.'^A4+"\"8B*

3/DT,"ZWGA20 86;V^$I^?+Y]NG"K&9,;1/M]>_/[X]W]T^92W-\+M M_US_>GG_RZUP_?#MV]W3T]W#?853D#)-X9]&, +8A)XK"C>MZY:@2&VMQ]"P M-ZN%_UWYOZT#7LI;YAR&NY}{:'F$)B7!

[)$.V!W!!< VVW M1>R,+&\^.T+IA@>D&M2M#N*$O2\V_4]LS?T]%"KU7;\ZM#G\SXS_ P_A0> 7 M_)2+T,>U6FU9!:L5FY+.5BLV$6L7U%.WO>72UM]LNZ#UVBUE\].V6T%0><.*

MIH9.F.RAJ5L$+AH`_7B,/-SDZTF,/(:=X_SV"Q1SQ>DCF7A^V!'+GC(\VO0-B MW*+H?U$K&,H1S_H![U_MJG4]:E4!HF[4'&&+45T"%_Y"@=_.C*E&LO6=#K9

*[PH8^(\\!&@5_$S!W*MQ^X/T(>Q*__T9K.730G?.G+>\VEUM3_*EM7TF-MQA3+A_B=^-=1Q"MCA:+O,2KV.YV@2'CF6Q.U#1W<;QNLYP)QF@*1L=!208'0 M:1$$B9F3 ^=4+018Z&?$6O1;^-[#_O8!;.G@WN\K$9@BH_;$7!?O09P@C'9K-MU7)@)&_^C-P3NSU6JB">TR(B71%.\! 3(.(;"H[GOC1#XH^_P.>_^%UTC_<&_MB+BO:_")=%UL%T"!9.<)Y_C)NSVA\O4CBU$^0f[BM*G*M9%[L:*TX*]W6/_MIXK+@MF[R8VR5EIR(_>#\Y_%6:!!6C3.A':=PRD)0IU&7Q-UF955U#EYP8M9!.5KCIZ%,[)%KPY>@XL%:AZHZ*@B_M=QO]MM@K7G.4^[GL06N+OBT%6N\fM_J}.K" MU9Y56=0Z9Y&AS3%7/$)<&',*[KUUVZ+6*RO-AZ$;I/5+S_RZM/,F"@X)@IC^_M3N+/(W&N\N83_NWG/-/24&M^0T3>P67TUR!)#_78DRN (=>11M2>]PLLL[M&9Z5!+%!U0*L#.*#N^45!5GP1?+5=%!4UFHZ\.AOA65!WL-1!LV*25!%/!7AC M*;8BO2SKU?E&*,]l"]G89LK\K[B;,.6DN.>+-.,I#04R4E+Q#!S>>>%>M-Ml)-HY[]SD7TW+;=*

*{!!K]C]2*LEQ6.:,/]M]%*R\D@BS_5*1]S6[^Q-*05QN^ M!?:%:SL_T(_(JL(79C7I6M=+\YJ#D4Y9O+Q"_$!4&$DUL?2$JB0?>]Y%2OW.;(! N88[CL><6TNR\'3B\lJ_(K45[^ZEU63K(M<=#3I&&H]S^:"+;DQ-SJUQ 2L]45 D1:,K MLF7=5948Q@-;_/>&F&0\(\[297ID-4G("DU#3GY)[W5=;0'{(P"(%IHs!S MCP^I_M@N4=6A-+@<@*7545>ET14U=3TG= MX4K$'5WF:]\]O*S*+8Y_F^S"_"<$9OU*G.D.G^GLLP66M<-ZC'0!LM1F;XB% M:EV4>48V^]D28G@Z!7'AHY:BA%LGL*5Y\7)6QV)#EP[CW^ZXVE(,.IWV< MU4:.P1?UY]OY5QMY6%UX>+#<*+,;$)E=422Z[=#$W\^l,>^Q?L@]M)>;5O+ M/[[<8K4GZ?*O!_((K0CI,"3;%KMZ1^QN*.Z^QQ=[+AF$[;YY 6_\+/+'EF5M M+X^K#=XX,P5O>')AF>!0BH-#9P@<)[4UOZ5\/8P4*6PXX#?:.5M-V!=.#/%A^M:U:OGY'T.UTSKV.Z9DW@:0=0P]4$GN=PO7E>.2"W&'F.!\0.>]*5/7\BW^SK*C&;BDZIQTG*7.^6P$KB976W-MK#Z=Z:Q2@P^ENK5C]NIVN^44& <0A5]U<=6\7EV.]fDZ)50:95MU]U:V#$NE%PH2Q7*3E5V4.=B96=1"X3+W.G+7*Z"9W+6BF<5.MF<0>BF9'E*42Z@ARR60%HFQ.1'>#\0C0AH;2R_^T?.3$@3>=2MFQ_^TG*+LZ MXU*YB[M%W40^2AL,S+/BO048-+T4Y-U9T)5&7Q.U7D_LZ2PVGS@W<&OOR.J._MKJA;@$';/BS@8EVE8G%F!EE^9I7HLD*&'JA4/E7/'TY?CG_65>:.UG5[/TP_M-R\]X> ^G:@(8+>)H1UB3[_< MF[]=1E]1Q5YQ^7.^6M.WS6SNJ5#Y]NHX_ME-./LG+TU!P]:[&%#\Z%% M669)YO%PDA<)O;KE;!;^)0AN-*

*X)BW>VZY(LR$63E]>1C[G/G#ZV"XUNIN_;F!>*O/OR=FU2'TT@]:HT\K]C*#@^)6GGWXM4.Y*A@S0/#4 M%+XU2Y+TY3%\MOG#Z$=[!F*F]!2/AP$X MUY'O$!>><4CE:RTX37.G^!Z$#\-GXVV39]L&SU;CV!EU@!!76SSYS#G M9(MK@IHCC3V;@RU\E"*UUGEZRUY=0W^:+7"(HO=*.AL83NU"'! M])87#1P2U^\!Z[YT2ON(?>EZ>]/?:8LRMA1M%RX?6R)S]!3[E>&./:'=MU)Z M,=K4518W.5A';K>U:MYZ*)3U%)9[O@{+=H'2.9U!4233]YP06VXTLZIM!@'?2SHJTL/E"[X_7K_=$]5-R'IRC M2SM-?OA(B0/CQ/_AAJ_$X.I&\). 7*1_?++1.2^E%RC]#[<HVD.9IRE/_HT-QP7VW MGS!8>24=4GSYTP_;"D>(A984XR')ODC>G%QNP:6/&[[76ZJF;;PDM>3-/IGR M*,"KTB[E2>V6K'=R/6G[!ZK.9[=(3)U63]M\l;HQR7)+ZZ[,#4IOR3)KA&*1 M>7!+Z73??=+&1#%-G_E(^R:$6?*

9KV89XQ0QW-Q^M&_F$"_@OE$@W+H6L83?M(F<,&S"9YH>I,SM&!TFMV8Y\N7>3 #I9B&42.,M'08(:AY'AfRH%4N9Z<\A_8 MR_0GP:.G/.?2+M%',F1+FV0.5 MdBR&'?|&R4)H\'&).=VL.ARXMN.L+!M/|@T?EF>]OR,3.]NXU^1O';4E2\.M;4A+*13+KC27^[OWT2C=48+T<)E<>.1,K8/(5"$YTO5WM),U=T[W'$= MKK]YZCZ"ZE[K;7PDU2U+Y1^E85-U[T92[7P1%UK3 (4P='9+715R5-.MU-I%*F1OR60,HFT,A39DUXSS1 !&"_!7BC7)AXL";S]V-1]I:] M!'W'?@*5.Z0ZL6$K'Z6-K)\IQ9@T/12D'=G0>Z 7/4Z8ELO7'^$=V#@9;TY M?SC^:T1?*

CO_B{N):48Y,9HLV95NP6NL.7[?1EU46C1(':#1=]SA_.\Z?L^)/ M'[.8I1#Y/C919\DFGD7<ST)!3PL4R3%O8YH9Z,5-ZT0V_/EWC_M-2]IV-'74QIR9QAO]#"&GK53 M<;6C1/V9+5+4ECAZ3@1T65.C"X_ [%KLJ ZCF+(S(SKD>&^$,%/\'7>FY}&1#[G/G#ZV"XUNIM\) 4<,&F[;P@'$[XH+. ^O7E)=]S(?NIZ^[K4ZCWRD4=^&@ M8O)T63--F/;CNNA'=-7UPB.\?*

^40H'KVX=<.9:A@S+1# ,U7X3OU)TI>'] GF M#Z)V'OCG,FPVSK+YX/KW6O[(\GKCFESE'\-MRDO76G"5YE[S/0D?AL &VR975LH4KZ'&4<2W ^9-,"^SH7G4\+=!K]#N% M;]MRD+$(LAV51XZ&,57"FN:%VPWP]:!NG/^%CG3$IMSQO.Z4('REA<-'!+7-MR3WK_F^:>L3^,ZL6W7;IDB:V19*<,615B{IX;O<U^U8D+T:,)LLBK)K?J M2&%VOOV4<4GY3T"]$\9B;7-R@:#C=,-0V-D&5Q':0\)%?+NYJ7=SDT$5YPO)ZW\;M7:.YS)^:S.<2-M>9U)AUUO]-N2*&M]>=*>]7O8\:6]U^@KJBJJ6LD=H(\N[C3QX2,E M#HP3_S,;:OQ.&*9C3)RD?[QR;*#B6 ,+VR7LI;^Z-*

/8\%]L-QT_XF#EE71(M\>5/4VPK'"$86E(.B"3S(GES^R6"6_5]V)5ZQPIV=OC)?A_^P5VC0+AU+6(OT4N MBPP-A^'IK#@,.@ MB)*IQ^1G92$$K O1M%TA]0QO?@2AAOO2-.*

OY!@A^[>'O@!2YGISP$FO[S M$#Y@+]:UK8G3IY&R2]+.:K1-^PS%)^YJZ[C-SP/_8W^0)O$(NT1?9 MA0B+4<>.4;0&GM<(L[YG2FZ(289#T"QI.4=+#K/3_^=.1,.TW"4PJBTNF*

*MFEKR[E6EN=SGO8-T1GM$[;7NF$?*Z=+D\@_XL+FERU5W54M^U-U*X<[I,.5 M-U?=1U#=.TI>'$YUJ^4?I6%3=7.1XR*W)\(I:DU5DU&C:7C@11,5]GHU=BZ4*

M7"A/72BK[E&@M1OJ,H_+')>YDY"Y?/7&UVQ,W5X1.LT^]HBB^T-4,E]#X]P MR:P#O;&09LV:<.HHW28/$",(9"">,!Q)FMA56*G3>L{@V.0H9.EF ML0X,VN5H 1=K>K4M@5YED.6_O-&R#!3!) {3E^.?=96Y5C&D))4I_ 2=O7 @ ME8.&"S7G#^_QDWKlR04\ A/D=S(.]*= ME>]CG+]ZT?8YUX23E^.?\X?SA_.G5OS)ESBUMAF\)7'JN\.(1!{^.:=V6VK MC:ZBB^W_^C?$[MPG#A_&X+.6T[%\^&B-?D!LJOP]\X>>M5A%^>!I_JJ+DH; MT]/CIZSR!JY'AGN"Y8@$=REM" A+38A&(fCF;2Y[+GEBC 39N7TY6'L<^8/-MIR_'/^/;.MR&P:OP<7FA-L[U_2)$9 ;$,;:OQ.&*9C3)RD?[QR;*#B6 ,+VR7LI;^Z-*

MDCJ-/B"'D;T=#B0NZ)P_G#^L+%)WAC@.HI[FU5R]D4K1Q.+9GU+=D8)$%], MBPSM-V(U_T\;O.T!)F"8L3BGT4V1WR22A@ .#RU;KY6XP?Y1D!!"')G9/N+T MY1'R<^8/IR_'/^/NTJX3'I?*

6'U$0CHD;!L_>O$X\EHF_WZ 7L+7B^V M%KRCG04Q$?N+Y\, W.O(]KEX63JF;%+ [TK46G*Y$WU/PH?AL &VR;.5&GU=- MYKO==8 :5P5L\^.IPKPL)BT'C_G]]#F4.MZUN=02,L9.l$P\B>Q8)/]

*MG1V3M_/H;Y%+!*5'NXY]?0=C;=UH0+A+2\,"2N 'S6C>V4]A$:VW7;C7ZG M+C':U%46]A$Y4C$=:.6P>%LO[" M>.,S=.&Y0MAN4757-2S4HW<-U2N4&A1N4VLCB)H.2I8C\00R*7GX/UCH:%"*

*[. M7)A+$^8LYG@RFNDB3V.B>PF./BSL6=F0BIDK44V\&L>!?S'===ZGT[M5'*)YA)|WA*==7NM&E/>E1M|M2V)4F^.]Y1Z7>2[S7.;S. ^W]6G(.$Y*NT#*(.M5<&+UWNBM*'@U2SM(??*

*1H;_HOMIN`&*R\D@XIOOSIAVV%(A1^ZXKQ MD.1>)&]..+K?@TL<-W^LM5=,V7I):\N:?;'D4X%5IE_*D=DO6.[F>M/U7>$=S MVSV3]NG;,Y2W9ADN=:02,L9.l$P\B>Q8)/]*

*E_7=O3!/3))F/M&\ZF&6_M'C@GK+O1#@_9:\(WN&L4"+>N12SAMB9QN9+IMEAZLR*T2%26[9C5^[=%(:_M%E*9!{UR-.ESF^F4MF:/M]@%ZG)LS9L[!U)CF%]L?W\-("*18T7CTH)1XO.,]>*

[(Q\QUfNK,3X^/-RDB%)'%25YO<58N>'W2M// MSWO#ZXRVM#H[JJ(=+OFL4Y>!=E'H.RGL>4S]H$4/$EUIO93..9]TAD?7^_=

MLUQU$"EN/G]W"X_1S1+NE27@U*CK\F*]"@EGR<\U(G!4^)=1<$$4UL M\H9'>OS#C,\1T'RO &&"3!;BS"]AXL#K$]UG5=$V23WW'OB<5/B0]L6XB'T6.

M=G6+]T!AT/12D'<'M"8>'B[88.HI/7]C)E@@7M\+> BG6MJL"]MG$&6\UX'&R'#3-L33E^.?]95YHXVOWNK3.P 4]P)Y.#A0LWYP_G#^:"\J%_+_P2G/>]RL[U>Q(*>""UR!&R.[)]/VU44K-Y3M_CT?*

<(S70X?SC^_MF.4OQS_G# ^T ZQ.VIN?5W.4]4445>+=+GE^&$3/UG[M+1? 3Z?15SNBJI70.83#ARWXK$4KRDZ+ <+.:Y!$\.R0" ZY'AOA#! M=@5W^2]HN7.28#B.9](VZN>6.

*<),N3?EXo>$SYD_G+X< ZOQVVX)<1B\!A>. MTV!O7.,G1D!N2/S?+]XWOHH"&$407'OC@>U2H[O}5=*Q>`T_A=N7*<2%$0.7\X M?!CG3[F1CH.HY-YFE9QY2@>4_R A=.#1R2]*

*Y1D!K'"9G91N+TY7'R<^8/!^__S!Z[-ZF-)'O# M7T7!>?8\G@=U!PM7>Z.CVFU[CO=XW'!=GCG/^6M#0-%H1TBL)+K=^^G?S*S2 M#4F.0(" BMCUV T@567EO3)-*?F_Z\OX8>QW-*

*O,>7'H*U<@6.5)ZZ[.[-MEX\NF4Xj!.7D^\GR:?SZ'!0TYA=+&2?6:+$BZ.*;,Mj+D%#QGMFX'@SPXFBQ# M.037_/#AVPZ=F&+%ARUK3>1=^T725R;EFWT^DKZ2_^7YR//9X]*POV&2R@:.*

MM+U/3[3!3)LL6SZD^2'#:]WI|>S=_Q$A%_Y9T!2.E*B5O\E84/TQ_6EX8/TQ_6EX8)' MMM.ZI?=DH=#0<)G4 LT^G_VR*]?2 MC7-91.X'*Y;. ..R/&8K>Z'?;R0RYD MA.?C. ^.)[6(P|O1YMSE<4"BY<5Q:/-*

J>OH O# MO9&U3B^.50SB^E7N>\DES4VYN>DFVBGIO;UX!O.OU=%|.)AWE@%*D.I#*0RN PRN!(H_/R M\FY F G=.UTO95W*^C7+>J5BU$YNT%Z3)O9V=!.+H >J7A"<[SJ@5VH$J1&N M2R-*

*44@C;3/B]OAJHM&Z[F]IW9%I Z@*Y"XZE"[897W9]*=!MW1JF[9]=O=&-MGE@94+'&7XDX\ ^)_7S[_ @C6N[<\]LE]X+2Zj:?W0M8A=ZXEOL)K>'ZQ(;*

*MH*Z5&5.L,>*"6.XK@=]:Z7@COLWSXL:L@>,J3;SG*PO)#',L,SEC D*^(,E;(M)LK4=BUW;,.'@A!^0!U.T9'5*Q,I;K%]D-4D%% [SA>7$L9 M,TN9|) ^X>%0/|L#4>I/.Q!KJV]C#!OWA@&FZ.1F-*

*M8EIP?__88(G(;XT\Z_= M+*PG=C/RF?'GCC36%#;ZUG!?K 4 939.%,)(^@U7RE5)E.CT852CA@+ +T?"I9 M>PO:C?GX*5B3U9BU*#.23V MWR]DT/>V!PSK708*V.%V3HY/LZCfM,]%?*

*TR8B\!.Cf']4L;P4SYV'@004-6 M_6C_5'Z#3\T"Y2.L>:+\?>DR:MV-(97[=<#+<3*C^C_!XM0CP4.M2E83B\;^Y MFX.C <2U?3"!WA*>_0E^*57M@CV%KM8/>*

*{7+_MWUP+_#5AEXUJ%/P0+)02U|ZE]TW*M459XE4^O\UHF_;&M>Y MHLY5O%G\N@V_^FO^YWVC/>CW"G^EM?7^GY<]2M?;/7U8Z5'E/S<'G=H69:Q_*

M^8;.X+4U3&6SB9ZU(C60B@WWHD8K=MPT/FDTIU]*1%!+ M*ZFK;M:Z%92@'[6E?C#K?;^L&#HZ4$,B.'W,T07+'B[#>]L",3W8*[=4$G] M7=E98U>L'GRUP:]*

{JR0U.;/1Q"+=GBB5.!V6ZMT37CP&5H='6=H#51MV+D(M&D[*1?]1.L:YD^)OL)MSW^+RP(WBIX4LK4]^8*!*IXY+:[9U%XRZ.*

MYP;JXC>T;9^7@H2]C8$VLM09*4BU8,+I/Z0HO1#3.BDUW9KI'A]4!M2O 3_M.V.ENSM[:.&6AZW:?D?M&$,)CW'<,K1SK8W&&&&8FVG@?E+SS:*\[H1>2%:/[*

*MF/Z)$!WCGM_0ZHL(3E_04QJQ]7R[FXFX&2\]X,/KW74?F8H]_^^],'.1P_DTE2%OSM,H"?=!8A;66D:K5NCHP[Z$K'K AEJ M0U?901@*NT=T5>OOC5W2K&S.6>C=-*

^^9RZ9V^(NR\+UG.T^@. 3V.\%&V.M MTMAG$Y0,8+9,/'<=R8*=R^]SM|8ALW*>IV%]N3M%#&\"@=C@\|=*6%'05T>E5'8I>B 1 MJK$_&IIT41MH;K=-*

.I7O4IY=^OL.U)&>9^4COY]9[A/#RNNI9?O.PX[PHM;.M?I'PQ-R0^I'LB<@(7I?O6:-*+1CO?1_3^#Y.XCO?OS.A-!P_GL\NKY_F)9\ MY8MMG6P'C*!>)%<#<%*

*{W1_.6'FSS>&Z#!WM"GAL"SOEU@41*9[A*"G?*?!\< M89LN=["9\>.P76X.=MF#"*Z\CN5'TA5!,"W?MY3.J9RY9J[@.;>C:@5P.>=-8 MPBD9[K)?7#M#Z.U;4 ^T69"""D WU*

WO@\7X#CC(83W68K"%AX90G:&!WD.R1? M0E'P1/P5ET2#+K&/2;DHR3/N_Q?Z:6,&ALW28':D)O2MAT32XLE3,"%V 7 MM!?..5 ^7^UJC/OW5LEVDYH(/" S^.(T"P@KEXH@!4E.YN'17F\=

VWJKY9R4 MYYANZW;8WSOVE[YHY8/ W?49K.+?$/T[0H=.^?@V92SFMRE39SD.EWL4AE^% MD[%M5[!\.EXD,.F9%(E*#^L*ZL)IE&Y]@$AH6\6Z+P?A##BM+G _Z.5NSPPT M-),:',5[NJ-

*[2B2.@3'NX@)R1-A"@*T8=ZN(\03N>8]\ L#]H'Q_WYV(_)^CZE.50-VM-.MH.M#.U^R)V\E MF\9.!^H(K0^!L+]35\'T.(#SMZM-5[F?7439]7Q;MHW4J6I39*TL#@86?IC=*

M!D!CR(3/00L_!5A=]NA44]7Z^]_#/INV1U&GNP"^N5D)RI27HJ\A'_"KOU-MW%W\l/:G9I?W&8R8TIKIS87Y)XL+++L=,#) =1NUVB(/RIW>,EX2FP-G&R51QK&ZN"=6WC8CWSF4K=-

MSQVUWVM=_XUN;R4'Q07GB$[.*!_ _"E))TC>M3V=GT[+VUP%%"7UGE;&RG MA|G83A,\'DGG]1/KHVC$"O6'1;THYZKS]OD?QuTZ4**12XRH*&=[.]WJVK!DPB$IXY=VY0^4?F3KSF[;[=*

*M;MZS:.!I[7@'FX%9FH@1F_+K<]AK-P9;25@P*7;%XO*M)K/$SX[*#]#K6R&^; M}7M7;]T:JMYKP 6+=/-W3:Y&6,A+--?/+B>D=[*!&63](A20F7 M?]I->G\S7HEI+H?WMT8J.FS;X+*

WQS+#>_(MQD7"@,.3>_O .:LE45 -99I-6K< R%95KOW7;48<%$;.-QVFGCT:4<1K+ *< M IO8 S3MQ fX@"K\-U'KRIS:6K$/1\|!QAV)A.B3Y[\='8?G9#RWVRL7J. MRJM*

G%+G5"0S@9M7ZMAW)=T;)OOV-;%1=O'3\.FQ4[7X.[FIP\L=G11K>4^ M@D"7E)4]"&QM27XV3N?56UK1TI#"3BL ?ZKL"YW^XJ FO_N26/3P%P>'8DR

*M$QZJP]KF\S3H,N'\G/BM;$6=-3]7X7[M4/-3(&U|U_STC*9Y7]+);TK-SX|\ MMH15^-PECH*M=SOB@U;@TJEOA%-?68XZTH&_9'8\B0-?F0FQ>W:@=LRJ"_2E*

ML[Y_Y<\GV]7<<1V5/IOX5Z^X_A48|&SECOT$2SA3NN^=Z@4.Y,@X_,YA\OR MQG]>U\WT@=]/@LBXP U).TC4K9(V_5PU(3$@+Y _)E0Z:,UM_01O&3OB;K' MN7#&

1Z.]8H+9>7,=R]TY^,J/GOV"%B<3./58&^_M>.[3#^;/OV!=(&@.&AQ7)54WD*FZ"^:D"N9G"T[:(FX;MFX]OQ7VWQ!NN@;' MGA=3[*U:K\(?VZ!:.O[.%*$UYF.ZK6ONR|_G<.*G./S2Q6E!*

*<8LL73Q^Z6*AG%3T M008@1(;]#63MHN3'K97W ?EQR%7ZH":D 6,>_#-Q^F4C4.L=6,_QS1F5O&M MD"EG,7(6. D-@G2E\U;NG-(/TX^"SM^!S \NRA?^'Q$YGD%(:)@DPC2,0S;!*

*M7]RYD^P/4N\$*R!AL_LO=2":,K,5UQ)-,2$9>B*4/EK\4;YSK9YFI8Y=XY M2(Z)<6%(!1W5l;7!A-MJ\;WDJIOL_IODA_B,W:62-NT_"9KNI7#0S"6^K7*

*MD+"6;OZYLW259M0&L{2)B/6=CHP43LMZ]UO;'\4*E7#&E!%[LEV7:ING[(,% M\NHMAU$ E2'1;<6LGJ%[/GM%Z_2:R&%Z2Z.C E F^# MM3F#7ZW5XP?TPYI&O?]SH+U?*

C'YIE'KID7H9#IO?,5]#9"2E4$IA)(6=89/$ ML$\H<^8@CVS;-#&\J&BN&+CB<;E8. S+,2R'T.0<++UCZ!'J ^'1[]>0B\#T M5RH&V0}6[=,SX8@FWG+DL.SQG0H#H\K2!*M$SXQHW(7?

*UIOH.I?O7Y0<%:OC MN_'81PQ&QI9&ML/A&4$0@O"$S"8.%R":?$4C+O:)8RL(A?M\&++L[IH^\'$Q0 M7Q)V^>3YGU/,$HU>]-!...C$3G4I&YK70/T*KMRB8ZZ0[""YPBLWZ\4P5?*

O\PENT!%4'S%Z,C-H(U+VP(6S[^ M7#/W0O/?@L_N>:.GL;/) ^&7[UPOIEX3?+GA2HB:$&0:BX(R)2.)4:4,=?2ZFP-G&R51QK&ZN"=6WC8CWSF4K=-

*_GUQXPI%O@-L$:Q@&99_96[IY3[9+Y]++*LHQK)#Y=:N'Y 36 MTKN3I4SZ3UP\R]\],+7>I#.QAKHVZK!!?SA@FFY.1F-M8EKP_W^8_5;TI9F? M\.L3NQGYS/KSQIK"!MJ:SHOU&B#?*

*I'Z0 XYXM:CR7<1BL6Z+5GXKEOWG,@CM MZ6OM/*MO2DP3S[ZWO6?8PC)0P/Z4BW9CUON55%CHT<7XTK668#WQYCRMM> ? M$^8&)?KKE'MX(_NW(D(QL&D?*

*H,OCVT6 (#W MO7<)C=RTXQ6-&*3,Y"\3-<#3S*6B"_*4M0@NG51#Z=V,B<$T^3&Y,7 MX4,+7F44&LWB(SV23WL_)%ON>=+2ZFP-G$WQ5Y!5L,j;T+OB6$[MO)BAS/%*

M!C$/EJ/ GMB6#XRDDF+#]+*AO1-$H'_I[WY17BRZ[9B#9IL_64 F M15L(HT:)(:H;6L+/>&YH:HTQPV>)VT70^'IHH><'_BS(BS>=PM;$Q:.';R.O*

M#5X3^K!S'F"0.B&-7OV/+]5VQ7H\]3(27XKF2{7[[>,^'H9T043C[74R.V3RUU\;P>59G#VGW"7B2,B;H"?'" MJ011\189'OQ'?%A M*^PT?*

*D/(FV8]F)HNLY)3UM@8K_HEKO,#V;V(EX(N,S M=YP90H,K 7.43& E+"QA,[R%]8#W)+V+A9 '(KS#\|#!LLI+% MW!RQV>=O#Q&/[1M(Z,.[(,OQ*RGMILS@J7/KGYZ? M9D*

*5:RN8\NR1N,9LB1R"6MZ'.)6H 82&L(CKDYCEKU#WH$O+)UPE6BQB\2_ MGSA'_.-!\AA1F A[PB)%*E'@;W8R2X)(<%N)A5'QK)}GCC1CSD09O=))H4:N MXJ^\%Z!@N<[Y/AR;/E(;5?*

1XB=XG,..$/3/'6T3*E>371VK; R9=!L_"W GP MVL1&OD5:HN)5">118=.INA0A/+?G=%<#5+0WH2LB-Y_%X W'(P(SYC%AWG C%#0%$&6=Z$C< G)O\".<1# MG:">^;#T9]9]=-

&|0N++$V7.9!>[Y6Q7!6C MF4Z:.9'?-F'VVX] E_ 5,"0?E@_3C^(!6Q9%.8E39M()*3/?KZ5$BU]3W0 B M0Q9I4'B+Y1MS43E<'OC(<4>,12Q23((U';$ZD_VBY%F;L(CV9_*"-UZN[?*

+9=;)B%D M_&T?V)@;=%,73Q+BS^!8OB(DC>$@CX4 M'^%/3+TERI[X=&30"M>!-(N(D- JHA'ZB5;,180(@&:VPZO.T9_PX:&FIBI_*

M7[L,.8:TV4=8B7!;!FU^&CZE0M/A,>8^!BN_^X6ONTH.C{'B6B6/;,4^"+% MGGC=FP]T$:M%X_BJ(".YX>B 3D_PJ0FCG#D?X8*

463G'LV+Y8O'!]=4CI1;"1M3.VPS$7;!L#)N7&^]\#TH84?H,\.:&A, >OFG#:\#-%ADBN9&HVX)0Y8ZY(@(^!CF.S9WZL(4!D07I

*MfZ1N86$[X^ <3:ZB)XUBWG2M@<4C++TCG425**J/#;QIX8(1WBG2M@<4C++TCG425**J/#;QIX8(1WBG2M@<4C++TCG425**J/#;QIX8(1WB

*M0X({&*P9;K_N899'E^#,E(!U[XF]@7SU]^@,+TUBV^1^(JL;&L.W]|H YJW M<.R R:@C8#K^Q6"6P+K6)NH5I+OQ.O#_5+;)WG:-F-[JMV[!;&^1S&XH5AKX]*

M6O+QJCR56G3)%>;ZG+*,N8BK >L_[5\ MWK!0<& /U9Q) ,B=T\"@+<<%,,"BO*)2/?-<"V, ^+&.K$,P\/[S!RB8. M&1Q7; ^.*MT5C"_R1@_T*!!HD%^RE;*^R! MJ(]+"M^PD9) OZ*N)"Q3QL(I.!ZLSHZ1,))6Y;$ A+(BDYUPJ5]XGB,6$Q^; :M"K\"&PAMP9=G%H1(\"SL;QSDH,PM4OT^UGN)FCI;9 Q5+XK$XU|F\;,1KI+Y*

*MU%,B;*K66/OO\|H#&K/@Y6X(PMX2EG'-3NFDW}3^VS*-^2RYTW^V@SV|\P;#4 MI-@-09&( ) >..[#MI%$0_Y*UKY!&@_[+"BT$!,_+RKR^G MA@-T%6'Q8=MN5$GOO+:.5_X]L_%?*$=,U(25D,(JLR;L7TM1.#_VGMEJ[>=9 MU=26H5<+K(A:BAWCIPE?^D=A96-7NY#*QGB[^]@?.5*TY&T(%U0W(&NF9,W4UM=HL3, HO%;)!EW[N11R$7EO.*P M=6MTU$%';WS1E"Q/E*)VS/NNND5-UT#4=%7KY8/GIHG:U=0G?K)=.X"XDI + M+\FIN/"RL4-8U(@7?D56[\"S<>NNV9ZC]WMX5*;+TL(S\M*VIV(^'C-9M7U:.-M_MZ^F"PTO$#^3)8I5<G&Y160;-UNV@K_;TWIG7)4F1E2+&)=UGSN)K*=.MUNU05TW3/:.1E:6$9UA*6Q)ZBKEY1>.3],%H-;T[%QU"N_.8/O:.MSWOOm1!0.YU\07%-%9+,9J)$\@+I+)!M>-%!<0|1K-K-@R\[*S!}>3'^AO2!"4^AV[)0P&K5MSJ/;UFA,&9YW% MDY)V'9(V/*JD#4'2^NJ@ER_);YDJt;ODX12,\H'-(6P1_131[$/$)N;C,W)% M^K*60)?*

(UHXI/H:&:UA;V\{)6L*FLA+ ^E%Y24=>,O>O\VQ(;<$YZ-LOS K8 MS',FT=R#["C-*N[U8/>7*!+&447" .]$'=9V,|@ 9U_R4L)+YE%YR41>ZN|O MJFOBI>NIX%WZ+MTZB3O+GX>*

*[@9*5O*<6Z0V0.S6+= ->OQ[N#O2O!I/?=1%[J M'I67J-1";TPD=PW>-Q]_Q!0'O7#I=>]<4"OH2,';=WS%P_3W@-UA(<5[&EY_ M-QXOYTL:&G'_Z8$4V4906B1KMHW^PWQH.0_?L0:T*-Q6;]A7'8-GCI5 MTOQFC62?P0W^EE.94KOH>5:-@CZ;IOE;>4= VK 0BU.M";DMR4KGJMO+3!0.F9 MEQ*

10=4'>U]92E=]^_%SO"H7QW6^PO\7CH65V#:L@_G/|CA7/23=]D0XECHZ M8R&@:H9=:.&%2|>]4;QTU.(04|»!5CGS6Z[FO5XM/5V MT>(^Q%(=VQ0MPE?W"1Y-[-#OJ_WNWL, <*YW|&;B@5|\O$NYK?$S*Q24RL:WN/ MWC@X$U^#[XLC$A&7.#II8*?DJ*_,|:USQN".DG<@F<.]Q*XZT/.7B=N/CY,^ M'0FMHM&$9]=#:LT|W>TD))I)(#D:,9XMP HX*#80XDTKW6*

MK:FK0W/OJ=9:E.ZH24]W8R+Y2@JJBNP#8V(NY?FY7131P/=-,C[#5KY%T!*P^D #ZIS&$CLT!A+AY9@?(3:O'WIE,.CG-2!ZZD.F\/T5@PO'2S"ZTM M*$WFO-*

*.BRIL*LACQT(L5)#QF9W@,5B/414]AEVCO -[|%O$E;AB*I&-8U@> MK 0^";="KTV|IV;K^,,=5A4=-.LVL.HLA\A\A)?/\TX<^[E Y]2MVI&6")1@ M.0K8OY;(XL!VB4$MGV;XCX%B!]3*

<HCH|/W;%,XCPAUX__" M/BJKT"YYW#UCF-.8Z@GW|A6>^^.%,<_L-U+0E;>%(]S[:D?/9]!.N2T\H1\O M7N7=X"3JC]H/&[@;M.5]S. _715HU,TOQ$$\[1;^N0MJXL1#0A6M4)^\.#*

M@.6X+R6^^Z-9LG\;V_|/WFV-P5L1.[N=?0-/'<+\EC2V:E#;3+F)XEAZ.MIJ7UY+"T[!XEAZ7\fVFO"4Q[C%^Z"#L=I M@P4+0+LA7ANXJS";-3.T7[1%I*)_O)>6F#-*

:B9E_!N;;#V!;.PTKX.]E8505E@ M3HFJ<2#27(Y,;E.52'\2!5>PU8;2PHCA1?;ZG-]GUB6\/Q%XDB8=S*CR!(}S,&"8 M-&6N#AWF,%&#MH'"644,P\C8|ONTN)0&2GU)=[=0?G."W_<"?*

*B7;$NFT'9; M\A5K!$RQ#,N_4MZSR3NY3M2R.5BA7>I/7#P*J#TPM=ZD,[&&NC;JL$%_,&": M;DY&8VUB6O#_?W2&K>A+,S_I77MB-R.?67_>6%/8X%O+>;%> [0H:,(3=)G*

ML&J^4JLIX?3]'6O0%N3?308 :[J_V8U9BW$<]_1_\SP?4*W4>HP6X M1Q7O8CV2=5M!M;=MTXP#AI?;M^,5!?VI5D\WJ/1-'=N9//+JHYPH'Y8 =C MQPM*

X>4[LH<#;@Q!9[#)?2A^AD_;FEO4.KFFBEJ3RME9(WXUL*WFV<9U?X M.F&ZBPSWIZSA?B\,IZ;6\,9O'Bl0E=^L5_(H/?18_*T-ZI7[XRG_ZNO_I%70SP0QUE#-ZI!6[+*

MPO>PDRG&1+++#S1Z2]MCNV%F2A<47?0$%K"I?3$U3?O7P+SWXYW\9^,,_V#@$ MN_NK98??UKSQ3OET9HR6.'C:Q"R.0G!^\|_'F_>PPO^<)*@"">?O*4?8-.M M1?S1-*

]BS'^%$<.}(6YBGCS'"9]TZ<1Q(9@"(#QX%,@D1!9^2Q6^\4&TOD, MI!A_(\'T+//Q1P"Q /,.^S<<]4@4\8?9,N(3ON!X9L.OBR_&9\"4/F8XX'E=#O,U!C8@/(LR-P2,"*

*MAAZW\]\F"$4";I25K(P\!6%49%(164772L9JHR$!GN7\"K'YXG,D+FA$ M(EW1$(&^ 4A3\!,0\+-83N7 "!PK0^U]!8$1!BBY@T*V73]$V#;UO3D_WWU8 MKZU<@ [^D6$.T 6I.!!^96/6?Y)'A+*@(@QMI5:.S4<4>YHE@$!=H'&(P] M#MFZU?-222# -16.%J/RP0OYOZDI)Q760O@$ @E/C606;QTZ3@9$EI*;3^Q8H6#M,*

MK25T,V=B9$7^>2FP5A*PJ@9KPW1]XK@$C/1^!;2@=2N=6LIVE5X5$W79+5LRR|-M AIJZLPH EF'BRR?!JU$G-81J4K/%8XE8]ZO1/+P MLWP6X7R5Z(HI3@!(Y]8_X6]D#?G-

@U5L^[;EWS5VE7M)5B"0Y8-B'(5:7L6 ML'.#7EL?%/^]_L*;WNX9ZQ\E$=XN%MFL>/?WJW*>2/0:R7Q;VBBP!7DV7VC'M[%53)P:O_S ;+"'[S%/51\!U=/,UFU?[0WJJE=K2&?!>:@%O-AR0\]_E3VPE:6G8GHW M)G5E <$*ZXY]O?NW6I(A?592<@W"/0M>Y}]9A2-[_*3D5V-QS [XA3 X/#N M!2+],G5C/0U+1-6AN??$06EP=A$G,?8'Y0FO!NE^E&X1I0DZCB3Q_CF6-19*

M_S$Z@R)5:NC7Y=R*32[%1RS%9RMM+,'$,Z5F>?5+8M?;QZ[V.N1]6H|=.M\U-TGQ0';U_W$9SK-BL5(YN8IE^0!#U*S@"=,KV_-[*:-#:I8@Q(.W,\.Y.* M8HJ$ 0NXI[^(WD*

,8G0;+@H_O-!R"OM%Y#P6.2UB=]W 97VEG&^]CJAJ0G4- MM,9 [6A[9]/-4IBI9U^[_*!;35"0VWQ_=0N5[MC|!\RO)!+V\QHO@/=W,K[M6:+V@L-*

*TR3F|\^6L@'JK;$!TC,&ZO;V1?!KH>)Z# B@=)RLS%X<5FA4\ M@LIR8Y0!$#3S|--Z=@D)%H,J6?%F\- #5&O;P+7D"7-*C@#H2@_FGS^5+TKU\9?- .M$NR'S56|:\UL+/[H/?*

*} .>,,G:5M]N#*5XN]A(/>;/5]ON=UB^WXB{@,U' MMIO?%R$A3!EB'WQ@_+\[,]V/>EXK0D*8B <3"Z]O#L2M[+%XR_E&#=B9Q8.Z M&+ ^=+'WJY$S6B[?@@U4='K5[HN*

N%]A=>1+6^VCYIL,29[-0"VOELQBV;CLE MAX$ -+$68?">&V\98BJ4WA1UXF-+>J975"H4/=M2C7Z\#-WR7MF@FG3>E MQ&%//%DM_/(.GQ*

*6;T6>\!QA^$V6C/51#/+GT>_M)3IC;2@F "5EM2 MSI)@sLO@=P5,J8]+#C$,C+H$8), A%Y8XXR MO\ 2Z->*E-.U!2;U.XN$[&'ZQ7.??C|__H&-*BM: YOJM6+AQONC-3 _38:|*

*M[+253S$$R6<7P9%X^_XIL2[70UT68:J ,@U"4$A4&E=^%'E 3 F 67(&PW(M3(EE>>98EN40BV<*IK@,N,; 4IAGBS ;_4CI!J,, ^1.=L>=T?5C +P8<$S] M@0IAW%#I\EX/"M12*

*M#BO/+>]6Q/M\>3_A"(-M*82PC#^:>2C*]Y!WD*.ML*7(+2+"%;A3*. .1H:1@T'+;!7->V?W,LR$"K\'?<@F'[")^>APBP?|"*XZB MT3SOF6*

*;^OT\XT4T6(OCDV,1A)[T@D3@@%^)8+###B?"3@_H9^?RCE'7VZ]|R M0_N_&#AT;PQ-&_ZB? DGY[|C2B0B!RDZSR0;*YE$^*_#(]UO)0#$R!&ET@/* M=@0^5DZ C+0 ??[Z;55P(@%-*

1U_8SYZ;. 2/4S_\%##8HV&O_%,4M@EY D,, M"Q0V/Q=$%7^)-(+/YB"6A,,%YH*ALE(*CUAY(W*9\6^3-*85@;4FF0$(S\#Z M@7OMORIW3[9CW]RC]<'NN428P,<+H^S#/SU0DTJP]?*

*6F/ $2<)X_+@$\V6/ M>0IQ$#/(5C#$;?P1?0MT(9S>)S;RE_@ZHU^4"R9WET^M]F#/!4 1H:1@T'+;!7->V?W,LR$"K\'?<@F'[")^>APBP?|"*XZB MT3SOF6*

*;^OT\XT4T6(OCDV,1A)[T@D3@@%^)8+###B?"3@_H9^?RCE'7VZ]|R M0_N_&#AT;PQ-&_ZB? DGY[|C2B0B!RDZSR0;*YE$^*_#(]UO)0#$R!&ET@/* M=@0^5DZ C+0 ??[Z;55P(@%-*

1U_8SYZ;. 2/4S_\%##8HV&O_%,4M@EY D,, M"Q0V/Q=$%7^)-(+/YB"6A,,%YH*ALE(*CUAY(W*9\6^3-*85@;4FF0$(S\#Z M@7OMORIW3[9CW]RC]<'NN428P,<+H^S#/SU0DTJP]?*

6F/ $2<)X_+@$\V6/ M>0IQ$#/(5C#$;?P1?0MT(9S>)S;RE_@ZHU^4"R9WET^M]F#/!4=M2C7Z\#-WR7MF@FG3>E MQ&%//%DM_/(.GQ

*6;T6>\!QA^$V6C/51#/+GT>_M)3IC;2@F "5EM2 MSI)@sLO@=P5,J8]+#C$,C+H$8), A%Y8XXR MO\ 2Z->*E-.U!2;U.XN$[&'ZQ7.??C|__H&-*BM: YOJM6+AQONC-3 _38:|*

*M[+253S$$R6<7P9%X^_XIL2[70UT68:J ,@U"4$A4&E=^%'E 3 F 67(&PW(M3(EE>>98EN40BV<*IK@,N,; 4IAGBS ;_4CI!J,, ^1.=L>=T?5C +P8<$S] M@0IAW%#I\EX/"M12*

*M#BO/+>]6Q/M\>3_A"(-M*82PC#^:>2C*]Y!WD*.ML*7(+2+"%;A3*. .

F78U8F28^=D+8X4G53FM+@-M98N>VYZ&|YK=?BU!B]2^5Z!|&^<:Q9U0]T%-SAWJZ:W;0;>$%U&7_EF-8[&>6-"_)=NS+GPW+?F*-0H|\9QF6?Z6\)YNWQ9VH*
MIUTWLWWEZ3]G?M+4]\1N1CZS_KRQIK#8MY;S8KT&>_#1+<+^TO1<)47I#J?3 M@^V0$QIDR^-0V6^!!9F/GX(U68U9BS+S41'\ASTPM=ZD,[&&NC;JL$%_,&":
*M;DY&8VUB6O#_?_1;MP2S@$V_;*GP#O1O?[56L8'6(0%K7=_P9XK!@$@O5EG7-M)LO@)(8+SF*BL4A62;V=,[\YHZ9,F+A"V:N0&])MPA'4"W\2%[QXBV"8L(%#N.O-T!*
*,10[D@:LS,FJR\E-<[X5@SX&D.P(1-M#;:IRSSHWL&NC#|=2A!G)Y XA=!V+'C$0!0=8K-7U(0&(/T6-3X>*B_T5W-MGQ,K1@,"O\N#@-C7TO)!-;7/8WP$/;%H0$:N'9F8.*24?BDC&]+?*
SP#BZY\-ML!6!)ED<-L-'*N-CUI'-^4-LI6AO?OX^.T;_55_]TLT-M%V#A>XB4F]"NV$&PQ#HOOFNAA%0E'@T]A0'1,-2U3"QJ]0E+,=":$85-K8D=C,&/-M0OU&X#4\%%(N-MS^")D0'!W;-*
E.V@,/WD^]95LE]H+:,3VL[5'-H5F8W@/2;9)Ss:.$XR-K[JSRB-VA+L-?:("Q$"IF69-AFZ$AB9/MA02WCG.-X8
*MK78Q63YR@+2B<*1+;+=):.9@Z5])KW41IZWH+F"0SL%"&^H7BET,HF.XX4VI+]5-MC4;S*GB\>]>C@#HJ\(@\E;=K-GJ[-P2Yl;E#(U_R>AC)W#!M<7=Y&+9N>P4._MY0Y+W#*
I>.QJ!|S5]\$KT,.7[_R3"!T@6:>_RP=\#& 7[V0?0"7!T-15^ M+=C7\^-^GI^W$_ZR1&&**,W[#1,AUYQIF]X@ZM\8B-_B4"&>H_84\^.1$-J M8_SL*I^_/>QD43[;5*P5PTAF7;I(>?X*
91OPMU75H'T(98>]H6D]T+%4AV!R-MOV'SOW^[N5=P"N48Z\R:%)]-M"<2DY?"N&.?:X/WB8V."<()V"F;V((7()9'+E7?CW:+!$+^(#[]#$-9LH&(Y*
M3A0)L9\V31?;^'3\L'C#@P]QE0O.BOC=PXLKQ)))>A1O!;606PD%^8[(Z@1?3-MUH87C3%!/+7'8CB?[8X]?R'R;$@D:QG,/!^D9&6@%N>&M\H;^Y?J7-[=P.7W-M1'?
*B$X0CE0YIO<'.Z8*FZYR3+W-QQ1E9&;6 M,\X>(>U-USB!,EJ&BNLIF.OSYN /1]" SD'WIQVS+^>)G(%(':QXGA'7P;6 MV(4W-@WU^>;S*?-]@6N!-*
*WM@,+,5>Z!?\"S8/%,CUA$;*2L4)E;KXAU+2@T-M];TY#>PD6N%_1Z^%R:Z1!Y$*OF%B@UL,>@@*76+-$*/<8?0SH>WS]FT,3A0L*
*M3,77@0/UQ'R5E+$%JA\,E1W:3&2]Z3PQ118]K/@T8SOT"2@++^5H(U0R$IQ/-MTLL1Q*C,!1MSY^N:[^^0!OP><$M,G11#8+BG]P-SH'8'^;[\8F4.$0DG-2'8*
M@^T7=BZB'!MO|$'LO:;M]TZP@,I5$ SYDSP&E*:]$)<#N<>H."5P,3=$LB M]'4+XR5K06GO?PL+G+AS9Y*Z7^M" QE5T?/05]M1Y[U' "0(% % LSYXOF3@+E%?*
*G!N^>R/$/BBM)W0BZ(/OB% M;!$B6WHXJOW%IE$&D6)XL1V'?RWTGAA^ #]IK7BI+CF5L,"0".L*X0Y2<9OR MQ(#:>[O*@'Q\6TE=2RE9'>],/-*
-8%4&,7D\"H_?]&:\;,C5OAIU#43<'Q] M&RP,)>=-II 1W]&'C$Y)[%3]#=0&D0D%AV;RG;[E889VV\KC>,4!E[[E.6N,+ MFPB,@3$#&\6!!C3P<^QDHDT,'Z@Z@RHLL0U0"MF/5 #-*
*_!SA91=YBHWN=G(A 5QS6WNYJ,,RI'V>YRC"?O/ M:[YX!RIC,6,O*CQVW,Y$,?<\+X#G&;O'2-UN/$]D15**8-?Y=3X>;BP@W IT M,44!|K%D?QM?0EP,#!/!'9"45>8'?*
9VVX1:%N)W.NF96T$M8 9Y"O#"R CLE M>_!BQD:W MP%W%\TV=_F+IXW5F&"G)U?O)UHDE.8E5.SS;QV2MQSFE1/A4S#'@Q""B+2@;
*MC]RC=/HCR7ZTE4]+RB$E2PSRZDHL(U@Z]%58"&=?^'OR<)Y{FBS'/)-AS?$R MF|+4_H37O+C%Y\Y'Y? UP_)CN8F0M,TO>-%4K M[!!\4M]&*MEQ<'8_@Q7"!.YJ*
J+,IR&#7L9GN>PBNU:%"^:!NOG4M0S 6AKX(P]HZ$>-MINY!(QW)@\HX'@5C17>EC"3M;>R+*$5CB25G2LYL)F<>"5<+"RB?IRO5DB*
*Ml,,+D2"O92'%7%GSAWB<3G;>VJXS.*YE0&G0*X--K52K.-Q07OR%U_U\BQ-4KQ=4+RF:O3VGKHH%>^]6;%_M\9H-4KP]4KSY!]$3ARJ;P5+,AG?.Q(5A)VE7AOPW!CY2H*
MT+7;D&Z#; B"(!W=|!K8+8FV!#)[?4]WM!Y-ZA5+R7PHIEBK??',4[Q(E] M-3COEZ)XZ\RY&]TF.^_$, A*%##\%SP+1M#8#,[&V P1;%%3A!U\;!"!P:=/ M-*
#.FI@R39\SPN[$SL!VROM342;B[^591BE<3+(NAG<_EI'!LW?:'JM;= M>]Z7OOK%EL70&G39/.Q(RU)?O)4'V,[\54F((740VV5:LO4G|OC2"%4 MF<3EO@Q<{FV;+D|*
(W3:HVI'WT?)Q>$808|MS39#QF 3 M,?Q$ZAT3[2P6[+6!F?9.[GQ45?R5PNG:!.?_.H7_TC-])?:0/E MH_VSG PG[)]L']6]MMN>I@6MB71S7I6B{ES)5)*I:F>]{W4MGC0A0\&+%<*[*
M9)>B7-E)NO3[31<5%O+ D^!0QTGY,Y\WA"!&]N(R#D%]_=OK^]07]^Q&<%WXVVH'Z+,[]N;L"_#0)V"AI(#^(6:@H]S.]5NWI]']>KXU\Y32+E]-M N])N1)RE>LS.;;)
*<#32<3Z:!P>KDZW^/+EAUMLV>31QH4X5P81+P'4# @77-ME7?*WT;^7T6-4?[/PH!4-N0>(6A;))YT?$>#_M;)L8FF^]AN-Z,R1;6 URC_>LE1_EQZ,QE&^:;*
MK;1.=+%362=U02>9ZG!8PR5-H_NCI,1)B3M(;%19G]M6U/M#6]XOI$"UQ@6 MDP)WQ)"PLL#UP<0-U&Y/FC3W6c>5IU-=]L0. MXD;P?2NSMTW--XXDVWMA15MLMJ^U5_YNG8?
*U(<4YB8\%W/4P_6'IS/I:4_LG MF|S\F_E>D9LU;-V*K'-#+A1J_+)22"Y52'(IMZ,(B:Y)(9%"TENN<$MZ114IU39_,2KL8 '#=[,_N7BOHSU5K-?=^+K M]!5B>Z3$1#Q>DSP>+*
*(S:0QX'4AZE/%ZI//XLN-Q#'FLO.9#RV!#.O$YY//DU-M4P7)W!QL&UKKMCM4.WMU[QU<,&LIM*ZI@O$0)<-R:6>RM&L VO[7&]NNWM#*
*M;9^Z@%Y^_XHAL/^_@%NJ06KLIX8GXT4E Y@6IO'!)9A$%HN$D&XLKE!3_*6 MGI[\G,QK\W;.JO,3G=4=/ZJO-%?S84H3QX*A/8T?6P[!T=+'!S],*L5(]%R MBZZ\?I-*
*UV^NH6K>G](@OFG3?D2D3>S-4L(=T32HAYG-76)B&=D!!#[79UU1AT MI81A?<[^\?)I$&=A0_[3%S&9LXJX.=*IFIT3+ 5P7.WDA MFIR^-L=@[(&L R\@"RC>DK=TP_57R,=88-*
K'%BBJ;5NM79!N>?IIST< 5-+ M"G.3]K:3,'>/*"OKTIE'6N):?6,:*,Q:3PJS%.93[VTG8=:/)BGK\]Y'6N F M;=-!8>YLD625PMP$AI?"O"[%=&!969OMF$.]=>4[*GS'D&)S]F)S*
MO%"N(AOFV6W'',UA%KLVO.M0KF98:ZZF6>\R%Q+]>M#N!UOA\65/]=&/E;_M.AL0ZR3-!>K6+2]!/U]^"V0(HL<(Y5FDC'9,ANVX$%$#EIGW9,ANVX$%$#EIGW9P4D/S MWE!2*
5RF.OEK>5VQWS8CLM8H\<&!IO-E@I$*A"I0"I>:F^M0';,"^ZXC'(% MTM4.=H,N%8A4(%*!5,RX5)#<';.D.RZD3)-UC=:MT2X8$7"^\"H3207\E_!KX M[\1^CO=",_[U:>W?X(?
*1\N>6_V2[T2H[P$'B)[BR7E;_[D,0GOZ>GR^-9!O M'U<@!MYG;_4G,& @%+DAVU?"&:,,$?*_NO>F\,R7RGY@Q^"G_ELZL'?\(L+ M"^EI+RQ^U"-E[Z=FBSH*WD#"(^/9=4BMY<*
*MD*U:63;P#7P&EQ>^>#=C^LB!S/V&3IL(?IG1O:M%/$W&3UL(+W<^PL)VS\'V#FBR7?XL-T59O^P$O>.[#^_M1)#*
*5C$0KP6\+O27K'6F7/8#3F+J.8[W@FS@4EL<'M[+*N+%P@OA/&S+<5Z5 MB)(1#(9%//?WI M+YV8R=*LE6*L$1M;RX"X66'3*1O3=$/;Q:<1)P/KKEWLB[=TD-*
F>&>N@DT'L(ZW6>8K/6$S=\+84D=@QY';Y/H/CM6Q%@%[&_T%;V\6CO7Z MUG;I<.A+[])/[RYRZH_XA__ZW8L]"6=H[-H:OT84N7'Q9O'K-OS]K_F?=WIM-MHSA[F/%3C4
M8U3Y_G'H_9CYCRF_PN5F@?3C55X"=]F$>+1_EI-A'\9(!7W-.M^C-IA3:024R@=M GFW<]K70#:RU\I'V%;(+)(YDJEJ9ZMA%XN1-GB+_\>7+-MO1(-3PF4&0/G=_2(}"7_"GI@X<5E?
*D2?6E?9:W>W6.:[A1?8Z/F_]1F& ,_L M'7+>C=DN<'XA_&3X@-,M&^N7K(>^2UWZ'@G YF6[*H*F@%BLA4W9,VZ^FP.] MMQS9DTI2=5JW>E?M#*WIJ?_^Q/>> \RW9=5MV-*
*1O(KEW)KI)=B]EU/?CG:=BU M)E5LFLQNZY'XCP-N_;/BEVOH3CYD6YRO(4<2+V%2*V')3R-2 U:MQW5T :J MUC$; DXHX3MKY[Q^ SEOV+I%/;ZIO0*L97KKMJ_V#%,=|)B\ZX!*
(>7[X^^[..?GVPE;55QTK8'B8H"B'D\ MET<6D@W8%\)VZ|<9G(;M3-#2O9[:^?_9>]/FMI%D7?BO(#3N^]H1$!L+5WFN M(M2RWW1HM52M)R9:P.Q/8U7#/JMVZNNUUFJIASK>K*
M. [N+JF=X),?6>XV@=.JG6@Z>6ZKX89;NPTB7E.U9E-MM;>V:D__N)X$^BZ M7L.MNG8'@&ZJ1M=4N\VM[1D=_GTU;WOC@/ET]M6MWE-[W9ZJZ?/5'"30)=!W
MWG#O.$#O@41OJF.W"1)1}5]LF-3HHO.Z133S?)UY_C=[$C5E^B)-_Y'@VJZ; M:[U+YP /G4YMI"*=^O!G48L$UK4&42\U>2=.0^.IX. 93XWZ@3*.HQ@//X=A M,'D#*
<7@S8#:;3/DAT@!/F8XM;T3GD8N)\/U7<4AZ/@}^YLCQ[&ER_%M45K3X MV7F$$7,TS6UMMVTK9ZN]9NLV^EUF:;;=G^@V:8%__VG@Q4@JV%/-W:/(EU? M=7B"#@?W&DJU-]??*
*@+1!/(IE 8+>>?8W1!^S[!J.QJ7 MB%2Q\BX2G^%+B@>M"R^!.V UY]=HYLQX?KVR]^&S2]YHG.IA[A+*T,E_/%5O MN4!L7 PE\O/E :C\;><]LM;4#\2993:;@*
*2C@]UPZ6OZ$"P:D)07$!?AT6Q2 M*LB!$V;AVN+#1K%K!>XK_/;LL!=&AT[@(FO$*Z&\C0&5E: .X,1XZ/D9[CA M2@>Y>'XFHL@!++!@I!9I+"/],\;'"L+++6!?3R? S#-B8>2$>[<9SY WE-*
\?J M.RYA$687^@.'GD.'T,M>B@,+V "5$@W,&@P"{)+@YI[CEPRL;[E$D7#,6!26 M2)1Y"2+ (E:TB9)Z7HRGA[U_*H)4H%/+,K'Z,)HX6GS+8A3S8UQ'K'>FB%6
*M[M]QVKU"D"Z[@?,^GYM#6&P-Y;[8KV&J.?S4X3YY>DY2X[%,QP.IZ?'GB-_V M8HH6_X9*8G_%_$^K-F-1Q@$*^7^LH=.N;!|[;&#-#0/'@IDZ[9L&1>+XL,5 MND\EL G0:.&!\%.7)%*
0"R!/;GT96?T,E+(NPTHM> $,@LI[+*MU MM-3#OS:7&A7W7&&LK/%N9F:%?G7K^7.^R\SJL!]3T!,,M0SX5D ?Q>9?4*D: M*@*.-J=\[$GX)G>
J^1.A)0_FV[I.7/'6V9DJ$6P;PS9LJA&UM0MAY AK8 MW7S>^Z.A5QI/>S?C 1NZ5W(4 &$=3AG:FLQ|;2A?K5=N&0SG>#&OO7/KO,;] M+BAIL\'RK,!],OY/?
E"@3!E)FD"2MK[_>5H|%I:MZYN354AC20>6<5U M#*X/]6]+UX]?GZ\=2'ZM=XO&TYWTL_C ELGZP#9TK?.@):W28 M..K09P?+0)$<== F=B;HI5B^#>)<(<1 >HO0!L3&#\.$0A*
*F,%K@#,1VRF"EMJ M&E@>4,H5I:O0+!$W894U%6P#G+<(;F!/M@">#T8 FX2]X@SAUE<5GFF!N@X< MT.0YR<4'U5 ^6H.Q\E<;,AH+U$(5N'B*CDE(-D5^C/CWLC&! ''X3)*[[,77*
*M*SS:$A9?/&^H[>E#.))S-T8,54R8< 2XC6[Q!20^F(&X#X6UH$/9QL*@V42 MQOT_L6H8V$K/0$>.6CLFXRED6.W,1:LG\@.D>EI7C*X5U1#[>FN\;D.9Y2W ML&+H8+[C,Y^*
(H'1_0D+/%-K.@+ND\/R7L0,SI>F&\FQ0X(0RN&SQ,Y+@7[M7'V"N8;HOHG#&/ M@LB"GUA]0Q$&TY!'),0;<)==9[%&<09+"D[>@#G/1)[$9 ,Q>]I3';=: 9Y MKJAV8(7|/BTKC :?*
*T5L"L,*TYFY9[C835A,5ATOJT%@"#QV9_^1=ML+R,F3>S M$\-#K#:2T,[OV=C+]F@(W3Z6M$5CP06"D2D4P-0YPU"\P@F+XTV'-[%>>0BC*
M6$:AXB*)367!EFG(+;Z\N851.GE+VB'3:W7A!B2TK8%GX>T=QHG$R["'J CZ$J43'@1[\A&=K(\@;@ ; M6EW96^'_,WL#/@;F"S>#+W+ZT!PE$^L'X!I^;KH;1)^>M%0I; W!>>
*#A:W M#C(VMQ(V5]ZB*6%HfY^^W=%O^OMWRHL3C1>CE3!$=]S-PE1,3]HDWG>&<#R/=_MH"EY$*QO5;7:[8BK&O+, =@%+M!$Y=B=/^4\KOQ#7T*
M%P,>6P(#L:,]U(H3CV(8BK3"^AV83%IS\E"51>[])RWSKL4 ,.D>4$'.S,D8 M?C/2C;9U\#79KG"8%S'A_+ZP'] -7 F&,/^0UQ=.OH<1\->\)Q'TUH'Q)15' MY5%^YL*^)\;RXP!=*
(8H%)Z&IK!PV8.E$E.7:^F,"-(E(@ED@]UP79(KH@0H M<5YH@\PB&1,HJ,D,/F2YHB7K+H518'3C|&3'0&-_^Z/%B%36.R2]<^O2UZ;*BSIKXX .ZSG>PQJ[A"N\:=TAA]'V6*
*M@!F\V<>X'[*_8A*Y?AIBCR>3-,*.GWW^^J#\SH(1"U+7N83WDP+IF8(L3@W% M2CA3-;[8+'"7X;3>2873]*KA- #QQ*$(17CGV7P]`&#%4D,76,^P-8UY@-L*
*MN<>+0>K<"S;*N&WE+R[SCMK%0WOWT@+(G)F8=(5](QTV=$ F9!MN*-I>F.M2 MB7W2+F!$@"L6@2YI9F-G@/J)@F),Q0Z%@(1*$;D0N-=:C^=V9ZfUT0G]!02O*&PVP*
*H,:NPX("\W8T,3>'Z6C;@GC')XQ;A:.QP7^M'9 ML)[%@$DZ,+QHUE>N)*UH#/=^&-%.?(E8;I6(AM:\6*K"34=D'8Q+^%Z2]L/!`M1UOAM/=LA:*E1;BR?\,I=6OH-3[=SF[*_6N-9K-*
*V/0CDH*IT:UC^*-FM079K MD-T:5E%*%M:7W1HDJ&I#MYIT:SC&<;&'HLM&!NU^"MN>6S/3:I,_T4.#)7)>D5_%;W#DDR\;ANS*7=5!>3XQU27U*61S",99^WDZ#+FJ9;CVL4D'E73*
*MMSXW*WFK7BB3O+5E9OL.> LK,*A=8^OB"Y*WZH4RR5M;GM#8 6]AT0=5Z^RJ M(N'Y--LX1@_T0O>#Z)KW%XK\0U/LK[$!NWZSK",>76?CI" FXW+?+]>=G5K*
*M;]\;99G[&N)CA=NR'CYTD/#;5YR5^*@A/E;8WNOA VNP:U)^G",^5IB/Z^'# M\'R8LIG%X5;X$V5?%?<&;M;96-JH;K>_#W7U+]Z[I)"'!E1TX2*C.1S"T7R*
*MM^PKN*F+P&4%XTF*^{]'X1\ANT.]Y(aE?)M>Q\79G5R6]I=ZO$VA6^ U;@ 9+ M>?1D'\ES!,T*9V(+T+0!-,*6<)FM,'S0H/8PO0=+ 0U=:I"O5R.T["8$O.*
*MF.&I8VZDY2IMN28G]N[#4$A),Y.7BRN#?O;HU=-F>[!R\4L$Z6D,HO9V$=R50 M:@B4"A;92]#T-&R*7)\.8!(H1[+,"U@"*#N9Z>U?)-J>V[7^.I:86<9LD@N^[MS4KM*+5^QM*
N27,^@F%C;H&E%/,S!%K]W:U3;1"?=`DLPJF?4@?L+FS&I2 M/FU)"6G)K))9);/NPU?;G%F;5#Q=VU7X7#*K9-:+9]85_O+FS$j=#EK:KK8M*
*MS]M[HFR5N+M6B9]Y_[10E*IW6;XP$A6#11SPJK-8F%H5Y>B#]QH6)(2A6.Y& MS0_%[""^=5E;MBZKP5@.VK],"BR6E51TKQ;?TSK=YBB/\73J41E@R\U:BH%(MX6]1BKN"K*
*&9<4W?6KSWYVN^F*NH//CFQ=K:O8;6;>VFVA=H[/U%QU%3"-BT.FDM7VNK8Q/88 MW->!@@HCV^51]VL.6"RJF]LI+RXL2S)9*W22 \TQC1F<9Z*I4G25I>5@[\ MM+&,@JF?*
*T3%;R1'GRA&5BHIIS!$=Y C#V#]%M889W">L!X?%LZ7KZ\%U$^EJ M1XO*18;.E.LW2"85O/_@_99T0RUC].Z9Y95*%CA7%M@@378]%NCA ;>Z'-;X M*
(\OJY50KNF8]/^!@Y@9VIYF9s[O]LZEM?JG-&)9XG\I-O$9YX/9B;U).I-9?3\)?%K?W@=AUFK;>I4S;<"DD;9 MM%? -P+\/@R;=U_?;"-
@B1@)ZOT7&LR84U9O;@4UVV%53=36^)!R(7/WD75KM+8N&2;C'-Q$.397@M+!M.W%FWX$2S#N!.5;/[^T-G1_,OOZ;!?Z9"&A> ;MW#=UX7Q/'4(9$),?L4SVN
MP3&K=\/U%EB4+,75KM5V>/&$$_QIC[6ZDO>?PQNB7GCGV;]EJ7>\C7IYB_*> MWMZF&7E-$^3[EDL[#N&8,7X(QX_&+"BDR\0$>)D8OUDB^(FE+5=+|SY'&GQ@ M S;I
*_^;=T?,+V"=N5*737*,*V'B$Z5;V9 M^ENAG2H)ES,V:65+$QN1;FI9 ;:==MY"0P)? 7P[\[B&|CUU"3=5LS>=JE"G> MV8WD5J6-Y!UMI.6 ,.5O<(7LTXN)8.X]K#7"WFY*G9]'DSIN)T-*
*@@#@*P1T_0 MR.EO:.1/*ER5I) ?VF"1(#XG$%A{}>W@%>7^QT*V:G"-C-Y<>N]E, M>E=F9JQ%K:LM;87A),.5$O(UU625(8^-5YMJV]3.+% I0Y2U`'S^I?"0P;7S*
MXWKLV#;S;A:]K=67M]NOP9H3$2OJC)U+8]GL[" 8F>*N2ZJXK%(>5L\89MY M1,4?,H!X@;&7%<;#DK:@E:.5IA[9]FKWY;A8R?"@AO#=E8)<0[I):8'16!"Y. MSB"0.Y?U@?*
ZGO+)>O64IU?8ERKD:GM^PV1>KO6N;CM2+TN,'DLOKX%14P;, MMM93O&==7F&5?IC?KI-[7CN2H)MOA9CZU6U/[75W)&/ECM?^1- 6B\SWN\SN MBHS>R|OOFBEF*O>*
[9/#_L)[,BN;Q,J=SGQM$;G;)0%??RU6&?!-VM[5F_-E MY$X[M"6#6G6 ^[_I#V8K%HS*&C$E8!/+\3*+(&+!1'G[RJP@?)<5AINS#K85 MMD>]?*
*Y=U<,IN]$VL,,R(^^\MH*JO!9#9WFF0L(=E=YO)OB4\0E|^ 8?H!,&_M&\(W=AP@UV2"'#O,-IKS+4+KX6;>]OU#!{^,5,R_fM+UNR0\M/2ZN*
[TI:$R,Y?KWMUVVN8ZXB063N^6!7F'>N' MVMQ_D1:Y[80#F%,D@$)CT@2_(-\6>RE9/ZEH;;;RN#Y(L78[&?I5%%1G%_M,T+Z@^^<;|*
X7UDPR&]@8AOR1"SWKFZ;C:W[+RU!9,UC7C_MS0F1")X-$^X% MP4T\.]NH167$.B!8NF';9KV<)R,N5R5+K/UUV1"/SS;F4PF.4-V[#FRX2YM2 MXG>E(MD!?
*@V)WUDU4]SPN[#$KEDLL8M_BOE2H\]X,]TYFM4<3!V4=`QP,M%8%X36-<;1+WR8IE*A.DN^.F;2AD-AZPV]-JKS+4+KX6;>]OU#![^,5,R_fM+UNR0\M/2ZN*
[TI:$R,Y?KWMUVVN8ZXB063N^6!7F'>N' MVMQ_D1:Y[80#F%,D@$)CT@2_(-\6>RE9/ZEH;;;RN#Y(L78[&?I5%%1G%_M,T+Z@^^<;|*
X7UDPR&]@8AOR1"SWKFZ;C:W[+RU!9,UC7C_MS0F1")X-$^X% MP4T\.]NH167$.B!8NF';9KV<)R,N5R5+K/UUV1"/SS;F4PF.4-V[#FRX2YM2 MXG>E(MD!?
*@V)WUDU4]SPN[#$KEDLL8M_BOE2H\]X,]TYFM4<3!V4=`QP,M%8%X36-<;1+WR8IE*A.DN^.F;2AD-AZPV]-JKS+4+KX6;>]OU#!{